<SEC-DOCUMENT>0001564590-21-015274.txt : 20210325
<SEC-HEADER>0001564590-21-015274.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325081717
ACCESSION NUMBER:		0001564590-21-015274
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Harmony Biosciences Holdings, Inc.
		CENTRAL INDEX KEY:			0001802665
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				822279923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39450
		FILM NUMBER:		21770164

	BUSINESS ADDRESS:	
		STREET 1:		630 W GERMANTOWN PIKE
		STREET 2:		SUITE 215
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		(484) 539-9800

	MAIL ADDRESS:	
		STREET 1:		630 W GERMANTOWN PIKE
		STREET 2:		SUITE 215
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>hrmy-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:42.31%;margin-right:42.31%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-size:16pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:42.31%;margin-right:42.31%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December&#160;31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: 001-39450</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:42.31%;margin-right:42.31%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HARMONY BIOSCIENCES HOLDINGS, INC.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:42.31%;margin-right:42.31%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">82-2279923</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19462</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(484) 539-9800</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.00001 value per share</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HRMY</p></td>
<td valign="bottom"  style="width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Nasdaq Global Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(g) of the Act: None</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> &#160;&#160;&#160;&#160;No&#160;&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> &#160;&#160;&#160;&#160;No&#160;&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font><font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'"> </font></font>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font><font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'"> </font></font>&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:25.56%;"></td>
<td style="width:0.85%;"></td>
<td style="width:38.68%;"></td>
<td style="width:30.24%;"></td>
<td style="width:0.85%;"></td>
<td style="width:3.82%;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the registrant&#8217;s common stock was not listed on any exchange or over-the-counter market. The registrant&#8217;s common stock began trading on The Nasdaq Global Market on August 19, 2020.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 15, 2021, the registrant had 56,891,920 shares of common stock, $0.00001 par value per share, outstanding.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December&#160;31, 2020 are incorporated herein by reference in Part III where indicated.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="TABLE_CONTENTS"></a><font style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="TABLE_CONTENTS"></a>TABLE OF</font><font style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">Part I</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"><font style="text-decoration:underline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">ITEM 1. BUSINESS.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">ITEM 1A. RISK FACTORS.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">ITEM 1B. UNRESOLVED STAFF COMMENTS.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">ITEM 2. PROPERTIES.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">ITEM 3. LEGAL PROCEEDINGS.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">ITEM 4. MINE SAFETY DISCLOSURES.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">Part II</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">ITEM 6. SELECTED FINANCIAL DATA.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#F_PAGES_TABLE_OF_CONTENTS"><font style="text-decoration:underline;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">ITEM 9A. CONTROLS AND PROCEDURES.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">ITEM 9B. OTHER INFORMATION.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">Part III</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">ITEM 11. EXECUTIVE COMPENSATION.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">Part IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">ITEM 16. FORM 10-K SUMMARY.</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">SIGNATURES</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><a name="PART_I"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>Par</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">t I</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58363684"></a><a name="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"></a><font style="Background-color:#FFFFFF;"><a name="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"></a>Cautionary Note Regarding Forward-Looking Statements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="_Toc57927402"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, the anticipated impact of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic on our business, business strategy, products, prospective products, product approvals, research and development costs, anticipated timing and likelihood of success of clinical trials, expected timing of the release of clinical trial data, the plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, statements about:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our commercialization efforts and strategy for WAKIX;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ongoing and planned clinical trials;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to expand the scope of our license agreement with Bioprojet Soci&#233;t&#233; Civile de Recherche (&#8220;Bioprojet&#8221;);</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">the availability of favorable insurance coverage and reimbursement for WAKIX;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact of the COVID-19 pandemic;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our commercialization, marketing and manufacturing capabilities and strategy;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant competition in our industry;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our intellectual property position;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">loss or retirement of key members of management;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">failure to successfully execute our growth strategy, including any delays in our planned future growth;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">our failure to maintain effective internal controls; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;">the impact of government laws and regulations.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221;, or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Annual Report on Form 10-K titled &#8220;&#8212;Item 1A. Risk Factors.&#8221; and &#8220;Part II&#8212;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated, information contained in this Annual Report on Form 10-K concerning our industry, including industry statistics and forecasts, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, forecasts, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described herein under &#8220;&#8212;Item 1A. Risk Factors.&#8221; and &#8220;&#8212;Cautionary Note Regarding Forward-Looking Statements.&#8221; These and other factors could cause results to differ materially from those expressed and forecasts in the estimates made by the independent parties and by us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used herein, the terms &#8220;Harmony,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; refer to Harmony Biosciences Holdings, Inc., a Delaware corporation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report. You should carefully consider these risks and uncertainties when investing in our securities. The principal risks and uncertainties affecting our business include the following:</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Condition and Capital Requirements</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We have incurred significant losses for most periods since our inception and may never achieve or maintain profitability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We have only recently begun generating revenue from product sales and may never be profitable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We have a limited operating history and history of commercializing drugs, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We have only limited capital and may need to raise additional capital before we become profitable.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;">Raising additional funds by issuing securities may cause dilution to existing shareholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights to our technologies or product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">Our auditor has previously expressed substantial doubt about our ability to continue as a going concern and we may be unable to remain a going concern.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We have made and we may be required to make significant payments in the future to Bioprojet under our licensing and collaboration agreements for pitolisant.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We are substantially dependent on our ability to successfully commercialize WAKIX, which is currently our only approved product. If we are unable to successfully commercialize WAKIX, our ability to generate revenue and our financial condition will be adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">The commercial adoption of WAKIX and any other product candidates we develop will depend on the degree of their market acceptance.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">We rely on our license agreement with Bioprojet to provide rights to the core intellectual property relating to pitolisant, and any termination or loss of significant rights under the agreement would adversely affect our development and/or commercialization of pitolisant. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">The ongoing COVID-19 pandemic may result in disruptions to our commercialization, clinical trials, manufacturing and other business operations, which could have a material adverse effect on our business, financial condition, operating results, cash flows and prospects.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">Because a number of companies compete with us, many of which have greater resources that we do, and because we face rapid changes in science in our industry, we cannot be certain that our products will be accepted in the marketplace or capture market share.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Development, Regulatory Approval and Commercialization</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">The regulatory approval process of the FDA is costly, lengthy and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for pitolisant in other potential indications for which we may seek to develop pitolisant, our business will be substantially harmed. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">If we fail to obtain and sustain an adequate level of coverage and reimbursement for WAKIX and other product candidates by third-party payors, sales would be adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">WAKIX has been approved by the FDA for the treatment of EDS or cataplexy in adult patients with narcolepsy. Regulatory approval is limited by the FDA to the specific indications for which approval has been granted and, unless we seek regulatory approval for additional indications, we will be prohibited from marketing pitolisant for other indications. We may be subject to fines, penalties or injunctions if we are determined to have promoted or be promoting the use of pitolisant for unapproved or &#8220;off-label&#8221; uses, resulting in damage to our reputation and business.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future product candidates.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of our Common Stock</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">Our directors, officers and principal stockholders beneficially own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:15pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:15pt;"><font style="font-family:Times New Roman;font-size:10pt;">Future sales of our common stock in the public market, including our directors, officers, or significant shareholders, could cause our share price to fall.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58363685"></a><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. Our product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (&#8220;MOA&#8221;) specifically designed to increase histamine signaling in the brain by binding to H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors. In August 2019, WAKIX was approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the treatment of excessive daytime sleepiness (&#8220;EDS&#8221;) in adult patients with narcolepsy, and its U.S. commercial launch was initiated in November 2019. On October 13, 2020, WAKIX was approved by the FDA for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first-and-only approved product for patients with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;).</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to pursue label expansion for WAKIX in narcolepsy in pediatric patients and engage with the FDA in pursuit of pediatric exclusivity. We currently expect to initiate a Phase 3 clinical trial in pediatric patients in the second half of 2021 in pursuit of indications for both EDS and cataplexy. We believe that pitolisant&#8217;s ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological disorders that are mediated through H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors and histamine signaling. We are initially focusing on evaluating WAKIX for the treatment of EDS associated with Prader-Willi Syndrome (&#8220;PWS&#8221;) and myotonic dystrophy, otherwise known as dystrophia myotonica (&#8220;DM&#8221;). In December 2020, we initiated a Phase 2 clinical trial to evaluate pitolisant for the treatment of EDS and other key symptoms in patients with PWS and anticipate topline results in the first half of 2022. In January 2021, we opened an Investigational New Drug application (&#8220;IND&#8221;) for DM and are planning to commence a Phase 2 clinical trial in adult patients with DM1 in the first half of 2021, with topline results expected in the second half of 2022. Beyond these indications, we intend to further explore pitolisant in other rare neurological disorders, potentially including those in which fatigue and cognitive impairment are prominent symptoms with significant impact on daily functioning.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to expand our pipeline through the acquisition of additional assets that focus on addressing the unmet needs of patients with neurological disorders.&nbsp;&nbsp;We intend to target assets that will be complementary to WAKIX and our expanding list of potential new indications for WAKIX, and assets that will allow us to further leverage the expertise and infrastructure that we have successfully built at Harmony.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant was developed by Bioprojet and approved by the European Medicines Agency (&#8220;EMA&#8221;) in 2016 for the treatment of narcolepsy in adult patients with or without cataplexy. We acquired an exclusive license to develop, manufacture and commercialize pitolisant in the United States pursuant to our license agreement with Bioprojet (as amended, the &#8220;Bioprojet License Agreement&#8221;) in July 2017. See &#8220;&#8212;Strategic Agreement&#8212;License and Commercialization Agreement with Bioprojet&#8221; for further information regarding the Bioprojet License Agreement. Pitolisant was granted Orphan Drug Designation for the treatment of narcolepsy by the FDA in 2010. It received Breakthrough Therapy designation for the treatment of cataplexy in patients with narcolepsy and Fast Track designation for the treatment of EDS and cataplexy in patients with narcolepsy in April 2018.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>Our operating subsidiary, Harmony Biosciences, LLC, was formed in May 2017. We were formed in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company, and we converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017. In February 2020, we changed our name to Harmony Biosciences Holdings, Inc. Our operations to date have consisted of building and staffing our organization, acquiring the rights to pitolisant, raising capital, opening an IND for pitolisant in narcolepsy, initiating an Expanded </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Access Program (&#8220;EAP&#8221;) for pitolisant for appropriate patients in the United States, preparing and submitting our New Drug Application (&#8220;NDA&#8221;) for pitolisant, gaining NDA approval for WAKIX for the treatment of EDS or cataplexy in adult patients with narcolepsy, and launching and commercializing WAKIX in the United States. In addition, we have </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opened INDs for both PWS and DM and have </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initiated or intend to initiate clinical development programs in PWS, DM and pediatric narcolepsy to pursue potential new indications for WAKIX. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, we completed the initial public offering (&#8220;IPO&#8221;) of our common stock, in which we sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135.4 million, after deducting underwriting discounts and commissions and offering expenses of approximately $12.2 million. Upon the closing of the IPO, all outstanding shares of our convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of our convertible preferred stock, and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 410,239 shares of common stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity and Sources of Funding</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, we generated $159.7 million of net product revenues. We have financed our operations primarily with (a) proceeds from sales of our convertible preferred stock, (b) borrowings under (i) our Loan Agreement with CRG and (ii) our Credit Agreement with OrbiMed, and (c) proceeds from our IPO. As of December 31, 2020, we had cash, cash equivalents and restricted cash of $229.4 million and an accumulated deficit of $488.2 million. As of December 31, 2020, we had outstanding debt, net of issuance costs, of $194.3 million.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our anticipated cash from operating and financing activities and existing cash and cash equivalents will enable us to meet our operational liquidity needs and fund planned investing activities for the next 12 months. We have based this estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we expect. See &#8220;Part II&#8212;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources.&#8221;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues and expenses in future quarters may differ from our expectations as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">commercialize WAKIX in the United States for the treatment of EDS or cataplexy in adult patients with narcolepsy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur sales and marketing costs to support the commercialization of WAKIX and any additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pay royalties and make milestone payments to Bioprojet for the license of WAKIX;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur manufacturing costs for WAKIX and any additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">implement post-approval requirements related to WAKIX;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct clinical trials in PWS, DM and potential new indications for pitolisant or any additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct a pediatric narcolepsy program in pursuit of an indication and extension of our patents based on pediatric exclusivity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct earlier stage research and development activities for pitolisant;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">support independent investigator-initiated research for which there is a valid scientific rationale;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">hire additional personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">invest in measures to protect and expand our intellectual property;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur interest expenses in conjunction with our debt facility;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for pitolisant or any additional product candidates that successfully complete clinical development;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acquire certain ex-U.S. rights for WAKIX from Bioprojet and subsequently seek foreign regulatory approvals for WAKIX in certain of those jurisdictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acquire or in-license additional assets; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur additional costs associated with being a public company.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial Launch Metrics</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, over 2,400 unique healthcare professionals (&#8220;HCPs&#8221;) (out of a total of approximately 8,000 HCPs who treat approximately 90% of diagnosed narcolepsy patients) have prescribed WAKIX since it became available in November 2019. The average number of patients on WAKIX at the end of 2020 was approximately 2,500. We have secured formulary access for approximately 80% of all insured lives (Commercial, Medicare and Medicaid) in the United States. Within these covered lives, we have observed favorable access to WAKIX subsequent to the expanded approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy in October 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 Business Update</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the global impact of the COVID-19 pandemic, we have developed a response strategy that includes establishing cross-functional response teams and implementing business continuity plans to manage the impact of the pandemic on our employees, patients, HCPs, and our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite our response strategy, the COVID-19 pandemic is having an effect on our business and the pharmaceutical industry in general, and is impacting the way stakeholders interact with one another during this pandemic. We continue to leverage technology and virtual engagement initiatives to offset our reduced in-person access to HCPs. The COVID-19 pandemic, which has led to high unemployment and corresponding loss of medical insurance, has caused a change in relationship dynamics between patients and their HCPs and has impacted the way patients take, or do not take, their medication. Based on these factors, we expect that the revenue growth rate in future quarters may be adversely impacted by the ongoing COVID-19 pandemic.<font style="font-family:Arial;"> </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to identify new and innovative ways to maintain meaningful engagement, generate awareness and educate our patients, HCPs and payors to minimize the pressure from the COVID-19 pandemic on our business and support our commercial launch performance. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>With respect to our commercialization activities, we believe the COVID-19 pandemic is putting pressure on top-line prescription demand for WAKIX, primarily due to (i) our field sales team&#8217;s reduced ability to access HCPs in person, and (ii) fewer patients seeing HCPs for prescriptions or treatments. The impact on demand for WAKIX may also be related to a reduced ability of prescribers to diagnose narcolepsy patients given the limitations in access to sleep testing, the reduced ability to see patients due to (i) cancelled appointments and (ii) the reprioritization of healthcare resources toward the treatment of COVID-19, both of which lead to fewer prescriptions. Despite these challenges, we continue to engage and educate HCPs virtually on the overall benefit/risk profile of WAKIX and continue to provide support for people living with narcolepsy. As offices, clinics and institutions have begun to allow limited in-person interactions pursuant to health authority and local government guidelines, our field teams continue to re-initiate in-person interactions with HCPs and customers, but the timing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and level of engagement vary by account and region and may be adversely impacted in the future where reemergence or future outbreaks of COVID-19 may occur. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High unemployment and the corresponding loss of health insurance is causing some eligible patients to shift from commercial insurance to free goods and patient assistance programs, which impacts our ability to convert demand to revenue. Depending on the scale and ultimate duration of the COVID-19 pandemic and the extent of an economic slowdown, widespread unemployment and resulting loss of employer-sponsored insurance coverage, we may experience a shift from commercial payor coverage to government payor coverage or continued/increased demand for patient assistance and/or free drug programs, which could further impact our net revenue in the coming quarters.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Supply Chain</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently expect to have adequate supply of WAKIX through the first half of 2022, with additional API on-hand inventory to support 12 to 18 months beyond this time frame. We are working closely with our third-party manufacturers, distributors and other partners to manage our supply chain activities and mitigate potential disruptions to our product supplies as a result of the COVID-19 pandemic. We believe that our access to the required production lines to produce additional API and WAKIX finished product throughout the next 12-18 months will not be directly impacted by the potential need to reprioritize manufacturing resources due to the production of materials utilized for COVID-19 vaccines.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing partners in France and the United States continue to be operational. If the COVID-19 pandemic persists for an extended period of time and/or begins to impact essential distribution systems such as transatlantic freight, FedEx, UPS and postal delivery, we could experience disruptions to our supply chain and operations with associated delays in the manufacturing and supply of our products.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has negatively impacted the pharmaceutical industry&#8217;s ability to conduct clinical trials.&#160;While we initially experienced some challenges due to the COVID-19 pandemic, we have taken measures and put contingency plans in place in order to advance our clinical development programs. We have implemented remote and virtual approaches to clinical trials, including using telemedicine for remote clinic visits to perform efficacy assessments and sending out licensed HCPs to each patient to collect safety assessments (e.g. labs, electrocardiograms) as required by the protocols. We are also performing remote site visits and data monitoring where possible. These measures are being instituted with the intent of maintaining patient safety and trial continuity while preserving study integrity. One unique challenge we are facing is the ability to access sleep labs during the COVID-19 pandemic in order to conduct objective sleep testing, which is required for some of our clinical trials. In addition, we rely on contract research organizations (&#8220;CROs&#8221;) or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic. If the COVID-19 pandemic continues and persists for an extended period of time, or reemerges in the future, we could experience significant delays in our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Development and Other Financial Impacts</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of domestic and global financial markets. If the disruption persists and/or worsens, we may be unable to access additional capital, which could negatively affect our ability to execute on certain corporate development transactions or other important investment opportunities. The pandemic could also impact our ability to conduct in-person due diligence, negotiations, and other interactions to identify new opportunities.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>The COVID-19 pandemic has also affected, and continues to affect, our business operations and financial results. The extent of the impact of the COVID-19 pandemic on our ability to generate sales of, and revenues from, our approved products, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of or reemergence of outbreaks, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental travel restrictions, quarantines, social distancing and business closure requirements in the United States, France, and other countries, and the effectiveness of actions taken globally to contain and treat COVID-19.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Responsibility Impact</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to provide support to our local communities, patient-focused organizations and other charitable organizations during the COVID-19 pandemic with relief efforts, including corporate donations, supplying food, medical supplies and other resources.&nbsp;&nbsp;For the safety and well-being of our employees, consultants and their families, during the COVID-19 pandemic, we have abided by government-issued work from home orders.&nbsp;&nbsp;We continue to clean and sanitize our offices on a regular basis and have implemented COVID-19 screening procedures and social distancing guidelines before allowing employees or guests to enter our offices. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Narcolepsy Market Overview </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Narcolepsy is a rare, chronic and debilitating neurological disorder of sleep-wake state instability that is estimated to affect approximately 165,000 Americans, with fewer than 50% diagnosed. Narcolepsy is characterized by EDS, which is present in all patients with narcolepsy and is the primary reason why patients seek treatment. EDS is the inability to stay awake or alert throughout the day, including an irrepressible need for sleep, with lapses into drowsiness or sleep, which has a significant impact on a patient&#8217;s ability to function. Additional symptoms of narcolepsy may include cataplexy (which is characterized by sudden and transient episodes of muscle weakness accompanied by full conscious awareness), hallucinations, sleep paralysis and disrupted nighttime sleep. In most patients, narcolepsy is caused by the loss of hypocretin, a neuropeptide in the brain that, along with histamine, works to support sleep-wake state stability. This disorder affects men and women equally, with typical symptom onset in adolescence or young adulthood; however, it can take up to a decade after onset of symptoms to be properly diagnosed. The U.S. narcolepsy market had an approximate net sales value of $2.1&#160;billion in 2020. The market is expected to continue to grow based on several factors, including, but not limited to, the introduction of new innovative therapies that offer novel mechanisms of action resulting in improved safety/tolerability profiles while delivering clinically meaningful efficacy, additional investment in education, increased rates of diagnosis, and population growth. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the FDA&#8217;s approval of WAKIX in 2019, there were six approved medications to treat patients with narcolepsy, all of which are scheduled as controlled substances, and no new therapies had been approved for narcolepsy patients in the United States since 2007. These medications include Xyrem (sodium oxybate), Provigil (modafinil), Nuvigil (armodafinil), Ritalin (methylphenidate), Adderall (amphetamine salts) and Sunosi (solriamfetol). Following the approval of WAKIX, in July 2020 the FDA approved a new lower sodium formulation of Xyrem (Xywav). These approved drugs are prescribed in accordance with their individual labels for indications covering narcolepsy, cataplexy and/or EDS related to narcolepsy, and have demonstrated the ability to improve the lives of the patients suffering from these symptoms. Other prescription drugs are used off-label for the treatment of either EDS or cataplexy in patients with narcolepsy, including stimulants for EDS and antidepressants for cataplexy. Despite the benefits provided by the available medications, according to the American Academy of Sleep Medicine (&#8220;AASM&#8221;), traditional stimulants, wake-promoting agents and sodium oxybate, at best, provide only moderate improvement in narcolepsy symptoms and side effects may limit their use. Some of the current therapies have significant side effects (such as increased heart rate and blood pressure) and boxed warnings due to the risk of respiratory depression, abuse and dependence. These therapies also have the potential for rebound and withdrawal symptoms. The Voice of the Patient report from the FDA&#8217;s patient-focused drug development initiative, published in 2014, concluded that, based on the overall benefit-risk assessment of current medications, there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy. In a retrospective electronic chart review conducted by Rush University Medical Center from June 2011 to December 2018, over 75% (73 out of 97 respondents) of patients with narcolepsy reported at least one residual symptom while on their current treatment. In a third party survey that we commissioned prior to the commercialization of WAKIX, of the 200 patients with narcolepsy who were surveyed, 86% (173 out of 200 respondents) of patients reported narcolepsy is a life changing disorder and 93% (157 out of 169 respondents) expressed frustration with current treatment options, while 31 patients were not on treatment and, as such, did not provide a response to this question. The main drivers of patients&#8217; dissatisfaction were side effects and tolerability, loss of efficacy over time and concerns about abuse and dependence with current therapies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In market research sponsored by us prior to the commercial release of WAKIX, both patients and healthcare professionals (&#8220;HCPs&#8221;) expressed frustration and dissatisfaction with then-existing therapies, reflecting current unmet medical needs. These unmet needs included, in order of importance, the availability of: (i)&#160;non-scheduled treatment options, (ii)&#160;more tolerable treatment regimens, (iii)&#160;more effective treatment options, (iv)&#160;novel MOAs beyond currently available therapies and (v)&#160;once-daily treatment options. Based on our market research, we believe the most significant unmet need identified was the availability of non-scheduled treatment options. Other than WAKIX, all drugs approved by the FDA for the treatment of narcolepsy, including stimulants, are scheduled as controlled substances by the DEA. Controlled substances have the potential for abuse, misuse, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diversion. In addition, these products also have the potential for the development of tolerance and withdrawal symptoms. Despite their inherent drawbacks, due to the limited number of treatment options, stimulants have historically been a primary treatment for people with narcolepsy. In addition to having the potential for abuse, all of the treatments approved for narcolepsy, except WAKIX, require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) program, which is required by the FDA for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Solution </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WAKIX (pitolisant) represents a novel approach to narcolepsy treatment. We believe that WAKIX offers a meaningfully differentiated product profile over current treatment options for the following reasons: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">First-in-class molecule with a novel MOA</font>. WAKIX is the only selective H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor antagonist/inverse agonist approved by the FDA. It is approved for the treatment of EDS or cataplexy in adult patients with narcolepsy and is the only narcolepsy treatment that works primarily through histamine, a major wake-promoting neurotransmitter. Pitolisant is thought to work by regulating histamine, such that it activates wake-promoting neurons and inhibits sleep promoting neurons, which helps to stabilize states of sleep and wakefulness. We believe that these novel characteristics differentiate it from other narcolepsy treatments. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">First-and-only non-scheduled treatment for narcolepsy</font>. WAKIX is the first-and-only FDA-approved treatment for narcolepsy that is not scheduled as a controlled substance by the DEA. We believe one of the most significant unmet needs is the availability of non-scheduled treatment options. In a clinical trial, pitolisant demonstrated statistically significantly lower drug liking compared to phentermine (a Schedule IV stimulant), consistent with its lack of abuse potential. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">WAKIX is not a stimulant</font>. Stimulants are one of the most commonly prescribed treatments for patients with narcolepsy. Unlike stimulants, in clinical trials, WAKIX has shown no evidence for the development of drug tolerance or withdrawal symptoms. Therefore, there is no need for patients to temporarily stop the medication to reset efficacy. In addition, unlike stimulants, WAKIX does not increase dopamine levels in the brain&#8217;s reward center, which contributes to its lack of abuse potential. According to the National Sleep Foundation, stimulants have the potential for abuse, so their use must be considered carefully by patients and HCPs. WAKIX gives patients and HCPs a different therapeutic option. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">WAKIX can be used as monotherapy or administered concomitantly with other narcolepsy treatments</font>. Narcolepsy is a difficult disorder to manage and the majority of narcolepsy patients often require multiple medications to treat their symptoms. WAKIX was studied in combination with each of modafinil and sodium oxybate (two common treatments for narcolepsy) and demonstrated no effect on the pharmacokinetic (&#8220;PK&#8221;) profile of either treatment, and neither treatment had a clinically relevant effect on the PK profile of WAKIX. We believe the ability of WAKIX to be taken as monotherapy or concomitantly with other narcolepsy medications affords HCPs the flexibility to better manage their patients with narcolepsy. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">WAKIX is a once-daily oral tablet administered in the morning upon wakening</font>. Patients have identified a need for treatment options that are easier to take and are dosed less frequently. We believe that once-daily dosing with WAKIX addresses this need and may help improve patient compliance with treatment.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to become a leading pharmaceutical company dedicated to developing and commercializing novel treatment options for patients living with rare neurological disorders who have unmet medical needs, beginning with a focus on narcolepsy. The key elements of our strategy are</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outlined</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in our three pillars of growth</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pillar I: Optimize the Commercialization of WAKIX in Adult Patients with Narcolepsy</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Commercialize WAKIX in the United States</font>. We have assembled a team of approximately 150 professionals that possess comprehensive life sciences experience. We have also established a robust company infrastructure to execute on our core business and growth strategies. This team includes over 70 dedicated and experienced sales professionals who call on the approximately 8,000 HCPs who treat approximately 90% of narcolepsy patients in the United States. In November 2019, we launched commercial sales of WAKIX in the United States. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pillar II: Expand the Clinical Utility of WAKIX</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Expand WAKIX Label in Narcolepsy</font>. Building upon the EDS and cataplexy indications in adult patients with narcolepsy, we expect to initiate a Phase 3 clinical trial in pediatric narcolepsy patients in the second half of 2021 with the goal of gaining a pediatric indication for both EDS and cataplexy. We also plan to engage with the FDA to pursue pediatric exclusivity.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Pursue New Indications Beyond Narcolepsy</font>. We believe that pitolisant&#8217;s novel MOA offers a <font style="font-style:italic;">portfolio in a product</font> opportunity and has therapeutic potential in several other patient populations with rare neurological disorders. We submitted an IND for PWS in October 2019 and received acknowledgement from the FDA that the proposed clinical investigation may proceed. We subsequently completed a Phase 1 PK clinical trial in pediatric patients with PWS in the fourth quarter of 2019, and initiated a long-term, open-label safety trial in these patients. In December 2020, we initiated a Phase 2 clinical trial to evaluate pitolisant for the treatment of EDS and other key symptoms in patients with PWS, including behavioral symptoms and cognitive impairment. Topline results from this clinical trial are expected in the first half of 2022. For patients with DM, we are planning to evaluate pitolisant for the treatment of EDS and other key symptoms, including fatigue and cognitive impairment. We submitted an IND for DM at the end of 2020 and the IND opened in January 2021, after which we received a &#8220;Study May Proceed&#8221; letter from the FDA in February 2021. We plan to initiate a Phase 2 clinical trial in patients with DM1 during the first half of 2021 and anticipate topline results in the second half of 2022. We also plan to explore pitolisant&#8217;s potential as a treatment for EDS and related symptoms in other rare neurological disorders, potentially including those in which fatigue and cognitive impairment are prominent symptoms with significant impact on daily functioning. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pillar III: Acquire New Assets to Expand our Product Portfolio</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Explore Expansion of our Product Portfolio</font>. As we continue our commercial growth and the advancement of our clinical development programs with pitolisant, a key component of our strategy will be to expand our product portfolio beyond pitolisant by partnering, co-developing or acquiring assets focused on rare neurological disorders and/or other disorders with unmet medical needs that are complementary to our existing research and development expertise and/or commercial footprint.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our History </font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating subsidiary, Harmony Biosciences, LLC, was formed in May 2017. We were formed in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company, and we converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017. In February 2020, we changed our name to Harmony Biosciences Holdings, Inc. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have raised approximately $493&#160;million in equity financing.  We have assembled an experienced leadership team with a track record of developing and commercializing products to treat rare neurological disorders. We believe that the clinical development, regulatory, commercial, and operational expertise of our executive and senior leadership team will be essential as we execute on our strategy of becoming a leading pharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare neurological disorders while delivering significant value to both patients and shareholders. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Overview of Development Pipeline </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Label Expansion </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While all patients with narcolepsy have the primary symptom of EDS, for which WAKIX was originally approved in adult patients, it is estimated that 60% to 70% of those diagnosed with narcolepsy and treated also experience cataplexy, representing approximately 25,000 to 30,000 patients in the United States. On October 13, 2020, we received regulatory approval for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. We believe that the additional indication for cataplexy in adult patients strengthens the product profile of WAKIX and helps to facilitate access to WAKIX for adult patients suffering from both EDS and cataplexy associated with narcolepsy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are actively working on our goal of label expansion for WAKIX in narcolepsy by pursuing an indication for pediatric patients suffering from narcolepsy. Approximately 3,600 of the diagnosed narcolepsy patients in the United States are 19 years of age or under. We believe that pediatric patients could benefit from new treatment options. Accordingly, we currently expect to initiate a Phase 3 clinical trial in the second half of 2021 for indications of both EDS and cataplexy in pediatric patients. Topline results from this clinical trial are expected in the first half of 2023. We also intend to submit a Pediatric Written Request to the FDA with the goal of obtaining pediatric exclusivity. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Additional Indications </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that pitolisant&#8217;s ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological disorders that are mediated through the H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor and histamine signaling and offers a <font style="font-style:italic;">portfolio in a product</font> opportunity with pitolisant. We plan to explore the potential benefit of pitolisant in additional rare neurological indications beyond narcolepsy, initially focusing on the treatment of EDS associated with PWS and DM. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PWS is a rare genetic disorder caused by a loss of function of specific genes on chromosome 15 resulting in hypothalamic dysfunction. The hypothalamus controls both sleep-wake states and hunger-satiety. Therefore, two of the main symptoms in patients with PWS are EDS and insatiable hunger, or hyperphagia. Other consequences of PWS include low muscle tone, short stature, behavioral problems and cognitive impairment. It is estimated that approximately 15,000 to 20,000 people in the United States suffer from PWS, and over half of those suffering from PWS also have reported or experienced EDS, for which there are no FDA-approved treatments. We completed a Phase 1 PK clinical trial in the United States in pediatric patients with PWS in the fourth quarter of 2019, and initiated a long-term, open-label safety study in these patients. In December 2020, we initiated a Phase 2 clinical trial in patients with PWS and anticipate topline results from this clinical trial in the first half of 2022. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DM is a rare, multi-system genetic disease that affects the neuromuscular system as well as several other systems</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for which there are no FDA-approved treatments</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. It is inherited in an autosomal dominant pattern and there are two main types: type 1 (&#8220;DM1&#8221;) and type 2 (&#8220;DM2&#8221;). The underlying cause of DM1 is a mutation in the myotonic dystrophy protein kinase (&#8220;DMPK&#8221;) gene on chromosome 19. DM1 is the most common form of adult-onset muscular dystrophy and affects as many as 140,000 patients in the United States. EDS and fatigue are hallmark clinical characteristics in the majority of patients with DM1 and are referred to as the most frequent non-muscular symptoms in patients with DM1. Cognitive impairment is also a prominent symptom in patients with DM1 and all of these symptoms are thought to be mediated through H</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">3</sub></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> receptors and histaminergic pathways located throughout the central nervous system (&#8220;CNS&#8221;). DM2 is not as common as DM1 with an estimated prevalence of between 3,000 and 29,000&#160;patients in the United States. The underlying cause of DM2 is a mutation in the CCHC-Type Zinc Finger Nucleic Acid Binding Protein (&#8220;CBNP&#8221;) gene on chromosome 3. Patients with DM1 and DM2 share similar phenotypes but disease onset is later in patients with DM2 and symptoms tend to be milder. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We submitted an IND for DM at the end of 2020 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the IND opened in January 2021, after which we received a &#8220;Study May Proceed&#8221; letter from the FDA in February 2021. We </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plan to initiate a Phase 2 clinical trial in patients with DM1 during the first half of 2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and anticipate t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opline results from this clinical trial in the second half of 2022. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Development Pipeline Chart</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000001.jpg" title="" alt="" style="width:624px;height:330px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond the target indications listed above, we believe there are opportunities related to CNS disorders of hypersomnolence that we may pursue. We also intend to further explore pitolisant in other rare neurological disorders, potentially in those in which fatigue and cognitive impairment are prominent symptoms with significant impact on daily functioning. As we conduct our new clinical programs, we will generate new data and gain new insights that will help inform our development strategy in pursuit of additional indications in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our Commercialization Strategy </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We launched WAKIX into the narcolepsy market in November 2019 and are engaging with HCPs, patients and payors through the focused commercialization strategy outlined below to optimize adoption of WAKIX in the marketplace: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">HCP Awareness and Adoption</font>: To facilitate HCP awareness and adoption of WAKIX, we have deployed our dedicated, in-house, over 70-person sales team to educate a defined prescriber base of approximately 8,000 HCPs comprised of neurologists, pulmonologists, sleep specialists, psychiatrists and high-prescribing primary care physicians who specialize in or focus on sleep disorders. We believe these HCPs diagnose and treat approximately 90% of the narcolepsy patients in the United States. We began our commercial HCP outreach in August 2019 following FDA approval of WAKIX for the treatment of EDS in adult patients with narcolepsy and our efforts continue following the approval of the cataplexy indication in October 2020. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Patient Awareness</font>: It is estimated that narcolepsy affects approximately 165,000 Americans with fewer than 50% diagnosed. Of those living with narcolepsy in the United States, it is estimated that fewer than 45,000 are on narcolepsy medications, which we believe indicates a significant unmet medical need. To drive patient awareness of WAKIX and its differentiated product profile, we have been communicating with the narcolepsy patient community and providing them with educational materials and information on WAKIX. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Payor Coverage: </font>Recognizing the importance of payor coverage, our field market access team has been engaging with national and regional payors over the past two plus years to educate them on the clinical data and value proposition of WAKIX. Through December 31, 2020, we have secured formulary access for approximately 80% of all insured lives (Commercial, Medicare and Medicaid) in the United States. Within these covered lives, we have observed favorable access to WAKIX subsequent to the expanded approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy in October 2020.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the differentiating attributes of WAKIX that have facilitated and will continue to facilitate awareness, adoption, and coverage include: (i)&#160;it is a first-in-class molecule with a novel MOA, (ii)&#160;it is the first-and-only non-scheduled treatment approved for EDS or cataplexy in adult patients with narcolepsy, (iii)&#160;it is not a stimulant, (iv)&#160;it has broad clinical utility because it can be used as monotherapy or administered concomitantly with other narcolepsy treatments, and (v)&#160;it is a once-daily oral tablet administered in the morning upon wakening. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Development of WAKIX (pitolisant) </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strategy behind the clinical development of pitolisant is based on its MOA, which is thought to work by regulating histamine transmission. Pitolisant is a first-in-class molecule with a novel MOA, acting as a potent and highly selective antagonist/inverse agonist of the H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor. It activates histaminergic neurons in the brain, a neuronal system involved in the maintenance of wakefulness, attention, vigilance and cognition. Pitolisant binds to H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors on presynaptic neurons and blocks the normal negative feedback mechanism for histamine release, resulting in increased release of this wake-promoting neurotransmitter. It also functions as an inverse agonist, resulting in enhanced histamine synthesis and release from presynaptic neurons. Increased histamine available in the synapse binds to postsynaptic H<sub style="font-size:85%; vertical-align:bottom">1</sub> receptors, activating postsynaptic neurons, which stimulate wake-promoting brain regions and inhibit sleep-promoting regions of the brain. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">WAKIX&#174; (pitolisant) Mechanism of Action </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000002.jpg" title="" alt="" style="width:624px;height:376px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant also stimulates the release of other wake-promoting neurotransmitters (dopamine, norepinephrine, serotonin and acetylcholine) via H<sub style="font-size:85%; vertical-align:bottom">3</sub> heteroreceptors within those neuronal systems. Importantly, pitolisant does not increase dopamine levels in the striatum, including the nucleus accumbens, which is the brain&#8217;s reward center where an increase in dopamine levels is correlated with abuse potential. This feature of pitolisant&#8217;s MOA, along with primarily working through the histaminergic system, are two of the aspects that differentiate pitolisant from all other currently approved treatments for narcolepsy. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The safety profile of pitolisant is based on pooled safety data from 22 Phase 2 or Phase 3 clinical trials conducted by Bioprojet, eight of which were in patients with narcolepsy and 14 of which were in other indications. These trials included 1,513 unique patients, of whom 1,043 received pitolisant in double-blind placebo-controlled studies, and others received pitolisant in single-blind or open-label trials. Three successful pivotal trials in narcolepsy, HARMONY 1, HARMONY 1bis, and HARMONY CTP, were completed in Europe by Bioprojet and served as the foundation for the approval of pitolisant by the EMA in 2016 for the treatment of narcolepsy in adults with or without cataplexy. Pitolisant was evaluated in a long-term safety and tolerability trial, HARMONY 3, which further supported the results observed in HARMONY 1, HARMONY 1bis, and HARMONY CTP. The data from these trials were submitted, along with data from a human abuse potential (&#8220;HAP&#8221;) trial, to the FDA as part of the NDA for WAKIX (pitolisant), which the FDA approved on August&#160;14, 2019 for the treatment of EDS in adult patients with narcolepsy and on October 13, 2020 for the treatment of cataplexy in adult patients with narcolepsy. The table below provides an overview of the trial designs from these five clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.79%;">
<tr>
<td style="width:27.18%;"></td>
<td style="width:10.68%;"></td>
<td style="width:16.56%;"></td>
<td style="width:17.43%;"></td>
<td style="width:27.94%;"></td>
</tr>
<tr style="height:53.9pt;">
<td valign="top"  BGCOLOR="#538135" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name of Study</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Study Design</p></td>
<td valign="top"  BGCOLOR="#538135" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Patients</p></td>
<td valign="top"  BGCOLOR="#538135" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maximum Dose;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">% at that Dose</p></td>
<td valign="top"  BGCOLOR="#538135" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Primary Objective</p></td>
<td valign="top"  BGCOLOR="#538135" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results</p></td>
</tr>
<tr style="height:73.35pt;">
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 3pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Randomized, double-blind, placebo and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active control; patients with narcolepsy &#177;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cataplexy; 8 weeks of treatment</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 3pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N = 95</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 3pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.6 mg;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61%</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 3pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assess change in Epworth Sleepiness Scale (&#8220;ESS&#8221;) score from baseline to final visit</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 3pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-6.0 for WAKIX compared to -2.9 for placebo </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(treatment effect -3.1; p=0.022)</p></td>
</tr>
<tr style="height:74.95pt;">
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY 1bis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Randomized, double-blind, placebo and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active control; patients with narcolepsy &#177;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cataplexy; 8 weeks of treatment</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N = 166</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.8 mg</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76%</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assess change in ESS score from baseline to final visit</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5.0 for WAKIX compared to -2.8 for placebo </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(treatment effect -2.2; p=0.030)</p></td>
</tr>
<tr style="height:69.2pt;">
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY CTP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Randomized, double-blind, placebo control; patients with narcolepsy and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cataplexy; 7 weeks of treatment</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N = 106</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.6 mg</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assess change in Weekly Rate of Cataplexy (&#8220;WRC&#8221;)</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WRC decreased 75% for WAKIX compared to 38% for placebo </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(rate ratio 0.51; p&lt;0.0001)</p></td>
</tr>
<tr style="height:39.45pt;">
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term, open-label, real-world trial; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8805;1 year</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N = 104</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.6 mg</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88%</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term safety</p></td>
<td valign="top"  BGCOLOR="#E9EDE8" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety/tolerability profile consistent with that seen in the RCTs</p></td>
</tr>
<tr style="height:74.95pt;">
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Human Abuse Potential Study</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Randomized, double-blind, active &amp; placebo-controlled, 4-way crossover study</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N = 43</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.6 mg &amp; 213.6 mg;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phentermine 60 mg </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(active control)</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assess drug liking</p></td>
<td valign="top"  BGCOLOR="#D1D8CE" style="padding-left:7.2pt;padding-Right:7.2pt;padding-Top:3.6pt;padding-Bottom:3.6pt; border-top:solid 1pt #FFFFFF; border-bottom:solid 1pt #FFFFFF; border-left:solid 1pt #FFFFFF; border-right:solid 1pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WAKIX demonstrated a statistically significant and clinically relevant reduction in drug liking (p&lt;0.0001)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trial Highlights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key findings from these clinical trials are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pitolisant showed a statistically significant improvement in EDS in adult patients with narcolepsy. In HARMONY 1, the ESS score change from baseline to final visit was -6.0 for pitolisant compared to -2.9 for placebo (treatment effect -3.1; p=0.022).&nbsp;&nbsp;In HARMONY 1bis, the ESS score change from baseline to final visit was -5.0 for pitolisant compared to -2.8 for placebo (treatment effect -2.2; p=0.030). These findings were supported by statistically significant improvement on the Maintenance of Wakefulness Test (&#8220;MWT&#8221;).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>Pitolisant demonstrated a statistically significant reduction in measures of cataplexy in adult patients with narcolepsy. In HARMONY CTP, the reduction in the weekly rate of cataplexy in patients on pitolisant was </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75% compared to 38% in patients on placebo (rate ratio 0.51; 95% CI 0.44 &#8211; 0.60; p&lt;0.0001). This finding was supported by a significant reduction in cataplexy (a secondary endpoint) in the HARMONY 1 trial. However, the FDA initially stated that the cataplexy data from the HARMONY 1 trial in the NDA did not provide substantial evidence of effectiveness with respect to cataplexy because the statistical analysis plan did not prospectively control for Type 1 error of the secondary endpoints, and the subgroup of patients with cataplexy was not identified prospectively. As a result, the FDA issued a complete response letter (&#8220;CRL&#8221;) with respect to the cataplexy indication, and therefore did not originally approve WAKIX for the treatment of cataplexy in adult patients with narcolepsy. Subsequently, in June 2020, in response to our request for FDA to reconsider the cataplexy data from the HARMONY 1 trial, we received a general advice letter confirming that the cataplexy data from the HARMONY 1 clinical trial supported a statistically significant reduction in daily rate of cataplexy in the pitolisant group when compared with the placebo group. As a result, the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA recommended we submit a complete response resubmission in pursuit of the adult cataplexy indication for WAKIX. On October 13, 2020, we received regulatory approval for WAKIX for the treatment of cataplexy in adult patients with narcolepsy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pitolisant was generally well-tolerated in clinical trials. In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (occurring in <font style="text-decoration:underline;">&gt;</font>5% of patients and at twice the rate of placebo) with the use of pitolisant were insomnia (6%), nausea (6%), and anxiety (5%). In these trials, 6 of the 152 patients (3.9%) who received pitolisant and 4 of the 114 patients (3.5%) who received placebo discontinued because of an adverse event. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the HARMONY 3 trial, a favorable long-term safety/tolerability profile for pitolisant out to one year was demonstrated; safety findings were similar to those reported in the randomized controlled trials, with no new safety signals identified. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.5%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Times New Roman;">In this open-label, long-term real-world trial, improvement in EDS (as measured by a reduction in ESS scores) and reduction in cataplexy (as measured by reduction in mean daily cataplexy episodes) was maintained out to twelve months. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In a clinical HAP trial, pitolisant demonstrated statistically significant lower maximum drug liking (primary endpoint), overall drug liking, and willingness to take drug again compared to phentermine (C-IV), with responses similar to placebo. No evidence of abuse potential was demonstrated based on clinical and preclinical data, and WAKIX was therefore approved without being scheduled as a controlled substance by the DEA.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">HARMONY 1 </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Design </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HARMONY 1 was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of pitolisant in adult patients with narcolepsy on improvement in EDS over an eight-week period. The trial was conducted in the EU, and consequently was designed to include both a placebo arm and an active comparator, modafinil, which was used in doses up to 400 mg/day. HARMONY 1 consisted of 95 patients and had flexible dosing during the first three weeks of the trial, followed by five weeks of stable dosing. The maximum dose of pitolisant in this dose-to-effect trial was 35.6 mg and only 61% of the patients were titrated to this dose for the stable dosing period. Approximately 80% of the patients had a history of cataplexy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>The primary endpoint in the trial was the ESS score at final visit, adjusted for baseline, for pitolisant compared to placebo. ESS is a self-administered eight-item questionnaire scored 0 to 24 with lower scores corresponding to lower EDS. Secondary endpoints in HARMONY 1 included ESS responder rates, MWT (an objective measure of the ability to stay awake), the Sustained Attention to Response Task (&#8220;SART&#8221;) reduction in cataplexy, Clinical Global Impression of Change (&#8220;CGI-C&#8221;) for both EDS and cataplexy, the European Quality of Life Questionnaire (the &#8220;EQ-5D&#8221;), and the Patient&#8217;s Global Opinion on the Effect of Treatment Questionnaire. The main efficacy objective of the trial was to demonstrate superiority of pitolisant compared to placebo on the primary </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endpoint, while one of the secondary objectives was to explore the non-inferiority of pitolisant compared to modafinil on ESS score. It should be noted that there was no prospective plan to control for Type 1 error in this trial.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Efficacy Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant showed a significant reduction in the mean ESS score change from baseline to final visit at end of trial as compared to placebo (-6.0 versus -2.9, respectively) and between-group differences in ESS score were evident within the first two weeks of treatment. This resulted in a treatment effect (ESS score at final visit, adjusted for baseline, for pitolisant compared to placebo) of -3.1, which was statistically significant for pitolisant versus placebo (p=0.022). The change from baseline in ESS score for modafinil was -6.9 and, based on this score, pitolisant was not found to be non-inferior to modafinil (mean difference of 0.09, p=0.932) and the trial therefore did not meet this secondary efficacy objective. We believe there are several factors that contributed to this finding. First, 73% of the patients on modafinil in this trial were titrated up to a dose of 400 mg/day (the recommended dose of modafinil in the FDA-approved U.S. Prescribing Information (&#8220;USPI&#8221;) is 200 mg/day) while only 61% of the patients on pitolisant were titrated to the maximum pitolisant dose of 35.6 mg/day (which is the maximum approved dose in the USPI), such that a greater number of patients in the modafinil arm received the maximum effective dose than those in the pitolisant arm, raising the possibility that those subjects in the pitolisant arm could have seen greater treatment effect had they been dosed at the maximum dose available. Second, the margin of non-inferiority for the difference in the ESS scores pre-specified in the statistical analysis plan was narrow (2 points), meaning that the change in ESS score adjusted for baseline compared between pitolisant and modafinil&#160;had to have a lower 95% CI of no less than -2 points to declare pitolisant non-inferior to modafinil. The lower bound of the 95% CI of the analysis fell just outside this margin (-2.11). According to literature, however,&#160;a clinically relevant difference on the ESS ranges from 2&#8211;3 points, such that the non-inferiority margins pre-specified under the statistical analysis plan may have been too narrow. Ultimately, however, the trial results comparing pitolisant and modafinil did not impact the FDA&#8217;s findings that pitolisant was effective for improvement in EDS, and the FDA-approved label for WAKIX does not contain any data on modafinil. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in ESS Score Over Time </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000003.jpg" title="" alt="" style="width:605px;height:279px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Regarding the secondary endpoints, ESS responder rates (a responder was defined as having a final ESS score <font style="text-decoration:underline;">&lt;</font> 10) were significantly greater for those patients treated with pitolisant compared to those on placebo (45.2% vs. 13.3%, respectively; p=0.013). The responder rate for patients treated with modafinil was 45.5% and the difference compared to pitolisant was not statistically significant (p=0.892). On the MWT, pitolisant treatment improved performance when compared to placebo in a statistically significant manner (p=0.044), while improvement was not significantly different compared to modafinil (p=0.173). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Responders (Final ESS <font style="text-decoration:underline;font-weight:normal;">&lt;</font> 10)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000004.jpg" title="" alt="" style="width:281px;height:330px;"></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in MWT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000005.jpg" title="" alt="" style="width:293px;height:313px;"></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to other secondary endpoints, the overall pattern of response was that the findings for patients on both pitolisant and modafinil were superior to those on placebo while the responses were not significantly different for pitolisant compared to modafinil. The SART Total Score (a measure of attention) was significantly higher in the pitolisant group as compared to placebo (p=0.041), and while not significantly different from the modafinil group (p=0.363), the scores were similar (9.1 and 8.9 for pitolisant and modafinil, respectively). The CGI-C for EDS showed improvement in 56% of patients on placebo, 73% of patients on pitolisant, and 86% of patients on modafinil. Regarding the daily cataplexy rates endpoint, patients treated with pitolisant experienced a 62% reduction in the daily rate of cataplexy compared to a reduction of 8% in those on placebo and 25% in those on modafinil. Responses on the CGI-C for cataplexy were consistent with this outcome, with 29%, 45%, and 35% of patients who experienced cataplexy during the trial reporting an improvement in their cataplexy symptoms in the placebo, pitolisant, and modafinil groups, respectively. Lastly, the Patient&#8217;s Global Opinion on the Effect of Treatment Questionnaire recorded positive responses in 56% of patients in the placebo group, 81% of patients in the pitolisant group, and 86% of patients in the modafinil group. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Safety Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant was generally well tolerated in HARMONY 1. Sixty patients experienced a treatment emergent adverse event (&#8220;TEAE&#8221;) during the trial: 61% in the pitolisant group, 60% in the placebo group, and 70% in the modafinil group. The most commonly reported TEAE in the pitolisant treatment group was headache, reported by 35% of the patients, compared to 20% in the placebo group. Other frequently reported TEAEs in the pitolisant treatment group were insomnia, nausea and weight increase (each reported by two patients, or 6%). There were five serious adverse events during HARMONY 1 and none were considered treatment-related (two in the pitolisant group, two in the modafinil group, and one in the placebo group). There were no deaths during the trial and no significant changes in laboratory values or hemodynamic parameters (heart rate and blood pressure) from baseline to final visit in any group. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">HARMONY 1bis </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>HARMONY 1bis was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of pitolisant in adult patients with narcolepsy on improvement in EDS over an eight-week period. This trial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was designed in accordance with recommendations from European regulators, and as such, contained both a placebo and active comparator arm. The active comparator was modafinil used in doses up to 400 mg/day. HARMONY 1bis enrolled 165 patients and had flexible dosing during the first three weeks of the trial, followed by five weeks of stable dosing. The maximum dose of pitolisant in this dose-to-effect trial was 17.8 mg and only 76% of the patients were titrated to this dose for the stable dosing period. 75% of the patients had a history of cataplexy. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary endpoint in the trial was the ESS score at final visit, adjusted for baseline, for pitolisant compared to placebo. Secondary endpoints included ESS responder rates, MWT, SART, reduction in cataplexy, CGI-C for both EDS and cataplexy, the EQ-5D, and the Patient&#8217;s Global Opinion on the Effect of Treatment Questionnaire. The main efficacy objective of the trial was to demonstrate superiority of pitolisant compared to placebo on the primary endpoint, while one of the secondary objectives was to explore the non-inferiority of pitolisant compared to modafinil on ESS score. It should be noted that there was no prospective plan to control for Type 1 error in this trial.</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Efficacy Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant showed a significant reduction in the mean ESS score change from baseline to final visit as compared to placebo (-5.0 versus -2.8, respectively). This resulted in a treatment effect (ESS score at final visit, adjusted for baseline, for pitolisant compared to placebo) of -2.2 (p=0.030). The treatment effect between modafinil and pitolisant was -2.75 and, based on this score and the pre-specified statistical analysis plan, resulted in pitolisant not being non-inferior to modafinil. We believe the same factors that contributed to this result in HARMONY 1 also apply to HARMONY 1bis. In addition, in this trial, the maximum dose of pitolisant to which patients could be titrated (17.8 mg) was not the maximum labeled dose for pitolisant (which is 35.6 mg), and 24% of patients in this trial were on doses lower than 17.8 mg, which means that a substantial percentage of patients were on study drug at an amount less than the maximum approved dose in the USPI for pitolisant. In addition, modafinil was dosed up to 400 mg/day, while the recommended dose of modafinil in its USPI is 200 mg/day, which means that the respective doses of pitolisant and modafinil were not comparable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in Mean ESS Score </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000006.jpg" title="" alt="" style="width:606px;height:322px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>Regarding the secondary endpoints, ESS responder rates (a responder was defined as having a final ESS score <font style="text-decoration:underline;">&lt;</font> 10 or change in ESS score <font style="Background-color:#FFFFFF;color:#000000;font-family:'Times New Roman';font-size:15pt;line-height:11pt;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8805;</font></font> 3) were significantly greater for those patients treated with pitolisant compared to those on placebo (65% vs. 34%, respectively; p=0.001). The responder rate for patients treated with modafinil </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was 77% and the difference compared to pitolisant was not statistically significant (p=0.086). On the MWT, pitolisant treatment significantly improved performance when compared to placebo (p=0.022), while improvement was not significantly different compared to modafinil (p=0.294). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Responders (Final ESS<font style="font-family:Arial;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-family:'Times New Roman';font-weight:normal;"><font style="font-size:9pt;font-family:'Times New Roman'">&#8804;</font><font style="font-size:9pt;font-family:'Times New Roman'"> </font></font>10 or Change in ESS<font style="font-family:Arial;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-family:'Times New Roman';font-weight:normal;"><font style="font-size:9pt;font-family:'Times New Roman'">&#8805;</font></font><font style="font-family:Arial;"> </font>3)</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change in MWT</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000007.jpg" title="" alt="" style="width:292px;height:181px;"></p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000008.jpg" title="" alt="" style="width:292px;height:176px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to other secondary endpoints, the overall pattern of response was that the findings for patients on both pitolisant and modafinil were superior to those on placebo while the responses were not significantly different for pitolisant and modafinil. The pitolisant group&#8217;s SART Total Score was significantly improved compared to placebo (p=0.043), while not significantly different compared to modafinil (p=0.407). The CGI-C for EDS showed improvement in 37% of patients on placebo, 72% of patients on pitolisant, and 78% of patients on modafinil. Responses on the CGI-C for cataplexy showed improvement for 60% of patients treated with pitolisant compared to 54% of patients on modafinil and 36% of patients on placebo. However, the difference in the reduction in the daily rate of cataplexy between pitolisant (0.32) and placebo (0.31) was not statistically significant (p=0.873). Lastly, the findings on both the EQ-5D and the Patient&#8217;s Global Opinion on the Effect of Treatment Questionnaire did not show any meaningful differences between the pitolisant and placebo treatment groups in the HARMONY 1bis trial. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Safety Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant was generally well tolerated in HARMONY 1bis. Seventy-seven patients experienced a TEAE during the trial: 49% in the pitolisant group, 36% in the placebo group, and 49% in the modafinil group. The most commonly reported TEAEs in the pitolisant treatment group were headache (13%), dizziness (6%), vomiting (4.5%), insomnia (4.5%), and decreased appetite (4.5%). There were no serious adverse events in the pitolisant group and there was one serious adverse event during HARMONY 1bis in the modafinil treatment group, which was not treatment-related. There were no deaths during the trial and no significant changes in laboratory values or hemodynamic parameters (heart rate and blood pressure) from baseline to final visit. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">HARMONY CTP </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Design </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HARMONY CTP was a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of pitolisant on the reduction in cataplexy in adult patients with narcolepsy with frequent attacks of cataplexy over a seven-week period. HARMONY CTP consisted of 106 patients. The maximum dose of pitolisant in this dose-to-effect trial was 35.6 mg and only 65% of patients reached this dose during the stable dosing period. Both stimulants and wake-promoting agents were prohibited during the trial; only 11% of subjects were on stable doses of anti-cataplectic medications (7% in the pitolisant treatment group and 16% in patients on placebo). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>The primary endpoint in HARMONY CTP was the change in the weekly rate of cataplexy (&#8220;WRC&#8221;) from baseline to the stable dosing period (Weeks 4&#8211;7) expressed as the rate ratio (change in the pitolisant group/change in the placebo group). Secondary endpoints included proportion of patients with high cataplexy rate (WRC &gt;15), CGI-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C for cataplexy and EDS, mean change in ESS score and percentage of ESS responders, MWT, the EQ-5D, number of days with hallucinations (as recorded in the patient diaries), and Patient&#8217;s Global Opinion on the Effect of Treatmen</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t Questionnaire. It should be noted that there was no prospective plan to control for Type 1 error in this trial</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Efficacy Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In HARMONY CTP, pitolisant resulted in a significantly greater reduction than placebo in the WRC from baseline to the stable dosing period (Weeks 4&#8211;7), with a 75% reduction in the pitolisant group compared to a 38% reduction in the placebo group (rate ratio 0.51; 95% CI (0.44, 0.60; p&lt;0.0001). Further, significantly fewer patients had WRC &gt;15 at endpoint with pitolisant (6%) versus placebo (24%) (p=0.005). The clinical relevance of these findings was captured by the CGI-C related to cataplexy. Mean CGI-C score was 3.5&#177;1.1 with placebo versus 2.6&#177;1.1 with pitolisant. The mean reduction of the CGI-C score for pitolisant compared with placebo was -0.95 (95% CI (-1.36, -0.54); p&lt;0.0001). Overall positive response rates on the CGI-C related to cataplexy were 67% on pitolisant and 33% on placebo. </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Percent Reduction in WRC</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reduction in WRC Over Time</p></td>
</tr>
<tr>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000009.jpg" title="" alt="" style="width:276px;height:346px;"></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000010.jpg" title="" alt="" style="width:290px;height:355px;"></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to other secondary endpoints, pitolisant demonstrated a statistically significant reduction in mean ESS score from baseline to final visit at week seven as compared to placebo (-5.4&#160;vs. -1.9; p=0.0001) and significantly higher ESS responder rates compared to placebo (p=0.035 for Type 1 ESS responders rate and p=0.002 for Type 2 ESS responders rate; see graph below). On the CGI-C related to EDS, the mean score was 3.7 with placebo versus 2.6 with pitolisant, with a mean reduction of -0.99 (p&lt;0.0001). Overall positive response rates on the CGI-C related to EDS were 69% on pitolisant and 24% on placebo. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in ESS Score Over Time</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000011.jpg" title="" alt="" style="width:295px;height:344px;"></p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ESS Responder Rate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000012.jpg" title="" alt="" style="width:287px;height:332px;"></p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the remainder of the secondary endpoints, pitolisant showed a statistically significant improvement on the MWT from baseline to end of trial compared to placebo. Baseline geometric means on the MWT were 4.3 minutes and 3.7 minutes for placebo and pitolisant, respectively, with final MWT values of 4.6 minutes and 7.1 minutes for placebo and pitolisant, respectively; the improvement in MWT was 78% higher with pitolisant compared to placebo (p=0.003). On the Patient&#8217;s Global Opinion on the Effect of Treatment Questionnaire, overall improvement was reported in 54% of patients on pitolisant and 26% of patients on placebo (p=0.001). </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Safety Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant was generally well tolerated in HARMONY CTP. Thirty-five patients experienced a TEAE during the trial: 35% in the pitolisant group and 31% in the placebo group. The most commonly reported AE in the pitolisant group in HARMONY CTP was headache, which 9% of the group reported, compared to 10% in the placebo group. Other frequently reported AEs in the pitolisant group were irritability, anxiety and nausea (each reported by 3 patients, or 6%). There were no deaths or serious adverse events during HARMONY CTP and no significant changes in laboratory values or hemodynamic parameters (heart rate and blood pressure) from baseline to final trial visit in either group. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">HARMONY 3 </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Design </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HARMONY 3 was an open-label, real-world trial to assess the long-term safety and tolerability of pitolisant in the treatment of EDS in adult patients with narcolepsy, with or without cataplexy, over a one-year period (with a 5-year extension at the trial sites in France). HARMONY 3 enrolled 104 patients, 102 of whom were treated with pitolisant, and 68 completed out to one year. In HARMONY 3,&#160;75% of patients had a history of cataplexy and 76% of patients who completed out to one year were on the maximum dose of pitolisant of 35.6 mg. For the 5-year extension phase at the trial sites in France, 50 patients were eligible to continue, of which 48 patients elected to do so and 32 of them were maintained on pitolisant out to 5 years or until the study ended. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Efficacy Results </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the 68 patients with data at baseline and at 12 months in HARMONY 3, pitolisant reduced the mean ESS score by -4.63 over this period. The magnitude of the decrease in ESS score was larger in the subgroup of patients (n=86) who were not on pitolisant at trial entry (-5.25) as compared to the subgroup of patients (n=16) who came into the trial on pitolisant from the French Compassionate Use Program&#160;(-2.63).</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ESS Score Over Time </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000013.jpg" title="" alt="" style="width:606px;height:385px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In HARMONY 3, pitolisant also demonstrated a reduction in cataplexy and other symptoms of REM intrusion into wakefulness from baseline to month 12, showing a reduction of 65% to 76% in partial or total cataplexy attacks, respectively, out to one year. Reductions of more than 50% were also seen for other symptoms of REM dysfunction, such as hallucinations and sleep paralysis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reduction in Cataplexy and Other Symptoms of REM </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dysfunction </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">with Pitolisant </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000014.jpg" title="" alt="" style="width:604px;height:385px;"></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Safety Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant was generally well tolerated in HARMONY 3. AEs observed with long-term pitolisant treatment were consistent with those observed in short-term randomized, controlled trials such as HARMONY 1, HARMONY 1bis, and HARMONY CTP. Fifty-eight of the 102&#160;treated patients (57%) reported an aggregate of 168&#160;TEAEs in HARMONY 3, the most common of which are shown in the table below. During the one-year trial, there were no deaths and seven patients reported 10 serious adverse events, nine of which were deemed by the investigator to be unrelated to pitolisant, and one miscarriage which was considered possibly related. No clinically significant changes in laboratory parameters, vital signs or electrocardiogram parameters were recorded over the course of the one year trial. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Adverse Events</p>
<p style="margin-bottom:1pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Incidence <font style="font-family:Arial;"> </font><font style="Background-color:#FFFFFF;color:#000000;font-size:8pt;font-family:'Times New Roman';font-weight:normal;"><font style="font-size:8pt;font-family:'Times New Roman'">&#8805;</font><font style="font-size:8pt;font-family:'Times New Roman'"> </font></font>3%), n (%)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total&#160;Population<font style="font-weight:normal;"><br /></font>(N=102)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any adverse event</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58&#160;(56.9)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headache</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12&#160;(11.8)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insomnia</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9&#160;(8.8)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weight increased</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8&#160;(7.8)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anxiety</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7&#160;(6.9)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depression</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5&#160;(4.9)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nausea</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5&#160;(4.9)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Irritability</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#160;(3.9)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vomiting</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;Background-color:#CCEEFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#160;(3.9)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vertigo</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#160;(3.9)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical HAP Trial </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Design </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A clinical HAP trial was conducted to evaluate the human abuse potential of pitolisant. In this trial, nondependent, recreational stimulant users able to distinguish phentermine hydrochloride (HCl; 60&#160;mg), a CIV stimulant, from placebo in a drug discrimination test were randomized in a 4-period, double-blind, crossover design to receive single doses of pitolisant 35.6 mg (therapeutic dose), pitolisant 213.6&#160;mg (supra-therapeutic dose), phentermine HCl 60 mg, and placebo. The primary endpoint was maximum effect (Emax) on the 100-point Drug Liking (at the moment) visual analog scale. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 43 subjects were enrolled and 38 completed the trial. Mean Drug Liking Emax was significantly greater for phentermine (78.7) versus pitolisant 35.6 mg (57.3; p&lt;0.0001) and pitolisant 213.6 mg (59.0; p&lt;0.0001). Drug Liking Emax was similar for pitolisant (both doses) and placebo (56.1) (p&lt;0.001 for 35.6 mg versus placebo, and p=0.003 for 213.6 mg versus placebo). </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maximum Drug Liking</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000015.jpg" title="" alt="" style="width:604px;height:316px;"></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, for key secondary measures of Overall Drug Liking and willingness to Take Drug Again, mean Emax scores were significantly greater for phentermine (77.4 for Overall Drug Liking and 78.7 for Take Drug Again) versus pitolisant 213.6 mg (49.3 and 44.5) and 35.6 mg (52.7 and 49.4) ( <font style="font-style:italic;">p </font>&lt; 0.0001 for each comparison for both doses of pitolisant compared to phentermine). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overall Drug Liking </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000016.jpg" title="" alt="" style="width:604px;height:325px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Take Drug Again </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000017.jpg" title="" alt="" style="width:604px;height:339px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, in the clinical HAP trial, pitolisant demonstrated a statistically significant and clinically relevant reduction in drug liking compared to phentermine as well as an overall response profile similar to placebo. Based on these clinical data, along with data from preclinical abuse liability studies, the evidence pointed to a low risk of abuse for pitolisant, which supported the approval of WAKIX without being scheduled as a controlled substance by the DEA. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Hoc Analyses for Pitolisant </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62746659"></a>We conducted three post-hoc analyses from the database of the narcolepsy clinical trials for pitolisant, which focused on clinically relevant aspects of the product profile. The first analysis examined the time-to-onset of clinical response for pitolisant for improvement in both EDS and reduction in cataplexy based on data from 61 patients in the HARMONY 1 (pitolisant, n=31; placebo, n=30) and 105 patients in the HARMONY CTP (pitolisant, n=54; placebo, n=51) randomized, controlled clinical trials. Study medication was individually titrated to a potential maximum dose of pitolisant 35.6 mg/d and then remained stable; 61% of patients in HARMONY 1 and 65% in HARMONY CTP were titrated to the 35.6 mg dose.&nbsp;&nbsp;Efficacy assessments included the ESS and WRC or daily rate of cataplexy. Onset of clinical response was defined as the first timepoint at which there was a statistically significant difference between pitolisant and placebo. For time-to-response for EDS using the ESS, least-squares (&#8220;LS&#8221;) mean change from baseline was significantly greater for pitolisant compared with placebo beginning at Week 2 in HARMONY 1 and Week 3 in HARMONY CTP (when patients were first able to receive the 17.8 mg dose in each study) and continued through the end of treatment. More pitolisant-treated patients were classified as treatment responders (ESS reduction of &#8805; 3 points) at each post-baseline assessment than were patients in the placebo group. Pitolisant treatment resulted in a significantly greater proportion of responders versus placebo beginning at Week 3 in both studies.&nbsp;&nbsp;In HARMONY CTP, the frequency of cataplexy attacks was significantly reduced for pitolisant compared with placebo beginning at Week 2 and continued through the end of treatment. The percentage of cataplexy responders in HARMONY CTP was significantly greater with pitolisant versus placebo beginning at Week 1 for response defined as &#8805; 25% reduction in WRC and at Week 2 for response defined as &#8805; 50% reduction in WRC. There was no evidence of rebound cataplexy after a one-week placebo washout phase. In summary, the onset of clinical response was observed beginning at Week 2 (HARMONY 1) or Week 3 (HARMONY CTP) for mean change in ESS score and at Week 2 (HARMONY CTP) for mean change in WRC, with further improvements observed in pitolisant-treated patients through the end of treatment. The percentage of treatment responders was significantly greater with pitolisant versus placebo beginning at Week 3 for EDS (defined as ESS score reduction &#8805; 3) and at Week 2 for cataplexy (defined as &#8805; 50% reduction in WRC). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time-to-Onset of Response for EDS Based on ESS Scores in HARMONY 1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000018.jpg" title="" alt="" style="width:432px;height:326px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time-to-Onset of Response for EDS Based on ESS Responder Rate (ESS reduction of &#8805;3 points) in HARMONY 1 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font><img src="gym1fcavvjqs000019.jpg" title="" alt="" style="width:421px;height:295px;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time-to-Onset of Response for Cataplexy Based on WRC in HARMONY CTP&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gym1fcavvjqs000020.jpg" title="" alt="" style="width:479px;height:340px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time-to-Onset of Response for Cataplexy Based on WRC Reduction &#8805; 50% in HARMONY CTP</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><img src="gym1fcavvjqs000021.jpg" title="" alt="" style="width:477px;height:223px;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A second post-hoc analysis evaluated the efficacy of pitolisant in patients with narcolepsy who had a high symptom burden (both EDS and cataplexy) at baseline; this analysis was based on pooled data from both the HARMONY 1 and HARMONY CTP clinical trials, in which patients could be titrated up to a maximum dose of 35.6 mg/day. The analyses included three independent patient subgroups: baseline score of <font style="text-decoration:underline;">&#8805;</font>16 on the ESS, sleep latency of <font style="text-decoration:underline;">&lt;</font>8 minutes on MWT, and <font style="text-decoration:underline;">&#8805;</font>15 cataplexy attacks per week. The analysis populations included 118 patients for the ESS (pitolisant, n=60; placebo, n=58), 105 for the MWT (pitolisant, n=59; placebo, n=46), and 31 for cataplexy (pitolisant, n=20; placebo, n=11). LS mean change in ESS from baseline was significantly greater for pitolisant (-6.1) compared with placebo (-2.3; p&lt;0.001). A significantly greater percentage of pitolisant-treated patients were classified as treatment responders: for ESS score reduction <font style="text-decoration:underline;">&gt;</font>3, 69.0% in the pitolisant group versus 35.1% in the placebo group (p=0.001); for final ESS score <font style="text-decoration:underline;">&lt;</font>10, 36.2% versus 10.5%, respectively (p=0.005). Mean increase in sleep latency on the MWT was significantly greater for pitolisant (6.9 minutes) compared with placebo (3.4 minutes; p=0.017).&nbsp;&nbsp;In patients with a high burden of cataplexy, LS mean change in the WRC was significantly greater for pitolisant (&#8211;14.5) compared with placebo (&#8211;0.1; P = 0.004). On average, the frequency of cataplexy attacks was reduced by 60.6% in the pitolisant group and &lt;1% in the placebo group.<font style="font-style:italic;"> </font>Adverse events in the analysis populations were consistent with the known safety profile of pitolisant; headache was the most common adverse event in pitolisant-treated patients (10.0%&#8211;20.0%). These analyses demonstrated pitolisant resulted in significant improvement in patients who experience a high burden of the two most common symptoms in narcolepsy, EDS and cataplexy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High Burden of EDS: Reduction in ESS Scores</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000022.jpg" title="" alt="" style="width:418px;height:258px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High Burden of EDS: Treatment Responders Based on ESS Scores</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000023.jpg" title="" alt="" style="width:475px;height:322px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High Burden of Cataplexy: Reduction in WRC</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000024.jpg" title="" alt="" style="width:503px;height:340px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>In the third post-hoc analysis, we evaluated the cardiac safety events associated with pitolisant because cardiovascular diseases are comorbid conditions in patients with narcolepsy. Cardiovascular adverse effects are of concern with narcolepsy medications because of this comorbidity and most patients require lifelong pharmacotherapy for both narcolepsy and cardiovascular disorders. Data were obtained from a pooled analysis of the HARMONY 1 (8-week) and HARMONY CTP (7-week) clinical trials and from the 12-month, open-label </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HARMONY 3 trial. The pooled analysis included 166 patients (pitolisant, n=85; placebo, n=81). Mean change in heart rate from baseline to end-of-treatment was -0.5 beats/min with pitolisant and -0.2 beats/min with placebo (LS mean difference, -0.4; p=0.744). Mean change was also similar for pitolisant versus placebo in systolic (LS mean difference, 0.0; p=0.983) and diastolic (LS mean difference, -0.6; p=0.552) blood pressure, as was mean change in QTc interval (LS mean difference, 0.4; p=0.911). Cardiac adverse events with pitolisant included heart rate increase (n=4), right bundle branch block (n=1), sinus tachycardia (n=1), and palpitations (n=1), and with placebo included blood pressure increase (n=1). In the long-term study, mean change from baseline in QTc interval was 3.1 msec at Month 6 (n=70) and 6.1 msec at Month 12 (n=67); three patients had a post-baseline increase &gt;60 msec but none had QTc &gt;500 msec. Based on this analysis, no cardiac safety signals were observed during treatment with pitolisant administered up to the maximum dose of 35.6 mg and for up to one year. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Potential New Indications for Pitolisant </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are actively working on label expansion for WAKIX in narcolepsy, including indications for both EDS and cataplexy in pediatric patients. We also intend to work with the FDA toward gaining pediatric exclusivity for WAKIX. We believe that pitolisant&#8217;s ability to regulate histamine and histaminergic signaling gives it the potential to provide therapeutic benefit in other disorders that are mediated through the H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor and histamine signaling and offers a <font style="font-style:italic;">portfolio in a product</font> opportunity with pitolisant. Histamine plays an important role in normal physiologic functioning beyond wakefulness in the areas of attention, vigilance, behavior and cognition. The presence of H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors in the hypothalamus, brainstem and cerebral cortex account for different functions, which could provide an opportunity for pitolisant to treat symptoms other than EDS in different disorders. In addition, H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors are located mainly in the CNS as opposed to other parts of the body outside the CNS. This fact, along with pitolisant being highly selective for the H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor (as opposed to H<sub style="font-size:85%; vertical-align:bottom">1</sub> receptors, H<sub style="font-size:85%; vertical-align:bottom">2</sub> receptors and H<sub style="font-size:85%; vertical-align:bottom">4</sub> receptors), is the reason we believe in pitolisant&#8217;s unique MOA and its potential to improve symptoms in patients living with rare neurological disorders, in which impaired histamine signaling is part of the underlying pathophysiology. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:50pt;;text-indent:-20pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#8195;&#8194;&#8202;Role of histamine in normal physiologic functioning beyond wake promotion (e.g. attention, vigilance, behavior, cognition)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:50pt;;text-indent:-20pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#8195;&#8194;&#8202;Location of H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors in hypothalamus, brainstem, and cerebral cortex account for different functions (and potential symptoms in different disorders)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:50pt;;text-indent:-20pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#8195;&#8194;&#8202;Limited H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptor populations outside the CNS</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gym1fcavvjqs000025.jpg" title="" alt="" style="width:416px;height:288px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>Our initial plan is to seek new indications in patient populations that have symptom overlap with narcolepsy, such as EDS, while potentially pursuing opportunities in other CNS disorders of hypersomnolence. The initial clinical targets will focus on rare neurological disorders consistent with our overall strategy. We submitted an IND for PWS in October 2019 and received acknowledgement from the FDA that the proposed clinical investigation may proceed. We subsequently completed a Phase 1 PK clinical trial in pediatric patients with PWS in the fourth quarter of 2019, and initiated a long-term, open-label safety trial in these patients. In December 2020, we initiated a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 clinical trial to evaluate pitolisant for the treatment of EDS and other key symptoms in patients with PWS and anticipate topline results from this trial in the first half of 2022</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We submitted an IND for DM at the end of 2020 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the IND opened in January 2021, after which we received a &#8220;Study May Proceed&#8221; letter from the FDA in February 2021. We </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plan to initiate a Phase 2 clinical trial in patients with DM1 during the first half of 2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and anticipate t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opline results in the second half of 2022. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While conducting clinical programs to evaluate these indications, other clinical endpoints beyond EDS will be evaluated as secondary or exploratory endpoints, such as behavioral symptoms, vigilance, fatigue and cognition, to broaden the investigation of pitolisant with the hope of generating pilot data to help inform the next phase of our clinical development strategy. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Label Expansion in Narcolepsy </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cataplexy Indication </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NDA submission for WAKIX initially sought approval for the treatment of both EDS and cataplexy in adult patients with narcolepsy. Our application requesting approval for a cataplexy indication was based on the cataplexy results from HARMONY CTP and HARMONY 1. The FDA approved WAKIX for the treatment of EDS in adult patients with narcolepsy but issued a CRL for the cataplexy indication, . The FDA determined that, although we had submitted one positive clinical trial for cataplexy (HARMONY CTP), the NDA submission did not provide substantial evidence of effectiveness regarding cataplexy. The FDA therefore recommended that we conduct a second trial substantiating the results of HARMONY CTP in order to obtain approval for the cataplexy indication. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We attended a Type A post-CRL meeting with the FDA on December 12, 2019 to discuss the cataplexy indication, during which we pointed the FDA to additional analyses that were conducted in support of the HARMONY 1 cataplexy data and which were included in the NDA submission. Following additional interactions with the FDA, we received a general advice letter in June 2020 stating that the FDA had re-analyzed data from the HARMONY 1 clinical trial and confirmed that the cataplexy data from the HARMONY 1 clinical trial supported a statistically significant reduction in the daily rate of cataplexy in the pitolisant group when compared with the placebo group. As a result, the FDA recommended we submit a complete response resubmission in pursuit of the adult cataplexy indication for WAKIX, which we sent to the FDA in August 2020. On October 13, 2020 we received regulatory approval for WAKIX for the treatment of cataplexy in adult patients with narcolepsy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pediatric Narcolepsy </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 5% of diagnosed narcolepsy patients (approximately 3,600 patients) are 19 years of age or under. Symptoms often have a more profound effect in children, resulting in reduced function and greater psychological impact. Until the fourth quarter of 2018, no treatments were approved for pediatric patients with narcolepsy, at which time Xyrem received an expanded indication for the treatment of cataplexy or EDS in patients seven years of age or older with narcolepsy. Xywav (low sodium formulation of Xyrem) received the same indication in July 2020. We intend to engage with the FDA in pursuit of pediatric exclusivity and commence a Phase 3 trial in pediatric patients in the second half of 2021 in pursuit of pediatric indications for both EDS and cataplexy. Our current plan is to evaluate approximately 90 to 100 pediatric patients, ages six to up to 18, to assess the safety and efficacy of pitolisant in pediatric narcolepsy patients on improvement in both EDS and reduction in cataplexy. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Develop Pitolisant in New Patient Populations in Pursuit of Additional Indications </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prader-Willi Syndrome </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PWS is a rare genetic disorder caused by a loss of function of specific genes on chromosome 15 resulting in hypothalamic dysfunction and decreased levels of hypocretin in some patients with PWS. The hypothalamus controls both sleep-wake states and hunger-satiety; therefore, two of the main symptoms in patients with PWS are EDS and hyperphagia. Other features include low muscle tone, short stature, behavioral problems and cognitive impairment. It is estimated that approximately one in 15,000 to 20,000 people in the United States suffer from PWS, and over half of those suffering from PWS also have reported or experienced EDS. We submitted an IND for PWS in October 2019 and received acknowledgement from the FDA that the proposed clinical investigation may proceed. We subsequently completed a Phase 1 PK clinical trial in pediatric patients with PWS in the fourth quarter of 2019, and initiated a long-term, open-label safety trial in these patients. In December 2020, we initiated a Phase 2 clinical trial to evaluate pitolisant for the treatment of EDS and other key symptoms in patients with PWS and anticipate topline results from this trial in the first half of 2022. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PWS poses a heavy burden for both patients and caregivers and there are few therapeutic options available and no FDA-approved treatments for EDS in patients with PWS. C</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">linical</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> development programs </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in PWS have </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">focused on hyperphagia, with no other programs focusing on EDS or cognitive function. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EDS is thought to have a negative effect on behavior and cognitive function and could exacerbate these symptoms in patients with PWS.&nbsp;&nbsp;In addition, impaired histamine signaling in the brain can contribute to behavioral symptoms and impaired cognition. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe there is a compelling opportunity </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the mechanism of action of pitolisant</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to impact the EDS component of this disorder as well as other symptoms, such as behavioral issues and cognitive </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impairment</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have collaborated with the Foundation for Prader-Willi Research (the &#8220;FPWR&#8221;) to advance our clinical program and underscore our commitment to this patient population. We are members of the FPWR Clinical Trials Consortium and are working with members of its Scientific Advisory Board to gain their insights for our development program. Progress to date includes (i)&#160;opening an IND for PWS in October 2019, (ii) the completion of a Phase 1 PK trial in patients with PWS in the fourth quarter of 2019, with patients actively rolling over into an open-label, long-term safety trial, (iii)&#160;the submission of a Phase 2 clinical protocol to the FDA for review and comment, and (iv)&#160;initiation of a Phase 2 trial in December 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of pitolisant in patients with PWS ages 6 to 65. An estimated 60 to 70 patients will be enrolled at approximately 10 sites across the United States. Patients will be randomized to low-dose pitolisant, high-dose pitolisant or placebo in a 1:1:1 treatment ratio and titrated over three weeks up to their randomized dose, followed by eight weeks of stable dosing. The primary trial objective is to assess for improvement in EDS as measured by the Multiple Sleep Latency Test. Secondary endpoints include several behavioral symptom scales as well as specific measures of cognitive function using validated computer-based assessments. Clinician global impression of disease severity, caregiver global impression of EDS severity, and overall caregiver burden will be measured. Exploratory endpoints include the effect of pitolisant on hyperphagia and measurements of ghrelin levels. Patients who complete the trial will be eligible to participate in an open-label extension phase to assess the long-term safety and effectiveness of pitolisant in patients with PWS, which will run throughout the duration of the PWS development program. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Myotonic Dystrophy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DM is a rare, multi-system genetic disease that affects the neuromuscular system as well as several other systems. The primary symptom in patients with DM is myotonia, which is an impairment in the ability of muscles to relax; progressive muscle weakness is another prominent symptom of the disorder. It is inherited in an autosomal dominant pattern and there are two main types: DM1 and DM2. The underlying cause of DM1 is a mutation in the DMPK gene on chromosome 19. DM1 is the most common form of adult-onset muscular dystrophy and affects as many as 140,000 patients in the United States. EDS and fatigue are hallmark clinical characteristics in the majority of patients with DM1 and are referred to as the most frequent non-muscular symptoms in patients with DM1. EDS and fatigue occur in approximately 80% to 90% of patients with DM1. Cognitive impairment is also a prominent symptom in patients with DM1 and all of these symptoms are thought to be mediated through H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors and histaminergic pathways located throughout the CNS. DM2 is not as common as DM1 with an estimated prevalence of between 3,000 and 29,000&#160;patients in the United States. The underlying cause of DM2 is a mutation in the CBNP gene on chromosome 3. Patients with DM1 and DM2 share similar phenotypes but disease onset is later in patients with DM2 and symptoms tend to be milder. There are currently no FDA-approved treatments for patients with DM, which represents a significant unmet medical need. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The therapeutic application of pitolisant may provide benefits across the key symptoms of EDS and fatigue which are often among the chief complaints of patients with DM. In a survey of 451 DM1 patients, daytime sleepiness and fatigue were second only to muscle weakness in symptom prevalence and impact. Our clinical program will be designed to demonstrate effect on measures of EDS and fatigue, as well as assess performance related to cognitive function, such as attention, vigilance and working memory. Progress to date includes working with key opinion leaders to develop the scientific rationale for the investigation of pitolisant in patients with DM, development of a Phase 2 clinical protocol, submission of an IND at the end of 2020, the opening of an IND in January 2021 and receipt of a &#8220;Study May Proceed&#8221; letter from the FDA in February 2021. We plan to initiate a Phase 2 clinical trial in patients with DM1 in the first half of 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proposed Phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of pitolisant in adult patients with DM ages 18 to 65. An estimated </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0 patients will be enrolled at approximately 1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sites across the United States. Patients will be randomized to low-dose pitolisant, high-dose pitolisant, or placebo in a 1:1:1 treatment ratio and titrated over three weeks up to their randomized dose, followed by eight weeks of stable dosing. The primary trial objective is to assess for improvement in EDS as measured by the MWT and the ESS. Secondary endpoints include assessments of fatigue as well as specific measures of cognitive function using validated computer-based assessments. Clinician and patient global impression of disease severity using the CGI-S and PGI-S, respectively, will be measured as well as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disease-specific</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patient assessments of overall disease burden. Plasma samples will be collected to generate pharmacokinetic data and a PK/PD analysis will be performed. Patients who complete the trial will be eligible to participate in an open-label extension phase to assess the long-term safety and effectiveness of pitolisant in patients with DM, which will run throughout the duration of the DM development program. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Potential Indications </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The next phase of clinical development for pitolisant will be guided by the signals generated from the clinical trials described above and other potential trials in patients with PWS and DM. If we observe favorable results in these trials on the symptoms of fatigue and cognitive dysfunction, we plan to investigate pitolisant in other rare neurological patient populations in which these symptoms are a prominent part of the disease process and result in significant impact on daily functioning. Furthermore, we believe opportunities exist in adjacent disorders to narcolepsy, including other CNS disorders of hypersomnolence, which could lead to additional potential new indications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing, Supply and Distribution</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sell WAKIX to our customers, a limited number of specialty distributors, that, in turn, distribute WAKIX to patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have secured a commercial drug supply to support the launch of WAKIX in the United States. Although we do not currently own or operate facilities for product manufacturing, storage and distribution, or testing, we have contracted directly with third parties for each of these functions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing is subject to extensive regulation that imposes various procedural and documentation requirements that govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, and more. Our systems and our contractors are required to be in compliance with these regulations, and compliance is assessed regularly through monitoring of performance and a formal audit program. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current supply chain for WAKIX involve several manufacturers that specialize in specific operations of the manufacturing process, specifically, intermediate and starting material manufacturing, drug substance manufacturing, and drug product manufacturing, labeling and secondary packaging, and distribution services: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interor S.A. manufactures our BF4 and BF6 intermediate and starting material used in the active pharmaceutical ingredient (&#8220;API&#8221;). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Corden Pharma Chen&#244;ve SAS, a full-service contract development and manufacturing organization (&#8220;CDMO&#8221;) manufactures our API. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Patheon UK Limited, a CDMO owned by Thermo Fisher Scientific Inc., manufactures our finished product tablets and fills them into unlabeled bottles. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Carton Service, Inc., d/b/a Pharma Packaging Solutions, handles our labeling and secondary packaging. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Integrated Commercialization Solutions, LLC (ICS), a division of AmerisourceBergen Corporation, is our third-party logistics provider. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inmar Rx Solutions, Inc., an advanced technology and data analytics company, specializes in reverse distribution of our product and manages our pharmaceutical returns and product recall, if needed.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry is highly competitive and subject to rapid and significant change as research provides a deeper understanding of rare neurological disorders, including narcolepsy, and as new therapies are developed. We face potential competition from multiple sources, including large pharmaceutical, biotechnology and specialty pharmaceutical companies. The key competitive factors affecting the success of WAKIX, and any other product candidates that we develop, if approved, are likely to be efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WAKIX competes with currently FDA-approved products for the treatment of EDS or cataplexy in adult patients with narcolepsy, all of which are controlled substances. Jazz Pharmaceuticals&#8217; Xyrem (sodium oxybate) is an FDA-approved product for the treatment of cataplexy or EDS in patients 7 years of age and older with&nbsp;&nbsp;narcolepsy Xyrem is a Schedule III controlled substance available only through a restricted access REMS program. Xywav, a lower sodium formulation of Xyrem, was approved in July 2020, (became commercially available in November 2020), and is also a Schedule III controlled substance subject to the same restricted access REMS program as Xyrem. Provigil and Nuvigil, which are Schedule IV WPAs, and stimulants such as methylphenidate and amphetamine (both Schedule II controlled substances), are approved for the treatment of EDS in narcolepsy. Anti-depressants and certain other agents are sometimes used off-label for the treatment of cataplexy in narcolepsy. Jazz Pharmaceuticals&#8217; Sunosi (solriamfetol) was approved by the FDA in March 2019 and launched in July 2019. Sunosi (solriamfetol) is a Schedule IV controlled substance and is indicated to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea. It is not indicated for cataplexy in patients with narcolepsy. Additionally, Avadel Pharmaceuticals is working on a once nightly formulation version of sodium oxybate, with approval expected in 2021 or beyond, and Xyrem is expected to go generic in 2023. Beyond 2023, there are other potential future competitive products in development, including Axsome Therapeutics&#8217;s AXS-12 (reboxetine) product candidate and Takeda&#8217;s TAK-925/994 (orexin 2 receptor agonist) product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe WAKIX offers a differentiated product profile that is competitive with each of the products listed above, some of which are only approved for EDS while others (Xyrem and Xywav) are approved for the treatment of both EDS or cataplexy in&nbsp;&nbsp;patients with narcolepsy. It  should be noted that WAKIX has not been compared with these products in head-to-head clinical trials, but its non-scheduled status represents a distinct competitive advantage relative to those same products. Additionally, WAKIX is priced lower than Xyrem and Xywav, which we believe is a competitive advantage for WAKIX and may contribute to third-party payor preferences for WAKIX relative to Xyrem and Xywav. Conversely, WAKIX is priced higher than other competitors such as Provigil, Nuvigil, Sunosi and certain generic competitors, such as methylphenidate and amphetamine, which may contribute to third-party payor preferences for those lower-priced treatment options relative to WAKIX. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Customers and Suppliers</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on a few major customers. For the year ended December 31, 2020, three customers accounted for 100% of gross product revenues; Caremark LLC accounted for 40% of gross product revenues; PANTHERx Specialty Pharmacy LLC accounted for 33% of gross product revenues; and Accredo Health Group, Inc. accounted for 27% of gross product revenues. We also depend on a single source supplier for our product, product candidates and active pharmaceutical ingredient.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Strategic Agreement </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Commercialization Agreement with Bioprojet </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>On July&#160;28, 2017, we and Bioprojet entered into the Bioprojet License Agreement. Bioprojet granted to us an exclusive, sublicensable license to commercialize, in the United States and its territories, commonwealths, and protectorates, including Puerto Rico, a product containing pitolisant currently known as WAKIX for narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, Parkinson&#8217;s disease, and any other indication agreed upon by the parties (which currently include PWS and DM), or the field, as well as rights to related patent rights, know-how, trademarks, trade dress, regulatory filings and approvals (the &#8220;Bioprojet Assets&#8221;). Bioprojet also granted us a co-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusive (with Bioprojet), sublicensable license to Bioprojet Assets to clinically develop and register the pitolisant product in the field in the United States. Bioprojet retains the right to manufacture the product in the United States, and to develop outside the United States and commercialize other products that contain pitolisant as an active ingredient anywhere in the world. Bioprojet also granted us an exclusive license to use certain trademarks and trade names in connection with the commercialization of the product under the Bioprojet License Agreement. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bioprojet License Agreement, Bioprojet is responsible for conducting all preclinical studies and clinical trials necessary for achieving and maintaining regulatory approval in the United States for narcolepsy and cataplexy indications, including all costs and expenses. We are responsible for all other costs associated with other development and regulatory activities, unless Bioprojet otherwise agrees to participate in funding such activities. Bioprojet was responsible for filing, with our participation, the initial new drug application for the product with the FDA and Bioprojet did transfer such application to us upon approval by the FDA in accordance with the terms of the Bioprojet License Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon approval by the FDA, we were required under the Bioprojet License Agreement to promptly launch the product and use commercially reasonable efforts to commercialize the approved products in the United States in the field for each approved indication. In addition, we are required to deploy a number of sales representatives and spend an amount of expenditure, each as agreed upon in a commercialization plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bioprojet License Agreement, Bioprojet has the right and authority to prepare, file, prosecute and maintain all Bioprojet patents on a worldwide basis at its own cost. Bioprojet shall keep us informed of the course of prosecution and other proceedings in the United States. We have the first right to enforce the licensed patent rights with respect to any infringing products in the United States. If we do not bring an action to enforce such patents against infringing activities that involve such infringing products, Bioprojet has the right to bring such action. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We paid Bioprojet an initial license fee of $150.0&#160;million, a milestone payment of $50.0&#160;million upon FDA acceptance of the NDA in February 2019, and a milestone payment of $75.0&#160;million plus an addition $2.0&#160;million fee for approval of the NDA in November 2019. Upon the Cataplexy Milestone Trigger Date, we became obligated to make the Cataplexy Milestone Payment to Bioprojet pursuant to the terms of the Bioprojet License Agreement. Subsequently, in October 2020, we made a payment to Bioprojet of $2.0 million to extend the Cataplexy Milestone Payment due date to within 90 days of the Cataplexy Milestone Trigger Date. On January 6, 2021, we made the $100.0 million Cataplexy Milestone Payment in full to Bioprojet. In addition, we are subject to a milestone payment of $40.0 million upon the attainment of aggregate net sales of WAKIX in the United States of $500.0 million subsequent to the date of NDA approval by the FDA pursuant to the Bioprojet License Agreement. We agreed to pay royalties on the product at tiered royalty rates of 13% to 24% based on annual total net sales during the period commencing on first commercial sale of the product and ending on the latest of 10 years from first commercial sale of the product, expiration of all regulatory exclusivity, or expiration of the last Bioprojet patent covering the product. Such royalty payments are subject to reductions based on royalties paid to any third party in order for us to commercialize the product. We also agreed to pay royalties in consideration for a trademark license at a rate of 3% of net sales for 20 years after first commercial sale of the product. We further agreed to pay minimum royalties during the third through tenth year of the Bioprojet License Agreement if the product is approved for narcolepsy to the extent such minimum royalties exceed the royalties payable as described above, which minimum amounts were calculated based on sales materially below our sales forecast. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bioprojet License Agreement will continue until the expiration of the obligation to pay royalties with respect to the product. We and Bioprojet may each terminate the Bioprojet License Agreement for a material breach by the other party that remains uncured for 90 days. Bioprojet may terminate the Bioprojet License Agreement in its entirety if we or our sublicensees challenge the licensed patents. In addition, we and Bioprojet have the right to terminate the Bioprojet License Agreement upon the other party&#8217;s insolvency. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a>Intellectual property, including patents, trade secrets, trademarks and copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary intellectual property protection for our WAKIX product and potential future pitolisant-based products, as well as for future </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates and novel discoveries, product development technologies, and know-how. Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, licensing or filing U.S. and foreign patents and applications relating to our technology, inventions, and improvements that are important to the development and implementation of our business. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio comprises three U.S. patents exclusively licensed to us from Bioprojet. One U.S. patent, No. 8,207,197, has claims directed to a polymorph, i.e. a specific crystalline form, of pitolisant and, methods for preparing that polymorph of pitolisant, which is expected to expire in February 2029 without taking into consideration any possible patent term extension. A second U.S. patent, No. 8,486,947, has claims directed to methods of treating excessive daytime sleepiness by administering pitolisant, which is expected to expire in September 2029 without taking into consideration any possible patent term extension. With all applicable patent term adjustments available and granted to us, the term of the last-to-expire pitolisant-related patent in our portfolio extends to September 2029. We may receive additional patent term based on the patent term extension described below. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents in our portfolio depends upon the legal term of patents in the countries in which they are obtained. In the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. The term of a U.S. patent may be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) during the patent prosecution process. In addition, for patents that cover an FDA-approved drug, the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Act&#8221;) permits a patent term extension of up to five years beyond the expiration of the patent. While the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent per approved drug may be extended under the Hatch-Waxman Act. We have applied for patent term extension on two patents covering pitolisant, only one of which will receive patent term extension, if at all. While we have received confirmation from the USPTO that the patents are eligible for patent term extension, there is no guarantee that the applicable authorities, including the USPTO and the FDA, will agree with our assessment of whether such extension should be granted. We estimate the length of such extension to be 389 days; however, the USPTO, in conjunction with the FDA, will calculate the length of such extension and there is no guarantee that their calculation will align with our estimate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. Changes in either the patent laws or their interpretation in the United States may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our products. Issued patents only allow us to block potential competitors from practicing the claimed inventions of the issued patents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and/or our licensor also rely on protections under trade secret laws, and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Our trade secrets include, for example, certain program specific synthesis, formulations, patient selection strategies and certain aspects of our research. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us, and for employees and consultants to enter into invention assignment agreements with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Where applicable, the agreements provide that all inventions to which the individual contributed as an inventor shall be assigned to us, and as such, will become our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we have in-licensed from Bioprojet the registered trademark product name &#8220;WAKIX&#8221; in the United States. We also have registered trademark protection in the United States for &#8220;KNOW NARCOLEPSY&#8221; as well as our brand and logo &#8220;HB,&#8221; &#8220;HB HARMONY BIOSCIENCES&#8221; and &#8220;HARMONY BIOSCIENCES.&#8221; We also have trademark applications pending with the U.S. Patent and Trademark Office for &#8220;REM AT THE WRONG TIME&#8221; and &#8220;NON-REM AT THE WRONG TIME.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S. Drug Development Process </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">approval by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug product for each indication; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission to the FDA of an NDA; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA advisory committee review, if applicable; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; and </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing or sale of the drug in the United States; and </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Compliance with any post-approval requirements, including the potential requirement to implement a REMS program or to conduct a post-approval study.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Approval </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision. Specifically, the FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety and quality. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a REMS to ensure that the benefits of the drug outweigh its risks. The REMS could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pediatric Research Equity Act (&#8220;PREA&#8221;) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FDA Expedited Development and Review Programs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including fast track designation, accelerated approval priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review and decision from the date of submission. Products that are eligible for fast track designation may also be considered appropriate to receive a priority review. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;) passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. The designation includes all of the benefits of a fast track designation. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warning or other safety information about the product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fines, warning letters or holds on post-approval clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Exclusivity </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or an NDA submitted under Section&#160;505(b)(2) (&#8220;505(b)(2) NDA&#8221;) submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation and Exclusivity </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that (i) affects fewer than 200,000 individuals in the United States, or (ii) if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants an orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Among other benefits of an orphan drug designation are tax credits for certain research and a waiver of the user fee for the NDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received an orphan designation for pitolisant for the treatment of narcolepsy and, upon approval of WAKIX, we received orphan exclusivity until 2026. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">DEA Regulation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Controlled Substances Act of 1970 (&#8220;CSA&#8221;) establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements administered by the DEA. The DEA is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. The FDA did not recommend that the DEA schedule WAKIX as a controlled substance, and WAKIX is therefore not scheduled as a controlled substance by the DEA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages, surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to the DEA, for example distribution reports for Schedule I and II controlled substances, Schedule III substances that are narcotics, and other designated substances. Reports must also be made for thefts or losses of any controlled substance, and to obtain authorization to destroy any controlled substance. In addition, special authorization and notification requirements apply to imports and exports. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a DEA quota system controls and limits the availability and production of controlled substances in Schedule I or II. Distributions of any Schedule I or II controlled substance must also be accompanied by special order forms, with copies provided to the DEA. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. To meet its responsibilities, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Individual states also regulate controlled substances. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to FDA regulation of pharmaceutical products, pharmaceutical companies are subject to federal healthcare laws and regulations as well as regulation by the states and foreign jurisdictions in which they conduct their business that restrict business practices in the pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business or financial arrangements and relationships with healthcare providers and other parties through which we market, sell and distribute our products for which we obtain marketing approval. These laws include U.S. federal and state anti-kickback and false claims laws, civil monetary penalties laws, consumer protection and transparency laws as well as similar foreign laws in the jurisdictions outside the U.S., including, without limitation, those laws described below. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute. The False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of Medicare or Medicaid payable items or services. Federal government price reporting laws require manufacturers to calculate and report complex pricing metrics to government programs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, these reporting obligations will extend to include payments and transfers of value made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified nurse midwives.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing information and marketing expenditures or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Violation of any of such laws or any other governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, implementation of corporate compliance programs, and reporting of payments or transfers of value to healthcare professionals. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Data Privacy and Security Laws </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a>Pharmaceutical companies may be subject to U.S. federal and state health information privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. In the U.S., HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the Department of Health and Human Services (&#8220;HHS&#8221;), affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information (&#8220;PHI&#8221;), a complaint about privacy practices or an audit by the HHS may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the Federal Trade Commission Act (&#8220;FTCA&#8221;). The FTC expects </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA, many of which may differ from each other, thus, complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted legislation, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act (the &#8220;CPRA&#8221;) recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, the General Data Protection Regulation (&#8220;GDPR&#8221;), went into effect in May 2018 and imposes stringent data protection requirements for controllers and processors of personal data of persons within the European Economic Area (&#8220;EEA&#8221;). The GDPR applies to any company established in the EEA as well as to those outside the EEA if they collect and use personal data in connection with the offering of goods or services to individuals in the EEA or the monitoring of their behavior. The GDPR, together with national legislation, regulations and guidelines of the EEA member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of the data protection obligations. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR (&#8220;UK GDPR&#8221;) which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a>Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">managed healthcare organizations, and the level of reimbursement for such product by third-party payors. In the United States, no uniform policy exists for coverage and reimbursement for pharmaceutical products among third-party payors. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. The process for determining whether a third-party payor will provide coverage for a product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher cost-sharing obligation imposed on patients. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service and the level of coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process will often require us to provide scientific and clinical support for the use of our products to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. Furthermore, there can be no assurance that a product will be considered medically reasonable and necessary for a specific indication, that a product will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability to sell a product profitably. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly affected the pharmaceutical industry. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70&#160;percent pursuant to the Bipartisan Budget Act of 2018, effective as of January&#160;1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>Since its enactment, there have been judicial, executive and Congressional legislative challenges to certain aspects of the ACA. The U.S. Supreme Court is currently reviewing the constitutionality of the ACA in its entirety, although it is unclear how the Supreme Court will rule. Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year, which was temporarily suspended from May 1, 2020 through </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31, 202</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), and reduced payments to several types of Medicare providers. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products in an attempt to control drug costs. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Facilities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located 630 W. Germantown Pike Plymouth Meeting, Pennsylvania. In December 2020, we leased additional office space at this same location, which increased our footprint to approximately 28,638 square feet of office space. As of December 31, 2020, approximately 40 of our employees are located at our corporate headquarters. Pursuant to our Right of Use Agreement with Paragon, we also utilize office space at 330 N. Wabash Ave, Suite 3500, Chicago, Illinois 60611, where approximately 10 of our employees are located. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Human Capital Management</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we have approximately 150 full-time employees, 100 of whom are dedicated to commercial functions, which includes sales, marketing, market access, commercial operations and insights, and 25 of whom are dedicated to research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees.&#160;We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that much of our success is rooted in the diversity of our teams and our commitment to inclusion.&#160;We value diversity at all levels and focus on extending our diversity and inclusion initiatives across our entire workforce.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Corporate Social Responsibility</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Social responsibility has always been integral to our core values.&nbsp;&nbsp;We are committed to doing business with integrity and ethics.&#160;We focus on providing our employees safe and healthy working conditions, and actively participate in the communities where we are located.&#160;In addition, we support <font style="color:#000000;">philanthropic organizations, patient-focused associations, local and national charitable organizations, and areas of need across the country by providing monetary donations or supplying food, medical supplies and other resources. We collaborate with patient advocacy organizations to understand the needs of patients living with rare, neurological disorders including narcolepsy, and are committed to addressing those needs.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Corporate Information</font><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#000000;">Our operating subsidiary, Harmony Biosciences, LLC, was formed in May 2017. We were formed in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company, and we converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017. In February 2020, we changed our name to Harmony Biosciences Holdings, Inc. Our principal executive offices are located at 630 W. Germantown Pike, Plymouth Meeting, PA 19462, and our telephone number is (484) 539-9800. Our internet website is www.harmonybiosciences.com. We routinely make available important information free of charge, including copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Annual Report on Form 10-K, and any website references are not intended to be made through active hyperlinks.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ri</font><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">sk Factors.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927404"></a>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information included or incorporated by reference in this Annual Report on Form 10-K before making an investment in our common stock. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. See &#8220;Part I&#8212;Cautionary Note Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Our Financial Condition and Capital Requirements</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception, expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or fail to become commercially viable. We have only recently begun to generate revenue from product sales and have incurred losses in each year since our inception for most periods. Our ability to generate revenue and achieve profitability depends on our ability to successfully commercialize WAKIX for the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, and to successfully develop and obtain the regulatory approvals necessary to commercialize pitolisant for other indications. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we commercialize WAKIX and as we continue to develop and potentially commercialize pitolisant for other indications.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have only recently begun generating revenue from product sales and may never be profitable.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than WAKIX, we do not currently have any products that are available for commercial sale, and we may never achieve profitability. Our net loss was $36.9 million and $152.0 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $488.2 million. Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue until we further commercialize WAKIX and/or and obtain regulatory approval for potential additional indications for pitolisant. We generated net product revenues of $159.7 million and $6.0 million for the years ended December 31, 2020 and 2019, respectively. Successful commercialization will require achievement of many key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory approval, including marketing approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history and history of commercializing drugs, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>We commenced operations in 2017, and our operations to date have been largely focused on staffing our company, business planning, raising capital, acquiring the rights to pitolisant, seeking registration in the United States for our product WAKIX, which is approved for the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, the commercialization of WAKIX, manufacturing WAKIX on a commercial scale, and preparing to develop pitolisant for other potential indications. This has </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">included preparing the application for regulatory approval and other activities that were required for us to obtain approval of our NDA, and activities related to commercializing WAKIX. WAKIX is our only drug candidate for which we have obtained regulatory approval. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a longer history of successfully developing and commercializing drugs.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have only limited capital and may need to raise additional capital before we become profitable.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had an accumulated deficit of $488.2 million, and available cash and cash equivalents and restricted cash of $229.4 million. We have $194.3 million of debt outstanding under our Credit Agreement with OrbiMed. We believe that our anticipated cash from operating and financing activities and existing cash and cash equivalents will enable us to meet its operational liquidity needs and fund our planned investing activities for the next twelve months.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This estimate is based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we currently expect. Because the length of time and activities associated with the successful development of our product candidates is highly uncertain, we are unable to estimate with certainty the actual funds we will require for development and any approved marketing and commercialization activities.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fund future operations to the point at which we are able to generate positive cash flow from sales of WAKIX or other potential product candidates, we may need to raise significant additional capital. The amount and timing of future funding requirements will depend on many factors, including, but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the results of our commercialization of WAKIX;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of sales, marketing and distribution capabilities for our product candidates in regions where those product candidates are approved and where we choose to commercialize our products on our own;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effect of competing technological and market developments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost and timing of manufacturing activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the payment of royalties and milestone payments to Bioprojet;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the FDA and other comparable regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned clinical trials and preclinical studies and other work, as the basis for the review and approval of pitolisant for other potential indications or of any other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential expansion of our current development programs to seek new indications for pitolisant, potential new development programs for additional indications, and related general and administrative support;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, progress, timing, and results of our clinical trials through all phases of development for pitolisant as a treatment for other indications and any other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights, in-licensed or otherwise;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us for pitolisant or future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of acquiring rights to other pharmaceutical products in the future to further develop and commercialize;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the cost of general operating </font><font style="font-family:Times New Roman;">expenses;</font><font style="font-family:Times New Roman;"> and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of operating as a public company.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no committed source of additional capital and we anticipate that we may seek to fund our operations through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. We cannot assure you that anticipated additional financing will be available to us on favorable terms, or at all. Although we have been successful in obtaining financing through the issuance of our equity securities and debt facilities, we cannot assure you that we will be able to do so in the future. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us to fund our commercialization of WAKIX and clinical development and commercialization of pitolisant for other indications, if approved, and other business activities, we could be forced to significantly delay, scale back, or discontinue the development or commercialization of our product candidates or curtail or cease our operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional funds by issuing securities may cause dilution to existing shareholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights to our technologies or product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that significant additional capital will be needed in the future to continue our planned operations. Until such time, if ever, that we can generate sufficient product revenue from the sale of WAKIX, we may need to finance our cash needs through a combination of equity offerings, debt financings, including our Credit Agreement, strategic alliances and license and development agreements or other collaborations. To the extent that we raise additional capital by issuing equity securities, our existing shareholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of a common shareholder. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely affect our ability to conduct our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our auditor has previously expressed substantial doubt about our ability to continue as a going concern and we may be unable to remain a going concern.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of our recurring losses, accumulated deficit and negative cash flow as described in our notes to our consolidated financial statements, we had previously concluded there was substantial doubt regarding our ability to continue as a going concern and the report of our independent registered public accounting firm on our financial statements for the year ended December 31, 2019 contained an explanatory paragraph communicating this matter. Our financial statements did not include any adjustments that may have been necessary in the event we were unable to continue as a&#160;going concern. Had we been unable to establish to the satisfaction of our independent registered public accounting firm that our expected operational performance and liquidity would be sufficient to allow for the removal of this&#160;going concern&#160;qualification, we would have needed to significantly modify our operational plans for us to continue as a&#160;going concern. We believe that our anticipated cash from operating and financing activities and existing cash and cash equivalents, will enable us to meet our operational liquidity needs and fund our planned investing activities for the next twelve months.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have made and may be required in the future to make significant payments to Bioprojet under our licensing and collaboration agreements for pitolisant.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our agreements with Bioprojet, we are subject to significant obligations, including payment obligations upon the achievement of specified milestones and payments based on product sales, as well as other material obligations. Certain of the milestone payments payable by us under these agreements were paid prior to our commercialization of WAKIX. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the Cataplexy Milestone Trigger Date, we became obligated to make the $100.0 million Cataplexy Milestone Payment to Bioprojet pursuant to the terms of the Bioprojet License Agreement. Subsequently, in October 2020, we made a payment to Bioprojet of $2.0 million to extend the Cataplexy Milestone Payment due date to within 90 days of the Cataplexy Milestone Trigger Date. On Jan</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uary</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we made the $100.0 million Cataplexy Milestone Payment in full to Bioprojet. In addition, we are subject to a milestone payment of $40.0 million upon the attainment of aggregate net sales of WAKIX in the United States of $500.0 million subsequent to the date of NDA approval by the FDA pursuant to the Bioprojet License Agreement.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that we will have the funds necessary to make such payments in the future, or be able to raise such funds when needed, on terms acceptable to us, or at all. If we fail to comply with our payment obligations, Bioprojet has the right to terminate the license agreement, in which event we would not be able to develop, manufacture or market WAKIX or any other pitolisant-based product candidate. Furthermore, if we are forced to raise additional funds to make such payments, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards may be limited.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had U.S. federal and state net operating loss carryforwards of approximately $159.4 million and $157.7 million, respectively. As of December 31, 2019, we had U.S. federal and state net operating loss carryforwards of approximately $147.8 million and $139.3 million, respectively. Our ability to utilize our federal net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). The limitations apply if we experience an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change (by value) in the ownership of our equity by certain stockholders over a rolling three-year period. Similar provisions of state tax law may also apply to limit the use of our state net operating loss carryforwards. We have not assessed whether such an ownership change has previously occurred. If we have experienced an ownership change at any time since our incorporation, we may already be subject to limitations on our ability to utilize our existing net operating loss carryforwards to offset taxable income. In addition, future changes in our stock ownership, which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Section 382 of the Code. As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset such taxable income may be subject to limitations, which could adversely affect our future cash<font style="letter-spacing:-0.25pt;"> </font>flows.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our credit agreement contains restrictive and financial covenants that may limit our operating flexibility.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Credit Agreement with OrbiMed contains certain restrictive covenants that either limit our ability to, or require a mandatory prepayment in the event that, we engage in new lines of business, incur additional indebtedness or liens, make certain investments, make certain payments, pay cash dividends, merge with other companies or consummate certain changes of control, acquire other companies, transfer or dispose of certain assets, liquidate or dissolve, amend certain material agreements, enter into sale and leaseback transactions, enter into various other specified transactions, or change our name, location, executive office or executive management without notice. We, therefore, may not be able to engage in any of the foregoing transactions unless we obtain the consent of OrbiMed or prepay the outstanding amount under the Credit Agreement. The Credit Agreement also contains certain financial covenants, including minimum revenue and cash balance requirements (which include maintaining minimum liquidity of $12.5 million), and financial reporting requirements.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our obligations under the Credit Agreement are secured by all of our property, with certain exceptions. We may not be able to generate sufficient cash flow or sales to meet the financial covenants or pay the principal and interest under the Credit Agreement. Furthermore, our future working capital, borrowings or equity financing could be unavailable to repay or refinance the amounts outstanding under the Credit Agreement. In the event of a liquidation, OrbiMed would be repaid all outstanding principal and interest prior to distribution of assets to unsecured creditors, and the holders of our common stock would receive a portion of any liquidation proceeds only if all of our creditors then existing, including OrbiMed, were first repaid in<font style="letter-spacing:-0.05pt;"> </font>full.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Our Business</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We are substantially dependent on our ability to successfully commercialize WAKIX, which is currently our only approved product. If we are unable to successfully commercialize WAKIX, our ability to generate revenue and our financial condition will be adversely affected.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have invested substantially all of our capital resources on the development, registration and commercialization of WAKIX, which was approved for the treatment of EDS in adult patients with narcolepsy in August 2019 and for the treatment of cataplexy in adult patients with narcolepsy in October 2020. We cannot be certain that WAKIX will be successfully commercialized.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from product sales depends heavily on our success in many areas, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successfully commercializing WAKIX, either independently or with marketing service providers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effectiveness of our sales and marketing strategy and operations, and obtaining market acceptance of WAKIX, including garnering market share from existing and future treatment alternatives;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintaining compliance with all regulatory requirements applicable to WAKIX and our commercial activities, including the post-marketing requirements and post-marketing commitments required by the FDA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining coverage and adequate reimbursement from third-party payors for each of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the continued acceptability of the safety profile of WAKIX and the occurrence of any unexpected side effects, adverse reactions or misuse, including potential business impact such as the need to withdraw the product (either voluntarily or as mandated by the FDA), loss of support by the advocacy communities or loss of positive corporate reputation resulting in related unfavorable media coverage in these areas;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successfully managing third-party service providers involved in the manufacturing and development of pitolisant;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successfully completing the development of pitolisant in other indications by demonstrating safety, tolerability and efficacy profiles that are satisfactory to the FDA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining regulatory approvals to market pitolisant for other indications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">complying with the terms of the license agreement with Bioprojet;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintaining, protecting and expanding the portfolio of intellectual property rights, including patents, trade secrets and knowhow; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">attracting, hiring and retaining qualified personnel.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our efforts to market WAKIX for the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, our revenue will be dependent, in part, on the size of the markets in the United States, or in other territories where we may seek and obtain regulatory approval, the number of competitors in such markets, the acceptance of the price of the product in those markets and the ability to obtain reimbursement at any price. If the number of our addressable patients is not as large as we estimate or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products. If we are not able to generate substantial revenue from the sale of approved products, we may never become<font style="letter-spacing:-0.3pt;"> </font>profitable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">The commercial adoption of WAKIX and any other product candidates we develop will depend on the degree of their market acceptance.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even with the requisite approvals from the FDA and other regulatory authorities, the commercial adoption of WAKIX for the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, and any other indications and product candidates we may develop, will depend on the degree of their acceptance by physicians, patients, third-party payors and others in the medical community. If WAKIX or any other product candidates we develop do not achieve an adequate level of market acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of WAKIX or any other product candidates we develop, if approved for commercial sale, will depend on a number of factors, some of which are beyond our control,<font style="letter-spacing:-0.1pt;"> </font>including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the safety and efficacy of the product as demonstrated in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the perception of physicians, patients, third-party payors and others in the medical community of the relative safety, efficacy, convenience, effect on quality-of-life and cost-effectiveness of the product, compared to those of other available treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the product&#8217;s approved labeling, including the description of the product&#8217;s approved indications, the description of its efficacy, including the endpoints in which it showed an improvement, and the prevalence and severity of any side effects, including any associated limitations or warnings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to differentiate WAKIX or other approved products from other treatments in the same space;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the adoption of WAKIX as a first-line therapy for EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects, including those that may be discovered following approval and commercialization;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support and timing of market introduction of competitive products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the publicity concerning our products or competing products and treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product liability litigation alleging injuries relating to our products or similar classes of drugs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any post-approval study requirements for our products and the results thereof; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sufficient third-party insurance coverage and reimbursement.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our continuing efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits and risks of WAKIX may require significant resources and may never be successful. The adoption of WAKIX could be limited if physicians prescribe it only as a second line therapy. Physicians may opt to prescribe the products of our competitors for a variety of reasons. For example, WAKIX did not demonstrate non-inferiority to modafinil and, as such, physicians and patients may choose modafinil rather than WAKIX. Furthermore, because the clinical response to WAKIX may take several weeks before addressing EDS and cataplexy symptoms, patients and physicians may choose other fast acting, stimulant and wake promoting agents over WAKIX. If WAKIX fails to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient revenue to become or remain<font style="letter-spacing:-0.3pt;"> </font>profitable.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a>We cannot guarantee that WAKIX or any other product candidates we may seek to develop will ever be commercially successful, and to the extent they are not commercially successful, such product candidates would incur significant expense with no corresponding revenue. Because we expect the sales of WAKIX to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generate substantially all of our revenue for the foreseeable future, the failure of WAKIX to find market acceptance would substantially harm our business and could require us to seek additional financing.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunity for WAKIX or any future product candidate we develop may be smaller than we estimate.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential market opportunity for WAKIX and any future product candidate is difficult to precisely estimate. Our estimates of the potential market opportunity for our product candidates include several key assumptions of the current market size and current pricing for commercially available products and are based on industry and market data obtained from industry publications, studies conducted by us, our industry knowledge, third-party research reports and other surveys. While we believe our estimates are reasonable and reliable, they may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of diseases and disorders. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for WAKIX or any future product candidate we develop may be limited or may not be amenable to treatment with WAKIX or such future product candidate, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We rely on our license agreement with Bioprojet to provide rights to the core intellectual property relating to pitolisant, and any termination or loss of significant rights under the agreement would adversely affect our development and/or commercialization of pitolisant.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed our core intellectual property relating to pitolisant from Bioprojet. If, for any reason, our license and commercialization agreement with Bioprojet is terminated or we otherwise lose those rights, it would materially adversely affect our business. Pursuant to our license and commercialization agreement, we obtained intellectual property rights in connection with the commercialization of pitolisant in the United States and its territories, commonwealths and protectorates, including Puerto Rico, which includes an exclusive license to use certain intellectual property owned by Bioprojet related to clinically developing and commercializing the pitolisant product candidate for narcolepsy, obstructive sleep apnea, idiopathic hypersomnia and Parkinson&#8217;s Disease.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement, Bioprojet is responsible for conducting all preclinical studies and clinical trials necessary for achieving and maintaining regulatory approval in the United States for narcolepsy and cataplexy indications, including all costs and expenses. We are responsible for all other costs associated with other development and regulatory activities, unless Bioprojet otherwise agrees to participate in funding such activities. We must obtain consent from Bioprojet before commencing any clinical trials related to pitolisant. Our ability to pursue indications other than the ones specifically enumerated in the license agreement is also contingent on mutual agreement of Bioprojet and us as to those indications and such agreement may be withheld at Bioprojet&#8217;s discretion. If Bioprojet denies consent for us to conduct clinical trials or pursue any such other indication for any reason, we will not have the right under our license and commercialization agreement to commercialize our product for such indication. In such event, Bioprojet may pursue commercialization of such indication for itself in our territory, or it may license the right to commercialize such indication in our territory to third parties, including our competitors.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license and commercialization agreement also imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, insurance, intellectual property protection and other matters. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Bioprojet, and Bioprojet may have the right to terminate our license, which would result in us being unable to develop, manufacture and sell pitolisant and would materially adversely affect our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic may result in disruptions to our commercialization, clinical trials, manufacturing and other business operations, which could have a material adverse effect on our business, financial condition, operating results, cash flows and prospects.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>The outbreak of COVID-19, which has been declared a global pandemic by the World Health Organization, has spread across the globe and is impacting worldwide economic activity. A public health epidemic, including COVID-19, poses the risk that we or our employees, contractors, suppliers, distributors and other partners, as well as physicians treating narcolepsy patients, may be prevented from conducting business and patient-care activities for an indefinite period of time, including due to shutdowns and quarantines that may be requested or mandated by governmental authorities. Beginning in March 2020, we transitioned our field-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based sales, market access, and medical employees to remote work and suspended work-related travel and in-person customer interactions with healthcare professionals and customers. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of these activities have resumed in moderation following</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the establishment of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> proper protocols and procedures as COVID-19 restrictions have been revised. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our increased reliance on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. In addition, remote working could increase our cyber security risk.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General protective measures put into place at various governmental levels, including quarantines, travel restrictions and business shutdowns, may also negatively affect our operations. The responses to the COVID-19 pandemic may have had an impact on demand for WAKIX as a result of a reduced ability of prescribers to diagnose narcolepsy patients given the limitations in access to sleep testing, the reduced ability to see patients due to cancelled appointments and the reprioritization of healthcare resources toward treating COVID-19. The COVID-19 pandemic has affected our ability to access HCPs, and has caused fewer patients visits to their HCP, resulting in fewer prescriptions being written. The COVID-19 pandemic is leading to high unemployment and corresponding loss of insurance, resulting in more eligible patients taking advantage of patient assistance and/or free good programs, which is impacting our ability to convert demand to revenue and the corresponding revenue growth rate in possible future quarters will be adversely impacted by the ongoing COVID-19 pandemic.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The continued spread of COVID-19 and the measures taken by the governments of countries affected, particularly the United States and France, could also disrupt the supply chain and the manufacture or shipment of WAKIX and of drug substance and finished drug product. For example, we may face supply chain and manufacturing limitations or difficulties as resources are shifted toward vaccine manufacturing and distribution. Any delays or interruptions in the manufacture and supply of WAKIX could result in delays for our planned clinical trials, impair our ability to meet demand for new WAKIX prescriptions and impede our clinical trial recruitment, testing, monitoring, data collection and analysis and other related activities.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing factors could have a material adverse impact on our business, financial condition, operating results, cash flows and prospects. The extent to which COVID-19 impacts our operations and those of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, additional or modified government actions, new information which emerges concerning the severity of COVID-19 and the actions taken to contain the virus or treat its impact, among others. In particular, the speed of the continued spread of COVID-19 globally, and the magnitude of interventions to contain the spread of the virus, will determine the impact of the pandemic on our operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify, in-license or acquire, discover, develop or commercialize additional product candidates, or identify other indications for pitolisant beyond EDS or cataplexy in adult patients with narcolepsy.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although a substantial amount of our effort will focus on the commercialization of WAKIX for the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, we also may seek to identify, in-license or acquire, discover, develop and commercialize additional product candidates in the rare neurological disorders field, and to identify other indications for pitolisant beyond the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy. We cannot assure you that our efforts to do so will be successful. Even if we are successful at in-licensing or acquiring additional product candidates, their requisite development activities may require substantial resources, and we cannot assure you that these development activities will result in regulatory approvals. We also cannot assure you that our efforts to develop and commercialize pitolisant for other indications beyond the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy will be successful.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our business, products or product pricing could be subject to negative publicity, which could have a material adverse effect on our reputation, business, financial position, results of operations, liquidity and cash flows.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>In recent years, the pharmaceutical industry has been the subject of public complaints and significant publicity regarding the pricing of pharmaceutical products, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that the public has deemed excessive. We may experience downward pricing pressure on the price of WAKIX and any other future approved products due to social or political pressure to lower the cost of drugs, which could reduce our revenue and future profitability. Orphan drugs in particular have received recent negative publicity for the perceived high prices charged for them by their manufacturers, and as a result orphan drug developers such as us may be negatively impacted by such publicity </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and any U.S. or other</font><font style="letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government regulatory response. Due to these factors, we may suffer public criticism and negative publicity in media coverage, by industry trade associations and</font><font style="letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legislators.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the events or developments described above could result in reputational harm and reduced market acceptance and demand for our products, could harm our ability to market our products in the future, could cause us to incur significant expense, could cause our senior management to be distracted from execution of our business strategy, and could have a material adverse effect on our business, reputation, financial condition, results of operations, liquidity, cash flows and/or share price.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Third-party relationships are important to our business. If we are unable to enter into and maintain strategic collaborations or if these relationships are not successful, our business could be adversely affected.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited product development and distribution capabilities and we do not yet have any product manufacturing capabilities. In addition, we may enter into collaborations for the development and commercialization of certain of our product candidates. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. Relationships we enter into may pose a number of risks, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">current or future third parties have, and future third-party collaborators may have, significant discretion in determining the efforts and resources that they will apply;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties may not perform their obligations as expected;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties may not pursue development and commercialization of any product candidates that we decide to develop as drugs and that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical study or trial results, changes in the third parties&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties may delay preclinical studies or clinical trials, provide insufficient funding for a preclinical study or clinical trial, stop a preclinical study or clinical trial or abandon one of our product candidates, repeat or conduct clinical studies or new clinical trials or require a new formulation of a product candidate for clinical testing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties could independently develop, or develop with other third parties, products that compete directly or indirectly with our products and product candidates if the third parties believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product candidates discovered in collaboration with us may be viewed by our current or future collaborators as competitive with their own product candidates or products, which may cause such third parties to cease to devote resources to the commercialization of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties may fail to comply with applicable regulatory requirements regarding the development, manufacture, packaging, labeling, holding, distribution and/or marketing of a product candidate or product;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties with marketing and distribution rights to pitolisant or any future product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disagreements with third parties, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of pitolisant or any future product candidates, might lead to additional responsibilities for us with respect to pitolisant or any future product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">third parties may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties may infringe the intellectual property rights of other third parties, which may expose us to litigation and potential liability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">if one of our third parties is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">relationships may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationships do not result in the successful discovery, development and commercialization of products or if a third party terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under any third party agreements we enter into, our development of pitolisant or any future product candidates could be delayed and we may need additional resources. Additionally, if any third party terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relationships are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of future collaborators. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable third parties on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into relationships or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We expect to rely on third parties to conduct our clinical trials for pitolisant and any future product candidate that we decide to develop. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates on a timely basis or at all.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to rely upon third parties, including independent investigators, to conduct preclinical studies or clinical trials under agreements with universities, medical institutions, CROs, strategic partners and others. We expect to have to negotiate budgets and contracts with CROs and study or trial sites, which may result in delays to our development timelines and increased costs.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will have to rely heavily on third parties over the course of our preclinical studies and clinical trials and, as a result, will have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol and regulatory requirements. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements for clinical trials, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities enforce these GCP requirements through periodic inspections of study or trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these clinical trials or perform additional clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP or other applicable requirements. In addition, our clinical trials must be conducted with drug products produced under cGMP requirements and may require a large number of patients. Our failure or any failure by these third parties to comply with these regulations, which would delay the regulatory approval or commercialization process. Moreover, our business may be implicated if any of these third parties violates federal or state laws or regulations including fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any parties conducting our future clinical trials, if any, generally will not be our employees and, except for remedies that may be available to us under our agreements with the third parties conducting such clinical trials, if any, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our current and future product candidates. As a result, our financial results and the commercial prospects for our current and future product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into contractual and other arrangements with alternative CROs or other third parties in a timely manner to meet projected clinical development deadlines or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially affect our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in meeting or fail to meet the regulatory requirements for commercialization of our current or future potential product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We rely completely on third parties to manufacture and distribute our supply of WAKIX, including certain sole-source suppliers and manufacturers, and intend to rely on third parties to manufacture and distribute any future product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have, nor do we plan to acquire, the infrastructure or capability to manufacture or distribute commercial quantities of WAKIX. Our ability to commercially supply WAKIX depends, in part, on the ability of third-party manufacturers to supply and manufacture the raw materials, API and other important components related to the manufacture of WAKIX. We also rely on third parties to package the finished product. These third-party manufacturers have limited experience manufacturing the raw materials and API for WAKIX to be supplied to patients in the United States. Prior to the approval of WAKIX, we experienced minor issues related to product specifications and other minor delays in supply related to our third-party suppliers and manufacturers. While we continue to work with our third-party suppliers and manufacturers to optimize the manufacturing process for WAKIX and will work to optimize the manufacturing process for any future product candidates, we cannot guarantee that even minor changes in the process will result in products that are safe and, where applicable, effective. If we fail to develop and maintain supply relationships with these third parties, we may be unable to continue to successfully commercialize WAKIX.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>We rely and will continue to rely on certain third parties as the sole source of the materials they supply or the finished products they manufacture. For example, we rely on Interor S.A., Corden Pharma Chen&#244;ve SAS and Patheon UK Limited to provide intermediate supply ingredients, API and finished products, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we rely on our suppliers and manufacturers to purchase materials from other third parties. Any of our existing suppliers or manufacturers may:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fail to supply us with product on a timely basis or in the requested amount due to unexpected damage to or destruction of facilities or equipment or otherwise;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fail to increase manufacturing capacity and produce drug product and components in larger quantities and at higher yields in a timely or cost-effective manner, or at all, to sufficiently meet our commercial needs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be unable to meet our production demands due to issues related to their reliance on sole- source suppliers and manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">supply us with product that fails to meet regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">become unavailable through business interruption or financial insolvency;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">lose regulatory status as an approved source;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be unable or unwilling to (i) honor current supply agreements or (ii) renew current supply agreements when such agreements expire on a timely basis, on acceptable terms or at all; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">discontinue production or manufacturing of necessary drug substances or products.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any of the foregoing, if we do not have an alternative supplier or manufacturer in place, we would be required to expend substantial management time and expense to identify, qualify and transfer technical processes to alternative suppliers or manufacturers. Transferring technology to other sites may require additional processes, technologies and validation studies, which are costly, may take considerable amounts of time, may not be successful and, in most cases, require review and approval by the FDA. Any need to find and qualify new suppliers or manufacturers could significantly delay production of WAKIX, adversely impact our ability to market WAKIX and adversely affect our business. There can be no assurance that replacements would be available to us on a timely basis, on acceptable terms or at all. Additionally, we and our manufacturers do not currently maintain significant inventory of drug substances and other materials beyond our currently forecasted needs. Any interruption in the supply of a drug substance or other material or in the manufacture of WAKIX could have a material adverse effect on our business, financial condition, operating results and prospects.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on our contract suppliers and manufacturers for day-to-day compliance with cGMP for production of both drug substances and finished products. Facilities used by our contract suppliers and manufacturers to produce the drug substances and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. A number of our contract suppliers and manufacturers must comply with cGMP requirements enforced by the FDA through its facilities inspection program and review of submitted technical information. If the safety of WAKIX is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could adversely impact our ability to effectively commercialize WAKIX.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Because a number of companies compete with us, many of which have greater resources than we do, and because we face rapid changes in science in our industry, we cannot be certain that our products will be accepted in the marketplace or capture market share.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>Competition from other biotechnology and pharmaceutical companies is intense and is expected to increase. There may be a number of companies pursuing the development of pharmaceuticals in rare neurological disorders, our area of focus. These companies may be very large, and may have financial, technical, sales and distribution and other resources substantially greater than ours. The greater resources of these competitors may enable them to develop, obtain regulatory approval for or market competing products </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more quickly or effectively, making it extremely difficult for us to capture a share of the market for our product. We also face competition, and may in the future face additional competition, from manufacturers of generic drugs. Certain U.S. state laws allow for, and in some instances in the absence of specific instructions from the prescribing physician mandate, the dispensing of generic products rather than branded products when a generic version is available. Generic competition often results in decreases in the prices at which branded products can be sold. The commercial potential of our current products and any future products may be reduced or eliminated if our competitors develop or acquire and commercialize generic or branded products that are safer or more effective, have fewer side effects, are easier to administer or are less expensive than our products. We also face competition from off-label uses of approved drugs. Additionally, the biotechnology and pharmaceutical industries are subject to rapid changes in science, and our competitors may develop and market products with improved therapeutic profiles relative to pitolisant or any future product candidates that would render pitolisant or any future product candidates noncompetitive.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may need to increase the size and capabilities of our organization based on business need, and we may experience difficulties in managing our growth.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2017 and, as of December 31, 2020, had approximately 150 employees. As we advance the development of pitolisant in other indications and commercialize WAKIX as a treatment for EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, we must continue to grow the size of the organization. Future growth will impose significant added responsibilities on members of management, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identifying, recruiting, integrating, retaining and motivating additional employees;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effectively managing our development efforts, including the clinical development and FDA or other regulatory authority review processes for pitolisant or any future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effectively managing any third-party service providers involved in the development and manufacture of pitolisant or any future product candidates; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">improving our operational, financial and management controls, reporting systems and procedures.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to successfully develop and commercialize WAKIX or any future product candidates will depend, in part, on our ability to effectively manage any future growth. Our management will have to dedicate a significant amount of its attention to managing these growth activities. In addition, we expect to incur additional costs in hiring, training and retaining such additional personnel.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization, we may not be able to successfully execute the tasks necessary to further develop and commercialize pitolisant or any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the principal members of our management and scientific teams. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity award grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by changes in the price of our common stock that are beyond our control, and may at any time be insufficient to retain employees who receive more lucrative offers from other companies. Any of our employees could leave our employment at any time, with or without notice.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a>Recruiting and retaining qualified operations, finance and accounting, quality and compliance, scientific, clinical, manufacturing and sales and marketing personnel or consultants will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms, given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. If we are unable to attract, retain and motivate qualified and experienced personnel, it could harm our business, results of operations and financial condition. Even if we are successful in attracting and retaining such personnel, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competition for such employees may significantly increase our compensation costs and adversely affect our business, results of operations and financial condition.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loss of the services of any of our executive officers, key employees or consultants could seriously harm our ability to successfully implement our business strategy. Replacing executive officers, key employees or consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel or consultants on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may hire part-time employees or use consultants. As a result, certain of our employees, officers, directors or consultants may not devote all of their time to our business, and may from time to time serve as employees, officers, directors and consultants of other companies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, the manufacturing facilities of our third-party contract manufacturers or our or their distribution networks, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, or interruptions in the commercialization of WAKIX or our business operations. Natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities, the manufacturing facilities of our third-party contract manufacturers or our or their distribution networks, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We depend on our information technology systems, and any failure of these systems could harm our business. Any real or perceived security breaches, loss of data, and other disruptions or incidents could compromise the privacy, security, integrity or confidentiality of sensitive information related to our business or prevent us from accessing critical information and expose us to liability and reputational harm, which could adversely affect our business, results of operations and financial condition.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>We collect and maintain data and information that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including systems infrastructure operated and maintained by our third party suppliers or providers. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems and facilities to prevent an information compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result, a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage or unauthorized access or use resulting from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, denial-of-service attacks, cyber- attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks, attachments to emails, persons inside our organization (including employees or contractors), lost or stolen devices, or persons with access to systems inside our organization.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk of a security breach or disruption or data loss, particularly through social engineering attacks, cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. The costs to us to mitigate, investigate and respond to potential security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result<font style="letter-spacing:-0.6pt;"> </font>in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a real or perceived security breach affects our systems (or those of our third party providers or suppliers) or results in the loss of or accidental, unlawful or unauthorized access to, use of, release of or other processing of personally identifiable information or clinical trial data, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss, negative publicity, harm to our reputation, governmental investigation and/or enforcement actions, claims or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we begin to operate in foreign jurisdictions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a>We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse laws, data privacy and security laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use or misrepresentation of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare</font><font style="letter-spacing:-0.5pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, other sanctions, contractual damages, reputational</font><font style="letter-spacing:-0.3pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations.</font></p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Development, Regulatory Approval and Commercialization</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval process of the FDA is costly, lengthy and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for pitolisant in other potential indications for which we may seek to develop pitolisant, our business will be substantially harmed.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the commercialization of WAKIX is our primary focus, as part of our longer-term growth strategy, we plan to evaluate pitolisant in other indications and develop other product candidates. The research, testing, manufacturing, labeling, approval, selling, import, export, pricing and reimbursement marketing and distribution of drug products are subject to extensive regulation by the FDA and other regulatory agencies in the United States. Although we have obtained regulatory approval for WAKIX in the United States for the treatment of EDS or cataplexy in adult patients with narcolepsy, it is possible that we may not obtain regulatory approval for pitolisant for other indications, or for any other product candidates we may seek to develop in the future. We received a Complete Response Letter for pitolisant for the treatment of cataplexy in adult patients with narcolepsy, and therefore the FDA did not approve WAKIX for this indication during the initial NDA review. Subsequently, in June 2020, we received a general advice letter from the FDA stating that the FDA had re-analyzed data from the HARMONY 1 trial that we submitted in the NDA in support of the adult cataplexy indication for WAKIX. As a result, the FDA recommended we submit a complete response resubmission in pursuit of the adult cataplexy indication for WAKIX. Following such resubmission, we received acknowledgement from the FDA that it considers the resubmission to be a complete Class 1 response to its August 14, 2019 action letter, and the user fee goal date, or decision date, was October 13, 2020. On October 13, 2020 we received regulatory approval for WAKIX for the treatment of cataplexy in adult patients with narcolepsy. Nevertheless, obtaining regulatory approval of an NDA can be a lengthy, expensive and uncertain process.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA can delay, limit or deny approval of a drug candidate for many reasons or require us to conduct additional preclinical or clinical testing, including, but not limited to, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a drug candidate may not be deemed safe or effective, or the clinical and other benefits may be deemed to not outweigh the candidate&#8217;s risks;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA might not approve our trial design and analysis plan;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA may not find the data from nonclinical and clinical studies and trials sufficient or may disagree with our interpretation of data from nonclinical or clinical studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing the active ingredient in our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical inspection(s) by the FDA or other regulatory authorities may result in unacceptable findings that could negatively impact approval of pitolisant;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA might not accept or deem acceptable a third-party manufacturers&#8217; processes or facilities; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA may change its approval policies or adopt new regulations.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a drug candidate in the United States, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, that such drug candidates are safe and effective for their intended uses. The number of nonclinical and clinical studies and trials that will be required for FDA approval varies depending on the drug candidate, the disease or condition that the drug candidate is designed to address, and the regulations applicable to any particular drug candidate. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit or prevent development efforts, clinical trials or marketing approval. Furthermore, as more competing drug candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. If pitolisant fails to demonstrate safety and efficacy in clinical trials or does not gain regulatory approval for other indications, our business and results of operations will be materially and adversely harmed. Additionally, if the FDA requires that we conduct additional clinical trials, places limitations on pitolisant in our label, delays approval to market pitolisant or limits the use of pitolisant, our business and results of operations may be harmed.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to obtain and sustain an adequate level of coverage and reimbursement for WAKIX and other product candidates by third-party payors, sales would be adversely affected.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful sales of WAKIX and any other product candidates that may receive regulatory approval depend on the availability of coverage and adequate reimbursement from third-party payors. Patients who are prescribed medications for the treatment of their conditions generally rely on third- party payors to reimburse all or part of the costs associated with their prescription drugs. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Regulatory approvals, pricing and reimbursement for new drug products vary widely from country to country. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. Commercial third-party payors, such as private health insurers and health maintenance organizations, also decide which medications they will pay for and establish reimbursement levels, though commercial third-party payors often follow CMS&#8217; reimbursement determinations. The availability of coverage and the extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments. Sales of WAKIX or other product candidates that we may identify will depend substantially, both domestically and abroad, on<font style="letter-spacing:-0.55pt;"> </font>the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party<font style="letter-spacing:-0.3pt;"> </font>payors.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a covered benefit under its health plan;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">safe, effective and medically necessary;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">appropriate for the specific patient;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">cost-effective; and</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">neither experimental nor investigational.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that reimbursement will be available for WAKIX and, if coverage and reimbursement are available, what the level of reimbursement will be. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement approval for a product from a government or other third- party payor can be an expensive and time-consuming process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. The industry competition to be included in third-party payors&#8217; drug formularies, or lists of medications for which third- party payors provide coverage and reimbursement, often leads to downward pricing pressures on pharmaceutical products. In addition, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access through formulary controls or otherwise to a branded drug when a less costly generic equivalent or other alternative is available. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average manufacture price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of<font style="letter-spacing:-1.9pt;"> </font>reimbursement.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement<font style="letter-spacing:-0.3pt;"> </font>does<font style="letter-spacing:-0.3pt;"> </font>not<font style="letter-spacing:-0.3pt;"> </font>imply<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>product<font style="letter-spacing:-0.3pt;"> </font>will<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>paid<font style="letter-spacing:-0.3pt;"> </font>for<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>all<font style="letter-spacing:-0.3pt;"> </font>cases<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>at<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.3pt;"> </font>rate<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.3pt;"> </font>covers<font style="letter-spacing:-0.3pt;"> </font>our<font style="letter-spacing:-0.3pt;"> </font>costs, including research, development, intellectual property, manufacture, sale and distribution<font style="letter-spacing:0.15pt;"> </font>expenses.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have obtained coverage for WAKIX from certain third-party payors, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use WAKIX unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of WAKIX. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. We may suffer loss<font style="letter-spacing:-0.45pt;"> </font>of corporate reputation due to industry-wide legislative or public scrutiny of our pricing decisions and practices within an increasingly price-sensitive<font style="letter-spacing:-0.25pt;"> </font>environment.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>Despite obtaining formulary approval from certain third-party payors, sometimes with prior authorization or other formulary restrictions and requirements, including documented failure or inadequate response to alternative treatments, we expect to experience pricing pressures in connection with the sale of WAKIX due to the trend toward cost containment, managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. Large public and private payors, managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, are questioning the coverage of, and challenging the prices charged for medical products and services, and many third- party payors limit coverage of, or reimbursement for, newly approved health care products. The downward pressure on healthcare costs in general, particularly prescription medicines, medical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for WAKIX.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These cost-control initiatives could decrease the price we have established for WAKIX, which could result in product revenues being lower than anticipated. The pricing, coverage and reimbursement of WAKIX must be adequate to support a commercial infrastructure. If the price for WAKIX decreases or if governmental and other third-party payors do not provide adequate coverage and reimbursement levels, our revenue, gross margins and prospects for profitability will suffer.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have not taken any steps to attain regulatory or patent approvals in any specific markets outside of the United States, we plan to explore obtaining additional licensing rights from Bioprojet to expand into international markets with WAKIX<font style="font-weight:bold;">. </font>Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries will likely put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for WAKIX. Accordingly, in markets outside the United States, the reimbursement for WAKIX may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and<font style="letter-spacing:-0.4pt;"> </font>profits.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">WAKIX has been approved by the FDA for the treatment of EDS in adult patients with narcolepsy, and cataplexy in adult patients with narcolepsy. Regulatory approval is limited by the FDA to the specific indication for which approval has been granted and, unless we seek regulatory approval for additional indications, we will be prohibited from marketing pitolisant for other indications. We may be subject to fines, penalties or injunctions if we are determined to have promoted or be promoting the use of pitolisant for unapproved or &#8220;off-label&#8221; uses, resulting in damage to our reputation and business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we received approval for the indications of the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy, WAKIX is not indicated to treat any other conditions. We are prohibited from promoting WAKIX for any other indication unless we are granted FDA approval for such indication. The FDA strictly regulates the promotional claims that may be made about prescription products, and WAKIX may not be promoted for uses that are not approved by the FDA as reflected in its approved labeling. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While physicians may choose to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications that are not specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biotechnology or pharmaceutical companies on off-label use. If the FDA determines that our promotional activities constitute promotion of an off-label use, it could request that we modify our promotional materials and subject us to FDA regulatory or enforcement actions as well as actions by other agencies, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, mandatory or voluntary recalls, civil fines, disgorgement of money, operating restrictions, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement, injunctions or criminal prosecution, any of which could significantly harm our<font style="letter-spacing:-0.25pt;"> </font>business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">WAKIX or any of our future product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, reduce the commercial attractiveness of a prescribing label or result in significant negative consequences following regulatory approval, if approved.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a>Clinical trials of WAKIX or other product candidates we may develop could reveal a high and unacceptable incidence and severity of undesirable side effects. Undesirable side effects could adversely affect patient enrollment in clinical studies, cause us or regulatory authorities to interrupt, delay or halt clinical studies </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or result in the delay, denial or withdrawal of regulatory approval by the FDA or other regulatory authorities. Undesirable or adverse side effects also could result in regulatory authorities mandating a more restrictive prescribing label for the product, which, in turn, could limit the market acceptance of the product even if approved for marketing and commercialization.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug-related side effects could result in potential product liability claims. We believe our product liability insurance coverage is sufficient in light of our clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts or maintain coverage at all to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations, business and financial condition. In<font style="letter-spacing:-0.4pt;"> </font>addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, significant negative media attention, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our current product candidate or any future product candidate, product recalls, restrictions on labeling, marketing or promotion, decreased demand for our product candidates, if approved for marketing, and loss of<font style="letter-spacing:-0.15pt;"> </font>revenue.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if we or others later identify undesirable side effects caused by WAKIX, either in the post-marketing setting or in clinical trials in other potential indications for which we develop pitolisant, or in clinical trials for other product candidates, a number of potentially significant negative consequences could result, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the delay, prevention or withdrawal of approvals by regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the requirement of additional warnings on the prescribing label;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the requirement of a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">designation as a controlled substance by the DEA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">litigation and the potential to be held liable for harm caused to patients; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an adverse effect on our reputation.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of pitolisant and could significantly harm our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have never commercialized a product candidate prior to WAKIX and we may lack the necessary expertise, personnel and resources to successfully commercialize WAKIX or any other potential product candidates that receive regulatory approval on our own or together with collaborators.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WAKIX is our first commercialized product. Prior to this, our operations had been limited to organizing and staffing our company, business planning, raising capital, acquiring the rights to our product candidates and undertaking preclinical studies and clinical trials of our product candidates. We currently have no in-house manufacturing, distribution or supply capabilities. To achieve commercial success of WAKIX or any other product candidate, if approved, we will have to develop our own manufacturing, distribution and supply capabilities or outsource these activities to a third party.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are early in our commercialization efforts. Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization in the United States or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may have difficulties generating revenue from them.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an NDA is approved, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of ANDAs in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity (&#8220;NCE&#8221;). Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference listed drug.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have received five years of NCE exclusivity for WAKIX, manufacturers may seek to launch generic products following the expiration of the applicable exclusivity period we obtain, even if we still have patent protection for our product.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition that our products may face from generic versions of our products could materially and adversely affect our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators, IRBs or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of subjects or patients required for clinical trials of pitolisant in additional indications or any other product candidate may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to resubmit to an IRB and regulatory authorities for re-examination;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators, IRBs or other reviewing bodies may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, or the supply or quality of pitolisant or any other product candidate or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulators, IRBs of the institutions in which clinical trials are being conducted or data monitoring committees may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Negative or inconclusive results from our ongoing clinical trials of pitolisant for the treatment of narcolepsy, or any other clinical trial or preclinical studies in animals that we conduct, could mandate repeated or additional clinical trials and could result in changes to or delays in clinical trials in other indications. We do not know whether any clinical trials that we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market pitolisant for our initial or potential additional indications, or any other product candidate. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for pitolisant for initial or potential additional indications, or any other product candidate, may be adversely impacted.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to successfully initiate and complete clinical trials of pitolisant for potential additional indications or any other product candidate and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market pitolisant or any other product candidate would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of pitolisant or any other product candidate.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, prior to our acquisition of the rights to pitolisant, we had no involvement with or control over the nonclinical or clinical development of pitolisant. Additionally, pursuant to our collaboration agreement with Bioprojet, we will rely on data generated by Bioprojet in connection with seeking regulatory approval of pitolisant in the territories in which we have rights to develop and commercialize pitolisant. We are dependent on Bioprojet having conducted such research and development in accordance with the applicable protocols and legal, regulatory and scientific standards, having accurately reported the results of all clinical trials and other research they conducted prior to our acquisition of the rights to pitolisant, having correctly collected and interpreted the data from these trials and other research, and having supplied us with complete information, data sets and reports required to adequately demonstrate the results reported through the date of our acquisition of these assets. Problems related to predecessors could result in increased costs and delays in the development of pitolisant for additional indications, which could adversely affect our ability to generate any future revenue from sales of pitolisant, if approved for additional<font style="letter-spacing:-0.25pt;"> </font>indications.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Interim, &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose interim, &#8220;topline&#8221; or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available topline data, and the results and related findings and conclusions are subject to change following completion of the study or a full analyses of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, &#8220;topline&#8221; or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. &#8220;Topline&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, &#8220;topline&#8221; data should be viewed with caution until the final data are available. We may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim, &#8220;topline&#8221; or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials on our current timelines, or at all, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Enrollment in our clinical trials may be slower than we anticipate, leading to delays in our development timelines. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial and the proportion of patients screened that meets those criteria, our ability to obtain and maintain patient consents, and the risk that patients enrolled in clinical trials will drop out of the trials before completion.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, any negative results or new safety signals we or third parties may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in our clinical trials. Similarly, negative results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials. In addition, marketing authorization of competitors in this same class of drugs may impair our ability to enroll patients into our clinical trials, delaying or potentially preventing us from completing recruitment of one or more of our trials. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop pitolisant or any future product candidates, or could render further development impossible. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials, and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Even though the FDA granted orphan drug designation to pitolisant for the treatment of narcolepsy, we may not be able to obtain or maintain orphan drug marketing exclusivity for this product candidate or any other product candidates.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. Pitolisant was granted orphan drug designation for the treatment of narcolepsy in 2010. Generally, if a drug with an orphan drug designation subsequently receives the first marketing<font style="letter-spacing:-0.35pt;"> </font>approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication for that time period. Under the FDA&#8217;s regulations, the FDA will deny orphan drug exclusivity to a designated drug upon approval if the FDA has already approved another drug<font style="letter-spacing:-0.45pt;"> </font>with the same active ingredient for the same indication, unless the drug is demonstrated to be clinically superior to the previously approved drug. The applicable exclusivity period is seven years in the United States. Orphan drug exclusivity in the United States may be unavailable where the indication for which the product candidate is approved is broader than the orphan-designated indication, or is otherwise different from the orphan-designated indication. For example, the FDA granted orphan drug designation for pitolisant for the treatment of narcolepsy. Even if we obtain orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the candidate from competition. WAKIX may face additional competition because different drugs with a different active moiety can still be approved for the same condition. Even after an approved drug is granted orphan exclusivity, exclusivity may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the drug to meet the needs of patients with the rare disease or condition following approval. In addition, the FDA can subsequently approve products with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. There have been legal challenges to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to<font style="letter-spacing:-0.05pt;"> </font>predict.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017 (&#8220;FDARA&#8221;). FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease or condition in order to receive orphan drug exclusivity. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to ongoing regulatory obligations and continued regulatory review with respect to WAKIX, which will result in significant additional expense. Additionally, WAKIX could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with WAKIX.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WAKIX is subject to extensive and ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, distribution, import, export, record keeping and submission of safety and other post-market information, including both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing<font style="letter-spacing:-0.5pt;"> </font>procedures conform to cGMP. As such, we and our contract manufacturers are subject to continual review and periodic inspections to assess compliance with cGMP. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality<font style="letter-spacing:-0.2pt;"> </font>control.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a>Our regulatory approval for WAKIX for the treatment of EDS or cataplexy in adult patients with narcolepsy, and any other regulatory approvals we may receive for pitolisant or any future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, which must comply with applicable GCP regulations. We could also be asked to conduct post marketing clinical studies to verify the safety and efficacy of future product candidates in general or in specific patient subsets. For example, as a part of the regulatory approval for WAKIX for the treatment of EDS in adult patients with narcolepsy, we are required to conduct post-marketing studies in women exposed to pitolisant in pregnancy, including a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">registry-based observational cohort study to assess maternal, fetal, and infant outcomes of women exposed to pitolisant during pregnancy, and another study of a different design such as a case control study or a retrospective cohort study using electronic medical record data, and a lactation study.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will also be required to report certain adverse events and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for WAKIX. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote WAKIX for indications or uses for which it does not have FDA approval. The holder of an approved NDA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a regulatory agency discovers previously unknown problems with WAKIX, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, the regulatory agency may impose restrictions on the product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issue warning or untitled letters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">impose civil or criminal penalties, including product seizures and injunctions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limit or suspend regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend any of our ongoing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to approve pending applications or supplements to approved applications submitted by us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities, on the manufacturing of our products, or on the labeling or marketing of our products; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seize or detain products or require a product recall or withdrawal of the products from the market.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from WAKIX or future product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from the sale of WAKIX or future product candidates, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory requirements and policies may change, and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or any future collaboration partner are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, may face government enforcement action and our business will suffer.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a>We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, the results of the 2020 U.S. Presidential election may affect our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these executive actions will be implemented, or whether they will be rescinded or replaced under the Biden Administration.&nbsp;&nbsp;The policies and priorities of the Biden Administration are unknown and may materially impact the regulatory framework governing our products. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforcement action</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population can also result in significant financial penalties.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. The laws that affect our current and future operations include, but are not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, in exchange for, or to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item, or service for which payment may be made, in whole or in part, under any U.S. federal healthcare programs, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers, among others, on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal civil and criminal false claims laws, such as the False Claims Act (&#8220;FCA&#8221;), which imposes significant penalties and can be enforced by private citizens through civil qui tam actions, and prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the U.S. federal government, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">state law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and may be broader in scope than their federal equivalents;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal transparency requirements detailing interactions with and payments to healthcare providers, such as the federal reporting requirements under the Physician Payments Sunshine Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the HHS information related to payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals starting January 1, 2022, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members. Failure to submit required information may result in civil monetary penalties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">state laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other health care providers and other potential referral sources, state laws that require drug manufacturers to file reports relating to pricing information and marketing expenditures, state and local laws requiring the registration of pharmaceutical sales representatives; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">similar healthcare laws in the European Union and EEA and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our business operations and current and future arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including, without limitation, our patient support and financial assistance programs, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil, administrative and criminal penalties, damages, fines, the curtailment or restructuring of our operations, contractual damages, disgorgement, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, the exclusion from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to market pitolisant, if approved, and adversely impact our financial results. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the applicable regulatory agencies or the courts, and their provisions are open to a variety of interpretations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;) went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the California Privacy Rights Act (the &#8220;CPRA&#8221;) recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or<font style="letter-spacing:-0.4pt;"> </font>conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a>Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. If we or third-party CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Clinical practice guidelines and recommendations published by various organizations could have significant influence on the use of WAKIX.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may publish guidelines or recommendations to the healthcare and patient communities. The recommendations of these groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines suggesting the reduced use of WAKIX or the use of competitive or alternative products as the standard of care to be followed by patients and healthcare providers could result in decreased use of WAKIX.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Product candidates we develop in the future may be classified as controlled substances, the making, use, sale, importation, exportation and distribution of which are subject to regulation by state, federal and foreign law enforcement and other regulatory agencies.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates we develop in the future may be classified as controlled substances, which are subject to state, federal and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation and distribution. Controlled substances are regulated under CSA and regulations of the DEA.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a>The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various states also independently regulate controlled substances. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rulemaking or a legislative action. State scheduling may delay commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. We or our collaborators must also obtain separate state registrations in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any of our products or product candidates classified as controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates, and, in the case of our approved products, the ability to produce and distribute our products in the volume needed to meet commercial demand.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and commercializing our product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our approved products or product candidates that are classified as controlled substances.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Enacted and future healthcare legislative changes may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the European Union and other some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any products for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the ACA, was enacted to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the healthcare industry, and impose additional healthcare policy reforms. The law has continued the downward pressure on pharmaceutical pricing, especially under the Medicare program, and increased the industry&#8217;s regulatory burdens and operating costs. Among the provisions of the ACA of importance to the pharmaceutical industry and our potential product candidates are the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, non-deductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program for branded and generic drugs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries under their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishment of a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, executive and legislative challenges to certain aspects of the ACA. The U.S. Supreme Court is currently reviewing the constitutionality of the ACA in its entirety. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. Additionally, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period in which the government may recover overpayments to providers from three to five years.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. While any proposed measures will require authorization through additional<font style="letter-spacing:-0.4pt;"> </font>legislation to become effective, the probability of their success is uncertain, particularly in light of the new Presidential administration.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third- party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our commercial products and product candidates, once approved, or put pressure on our product pricing.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a>In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost containment measures, legislative developments at the European Union</font><font style="letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post- approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare</font><font style="letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs that we participate in, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We participate in and have certain price reporting obligations to the Medicaid Drug Rebate Program. Under the Medicaid Drug Rebate Program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part B. Those rebates are based on pricing data we have to report on a monthly and quarterly basis to the CMS, the federal agency that administers the Medicaid Drug Rebate Program. These data include, among other things, the average manufacturer price (&#8220;AMP&#8221;) and, in the case of innovator products, the best price (&#8220;BP&#8221;) for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the U.S. in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. We are liable for errors associated with our submission of pricing data and for any overcharging of government payors. For example, failure to submit monthly and/or quarterly AMP and BP data on a timely basis could result in a civil monetary penalty for each day the submission is late beyond the due date. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the Federal False Claims Act and other laws and regulations.<font style="letter-spacing:-0.65pt;"> </font>Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial<font style="letter-spacing:-0.3pt;"> </font>condition.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a>Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the 340B program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The ACA expanded the list of covered entities to include certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, but exempts &#8220;orphan drugs&#8221; from the ceiling price requirements for these covered entities. The 340B ceiling price is calculated using a statutory formula based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program, and in general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or other legislation or regulation could affect our 340B ceiling price calculations and negatively impact our results of operations commercializing pitolisant. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to be eligible to have our products that we successfully commercialize paid for with federal funds under the Medicaid program and purchased by certain federal agencies and grantees, we also have to participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;), Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. As part of this program, we are obligated to make our products available for procurement on an FSS contract under which we must comply with standard government terms and conditions and charge a price that is no higher than the statutory Federal Ceiling Price (&#8220;FCP&#8221;) to four federal agencies (VA, U.S. Department of Defense (&#8220;DOD&#8221;), Public Health Service, and U.S. Coast Guard).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and antimony laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the United States domestic bribery statute contained in 18 U.S.C. &#167; 201, the United States Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government- affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and<font style="letter-spacing:-0.25pt;"> </font>unpredictable.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a>Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability of the FDA to timely review and process our regulatory submissions, which </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could have a material adverse effect on </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our business. Further, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon closing of this offering and in our operations as a U.S. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public company, future government shutdowns</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or delays</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> could </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We will need to obtain FDA approval of any proposed product names, and any failure or delay associated with such approval may adversely affect our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any proprietary name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the USPTO. The FDA reviews proposed product names, considering both the potential for the name to lead to medical errors due to confusion with other product names and whether the proposed name is overly fanciful, misleadingly implies unique effectiveness or composition, or contributes to overstatement of product efficacy, minimization of risk, broadening of product indications or unsubstantiated superiority. If the FDA objects to any of our proposed product names, we may be required to adopt an alternative name for our product candidates. If we adopt an alternative name, we would lose the benefit of our existing trademark applications for such product candidate, and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely, and will continue to rely, on a combination of patents, trademarks and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our current and future product candidates. Our success depends in large part on our licensor&#8217;s ability to obtain and maintain patent protection in the United States with respect to WAKIX and our ability to obtain and maintain patent protection in the United States and any other relevant foreign jurisdictions with respect to any future product candidates that we develop. We seek to ensure that our current and future licensors obtain appropriate patent protection to all product candidates that we license from them. The patent prosecution process is expensive and time- consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely<font style="letter-spacing:-0.25pt;"> </font>manner.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio comprises three U.S. patents exclusively licensed to us from Bioprojet. One U.S. patent, No. 8,207,197 has claims directed to a polymorph, i.e. a specific crystalline form, of pitolisant and, methods for preparing that polymorph of pitolisant, which is expected to expire in February 2029 without taking into consideration any possible patent term extension. A second U.S. patent, No. 8,486,497, has claims directed to methods of treating excessive daytime sleepiness by administering pitolisant, which is expected to expire in September 2029 without taking into consideration any possible patent term extension. With all applicable patent term adjustments available and granted to us, the term of the last-to-expire pitolisant-related patent in our portfolio extends to September 2029.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patents that we in-license now or the patents and patent applications that we own or in-license in the future may not have patentable claims that protect our current and future product candidates in the relevant jurisdictions where we intend to commercialize such products. There is no assurance that we and our licensor are aware of all potentially relevant prior art relating to future patent applications. As such, the patent examiner may find prior art that can prevent a patent from issuing from a pending patent application. During the patent examination process, we or our licensor may be required to narrow the pending claims to overcome prior art, a process that may limit the scope of patent protection. Even if patents do successfully issue based on our future patent applications, and even if the issued patents cover our current and future product candidates, including their compositions formulation, method of manufacture, and method of use, third parties may challenge our issued patents&#8217; validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us in the future could deprive us of rights necessary for the successful commercialization of any of our current or future product candidates, if approved. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be<font style="letter-spacing:-0.1pt;"> </font>reduced.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we may own or in-license in the future with respect to our current and future product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our current or future product candidates, it could dissuade other companies from collaborating with us to develop future product candidates, and threaten our ability to commercialize our current and future product candidates. Notably, pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any such outcome could have an adverse effect on our business.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and<font style="letter-spacing:-0.6pt;"> </font>other jurisdictions are typically not published until 18 months after filing, or in some cases not at<font style="letter-spacing:-0.45pt;"> </font>all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act made a number of significant changes to United States patent laws. These include provisions that affect the way patent applications are prosecuted and challenged at the USPTO and may also affect patent litigation. The USPTO has developed and continues to develop new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it remains unclear what impact the Leahy-Smith Act, subsequent rulemaking, and judicial interpretation of the Leahy-Smith Act and regulations will have<font style="letter-spacing:-0.65pt;"> </font>on the operation of our business. However, the Leahy- Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business and financial condition. Moreover, future changes to the patent laws of the United States and foreign jurisdictions may adversely affect the term, scope, validity and enforceability of our or our licensor&#8217;s patent rights. For example, a new bill (Terminating the Extension of Rights Misappropriated Act, or TERM Act, H.R. 3199) percolating through the United States Congress aims to reduce the term of certain drug patents in order to ease generic entry and increase competition.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inventorship and ownership rights for patents that we in-license or may own or in-license in the future may be challenged by third parties. Such challenges could result in loss of exclusive rights to such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or require us to obtain a license from such third parties on commercially reasonable terms to secure exclusive rights. If any such challenges to inventorship or ownership were asserted, there is no assurance that a court would find in our favor or that, if we choose to seek a license, such license would be available to us on acceptable terms or at all.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in pre- and post-issuance opposition, derivation, re-examination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications, whether owned or in-licensed now or in the future, is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a>The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our licensed patents may be challenged in the courts or patent offices in the United States. Such challenges may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after the filing of the earliest non-provisional application to which the patent claims priority. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. We may be required to disclaim a portion of patent term in order to overcome double patenting rejections from the patent office, thus potentially shortening our exclusivity period. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed certain intellectual property rights covering pitolisant from Bioprojet, and we may license intellectual property rights from others in the future. If, for any reason, our license agreement with Bioprojet or any future licensor is terminated or we otherwise lose the rights associated with a license, it could adversely affect our business. Our license agreement with Bioprojet imposes, and any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology, or having to negotiate new or reinstated licenses on less favorable terms, or enable a competitor to gain access to the licensed technology.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term for our current and future product candidates, our business may be harmed.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will largely depend on our licensor&#8217;s ability to obtain and maintain patent and other intellectual property in the United States for pitolisant, and our target indications, and our ability to maintain obtain and maintain patent and other intellectual property in the United States for any product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting product candidates might expire before or shortly after such candidates begin to be commercialized. We expect to seek extensions of patent terms in the United States.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our current and future product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during drug development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our licensor are unable to extend the expiration date of our or their existing patents or obtain new patents with longer expiry dates, as applicable, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our current and future product candidates can be challenged by third parties.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One or more third parties may challenge the current patents, or future patents within our portfolio, which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non-infringement. For example, if a third party files an ANDA for a generic drug containing pitolisant, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1) there is no patent information listed in the FDA&#8217;s Orange Book with respect to our NDA for the applicable approved product candidate; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved product candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, a third party may challenge the current patents, or future patents within our portfolio, which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing, for example, pitolisant, and relies in whole or in part on studies conducted by or for us.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our current and future product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain patents and patent applications, whether owned or in-licensed now or in the future, covering any of our current or future product candidates, our competitors might be able to enter the market, which would have an adverse effect on our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may need to acquire or license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our current and future product candidates. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future product candidates. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize our current and future product candidates, if approved, would likely be delayed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse effect on our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our current or future product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the pharmaceutical and biotechnology industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are or may in the future be developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third<font style="letter-spacing:-0.05pt;"> </font>parties.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current and future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our current and future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our current and future product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may<font style="letter-spacing:-0.45pt;"> </font>be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and<font style="letter-spacing:-0.3pt;"> </font>inventions.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current and future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our current and future product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our current and future product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our current and future product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our current product candidate in any jurisdiction.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that we and our current and future licensors will fail to identify patentable aspects of research and development output before it is too late to obtain patent protection. The patent applications that we may own or in-license in the future may fail to result in issued patents with claims that cover our current and future product candidates. We and our current and future licensors may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of the patent applications, which may result in such patents being narrowed, invalidated or held unenforceable.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively affect our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively affect our ability to develop and market our products.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe or otherwise violate the patents of our licensor or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that an asserted patent is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the asserted patent does not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of asserted patents at risk of being invalidated or interpreted narrowly and could put a related patent application at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte re-examinations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we may license in the future, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a>We may not be able to detect or prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our in-licensed patents, any patents that may be issued as a result of our future patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States has recently enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have issued numerous precedential opinions in recent years narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce<font style="letter-spacing:-0.6pt;"> </font>patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the<font style="letter-spacing:-0.15pt;"> </font>future.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, non-transferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a>We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self- executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our licensors fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we and our licensors are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Any trademarks we have obtained or may obtain may be infringed or be successfully challenged, resulting in harm to our business.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely on trademarks as one means to distinguish any of our current and future product candidates that are approved for marketing from the products of our competitors. For example, we are marketing pitolisant for the treatment of EDS or cataplexy in adult patients with narcolepsy under the brand name WAKIX, which we have licensed from Bioprojet. We may design or create new trademarks and apply to register them, our trademark applications may not be approved in the United States or any relevant foreign jurisdiction. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Being a Public Company</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes Oxley Act&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies. Our management and other personnel will need to devote a substantial amount of time to compliance with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. If, notwithstanding our efforts to comply with new or changing laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. Further, failure to comply with these laws, regulations and standards may make it more difficult and more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, which could make it more difficult for us to attract and retain qualified members to serve on our board of directors or committees or as members of senior management. We cannot predict or estimate the amount of additional costs we will incur as a public company or the timing of such costs.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of becoming a public company, we will be obligated to develop and maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common shares.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a>We will be required, pursuant to Section 404 of the Sarbanes Oxley Act (&#8220;Section 404&#8221;), to furnish a report by management on, among other things, the effectiveness of our internal controls over financial reporting for the fiscal year beginning January 1, 2022. This assessment will need to include disclosure of any material </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weaknesses identified by our management in our internal controls over financial reporting. Our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting until our first annual report required to be filed with the SEC following the date we are no longer an emerging growth company, as defined in the JOBS Act. At such time as we are required to obtain auditor attestation, if we then have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm. We will be required to disclose significant changes made in our internal controls procedures on a quarterly</font><font style="letter-spacing:-0.25pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are beginning the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404, and we may not be able to complete our evaluation, testing and any required remediation in a timely fashion. Our compliance with Section 404 will require that we incur substantial legal, accounting and other compliance expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and finance staff and consultants with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the evaluation and testing process of our internal controls, if we identify one or more material weaknesses in our internal controls over financial reporting, we will be unable to assert that our internal controls over financial reporting are effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal controls over financial reporting in the future. Any failure to maintain effective internal controls over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal controls over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal controls over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal controls over financial reporting, or to implement or maintain other effective control systems required of public companies, could also negatively impact our ability to access to the capital markets.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, effective disclosure controls and procedures enable us to make timely and accurate disclosure of financial and non-financial information that we are required to disclose. As a public company, if our disclosure controls and procedures are ineffective, we may be unable to report our financial results or make other disclosures accurately on a timely basis, which could cause our reported financial results or other disclosures to be materially misstated and result in the loss of investor confidence and cause the market price of our common shares to decline. If we were to subsequently elect instead to comply with these public company effective dates, such election would be irrevocable pursuant to the JOBS Act.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that have not made this election.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For as long as we continue to be an emerging growth company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a>We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of the date of the closing of our IPO; (iii) the date on which we have issued more than $1.0 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">billion in nonconvertible debt during the previous three fiscal years; or (iv) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our management team has limited experience managing a public company.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our chief executive officer does not have experience managing a public company, interacting with public company investors or complying with the increasingly complex laws pertaining to public companies. Our management team, as a whole, may not successfully or efficiently manage the transition to being a public company subject to significant regulatory oversight and reporting<font style="letter-spacing:-0.35pt;"> </font>obligations under the federal securities laws and the continuous scrutiny of securities analysts and<font style="letter-spacing:-0.45pt;"> </font>investors. These new obligations and constituents will require significant attention from our senior management, particularly from our chief executive officer, and could divert their attention away from the day-to-day management of our business, which could adversely affect our revenue, business, results of operations and financial condition.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Risks Related to Ownership of our Common Stock</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our directors, officers and principal stockholders beneficially own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our directors, officers, five percent or greater stockholders, and their respective affiliates beneficially owned in the aggregate approximately 80% of our outstanding voting stock. As a result, these stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, and approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders<font style="font-style:italic;">.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Future sales of our common stock in the public market, including our directors, officers, or significant shareholders, could cause our share price to fall.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Certain holders of our common stock are entitled to rights with respect to registration of such shares under the Securities Act pursuant to a registration rights agreement between such holders and us. If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. Subject to compliance with applicable securities laws, our officers, directors and other shareholders and their respective affiliates may sell some or all of their common shares in the future. No prediction can be made as to the effect, if any, such future sales will have on the market price of the common shares prevailing from time to time.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if our operating results do not meet the expectations of the investor community, one or more of the analysts who cover our company may change their recommendations regarding our company, and our stock price could decline.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our quarterly operating results may fluctuate significantly.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variations in the level of expenses related to our development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">addition or termination of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any intellectual property infringement lawsuit in which we may become involved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory developments affecting pitolisant;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the achievement and timing of milestone payments under our existing collaboration and license agreements; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the level of underlying demand for WAKIX and customers&#8217; buying patterns.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be maintained.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock only recently began trading on the Nasdaq Global Market, and we can provide no assurance that we will be able to maintain an active trading market on The Nasdaq Global Market or any other exchange in the future. If an active trading market for our common stock is not maintained, or if we fail to satisfy the continued listing standards of The Nasdaq Global Market for any reason and our common stock is delisted, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase our common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the stock price of our common stock to decline.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. We also expect to issue common stock to employees, consultants and directors pursuant to our equity incentive plans. If we sell common stock, convertible securities or other equity securities in subsequent transactions, or common stock is issued pursuant to equity incentive plans, investors may be materially diluted. New investors in such subsequent transactions could gain rights, preferences and privileges senior to those of holders of our common stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">We have never paid dividends on our common stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments. Furthermore, we are party to a Credit Agreement with OrbiMed that contains negative covenants that limit our ability to pay dividends. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">providing for a classified board of directors with staggered, three-year terms;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">authorizing our board of directors to issue preferred stock with voting or other rights or preferences that could discourage a takeover attempt or delay changes in control;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">prohibiting cumulative voting in the election of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">providing that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">prohibiting the adoption, amendment or repeal of our amended and restated bylaws or the repeal of the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors without the required approval of at least 66.67% of the shares entitled to vote at an election of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">prohibiting stockholder action by written consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limiting the persons who may call special meetings of stockholders; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requiring advance notification of stockholder nominations and proposals.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Under Section 203 of the DGCL, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and under Delaware law could discourage potential takeover attempts, reduce the price investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any derivative action or proceeding brought on our behalf;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any of our current or former directors, officers, employees or our stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws (as either may be amended from time to time) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stockholders are deemed to have notice of and have consented to the provisions of our amended and restated certificate of incorporation related to choice of forum. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58363687"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927405"></a><a name="_Toc58363688"></a><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own any real property. Our corporate headquarters are located in Plymouth Meeting, Pennsylvania.&nbsp;&nbsp;In December 2020, we leased additional office space at this same location, which increased our footprint to approximately 28,638 square feet of space pursuant to a lease that expires in 2024. We believe that our facilities are suitable to meet our current needs.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927406"></a><a name="_Toc58363689"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.98%;"><a name="_Toc57927407"></a>From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We do not believe that we have any pending litigation that, individually or in the aggregate, would have a material adverse effect on our results of operations, financial condition or cash flows.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58363690"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><a name="PART_II"></a><font style="font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><a name="PART_II"></a>Part</font><font style="font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"> II</font></p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927409"></a><a name="_Toc58363692"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Market Information</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;HRMY&#8221; on August 19, 2020. Prior to that date, there was no public trading market for our common stock.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Holders</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 15, 2021, we had 53 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of beneficial owners of our common stock represented by these holders.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay future indebtedness, if any, and therefore we do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to compliance with contractual restrictions and covenants in the agreements governing our current and future indebtedness. Any such determination will also depend upon our business prospects, results of operations, financial condition, cash requirements and availability, industry trends and other factors that our board of directors may deem relevant. </p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">IPO Summary</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, we completed the IPO of our common stock, in which we issued and sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option at a price of $24.00 per share for an aggregate price of approximately $147.6 million. The shares began trading on the Nasdaq Global Market on August 19, 2020. The offer and sale of the shares in our IPO was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-240122), which was declared effective by the SEC on August 18, 2020 (the &#8220;Registration Statement&#8221;). The offering commenced on August 6, 2020 and terminated after the sale of all securities registered pursuant to the Registration Statement. Goldman Sachs &amp; Co. LLC, Jefferies LLC and Piper Sandler &amp; Co. acted as managing underwriters for the offering. We raised approximately $135.4 million, after deducting underwriting discounts and commissions and offering expenses of approximately $12.2 million. None of these expenses consisted of direct or indirect payments made by us to (i) our directors, officers or their associates, (ii) persons owning 10% or more of our common stock or (iii) to our affiliates. There has been no material change in the planned use of proceeds from our IPO as described in the Prospectus. Net proceeds from our IPO have been invested in short-term, interest-bearing, investment grade securities. </p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Between January 1, 2020 and August 17, 2020, we issued to certain employees and directors an aggregate of 21,836 shares of our common stock upon the exercise of options issued under the 2017 Equity Plan at an exercise price of $8.22 per share, for an aggregate exercise price of $0.2 million.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated thereunder), or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927410"></a><a name="_Toc58363693"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927411"></a><a name="_Hlk66100731"></a><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of</font><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> Financial Condition and Results of Operations.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; and in other parts of this Annual Report.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927413"></a>We are a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. Our product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (&#8220;MOA&#8221;) specifically designed to increase histamine signaling in the brain by binding to H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors. In August 2019, WAKIX was approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the treatment of excessive daytime sleepiness (&#8220;EDS&#8221;) in adult patients with narcolepsy, and its U.S. commercial launch was initiated in November 2019. On October 13, 2020, WAKIX was approved by the FDA for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first-and-only approved product for patients with narcolepsy that is not scheduled as a controlled substance by the Drug Enforcement Administration (the &#8220;DEA&#8221;).</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to pursue label expansion for WAKIX in narcolepsy in pediatric patients and engage with the FDA in pursuit of pediatric exclusivity. We currently expect to initiate a Phase 3 clinical trial in pediatric patients in the second half of 2021 in pursuit of indications for both EDS and cataplexy. We believe that pitolisant&#8217;s ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological disorders that are mediated through H<sub style="font-size:85%; vertical-align:bottom">3</sub> receptors and histamine signaling. We are initially focusing on the treatment of EDS associated with Prader-Willi Syndrome (&#8220;PWS&#8221;) and myotonic dystrophy, otherwise known as dystrophia myotonica (&#8220;DM&#8221;). In December 2020, we initiated a Phase 2 clinical trial to evaluate pitolisant for the treatment of EDS and other key symptoms in patients with PWS and anticipate topline results in the first half of 2022. We are also planning to commence a Phase 2 clinical trial in adult patients with DM in the first half of 2021, with topline results expected in the second half of 2022, under our open Investigational New Drug application (&#8220;IND&#8221;). Beyond these indications, we intend to further explore pitolisant in other rare neurological disorders in which fatigue and cognitive impairment are prominent symptoms with significant impact on daily functioning.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to expand our pipeline through the acquisition of additional assets that focus on addressing the unmet needs of patients with neurological disorders. We intend to target assets that will be complementary to WAKIX and our expanding list of potential new indications for WAKIX, and assets that will allow us to further leverage the expertise and infrastructure that we have successfully built at Harmony.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pitolisant was developed by Bioprojet and approved by the European Medicines Agency (&#8220;EMA&#8221;) in 2016 for the treatment of narcolepsy in adult patients with or without cataplexy. We acquired an exclusive license to develop, manufacture and commercialize pitolisant in the United States pursuant to our license agreement with Bioprojet (as amended, the &#8220;Bioprojet License Agreement&#8221;) in July 2017. See &#8220;Part I&#8212;Item 1. Business.&#8212;Strategic Agreement&#8212;License and Commercialization Agreement with Bioprojet&#8221; for further information regarding the Bioprojet License Agreement. Pitolisant was granted Orphan Drug Designation for the treatment of narcolepsy by the FDA in 2010. It received Breakthrough Therapy designation for the treatment of cataplexy in patients with narcolepsy and Fast Track status for the treatment of EDS and cataplexy in patients with narcolepsy in April 2018.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating subsidiary, Harmony Biosciences, LLC, was formed in May 2017. We were formed in July 2017 as Harmony Biosciences II, LLC, a Delaware limited liability company, and we converted to a Delaware corporation named Harmony Biosciences II, Inc. in September 2017. In February 2020, we changed our name to Harmony Biosciences Holdings, Inc. Our operations to date have consisted of building and staffing our organization, acquiring the rights to pitolisant, raising capital, opening an IND for pitolisant, initiating an Expanded Access Program (&#8220;EAP&#8221;) for pitolisant for appropriate patients in the United States, preparing and submitting our NDA for pitolisant, gaining NDA approval for WAKIX for the treatment of EDS or cataplexy in adult patients with narcolepsy, and launching and commercializing WAKIX in the United States. In addition, we have initiated or intend to initiate clinical development programs in PWS, DM and pediatric narcolepsy to pursue potential new indications. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, we completed the initial public offering (&#8220;IPO&#8221;) of our common stock, in which we sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135.4 million, after deducting underwriting discounts and commissions and offering expenses of approximately $12.2 million. Upon the closing of the IPO, all outstanding shares of our convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of our convertible preferred stock, and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 410,239 shares of common stock.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Sources of Funding</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, we generated $159.7 million of net product revenues. We have financed our operations primarily with (a) proceeds from sales of our convertible preferred stock, (b) borrowings under (i) our multi-draw term loan agreement (the &#8220;Loan Agreement&#8221;) with CRG Servicing LLC (&#8220;CRG&#8221;) and (ii) our credit agreement (the &#8220;Credit Agreement&#8221;) with OrbiMed Royalty &amp; Credit Opportunities III, LP (&#8220;OrbiMed&#8221;), and (c) proceeds from our IPO. As of December 31, 2020, we had cash, cash equivalents and restricted cash of $229.4 million and accumulated deficit of $488.2 million. As of December 31, 2020, we had outstanding debt, net of issuance costs, of $194.3 million.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our anticipated cash from operating and financing activities and existing cash and cash equivalents will enable us to meet our operational liquidity needs and fund planned investing activities for the next twelve months. We have based this estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues and expenses in future quarters may differ from our expectations as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">commercialize WAKIX in the United States for the treatment of EDS or cataplexy in adult patients with narcolepsy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur sales and marketing costs to support the commercialization of WAKIX and any additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pay royalties and make milestone payments to Bioprojet for the license of WAKIX;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur manufacturing costs for WAKIX and any additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">implement post-approval requirements related to WAKIX;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct clinical trials in PWS, DM, and potential new indications for pitolisant or any additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct a pediatric narcolepsy program in pursuit of an indication and extension of our patents based on pediatric exclusivity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct earlier stage research and development activities for pitolisant;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">support independent investigator-initiated research for which there is a valid scientific rationale;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire additional personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">invest in measures to protect and expand our intellectual property;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur interest expenses in conjunction with our debt facility;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for pitolisant or any additional product candidates that successfully complete clinical development;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">conduct additional clinical trials in pursuit of potential new indications for pitolisant; acquire or in-license other assets and technologies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur additional costs associated with being a public company.</font></p></td></tr></table></div>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Commercial Launch Metrics</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927414"></a>As of December 31, 2020, over 2,400 unique healthcare professionals (&#8220;HCPs&#8221;) (out of a total of approximately 8,000 HCPs who treat approximately 90% of diagnosed narcolepsy patients) have prescribed WAKIX since it became available in November 2019. The average number of patients on WAKIX at the end of 2020 was approximately 2,500. We have secured formulary access for approximately 80% of all insured lives (Commercial, Medicare and Medicaid) in the United States. Within these covered lives, we have observed favorable access to WAKIX subsequent to the expanded approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy in October 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Business Update</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the global impact of the COVID-19 pandemic, we have developed a response strategy that includes establishing cross-functional response teams and implementing business continuity plans to manage the impact of the pandemic on our employees, patients, HCPs, and our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite our response strategy, the COVID-19 pandemic is having an effect on our business and the pharmaceutical industry in general, and is impacting the way stakeholders interact with one another during this pandemic. We continue to leverage technology and virtual engagement initiatives to offset our reduced in-person access to HCPs. The COVID-19 pandemic, which has led to high unemployment and corresponding loss of medical insurance, has caused a change in relationship dynamics between patients and their HCPs and has impacted the way patients take, or do not take, their medication. Based on these factors, we expect that the revenue growth rate in possible future quarters may be adversely impacted by the ongoing COVID-19 pandemic.<font style="font-family:Arial;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to identify new and innovative ways to maintain meaningful engagement, generate awareness and educate our patients, HCPs and payors to minimize the pressure from the COVID-19 pandemic on our business and support our commercial launch performance. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our commercialization activities, we believe the COVID-19 pandemic is putting pressure on top-line prescription demand for WAKIX, primarily due to (i) our field sales team&#8217;s reduced ability to access HCPs in person, and (ii) fewer patients seeing HCPs for prescriptions or treatments. The impact on demand for WAKIX may also be related to a reduced ability of prescribers to diagnose narcolepsy patients given the limitations in access to sleep testing, the reduced ability to see patients due to (i) cancelled appointments and (ii) the reprioritization of healthcare resources toward the treatment of COVID-19, both of which lead to fewer prescriptions. Despite these challenges, we continue to engage and educate HCPs virtually on the overall benefit/risk profile of WAKIX and continue to provide support for people living with narcolepsy. As offices, clinics and institutions have begun to allow limited in-person interactions pursuant to health authority and local government guidelines, our field teams continue to re-initiate in-person interactions with HCPs and customers, but the timing and level of engagement vary by account and region and may be adversely impacted in the future where reemergence or future outbreaks of COVID-19 may occur. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High unemployment and the corresponding loss of health insurance is causing some eligible patients to shift from commercial insurance to free goods and patient assistance programs, which impacts our ability to convert demand to revenue. Depending on the scale and ultimate duration of the COVID-19 pandemic and the extent of an economic slowdown, widespread unemployment and resulting loss of employer-sponsored insurance coverage, we may experience a shift from commercial payor coverage to government payor coverage or continued/increased demand for patient assistance and/or free drug programs, which could further impact our net revenue in the coming quarters.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Supply Chain</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently expect to have adequate supply of WAKIX through the first half of 2022, with additional API on-hand inventory to support 12 to 18 months beyond this time frame. We are working closely with our third-party manufacturers, distributors and other partners to manage our supply chain activities and mitigate potential disruptions to our product supplies as a result of the COVID-19 pandemic. We believe that our access to the required production lines to produce additional API and WAKIX finished product throughout the next 12-18 months will not be directly impacted by the potential need to reprioritize manufacturing resources due to the production of materials utilized for COVID-19 vaccines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing partners in France and the United States continue to be operational. If the COVID-19 pandemic persists for an extended period of time and/or begins to impact essential distribution systems such as transatlantic freight, FedEx, UPS and postal delivery, we could experience disruptions to our supply chain and operations with associated delays in the manufacturing and supply of our products.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has negatively impacted the pharmaceutical industry&#8217;s ability to conduct clinical trials.&#160;While we initially experienced some challenges due to the COVID-19 pandemic, we have taken measures and put contingency plans in place in order to advance our clinical development programs. We have implemented remote and virtual approaches to clinical trials, including using telemedicine for remote clinic visits to perform efficacy assessments and sending out licensed HCPs to each patient to collect safety assessments (e.g. labs, electrocardiograms) as required by the protocols. We are also performing remote site visits and data monitoring where possible. These measures are being instituted with the intent of maintaining patient safety and trial continuity while preserving study integrity. One unique challenge we are facing is the ability to access sleep labs during the COVID-19 pandemic in order to conduct objective sleep testing, which is required for some of our clinical trials. In addition, we rely on contract research organizations (&#8220;CROs&#8221;) or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic. If the COVID-19 pandemic continues and persists for an extended period of time, or reemerges in the future, we could experience significant delays in our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Development and Other Financial Impacts</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of domestic and global financial markets. If the disruption persists and/or worsens, we may be unable to access additional capital, which could negatively affect our ability to execute on certain corporate development transactions or other important investment opportunities. The pandemic could also impact our ability to conduct in-person due diligence, negotiations, and other interactions to identify new opportunities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has also affected, and continues to affect, our business operations and financial results. The extent of the impact of the COVID-19 pandemic on our ability to generate sales of, and revenues from, our approved products, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of or reemergence of outbreaks, governmental travel restrictions, quarantines, social distancing and business closure requirements in the United States, France, and other countries, and the effectiveness of actions taken globally to contain and treat COVID-19.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Responsibility Impact</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to provide support to our local communities, patient-focused organizations and other charitable organizations during the COVID-19 pandemic with relief efforts, including corporate donations, supplying food, medical supplies and other resources. For the safety and well-being of our employees, consultants and their families, during the COVID-19 pandemic, we have abided by the government issued work from home orders. We continue to clean and sanitize our offices on a regular basis and have implemented COVID-19 screening procedures and social distancing guidelines before allowing employees or guests to enter our offices. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</font></p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not generate any revenue from inception until the fourth quarter of 2019. Our current product, WAKIX, was approved by the FDA for the treatment of EDS in adult patients with narcolepsy in August 2019, became commercially available in November 2019 and was approved by the FDA for the treatment of cataplexy in adult patients with narcolepsy in October 2020. For the years ended December 31, 2020 and 2019, we had $159.7 million and $6.0 million, respectively, of net product revenue. </p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue consists of net sales of WAKIX. Net sales represent the gross sales of WAKIX less provisions for product sales discounts and allowances. At this time, these provisions include trade allowances, rebates to government and commercial entities, and discounts. Although we expect net sales to increase over time, the provisions for product sales discounts and allowances may fluctuate based on the mix of sales to different customer segments and/or changes in our accrual estimates. For further discussion of the components of Revenue, see &#8220;&#8212;Critical Accounting Policies and Significant Judgments and Estimates.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Product Sales</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales includes manufacturing and distribution costs, the cost of the drug substance, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs and salaries of employees involved with production. We began capitalizing inventory upon FDA approval of WAKIX. A portion of the inventory sold during the year ended December 31, 2020 was produced prior to FDA approval and, therefore, expensed previously as research and development expense in 2019 in the amount of $1.3 million. Excluded from cost of product sold is amortization of acquired developed technology of $9.8 million and $2.8 million in the years ended December 31, 2020 and 2019, respectively. </p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Previously expensed inventory that was manufactured in anticipation for commercialization preapproval has not had a material impact on our historical results of operations and is not expected to have a material impact on future results of operations. Further, previously expensed inventory has not had a material impact on our gross margin percentage historically, and we do not anticipate a material impact on our gross margin percentage once our previously expensed inventories have been exhausted. Our cost of product sales is increasing moderately as we continue to ramp up production and sales infrastructure to meet expected demand for WAKIX.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shelf life of our product is three years from date of manufacture, with the earliest expiration of current inventory expected to be May 2022. As of December 31, 2020, we expect our existing inventory to have minimal obsolescence. We will continue to assess obsolescence in future periods as demand for WAKIX and the rate of inventory turnover evolves.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses have primarily been limited to the license of the rights to pitolisant, the establishment of an EAP to provide appropriate patients with pitolisant at no cost as part of a clinical trial to assess safety prior to the approval of WAKIX, the preparation of the NDA, and the initiation of a development program for new indications for pitolisant in patients with PWS, DM and pediatric narcolepsy. We also have research and development expenses related to our team of Medical Science Liaisons (&#8220;MSLs&#8221;) who interact with key opinion leaders, with a focus on the science, the role of histamine in sleep-wake state stability and the novel mechanism of action of pitolisant. In addition, our MSLs support our market access team with clinical data presentations to payors upon request. Research and development costs are expensed as incurred. We expect to significantly increase our research and development efforts as we advance our clinical programs in patients with PWS, DM and pediatric narcolepsy, and continue to expand our product-candidate pipeline. Research and development expenses include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our research and development personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">direct third-party costs such as expenses incurred under agreements with CROs, and contract manufacturing organizations (&#8220;CMOs&#8221;);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing costs in connection with producing materials for use in conducting clinical trials; other third-party expenses directly attributable to the development of our product candidates; and</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">amortization expense for assets used in research and development activities.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, WAKIX is our only product and we do not currently track our internal research and development expenses on an indication-by-indication basis as they primarily relate to personnel, early research and consumable costs, which are deployed across multiple programs. A significant portion of our research and development costs are external costs, such as fees paid to CROs and CMOs, central laboratories, contractors, and consultants in connection with our clinical development activities.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, milestone payments, and the cost of submitting an NDA to the FDA (and/or other regulatory authorities). We expect our research and development expenses to be significant over the next several years as we advance our current clinical development programs and prepare to seek regulatory approval for additional indications for pitolisant as well as potential new product candidates.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any additional indications for pitolisant or other product candidates that we move forward for regulatory approval. There are numerous risks and uncertainties associated with developing product candidates, including uncertainty related to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the duration, costs and timing of clinical trials of our current development programs and any further clinical trials related to new product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impact of the COVID-19 pandemic on the ability to initiate new clinical trials and/or maintain the continuity of ongoing clinical trials that could be impacted by future shelter-in-place orders and needs of the health care system to focus on managing patients affected by COVID-19;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">receiving Bioprojet&#8217;s consent to pursue additional indications for pitolisant;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the acceptance of INDs for our planned clinical trials or future clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the successful and timely enrollment and completion of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the successful completion of preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended populations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the entry into collaborations to further the development of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successfully launching our product candidates and achieving commercial sales, if and when approved.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of any of our programs or any product candidate we develop would significantly change the costs, timing and viability associated with the development and/or regulatory approval of such programs or product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our sales and marketing expenses have primarily been limited to the market development and launch activities of WAKIX for the treatment of EDS in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy. Market development and commercial launch activities account for a significant portion of the overall company operating expenses and are expensed as they are incurred. Our sales and marketing expenses are increasing in the near- and mid-term to support our indications for the treatment of EDS or cataplexy in adult patients with narcolepsy and to expand our portfolio with the anticipated growth from potential additional indications. </p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our sales and marketing personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">healthcare professional-related expenses, including marketing programs, healthcare professional promotional medical education, disease education, conference exhibits and market research;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">patient-related expenses, including patient awareness and education programs, disease awareness education, patient reimbursement programs, patient support services and market research;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market access expenses, including payor education, specialty pharmacy programs and services to support the continued commercialization of WAKIX; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">secondary data purchases (i.e. patient claims and prescription data), data warehouse development and data management.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these expenses include external costs such as website development, media placement fees, agency fees for patient, medical education and promotional expenses, market research, analysis of secondary data, conference fees, consulting fees and travel expenses.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for our personnel in executive, legal, finance and accounting, human resources, investor relations, and other administrative departments. General and administrative expenses also consist of office leases, and professional fees, including legal, tax and accounting and consulting fees.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future to support our continued commercialization efforts, ongoing and future potential research and development activities, and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees paid to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. If any of our current or future indication expansion programs or new product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-weight:bold;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Paragon Agreements</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were party to a management services agreement (the &#8220;Management Services Agreement&#8221;) with Paragon Biosciences, LLC (&#8220;Paragon&#8221;), entered into on September 22, 2017, pursuant to which Paragon provided us with certain professional services. In exchange for services provided to us under the Management Services Agreement, we paid Paragon a management fee of $0.3 million per each calendar month. We terminated the Management Services Agreement upon the consummation of our IPO. In connection with such termination, we paid Paragon a termination fee of $2.6 million. </p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also party to a right-of-use agreement with Paragon whereby we have access to and the right to use certain office space leased by Paragon in Chicago, Illinois. For the year ended December 31, 2020, we paid fees of $0.3 million pursuant to this agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><font style="font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Loss on Debt Extinguishment</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on debt extinguishment consists primarily of costs of extinguishment of debt during the period related to the prepayment of Loan Agreement with CRG. </p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Other Income / Expense, Net</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income / expense, net consists primarily of costs of the fair value of the warrants associated with the Credit Agreement we entered into with OrbiMed.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Interest Income / Interest Expense</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income / expense, net consists primarily of interest expense on debt facilities and amortization of debt issuance costs offset by interest income earned on our cash balances.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth selected items in our consolidated statements of operations for the periods presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,742</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,738</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,004</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,418</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,448</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,824</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,318</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,986</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(145,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,639</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,071</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,220</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,073</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Product Revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product revenue increased by $153.7 million, or 2,564.6%, for the year ended December 31, 2020 compared to the same period in 2019.&nbsp;&nbsp;The increase was due to the growing commercial sales of WAKIX which was launched on November 1, 2019.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Product Sales</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales increased by $26.2 million, or 1,658.9%, for the year ended December 31, 2020 compared to the same period in 2019.&nbsp;&nbsp;The increase was due to the growing commercial sales of WAKIX, which was launched on November 1, 2019. Cost of product sales is primarily comprised of the royalty payment to Bioprojet.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses decreased by $50.1 million, or 72.1%, for the year ended December 31, 2020 as compared to the same period in 2019.&nbsp;&nbsp;The decrease was primarily due to a milestone payment in February 2019 upon the acceptance of our NDA for WAKIX by the FDA in accordance with the Bioprojet License Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.04%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses increased by $11.5 million, or 26.0%, for the year ended December 31, 2020 as compared to the same period in 2019. The increase was primarily due to field sales force personnel expenses and related field sales operations associated with the commercialization of WAKIX and patient engagement and marketing activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by $3.3 million, or 9.2%, for the year ended December 31, 2020 as compared to the same period in 2019. This is primarily due to intangible asset amortization for a full year in 2020 and the amortization of the Cataplexy Milestone, additional fees associated with our IPO and expenses related to becoming a public company in 2020 and the termination fee in connection with the Management Services Agreement, offset by employee stock awards and the legal settlement with our former CEO.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loss on Debt Extinguishment</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on debt extinguishment increased $22.6 million, or 100%, for the year ended December 31, 2020 as compared to the same period in 2019 due to costs of extinguishment of debt during the period related to the prepayment of the Loan Agreement with CRG.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Expense, Net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net increased by $3.1 million, or 100%, for the year ended December 31, 2020, as compared to the same period in 2019 primarily due to the change in the fair value of warrants issued during 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Expense, Net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense increased by $22.1 million, or 364.7%, for the year ended December 31, 2020, as compared to the same period in 2019 primarily due to payment of interest on the Loan Agreement and amortization of debt issuance costs compared to the payment of interest on the Credit Agreement and amortization of debt issuance costs.&nbsp;&nbsp;This was partially offset by interest income earned on our cash balances. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For interim periods, we estimate the annual effective income tax rate and apply the estimated rate to the year-to-date income or loss before income taxes. The effective income tax rate was 0.0% for all periods. Currently, we have recorded a full valuation allowance against our net deferred tax assets, primarily related to federal and state net operating losses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have financed our operations primarily with (a) proceeds from sales of our convertible preferred stock, (b) borrowings under (i) our Loan Agreement with CRG and (ii) our Credit Agreement with OrbiMed, and (c) the proceeds from our IPO. From our inception through December 31, 2020, we have received aggregate proceeds of $345.0 million from sales of our convertible preferred stock. On August 21, 2020, we completed the IPO of our common stock, in which we sold 6,151,162 shares of our common stock, including 802,325 shares of our common stock pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at a price of $24.00 per share for net proceeds of approximately $135.4 million. As of December 31, 2020, we had cash, cash equivalents and restricted cash of $229.4 million&nbsp;&nbsp;and accumulated deficit of $488.2 million. As of December 31, 2020, we had outstanding debt, net of issuance costs, of $194.3 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a>The consolidated financial statements have been prepared as though we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business. We have incurred operating losses and negative cash flows from operations since inception resulting in an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$488.2 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of December 3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our anticipated cash from operating and financing activities and existing cash and cash equivalents will enable us to meet our operational liquidity needs and fund our planned investing activities for the next 12 months. We have based this estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we expect. See &#8220;&#8212;Overview&#8212;Liquidity and Sources of Funding.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">OrbiMed Credit Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 28, 2019, we entered into the Loan Agreement with CRG for an aggregate of $200.0 million of which $102.5 million was outstanding as of December 31, 2019. On January 9, 2020, we entered into the Credit Agreement with OrbiMed for an aggregate of $200.0 million and paid off all of our obligations under the Loan Agreement. Borrowings under the Credit Agreement are collateralized by all of the Company&#8217;s assets, excluding the intellectual property licensed through the Bioprojet License Agreement. At the time of prepayment or repayment of all or any portion of the principal of the OrbiMed Loan, the Company is required to pay an exit fee of 7.0% of the principal amount of the OrbiMed Loan prepaid, repaid, or required to be prepaid or repaid.&nbsp;&nbsp;The Credit Agreement matures on January 9, 2026 and bears an interest rate of the greater of (a) LIBOR or (b) 2.00% per annum, plus 11.00% per annum. When the LIBOR rate is no longer used post-2021, the Prime Rate will be used in the determination of the interest rate. The Credit Agreement requires compliance with certain financial covenants, including minimum net revenue thresholds and cash balance requirements (which include maintaining minimum liquidity of $12.5 million), and financial reporting requirements. We have been in compliance with the financial covenants under the Credit Agreement since it was entered into on January 9, 2020. The Credit Agreement also contains certain negative restrictive covenants that either limit our ability to, or require a mandatory prepayment in the event we, engage in new lines of business, incur additional indebtedness or liens, make certain investments, make certain payments, pay cash dividends, merge with other companies or consummate certain changes of control, acquire other companies, transfer or dispose of certain assets, liquidate or dissolve, amend certain material agreements, enter into sale and leaseback transactions, enter into various other specified transactions, and change our name, location, executive office or executive management without notice.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Milestone Payment</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the Cataplexy Milestone Trigger Date, we became obligated to make the $100.0 million Cataplexy Milestone Payment to Bioprojet pursuant to the terms of the Bioprojet License Agreement. In October 2020, we made a payment to Bioprojet of $2.0 million to extend the Cataplexy Milestone Payment due date to within 90 days of the Cataplexy Milestone Trigger Date. On January 6, 2021, we made the $100.0 million Cataplexy Milestone Payment in full to Bioprojet.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows<font style="margin-left:130pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth a summary of our cash flows for the years ended December 31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Selected cash flow data</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,985</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,769</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities decreased to $3.0 million for the year ended December 31, 2020 as compared to $75.4 million for the same period in 2019. This decrease was primarily attributable to company revenue growth associated with the commercialization of WAKIX for a full year in 2020. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2020 consisted of our net loss of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$36.9 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> adjusted for non-cash items of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.6 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> associated with loss on extinguishment of debt and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.0 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> related to intangible amortization and fair value of warrants.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2019 consisted of net loss of $152.0 million adjusted for a reclassification of $52.0 million to investing activities related to a milestone payment associated with the Bioprojet License Agreement, $9.9 million related to stock compensation expense, and $2.8 million of intangible amortization. Net working capital excluding cash increased $8.2<font style="letter-spacing:1pt;"> </font>million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities decreased to $2.0 million for the year ended December 31, 2020 as compared to $127.1 million for the same period in 2019. This change was primarily attributable to $50.0 million and $75.0 million of milestone payments associated with the Bioprojet License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2020 was $209.2 million, which primarily consisted of $194.2 million associated with the OrbiMed Credit Agreement net of issuance costs and net proceeds from our IPO of $135.4 million, offset with $120.9 million of repayment and exit fees associated with the CRG Loan Agreement. </p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2019 was $143.8 million, which primarily consisted of $94.8 million associated with the CRG Loan Agreement net of issuance costs and $48.9 million in proceeds from the issuance of our Series C Preferred Stock net of issuance costs.</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:10pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927426"></a>Off-Balance Sheet Arrangements</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of and for the years ended December 31, 2020 and 2019, we did not have any off-balance sheet arrangements, as defined under SEC rules.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927427"></a>Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk58827655"></a>Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with GAAP, we evaluate our estimates and judgments on an ongoing basis.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include assumptions used in the determination of some of our costs incurred under our services type agreements and which costs are charged to research and development and general and administrative expense. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or<font style="letter-spacing:1.15pt;"> </font>conditions.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We define our critical accounting policies as those under GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our accounting policies are more fully described in Note 3 to our financial statements included herein under &#8220;Part II&#8212;Item 8. Financial Statements and Supplementary Data.&#8221;, we believe the following are the critical accounting policies used in the preparation of our consolidated financial statements that require significant estimates and judgments.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Toc57927428"></a>Revenue Recognition</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a>Effective January 1, 2019, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606), or ASC 606. This standard applies to all contracts with customers, except for contracts that are within the scope </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. We have determined that the delivery of our product to our customer constitutes a single performance obligation as there are no other promises to deliver goods or services. Shipping and handling activities are considered to be fulfilment activities and are not considered to be a separate performance obligation. We have assessed the existence of a significant financing component in the agreements with our customers. The trade payment terms with our customers do not exceed one year and therefore, no amount of consideration has been allocated as a financing component. Taxes collected related to product sales are remitted to governmental authorities and are excluded from revenue.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product Sales, Net</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began commercial sales of WAKIX in November 2019. We sell WAKIX to our customers (a limited number of specialty distributors) that, in turn, distribute WAKIX to patients.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue on sales of WAKIX when the customer obtains control of the product, which occurs at a point in time, typically upon delivery. Product revenues are recorded at the product&#8217;s wholesale acquisition costs, net of applicable reserves for variable consideration that are offered within contracts between us and our customers, payors, and other indirect customers relating to the sale of WAKIX. Components of variable consideration include government and commercial contracts, product returns, commercial co-payment assistance program transactions, and distribution service fees. These deductions, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as a current liability or reduction of receivables, based on the expected value method and a range of outcomes and are probability weighted in accordance with ASC 606.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. Our analyses contemplate the application of the constraint in accordance with ASC 606. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Government Contracts</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into contracts (i) to participate in the Medicaid Drug Rebate Program and the Medicare Part D program, and (ii) to sell to the U.S. Department of Veterans Affairs, 340b entities and other government agencies, or Government Payors, so that WAKIX will be eligible for purchase by, in partial or full reimbursement from, such Government Payors. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accounts payable or accrued expenses. For Medicare Part D, we estimate the number of patients in the prescription drug coverage gap for whom we will owe a payment under the Medicare Part D program.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the rebates that we will provide to Government Payors for those programs that require rebates. These rebate estimates are based upon (i) the government-mandated discounts applicable to government-funded programs, (ii) information obtained from its customers and (iii) information obtained from other third parties regarding the payor mix for WAKIX. The liability for these rebates consists of estimates of claims for the current year and estimated future claims that will be made for product shipments that have been recognized as revenue but remain in the distribution channel inventories at the end of each reporting period.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Toc57927429"></a><a name="_AEIOULastRenderedPageBreakAEIOU109"></a><font style="font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed and some require advanced payments. We make estimates of our accrued expenses of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CROs in connection with performing research services on our behalf and any clinical</font><font style="font-family:Times New Roman;letter-spacing:2.2pt;"> </font><font style="font-family:Times New Roman;">trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">investigative sites or other providers in connection with studies and any clinical</font><font style="font-family:Times New Roman;letter-spacing:2.05pt;"> </font><font style="font-family:Times New Roman;">trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">vendors</font><font style="font-family:Times New Roman;letter-spacing:-0.25pt;"> </font><font style="font-family:Times New Roman;">in</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">connections</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">with</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">the</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">preparation</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">of</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">our</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">NDA</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">file,</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">market</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">and</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">patient</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">awareness</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">programs,</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">website</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;">development,</font><font style="font-family:Times New Roman;letter-spacing:-0.2pt;"> </font><font style="font-family:Times New Roman;letter-spacing:-0.1pt;">market </font><font style="font-family:Times New Roman;">research and analysis and medical</font><font style="font-family:Times New Roman;letter-spacing:1.2pt;"> </font><font style="font-family:Times New Roman;">education;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.98%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">vendors related to product manufacturing, development and distribution of clinical</font><font style="font-family:Times New Roman;letter-spacing:1.15pt;"> </font><font style="font-family:Times New Roman;">supplies.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="letter-spacing:-0.2pt;"> </font>base<font style="letter-spacing:-0.15pt;"> </font>our<font style="letter-spacing:-0.2pt;"> </font>expenses<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:-0.2pt;"> </font>services<font style="letter-spacing:-0.15pt;"> </font>rendered<font style="letter-spacing:-0.15pt;"> </font>on<font style="letter-spacing:-0.2pt;"> </font>our<font style="letter-spacing:-0.15pt;"> </font>estimates<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>services<font style="letter-spacing:-0.2pt;"> </font>received<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>efforts<font style="letter-spacing:-0.15pt;"> </font>expended<font style="letter-spacing:-0.2pt;"> </font>pursuant<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>quotes, contracts and communicating with our vendors. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payments. There may be instances in which payments made to our vendors will exceed the level<font style="letter-spacing:1.7pt;"> </font>of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid or accrued expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Toc57927430"></a>Stock-Based Compensation</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize stock-based compensation expense related to stock options granted to employees based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation expense, for stock options that only have service vesting requirements or performance-based vesting requirements without market conditions using the <font style="letter-spacing:-0.1pt;">Black- </font>Scholes option-pricing model. The grant date fair value of the stock-based awards with service vesting requirements is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Determining <font style="letter-spacing:-0.1pt;">the </font>appropriate amount to expense for performance-based awards based on the achievement of stated goals requires judgment. The estimate of expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revisions is reflected in the period of change. If any applicable financial performance goals are <font style="letter-spacing:-0.1pt;">not </font>met, no compensation cost is recognized and any previously recognized compensation cost is<font style="letter-spacing:0.2pt;"> </font>reversed.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize stock-based compensation expense related to stock options granted to non-employees issued in exchange for services based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model; however, the fair value of the stock options granted to non-employees is remeasured each reporting period until the service is complete, and the resulting increase or decrease in value, if any, is recognized as expense or a reduction in previously recognized expense, respectively, during the period the related services are rendered.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model requires the use of highly subjective assumptions, which determine the fair value of share- based awards. These assumptions include:</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a>Expected term. <font style="font-style:normal;">Our expected term represents the period that our stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">the end of the contractual term). For stock- based awards granted to non-employees, the expected term represents the contractual term of the award.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common stock price. <font style="font-style:normal;">Our board of directors determines the fair value of each share of underlying common stock based on the closing price of our common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in our assumptions or market conditions.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <font style="font-style:normal;">Prior to the initial public offering of our common stock, we were a privately held company and did not have any trading history for our common stock and the expected volatility was estimated using weighted-average measures of implied volatility and the historical volatility of our peer group of companies for a period equal to the expected life of the stock options. Our peer group of publicly traded biopharmaceutical companies was chosen based on their similar size, stage in the life cycle or area of specialty.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <font style="font-style:normal;">The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the stock options.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend. <font style="font-style:normal;">We have never paid, and do not anticipate paying, cash dividends on our common stock. Therefore, the expected dividend yield was assumed to be zero.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reflects the range of assumptions used to estimate the fair value of awards.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:53.21%;"></td>
<td style="width:26.99%;"></td>
<td style="width:19.8%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="top" >
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.00%&#160;-&#160;95.80%</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.30% - 99.30%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32% - 0.56%</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60% - 2.59%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%&#160;-&#160;20.48%</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.00% - 31.00%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.40 - 6.50</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Toc57927431"></a>Common Stock Valuations</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the consummation of our IPO, our common stock was not publicly traded. As such, we were required to estimate the fair value of our common stock. Our board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including our stage of development or commercial performance; our actual operating results and financial performance; <font style="letter-spacing:-0.1pt;">the </font>progress of our commercialization and research and development efforts; conditions in the industry and economy in general; the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock; the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a sale of our company, given prevailing market conditions; equity market conditions affecting comparable public companies; the lack of marketability of our common stock and the results of independent third party valuations. Our board of directors also took into consideration the valuations of our common stock that were prepared by an independent third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially<font style="letter-spacing:0.35pt;"> </font>different.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a>For our valuations performed as of, and prior to, December 31, 2018, we used the Option Pricing Model Backsolve method to estimate the fair value of our common stock. In an option pricing method, or<font style="letter-spacing:-0.25pt;"> </font>OPM,<font style="letter-spacing:-0.2pt;"> </font>framework,<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>backsolve<font style="letter-spacing:-0.25pt;"> </font>method<font style="letter-spacing:-0.45pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>inferring<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>equity<font style="letter-spacing:-0.2pt;"> </font>value<font style="letter-spacing:-0.25pt;"> </font>implied<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>a<font style="letter-spacing:-0.2pt;"> </font>recent<font style="letter-spacing:-0.25pt;"> </font>financing<font style="letter-spacing:-0.2pt;"> </font>transaction<font style="letter-spacing:-0.25pt;"> </font>involves<font style="letter-spacing:-0.2pt;"> </font>making<font style="letter-spacing:-0.25pt;"> </font>assumptions for the expected time to liquidity, volatility and risk-free rate and then solving for the value of equity such that value for the most <font style="letter-spacing:-0.1pt;">recent </font>financing equals the amount paid. For our February 13, 2019 valuation, we used an income-based approach of a Discounted Cash Flow, or DCF, method to estimate the fair value of our common stock. The DCF method is based upon the theory that the value of a business is equal to the present value of its projected future cash flows. For our valuations performed August 14, 2019 through December 31, 2019, we used a combination of both, Backsolve and DCF, to estimate the fair value of our common stock. For our valuations performed as of March 31, 2020 and June 30, 2020, we used a DCF to estimate the fair value of our common stock. Furthermore, as of each of the valuation dates and even being an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">early</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage commercial company, the future liquidity events were difficult to forecast. We applied a discount for lack of marketability to account for a lack of access to an active public</font><font style="letter-spacing:0.25pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For valuations after the completion of the IPO, our board of directors will determine the fair value of each share of underlying common stock based on the closing price of our common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in our assumptions or market conditions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Options Granted</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth by grant date the number of shares of common stock subject to options granted from January 1, 2019 through December 31, 2020, the per share exercise price of the options, the per share fair value of the shares of common stock on each grant date and the per share estimated fair value of the options on each grant date:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:42.24%;">
<p style="text-align:left;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom"  style="width:12.76%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Subject to Options Granted</p></td>
<td valign="bottom"  style="width:15%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Per Share Exercise Price of Options</p></td>
<td valign="bottom"  style="width:15%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Fair Value per Share on Grant Date</p></td>
<td valign="bottom"  style="width:15%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Per Share Estimated Fair Value of Options on Grant Date</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 7, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,166</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.28</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.29</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 28, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,172</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.28</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.29</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 11, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,434</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.28</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.29</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,086</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,520</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 15, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,734</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 22, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,822</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 29, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,909</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 20, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,389</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 17, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,483</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 24, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,868</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 1, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,332</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,520</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 26, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">608</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.66</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.10</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,651</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.66</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.10</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 21, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,651</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.66</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.10</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 28, 2019</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,518</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.66</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.10</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,215</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 13, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">608</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 22, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,434</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 26, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,651</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,043</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,434</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,845</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,346</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,651</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.15</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.67</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 7, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,172</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.72</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.72</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.68</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 23, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,129</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.72</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.72</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.68</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 18, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,560,230</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.00</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.00</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14.36</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 18, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,248</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.00</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.00</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.87</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 5, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,078</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47.77</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47.77</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.46</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 11, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,208</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47.47</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47.47</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.15</p></td>
</tr>
<tr>
<td valign="top"  style="width:42.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 10, 2020</p></td>
<td valign="top"  style="width:12.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,979</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$42.88</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$42.88</p></td>
<td valign="top"  style="width:15%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.80</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a><font style="font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights Granted</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth by grant date the number of shares of common stock subject to stock appreciation rights, or SARs, granted from January 1, 2019 through December 31, 2020, the per share base price of the SARs, the per share fair value of the shares of common stock on each grant date and the per share estimated fair value of the SARs on each grant date:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:37.46%;"></td>
<td style="width:13.78%;"></td>
<td style="width:16.25%;"></td>
<td style="width:16.25%;"></td>
<td style="width:16.25%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:left;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom" >
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Subject to SARs Granted</p></td>
<td valign="bottom" >
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Per Share Base Price of SARs</p></td>
<td valign="bottom" >
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Fair Value per Share on Grant Date</p></td>
<td valign="bottom" >
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Per Share Estimated Fair Value of SARs on Grant Date</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 7, 2019</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,165</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.28</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.29</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 22, 2019</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,086</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.22</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.34</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.11</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 23, 2020</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,129</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.72</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.72</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.68</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Toc57927432"></a>Income Taxes</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets may be reduced by a valuation allowance if, based on all available evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Management judgment is required in determining the period in which a reversal of a valuation allowance should occur. We are required to consider all available evidence, both positive and negative, such as historical levels of income and future forecasts of taxable income among other items, in determining whether a full or partial release of its valuation allowance is required. Our accounting for deferred tax consequences represents the best estimate of those future events. We present deferred income taxes on the Consolidated Balance Sheet on a jurisdictional basis as either a net noncurrent asset or liability.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record liabilities for uncertain tax positions based on a two-step approach.&nbsp;&nbsp;The first step is recognition, where we evaluate whether an individual tax position has a likelihood of greater than 50% of being sustained upon examination based solely on the technical merits of the position, including resolution of any related appeals or litigation processes.&nbsp;&nbsp;For tax positions that are currently estimated to have less than a 50% likelihood of being sustained, no tax benefit is recorded.&nbsp;&nbsp;For tax positions that have met the recognition threshold in the first step, we perform the second step of the approach of measuring the benefit (expense) to be recorded.&nbsp;&nbsp;The actual benefits (expense) ultimately realized may differ from our estimates.&nbsp;&nbsp;In future periods, changes in facts, circumstances, and new information may require us to change the recognition and measurement estimates with regard to individual tax positions.&nbsp;&nbsp;Changes in recognition and measurement estimates are recorded in the statement of income and balance sheet in the period in which such changes occur.&nbsp;&nbsp;As of December 31, 2020, and 2019, we did not have any liabilities for unrecognized tax positions.&nbsp;&nbsp;As it relates to any interest and penalties associated with any uncertain tax positions, our position is to include those interest and penalties as a component of income tax expense.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927433"></a>Recent Accounting Pronouncements</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 3 to our financial statements included herein under &#8220;Part II&#8212;Item 8. Financial Statements and Supplementary Data.&#8221; for more information.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927434"></a>The JOBS Act</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221;, or EGC, as defined in the Jumpstart Our Business Startups Act, or JOBS Act, of 2012. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an EGC or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. If we were to subsequently elect instead to comply</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dates,</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">election</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irrevocable</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JOBS</font><font style="letter-spacing:0.2pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act.</font></p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an EGC until the earliest of (i) the last day of our fiscal year (a) following the fifth anniversary of the completion of the initial public offering of our common stock, (b) in which we have total annual gross revenues of at least $1.07 billion or (ii) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities over a three-year period.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP Financial Measures</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our GAAP results, we provide certain non-GAAP metrics including adjusted net income and adjusted net income per share. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, and the manner in which we calculate adjusted net income and adjusted net income per share may not be identical to the manner in which other companies calculate adjusted net income and adjusted net income per share. Management uses these non-GAAP measurements as an aid in monitoring our on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBITDA is intended to provide a measure of the Company&#8217;s operating performance as it eliminates the effects of financing and capital expenditures. EBITDA consists of GAAP net loss excluding: (i) interest expense, (ii) income tax provision, (iii) depreciation and (iv) amortization of intangibles.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP adjusted net income (loss) and non-GAAP adjusted net income (loss) per share are intended to provide an enduring, normalized view of net income and our broader business operations that we expect to experience on an ongoing basis by removing items which may be irregular, one-time, or non-recurring from net income. This enables us to identify underlying trends in our business that could otherwise be masked by such items.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP adjusted net income (loss) consists of GAAP net loss excluding: (i) interest expense, (ii) income tax provision, (iii) depreciation, (iv) amortization of intangibles, (v) stock-based compensation, (vi) loss on debt extinguishment, and (vii) warrant expense.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of GAAP net loss to non-GAAP adjusted net income (loss) appears in the table below (in thousands except share and per share data):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP Adjustments:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,220</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,073</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBITDA</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,513</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(142,694</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Non-GAAP Adjustments:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,639</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP adjusted net income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(132,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulation of yield on preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP adjusted net income (loss) available to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168,016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GAAP reported net loss per diluted share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-GAAP adjusted net income (loss) per diluted share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock used in non-GAAP diluted per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,982,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitat</font><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ive Disclosures About Market Risk.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Interest Rate Fluctuation Risk</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates. As of December 31, 2020, our cash and cash equivalents consisted of cash and money market accounts. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, an immediate 10% change in market interest rates would not have a material impact on the fair market value of our investment portfolio or on our financial position or results of operations. </p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had $200.0 million in borrowings outstanding. The term loan bears interest at an interest rate of the greater of (a) LIBOR or (b) 2.00% per annum, plus 11.00% per annum. Based on the $200.0 million of principal outstanding as of December 31, 2020, an immediate 10% change in the Prime Rate would not have a material impact on our debt-related obligations, financial position or results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Fluctuation Risk</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Inflation Fluctuation Risk</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations for the years ended December 31, 2020 or 2019.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58363696"></a><a name="_Toc57927436"></a><a name="F_PAGES_TABLE_OF_CONTENTS"></a><a name="F_PAGES_TABLE_OF_CONTENTS"></a>Item 8. Financial Statements and Supplementary Data.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#AUDIT_REPORT"><font style="Background-color:#FFFFFF;text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="Background-color:#FFFFFF;text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="Background-color:#FFFFFF;text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><font style="Background-color:#FFFFFF;text-decoration:underline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="Background-color:#FFFFFF;text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="Background-color:#FFFFFF;text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a><a name="AUDIT_REPORT"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="AUDIT_REPORT"></a>R</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the shareholders and the Board of Directors of Harmony Biosciences Holdings, Inc. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Harmony Biosciences Holdings, Inc. and subsidiary (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders' equity (deficit), and cash flows, for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chicago, Illinois&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2017.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58363697"></a><a name="_Toc57927437"></a><a name="_AEIOULastRenderedPageBreakAEIOU117"></a><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="UNAUDITED_CONDENSED_CONSOLIDATED_BALANCE"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT ASSETS:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,176</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,255</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,959</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,891</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NONCURRENT ASSETS:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible asset, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,343</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other noncurrent assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total noncurrent assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,183</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,206</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,074</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT LIABILITIES:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,556</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,360</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,917</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,892</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NONCURRENT LIABILITIES:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term debt, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,946</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other noncurrent liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total noncurrent liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,396</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329,894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMMITMENTS AND CONTINGENCIES (Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONVERTIBLE PREFERRED STOCK</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock, net of placement costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock - $1.00 stated value; 0 shares and 286,000,000 shares authorized at December 31, 2020 and 2019, respectively; 0 shares and 285,000,000 shares issued and outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348,203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock - $1.25 stated value; 0 shares and 8,030,000 shares authorized at December 31, 2020 and 2019, respectively; 0 shares and 8,000,000 shares issued and outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C convertible preferred stock - $1.96 stated value; 0 shares and 25,600,000 shares authorized at December 31, 2020 and 2019, respectively; 0 shares and 25,510,205 shares issued and outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STOCKHOLDERS&#8217; EQUITY (DEFICIT):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock - $0.00001 par value; 10,000,000 shares and 0 shares authorized at December 31, 2020 and 2019, respectively; 0 shares issued and outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock&#8212;$0.00001 par value; 500,000,000 shares and 423,630,000 shares authorized at December 31, 2020 and 2019, respectively; 56,890,569 shares and 7,787,470 issued and outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,374</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(488,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(422,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(422,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; EQUITY (DEFICIT)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,074</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of the consolidated financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU118"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,742</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sold</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,738</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,004</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,418</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,448</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,824</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,318</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,986</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(145,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,639</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,071</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,220</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,073</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulation of dividends on preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,904</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,231</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,848</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187,208</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET LOSS PER SHARE:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - basic</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of the consolidated financial statements </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU119"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A, B, &amp; C</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(242,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(242,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,510,205</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,868</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock dividend, Series A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,166</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock accretion, Series A</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,742</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,742</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,742</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock dividend, Series B</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock accretion, Series B</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock dividend, Series C</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock accretion, Series C</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,370</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,510,205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411,275</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,787,470</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(422,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(422,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock dividend, Series A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock accretion, Series A</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,572</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,990</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock dividend, Series B</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(778</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock accretion, Series B</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock dividend, Series C</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock accretion, Series C</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">921</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(922</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock upon initial public offering, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,151,162</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series A, B, C convertible stock to common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(318,510,205</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(444,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,926,630</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444,716</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase and cancellation of common units</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,175</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase and cancellation of common units withheld for taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(465</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,890,569</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,374</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(488,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;">Common stock of Harmony Biosciences Holdings, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of the consolidated financial statements<font style="font-family:Arial;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>HA</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM OPERATING ACTIVITIES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones associated with acquired in-process research &amp; development (IPR&amp;D)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock appreciation rights market adjustment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash paid-in-kind interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,639</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,255</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,735</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade payables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,804</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,898</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,985</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone associated with acquired in-process research &amp; development (IPR&amp;D)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone and acquisition of intangible asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,628</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,193</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from long term debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,184</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of debt exit fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercised options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax payments for employees shares withheld</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,769</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,816</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH&#8212;Beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,207</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH&#8212;End of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,207</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Disclosure of Cash Flow Information:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during the year for interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,230</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during the year for milestones</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Disclosures of Noncash Investing and Financing Activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock accrued return</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,160</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A accretion of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred Stock accrued return</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">777</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B accretion of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred Stock accrued return</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,347</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C accretion of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">921</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant financing</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability reclassified to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of the consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="_AEIOULastRenderedPageBreakAEIOU121"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Company</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating subsidiary, Harmony Biosciences, LLC, was formed on May&#160;17, 2017. Harmony Biosciences Holdings, Inc. (the &#8220;Company&#8221;) was founded on July&#160;25, 2017 as Harmony Biosciences&#160;II, LLC, a Delaware limited liability company, and the Company converted to a Delaware corporation named Harmony Biosciences II, Inc. on September&#160;19, 2017. On February&#160;3, 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company is a holding company and has no operations. The Company&#8217;s operations are conducted in its wholly owned subsidiary, Harmony Biosciences,&#160;LLC (&#8220;Harmony&#8221;). The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.78%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company&#8217;s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company&#8217;s convertible preferred stock. Warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 410,239 shares of common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 11, 2020, the Company implemented a 1-for-8.215 reverse stock split of the Company&#8217;s common stock. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s Preferred Stock and preferred dividend were proportionately reduced. <font style="Background-color:#FFFFFF;"> All references in the accompanying consolidated financial statements and related notes to the number of shares of common stock, convertible preferred stock, warrants and options to purchase common stock and per share data reflect the effect of the reverse stock split.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2. LIQUIDITY AND CAPITAL RESOURCES</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operations since inception resulting in an accumulated deficit of $488,195 and $422,862, as of December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company had cash and cash equivalents of $228,631.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk53756782"></a>On August 21, 2020, the Company received aggregate proceeds from a common stock offering of approximately $135,435, net of underwriting discounts and commissions and other estimated offering expenses (see Note 11). Additionally, on January 9, 2020, the Company received aggregate proceeds of approximately $200,000 through the loan agreement with OrbiMed Royalty&#160;&amp; Credit Opportunities, LP. This capital raise and debt issuance has resolved the Company&#8217;s significant risks and uncertainties regarding sources of liquidity, which previously raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">twelve</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> months from the date of issuance of these consolidated financial statements.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position<font style="Background-color:#FFFFFF;color:#000000;font-family:Arial;"> </font>for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.98%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Risks and Uncertainties</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of clinical testing and trial activities of the Company&#8217;s product candidates; the Company&#8217;s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#8217;s products, if approved; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates; and the Company&#8217;s ability to raise capital.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company&#8217;s research and development and clinical trials will result in any successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.02%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the Consolidated Financial Statements, including the notes thereto, and elsewhere in this report.&nbsp;&nbsp;Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Segments</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds all its tangible assets, conducts its operations, and revenues are generated in the U.S. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:6.86%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements include cash, cash equivalents, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. Additionally, prior to the IPO, the Company&#8217;s consolidated financial statements included a warrant liability that was carried at fair value and was re-measured at each balance sheet date until it would be exercised or expired. In connection with the IPO, the Warrants were re-evaluated under the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480 <font style="font-style:italic;">Distinguishing Liabilities from Equity</font> and reclassified to equity. See Note 13 for a further discussion of the warrants.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is the Company&#8217;s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, <font style="font-style:italic;">Fair Value Measurements and Disclosures</font>. ASC&#160;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC&#160;820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in the statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of cash flows</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,381</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,207</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in restricted cash represent those amounts required to be held as a security deposit in the form of letters of credit for the Company&#8217;s credit card program and the fleet program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a>The Company is also subject to credit risk from its trade receivables related to its product sales.&nbsp;&nbsp;The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of December&#160;31, 2020, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#8220;CVS Caremark&#8221;), which accounted for 44% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (&#8220;Pantherx&#8221;), which accounted for 23% of gross accounts receivable; and Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for 33% of gross accounts receivable.&nbsp;&nbsp;As of December&#160;31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 27% of gross product revenues. For the year ended December&#160;31, 2019 two customers accounted for 88% of gross product revenues, CVS Caremark accounted for 59% of gross product revenues and Pantherx accounted for 29% of gross product revenues.</p>
<p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the&#160;first-in,&#160;first-out&#160;method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We capitalize inventory costs associated with our products prior to regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We did not capitalize preapproval inventory during 2019.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Asset</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.86%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January&#160;1, 2019, the Company adopted ASC 606,&#160;Revenue from Contracts with Customers (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company has determined that the delivery of its product to its customer constitutes a single performance obligation as there are no other promises to deliver goods or services. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore, no amount of consideration has been allocated as a financing component. Taxes collected related to product sales are remitted to governmental authorities and are excluded from revenue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Sales, Net</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company began commercial sales of WAKIX&#160;in November 2019. The Company sells WAKIX&#160;to its customers (a limited number of specialty distributors) that, in turn, distribute WAKIX&#160;to patients.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue on sales of WAKIX&#160;when the customer obtains control of the product, which occurs at a point in time, typically upon delivery. Product revenues are recorded at the product&#8217;s wholesale acquisition costs, net of applicable reserves for variable consideration that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the sale of WAKIX. Components of variable consideration include government and commercial contracts, product returns, commercial&#160;co-payment&#160;assistance program transactions, and distribution services fees. These deductions are based on the amounts earned or to be claimed on the related sales and are classified as a current liability or reduction of receivables, based on expected value method and a range of outcomes and are probability weighted in accordance with ASC 606.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognition under contracts will not occur in a future period. The Company&#8217;s analyses contemplate the application of the constraint in accordance with ASC 606. Actual amounts of consideration ultimately received may differ from its estimates. If actual results in the future vary from its estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Product Sold </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><a name="_Hlk53573405"></a>Cost of product sold includes manufacturing and distribution costs, the cost of drug substance, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs, and salaries of employees involved with production. The Company began capitalizing inventory upon FDA approval of WAKIX with a portion of the inventory sold during the year ended December&#160;31, 2020 produced prior to FDA approval and, therefore, was previously expensed as research and development expense in 2019 in the amount of $1,323. Excluded from cost of product sold shown and included in general and administrative on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk53573405"></a>consolidated statements of operations and comprehensive loss is </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amortization of acquired developed technology of $9,843 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and $2,815 for the years ended December&#160;31, 2020 and 2019, respectively. </font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and&#160;pre-FDA&#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advertising Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expensed the costs of advertising, including promotional expenses, as incurred. Advertising expense was $13,301 and $7,072 a for the years ended December 31, 2020 and 2019, respectively. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66777698"></a><a name="_Hlk66777698"></a>The Company recognizes compensation expense relating to stock-based payment transactions in operating results using a fair value measurement method, in accordance with FASB ASC 718,&#160;Compensation-Stock Compensation. ASC&#160;718 requires all stock-based payments to employees to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The vesting periods have a time-based provision consisting of three to five years and expire no more than 10 years after the date of grant. Upon a change of control, certain unvested awards will immediately vest. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;1, 2019, the Company early adopted and accounts for stock-based payments granted to nonemployees in accordance with ASU&#160;2018-07,&#160;Compensation &#8211; Stock Compensation (ASC 718): Improvements to Nonemployee Share &#8211; Based Payment Accounting. The Company determines the fair value of the stock-based payment as the fair value of the equity instruments issued. It is measured on the grant date.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also had nonemployee stock awards subject to a performance condition that are recognized based on probable outcome. On November&#160;15, 2019 the Company modified the award to remove the performance condition resulting in $8,400 of noncash expense that is included in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019 (see Note 13 for further details).</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect. The basic and diluted computations of net loss per share for the Company are the same because the effects of the Company&#8217;s convertible securities would be anti-dilutive (see Note&#160;14 for further detail).</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU126"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets may be reduced by a valuation allowance if, based on all available evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Management judgment is required in determining the period in which a reversal of a valuation allowance should occur. The Company is required to consider all available evidence, both positive and negative, such as historical levels of income and future forecasts of taxable income among other items, in determining whether a full or partial release of its valuation allowance is required. The Company&#8217;s accounting for deferred tax consequences represents the best estimate of those future events. The Company presents deferred income taxes on the Consolidated Balance Sheet on a jurisdictional basis as either a net noncurrent asset or liability.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#8217;s widely understood administrative practices and precedents. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which a change in judgment occurs. At December&#160;31, 2020 and 2019, the Company did not have any unrecognized uncertain tax positions. The Company&#8217;s policy is to include any interest and penalties as a component of income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued amended guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities in the balance sheet and disclosing key information about leasing arrangements. The new guidance clarifies the criteria for distinguishing between a finance lease and operating lease, as well as classification between the two types of leases, which is substantially unchanged from the previous lease guidance. Further, the new guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a&#160;right-of-use&#160;asset, initially measured at the present value of the lease payments. For finance leases, a lessee should recognize interest on the lease liability separately from amortization of the&#160;right-of-use&#160;asset. For operating leases, a lessee should recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis. For leases with a term of 12&#160;months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and lease liabilities. The new standard will become effective for the Company&#8217;s fiscal year ending December&#160;31, 2022. The Company is currently assessing the impact of this amended guidance and the timing of adoption.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,&#160;<font style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font>. ASU&#160;No.&#160;2016-13&#160;introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for&#160;available-for-sale&#160;debt securities. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2022 for companies deemed to be small reporting companies as of November&#160;15, 2019, with early adoption permitted. The Company is currently evaluating the potential impact of adoption of this standard on its results of operations, financial position and cash flows and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,&#160;<font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting guidance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU127"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU No. 2020-04, </font><font style="font-style:italic;">Reference Rate Reform (Topic 848)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which provides </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guidance related to reference rate reform. The pronouncement provides temporary optional expedients and exceptions to the current guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) and other interbank offered rates to alternative reference rates. The guidance was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are currently evaluating the impact of the transition from LIBOR to alternative reference rates but do not expect a significant impact to our consolidated financial statements.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4. INVENTORY </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66100734"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, gross</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for obsolescence</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">5. INTANGIBLE ASSET </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;15, 2019, the Company received FDA approval of WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pitolisant) for the treatment of excessive daytime sleepiness (&#8220;EDS&#8221;) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 associated with the License Agreement which the Company capitalized as an intangible asset and paid in November of 2019. The Company determined a useful life of 10 years for such intangible asset, and, as of December 31, 2020 the remaining useful life was 9 years. Prior to this event, all other milestones associated with the License Agreement were expensed through research and development as they did not meet the criteria to be recognized as an intangible asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 13, 2020, the Company received notice that the FDA approved the NDA for WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 associated with the License Agreement which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of December 31, 2020 the remaining useful life was 9 years. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.86%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.86%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The gross carrying amount and net book value of the intangible asset is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,657</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Book Value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,343</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">6. LICENSE AGREEMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;28, 2017, Harmony entered into the License Agreement whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson&#8217;s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant&#8217;s New Drug Application (&#8220;NDA&#8221;), which was achieved on February&#160;12, 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, including a $2,000 fee, was due upon FDA approval of WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved on August&#160;14, 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a payment of $2,000 is due upon the FDA approval of the NDA for WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for the treatment of cataplexy in adult patients with narcolepsy (the &#8220;Trigger Date&#8221;) which was paid in October 2020 and a $100,000 milestone payment which was paid in January 2021. An additional $40,000 milestone payment is due to Bioprojet upon WAKIX attaining $500,000 in aggregate net sales in the United States. The License Agreement also requires sales-based milestone payments, a fixed trademark royalty and a tiered royalty, all based on net sales, which become due and payable to Bioprojet on a quarterly basis. During the year ended December&#160;31, 2020, the Company incurred $25,580 for sales-based, trademark and tiered royalties recognized as cost of product sold. As of December&#160;31, 2020 and 2019, the Company had accrued $9,006 and $938, respectively, for sales-based, trademark and tiered royalties. At December 31, 2020 the Company had accrued $100,000 for the milestone payment to Bioprojet. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7. ACCRUED EXPENSES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payment</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties due to third parties</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rebates and other sales deductions</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,803</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees, consulting, and other services</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">8. DEBT </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Credit Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU128"></a>On February&#160;28, 2019, the Company entered into a multi-draw loan agreement with CRG Servicing LLC for an aggregate of $200,000 (the &#8220;CRG Loan&#8221;), which matured in March 2025. The Loan bore a fixed rate of 12%. The Loan agreement required compliance with certain financial covenants. The Company could draw three tranches of the Loan based on achieving specific milestones and dates. The Company could elect to pay the interest on the outstanding principal amount as follows: (i)&#160;only 7.5% of the 12% per annum in cash, paid quarterly, starting in March 2019, and (ii) 4.5% of the 12% per annum interest as compounded interest, added to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the aggregate outstanding principal balance quarterly; the amount of any such compounded interest being a paid-in-kind loan. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had borrowed $100,000, resulting in cash proceeds received of $94,816, net of issuance costs. The issuance costs of $5,184 were being amortized over the six-year loan term of the CRG Loan. Unamortized debt issuance costs as of December&#160;31, 2019 are $4,592 and are presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;9, 2020 the Company entered into a credit agreement with OrbiMed Royalty&#160;&amp; Credit Opportunities, LP for an aggregate amount of $200,000 (the &#8220;OrbiMed Loan&#8221;), which matures in January 2026. Borrowings under the OrbiMed Loan are collateralized by all of the Company&#8217;s assets, excluding the intellectual property licensed through the License Agreement. The OrbiMed Loan bears an interest rate equal to the sum of (i)&#160;the greater of (a)&#160;1-month LIBOR or (b) 2.00% per annum, plus (ii) 11.00% per annum, paid in cash monthly in arrears on the last day of each month starting in January 2020. At the time of prepayment or repayment of all or any portion of the principal of the OrbiMed Loan, the Company is required to pay an exit fee of 7.0% of the principal amount of the OrbiMed Loan prepaid, repaid, or required to be prepaid or repaid.&nbsp;&nbsp;The Company recorded as a liability and debt discount the exit fee at the origination of the term loan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to entering into the OrbiMed Loan, the Company extinguished the CRG Loan which required a payoff amount of $120,893 consisting of principal repayment, interest, and exit fees. In connection with extinguishment of the CRG Loan, we recognized a loss on extinguishment of $22,639, which included an exit fee of $18,047 and the write-off of the remaining unamortized debt issuance costs of $4,592. The loss on extinguishment of debt was recorded in loss on debt extinguishment within the Company&#8217;s consolidated statements of operations. The net cash received as a result of the transaction, less debt issuance costs of $5,804, was $73,313. These debt issuance costs will be amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The fair value of the OrbiMed loan as of December 31, 2020 was $245,700.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the OrbiMed Loan, the Company issued warrants (the &#8220;Warrants&#8221;) to OrbiMed Royalty&#160;&amp; Credit Opportunities, LP on January&#160;9, 2020. See Note 13 for further discussion of the Warrants. Pursuant to the Warrants, OrbiMed Royalty&#160;&amp; Credit Opportunities, LP, may purchase up to 410,239 shares of the Company&#8217;s Common Stock for an initial exercise price of $16.10 at any time from the date of execution of the Warrants through the expiration date, defined within the Warrants as the earlier of (i)&#160;January&#160;9, 2027 and (ii)&#160;the closing date of a Corporate Reorganization. The fair value of the Warrants using the Black-Scholes option-pricing model was $2,359 at January&#160;9, 2020. The portion of the OrbiMed Loan proceeds allocated to the warrant liability resulted in a debt discount, which is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt and is being amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The unamortized debt discount as of December&#160;31, 2020 is $2,097 and is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The balances of the OrbiMed Loan as of December 31, 2020 and the CRG Loan as of December 31, 2019 were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component - principal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,538</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exit fee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component - net carrying value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,946</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense related to the OrbiMed Loan and CRG Loan were included in interest expense, net in the Consolidated Statements of Operations as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on principal balance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on PIK</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of deferred financing costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Total term loan interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,615</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,361</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU129"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">9. COMMITMENTS AND CONTINGENCIES </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2019 the Company was involved in ongoing litigation with its former chief executive officer related to arbitration and the value of vested common shares. On October&#160;24, 2019, the Company reached a settlement resulting in $3,466 of general and administrative expense reflected in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into an operating lease for approximately nine thousand square feet of office space in Northbrook, IL, which expired in January 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an operating lease for approximately thirteen thousand square feet of additional office space in Plymouth Meeting, PA, which expires in May 2024.&nbsp;&nbsp;The term will not commence until the Company takes occupancy in mid-2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not paid. In addition, tenant improvement allowances recorded are amortized as a reduction to rent expense on a straight-line basis over the lease term. Rent expense was $686 for the year ended December&#160;31, 2020, compared to $1,051 for the year ended December&#160;31, 2019. The following table sets forth the lease payment obligations as of December&#160;31, 2020, for the periods indicated below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">892</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10. CONVERTIBLE PREFERRED STOCK </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all outstanding shares of the Company&#8217;s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company&#8217;s convertible preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series A Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;22, 2017, the Company issued 270,000,000 shares of Series&#160;A convertible preferred stock for a purchase price of $1.00 per share, or $270,000 in the aggregate. On January&#160;8, 2018, the Company issued an additional 15,000,000 shares of Series A convertible preferred stock for a purchase price of $1.00 per share, or $15,000 in the aggregate. As of December&#160;31, 2019, there were 286,000,000 Series&#160;A convertible preferred stock authorized of which 285,000,000 were issued and outstanding. Each outstanding share of Series A convertible preferred stock accrued dividends at 10% per annum of the Series&#160;A original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series&#160;A convertible preferred stock were cumulative and were compounded annually.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU130"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series B Preferred Stock </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;8, 2018, the Company issued 8,000,000 shares of Series&#160;B convertible preferred stock for a purchase price of $1.25 per share, or $10,000 in the aggregate. As of December&#160;31, 2019, there were 8,030,000 shares of Series&#160;B convertible preferred stock authorized, of which 8,000,000 were issued and outstanding.&#160;Each outstanding share of Series&#160;B convertible preferred stock accrued dividends at 10% per annum of the Series&#160;B original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series B convertible preferred stock were cumulative and were compounded annually.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series C Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;9, 2019, the Company issued 25,510,205 shares of Series C convertible preferred stock for a purchase price of $1.96 per share, or $50,000 in the aggregate. As December&#160;31, 2019, there were 25,600,000 shares of Series C convertible preferred stock authorized, of which 25,510,205 were issued and outstanding. Each outstanding share of Series C convertible preferred stock accrued dividends at 10% per annum of the Series C original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series C convertible preferred stock were cumulative and were compounded annually.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of Series A, Series B, and Series C convertible preferred stock were entitled to receive, when and if declared by the board of directors of the Company, cumulative dividends equal to a 10% per annum of Series A, Series B, and Series C convertible preferred stock. In addition, the holders of the outstanding shares of Series A, Series B, and Series C convertible preferred stock were entitled to receive, when and if declared by the board of directors of the Company, a dividend at least equal to any dividend payable on the Company&#8217;s common stock as if all convertible preferred stock had been converted to common stock. No dividends were declared as of December&#160;31, 2019. As part of the Company&#8217;s IPO, the Company&#8217;s accrued cumulative dividend was paid out to holders of Series A, Series B, and Series C convertible preferred stock in shares of the Company&#8217;s common stock and reflects the reverse stock split in connection with the mandatory conversion of the Series A, Series B, and Series C convertible preferred stock into shares of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11. STOCKHOLDERS&#8217; EQUITY (DEFICIT) </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;11, 2020, the Company implemented a 1-for-8.215 reverse stock split of the Company&#8217;s common stock. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split with the exception of the preferred stock. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s Preferred Stock were proportionately reduced. As of August 11, 2020, all outstanding shares of preferred stock and preferred stock dividend were convertible into shares of common stock on a 1-for-8.215 basis. On August 21, 2020, the Company completed its IPO of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 incurred by the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company&#8217;s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the Company&#8217;s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company&#8217;s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a>1,217,285 common shares held by an investor were subject to certain forfeiture provisions that are dependent upon the outcome of certain future events. On November&#160;15, 2019, the Company removed the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provision associated with this forfeiture resulting in $8,400 of noncash stock compensation expense reflected in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;7, 2017, the Company adopted an equity incentive plan (the &#8220;2017 Plan&#8221;). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company&#8217;s common shares through grants of stock options, stock appreciation rights, or restricted stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In connection with the Company&#8217;s IPO, the board of directors adopted, and its stockholders approved, the 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company&#8217;s named executive officers) and consultants of the Company and its subsidiaries. Upon the effectiveness of the 2020 Plan, no further grants will be made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it. The 2020 Plan provides for the grant of stock options, including ISOs and NSOs, SARs, restricted stock, dividend equivalents, RSUs and other stock or cash based awards.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options under the 2017 Plan and the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in awards granted under the Plan as of December&#160;31, 2020 and 2019, are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Awards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54610948"></a>Awards outstanding&#8212;December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,375,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,545</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards outstanding&#8212;December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.58</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, stock awards issued under the 2017 and 2020 Plans of 987,538 and 573,098 common shares, respectively, were vested. The Company has elected early adoption of ASU No.&#160;2016-09 to recognize forfeitures as they occur. As a result of the adoption, for the year ended December&#160;31, 2020 and 2019, respectively, the Company reversed $3 and $4 out of stock-based compensation previously recorded. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.78%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Value of Stock Options </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has valued awards for each of the plans included herein using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, the Company estimates its expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value the awards are summarized in the following table. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54610974"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.00&#160;-&#160;95.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.30&#160;-&#160;99.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32 - 0.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60 - 2.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00&#160;-&#160;20.48</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.00&#160;-&#160;31.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4 - 6.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average per share fair value of awards issued under the Plan was $10.06 and $3.45 in 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was $5,190 and $9,909 for the years ended December&#160;31, 2020 and 2019, respectively, and was recorded in the consolidated statements of operations and comprehensive loss in the following line items: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,901</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued under the 2017 Plan and 2020 Plan are reflected as a component of equity in these consolidated financial statements. Stock appreciation rights are reflected as other non-current liability. The Company will recognize compensation expense for these awards as summarized in the following table. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,046</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,915</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,949</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.98%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">13. WARRANTS</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU133"></a>In connection with the OrbiMed Loan, the Company issued Warrants to OrbiMed Royalty&#160;&amp; Credit Opportunities, LP on January&#160;9, 2020. Pursuant to the Warrants, OrbiMed Royalty&#160;&amp; Credit Opportunities, LP, may purchase up to 410,239 shares of the Company&#8217;s Common Stock for an initial exercise price of $16.10 at any time from the date of execution of the Warrants through the expiration date, defined within the Warrants as the earlier of (i)&#160;January&#160;9, 2027 and (ii)&#160;the closing date of a Corporate Reorganization. The fair value of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants using the Black-Scholes option-pricing model was $2,359 on January&#160;9, 2020 and was initially recorded as a warrant liability which was included in warrant liability in the consolidated balance sheet. The portion of the OrbiMed Loan proceeds allocated to the warrant liability resulted in a debt discount, which is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt and is being amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The unamortized debt discount as of December&#160;31, 2020 is $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and is presented in the consolidated balance sheet as a direct deduction from the carrying value of the debt. During the year ended December&#160;31, 2020, a loss of $3,109 was recorded in other expense in the consolidated statements of operations due to the change in the fair value of the warrant liability. See footnote 1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the fair value of the Warrants.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO, the financial instrument underlying the warrants was converted from the Company&#8217;s Series C Preferred Stock to the Company&#8217;s Common Stock.&nbsp;&nbsp;As a result of this conversion the Warrants were re-evaluated under ASC 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging and reclassified to equity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the changes in the warrant liability for the year ended December 31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66100792"></a>Balance, beginning of period</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair Value at Issuance</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value included in the statement of operations</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk54557918"></a><a name="_Hlk54557919"></a><a name="_Hlk54557920"></a>14. EARNINGS PER SHARE </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63694942"></a>For the years ended December 31, 2020 and 2019, the Company used the two-class method to compute net loss per common share because the Company has issued securities (convertible preferred stock) that entitle the holder to participate in dividends and earnings of the Company. Under this method, net income is reduced by the amount of any dividends earned and the accretion of convertible preferred stock to its redemption value during the period. The remaining earnings (undistributed earnings) are allocated to common stock and each series of convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. The total earnings allocated to common stock is then divided by the number of outstanding shares to which the earnings are allocated to determine the earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per common share is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effects of the outstanding convertible preferred stock under the &#8216;if-converted&#8217; method when calculating diluted earnings per share, in which it is assumed that the outstanding convertible preferred stock converts into common stock at the beginning of the period or when issued if later. The Company reports the more dilutive of the approaches (treasury stock or &#8216;if converted&#8217;) as their diluted net income per share during the period. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU134"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reported a net loss for the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ended </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dec</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ember&#160;3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2019, and the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> weighted average number of shares utilized for</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> basic and diluted net loss per share attributable to common stockholders are the same for these periods because all convertible preferred stock and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Additionally, the fair value adjustment for the warrants was excluded from the computation of diluted net loss for the year ended December 31, 2020 since the additional income would have an antidilutive impact.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulation of dividends on preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common shareholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,848</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - basic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - basic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential common shares issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,271,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,891,576</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,670,365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,163,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_Toc58363694"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;text-transform:uppercase;font-size:10pt;font-variant: normal;">15. income taxes<font style="text-transform:none;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Details of the provision for income taxes consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,198</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,641</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU135"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reasons for the difference between the statutory federal income tax rate and the Company&#8217;s effective income tax rate as of December&#160;31, 20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019, are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired in-process research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,346</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,628</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforward</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,682</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disallowed interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,751</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,661</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,116</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,823</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,656</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,874</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has considered available positive and negative evidence to estimate if sufficient future taxable income will be generated to allow utilization of the existing deferred tax assets. The Company has incurred operating losses and negative cash flows from operations since inception. In light of these considerations, as well as the uncertainty as to when the Company might generate taxable income, the Company has recorded a full valuation allowance of $102,874, which represents an increase of $2,218 in the Company&#8217;s valuation allowance from December&#160;31, 2019 to December&#160;31, 2020. The amount of the net deferred tax asset considered realizable could be adjusted in the future if estimates of taxable income change or if objective negative evidence in no longer present and additional weight may be given to subjective evidence. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company has approximately $159,395 and $147,823, respectively, of federal net operating loss ("NOL") carryforward available to offset future federal taxable income.&nbsp;&nbsp;The Company also has approximately $157,743 and $139,336 of state NOL carryforwards as of December 31, 2020 and 2019, respectively, available to offset future state taxable income.&nbsp;&nbsp;All of the Company's tax years remain open to examination by federal and state taxing authorities.&nbsp;&nbsp;The Company's pre-2018 federal NOLs expire in 2037 whereas the Company's NOLs arising in 2018, and subsequent years, have an unlimited carryforward period. The Company's state NOLs begin to expire in 2037. Utilization of the net operating loss carryforwards may be subject to a substantial limitation due to ownership change limitations that may occur in the future, as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), as well as similar state provisions. These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section&#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company has federal tax credits of $1,603 and $837, respectively.&nbsp;&nbsp;These credits begin to expire in 2037.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">16. FINANCIAL INSTRUMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company primarily applies the market approach to determine the fair value of financial instruments that are measured at fair value on a recurring basis. There were no changes to its valuation techniques used to determine the fair value of financial instruments during the year ended December&#160;31, 2020. The Company&#8217;s financial assets and liabilities which are measured at fair value on a recurring basis were comprised of cash, cash equivalents, and restricted cash of $229,381 and $25,207 as of December&#160;31, 2020 and 2019, respectively, based on Level&#160;1 inputs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of the warrant liability using the Black-Scholes option-pricing model at each balance sheet date or when specific events occur. As discussed in Note 13, in connection with the Company&#8217;s IPO the warrant fair value was updated on August 19, 2020 with the change in fair value recorded in current period earnings as other expense in the consolidated statement of operations and reclassified to equity. During the year ended December&#160;31, 2020, a loss of $3,109 was recorded in other expense in the consolidated statements of operations due to the change in the fair value of the warrant liability.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The range of assumptions used to determine the fair value of the warrant liability through August&#160;19, 2020 were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66100737"></a>Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.2% - 68.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17% - 1.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 4.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">17. RELATED-PARTY TRANSACTIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was party to a management agreement for professional services provided by a related party, Paragon. The related party is an entity that shares common ownership with the Company. In addition, the Chairman of the Company&#8217;s board of directors was the President and owner of the entity. For the year ended December&#160;31, 2020 and 2019, respectively, the Company incurred $7,384 and $5,378, respectively, in management fee expense and other expenses to this related party, which are included in general and administrative expense in the consolidated statements of operations and comprehensive loss. The Company terminated the Management Services Agreement upon the consummation of its IPO. The Company is<font style="Background-color:#FFFFFF;"> also party to a right of use agreement with the related party whereby it has access to and the right to use certain office space leased by the related party in Chicago, Illinois</font>. In addition, the Company had participated in certain transactions with separate related parties that also share common ownership with the Company, primarily related to combined employee health plans. As of December&#160;31, 2020 and 2019, respectively, the amounts due to related parties included in current liabilities were $0 and $1,208, respectively, and the amount included in other assets was $1 and $210, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">18. SUBSEQUENT EVENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 6, 2021, the Company paid the $100,000 milestone payment to Bioprojet for the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January and F<font style="font-size:9pt;">e</font>bruary 2021, the board of directors granted to various employees 882,606 employee stock options to purchase the Company&#8217;s common stock.&nbsp;&nbsp;These awards were granted under the 2020 Plan and vest over a four-year period where 50% cliff vest after the second year and monthly thereafter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU136"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements with Accou</font><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ntants on Accounting and Financial Disclosure.</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:10pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927438"></a><a name="_Toc58363698"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and&#160;15d-15(e) under the&#160;Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our principal executive officer and principal financial officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the&#160;Exchange Act&#160;is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of the Company&#8217;s registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Limitations on Effectiveness of Controls and Procedures</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:10pt;text-indent:6.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#160;does&#160;not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any,&#160;within our Company&#160;have been detected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927439"></a><a name="_Toc58363699"></a><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:6.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU137"></a><a name="PART_III"></a><font style="font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><a name="PART_III"></a>Part</font><font style="font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"> III</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927441"></a><a name="_Toc58363701"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be set forth in our&#160;Proxy Statement&#160;for the 2021 Annual Meeting of Stockholders and is incorporated by reference. The Proxy Statement will be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers. The full text of our code of business conduct and ethics is posted on the investor relations page on our website which is located at https://ir.harmonybiosciences.com. We will post any amendments to our code of business conduct and ethics other than technical, administrative or other non-substantive amendments, or waivers of its requirements, on our website or in a Form 8-K filed with the SEC.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927442"></a><a name="_Toc58363702"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be set forth in our Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927443"></a><a name="_Toc58363703"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be set forth in our Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927444"></a><a name="_Toc58363704"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be set forth in our Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927445"></a><a name="_Toc58363705"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be set forth in our Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days of the fiscal year ended December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU138"></a><a name="PART_IV"></a><font style="font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><a name="PART_IV"></a>Part</font><font style="font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"> IV</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927447"></a><a name="_Toc58363707"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">(a)(1) Financial Statements</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;Part II&#8212;Item 8. Financial Statements and Supplementary Data.&#8212;Index to Financial Statements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">(a)(2) Financial Statement Schedules</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted as the information is not required under the related instructions or is not applicable or because the information required is already included in the financial statements or the notes those financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">(a)(3) Exhibits.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents set forth below are filed herewith or incorporated herein by reference to the location indicated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td rowspan="2" valign="bottom"  style="width:10.06%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="border-bottom:none 0pt;padding-bottom:0pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td rowspan="2" valign="bottom"  style="width:30%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td colspan="7" valign="top"  style="width:46.78%; border-bottom:solid 0.75pt #000000;">
<p style="border-bottom:none 0pt;padding-bottom:0pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td rowspan="2" valign="bottom"  style="width:12.26%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top"  style="width:0.9%;">
<p style="border-bottom:none 0pt;padding-bottom:0pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:0.88%; border-top:solid 0.75pt #000000;">
<p style="border-bottom:none 0pt;padding-bottom:0pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:0.76%; border-top:solid 0.75pt #000000;">
<p style="border-bottom:none 0pt;padding-bottom:0pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="width:0.58%; border-top:solid 0.75pt #000000;">
<p style="border-bottom:none 0pt;padding-bottom:0pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:21.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520226978/d97999dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of Harmony Biosciences Holdings, Inc.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 21, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520226978/d97999dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 21, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520211023/d755703dex41.htm"><font style="text-decoration:underline;">Form of Common Stock Certificate.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 6, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex43_1166.htm"><font style="text-decoration:underline;">Description of Registrant&#8217;s Securities.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex101.htm"><font style="text-decoration:underline;">Credit Agreement, dated as of January 9, 2020, among Harmony Biosciences, LLC, the Lenders from time to time party thereto and OrbiMed Royalty &amp; Credit Opportunities III, LP.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex102.htm"><font style="text-decoration:underline;">Pledge and Security Agreement, dated as of January 9, 2020, among Harmony Biosciences, LLC, the Registrant, OrbiMed Royalty &amp; Credit Opportunities III, LP and the Secured Parties as defined therein.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520227079/d91238dex102.htm"><font style="text-decoration:underline;">Harmony Biosciences Holdings, Inc. 2020 Incentive Award Plan</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 21, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520227079/d91238dex103.htm"><font style="text-decoration:underline;">Form of Option Agreement under Harmony Biosciences Holdings, Inc. 2020 Incentive Award Plan.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 21, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex106.htm"><font style="text-decoration:underline;">Form of Restricted Stock Unit Agreement under Harmony Biosciences Holdings, Inc. 2020 Incentive Award Plan.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex107.htm"><font style="text-decoration:underline;">Harmony Biosciences Holdings, Inc. 2020 Employee Stock Purchase Plan.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU139"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</font></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex108.htm"><font style="text-decoration:underline;">Amended and Restated Employment Agreement, dated August 11, 2020, by and between Harmony Biosciences, LLC and </font></a><font style="font-family:Arial;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">John C. Jacobs.</font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex1012.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between Harmony Biosciences, LLC and each director and executive officer.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex1013.htm"><font style="text-decoration:underline;">Harmony Biosciences, LLC Separation Plan.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex103.htm"><font style="text-decoration:underline;">Harmony Biosciences Holdings, Inc. Amended and Restated 2017 Equity Incentive Plan.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000156459020053320/hrmy-ex109_551.htm"><font style="text-decoration:underline;">Harmony Biosciences Holdings, Inc. Non-Employee Director Compensation Program.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex109.htm"><font style="text-decoration:underline;">Offer Letter, dated October 10, 2017, by and between Harmony Biosciences, LLC and Jeffrey Dayno.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520215643/d755703dex1010.htm"><font style="text-decoration:underline;">Offer Letter, dated September 8, 2017, by and between Harmony Biosciences, LLC and Andrew Serafin.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 11, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex1010.htm"><font style="text-decoration:underline;">License and Commercialization Agreement, dated July 28, 2017, by and between Bioprojet Soci&#233;t&#233; Civile de Recherche and Harmony Biosciences, LLC.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex1011.htm"><font style="text-decoration:underline;">Amendment No. 1 to License and Commercialization Agreement, dated August 27, 2018, by and between Bioprojet Soci&#233;t&#233; Civile de Recherche and Harmony Biosciences, LLC.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex1012.htm"><font style="text-decoration:underline;">Trademark License Agreement, dated August 23, 2018, by and among Bioprojet Europe, Ltd., Bioprojet Soci&#233;t&#233; Civile de Recherche and Harmony Biosciences, LLC.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex1013.htm"><font style="text-decoration:underline;">Management Services Agreement, dated September 22, 2017, by and between Paragon Biosciences, LLC and Harmony Biosciences, LLC.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex1014.htm"><font style="text-decoration:underline;">Right of Use Agreement, dated November 1, 2019, by and between Paragon Biosciences, LLC and Harmony Biosciences, LLC.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312520199773/d755703dex1015.htm"><font style="text-decoration:underline;">Second Amended and Restated Investors&#8217; Rights Agreement, dated August 9, 2019, by and among the Registrant and the other parties thereto.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2020</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU140"></a><a href="hrmy-ex1020_1164.htm"><font style="text-decoration:underline;">Offer Letter, dated September 7, 2017, by and between Harmony </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Biosciences, LLC and Jeffrey Dierks</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU141"></a>10.21</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312521076202/d141546dex101.htm"><font style="text-decoration:underline;">Confidential Separation Agreement and General Release, between Harmony Biosciences, LLC and Susan L. Drexler, dated March 4, 2021.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001802665/000119312521080566/d138171dex101.htm"><font style="text-decoration:underline;">Employment Agreement, dated March 4, 2021, between Harmony Biosciences, LLC and Sandip Kapadia.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex211_1165.htm"><font style="text-decoration:underline;">List of Subsidiaries of Harmony Biosciences Holdings, Inc</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex231_1163.htm"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex311_1162.htm"><font style="text-decoration:underline;">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex312_1161.htm"><font style="text-decoration:underline;">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1**</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex321_1160.htm"><font style="text-decoration:underline;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2**</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrmy-ex322_1159.htm"><font style="text-decoration:underline;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following financial statements from the Company's Yearly Report on Form 10-K for the fiscal year ended December 31, 2020 formatted in Inline XBRL: (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:87.75%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan or arrangement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU142"></a>This certification is deemed furnished, and not filed, with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Harmony Biosciences Holdings, Inc. under the </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.99%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Certain portions of this document that constitute confidential information have been redacted in accordance with Regulation S-K, Item 601(b)(10)</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927448"></a><a name="_Toc58363708"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:10pt;text-indent:0%;color:#auto;font-family:Arial;font-size:13pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc57927449"></a><a name="_Toc58363709"></a><br /><a name="_Toc57927449"></a><a name="_Toc58363709"></a></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><font style="text-decoration:underline;">Table of Contents</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU143"></a><a name="SIGNATURES"></a><font style="color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>Signa</font><font style="color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tures</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr style="height:15.3pt;">
<td colspan="2" valign="top"  style="padding-left:3pt;padding-Right:2pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HARMONY BIOSCIENCES HOLDINGS, INC.</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;width:84.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
</tr>
<tr style="height:15.3pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;width:15.96%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;width:84.04%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John C. Jacobs</p></td>
</tr>
<tr style="height:15.3pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;width:84.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John C. Jacobs</p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:2pt;width:15.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:2pt;width:84.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="font-weight:normal;"> March 25, 2021</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:7.98%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:42.4%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:18pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John C. Jacobs</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer, and Director (Principal Executive Officer)</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:18pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John C. Jacobs</p></td>
</tr>
<tr style="height:4pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:17pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Susan L. Drexler</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:20.8pt;">
<td valign="top"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Susan L. Drexler</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey S. Aronin</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey S. Aronin</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:18pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Antonio Gracias</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Antonio Gracias</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:17.55pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ R. Mark Graf</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Mark Graf</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:22.5pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Eric Motley</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eric Motley</p></td>
</tr>
<tr style="height:5pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jack Bech Nielsen</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jack Bech Nielsen</p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:20.7pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Juan A. Sabater</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Juan A. Sabater</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:27pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Gary Sender</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary Sender</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:3pt;padding-Right:0pt;width:37.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:3pt;padding-Right:0pt;width:20.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:27pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andreas Wicki</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:37.18%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td rowspan="2" valign="middle"  style="padding-left:3pt;padding-Right:3pt;width:20.44%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:14pt;">
<td valign="bottom"  style="padding-left:3pt;padding-Right:3pt;width:42.4%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andreas Wicki</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_Toc57927412"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:3.99%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>hrmy-ex43_1166.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex43_1166.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 4.3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGISTERED PURSUANT TO SECTION 12 OF</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a brief description of the capital stock of Harmony Biosciences Holdings, Inc. (&#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;). As of December 31, 2020, our common stock is the only class of our securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our amended and restated certificate of incorporation (&#8220;Certificate of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;), each of which is filed as an exhibit to the Annual Report on Form 10-K of which this Exhibit [4.3] is a part, and the applicable provisions of the Delaware General Corporation Law (&#8220;DGCL&#8221;). We encourage you to read the Certificate of Incorporation, the Bylaws and the applicable provisions of the DGCL for additional information.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our authorized capital stock consisted of 500,000,000 shares of common stock, par value $0.00001 per share; and 10,000,000 shares of preferred stock, par value $0.00001 per share.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and non-assessable.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon our dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our common stock will be entitled to receive pro rata our remaining assets available for distribution for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our Certificate of Incorporation, our board of directors is authorized to provide for the issuance of up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forum Selection</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, other employees or stockholders to us or our stockholders; (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws, or as to which the DGCL confers exclusive jurisdiction on the Court of Chancery; or (iv) any action asserting a claim governed by the internal affairs doctrine. Unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock will be deemed to have notice of and consented to this provision.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Declaration and payment of any dividend will be subject to the discretion of our board of directors. The time and amount of dividends will be dependent upon our business prospects, results of operations, financial condition, cash requirements and availability, debt repayment obligations, capital expenditure needs, contractual restrictions, covenants in the agreements governing our current and future indebtedness, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors our board of directors may consider relevant. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and therefore do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Provisions</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>Our Certificate of Incorporation and Bylaws contain provisions that may delay, defer or discourage wanother party from acquiring control of us. We expect that these provisions, which </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are summarized </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">below, will discourage coercive takeover practices or inadequate takeover bids.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions are also designed to encourage persons seeking to acquire control of us to first</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiate with our board of directors, which we believe may result in an impro</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vement of the terms of any</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such acquisition in favor of our stockholders. However, they also give our board of directors the power to</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discourage acquisitions that some stockholders may favor. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Authorized but Unissued Shares</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The authorized but unissued shares of our common stock and our preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classified Board of Directors</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Certificate of Incorporation provides that our board of directors will be divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. In all other cases and at any other time, directors may only be removed from our board of directors for cause by the affirmative vote of a majority of the shares entitled to vote. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stockholder Action; Special Meeting of Stockholders</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Certificate of Incorporation provides that our stockholders will not be able to take action by written consent for any matter and may only take action at annual or special meetings. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with Bylaws, unless previously approved by our board of directors. Our Certificate of Incorporation further provides that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer, our president or another officer selected by a majority of our board of directors, thus limiting the ability of a stockholder to call a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>In addition, our Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder must comply with advance notice and duration of ownership requirements and provide us with certain information. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a qualified stockholder of record on </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notice in proper form to our secretary of the stockholder&#8217;s intention to bring</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such business before the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting. These provisions could have the effect of delaying stockholder actions that are favored by the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holders of a majority of our outstanding voting securities until the next stockholder meeting.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amendment of Certificate of Incorporation or Bylaws</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DGCL provides generally that the affirmative vote of the holders of a majority in voting power of the shares entitled to vote is required to amend a corporation&#8217;s certificate of incorporation, unless a corporation&#8217;s certificate of incorporation requires a greater percentage. Upon consummation of this offering, our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders a majority of the votes which all our stockholders would be eligible to cast in an election of directors.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Section 203 of the DGCL</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the DGCL, which prohibits persons deemed &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations on Liability and Indemnification of Officers and Directors</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Bylaws provide indemnification for our directors and officers to the fullest extent permitted by the DGCL, along with the right to have expenses incurred in defending proceedings paid in advance of their final disposition. We have entered into indemnification agreements with each of our directors and executive officers that may, in some cases, be broader than the specific indemnification and advancement provisions contained under our Bylaws and provided under Delaware law. In addition, as permitted by Delaware law, our Certificate of Incorporation includes provisions that eliminate the personal liability of our directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders to recover monetary damages against a director for breach of fiduciary duties as a director. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dissenters&#8217; Rights of Appraisal and </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of Harmony Biosciences Holdings, Inc. Pursuant to the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such mergers or consolidations will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery, subject to certain limitations.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; Derivative Actions</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, in certain circumstances. Among other things, either the stockholder bringing any such action must be a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock must have thereafter devolved by operation of law, and such stockholder must continuously hold shares through the resolution of such action.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol and Market</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;HRMY.&#8221;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>hrmy-ex1020_1164.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex1020_1164.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit10.20</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 7<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> , 2017</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey Dierks</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428 W. 5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Avenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conshohocken, PA 19428</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Jeff:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On behalf of Harmony Biosciences, LLC (&#8220;Harmony Biosciences&#8221; or the &#8220;Company&#8221;), I am pleased to extend an offer of employment with the Company as Vice President, Marketing.&nbsp;&nbsp;Except for business travel on behalf of the Company, you will work out of the Company&#8217;s Philadelphia Regional Office and other Company venues.&nbsp;&nbsp;This position will report to the Chief Commercial Officer or his designee.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your start date will be mutually determined but we anticipate it to be on or around October&#160;2,&#160;2017.&nbsp;&nbsp;We are excited about the possibility of you joining our team at Harmony Biosciences and hope you will accept our offer to join us in executing our growth plans for the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of your employment offer are outlined below:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Bi-monthly base pay of $10,417 which, when annualized, is equivalent to a base salary of $250,000 per year.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Participation (pro-rated for the calendar year in which your actual start date occurs) in the Harmony Biosciences, LLC Performance Bonus Plan at up to 35% of your base salary based on Company and individual achievement.&nbsp;&nbsp;Your bonus will be based on your performance meeting established individual goals and objectives to support the growth strategy of the Company, as well as the Company&#8217;s overall performance.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Equity in the Company&#8217;s parent company, Harmony Biosciences II, Inc. (&#8220;Parent&#8221;) 400,000 stock options for Parent common stock at an exercise price equal to the greater of $1.00 and the fair market value per share of common stock as of your start date, to be determined by the Parent&#8217;s Board of Directors or its Compensation Committee, if applicable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">As a full-time Company employee, you will accrue paid vacation and sick leave.&nbsp;&nbsp;Vacation will accrue at a rate of 1.25 days per month, or 15 days per year.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">In consideration of the money left behind at your current employer for 2017 pro-rated annual bonus and LTI, you will receive a sign-on bonus of $100,000 (subject to applicable tax and other withholding), paid to you in two installments.&nbsp;&nbsp;The first will be 50% ($50,000) and paid no later than 12/31/2017.&nbsp;&nbsp;The second will be 50% ($50,000) and paid on 12/31/2018.&nbsp;&nbsp;Both payments require that you are an active employee in good standing at the time of payment.&nbsp;&nbsp;If you leave the company for any reason within 12 months after receiving the first payment or 6 months after receiving the second sign-on bonus payments, you must pay back the full pre-tax amount of that payment to Harmony Biosciences.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Harmony Biosciences, LLC 1033 Skokie Boulevard, Suite 600 &#x2022; Northbrook, IL 60062</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">This offer is contingent upon successful completion of Harmony&#8217;s pre-employment process.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will devote all of your time and attention to the Company (including, but not limited to, its business, operations and success) and shall not compete with the Company in any way during your employment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a full-time employee of the Company, except as expressly provided for above, you are eligible to participate in the provided Harmony Biosciences, LLC Employee Benefit Plans.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This offer of employment, if not previously accepted by you, will expire ten days after the date first set forth above.&nbsp;&nbsp;This offer of employment does not represent an employment contract.&nbsp;&nbsp;Just as you retain the right to resign, with or without notice or cause, Harmony Biosciences has the same right with respect to termination of your employment.&nbsp;&nbsp;You will be an employee at will, and your employment is for no definite term, regardless of any other oral or written statement by any Harmony Biosciences officer or representative, with the exception of an express written employment contract signed by the CEO, President or Chief Legal Officer of the Company.&nbsp;&nbsp;Notwithstanding anything in this offer of employment to the contrary, if your actual start date does not occur on or prior to October 2, 2017, this offer of employment will be null and void in its entirety (even if previously accepted by you).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you understand and accept these terms, please sign and return one copy of this offer letter to me.&nbsp;&nbsp;We would love to have you join Harmony Biosciences and be a part of building a great company.&nbsp;&nbsp;Should you have any questions regarding this offer, please feel free to contact me at 847-715-0611.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Anna Fenkanyn</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anna Fenkanyn</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human Resources</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreed to and Accepted by:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:48.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey Dierks</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/9/17</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey Dierks</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Harmony Biosciences, LLC 1033 Skokie Boulevard, Suite 600 &#x2022; Northbrook, IL 60062</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>hrmy-ex211_1165.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex211_1165.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Subsidiaries of Harmony Biosciences Holdings, Inc.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Subsidiary</font></p></td>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Jurisdiction</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Harmony Biosciences, LLC</p></td>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\121964576.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>hrmy-ex231_1163.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex231_1163.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66342894"></a>Exhibit 23.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement No. 333-248243 on Form S-8 of our report dated March 25, 2021, relating to the financial statements of Harmony Biosciences Holdings, Inc. appearing in this Annual Report on Form 10-K of Harmony Biosciences Holdings, Inc. for the year ended December 31, 2020. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">/s/&#160;DELOITTE&#160;&amp; TOUCHE LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chicago, Illinois</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>hrmy-ex311_1162.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex311_1162.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Certification of Principal Executive Officer</p>
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, John C. Jacobs, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Harmony Biosciences Holdings, Inc.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:102%;">
<tr>
<td style="width:6.56%;"></td>
<td style="width:95.44%;"></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:20.25pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ John C. Jacobs</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John C. Jacobs</p></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer (Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;margin-left:14.04%;text-indent:-3.51%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>hrmy-ex312_1161.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex312_1161.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Certification of Principal Financial Officer</p>
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Susan L. Drexler, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Harmony Biosciences Holdings, Inc.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.53%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:101.85%;">
<tr>
<td style="width:6.56%;"></td>
<td style="width:95.29%;"></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:20.25pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Susan L. Drexler</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Susan L. Drexler</p></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Treasurer (Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:7pt;margin-top:7pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>hrmy-ex321_1160.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex321_1160.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Certification of Principal Executive Officer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant To 18 U.S.C. Section&#160;1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as Adopted Pursuant to </p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;906 of The Sarbanes-Oxley Act of 2002 </p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Harmony Biosciences Holdings, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:101.85%;">
<tr>
<td style="width:6.56%;"></td>
<td style="width:95.29%;"></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ John C. Jacobs</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John C. Jacobs</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer (Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:7pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as a part of the Report or on a separate disclosure document.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>hrmy-ex322_1159.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrmy-ex322_1159.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Certification of Principal Financial Officer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant To 18 U.S.C. Section&#160;1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as Adopted Pursuant to </p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;906 of The Sarbanes-Oxley Act of 2002 </p>
<p style="text-align:center;margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Harmony Biosciences Holdings, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:7pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:101.85%;">
<tr>
<td style="width:6.56%;"></td>
<td style="width:95.29%;"></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Susan L. Drexler</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Susan L. Drexler</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Treasurer (Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:7pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-bottom:7pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as a part of the Report or on a separate disclosure document.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gym1fcavvjqs000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000009.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ,9 G@# 2(  A$! Q$!_\0
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M^$O%&D_%CP';7&!_PD'B_P (VC6,;%U4*_\ 9][=3+]XMN\K: K9(. ?H?\
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M@9XB^-O@GX.ZIX+A\.^)CHTVGZKJ<=VTS>1'*)%>-5P,28P1U'6OKG-?R_\
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M]C/]@SP]\1;.S\+^.-"\*6?Q(TNZT&VN)K^YN+P6ET?M$J-+&<*<%&7GDYH
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M^)[BYU+XP>,M'M[6P\-Z8<I;6"0P6[))/))%*5=XIF*ALJ ID4 _?[<*\O\
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M"SGB7QKH_AW7O^#>3X@:78ZAJEO;7NI2:]>;;2%Y%5YCNTY5PJDMR0..2.M
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M>RHH'X4 ?H]\,_\ @LSX@N/^"S_BS_@D?\>?@-:^$Y+?2WOOA_XPM]>:X7Q
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M?#UAXET+X[>*?&7@+QEX7U*[T[4? .N>!;^>]GFA=D(BDMXI(,-CCS9(CSR
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MD"49YK]_-(_8,_8=\/\ Q-_X75H/[&?PHL?&7VIKD^+K/X=Z9'J?G'K)]J6
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M23R375_\,V?LZ_\ 1 O!7_A*VG_QNI?V>_\ D@O@K_L5-/\ _29*["@#BO\
MAFS]G7_H@7@K_P )6T_^-T?\,V?LZ_\ 1 O!7_A*VG_QNNUHI ?/?[:'P+^"
M7A?]E7QUXA\,_!SPKINH6?A^:2TOK'P];0S0.,89'1 RGW!!K\E%UK6E_P"8
MQ=?^!#?XU^RO[=O_ "9]\0_^Q;F_I7XPT"+7]N:U_P!!>Z_\"&_QH_MS6O\
MH+W7_@0W^-5:* +7]N:U_P!!>Z_\"&_QH_MS6O\ H+W7_@0W^-5:* +7]N:U
M_P!!>Z_\"&_QH_MS6O\ H+W7_@0W^-5:* +7]N:U_P!!>Z_\"&_QH_MS6O\
MH+W7_@0W^-5:* +7]N:U_P!!>Z_\"&_QH_MS6O\ H+W7_@0W^-5:* +7]N:U
M_P!!>Z_\"&_QH_MS6O\ H+W7_@0W^-5:* +7]N:U_P!!>Z_\"&_QH_MS6O\
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MQO\ ]#GJW_@PD_QJYX=\:>,9_$%C#-XMU.17O(@ZO?2$,"XX(STKGZO>&/\
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MG4]'^1^+5%%%?D9\*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?3__ $FCK\+^]?NA\$/^2+>$/^Q7T_\ ])HZ .HHHHH **** "BBB@ HHHH
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MQAK]GOV[?^3/OB'_ -BW-_2OQAH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@N/^PA_P2PM(]"^.'CBXUSQM=1"6R^'WA-4N=4,9 (EF!98[5"""IF9"_5
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MKMM[.QMEABB7T5$  'T% %RO,_VR?^37/''_ & 9?YBO3*\S_;)_Y-<\<?\
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MVR?^37/''_8!E_F*<?B W/V>_P#D@O@K_L5-/_\ 29*["N/_ &>_^2"^"O\
ML5-/_P#29*["D 4444 >2_MV_P#)GWQ#_P"Q;F_I7XPU^SW[=O\ R9]\0_\
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M7G[*?[- A/[1/[2G@/P+]H7,(\7^++/3C(,XR!/(N1DT >B45R?P?^/?P/\
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M$<5E!:A?WC3O*0BQ[<Y+<8ZU^ ?Q7\5_L$_#;]L.7]H?_@W+_P""BOA'PO\
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MC/A0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KWAC_ )&;3_\
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M110 =Z_=#X(?\D6\(?\ 8KZ?_P"DT=?A?WK]T/@A_P D6\(?]BOI_P#Z31T
M=11110 4444 %%%% !1110 5\J?\%H/^3!?$G_86TS_TKCKZKKY4_P""T'_)
M@OB3_L+:9_Z5QUY^:_\ (MK?X9?D<N._W.IZ/\C\6J***_(SX4**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J]X8_Y&;3_^OZ'_ -#%4:O>&/\
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MW9-)KGANWT..WE=2/WD5D;LO'=(5X*OY+L/NY)"U^RO_  2B_:@_:/\ VO\
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M@04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]?NA\$/\
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M/_!6V3PKX9^(GB"ZU?5O ?Q%L?M5OHUQ<.TDWV&1K:[6-2[9'EQ0L!U=R 2
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M?_97AC0[O5M3^RQ[Y/L]M"TTFQ<C<VU#@9&3W%?SQ_M*_P#!UCX&^(?_  5
M^#7[1OP3\1_'+P_\"?".BR6_Q'^'<L5E;S:Y=,UW^]%I%J#V]P LEM@RRH5,
M38 P"W]&6J:;IVLZ9<:/K%A#=6=W \-U:W$8>.:-@59&4\%2"00>"#7X]?\
M!8C]GC_@@C_P3X_:C^%'[8'[3_A*XT?5-*TZXAT?X,?#OP=ITUEXGB0S;KF[
MM7C1,*UP%\QY4#&- .4- '(?M2?\'E'["'C[]G+QOX'^ /PB^.VD^-=8\,7E
MEX7U:\TW2K".QO98F2*X-Q!J<TD7EL=X9(V;*C&.H^SO^#;SXP_M._'G_@D_
MX'^*?[6'C'6O$7B+4]4U0V.O>(KEYKR_TY;IE@EDD?YGZ, Q)RJKS7Y_:?\
M\'$G_!M'I=Y'J%A_P2C\5131-NCD7X-^%<J?_!G7Z_\ _!.O]MCX'?\ !07]
MD_P[^TU^SGX1US0?".IR7%GI>D^(=-@M+FU%K*T!0Q6\LL2J"GR['(VXZ=
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MQI\TVDQ2;K@>?;#=*(D9Y1$^5(5P,$@'V#_@D'^U7\(/VS?^">7PW^.7P/\
MA;8>!]!N-):P7P9I87[/HDUK(T$MK%M508PR$J=H)5@2 <T ?2U%%% !1110
M 4444 %%%% !1110 4444 %>9_MD_P#)KGCC_L R_P Q7IE>9_MD_P#)KGCC
M_L R_P Q3C\0&Y^SW_R07P5_V*FG_P#I,E=A7'_L]_\ )!?!7_8J:?\ ^DR5
MV%( HHHH \E_;M_Y,^^(?_8MS?TK\8:_9[]NW_DS[XA_]BW-_2OQAH ****
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ME<__ !RC_AV=^Q9_T1R+_P &5S_\<H _("BOU_\ ^'9W[%G_ $1R+_P97/\
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MK7PW-J]QHOB#3M6L/$T,3$"2SN/ MQ%<*Q[9+X&?XBM>D_&?_@@=^T?^S?\
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M4>8B-N56QR <#(]\#Z"I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKY4_X+0?\F"^)/\ L+:9_P"E<=?5=?*G_!:#_DP7Q)_V%M,_]*XZ\_-?^1;6
M_P ,OR.7'?[G4]'^1^+5%%%?D9\*%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5>\,?\C-I_P#U_0_^ABJ-7O#'_(S:?_U_0_\ H8H6Z''XC^CK
M2O\ D%VW_7NG_H(JQ5?2O^07;?\ 7NG_ *"*L5^V'Z&%%%% !1110!XM^W-_
MP4!_98_X)Q?""U^.7[6WQ$?P]H%]K46DZ?);Z9/>375Y)')(L210(S']W#*Q
M8@* G)R0#\*_\%6/B9_P;/?''QK\-?C9_P %+?'%O>ZSXL^&=GJGP^U&&Q\3
M;KOPY-/-+!(5TV$B,&5Y\+,%D!W @8P/N3]O7_@GA^RU_P %*?@]9_ []K+P
M5<ZUH>FZ[%K&F_8=3ELY[6\CBEB$BR1,#@QS2J5.5(;.,JI'E'[07_!!'_@E
MM^U'IO@72OC7^SM-JD7PW\$VGA'PCY/BK4;5K32+8L88&,,ZF4J7<[WW,2YR
M>: /S'V?\&.O_0U?^4WQY_\ (]?KE_P2K'[ X_8M\-C_ ()G7:3?"'[7??V#
M)''?KF;[0_VC(U!5N ?-W?? ]N,5\^_\0K__  1$_P"C3K[_ ,.!K7_R77V)
M^R5^R-\!/V'?@AIG[.G[-/@QM \(Z1-/+8Z:^H3W3(\TC2R,9)W=VR[$\L<=
M!Q0!Z51110 4444 !&1BOB#Q9_P;B?\ !%GQOXHU+QGXF_8<TRXU+5K^:]U"
MX7Q;K<8EGE<O(^Q+T*N68G"@ =@!Q7V_10!^(_\ P1:_X-ZO$W[.'_!27XL_
M'7]K7]CZUTKP;X;\2-?_ +/>I2>,(KH6I34)FAE2*UO'D.VV\KB[4GID;LU4
MUK_@F-_P6E_X)._\%'OBG^U?_P $E/@[X(^*7@?XM7D]Q>>%?$&M6UH+(33M
M<^7+'/=VF##,T@C>*4Y23!49('[AT4 ?E1_P12_X)'_MG_#+]M?XD?\ !5W_
M (*=2:#!\5_'EK-;:3X8T6\CNETA)VC,TC/$SQ(1'%'!&D;OA/,RQW4__@HG
M\!_VL_\ @LE_P4.T7]@S6_A1XV\"_LM_"F^M];^)7B[6-(NK&W\?7R_-'96$
MCHJ7,2_<WHS*A:60\K$&_50C-)M]Z /R\_X*:?\ !.S]L3X>_P#!2G]GC_@J
M'_P3D_9WT'XACX.^"Y?"%]\(?^$DM- 3^S=E]#&;6:XVP1 0ZG<+T/EF"(A)
M!\H['_@AY_P3_P#VLOV?_C+^T9^W/^VIX+TGP;XV_:$\:0ZK'\/='UB+4$T&
MUBENY@DES"6CED9KO;E21B'=G+X7]$Z* "O,_P!LG_DUOQQ_V 9?YBO3*\S_
M &R?^37/''_8!E_F*<?B W/V>_\ D@O@K_L5-/\ _29*["N/_9[_ .2"^"O^
MQ4T__P!)DKL*0!1110 4444 %%%% !1110 55UF.&72[A9]-6\7R6/V1T#"7
M R%P0>I]JM5Y'^W3\5_VC_@=^RYXH^+/[)_P.B^)'CC0HK>YTWP3).T;:K"+
MB/[3'&5(;S?L_FL@&XEPH".<(P!^"G_!=O\ X+._M_\ [5'[*]S^R[\9?^"4
M'C?]GWP+K7B2V36O&GCK3]3NENDMYP\:V[S:=:1Q_,%8[3*S 84C.3^BO[#7
M[)G[$WQU_P"#<%?V2/@O^U-9WOP^USP#JD&M?$J]06BZ;JCW$EW=7%S#,R&W
M2"Z.3#(R_N47YL,'/QO_ ,%0_P#@X U[_@H9^QGXG_X)\?"#_@EQ\:K7XH>.
MH;?3=5T37O#+7']DR+-',WV>*%&N+B8% J[H82-V['&T]Y^SK_P16_;H^#G_
M  ;7?%C]DPZ8T7Q:^)&J'Q-'X)M[]5D@MT:T_P"):S[O+-Q+%:MN7=MW2*A.
M030!^<7P4_X+(?MG_L8_\$Y/BO\ \$T?A9X/\.>/OAFM[JGAW3OC!I.DWK6>
MEV^H/-]K$<C1(LHG629X3*$="Y8;U"@?=?PU_P""*O@#]L7_ (-KO#WP2_X)
MV_'G1_'WBZ]^)4'Q"U?4)+HV=O?:XEI)87&ELLN&M##;2JJK*!N>)9#M64$>
M7?L??\%C] _8X_X)6:E_P2@^+G_!)CXC77Q*CT/5M$?26\([;+7+F]>9DN+Z
M*5%N5E'G*"HCE+")=K(" GV__P &K?[$G[0'_!/']@WX@?$O]LG3IO MMXRU
MQ/$%KH/B*;[-)I&FVUIMDO+M'Q]E9QDLKX94A0OCH #Q']I'QG^VK\-_VT?!
M?_!<S_@K!^S)X=^!?A_X _#F;0/"?@/3_B#8:UJ/CWQ%<P7D44%NUHSB&-Y+
MV24J0QABMV)\P;I [_@F%^U=^P_^R!\>M<_X*#?\%B_VO?#NE?M0_':WCN++
MPK-I-[=-X%T&81FVLYOL\,PTUY(_*8I<-&4A$8/61CWW[-_ASQ5_P<3?\%&3
M^VM\5-)NH_V4?@+KLEK\'O#]Y8O'%XQUE"A?4)EDQYD:D!SQ@ 10]?.S\G?&
M'7-,_8O^//\ P4._9_\ VP?V2?&WBKQK^T+K5V_P/U2S\!2:E'J,,\]\]LL$
M^UMH3[59G,>2K6^W =0* /Z,?"OBGPOXX\-6'C/P3XBL-8T?5;..[TO5M+NT
MN+:\MY%#)+%+&2LB,I#!E)!!!!K0KY6_X(E? +XP_LP?\$L_@W\$?CUI%QIO
MBK1_"^=4TJ[?=+IYEGEF2V?DX:-)%4KGY2"O:OJF@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *^5/^"T'_ "8+XD_["VF?^E<=?5=?*G_!:#_DP7Q)
M_P!A;3/_ $KCKS\U_P"1;6_PR_(Y<=_N=3T?Y'XM4445^1GPH4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5[PQ_P C-I__ %_0_P#H8JC5[PQ_
MR,VG_P#7]#_Z&*%NAQ^(_HZTK_D%VW_7NG_H(JQ5?2O^07;?]>Z?^@BK%?MA
M^AA1110 4444 %>"_MU_\%,OV+?^";OA;2_%/[7?QFM?#8UR:2/1--CM9;J]
MOR@!<QP0JS%%R-SD!064$Y8 ^]'I7X)?\'+_ .SW\+K;_@L)^SC^TM^W)>7-
MY^SKK&D6?AOQ9%9WLBR:=)#=WL\BNL1$B0RB>)C(F&98I@#E%H ^N)/^#N+_
M ((QH[(/B=XV;:V-R^ KK!]Z^W_V+?VS/@7^WU^S]I7[37[.6MWFH>%=9N+B
M&SN-0T][6;?!*T4@:-^5PRGZBOA&+]F'_@T;$*A/$O[(N-HQN^+VF9_'-_G/
MUK[M_8J\)?L<>"?V>M'\/_L%S>"Y/AG%-<-HDGP_U:&^TMI&E8S&.>&21'/F
M;MWS$AL@],4 >KT444 %%%% !1110 4444 %%%% !1110 5YG^V3_P FN>./
M^P#+_,5Z97F?[9/_ ":YXX_[ ,O\Q3C\0&Y^SW_R07P5_P!BII__ *3)785Q
M_P"SW_R07P5_V*FG_P#I,E=A2 **** "BBB@ HHHH **** "BBB@   Z"C'M
M110 !0.@J&_T[3]5L9M,U2QAN;:XC:.XM[B,.DJ,,%64\,"."#P:FHH IZ#X
M=\/^%M*AT'PQH=GIMC;@B"SL+988H\G)VH@ &22>!U-7, <XHHH   .E%%%
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M_I,E=A7'_L]_\D%\%?\ 8J:?_P"DR5V%( HHHH **** "BBB@ HHHH ****
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M>&/^1FT__K^A_P#0Q0MT./Q']'6E?\@NV_Z]T_\ 015BJ^E?\@NV_P"O=/\
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MXU_'[7IM7\6VVIZCHVK:U<0HCZD;:<JDY" *6*,BD@#+*U 'W!1110 4444
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M%?\ 8J:?_P"DR5V%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^S1K']J>%?#=H\<.KM?1W$FH7#.7GN9)(OD+O*68A0 N<   "OQ&_P""@_\
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MO^O=/_015BJ^E?\ (+MO^O=/_015BOVP_0PHHHH **** $SD<BOS(_X+<?\
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M\FN>./\ L R_S%>F5YG^V3_R:YXX_P"P#+_,4X_$!N?L]_\ )!?!7_8J:?\
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M/$$%I)<+G&Y$=@S+D$;@,9&*^*?^"2.A?\&Z/Q!_:&N/B]_P2@N?"T/C[1=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^5/^"T'_)@OB3_ +"VF?\ I7'7U77RI_P6@_Y,%\2?]A;3/_2N.O/S
M7_D6UO\ #+\CEQW^YU/1_D?BU1117Y&?"A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %7O#'_(S:?\ ]?T/_H8JC5[PQ_R,VG_]?T/_ *&*%NAQ
M^(_HZTK_ )!=M_U[I_Z"*L57TK_D%VW_ %[I_P"@BK%?MA^AA1110 4444 %
M%%% !1110 4444 %%%%  <XK^:K]G[X*_LD>"O\ @ZH^,WPE_P""CWP_\*:C
MX;US6M>O?"]O\0X(SI;WUT\%_8S2+./)D#VS2JJR H6D P6VU_2J>:^6?V_/
M^",__!/G_@I=K>G^,/VJO@PVH>(=+L_LEGXDT?4YK"^^S!]XA>2(CS$!+8#A
MMNYMN-QH _'*V\"?LQZ;_P ';_PW\/?\$Q?#WA^S\+Z0UM-XPM?A];HND6DZ
MZ?<?V@(5MQY,<7D-$KB/""5G7ALBNO\ ^#8+XG_#G]B+_@HE^U5^QU^T/X_T
MGPKKAUAAI9\1:A%9I?-8WUS'(L;2E0S&.:.4*.2FY@,*2/UQ_8$_X))_L(?\
M$S[?5)?V3?@Q'H^J:U$L.K>(=1OI;W4+F%2"(3/*24CW#<43:I;!() QQ7[<
MO_!!7_@F5_P4+^)K?&G]H/X&2KXMFCCCU#Q!X9U>;3;C4%1=J?:/*.V9@N%#
MLI?:BKNPH  /S)_8=@T']N__ (.]/'_[4_P8U6#6_!/PVL]0N[C7["026EP4
MT9=$CV2+E7W33LRX/S+"S#(!K[:_X+8_M!?LO?\ !/73K'QI^SQ^R-\/]:_:
MU^,-XVB?"W5-,\#Z>VO&\EVPMJ$MR(O/9(MR 9;YWV*2%#%?K3]AO_@G-^Q[
M_P $Y/AY=?#;]D?X/V?AJUU*99M8U!I7N+[4I%7:K3W$I:20*,[5R$4LQ506
M;/*^'/\ @E1^SS8?\%$M6_X*;>-O%'BKQA\1+G25TWPW;>*+RWFTWPI;A"A7
M384@1H25:0%G=V_?2D$%V) /Q]T7]CGX\?L8?MY_LY_\$>;3]K#QA\.-<^/V
MBW7CO]HCXV> -=>RUWQ)JQ.IRQZ7!J3@R*L)L#&G7?+J+2.CEPA^U/\ @WL_
M:4_:>U[]HS]J_P#8/^./[0VO?%SP_P# GQ];Z?X+\?>*;UKS4YX))]0A:&YN
MB6\YMMG$PR25?S>2"H7Z^_;\_P""5O[%W_!2_2=!LOVK/AO<:E>^%YI'\/Z[
MI&J2V-_8B0H9$2:(@E&*+E6R,C(P>:Z#]AS_ ()\_LK?\$Z?A3<?![]E/X<K
MH6F7U^;[5KJXNGN;S4KHJ%\ZXGD)>1@H  )VJ,X R<@'LE\UXEC,^GQ*]P(6
M,*2'Y6?' /MFOD_]H[QA^W1?_ SQ/9_$/X0^#K+1)-*==2NK'5&>:*+C+*/-
M.3^!KZV' Q7F?[9/_)KGCC_L R_S%5'<&;G[/?\ R07P5_V*FG_^DR5V%<?^
MSW_R07P5_P!BII__ *3)785(!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\J?\ !:#_
M ),%\2?]A;3/_2N.OJNOE3_@M!_R8+XD_P"PMIG_ *5QUY^:_P#(MK?X9?D<
MN._W.IZ/\C\6J***_(SX4**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J]X8_P"1FT__ *_H?_0Q5&KWAC_D9M/_ .OZ'_T,4+=#C\1_1UI7_(+M
MO^O=/_015BJ^E?\ (+MO^O=/_015BOVP_0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\S_ &R?^37/''_8!E_F*],KS/\ ;)_Y
M-<\<?]@&7^8IQ^(#<_9[_P"2"^"O^Q4T_P#])DKL*X_]GO\ Y(+X*_[%33__
M $F2NPI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7RI_P6@_Y,%\2?]A;3/_2N.OJN
MOE3_ (+0?\F"^)/^PMIG_I7'7GYK_P BVM_AE^1RX[_<ZGH_R/Q:HHHK\C/A
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KWAC_D9M/_Z_H?\
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M )-<\<?]@&7^8KTRO,_VR?\ DUSQQ_V 9?YBG'X@-S]GO_D@O@K_ +%33_\
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M ":YXX_[ ,O\Q7IE>9_MD_\ )KGCC_L R_S%./Q ;G[/?_)!?!7_ &*FG_\
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M1110 4444 %%%% !7F?[9/\ R:YXX_[ ,O\ ,5Z97F?[9/\ R:YXX_[ ,O\
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M>9_MD_\ )KGCC_L R_S%>F5YG^V3_P FN>./^P#+_,4X_$!N?L]_\D%\%?\
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M_P#ZKYMV7WH^7_L?'=E]Y^2NX>M&X>M?K5_PX2_9?_Z*9XR_\"+;_P"-4?\
M#A+]E_\ Z*9XR_\  BV_^-4?ZKYMV7WH/['QW9?>?DKN'K1N'K7ZU?\ #A+]
ME_\ Z*9XR_\  BV_^-4?\.$OV7_^BF>,O_ BV_\ C5'^J^;=E]Z#^Q\=V7WG
MY*[AZT;AZU^M7_#A+]E__HIGC+_P(MO_ (U1_P .$OV7_P#HIGC+_P "+;_X
MU1_JOFW9?>@_L?'=E]Y^2NX>M&X>M?K5_P .$OV7_P#HIGC+_P "+;_XU1_P
MX2_9?_Z*9XR_\"+;_P"-4?ZKYMV7WH/['QW9?>?DKN'K1N'K7ZU?\.$OV7_^
MBF>,O_ BV_\ C5'_  X2_9?_ .BF>,O_  (MO_C5'^J^;=E]Z#^Q\=V7WGY*
M[AZT;AZU^M7_  X2_9?_ .BF>,O_  (MO_C5'_#A+]E__HIGC+_P(MO_ (U1
M_JOFW9?>@_L?'=E]Y^2NX>M&X>M?K5_PX2_9?_Z*9XR_\"+;_P"-4?\ #A+]
ME_\ Z*9XR_\  BV_^-4?ZKYMV7WH/['QW9?>?DKN'K1N'K7ZU?\ #A+]E_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gym1fcavvjqs000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& ET# 2(  A$! Q$!_\0
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M_A^0VA?2X7^R*%AW$G"AMP!Y^8!N0#G!H YG1?$FL77B+39)[P/9:E=WUO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M! ) .*Z:B@ K"\7_ /(MS?\ 7:W_ /1R5NUA>+_^1;F_Z[6__HY* -VBBB@
MHHHH **** "BBB@ HHHH **** "BBF311SPR0S('CD4HZL.&!X(- #Z*\IT_
M0+C^R=8O]"T1HH-7O5MA;6Y6!UL8\JS+O*@,YW=\@.".E%G<W:_!TZ-#97L&
MH_8I76%8SN:$2X?!' )5B N<^U 'JH((R#D>U+7&^!(8([K7Y-,@:#1)+M#8
MIY1C7B)!(54@8&[/;J#794 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUKK8HHX(DBB18XT4*B(,!0.  .PK%U3_ )&K0/\ MX_] %;M !1110 4444
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MY;QII.FSZ8VHRZ?:R7T4MNL=R\*F1!YR\!L9'4_F: .IHHHH **** "BBB@
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MA<6<<JAXEG9"70@$-\C-CKWYK1H **** "BBB@ HHHH **** "BBB@ HHHH
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M][_S]S_]_#4=S?WAM9@;N?[A_P"6A]*\M9G'^4]9Y5+^;\#U'PS_ ,BIH_\
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M84445Z)YH4444 %%%% &%JG_ "-6@?\ ;Q_Z *W:PM4_Y&K0/^WC_P! %;M
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MP7<55R,$XK;H **** "FR?ZMOH:=39/]6WT-#!'C%%%%?)GV 4444 >Q6/\
MR#[;_KDO\A4]06/_ "#[;_KDO\A4]?51^%'R,OB8A(52S$  9)/:H?MMIY+3
M?:H?*4X9_,&T?4U!K4*7&A:A#(9!');2(QBC+N 5(.U1RQ] .M>9VEM&GAG4
MK&33X$L(YXULKT^')"9F\HAF: #.1]T.1U-42>L@@KN!!4C(-(CI(@>-E9&&
M0RG(-<1H4L,7@"RT?6-)U"+R],1YH3!))\N[:%)49+' )3&0#R,5H?#HLO@/
M2K>6"X@FMH1#+'/"\3*PZ\,!D<]1Q0!U-%%% !1110 4444 %%%% '.^-?\
MD7S_ -=5_K7G%>C^-?\ D7S_ -=5_K7G%>%F/\;Y'T&6?P/F%%%%<!Z!L>%?
M^1EL_JW_ *":]1KR[PK_ ,C+9_5O_037J->WEG\)^O\ D>#FG\5>GZL****]
M$\T**** "BBB@#"U3_D:M _[>/\ T 5NUA:I_P C5H'_ &\?^@"MV@ HHHH
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MWD.FV0LA/$6$<$=OM\O=D''RX&<$>^*V;/3K'3HV2QL[>U1SN98(E0$^IP*
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M5$.001T:O1/-.CHKS&Q^)-V9+U[BV+SQFSM!9;2/)NG:9902JLV/W>> 3@#
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M-QI=Q;6L*RO/$\7S/M"Y4C/O5FU:9X 9X1"XXVA]WZU/10!;TOC5[,^DZ?\
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MS_Z[)_,5SE='IG_(6L_^NR?S%<Y7GX[[/S.?$= HHHKSSF"N6\7_ /(TWG_
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MFD=$)VBD?0S>(]"_X3:.;^VM.\K^SF7?]J3;GS%.,YZUM?\ "4^'O^@]I?\
MX&1_XU\M?\O8_P"N?]:EK;VS[%^T9]$>*-7TW4M"D2QU&TNF21"P@F5RHYZX
M-<)6!X*_X]=6_P!V+_T(UOUXV/ES5;^1]'E;O0OYA1117&>D;'A7_D9;/ZM_
MZ":]1KR[PK_R,MG]6_\ 037J->WEG\)^O^1X.:?Q5Z?JPHHHKT3S0HHHH **
M** *TU]!!>VMHY/FW.[RP!P=HR?TJS6%JG_(U:!_V\?^@"MV@ HHHH ****
M/,?B'J$LFJI97NBM%9P -;ZJ;^6V4EMI92Z1L%&5'#$?=!KM_"\4</AFQCAB
M@CC$>0L%S]H3DDY$A W9ZD^I-<[XG\*^(]<UF22/5+5](**JZ?.TJ)G'.[RB
MI;)[$D>U=3H=B^FZ+:V;PVD+1+M,=FA2)>3]T'G\^] &A6;JF@:3K*J-0L(9
MRKHX9E^;*L&'(YQD=.AK2HH P%\&:&EY=72VL@DN%E5@+B3:GF_ZPHN["%NY
M7!IR^#]$75(=1%M(;B(HPS/(4+(NU'9<[6<+P&()K=HH *PO%_\ R+<W_7:W
M_P#1R5NUA>+_ /D6YO\ KM;_ /HY* -34/\ D&W7_7%_Y&O+J]1U#_D&W7_7
M%_Y&O+J "BBB@"WIG_(6L_\ KLG\Q7.5T>F?\A:S_P"NR?S%<Y7GX[[/S.?$
M= HHHKSSF"N6\7_\C3>?\ _] 6NIKEO%_P#R--Y_P#_T!:Z</U-*?4Q****Z
M30*]-B_Y!NF_]>4/_H(KS*O38O\ D&Z;_P!>4/\ Z"*Y<9_"^9ZN4?QWZ?Y!
M1117EGT@5Z%X$_Y DW_7RW_H*UY[7H7@3_D"3?\ 7RW_ *"M=N7_ ,<X,R_@
M?,Z>N;\9_P#(,@_Z[?T-=)7-^,_^09!_UV_H:]\^>.)HHHH *?)_R![SZQ_S
M-,I\G_('O/K'_,UE7_AR]"*GPLQ****\0X0J>V_Y>?\ KTN/_13U!4]M_P O
M/_7I<?\ HIZNG\:]2H[H\THHHKO-@K8\*?\ (W:1_P!?D7_H0K'K8\*?\C=I
M'_7Y%_Z$*%N..YVM%%%>"?<!1110![%8_P#(/MO^N2_R%3U!8_\ (/MO^N2_
MR%3U]5'X4?(R^)G >*_^0])_N+_*L2MOQ7_R'I/]Q?Y5B51(4444 1ZQ_J]/
M_P"O<_\ HQZRZU-8_P!7I_\ U[G_ -&/677BXC^+(X:GQL****Q(*/B3_D5?
M^WV/_P! >N)KMO$G_(J_]OL?_H#UQ-=U+X$;QV1!MF^T;\)MQMZG.,_2IZ**
MT;*.N\%?\>NK?[L7_H1K?K \%?\ 'KJW^[%_Z$:WZ\S&?Q%Z'TN4_P"[_-A1
M117(>F;'A7_D9;/ZM_Z":]1KR[PK_P C+9_5O_037J->WEG\)^O^1X.:?Q5Z
M?JPHHHKT3S0HHHH **** ,+5/^1JT#_MX_\ 0!6[6%JG_(U:!_V\?^@"MV@
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M6Y2%I '8><G1>IZ'\JZ2N>\8V\#Z#).T,9E6:W"R%1N'[Y.] &QJ'_(-NO\
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M=D_F*YRNCTS_ )"UG_UV3^8KG*\_'?9^9SXCH%%%%>><P5RWB_\ Y&F\_P"
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M38O^0;IO_7E#_P"@BN7&?POF>KE'\=^G^04445Y9](%>A>!/^0)-_P!?+?\
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MEN49G<!3N4*#DD'CC!'%=S\/8([?PJL:6+VA^TS,VY0!*Q<DNORK\ISQ\HX
M% '54444 %%%% 'DNBWRVWBR&[GGG6_@N-2DUK)<[+=<F+<O]T83;@>N*=>7
M8NO''FQS3MJCZO9-9 %QFQ,:ER!TV8+[O?KS7K%% !7+>-%UJ72Y(M/M+2:
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MG]-(_P# F7_XW3F\)>)VM)K?&D8D*G/VF7C!_P"N=>BT4I14E9B:35F>6_\
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M.<]L5L@AE!!R",BM%2@E9(KDBCPW_A3/B/\ Y_M*_P"_DG_Q%'_"F?$?_/\
M:5_W\D_^(KW.BG[./8.2)Y%HWPU\2Z/%=(LVDR_: H),T@V[3G_GG5__ (0?
MQ-ZZ1_X$2?\ QNO3J*RGA:,W>2.FEB:M*/+!V1YC_P (/XF]=(_\")/_ (W1
M_P (/XF]=(_\")/_ (W7IU%3]1H?R_F:_7\1_-^1YYI?A7Q/IFHPW@72)#&2
M=IN91G((_P">?O713:AXDL_)DN=,TZ2!IXHG%M=2.ZAW5"P!C (&[)Y' -=#
M16U.E"DK05CGJUIU7S3=V%%%%:&84444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9Q98P0MCS&#D8X*\=<G %:4?CC1YHFEB\^2,/:('5!AOM./+(R>GS#/I3)_
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MM$T7[IY 2K '!V<<<YS4UGX@L;N&)O,_>-;+</Y:.Z(&3=C?M SCD X)'.*
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MKGR\LT@CY.#@ GTJNWC.VALIKJZMGC%NDYFBC/F.&BD6-MH PRY;[V1CN.N
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MAN*;PNX#&2O(&<GM5:V\7:3<:9;W[23PQSJS*LEN^\*N-S$ 'Y1D9;[HSUH
MW:*R9O$NCV\MS')>J#;%!,0C%4+E0H+ 8R=ZX&>_UJ-?%6DS)(+>Z#RHDC;)
M$>,90$LI)7AACE?O <XH VJ*RHO$6F27<=F;E1=,54H%8JK,@=5+8QD@Y&<9
M[5-9:S8:C,\5K/YCJN[[C*&7.-RDC#+GC*Y% %^BN?B\6V4OV= 8_.EOY;(Q
M><NY-C2*7(ZX/EY_$4Q/$]P^D-JYTMETYXA+!(9QO=20%++CY<@Y')]\4 ='
M15#6-5AT;3'O9AN 9$5=P7<S,%4$G@#)&2>@R:RY/$\P@B^S65O>3M;R7+BW
MO T8C0@?*^WYF)/ P!P<D4 ='16&/%^ADH/MIW/MPHB<G<R!U3@$;BI!"]3V
M%2OXGT=$MW^UEEG5&0QQ._#MM7. =N6RHSC)!'44 :]%%% !1110 4444 %%
M%% !1110 5F_V'9?VE]OP_G[M^=W&?I110 R+0;)-=N=7DAAENI=GEN\(+Q!
M5V_*W7G\*QV\%.QLD_M,F"V,#"-XB>8YO,ROS@+NX!R"< =*** )7\)32:6N
MG/J$;6UO,)K16MLE"&)Q)\_SC!(XV_GS23>$9C"$MKZVM2]K+:S"*S^1ED;<
MS*"^5;W);G)(-%% $\'A8V]U&J7H_LZ.Z%XEN8OG\S;C'F;ONYYQMS[XXKHJ
M** "BBB@ HHHH *R3X<T]M7_ +3*R?:=X?._C/THHJ914MQ-)[BPZ#91Z[=:
MO)##+=3%-DC0C?$%7;A6Z\UEGP=_HGV07Y$+V)LI?W/S$99E93G (+'@@Y]J
M**H987PU-+J":A>WZ2W8F21C%!Y:%4CD15"EB1_K6).3^%5D\'S11010:H;;
MR; 68FMX3'*^(O+#,V_! /S 8R#C!]2B@";2_"G]GWB73W:O(MV;HK'"57)@
M\G RS'H,Y)-3Z3X>?2+FVDBO%>..S2TE5HN7"%BK [OEY<Y&#GCI110 LV@W
M%QKL6I/=VZFW\PP>7:[9,LI7$C[OG49SC Y ]*6RT6[MKVYOY+Z%KNY,*RF*
MUV1F.,M\H4L3N.]LL2>W'%%% $6C^&?[*O+>5KM98K2"2VM46'85C=U8[VR=
MY&Q0#@=^"34D'AQ898'^TD^5->2XV=?M#LY'7^'=CW]J** .,LHUTCQY:Z.L
MK37$36XC$BGRO+6W5&? ; DP'Q\K=<9YX]/HHH **** "BBB@ K+U_P_8^)-
M/6QU 2&%9!(/+;:<@$?U-%%#5P*8\(:='X=@T*$'[%%<1S%)@)-X642%3GJ#
MC'XT[4O"]M>QM% Z6D7V&6S2.*(!4WLC;@!@<%.G?-%% $<WAJYN;B9I=0C\
MF[D@FNXTMR"\D>W&PESL4[%R#N/!P1G-1_\ "(A89$6YADWQF/;<6^].9FES
M@,#D%N,$8(!HHH C'@^<W5C+-J\MPMJ8&'G(S,6CZX._ #=\@GW-2/X01],B
ML_MK#RM.EL0_E_WRAWXSVV=/?K110!?UC2K[5=(CLA?Q0N67[2PMR4F7'S)M
MW@A2<9^;IQWJ*ZT?4;FXTF47]G'_ &?)YNU;)L.Q1XSC]Y\HVN<#GD YQQ11
M0 S^P+HZQ)J9OK=+A8)88&BM-I&\@@R'<?,V[1@?*.M-_P"$9/\ :QN3=K]F
M-XM\81!\_G",)P^?N\9QC/7G'%%% %BZ\/K=75Q.;DKYUS;7&-F<>2RMCKWV
M_A7#^+8$T/5[=#*TCW7GO A4^6\DDP?9* RY0$K_ 'L\\#N44 >H#.!G&>^*
M6BB@ HHHH **** (KJWCN[62WESY<BE6P<'!JIIFCVFDI*MJ' D(+;FSTHHJ
M7"+ES-:E*<E'E3T9G6?A&RL/#UEI5JL,+6[VKR3QP*IG:%T;+ =VV=23C/>J
M]WX-2XN_M27$+2F2=BMQ;F2,K*5)& ZG(*#!SW/%%%427(_#<<<A9)PJF_CO
M BQX"[(4B"#GI\F?QQ6>W@MC#9H;NVE:TCD@C$]H70Q.5(# 2#+#;]X$ Y/R
MT44 :)\-Q^1=1+/L6>_M[T!8\!/)\G" 9Z'R1SVW>U17'A59XV7[65W7%S/G
MR_\ GM&Z8Z]M^??%%% #H_#*QJP^U$[KR"Z^Y_SRCC3;U[^7G/O1X=\,1^']
MJ(UM(D4(@A=;<K*$&.&?<0W0= O3-%% !'X6MHX[8;D+PW\MZ9/*&7\QY&V$
M^@\S&?:H%\,7JZ&VB_VLAL8X1#; VOSH%(V[VW?/@#' 7/>BB@"_>Z3=:EHZ
MVMY>0FZ29)DGCMRJ!D<.N4+'(XP?FY&>E9H\)7$;RW%OJB17ERLRW4GV;*,)
M""=B[OE(V\$ENIR#110!:MO"T-H\7DW#".*]2[1"O0+ (0F<^@SFN-U6!="\
M66-B)6FFE6'[.KJ?*=OM$CYD 8?=+C'#8(SQ110!ZC1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gym1fcavvjqs000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 ?@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJEJEY/86;W$-LLX
MC5GDWRB,*H&3S@\_YS0!=HK%.OXO-.B^R_N[X+L_>CS5W(6R8\?=&,$YHU+Q
M +"ZGC6U:6*U2.2YD#X**[$# Q\QX)/3B@#:HHHH **** "BBB@ HHHH ***
M* "BBB@"*6Y@@:-9IHXVD;:@=@-Q]!GJ:EKC/B2]LF@0F_DB@L#-BXN7LUN#
M""#@J">#GC< <>E6O FFV]GH45Q9W6KR6MP@,<>I3!R ,X91_"&&#C/3' H
MZFBBO-O$6MZCIWQ-TI+?5)&LIIA;RVD=S$_S&)B$,&W>.0&\S<<9QB@#TFJ>
MK_\ (%OO^O>3_P!!-><_#CQ%J>J:] EQK,FHQWND_;KJ)MA%G<>;M"+M'RC&
M?E//RYKT#7IS#H]V!!++O@D!,8!V_*>3DCB@"_%_J4_W13Z9%_J4_P!T4^@
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M9 _VKJ1P<%X\?]\"@#0HHHH **** "BBB@ K/NO^0WI__7.;_P!EK0K/NO\
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M97,-Q$&VEXG##/ID5\PX'I7M7PD_Y%"7_K\D_P#05H [RBBB@ HHHH ****
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MYG R.-Y3 (P>A/X5H^&]3T>[M&L](MGLUM0 UH]JT!CSG'RD#KSTH W****
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M9X(D67PQ"T=DUG%YLHCA8."$#G:2');)&#SZT =%6-)XDM(_%4'AYH;K[5-
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M!QW'I0!P^EZ)KMMXMTF\O[2.98;1K9KI;C=Y:!$P"I7J6#$\G/X5W@ 4
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M)YX4444 %%%% "'[I^E>LZK_ ,DSN/\ L%_^TZ\F/W3]*]9U7_DF=Q_V"_\
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MKJEW-#$)R5CB@,ID;8P^[D?=^]GVK3^'\%O:^#K2WM;D7$<3R*9!#Y0W;VR
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MKD_MF?\ )^)G]9?8]F&I6/\ ;[/]MMMOV4#/FKC.X^]7_P"U-/\ ^?\ M?\
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M_P BA+_U^2?^@K7BM>U?"7_D4)?^OR3_ -!6@#O**** "BBB@ HHHH ****
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M_%_J4_W13Z9%_JD_W13Z "BBB@ KC/B1_P @2U_Z^1_Z"U=G7&?$C_D"6O\
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M0^%"T445N4%%%% !1110!ZK\&_\ 5:S_ +\/\FKU&O+O@W_JM9_WX?Y-7J-
M!1110 4444 %%%% !1110 4444 %%%% !5/5_P#D"WW_ %[R?^@FKE4]7_Y
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M'_'RO^%+]KU+_H%C_P "%_PK1HH SOM>I?\ 0+'_ ($+_A1]KU+_ *!8_P#
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M_P")H_X53XD];'_O\?\ XFO;Z* /$/\ A5/B3UL?^_Q_^)H_X53XD];'_O\
M'_XFO;Z* /$/^%4^)/6Q_P"_Q_\ B:[WP9H^L^%]$>PGLX9W:=I=T=P ,$ 8
MY'M7944 9WVO4O\ H%C_ ,"%_P */M>I?] L?^!"_P"%:-% &=]KU+_H%C_P
M(7_"C[7J7_0+'_@0O^%:-% &=]KU+_H%C_P(7_"C[7J7_0+'_@0O^%:-% &=
M]KU+_H%C_P "%_PH^UZE_P! L?\ @0O^%:-% &=]KU+_ *!8_P# A?\ "C[7
MJ7_0+'_@0O\ A6C02 ,DX H YOQ!;:MK.BSV,>GQQO(5(9[@8&&![#VKB_\
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MO^%'VO4O^@6/_ E?\*T:* &QEFC5G38Q'*YS@_6BG44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>,:'X=U^Q\6WM]!I%]OC.I'?.L,
M4>)&+1>2Z_.68A<E\@ \8KV>B@#PVRA^(XT?$\6O%TOXY(8?/^9T*?,KR%RP
M0-]1GJ,&M.XL/'5UXC\2PWGVU["XM+Q((0-T$BLA\I5.["L./X03SDUZ_10!
MY#9Z#XM>>*R+ZK8V328D>UF$;!%LD"C([>:N/KFDOX_B)+?>%Y0^H11BSMQ=
M>2-VV<-^]\U0P!!7'7(ZXYKU^B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *IZM"+C1KZ!H))UDMW0Q1MM9P5(V@]B?6KE% 'BMIX8UD:;IH&EZM%I
M^GZQ"]ND8BM[QH?**,THC;:Q4[0&SDJ6I)].\=ZE_P )?:7=CJ)L[NQG2V@E
MG\Q3*)1LV$M@90D\ #\J]KHH \;BT;QE+-;36UOJ>+6ZN&L#JDJ22PDVA7+,
M"1L,OW?\*V? D/CR/2;A;VX(G^U1G;J\3L0FW]YL8.2<G&,G YXKTNB@#Q[2
M=*\:'5[Z^E@U,:LNEWT*7%Y*C0?:6D4Q"$ _*F .H XJ&XM/'']A7)L1XG6(
MW,)AAN;A#<LP1O,RX;*Q%MN,$\CICBO9Z* /,M-B\;_\+4>:_>\CT=G;:@^>
MW,7E_*O#85@_?;DGO@U4NO#WB"WU_7DT\ZY"M_K%K*;J*Y&PVS!1(4YX88(/
M' "^E>L44 >46]MX\MO'>I>9)J$VG)'.MJF_,4R"+]R-Y;"/N RVW.<Y/-8U
MOHWC/4O"MPFM6VNN;;5+.[MXDN?](,8(\T*S,22O49/!Y&*]PHH \I?0?%MY
MJTCR:GXAM[:6^O$*1704);B/="1UP2XQGKU' JCY7Q(DUS0YIGU".'[%;"41
MC<GF;,3"4!@ Q;N0<<8Q7LE% 'CK>'?%]YX2U/3KV76+I[W08I66>Y!(O S;
MHU/8%0N1T/KS6SXNN[VQ\,^%(+5]=A^T7D<,T,<X%[(AB<E"Q."W'KVZUZ33
M'BCD*ET5BAW*6&=I]1[T >.+:_$E-2\.&XFU%;=8XO,*$2%3YK;A. P#'R]@
M)(;N1S6F=)\8@P7<<M_)>MJ]V52YE#10PA)A 0.RDLGN>/2O4Z* /&[>U\<#
M3)#M\3"T+V@O(YKF,W;L-WGFW(;Y4/R8&1QG&*[OX>:?>Z9X-M[74()H+D33
MLR3L"^&E=@6(X)((/%=310 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gym1fcavvjqs000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000008.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" &3 IT# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@ ) I-XK\RO^#K[]H#XW_LU?\ !,_0OB5^S_\
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MO!&CV>J:M<^#M8A7%M/%"_F&(Q,RJK3QH23R3[U]:_L4_M#_ !2_:A^!UO\
M%;XP_LM>*/@[K4NI7%M)X+\7S+)>1QQL LY*JHVOG(X[5\+?M<_\$G/^"FWA
MW_@H9\5?^"F7_!/+]M?P/X&UGQIX/M=+DT'Q%X/6^::WM8+?,+231RQQ[Y+5
M6#JF0./6O4/^#?/_ (*D?&+_ (*C?LE>(/&G[0WA/2-.\;> _&$OAS7;O0(&
MAM-29(8Y4N%C9W\MRLFUP&VEE+*%5@J@'WI1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *0!?M&?^0/_ (B@#]&J*_.7_A]I^W3_ -( OVC/_('_ ,11_P /M/VZ?^D
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M[6'B3XP:Q_PD$FL:3\4O[#@TG4M,N,8@,42/+&1&&=2&)#K(P('!'$_LM_\
M!!35? O[3?@O]J_]NO\ ;V\<?M&^(_A?;>5\,;/Q5I,=C8Z$XV[;@QB:=IYU
M9582%E)=$9MS(I%7_A]I^W3_ -( OVC/_('_ ,11_P /M/VZ?^D 7[1G_D#_
M .(H ZK]K7_@DG^V7\>?BKXH\3?!G_@L]\7_ (;^#?&5V\VL^ UTF#4XK1)%
M59(-/N6FBDLHBH;" ,%+Y''!]V_X)T?\$Z?V=_\ @F)^SM;_ +.'[.5CJ+:?
M]M>_U?6-:N5FOM6OG55>YG=%1=Q5%4*JJJJH '<_+_\ P^T_;I_Z0!?M&?\
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M_H>LV+$Q74#CAAD!E(.058!E8%6 (( !U%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^;O_!OP,_%W]N\Y_P";W/&7_I17Z15\)?\ !%C]G+XY
M? #XF?MAZM\9?AGJ?AVV\=?M:>*?$GA&;48PJZKI-Q-F&[BP3F-QR"<'VH ^
M[:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+Q%XC\/\
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MV-QX=U1I996EVEE695DFE92K-N63#(I4%OUPHH _,3]CW_@E9^WE_P $R_\
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M_!2K1?\ @EU^Q???M+W?@C_A)M<NM2M=(\*^'?M!ACOM1N,E1(X!*QJB2.<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_.'_ (.' /[2_8V&/^;QO"__ *)NZ_1Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BC-% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7PG_P<E>,/C?X'_X([?%G7?@-?:I:ZE]ELX=6O-'9EG@TJ2ZC
M2\8,GS*OE%@[#HA;/&:^[*\[_:L^(GQ/^%/P!\2>/?@W\ [GXH>(M/M5-AX#
ML]0AM9-6#2(DD8DF^08C9WP?O!<#DB@#^:7]NWQW_P $C?V>_P!@']F?]H?_
M ();_%30]"_:5\':QHU[KDGAZ:Z.I2C[#*][)?AP4WI>)" '(#))(JAD; _J
M*\$:_)XK\&:1XIEMO);4M,M[IH1_ 9(U?;^&<5^(WQ<_8S_:,_X+(_$OX?\
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MZO>R6,.EQ2VZW9O4G5$+E&O^!O0.]NT3!G0G^D.]NH[&RFOIG55AB:1F8X
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M#?A7;%<.B[K"?. Q'_/:O'S3.<%D_)]8O[U[65]K7_,Y,5C\/@TG4OKY=O\
MAS]&*QO'OPZ^'WQ5\*W7@7XH>!-&\2:'?)LOM'U[2XKRUN%ST>*561Q[$&OS
MY_X>W_M)?]"UX4_\%\__ ,>H_P"'M_[27_0M>%/_  7S_P#QZO)_UTR3O+_P
M'_@G'_;V7]W]Q]P?!3]E#]EK]FI+J/\ 9S_9J\ > %OFW7J^"?!MCI0N#QR_
MV6)-W0=<]!5W0OV<_P!GOPOXL\4>/?#/P(\&Z=KOC=57QIK5CX7M(;O7P 0!
M>S)&'N@ 2!YI;@GUKX2_X>W_ +27_0M>%/\ P7S_ /QZC_A[?^TE_P!"UX4_
M\%\__P >H_UTR3O+_P !_P""']O9?W?W'V7\-_V%_P!B3X-^.I/BC\(?V.OA
M7X5\32[_ #?$7AOX>Z;8WS[VW/FXA@60[F )^;D\FO5*_.#_ (>W_M)?]"UX
M4_\ !?/_ /'J/^'M_P"TE_T+7A3_ ,%\_P#\>H_UTR3O+_P'_@A_;V7]W]Q^
MC]%?G!_P]O\ VDO^A:\*?^"^?_X]1_P]O_:2_P"A:\*?^"^?_P"/4?ZZ9)WE
M_P" _P#!#^WLO[O[C]'R0.]%>0_L2_';Q?\ M&?!-?B-XWL[&"^;5KBV,>GQ
MLD>Q N#AF8YY/>O7J^EPN(IXS#QK4_ADKKT9ZM*I&M34X[-7"BBBMS0****
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MCP^(/]Q7^)?DSP6BBBOR<^+"BBB@ HHHH **** /KW_@CU_R6'Q7_P!BTO\
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M_'7@G6K&+XE>*)/"]QI>FVFFQO"2=2D9BEP^U+GS9'/^D+NC;S2RJ/V,T/\
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M^T?X#^ %YXXA\"V6GV^F^!]#NC:M+"]S!:JHD6&8Q1Q)(')$;86,\=Z^@J*
M/@7]J_\ X*8?LD7'[''PD^+'[?/_  3]\7^*/!'Q2T"'Q!>:%=?#./Q7IWAF
MZ6*-TCO5FC"K)^^(CD,2E@&.%Z5^?_\ P2,^%/C#XR_\%\-4_:__ .":/[/O
MC3X1_LKQ:;<CQ1:ZQH\VDZ5K+/I[Q&"WM#^Z^:_$4RPH2(1#N^3Y8Z_?JB@
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M ."3GB;6/A!XDN='U[QMX@L?"L.K63[9[2WN1+)<M&PY1F@@DB##YE\W*D$
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M7ZV5^J<!_P#(MJ_X_P#VU'V'#O\ NDO\7Z(****^X/H ;I7XW_MW_P#!P_\
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M_!PY_P A+]C7_L\;PO\ ^B;NOT>K\X?^#AS_ )"7[&O_ &>-X7_]$W=?H]0
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M (-$/&OBGQ5_P1RT?2?$5[--;^'_ (@:YIVC"4G]W:EX[G8N>WG7$QXX&2*
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M_DU1/^QBO/Y1U]*5^[9#_P B7#_X%^1^B9?_ +C3_P *_(****]8[ K\M_\
M@YX_Y)C\)?\ L/:I_P"B;>OU(K\M_P#@YX_Y)C\)?^P]JG_HFWH%+8_'NBBB
MM# **** "BBB@ HHHH Z#X4?\E2\-?\ 8P6?_H]*_6#_ (*3_P#)W7B#_KTL
M?_2:.OR?^%'_ "5+PU_V,%G_ .CTK]8/^"D__)W7B#_KTL?_ $FCKXGCS_D3
MP_QK\I'CYY_N*_Q+\F>#T445^2GQX4444 %%%% !1110!]>_\$>O^2P^*_\
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M'_*,?]F+_L$^(/\ TN2ORLK]4[C_ )1C_LQ?]@GQ!_Z7)7S?%W_)/UO^W?\
MTN)Y^;?\BVI\O_2D>:4445^)GPX4444 %%%% !1110!ZQ^PQ_P G;>!?^PS_
M .TWK];*_)/]AC_D[;P+_P!AG_VF]?K97ZIP'_R+:O\ C_\ ;4?8<._[I+_%
M^B"BBBON#Z _*O\ X.IOV:_'_P"U+\$OV?OAKX/^&?B+Q+8S_'FQC\21^&].
MEN)+33Y;::*69S&K>4H5C\Y& <5:'_!G[_P1Y/\ S"/B5_X7'_VFOU*XZUX_
M\;?^"@O["O[-GBC_ (0C]H']L'X:^"]9"*S:5XF\96=G<*I&03'+(&&1SR*
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M,7_8)\0?^ER5^5E?JG<?\HQ_V8O^P3X@_P#2Y*^;XN_Y)^M_V[_Z7$\_-O\
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MP;/:UX8T;_@AE^T])\1[RWADT_Q!XKE\62:@PPD/]@P;S+GM\LN<]>:^@/\
M@T&T;Q+I/_!'73;W7K:XCMM2^(VN7.C-,#MDM0T,19,_P^?%../X@WO0!U'_
M  <.?\A+]C7_ +/&\+_^B;NOT>K\>?\ @N;\6?VR_$7[9'[-?PR^)O[)VF^'
M?A+I/[6OA:7P7\3H/'%O=W&O7/E29A?3T'FVPP\YW,<?N1_?%?L-0 5^ /\
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M.GR_$MF=235(;"RNV&)6C-N5,2,<-<%6'.*_<D].E?SJ_P#!0KXC_P#!0/\
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M_!PY_P A+]C7_L\;PO\ ^B;NOT>K\X?^#AS_ )"7[&O_ &>-X7_]$W=?H]0
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MX\FBN/'&EZ/KD-]I>LW,;JZW#VQEA(?>BR??*^8-X ;)K]%/^"Z__!)/6_\
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MT, HHHH **** "BBB@#H/A1_R5+PU_V,%G_Z/2OU@_X*3_\ )W7B#_KTL?\
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M,7_8)\0?^ER5^5E?JG<?\HQ_V8O^P3X@_P#2Y*^;XN_Y)^M_V[_Z7$\_-O\
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M>\16 46.O:UX6M+J\M]OW=D\L;2)CM@C%=J!SDTM% 'YP_\ !PY_R$OV-?\
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M1/\ L8KS^4=?2E?NV0_\B7#_ .!?D?HF7_[C3_PK\@HHHKUCL"ORW_X.>/\
MDF/PE_[#VJ?^B;>OU(K\M_\ @YX_Y)C\)?\ L/:I_P"B;>@4MC\>Z***T, H
MHHH **** "BBB@#H/A1_R5+PU_V,%G_Z/2OU@_X*3_\ )W7B#_KTL?\ TFCK
M\G_A1_R5+PU_V,%G_P"CTK]8/^"D_P#R=UX@_P"O2Q_])HZ^)X\_Y$\/\:_*
M1X^>?[BO\2_)G@]%%%?DI\>%%%% !1110 4444 ?7O\ P1Z_Y+#XK_[%I?\
MTH2OT'K\^/\ @CU_R6'Q7_V+2_\ I0E?H/7[)P=_R(8>LOS9]SD?_(NCZO\
M,****^H/7"OF[_@KW_RC8^+7_8N)_P"E,-?2-?-W_!7O_E&Q\6O^Q<3_ -*8
M:<?B _G$'2B@=**LYPHHHH **** "BBB@ K]4Y_^48_[,6/^@3X@_P#2Y*_*
MROU3N/\ E&/^S%_V"?$'_I<E?-\7?\D_6_[=_P#2XGGYM_R+:GR_]*1YI111
M7XF?#A1110 4444 %%%% 'K'[#'_ "=MX%_[#/\ [3>OULK\D_V&/^3MO O_
M &&?_:;U^ME?JG ?_(MJ_P"/_P!M1]AP[_NDO\7Z(****^X/H HHHH ****
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MLK]B?^'3O_!++_I&G^S_ /\ AF]#_P#D6C_AT[_P2R_Z1I_L_P#_ (9O0_\
MY%KP,\R*CGBI^TFX\E]K=;=_0\_'9;3QT8J4FK7V\[?Y'XV_\-J_L??]'1_#
M_P#\*ZS_ /CE'_#:O['W_1T?P_\ _"NL_P#XY7[)?\.GO^"67_2-/]G_ /\
M#-Z'_P#(M'_#IW_@EE_TC3_9_P#_  S>A_\ R+7@?ZA8/_G]+[D>?_JY0_G?
MX'XV_P##:O['W_1T?P__ /"NL_\ XY1_PVK^Q]_T='\/_P#PKK/_ ..5^R7_
M  Z=_P""67_2-/\ 9_\ _#-Z'_\ (M'_  Z=_P""67_2-/\ 9_\ _#-Z'_\
M(M'^H6#_ .?TON0?ZN4/YW^!^-O_  VK^Q]_T='\/_\ PKK/_P".4?\ #:O[
M'W_1T?P__P#"NL__ (Y7[)?\.G?^"67_ $C3_9__ /#-Z'_\BT?\.G?^"67_
M $C3_9__ /#-Z'_\BT?ZA8/_ )_2^Y!_JY0_G?X'XV_\-J_L??\ 1T?P_P#_
M  KK/_XY1_PVK^Q]_P!'1_#_ /\ "NL__CE?LE_PZ=_X)9?](T_V?_\ PS>A
M_P#R+1_PZ?\ ^"6/_2-/]G__ ,,WHG_R+1_J%@_^?TON0?ZN4/YW^!\Y_P#!
M-C_@J/\ \$V/A_\ LUKX?\<_M]_!W1K[^WKJ3['JGQ'TV"780F&VO,#@XX-?
M0'_#W[_@E+_TDE^!?_AU-*_^/U<_X=._\$LO^D:?[/\ _P"&;T/_ .1:/^'3
MO_!++_I&G^S_ /\ AF]#_P#D6OLL#A8X'"0H1=U%)7]#W*%%4*,::=[*Q3_X
M>_?\$I?^DDOP+_\ #J:5_P#'Z/\ A[]_P2E_Z22_ O\ \.II7_Q^LGXN?\$7
M?^"6_P 5_A=XA^&4/[!?P?\ #+>(-&N=/7Q%X5^%>B6FI:9YT93[1:S?9#Y4
MZ9W(^#M8 X.*B^"?_!%+_@EM\&?A#X9^$TW["OPD\6-X;T6WTYO$_C'X7:)>
MZMJOE1A/M-W<?8U\Z=\;G? W,2<5U&QM_P##W[_@E+_TDE^!?_AU-*_^/U^<
M?_!Q)_P4$_85^.OP[^&-C\$_VQOACXNFT[6M2DU"'PWXXL+UK96A@"LXBE;:
M"00">N#7Z4?\.G?^"67_ $C3_9__ /#-Z'_\BT?\.G?^"67_ $C3_9__ /#-
MZ'_\BT ?S$CXY_!CO\5_#O\ X.(?_BJ/^%Y_!?\ Z*OX=_\ !Q#_ /%5_3M_
MPZ=_X)9?](T_V?\ _P ,WH?_ ,BT?\.G?^"67_2-/]G_ /\ #-Z'_P#(M5S$
M\B/YB?\ A>?P7_Z*OX=_\'$/_P 51_PO/X+_ /15_#O_ (.(?_BJ_IV_X=._
M\$LO^D:?[/\ _P"&;T/_ .1:/^'3O_!++_I&G^S_ /\ AF]#_P#D6CF#D1_,
M3_PO/X+_ /15_#O_ (.(?_BJ/^%Y_!?_ **OX=_\'$/_ ,57].W_  Z=_P""
M67_2-/\ 9_\ _#-Z'_\ (M'_  Z=_P""67_2-/\ 9_\ _#-Z'_\ (M','(C^
M8G_A>?P7_P"BK^'?_!Q#_P#%4?\ "\_@O_T5?P[_ .#B'_XJOZ=O^'3O_!++
M_I&G^S__ .&;T/\ ^1:/^'3O_!++_I&G^S__ .&;T/\ ^1:.8.1'\TGPT^/W
MP-T_XC^'[^^^,/AF&"#6[22::76X%6-1,I+$EN !R37Z7_M_?\% _P!A?QO^
MU#K?B/P=^V+\,=5T^:ULQ%>Z?XXL9HG*VZ @,DI!P00>>#7Z6?\ #IW_ ()9
M?](T_P!G_P#\,WH?_P BT?\ #IW_ ()9?](T_P!G_P#\,WH?_P BUX^=933S
MK"JA4DXI-.Z\DUU]3CQF!AC*/LY-K6Y^-O\ PVK^Q]_T='\/_P#PKK/_ ..4
M?\-J_L??]'1_#_\ \*ZS_P#CE?LE_P .G?\ @EE_TC3_ &?_ /PS>A__ "+1
M_P .G_\ @ECG'_#M3]G_ /\ #-Z'_P#(M?,_ZA8/_G]+[D>7_JY0_G?X'XV_
M\-J_L??]'1_#_P#\*ZS_ /CE'_#:O['W_1T?P_\ _"NL_P#XY7[)?\.GO^"6
M)_YQJ?L__P#AF]#_ /D6C_AT[_P2R_Z1I_L__P#AF]#_ /D6C_4+!_\ /Z7W
M(/\ 5RA_._P/QM_X;5_8^_Z.C^'_ /X5UG_\<H_X;5_8^_Z.C^'_ /X5UG_\
M<K]DO^'3O_!++_I&G^S_ /\ AF]#_P#D6C_AT[_P2R_Z1I_L_P#_ (9O0_\
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M4_\ A[]_P2E_Z22_ O\ \.II7_Q^C_A[]_P2E_Z22_ O_P .II7_ ,?JX?\
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M'_"\_@O_ -%7\._^#B'_ .*K^G;_ (=._P#!++_I&G^S_P#^&;T/_P"1:/\
MAT[_ ,$LO^D:?[/_ /X9O0__ )%HY@Y$?S$_\+S^"_\ T5?P[_X.(?\ XJC_
M (7G\%_^BK^'?_!Q#_\ %5_3M_PZ=_X)9?\ 2-/]G_\ \,WH?_R+1_PZ=_X)
M9?\ 2-/]G_\ \,WH?_R+1S!R(_F)_P"%Y_!?_HJ_AW_P<0__ !5'_"\_@O\
M]%7\._\ @XA_^*K^G;_AT[_P2R_Z1I_L_P#_ (9O0_\ Y%H_X=._\$LO^D:?
M[/\ _P"&;T/_ .1:.8.1'\Q/_"\_@O\ ]%7\._\ @XA_^*K])+C]O+]B8_\
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MDO\ AT[_ ,$LO^D:?[/_ /X9O0__ )%H_P"'3O\ P2R_Z1I_L_\ _AF]#_\
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M65G+<^0)-K>7O\O;NVMMSG!QBORM\5?$O]LW_@L7_P %BOC5^PQX'_;<\>?
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M4IM/FDN;"-I)Y4>[DT]G%O=3QQ*WE&4':X4@KC(@_81^(/[9?["G_!?S6/\
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MS?!S2)['_A"_^$9^T?VOYGVK#_:_M*?9\?:>GDR9V=1GCSWXF_\ !$?XE?\
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MN6GAP:5-81ZA9I:E(XS<W 9X]F]7+ %L K@<_=E% 'QO_P $C_\ @F)\>_\
M@F)\/[GX)^,OV]]4^*W@#3;5K;P#X2O/ =MI*>'$DNI;F9O/2>:6[9WE(^=@
MJ $(J@[1\T_\'77P@\2:/^S_ /!?_@H?\/[%KC7?V=?BW8ZPZKD;+"XF@=WR
M,\BZL[ =. S'M@_J]5'Q%X:\.^+]%N/#?BS0;/5-/O(]EU8:A:I-#,N<X='!
M5AD#@B@#XS^-7_!.7PM^W[^W+^S9_P %7?!W[0W]F:3\-_#ZWVF>&%\,BZ&N
MV]VK3QO]J%TGV? F&1Y4N<=JZ#6?^"5<>L?\%B])_P""LY^.K1G2_ARWA8>
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MPIINM:;,RM+I^K6,=S [*<J2D@*D@C(XX-:,$$-K EM;1+''&H6.-% 55 P
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MI_;97_@HS^VU^VQXC_: ^,%CILECX?UK4/"MKH.GZ3"T;QYAL;:21$81R2*
MK*@,CMLW'-> _LP:9<_MW_\ !T?\7?VH_"D7VKP+^SCX#B\%)JX;]W-KDB-$
M\*?WBLCZF"0>/(3/WUK]=CR,5D^&? ?@CP7+?3^#O!VE:3)JETUUJ3Z;I\5N
M;N<]992BC>Y_O-D^] &L.G2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_LRZ[8:E83+HZ,=?:VT]K,)(/,_T<,&WDC?C&/>OJJ@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gym1fcavvjqs000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A :$# 2(  A$! Q$!_\0
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *J7UUY$>Q!F5P0OM[U;Z#)K&:1KN?SB<(.$'M0 R%6C4
M#82/45,\O&#3V;9$/>J4C%VVCKW]J8B2$CS&^E3LQ\H@<GMS4'V?9'NSS6=K
M&O66@V#7%[+M7HJ#EG/H!2;MN!L1 11@ 9;N37/ZOXUT/2'9)[U))AUCA^=L
M^G' _$BN85/$?C/Y[B632M(;[L4>?,E7W_\ K\>QKH=*\(Z1I"JT%FGF*/\
M62C>_P!<GI^&*F[>Q-V]C)/C?5]3_P"0-X;NI4/W99SM7_#]:18OB#>$MY>F
M66[^\=V/_0J[.-\G$:,Q]%&:LBTN9.6*QCWY-'*^K'9]SAAX>\;OS)XDM8\]
MHHAC_P!!%/7PKXM;[WB]E^D1_P :[G[!(!Q./^^?_KU&UK<IR K_ .Z<&CD0
M<IQ9\)>*EY'C!R?>(_XU%+HGC:$A(?$T,Y/59H@!_P"@FNR>5T.'5U^HQ2PL
MH.[%'(A<J.(N-8\=:/;$76BVUX@Z36X)/X@'/Z"L*U^(FN3WA@CM-,BD8_\
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MH"2T2S,VY!&LA((3KA@.<#/?FGH/0I/X&(B9U-C-<&]6Y87$.Y)4$7EA'[D
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M!(_F/QJ9NR%)V1V?AC2I-$\/6=A(%\R-,R8/\1))_4UK?ZJ/D\GDU)),B#C
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M V6&3[U9$H'05$T47( PP?\ ASTSBG/;H4W1$JQ!(4GKBF DTVX $]Q_.IW
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M/*,9'!#2-S].XS5>+PI]B2P2PN1%]FF4^:8EW^6L4B*.GS',G?W[];R+KO\
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MHVNGI!(9Y7:>Z88:9QR!Z*/X5]A^.3S4LEG!(Y<J58]2K$9_*E:^X;@D80\
M 8P .U<'\3!LD\.W'_//4%Y_(_TKMX0D)D"9"!MH&<\]_P#/M7$_%<[?#5C<
MK_RQOXV_#:W_ -:IG\(I;'2WO$Z-_>CQ^5):X#,A.WS!P:?J(S%$PYVL14<8
M62+:P!(K099R4RIZ=^>U*7QU;<P(_G_]>H4W0L2GS*P ()H,A+JWE$#.2,T
M6 0H+'IUS5-1YK/(X!)I[9F8<,$7HI[^]"X5MOJ : 'J,8'ID4A.%S_LT;P.
MII(HGO9 D9(C'#O_ $'O0 _3H3/=&X(_=H?E]S6Q3(XUBC6-!A5& *?2&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%07MY!IUC/>W3^7;P1M)(^"=J@9)P.35:RUK3]0B:2
M"XP%E\EEF1HG#\?*5< Y^9>W<>M &A15-M4LPT(6=765V0/&=RJ54L=Q'"\
M]:E^VVNU6^TP[6?RU/F#EO[OU]J )Z*IVVJZ?=P1SV]Y!)%(YC1@X^9@<$#W
MJ7[=:;]GVJ#=N"[?,&<GH/KP?RH GI"0H)/0#)H5E8$J0<$C@]Z6@#DM*U'6
M=<U*Z@NK6[LM.+LT4GDF-F08 7<>1GDY SZ$5U,$$5M"L,$:QQJ,*JC %245
M,8VW$E8****H9GH3L//5W)_[Z-<C\3$\SP/<G!/ERQOGT^;']:ZR/.&'=9&!
M_//]:Y#XGW7E>#GM^K74\<2CN<'=_P"RU,_A9,MCHD8SZ);2GG?%%)GZJ/\
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M9V-[XJ[59AY=YD=)5Y^H_P#K?RH EJD?W>KCTE3]1_\ JJ[5&^^2>VD]'Q0
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M2/?-$5C#-G,[A3O8$J1NP5+8^4_+[<UA'PWKDES,9+N(AK0P&5)F5I#^ZPQ
M&0?D?G=QNX R:L#PQ>P3%K698U+RY'G/]TSQ.@^@19!CMN]S0!NG1=.8H3;
ME':1?F/#-*)2>O=U5OP]*EM=.M+)@;>$1D1+",$GY%)('/NQ_.N8E\+ZE]G=
M8;H!I2&G'G-^]Q,7QEE(^X<=".W2NETNU>RTRWMI'=VC7!+R;S]-V!G'3H*
M+E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!F^(/^1>U#_KW?^5:5%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gym1fcavvjqs000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 2@# 2(  A$! Q$!_\0
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MA7QMJ>M>*FTZY-D8V6Y+PQ1LK6YCD"*/,+%9=PY.T<>U 'H)Z5B>#?\ D1]
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M ",[..Q;L/%.DZAA5N1#(?X)OE/Y]/UK9!!&1R#7#+=Z?>W!L/$VGI:WW07
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MJ]UK7AQ;F\GBN98[B: 742[4N%1RHD Z $#M0!T5%%%  >E8G@W_ )$?0/\
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M\B5KW_8.N/\ T6U:\?\ JU^@K(\7?\B5KW_8.N/_ $6U:\?^K7Z"J&.HHHH
M**Q_$]_?Z5H-YJ5A]F+6D$D[I.C'>%4G P1@\=>:T+,7@MP+YX'FR<F!"JX[
M<$D_K0!8HHHH XGQ[+?I>:2D+^(%L6\[[1_8<):7< NS<<'"_>X[_A6WX4(.
M@0X;6&^9N=77%QU_B&!QZ>U<_P#$G3[B\BL9!?I:VD:3 JU]]E#S$*8N<C=D
MJRX[;\]JUO =K/:>%XTN(C$6GF=$:Z%PRH7.T-("0Q XX/:@#9EU6Q@U2WTR
M2Y1;VX1GBA_B95ZGV'UJI8>*=#U/4Y=.LM2@FNX]VZ-2>=IP<'HV#UQFL34=
M#2+XF:%JMI8-^\CNS>7*(3SLC5 S=NA 'U]ZR?#,TNJ>-4NKO0=1TRVLEFAT
MNW_L]HH8U;EY'; &Y\<+T'N3F@#T@]*Q/!O_ "(^@?\ 8.M__1:UH:A;W=S
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M#1110!Q'Q'@OYM(?_3M.MM-P@/GP2O,)MWR&(QL#NSMQ@9S[57^%D4=MI5U
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CKPS8S:;X9TZTN0%GC@42*#D*QY(_ G'X5JT44 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gym1fcavvjqs000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z 28# 2(  A$! Q$!_\0
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M',MG]@N9HV3==0D@LKY4@$D9R,=37411)!#'#$H6.-0JJ.P' %/HH PO%_\
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MPA8;C_I$?:NAH **** "BBB@ HHHH Y ?$"S_M!H'TR_2V346TQKPJGE"<'
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M-=:]-R_DSQ)&$NI8U5?)0X 5@.I)_&@#JZ*PO^$0T?\ YYWG_@?/_P#%T?\
M"(:/_P \[S_P/G_^+H W:*PO^$0T?_GG>?\ @?/_ /%T?\(AH_\ SSO/_ ^?
M_P"+H W:*PO^$0T?_GG>?^!\_P#\71_PB&C_ //.\_\  ^?_ .+H W:*PO\
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MC/W ,8[UT587B'_C^\/_ /83'_HF6@#:B#K"BRN'D"@,RKM#'N<<X^E/HHH
M@BM((+FXN(XPLMP5:5LGYB!@?H*GHHH **** "LS7_\ D$2?[R_SK3K,U_\
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M -A.V_\ 0Z -VBBB@ HHHH *Q-5\03Z7J%M:+HE_=?:I/+ADA>$*[[&<CYI
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MIUF:_P#\@B3_ 'E_G45/@9,OA9Q]%%%>:<H5M>&?^/\ E_ZY'^8K%K:\,_\
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M)K/\7_\ (O'_ *^[7_THCK0UC_D!ZA_U[2?^@FD]@>Q\\4445Y1Q!71>#/\
MD,S?]>TG]*YVNB\&?\AF;_KVD_I3CN-;G7T444 %:>@?\A>/_=;^59E:>@?\
MA>/_ '6_E5T_C14?B1V%97B;_D5M5_Z])/\ T$UJUE>)O^16U7_KTD_]!->A
M+X6=+V/ ****\LXPKI_!/_(0O_\ KS/_ *,CKF*Z?P3_ ,A"_P#^O,_^C(Z<
M=QK<ZJBBB@ K6\.?\A3_ +9G^E9-:WAS_D*?]LS_ $JZ7QHJ'Q(ZVL+QE_R*
M&I_]<?ZBMVL+QE_R*&I_]<?ZBO0G\+.F6S/"****\LXPKJ_!/WM2_P"N*_\
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M9OKP95&"+A=S%G(4*H]22!5ZN5\<JPM]#N3_ ,>]MK-K+.>P3)4$^P9E/X4
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MQTQ4:^NXK=7)"F1L9Q4%]KME8Z;#?DR3PSR)'%]G7>79SA<#W-*ZO8#2  &
M, 45G:;K5KJ9N$1)X)K8CSH;B,QN@(R#SV.#R/0^E7O.B$8D,B;#T;<,?G3
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IBU*%HKAY0Y#.&)_=1@DD$]P:Z:BB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gym1fcavvjqs000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ 1H# 2(  A$! Q$!_\0
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M5;3[2TNXI%B,I:8+C ('8GUKYRKT/X,_\CK-_P!>4G_H24@/>Z*** "BBB@
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MKSRO0_@S_P CK-_UY2?^A)0![W1112 **** "BBB@ HHHH *YGP%_P BJ/\
MK]O/_2F6NFKF? 7_ "*H_P"OV\_]*9: .FHHHH **** "BBB@ HHHH ****
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MH>!?^1:7_KJ]=+7->!?^1:7_ *ZO72U[%'^&CMA\*"O+/C=_R!M*_P"OA_\
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M_P"15'_7[>?^E,M '34444 %%%% !1110 4444 %%%% 'DOB_P#Y&J^^J_\
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M****8!1110 5Z'\&?^1UF_Z\I/\ T)*\\KT/X,_\CK-_UY2?^A)0![W1112
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MB2&9F<?V=.F 1C^)!7L=%4,^3/[)U7_H$:E_X!R?_$T?V3JO_0(U+_P#D_\
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M\YVQH%&?7 J6@ HHHH X"71Y]4\9ZP]M:VR2PW]H_P#:+28EA18XF9% &2&
M(P2!\QSGN:?/</KND%;[[' ]SJB-!$B(DI2ZP 1CEF'?KU(Y)KO51%9F5%#.
M<L0.2>G-0F&SD<1F*!GA?S0NT$HQ).['8DYY^M ' -K]_>Z)')+J$5S_ &GI
MEU+<6:HH^QE8R<#'S<$[#NSR>W2K*7][;PWGV%H861[02,@B2:2/[.&(4R?*
MS],;OX0:[=;.U1YG2VA5IO\ 6L(P"_\ O>OXT2V-I.A2:U@D1B"5>,$$CIU]
M* .)NO%TK7>FR6%[/)%))8I(DD42(ZSLO)!/F;MK;OE&!CGH<6;35-8EOK1Y
M-1'D7FJWNGB)8%'E+'YY1P>I8>2.O!!Z9Y/6M9VKS+,]M"TJ@!7,8+  Y !^
MO-+$MM(BO$L3*'9U9 " QSDCWY.?J: ,+P+)--X/T^2>_>]E:)2[N060X&5)
M'<>_/-='4<4$-N&$,4<89B[!% RQZDX[U)0 5Q'C6.<>(='O+4.UQI]I=WD:
M*?O['M]R_P# D+K_ ,"KMZ:8T+ARBEU! 8CD XR/T'Y4 >:R:M,^O2>*[56G
M$FE:@UC$<X>*$P[./]IR[>N&%7KKQ'J%@MQ'#K$&H1M;6\IO/+3;:F298RQV
M\;=K%P#S\AR2*[C9;0>2-L4>T>5%P!C/\*_ET'I21V5I#%)%%:P1QR9+HL8
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M <=X>G#-X-EB:9C+IDT,C2G+.BB,[B>_S*,'T;WKNJR5BC;Q87*C=#8*L?\
3LAW.['UV)_WR*UJ "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gym1fcavvjqs000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $H :8# 2(  A$! Q$!_\0
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M&\36NKWUO%?Q+'%<21H# AP Q [5VOB6ZU>7Q%!9:;+?>>VFF:!+9U5!-Y@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%(S!5W,0 .Y--BFBGB66&19(W 960Y!!Z$&@!]%%% !1110
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M3;GYSR/45KUG#_D8V_Z]!_Z&:T: "BBB@ HHHH **** "BBB@ HHHH ****
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M9W<VFPRVWG.D<ZSDE(?*.1LV\'.3UY.!5K1KB*WUB_N SS6TZP(LZVS( V6
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M_@2/_B:3_A<B8_Y 3_\ @2/_ (FO5.@]2HJKIMY_:.EVEZ(_+^T0I+LSG;N
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M^OB3_P!"-5Z^U/2"OHOP?_R)NC_]>D?_ *"*^=*^B_!__(FZ/_UZ1_\ H(H
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M_P +'4AZ&EI#T->J=!])>&O^16TG_KSB_P#0!6K65X:_Y%;2?^O.+_T 5JT
M%%%% '$?$K_D&V/_ %W/_H->;UZ1\2O^0;8_]=S_ .@UYO7R^:?[R_D<-?XV
M%;OA?_7:I_V#9_Y5A5N^%_\ 7:I_V#9_Y5A@?]XAZDT_C1YTOW%^E+2+]Q?I
M2U]>>@'<?6OJ2/\ U2?[HKY;[CZU]21_ZI/]T4 .HHHH *\Y^)?_ !_:?_US
M?^8KT:O.?B7_ ,?VG_\ 7-_YBN#,_P#=9?+\S*O\#.&HHHKY4X#7LO\ D4/$
M_P#U[1_^A5P-=]9?\BAXG_Z]H_\ T*N!KZK+/]VC\_S.^A\""M'0/^1DTO\
MZ_(O_0Q6=6CH'_(R:7_U^1?^ABN\U/I6BBB@ HHHH **** "BBB@ HHHH \S
M^*<B+>Z8FHR7D>DM;71!MFD&;L*OD@[.<_>V@\9KN/#7V[_A%M(_M3=_:'V.
M'[3O^]YFP;L^^<YK4HH QR-4&JM=K8P%?*\H#[3@G#$Y^[5C[3JG_0-A_P#
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MBT\6ME<W-\F&@$=@\OFD.IV"8']P>.6QT/6O3T+%%++M8CD9S@TM% !1110
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MWV=SF,1$&1;C&U8P3S%W(S7L-%% !1110 4444 %%%% !1110 4444 %%%%
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B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gym1fcavvjqs000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %- 2 # 2(  A$! Q$!_\0
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M"LGQO_R(?B#_ +!UQ_Z+:M:Q_P"0?;?]<E_D* +%%%% !1110 4444 %%%%
M!1110 4444 %%%% !36C1RI=%8H=RDC.#TR/S-.HH **** "BBB@"N+ZT-X;
M,74'VH+N,/F#>!Z[>N*+6^L[X.;2[@N AVOY4@?:?0XZ5XUI<]]:W%]:RV8O
MKF<ZD=1@CLBES$,.483<YW_*J\8P1@'%7OA[?0:)<7UY>,)X$T^TC-W:6K*D
M9W%1"R!<M("V2WIZ4 >L/?6D=VEH]U MRXRD)D =A[+U--74;%[=[A;RW:!&
MV-()5VJV<8)S@')''O7E=H]];^/;Z%HX9[R[UMTD@DL295M#'\LRS?PJJX
M]_6JS03>'"MU:+]NTNVN/+A:9"B3S00%5;"CG'EA%/\ %(Q;^%00#V:BF0NT
ML$<C(8V=0Q1NJDCH:?0 4444 %>=:KHUE??$NV33+?9=6,3:C?3+(WS2$$0Q
MD9P,G+$8Z 5Z+2!%#,P4!FZD#DT >/\ @C4K"QU'3;]+W&-'EFUV1Y2VV42+
M@R#L^=X'?'M2ZG<Q3^+[J;[23KJZY9I8()3N-H50G:N?N$%RQQCUKUP00@2
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M0H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA\2O\
MD.6O_7L/_0FKT^O,/B5_R'+7_KV'_H35C7^ B?PG%T445PF 4444 =C\-O\
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M%.>!CT% 'M%%<I\/KZUO?#3I:V'V);6ZEMGB6X:="ZMRRNW+*<UU= !1110
M4444 %%%% !1110 5YA\2O\ D.6O_7L/_0FKT^O,/B5_R'+7_KV'_H35C7^
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MV/PV_P"1CN/^O1O_ $-*]2KRWX;?\C'<?]>C?^AI7J5=V'^ WI['GWC_ %N
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MH YCQZE\W@S7&@N+=+<:=/YB/ S,WR-G#!P!Q[&M^Q_Y!]M_UR7^0K)\;_\
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MM*[A]#S7#Z%I>LQ^(?%5VMU-;6;7TC"V-L/](_=* RN>>N.GI7-QZ9KFHZ9
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M444 5M1T^UU73KC3[V(2VUQ&8Y$)QD'W'3ZU-'&(HDC7)5%"C<<GCU/>GT4
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MBBB@ HHHH J6FFV=A/=S6T(26[E\Z=]Q)=\ 9Y/H ,#BK=%% !1110 4444
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MBE'V=QM$92%VC&W[R?-(H)Z_45Z'7,:KH%A!;/;6L*0+JFH0M<E5'(7;E1Z
0B(#_ ($373T %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gym1fcavvjqs000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" +T!98# 2(  A$! Q$!_\0
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M  H)O_C5'LY![2)^J5%?E;_Q$/?$W_HVC0?_  H)O_C5'_$0]\3?^C:-!_\
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M(GZI45\"_L1?\%D?'/[6?[2V@? ;6/@AI6C6^L1WC2:A:ZQ)*\?DVLLXPK(
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M3=6F^)GATZE=65QJ<D:V+"VLYMB,$)<9N2,D#[@]>/GG_B(>^)O_ $;1H/\
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M (4$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_ (4$W_QJC_B(>^)O_1M&@_\
MA03?_&J/9R#VD3]4J*_/G]CO_@M)X\_:?_:4\+_ C5O@7I.DV_B"XGCDU"WU
MB65X?+MI9LA60 Y,>.O>HOVN/^"UOCW]FO\ :,\4_ [2O@/I&J6_AZ]C@CU"
MXUJ6-Y@T,<F2JQD#E\=>U3[.5[%<\;7/T+HK\K?^(A[XF_\ 1M&@_P#A03?_
M !JC_B(>^)O_ $;1H/\ X4$W_P :JO9R)]I$_5*BORM_XB'OB;_T;1H/_A03
M?_&J/^(A[XF_]&T:#_X4$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J
M/^(A[XF_]&T:#_X4$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J/^(A
M[XF_]&T:#_X4$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J/^(A[XF_
M]&T:#_X4$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J/^(A[XF_]&T:
M#_X4$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J/^(A[XF_]&T:#_X4
M$W_QJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J/^(A[XF_]&T:#_X4$W_Q
MJCV<@]I$_5*BORM_XB'OB;_T;1H/_A03?_&J^@/V/?\ @J?XR_:=^#/QD^*F
MJ_"'3=)E^%_A==5L[.WU221;]C;7TWEN2@*#-H!D _?/I2=.2*52+/M*BORM
M_P"(A[XF_P#1M&@_^%!-_P#&J/\ B(>^)O\ T;1H/_A03?\ QJG[.9/M(GZI
M45^5O_$0]\3?^C:-!_\ "@F_^-4?\1#WQ-_Z-HT'_P *";_XU1[.0>TB?JE1
M7Y6_\1#WQ-_Z-HT'_P *";_XU1_Q$/?$W_HVC0?_  H)O_C5'LY![2)^J5%?
ME;_Q$/?$W_HVC0?_  H)O_C5'_$0]\3?^C:-!_\ "@F_^-4>SD'M(GZI45^5
MO_$0]\3?^C:-!_\ "@F_^-4?\1#WQ-_Z-HT'_P *";_XU1[.0>TB?JE17Y6_
M\1#WQ-_Z-HT'_P *";_XU1_Q$/?$W_HVC0?_  H)O_C5'LY![2)^J5%?E;_Q
M$/?$W_HVC0?_  H)O_C5'_$0]\3?^C:-!_\ "@F_^-4>SD'M(GZI45^5O_$0
M]\3?^C:-!_\ "@F_^-4?\1#WQ-_Z-HT'_P *";_XU1[.0>TB?JE17Y6_\1#W
MQ-_Z-HT'_P *";_XU1_Q$/?$W_HVC0?_  H)O_C5'LY![2)^J6:*^2_VJO\
M@H]XH_9W_8[^&?[3NF_#'3]3N_'UOILMQI$^H/'':?:M/-V0KA26VD;1D#(Y
M]J^8?^(A[XF_]&T:#_X4$W_QJI4)2V*<XH_5*BORM_XB'OB;_P!&T:#_ .%!
M-_\ &J/^(A[XF_\ 1M&@_P#A03?_ !JJ]G(GVD3]4J*_*W_B(>^)O_1M&@_^
M%!-_\:H_XB'OB;_T;1H/_A03?_&J/9R#VD3]4J*_*W_B(>^)O_1M&@_^%!-_
M\:H_XB'OB;_T;1H/_A03?_&J/9R#VD3]4J*_*W_B(>^)O_1M&@_^%!-_\:H_
MXB'OB;_T;1H/_A03?_&J/9R#VD3]4J*_*W_B(>^)O_1M&@_^%!-_\:H_XB'O
MB;_T;1H/_A03?_&J/9R#VD3]4J*_*W_B(>^)O_1M&@_^%!-_\:H_XB'OB;_T
M;1H/_A03?_&J/9R#VD3]4J*_*W_B(>^)O_1M&@_^%!-_\:H_XB'OB;_T;1H/
M_A03?_&J/9R#VD3]4J*_*W_B(>^)O_1M&@_^%!-_\:H_XB'OB;_T;1H/_A03
M?_&J/9R#VD3]4J*_-?X%_P#!=OXB?%[XW>#?A->_L]:-90^*/%6GZ3+>0ZY*
M[6ZW-S'"9 IC )4/G&><5SO_  45_P"#A+XF?L/?MD^,OV7=#_9KT/Q!:^%_
M[/\ )U:[U^:"2?[3IUM=G*+&0-K3E>#R%![U/)*]BN>.Y^I5%?B3_P 18/QA
M_P"C.?#?_A57'_QFC_B+!^,/_1G/AO\ \*JX_P#C-')(.>)^VU%?B3_Q%@_&
M'_HSGPW_ .%5<?\ QFC_ (BP?C#_ -&<^&__  JKC_XS1R2#GB?MM17XD_\
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M1R2#GB?MM17XD_\ $6#\8?\ HSGPW_X55Q_\9H_XBP?C#_T9SX;_ /"JN/\
MXS1R2#GB?MM17XD_\18/QA_Z,Y\-_P#A57'_ ,9H_P"(L'XP_P#1G/AO_P *
MJX_^,T<D@YXG[;45^)/_ !%@_&'_ *,Y\-_^%5<?_&:/^(L'XP_]&<^&_P#P
MJKC_ .,T<D@YXG[;45^)UE_P=<_&&\O8;3_ACWPVOFS*A;_A*;CC)Q_SQK]L
M0<C-#BX[@I*6P4445)04444 %%%% !7XB?\ !:O_ )2$^*/^P7I?_I%%7[=U
M^(G_  6K_P"4A/BC_L%Z7_Z115I2^(SJ_"?*5%%%=!SA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!]0?\$:/^4B?@?\ Z]]6_P#39=5YO^WA_P GJ_%;_LH&K?\ I5)7
MI'_!&C_E(GX'_P"O?5O_ $V75>;_ +>'_)ZOQ6_[*!JW_I5)4?\ +QE?81Y/
M1115DA1110 4444 %%%% !1110 4444 %%%% !1110 5^AG_  3V_P"417[1
M7^]J/_ILAK\\Z_0S_@GM_P HBOVBO][4?_39#4SV+AN?GG1115$!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?>W_!6[_DSW]E/_L06_P#3?I5?
M!-?>W_!6W/\ PQY^RG_V(+?^F_2J^":F'PEU/B"BBBJ("BBB@ HHHH ****
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M[_TPM7YO5^D/_!3;_E$W^SE_V#_#W_IA:OS>J*?PES"BB@Y-60%%?J)\)O\
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MZIH^L>(Y-(CM9]9,%S;-&3YMS,'C$:0H 22'+GA51F8*5S(?*SY6HK[LT_\
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M[JZG6^ED/V?F)%A9&7_24^](IX;C@9R?A5^RQ\=?C7\.?%7Q9^&O@I=0\/\
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M:'\-IOBSJ_[-_B"#1883+,66+[5'&!DN]IO^T(H )),8  R>*Y[]HSX6Z_\
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MX4RPIME3=MG:0-ACN_-&B,N:(2CRRT"BBBJ)"ONS_@DU_P FA?M<?]DWC_\
M3?K-?"=?=G_!)K_DT+]KC_LF\?\ Z;]9J9_"73^(^$Z***H@^\?^"(?Q,\,?
M#)_C#JVN>-M+T6Z;PM:MI<FI7T4/FS)]I8!!(0'(.WC!ZC(YKH?%O[2NM_\
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MX*EZY\./A'IOP.^/?[/'A/XL>'_#L?\ Q2L?B:-//TUAP@WRPS(\:+E5 17
M.T2;0JB'PO\ \%5?BR_[:%C^V/\ %?P;9Z]<:7HD^E:;X9TR\.GVMI;.C@*C
MLDS9WN[LS;F8MC(4*H^6:*.6(<TCZ0^ ?_!0F7X'S_&R8_"-=3_X7);W$;*-
M?,/]D&4WG/\ J'^T8^U_],\^7VW<?-]%%585PHHHH$%%%% !1110 4444 %%
M%% 'U!_P1H_Y2)^!_P#KWU;_ --EU7F_[>'_ ">K\5O^R@:M_P"E4E>D?\$:
M/^4B?@?_ *]]6_\ 39=5YO\ MX?\GJ_%;_LH&K?^E4E1_P O&5]A'D]%%%62
M%>]_L8?MPR?LA^#?B5X/'PQ'B!?B)H<>G?:/[:^R'3]D5RF_;Y$GFY^T9VY3
M[G4YX\$HH 0J.H49KW3]L#]M%OVK_ OPQ\%'X;_V%_PKCPV=)^U'6?M1U#,5
MLGF[?)C\K_CWSMR_W^O'/AE% 7/K_P"'/_!6/R?AEIO@+]I?]DOP+\6+[P[I
MJV/ACQ%XFMHFNK:%5PHG,L$WGD8090PLP3+%G8O7S-\8_BAJ?QK^)VM?%77/
M#>CZ5?:[?&ZNK'0+(V]I'(5 /EQEF*Y(+$EB69F).37,T4E%(IR<CTO]CW]H
M@_LG?M&^'?V@!X0_M[_A'_M?_$I&H?9?/\^TFMO];Y<FW;YV[[ASMQQG(]5^
M&'_!2,_#;6/C_JR_!K[9_P +TDNF:/\ X2+R_P"Q/.-\<9^SM]IQ]M](L^7V
MW<?+]%'*GN)2DMCZ$_X)_P#_  4+\?\ ["'B36)[#PU_PDWA_7;=?[0\.RZE
M]E7[4G^KN4E\J0HX4LA 7#JPW9*(5Z3]D?\ X*4:/^S+XF^+&K^(_P!GBU\8
MZ?\ %;4$FOM&O=>6&&WA#WA>WD#6LJW".MV5(*J"%.00V!\KT4N6(^:2/L;X
MF_\ !7WQ,G@S4/A_^R-^S9X,^#.GZS;>7K%UX;MXVOI'R1OBDBA@CC.PE=QB
M=UW%D=3@CXY4$#!.:**:7*)ML****8@K]#/^">W_ "B*_:*_WM1_]-D-?GG7
MZ&?\$]O^417[17^]J/\ Z;(:F>Q<-S\\Z***H@**** /?OV)OVYW_8[\+_$7
MPR/A?_PD2^/M%AL/._MO[)]AV)<KOQY$GFY^T=,IC9U.>/G]5*QA#V[>E.HH
M ^F/VA/^"BC_ !W^.?PG^-(^$']E_P#"K_[/*Z;_ ,)!YW]I?9KJ.?\ UGV=
M/)W;-OW7QG/.,'J]*_X*Z>)-)_:D\??'?_A0VC:AX;^)6FV-CXJ\#:QJ'VA9
MH;6S-LH6Y,('S!GW*\+JR2,I4\,/CRBIY8E<TD?4_P"T#_P4U3X[?LPW7[,U
MI^S3X7\(V)\2)J6FMX6F%M96D"2%U@^R+$ SG)+RAU#,20BYP.OT3_@LO?>%
M/#W]O^"OV*_A9HOQ&^RBS'C;3-+$,:VP55$0@5!-@(JJ ;DH-J_+@!:^*:*.
M6(<TCZ4_9=_X*3>,?@?X6U3X5_&+X4>'_BKX(UC5I=5N/#GBJ-&\B]DR6DA=
MXY(T5G.]D:)ANR5V%W+<)^UM^U'9_M/^*=+U#0O@=X/\ Z-H-I)::)HOA731
M#Y=NTAEV2NH59"'9V!6.-1O;Y<L2?)J*.57N'-*UCZC_ &!O^"B7@3]B'PY?
M0W7[*.C^+O$5QJLMS:^+9-5BL[ZTMY(8HS:I(;263R\QLV X!,A^7J3YA^V)
M^T-X+_:=^,;?%+P+\"M)^'MK+IL<-UH^CS1R)<7 DD=[IVC@A#2/Y@!)4L=H
MRQ[>5T4<JO<7,[6"BBBJ$%%%% 'WM_P5M_Y,\_93_P"Q!;_TWZ57P37WM_P5
MM_Y,\_93_P"Q!;_TWZ57P34P^$NI\044451 '..*]T^(/[:9\=?L)^"?V)Q\
M-?LH\'>))-6_X2;^V-YNRS7S>7]G\D>7S>_>\QO]7T&[Y?"Z* /1/V3/CZ?V
M6_VAO#?QZ7PF-<_X1^>>3^ROMWV7[1YEO+#CS=C[,>9N^Z<XQQG(]:^ W_!2
M&3X'_MJ^.OVP4^#G]I_\)M;WT7_".GQ%Y/V/[3=07&?M'V=O,V^3MQY:YW9X
MQ@_,-%)QOJ4I-'UE\,?^"JNL^#_V<M.^!/Q#_9F\"^.KSPNI7P3KWBBR6X72
MP7+!I+=T82NH.Q6C>$A57=N():+XQ_\ !4;4?B;^UQI?[5EA^SUX=\S3_!W_
M  CTWAOQ/<G5+:>%I)S+(&$<)1VCN'C^ZP +9#!BM?*5%+EB'/(^HOVI/^"F
M%Q\;O@W=?L[_  7_ &<?"/PL\%ZI>17FNZ9X?AC:6^N(W1PQ:**"-5+10DXB
MWDPH-^W*GIM(_P""P&JZWX4BD^/O[(GPU^(7C72]/CM- \<:YI<9G@1!E6G1
MXY&E.\LY$4D"Y8X )S7QO11RQ#FEW.RLOC!*?V@8/CYK'A#3FD'C!-?N]"T]
M?LUJ["Z%P]O&"'\J,G*C(;:"/O8Y^S_B!_P6D^ 'Q9UB/Q%\5/\ @F1X-\3:
MA#:K;0W_ (@UJTO9DA#,PC#S:8S! S,0H. 6)[FOS^HH<4P4FBUK=_!JNMWF
MJ6FG1V<-S=22QVD/W859B0@X' S@<#@=!56BBJ)"BBB@#Z*_X),?\I#?AKG_
M *"%[_Z;[FJ__!5'_E(#\3/^PQ!_Z2058_X),?\ *0WX:Y_Y_P"]_P#3?<U7
M_P""J/\ RD!^)G_88@_])(*G_EY\BOL_,^?:***HD*Z+X0>/S\*/BUX7^*0T
MG[>?#/B*QU46/VCROM'V>X2;R]^UMF[9MW;6QG.#C%<[10!ZQ^VO^U"W[8O[
M0.H?'5_ _P#PCOV^QM;?^RO[3^V>7Y,0CW>9Y4><XSC:,9ZGK6Y^S?\ MJ-^
MSW^SO\4O@&OPU&K_ /"R]-%FVK?VS]G_ +.'DRQ;O*\E_._UN<;D^[C/.1X7
M12MI8?,[W/H3P[^WUK7A/]B[3?V3?#_@ V]]I/B^+Q!8^+EU=6,<T5S]H1?L
MK0$'# <F0@XZ=J]ITW_@MS-%\1-!^+>I_L7> 7\3V]O)%XJ\161$-_JBF!HH
MT@N6A>6TC4[25=IRRIL!4'-?"5%)QBQJ4D?4OP<_X*0>$/ >O>,$^)W[&?@/
MQYH'BSQE?^)?[/\ $%O')>6EU<OD)]IE@E1TC4E1^Y4Y9CD;B*SO&G_!4_\
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M_P!EGX.:U^RM\._B?>_M<>&;#6/AMX'6S\*>$Y$M_M/C6*22PA:XM<W8;:B
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M )^1_P# E_F?#=%?<G_#JS]C+_I+S\,_^_.G_P#RVH_X=6?L9?\ 27GX9_\
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M?_ E_F?#=%?<G_#JS]C+_I+S\,_^_.G_ /RVH_X=6?L9?])>?AG_ -^=/_\
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M'5G[&7_27GX9_P#?G3__ );4?\.K/V,O^DO/PS_[\Z?_ /+:CVU/N'UK"_\
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MGP;_ (=6?L9?])>?AG_WYT__ .6U3&K34=65+%85O^)'_P "7^9\-T5]R?\
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M])>?AG_WYT__ .6U'MJ?</K6%_Y^1_\  E_F?#=%?<G_  ZL_8R_Z2\_#/\
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MJS]C+_I+S\,_^_.G_P#RVJ8U::CN5+%85O\ B1_\"7^9\-T5]R?\.K/V,O\
MI+S\,_\ OSI__P MJ/\ AU9^QE_TEY^&?_?G3_\ Y;57MJ?<GZUA?^?D?_ E
M_F?#=%?<G_#JS]C+_I+S\,_^_.G_ /RVH_X=6?L9?])>?AG_ -^=/_\ EM1[
M:GW#ZUA?^?D?_ E_F?#=%?<G_#JS]C+_ *2\_#/_ +\Z?_\ +:C_ (=6?L9?
M])>?AG_WYT__ .6U'MJ?</K6%_Y^1_\  E_F?#=%?<G_  ZL_8R_Z2\_#/\
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MO^DO/PS_ ._.G_\ RVH_X=6?L9?])>?AG_WYT_\ ^6U'MJ?</K6%_P"?D?\
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ML_AG_P"";3__ )=4>TAW#ZUA/^?D?_ E_F?E_17Z@?\ #@?]C/\ Z39_#/\
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]%\86;Z?XRM(]8N[I(=8$>3&GVN1Y,++;W\9((4^2A'W@6]>_9J;]F[_ ()
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MZK]L[]H?]C[Q1K_[(&H_ 3XF^%;?PWI?Q6L=7NM*@UFV1M LY;JUG87,0?\
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M@.678**-P]:-P]: Y9=@HHW#UHW#UH#EEV"BC</6C</6@.678**-P]:-P]:
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M3>IG5^$4^-%SC_A&['_OW_\ 6II\;J#C_A&K'_OC_P"M6*>M-?K6G+'L<_\
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M?^B9*.6/8/ZV1T__  F,7_0N67_?L4?\)C%_T+EE_P!^Q6)11RQ[!_6R-O\
MX3&+_H7+/_OV*3_A,8O^A<L_^_8K%HHY8]@_K9&U_P )C%_T+EG_ -^Q2_\
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M_P!"Y9_]^Q1_PF,7_0N6?_?L5B44<L>P?ULC;_X3&+_H7+/_ +]BC_A,8O\
MH7+/_OV*Q**.6/8/ZV1M_P#"8Q?]"Y9_]^Q1_P )C%_T+EG_ -^Q6)11RQ[!
M_6R-O_A,8O\ H7+/_OV*/^$QB_Z%RS_[]BL2BCECV#^MD;?_  F,7_0N6?\
MW[%'_"8Q?]"Y9?\ ?L5B44<L>P?ULC;_ .$QB_Z%RS_[]BC_ (3&+_H7+/\
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MB]G/_0/3_P#)O_DC]\/^'DW["?\ T=!X5_\  P_X4?\ #R;]A/\ Z.@\*_\
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M]YM/_P""D/["Z7=\6_:=\+ -= K_ *8>?W48_N^H-6O^'DW["?\ T=!X5_\
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M=!X5_P# P_X5>\-?\% ?V+O&'B"S\*^'/VE/"MQJ&H7*V]E;_P!H!#-*QPJ
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M(9/F0JD"8D200MU(VJW!P*^^L#KBHV'S=*8'Q3\2O G[3'PZ_:FT?]N#X:?
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MAOX3?%30?!5]KCZ!\.=+T;Q/X5L]1%C?PM!;DEHY"#SND=& 5B"H^5@25M_
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MJ***"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (X?]9-_UT_\
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M2)UJ-.M2)UH DC^^O^\*]6KRF/[Z_P"\*]6K.IT-J/4****S-@HHHH ****
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M $(6MJ4"2(0"F_"1EVCDE9AYFV,;@%[B7]G7QCX7_;Y^'UMIOAW7KKPGX?\
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M9M'SC3?X.?\ \C]_8D\):;I^C7>EZ3I-C#:VMK+##;6UO$$CAC4JJHJ@ *H
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M+NG_ /@$G^%'_")^&/\ H7=/_P# )/\ "M"BCECV#V-'^5?<C/\ ^$3\,?\
M0NZ?_P" 2?X4?\(GX8_Z%W3_ /P"3_"M"BCECV#V-'^5?<C/_P"$3\,?]"[I
M_P#X!1_X4?\ ")^&/^A=T_\ \ D_PK0HHY8]@]C1_E7W(S_^$3\,?]"[I_\
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M / */_"C_A$_#'_0NZ?_ . 2?X5H44<L>P>QH_RK[D9__")^&/\ H7=/_P#
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M/^$3\,?]"[I__@$G^%2:9_Q^:A_U^#_T3'5RCECV#V-'^5?<C/\ ^$3\,?\
M0NZ?_P" 4?\ A1_PB?AC_H7=/_\  )/\*T**.6/8/8T?Y5]R,_\ X1/PQ_T+
MNG_^ 2?X4?\ ")^&/^A=T_\ \ D_PK0HHY8]@]C1_E7W(S_^$3\,?]"[I_\
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MX8_Z%W3_ /P"3_"C_A$_#'_0NZ?_ . 2?X5H44<L>P>QH_RK[D9__")^&/\
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M2[AS1['I0^%7PPS_ ,E3MO\ P+@_QJ0?"SX9_P#13[7_ ,"X/_BJ\U &>E2
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M1['4)X5\+*<_\)7">>TT?^-=D.E>4QCYUX_B%>K5$KFE-I[(****@T"BBB@
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M[E9L?\4M8>G_ %RH_M7#=F"\6.&G]BK_ . Q_P#DC]P**_$7_A\__P %"O\
MHK>G_P#A*V'_ ,:H_P"'T'_!0O\ Z*WI_P#X2UA_\9H_M7#=F'_$6.&?Y*O_
M (#'_P"2/VZHK\1?^'T'_!0O_HK>G_\ A+6'_P 9H_X?0?\ !0O_ **WI_\
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M_@,?_DC]NJ*_$7_A]!_P4+_Z*WI__A+6'_QFC_A]!_P4+_Z*WI__ (2UA_\
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M9H_M7#=F'_$6.&?Y*O\ X#'_ .2/VZHK\1?^'T'_  4+_P"BMZ?_ .$M8?\
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MXL<-/[%7_P !C_\ )'[@45^(O_#Y_P#X*%#I\7-/_P#"5L/_ (U1_P /H/\
M@H7_ -%;T_\ \):P_P#C-']JX;LP_P"(L<,_R5?_  &/_P D?MU17XB_\/H/
M^"A?_16]/_\ "6L/_C-'_#Z#_@H7_P!%;T__ ,):P_\ C-']JX;LP_XBQPS_
M "5?_ 8__)'[=45^(O\ P^@_X*%_]%;T_P#\):P_^,T?\/G_ /@H5_T5O3__
M  E;#_XS1_:N&[,/^(L<,_R5?_ 8_P#R1^W5%?B+_P /H/\ @H7_ -%;T_\
M\):P_P#C-'_#Z#_@H7_T5O3_ /PEK#_XS1_:N&[,/^(L<,_R5?\ P&/_ ,D?
MMU17XB_\/H/^"A?_ $5O3_\ PEK#_P",T?\ #Z#_ (*%_P#16]/_ /"6L/\
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M_P#"6L/_ (S1_:N&[,/^(L<,_P E7_P&/_R1^W5%?B+_ ,/H/^"A?_16]/\
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M^%O!NIWCZYXD\06+QKJ5B)498EW*@/FB)5"JTA0W#$?*C,T@>\_L%_#WQMX
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M;)))?J4CX[M_%GBGQC_P2Z\1ZGXN\3:AJMQ'\4(XH[C4KUYY%C%O;$(&<D@
MDG'3)/K70_'OX/:?JW[4/P6LKKQQXEM4\8>'],$MQ;:H$;3V$4<(6S8IB'.U
M6(.[+.3WKZ<L?^">WP3TSX!7W[.-OK_B3^P[_7QJ\]RU]!]J$X2- H?R-H3$
M:\;"<YYK=^-W[&GP9^/O@30_ WCVVU#;X;M5M]'U*RO!'=0)MC5ADJ4?<(DS
MN0@8^7;DT D>@>"/#MOX/\'Z7X3M-8O=0CTRQBM4OM2N!-<7 C4+OE< ;G.,
MDX&3GBM ]:Y_X3?"GPA\%/ EC\-_ 5K-#I.G(PMX[BZ>9\LQ9V+.3RS$M@8
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M,_WH?][_ -E-!4?B)J***"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC^-M7EC"M=?#G4IF4=BUA(V/UKX8^!WA/Q9^SW\!/ G[>'PGM)KAK&ZO-/\
MB%HZR86_TXWKJ)/8C"J3R%987VX1\G0#[&_9,_:WB_:F3Q0T7@)M#_X1O4TL
MVW:D+C[1N#_-_JTV_<Z<]>M>P9XS7YS?L@_$O0O!/[+?QN\9WWCO6/#<=UJU
MJEAJVAVZ27L4TQD$0C1RH)).&^9"%W$.A 8,^%GQ3_:A^%G[1?PQD\2:O\0(
M=!\::G;VBVOCSQ6=134X)I(HVF6#:OV<A9D95;<RDXWL-P+Y65$_1AB,YS2-
MT(KXET?0OC)\?_V[/B1\)Q^T=XU\.^&]%D%W]ET/7)8Y!M$:1Q0DL5@7=(68
MJ"#MP1SN5WA!_BI^UI^T]\0OAS=_M*^*/!.D_#^273=$T7P_K3PW5VL<SP?:
MI&W S_-$CR,VXYG10RY%*P[GVJS!?O''UJ-CR:^.?VD/$/QF\#6'P<_99\*_
MM&ZHO_"87'EZE\2GD*W-V#+%Y?E2QON(Q(,#?N<-$&D(9F-SP)K'Q1_9N_;Q
MT/\ 9T/QTUWQQX=\6Z*]U-;>*+Y[NZTYTAN'7;(6X.;<DD!5*2$%"RJY07/8
MOV2/VHH?VJ/!^K^+(?!3:'_9>M-I_P!G;4!<&7$:/OSY:;<[\;<'IUKU8NN,
M;A7YH_"?XW>.?@3^PIXPU_X>WK66H:M\3ETO^TH\;[.-[(2-(A(.&(AV ]1O
MW @J*[/X/>._VB?!?QS^'LWAR7XXZMH^N7D.F>)(/B5I-Q]CF6;87N+?YY!&
M%023=2R+#DR,A>B426??&Y?[PIA=6; 85\,_!WPA\7OVBOB]\9;#5_VKO&OA
MC2_"OB*Y73X['7)52)FGNQ$S,SC9!&L1S&I4,"/F78*U/@=\8?VD_B]_P3_\
M33^'/&<DOB[3==32-*UNXO%AN;F FU.T3RL!]H(F:-7)#'*@?O"&H2$?:#G*
MY%-+*.K5\0_LD^(_%=U\9(?A'\9?B;\9]$U_7/"-U!_PCOBF_F:.>8J=UU:W
M#E9(L(DS)^ZX:/\ US8V-S=Q^TW\:/A%\%/'W[,OB[QIKE_\2++Q;#IGA_55
MO)9+RX@N#DO S$RXVPL5;.1]KB QBG8#[^+ L0#37ZUS?P<\&ZY\/_ACH?A#
MQ-XBO-7U*QTV--2U._OI+B2XN#\TC;Y"6*[RVT'HNT=A72/UI :?@G_D:+3_
M 'F_]!-?C%_P5$_Y/Z^)G_8;C_\ 2:&OV=\$_P#(T6G^\W_H)K\8O^"HG_)_
M7Q,_[#<?_I-#7E9M_!CZ_H?D_B]_R(Z'_7S_ -MD>!T445X!_/84444 %%%%
M !1110 4444 %%%% !1110 4444 %0R?Z^/_ 'F_E4U0R?Z^/_>;^5!4=R:B
MBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".'_63?]=/_914
ME1P_ZR;_ *Z?^RBI*!RW_KL%%%% @HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ;)_JV_W:(/]2O^[1)_JV_W:(/]2O\ NT!T'4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4,_WH?\ >_\ 934U0S_>A_WO_9305'XB:BBB
M@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".+_ %\GU'\JDJ.+
M_7R?4?RJ2@J04444$A1110 4444 %%%% !1110 4444 %%%% !77? _X%?%+
M]HWXBV?PN^$7A6;5M6N\NRQ?+';0@C=-*Y^6.-<C+$@9( R6 /6?L??L:?%_
M]M'XC)X(^&=AY.GVQ237_$5U&3::7 3C<Q'WY&PVR('<Y!Z*KNO[7?LC_L;_
M  :_8U^'G_"#?"K1V^U77ER:YKUVJM>:I,H(#2L!]U=S;(Q\B!FP,L[-W8/
MSQ+N](]S[W@_@?&<25%6JWA03UEUEY1[^;V7F]#C_P#@G-_P3C^%_P"Q-8V.
MJR+;ZYX\U!HUUKQ/)#Q$&8;K:U##,4(/5OOR'YFP B)ZO\;UV_%#5!_UP_\
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MJ?PSOOM&LZ;#\)[R.?PM8Z?J"F(A'MW6.8S)([J#;1CAE;!89Y!&EXH_9=\
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ME_/_ #!>'7!Z_P"8;_R>?_R1^;?_ !#LI_T> _\ X0(_^3J/^(=E/^CP'_\
M"!'_ ,G5^F%%']GX3^7\_P#,/^(<\'?] W_D\_\ Y(_,_P#XAV4_Z/ ?_P (
M$?\ R=1_Q#LI_P!'@/\ ^$"/_DZOTPHH_L_"?R_G_F'_ !#G@[_H&_\ )Y__
M "1^9_\ Q#LI_P!'@/\ ^$"/_DZC_B'93_H\!_\ P@1_\G5^F%%']GX3^7\_
M\P_XASP=_P! W_D\_P#Y(_,__B'93_H\!_\ P@1_\G4?\0[*?]'@/_X0(_\
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M"/\ Y.K],**/[/PG\OY_YA_Q#G@[_H&_\GG_ /)'YG_\0[*?]'@/_P"$"/\
MY.H_XAV4_P"CP'_\($?_ "=7Z844?V?A/Y?S_P P_P"(<\'?] W_ )//_P"2
M/S/_ .(=E/\ H\!__"!'_P G4?\ $.RG_1X#_P#A C_Y.K],**/[/PG\OY_Y
MA_Q#G@[_ *!O_)Y__)'YG_\ $.RG_1X#_P#A C_Y.H_XAV4_Z/ ?_P ($?\
MR=7Z844?V?A/Y?S_ ,P_XASP=_T#?^3S_P#DC\S_ /B'93_H\!__  @1_P#)
MU'_$.RG_ $> _P#X0(_^3J_3"BC^S\)_+^?^8?\ $.>#O^@;_P GG_\ )'YG
M_P#$.RG_ $> _P#X0(_^3J/^(=E/^CP'_P#"!'_R=7Z844?V?A/Y?S_S#_B'
M/!W_ $#?^3S_ /DC\S_^(=E/^CP'_P#"!'_R=1_Q#LI_T> __A C_P"3J_3"
MBC^S\)_+^?\ F'_$.>#O^@;_ ,GG_P#)'YG_ /$.RG_1X#_^$"/_ ).H_P"(
M=E/^CP'_ /"!'_R=7Z844?V?A/Y?S_S#_B'/!W_0-_Y//_Y(_,__ (AV4_Z/
M ?\ \($?_)U5KW_@W?2*YM8O^&O7/F3E?^1!''[MS_S_ /\ LU^G-4]2_P"/
M_3_^OIO_ $3)1_9^$_E_/_,/^(=<'K_F&_\ )Y__ "1^;8_X-V8_^CP)/_"
M'_R=1_Q#LI_T> __ (0(_P#DZOTPHH_L_"?R_G_F'_$.>#O^@;_R>?\ \D?F
M?_Q#LI_T> __ (0(_P#DZC_B'93_ */ ?_P@1_\ )U?IA11_9^$_E_/_ ##_
M (ASP=_T#?\ D\__ )(_,_\ XAV4_P"CP'_\($?_ "=1_P 0[*?]'@/_ .$"
M/_DZOTPHH_L_"?R_G_F'_$.>#O\ H&_\GG_\D?F?_P 0[*?]'@/_ .$"/_DZ
MC_B'93_H\!__  @1_P#)U?IA11_9^$_E_/\ S#_B'/!W_0-_Y//_ .2/S/\
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M)'4:=:DCH(EN2)TJ1.E1ITJ1.E B1.E2I]VHDZ5*GW: 'ITJ:H4Z5-0!(.E
MZT#I0.M3$J)(.M2I]ZHAUJ5/O51)*G6I$ZU&G6I$ZT 21_?7_>%>K5Y3']]?
M]X5ZM6=3H;4>H4445F;!1110 4444 %<1XST[4+CQ#-+;V$TBE4PR1$@_*/:
MNWKY-_:K_:A^-?PR^-.H>#_!GB:&VT^WM[=HHGT^&0J6B5FY923R37@\1<2X
M'A7 K&8M2<7)1]U)N[3?5K30YL56IT*?-/:_0]C.CZOG_D%77_@.W^%,?1M8
M)XTFZ_\  =O\*^6?^&W_ -I7_H=K?_P46_\ \12_\-O_ +2G_0[6W_@HM_\
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M (*+?_XBC_B-'"O_ #[J_P#@,?\ Y,K^T\+Y_=_P3W-O"GBDMQX:U#_P#?\
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MUO\ ^"FW_P#B*7_$9N%?^?=7_P !C_\ )B_M+"^?W?\ !/:!X1\7=_"VH_\
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M /Q%)_PV_P#M*_\ 0[6__@HM_P#XBC_B-'"W_/NK_P" Q_\ DP_M+"^?W?\
M!/JS^R-6_P"@7<?]^&_PH_LC5O\ H%W'_?AO\*^4_P#AM_\ :5_Z':W_ /!1
M;_\ Q%'_  V_^TK_ -#M;_\ @HM__B*/^(T<+?\ /NK_ . Q_P#DP_M+"^?W
M?\$^K/[(U;_H%W'_ 'X;_"C^R-6_Z!=Q_P!^&_PKY4_X;?\ VE/^AVM__!1;
M_P#Q%'_#<'[2G_0[6W_@HM__ (BC_B-'"W_/NK_X#'_Y,/[2POG]W_!/JO\
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M]D:M_P! NX_[\-_A7RG_ ,-O_M*_]#M;_P#@HM__ (BE_P"&W_VE/^AVM_\
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M_P -O_M*?]#M;_\ @HM__B*/^&W_ -I3_H=K?_P46_\ \11_Q&CA;_GW5_\
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M /Q%+_PV_P#M*?\ 0[6__@HM_P#XBC_B-'"W_/NK_P" Q_\ DP_M+"^?W?\
M!/JO^R-6_P"@7<?]^&_PH_LC5O\ H%W'_?AO\*^5/^&X/VE/^AVMO_!1;_\
MQ%'_  W!^TI_T.UM_P""BW_^(H_XC1PM_P ^ZO\ X#'_ .3#^TL+Y_=_P3ZK
M_LC5O^@7<?\ ?AO\*/[(U;_H%W'_ 'X;_"OE3_AN#]I3_H=K;_P46_\ \11_
MPW!^TI_T.UM_X*+?_P"(H_XC1PM_S[J_^ Q_^3#^TL+Y_=_P3ZK_ +(U;_H%
MW'_?AO\ "C^R-6_Z!=Q_WX;_  KY3_X;?_:5_P"AVM__  46_P#\11_PV_\
MM*_]#M;_ /@HM_\ XBC_ (C1PM_S[J_^ Q_^3#^TL+Y_=_P3ZL_LC5O^@7<?
M]^&_PH_LC5O^@7<?]^&_PKY3_P"&W_VE?^AVM_\ P46__P 11_PV_P#M*_\
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MM3"]G]W_  3WA/"WB?/_ "+E_P#^ ;_X5(GA?Q,.OAS4/_ -_P#"O S^V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #[+_CZC_ZZC^=?J7'_
M *M?]VORTLO^/J/_ *ZC^=?J7'_JU_W:_?O _P#AX[_N'_[>>YDVT_D.HHHK
M]Z/<"BBB@ HHHH *^#?VY_\ DX_5O^O6T_\ 1"5]Y5\&_MS_ /)Q^K?]>MI_
MZ(2OR?QD_P"25A_U]C_Z3,\O-O\ =5ZK\F>0T445_+Y\V%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZG\<5:5K=UNG_FCZ-_:'\ +\.?V8_#7A'P%J,FI1CQM'-H,UJOF/*DWVF2
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M!X66&PU.4H*-&FE.WOP@ZCFIVVYE.R2O9)=33Z]3C!QBGLEKU2O>_P!Y[/\
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MLKJUXW]W3I=I8G#^[>_NO3;7U_K8]V\+7&B^*+C]H9_ 5HTT%U9JEO';+O\
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MZX_X8F_9I_Z'_P 2?]_H?_D>C_AB?]FCK_PL#Q)_W^A_^1Z/^(1\8_R0_P#
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M ,CT?\0CXQ_DA_X&@_LO%>7WGR%17U[_ ,,-?LY=?^$Z\2_]_P"'_P"1Z/\
MAAK]G+K_ ,)UXE_[_P /_P CT?\ $(^,?Y(?^!H/[+Q7E]Y\A45]>_\ ##7[
M.7_0]>)?^_\ #_\ (])_PPU^SE_T/7B3_O\ P_\ R/1_Q"/C'^2'_@:#^R\5
MY?>?(=%?7G_##7[.73_A.O$G_?\ A_\ D>C_ (8:_9RZ?\)UXD_[_P /_P C
MT?\ $(^,?Y(?^!H/[+Q7E]Y\AT5]>_\ ##7[.7_0]>)?^_\ #_\ (]'_  PU
M^SE_T/7B7_O_  __ "/1_P 0CXQ_DA_X&@_LO%>7WGR%17U[_P ,-?LY=?\
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MXA'QC_)#_P #0?V7BO+[SY"H_"OKW_AAK]G(]?'7B7_O_#_\CT?\,-?LY?\
M0]>)?^_\/_R/1_Q"/C'^2'_@:#^R\5Y?>?(6/:BOKW_AAK]G+K_PG7B7_O\
MP_\ R/1_PPU^SE_T/7B7_O\ P_\ R/1_Q"/C'^2'_@:#^S,5Y?>?(6!Z48'I
M7U[_ ,,-?LY#IXZ\2_\ ?^'_ .1Z/^&&OV<O^AZ\2_\ ?^'_ .1Z/^(1\8_R
M0_\  T']EXKR^\^0L>U&/:OKW_AAK]G+I_PG7B7_ +_P_P#R/1_PPU^SE_T/
M7B7_ +_P_P#R/1_Q"/C'^2'_ (&@_LS%>7WGR%C/445]>_\ ##7[.7_0]>)?
M^_\ #_\ (]'_  PU^SE_T/7B7_O_  __ "/1_P 0CXQ_DA_X&@_LS%>7WGR%
M17U[_P ,-?LY=?\ A.O$O_?^'_Y'H_X8:_9R_P"AZ\2_]_X?_D>C_B$?&/\
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M\,-?LY=?^$Z\2_\ ?^'_ .1Z/^&&OV<O^AZ\2_\ ?^'_ .1Z/^(1\8_R0_\
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M[_P__(]'_$(^,?Y(?^!H/[+Q7E]Y\A45]>_\,-?LY?\ 0]>)?^_\/_R/2?\
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MXE_[_P /_P CT?\ $(^,?Y(?^!H/[+Q7E]Y\A45]>_\ ##7[.7_0]>)?^_\
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M]EXKR^\^0Z*^O/\ AAK]G+I_PG7B3_O_  __ "/2_P###7[.73_A.O$O_?\
MA_\ D>C_ (A'QC_)#_P-!_9>*\OO/D*BOK^']A3]G:YF2VA\<>)&>1@J+]H@
MY)[?\>]4M9_8W_9>\/ZE)I&M?$7Q)!<PX\R)IHF*Y (Z6Q'0BC_B$?&/\D/_
M  -#_LO%>7WGR;17U0/V3OV2SS_PL_Q'_P!_(_\ Y&IW_#)G[)O7_A9WB/\
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M_0#7HE>=^ ?^1IM_H_\ Z :]$!H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JG=?\A6U_WI/_ $"KE4[O_D*VO^])_P"@4 7**,T4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!3TS_ (_-0_Z_!_Z)CJY5/3#_
M *9J'_7X/_1,=7* "BBB@ HHHH **** "BBB@ HHHH **** "BB@_2@ HI >
M>E+0!'=_\>LG_7-OY4W3O^0?!_UQ7^5.N_\ CUD_ZYM_*FZ=_P @^#_KBO\
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MM:G\S^\ZC_A=?Q>_Z*1JW_@8U'_"Z_B]_P!%(U;_ ,#&KEZ*/[>SS_H*J?\
M@<O\P]K4_F?WG4?\+K^+W_12-7_\#&I/^%U_%[_HI&K_ /@8U<Q11_;V>?\
M054_\#E_F'M:G\S^\Z?_ (77\7O^BD:O_P"!C4?\+K^+W_12-7_\#&KF**/[
M>SS_ *"JG_@<O\P]K4_F?WG4?\+K^+W_ $4C5_\ P,:C_A=?Q>_Z*1JW_@8U
M<O11_;V>?]!53_P.7^8>UJ?S/[SJ/^%U_%[_ **1JW_@8U'_  NOXO?]%(U;
M_P #&KEZ*/[>SS_H*J?^!R_S#VM3^9_>=1_PNOXO?]%(U;_P,:D_X77\7O\
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M%']O9Y_T%5/_  .7^8>UJ?S/[SI_^%U_%[_HI&K_ /@8U+_PNOXO?]%(U?\
M\#&KEZ*/[>SS_H*J?^!R_P P]K4_F?WG4?\ "Z_B]_T4C5__  ,:C_A=?Q>_
MZ*1JW_@8U<O11_;V>?\ 054_\#E_F'M:G\S^\ZC_ (77\7O^BD:M_P"!C4?\
M+K^+W_12-7_\#&KEZ*/[>SS_ *"JG_@<O\P]K4_F?WG4?\+K^+W_ $4C5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8T7_ )#=E_U]1_\
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M$#?*XC<^84;Y3@@X!->;?MB?LC^,_!_[*GQ)^*?Q-^.6M?$+X@Z[I.AZ$GB
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MEGX@_LO^.M+FCN-4E;Q1=:/(FGHNPR(#(R@$LX>,;"P),9!(9MDV$=S\-O\
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MNFZ.+'5/$&H:4UI9:<(H0BR1&:-=ROM^92RNO11,>N7_ ,%6?AW\0_B%X?\
MA_#\/_ 6M:[)9>)FFO$T?3);DP1[%&Y_+5MH]S@4^H')^._VQ?&OQ+_X)W>,
MM2.NZGX;^)7@F\T_2_%2V-P]I=6]P+^&(R@QE602!9%8?+AUE3& "?4)/VUO
MAE^SC^S-\,?$_P :-6US4M6\1>"--GACM;5KFZOY!:0&:1I965"VZ0,V^0,=
MV>:\E_X*=_L=>/\ 6M5F^.?P$\-ZA?W&O6\6F^-M#T>W>::\19(WAN!$BDN
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M,R!3&7V$LJG:P<HQ!&[*MC@-._X*Q?LFZC<:5;SW/B*S74%8W4]SI *:;@D
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MHK[(Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZE_Q_Z?_P!?3?\
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M -#!X@_\"H/_ (S1_P 0AXT_Y]P_\#0?V?B>R/F+-&:^G?\ ABOX7?\ 0?\
M$'_@5!_\9I/^&+/A=_T'_$'_ (%0?_&:/^(0\:?\^X?^!H/[/Q/E]Y\QYHS7
MTY_PQ9\+O^@_X@_\"H/_ (S1_P ,6?"[_H/^(/\ P*@_^,T?\0AXT_Y]P_\
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M,6:,U]._\,5_"[_H/^(/_ J#_P",T?\ #%?PM_Z&#Q!_X%0?_&:/^(0\:?\
M/N'_ (&@_L_$]D?,6:,U]._\,5_"W_H8/$'_ (%0?_&:/^&*_A=_T'_$'_@5
M!_\ &:/^(0\:?\^X?^!H/[/Q/9'S%FC-?3O_  Q7\+O^@_X@_P# J#_XS1_P
MQ7\+O^@_X@_\"H/_ (S1_P 0AXT_Y]P_\#0?V?B?+[SY8L"/M=[_ -?0_P#1
M4=6LU]):;^Q;\+VO+\'Q!X@^6[ _X^H/^>,?_3&K?_#%?PN_Z#_B#_P*@_\
MC-4_"+C3_GW#_P #0?V?B?+[SYBS1FOIW_ABOX7?]!_Q!_X%0?\ QFC_ (8K
M^%W_ $'_ !!_X%0?_&:G_B$/&G_/N'_@:#^S\3Y?>?,6:,U]._\ #%?PN_Z#
M_B#_ ,"H/_C-'_#%?PN_Z#_B#_P*@_\ C-'_ !"'C3_GW#_P-!_9^)[(^8LT
M9KZ=_P"&*_A=_P!!_P 0?^!4'_QFC_ABOX7?]!_Q!_X%0?\ QFC_ (A#QI_S
M[A_X&@_L_$^7WGS%FC-?3O\ PQ7\+?\ H8/$'_@5!_\ &:/^&*_A=_T'_$'_
M (%0?_&:/^(0\:?\^X?^!H/[/Q/9'S%FC-?3O_#%?PN_Z#_B#_P*@_\ C-'_
M  Q7\+O^@_X@_P# J#_XS1_Q"'C3_GW#_P #0?V?B?+[SYBS1FOIS_ABSX7?
M]!_Q!_X%0?\ QFE_X8K^%W_0?\0?^!4'_P 9H_XA#QI_S[A_X&@_L_$]D?,6
M:,CO7T[_ ,,5_"[_ *#_ (@_\"H/_C-(?V+/A<!_R'O$#>QNH/\ XS37A#QI
M_)#_ ,#0_P"S\3V7WGA/PK^$OBGXM:Y_9NAP^5:Q,/MFHR+^[@7]-S>BCKWP
M,D?6OPZ^&?A3X8Z(NB>&+$IN -Q<R<RSM_>=OSX& ,G %:/ACPMH/@W18/#W
MAK38[6SMUQ'%&._<D]6)[D\D\FM"OV_@G@#+^$Z*JSM4Q#6L^B[J'9=WN_30
M]/"X2&'5]V1W?_'K)_US;^5-T[_D'P?]<5_E3KO_ (]9/^N;?RING?\ (/@_
MZXK_ "K]".LFHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>I?\
M?^G_ /7TW_HF2KE4]2_X_P#3_P#KZ;_T3)0!<HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"K:?\A*[_P!Y/_015JJMI_R$KO\ WD_]!%6J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:+_ ,ANR_Z^H_\
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M678Q;3_D)7?^\G_H(JU5BV\&>*8[ZXF?1VVNR[3YB\_+]:L?\(GXD_Z!+?\
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MQ_?7_>%>K5YW'X0\2!@3I;=<_P"L7_&O1 <C-1,TH]0HHHK,V"BBB@ HHHH
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M:,?[M']CY1_T#P_\ C_D']K9I_S_ )_^!/\ S/7?^&\?VN_^BVZG_P!^+?\
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M/]VC^Q\H_P"@>'_@$?\ (/[6S3_G_/\ \"?^9Z[_ ,-X_M=_]%MU/_OQ;_\
MQNC_ (;Q_:[_ .BVZG_WXM__ (W7D6/]VC'^[1_8^4?] \/_  "/^0?VMFG_
M #_G_P"!/_,]=_X;Q_:[_P"BVZG_ -^+?_XW1_PWC^UW_P!%MU/_ +\6_P#\
M;KR+'^[1C_=H_L?*/^@>'_@$?\@_M;-/^?\ /_P)_P"9Z[_PWC^UW_T6W4_^
M_%O_ /&Z/^&\?VN_^BVZG_WXM_\ XW7D6/\ =HQ_NT?V/E'_ $#P_P# (_Y!
M_:V:?\_Y_P#@3_S/7?\ AO']KO\ Z+;J?_?BW_\ C='_  WC^UW_ -%MU/\
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MT_Y_S_\  G_F>N_\-X_M=_\ 1;=3_P"_%O\ _&Z/^&\?VN_^BVZG_P!^+?\
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M8_W:,?[M']CY1_T#P_\  (_Y!_:V:?\ /^?_ ($_\SUW_AO']KO_ *+;J?\
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M\?VN_P#HMNI_]^+?_P"-UY%C_=HQ_NT?V/E'_0/#_P  C_D']K9I_P _Y_\
M@3_S/7?^&\?VN_\ HMNI_P#?BW_^-T?\-X_M=_\ 1;=3_P"_%O\ _&Z\BQ_N
MT8_W:/['RC_H'A_X!'_(/[6S3_G_ #_\"?\ F>N_\-X_M=_]%MU/_OQ;_P#Q
MNC_AO']KO_HMNI_]^+?_ .-UY%C_ ':,?[M']CY1_P! \/\ P"/^0?VMFG_/
M^?\ X$_\SUW_ (;Q_:[_ .BVZG_WXM__ (W1_P -X_M=_P#1;=3_ ._%O_\
M&Z\BQ_NT8_W:/['RC_H'A_X!'_(/[6S3_G_/_P "?^9Z[_PWC^UW_P!%MU/_
M +\6_P#\;H_X;Q_:[_Z+;J?_ 'XM_P#XW7D6/]VC'^[1_8^4?] \/_ (_P"0
M?VMFG_/^?_@3_P SUW_AO']KO_HMNI_]^+?_ .-T?\-X_M=_]%MU/_OQ;_\
MQNO(L?[M&/\ =H_L?*/^@>'_ (!'_(/[6S3_ )_S_P# G_F>N_\ #>/[7?\
MT6W4_P#OQ;__ !NC_AO']KO_ *+;J?\ WXM__C=>18_W:,?[M']CY1_T#P_\
M C_D']K9I_S_ )_^!/\ S/7?^&\?VN_^BVZG_P!^+?\ ^-T?\-X_M=_]%MU/
M_OQ;_P#QNO(L?[M&/]VC^Q\I_P"@>'_@$?\ (/[6S3_G_/\ \"E_F>N_\-X_
MM=_]%MU/_OQ;_P#QNC_AO']KO_HMNI_]^+?_ .-UY%C_ ':,?[M']CY1_P!
M\/\ P"/^0?VMFG_/^?\ X$_\SUW_ (;Q_:[_ .BVZG_WXM__ (W1_P -X_M=
M_P#1;=3_ ._%O_\ &Z\BQ_NT8_W:/['RC_H'A_X!'_(/[6S3_G_/_P "?^9Z
M[_PWC^UW_P!%MU/_ +\6_P#\;H_X;Q_:[_Z+;J?_ 'XM_P#XW7D6/]VC'^[1
M_8^4?] \/_ (_P"0?VMFG_/^?_@3_P SUW_AO']KO_HMNI_]^+?_ .-T?\-X
M_M=_]%MU/_OQ;_\ QNO(L?[M&/\ =H_L?*/^@>'_ (!'_(/[6S3_ )_S_P#
MG_F>N_\ #>/[7?\ T6W4_P#OQ;__ !NC_AO']KO_ *+;J?\ WXM__C=>18_W
M:,?[M']CY1_T#P_\ C_D']K9I_S_ )_^!/\ S/7?^&\?VN_^BVZG_P!^+?\
M^-T?\-X_M=_]%MU/_OQ;_P#QNO(L?[M&/]VC^Q\H_P"@>'_@$?\ (/[6S3_G
M_/\ \"?^9Z[_ ,-X_M=_]%MU/_OQ;_\ QNC_ (;Q_:[_ .BVZG_WXM__ (W7
MD6/]VC'^[1_8^4?] \/_  "/^0?VMFG_ #_G_P"!/_,]=_X;Q_:[_P"BVZG_
M -^+?_XW1_PWC^UW_P!%MU/_ +\6_P#\;KR+'^[1C_=H_L?*/^@>'_@$?\@_
MM;-/^?\ /_P)_P"9Z[_PWC^UW_T6W4_^_%O_ /&Z/^&\?VN_^BVZG_WXM_\
MXW7D6/\ =HQ_NT?V/E/_ $#P_P# (_Y!_:V:?\_Y_P#@4O\ ,]=_X;Q_:[_Z
M+;J?_?BW_P#C='_#>/[7?_1;=3_[\6__ ,;KR+'^[1C_ ':/['RC_H'A_P"
M1_R#^ULT_P"?\_\ P*7^9Z[_ ,-X_M=_]%MU/_OQ;_\ QNC_ (;Q_:[_ .BV
MZG_WXM__ (W7D6/]VC'^[1_8^4_] \/_  "/^0?VMFG_ #_G_P"!2_S/7?\
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M_P"^J/\ OJ@ X_O?^.T<?WO_ !VC_OJC_OJ@ X_O?^.T<?WO_':/^^J/^^J
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M0,X&UBA#8Z,"=K, Q&Q^UW^QMXJ_91U32S<Z\VN:1JD)$.L1Z?\ 9U6X4G=
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M[W_CM''][_QVC_OJC_OJ@ X_O?\ CM''][_QVC_OJC_OJ@ X_O?^.T<?WO\
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MZH_[ZH ./[W_ ([1Q_>_\=H_[ZH_[ZH ./[W_CM''][_ ,=H_P"^J/\ OJ@
MX_O?^.T<?WO_ !VC_OJC_OJ@ X_O?^.T<?WO_':/^^J/^^J #C^]_P".T<?W
MO_':/^^J/^^J #C^]_X[1Q_>_P#':/\ OJC_ +ZH ./[W_CM''][_P =H_[Z
MH_[ZH ./[W_CM''][_QVC_OJC_OJ@ X_O?\ CM''][_QVC_OJC_OJ@ X_O?^
M.T<?WO\ QVC_ +ZH_P"^J #C^]_X[1Q_>_\ ':/^^J/^^J #C^]_X[1Q_>_\
M=H_[ZH_[ZH ./[W_ ([1Q_>_\=H_[ZH_[ZH ./[W_CM''][_ ,=H_P"^J/\
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M_P"/4;A_LT;AT^6@+AQ_=_\ 'J./[O\ X]1N'^S1D?[- 7#C^[_X]1Q_=_\
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MU_T$S_\  F']C9/_ - \/_ 4>8?\.\OV*/\ H&:[_P"#2;_"C_AWE^Q1_P!
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M_#O+]BC_ *!FN_\ @TF_PH_X=Y?L4?\ 0,UW_P &DW^%>GT4?VYG7_034_\
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MMS.O^@FI_P"!,/[&R?\ Z!X?^ H\P_X=Y?L4?] S7?\ P:3?X4?\.\OV*/\
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M\'_7%?Y"C^W,Z_Z":G_@3#^QLG_Z!X?^ H\V_P"'>7[%'_0,UW_P:3?X4?\
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M:G_@3#^QLG_Z!X?^ H\\_P"'>7[%&,_V;KO_ (-)O\*/^'>7[%'_ $#-=_\
M!I-_A7I]%']N9U_T$S_\"8?V-D__ $#P_P# 4>8?\.\OV*/^@9KO_@TF_P *
M/^'>7[%'_0,UW_P:3?X5Z?11_;F=?]!-3_P)A_8V3_\ 0/#_ ,!1YA_P[R_8
MH_Z!FN_^#2;_  H_X=Y?L4?] S7?_!I-_A7I]%']N9U_T$U/_ F']C9/_P!
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M4?\ 0,UW_P &DW^%>GT4?VYG7_034_\  F']C9/_ - \/_ 4>8?\.\OV*/\
MH&:[_P"#2;_"C_AWE^Q1_P! S7?_  :3?X5Z?11_;F=?]!-3_P "8?V-D_\
MT#P_\!1YA_P[R_8H_P"@9KO_ (-)O\*/^'>7[%'_ $#-=_\ !I-_A7I]%']N
M9U_T$U/_  )A_8V3_P#0/#_P%'F'_#O+]BC_ *!FN_\ @TF_PH_X=Y?L4?\
M0,UW_P &DW^%>GT4?VYG7_034_\  F']C9/_ - \/_ 4>9V__!.O]BZZN([:
M#2]<+2,%4'5IADDX':L_7?V$_P!A3PUJTVB:S::]'<0;?,1=2G;&5##D#T(K
MV31?^0Y9?]?4?_H0KA_CC_R5'5/^V/\ Z(CI?VYG7-;ZS/\ \"97]BY/RW^K
MP_\  4<2/V+?V CTCU[_ ,#[C_XFC_ABK]@3_GEKW_@PN/\ "KJ?=J4=*?\
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M_P &<_\ A0/V#/V&CS]AU[_P9S_X5V"=*E3A<4?VYG7_ $$S_P# F']C9/\
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M_OCI_P!%L\6_^%'=?_'*/^%_?'3_ *+9XM_\*.Z_^.5]1_Q#W%_\_P"/W/\
MS/G?]?,+_P ^9?>O\C]0:*_+[_A?WQT_Z+9XM_\ "CNO_CE'_"_OCI_T6SQ;
M_P"%'=?_ !RC_B'N+_Y_Q^Y_YA_KYA?^?,OO7^1^H-%?E]_PO[XZ?]%L\6_^
M%'=?_'*/^%_?'3_HMGBW_P *.Z_^.4?\0]Q?_/\ C]S_ ,P_U\PO_/F7WK_(
M_4&BOR^_X7]\=/\ HMGBW_PH[K_XY1_PO[XZ?]%L\6_^%'=?_'*/^(>XO_G_
M !^Y_P"8?Z^87_GS+[U_D?J#17Y??\+^^.G_ $6SQ;_X4=U_\<H_X7]\=/\
MHMGBW_PH[K_XY1_Q#W%_\_X_<_\ ,/\ 7S"_\^9?>O\ (_4&BOR^_P"%_?'3
M_HMGBW_PH[K_ ..4?\+^^.G_ $6SQ;_X4=U_\<H_XA[B_P#G_'[G_F'^OF%_
MY\R^]?Y'Z@T5^7W_  O[XZ?]%L\6_P#A1W7_ ,<H_P"%_?'3_HMGBW_PH[K_
M ..4?\0]Q?\ S_C]S_S#_7S"_P#/F7WK_(_4&BOR^_X7]\=/^BV>+?\ PH[K
M_P".4?\ "_OCI_T6SQ;_ .%'=?\ QRC_ (A[B_\ G_'[G_F'^OF%_P"?,OO7
M^1^H-4[O_D*VI_VI/_0*_,K_ (7]\=/^BV>+?_"CNO\ XY5:?X^?'0WT!_X7
M3XMXW_\ ,R77I_UTI?\ $/<5_P _X_<_\P_U[PO_ #YE]Z/U*HK\OO\ A?WQ
MU_Z+9XM_\*.Z_P#CE'_"_OCI_P!%L\6_^%'=?_'*?_$/<5_S_C]S_P Q?Z^8
M7_GS+[T?J#17Y??\+^^.G_1;/%O_ (4=U_\ '*/^%_?'3_HMGBW_ ,*.Z_\
MCE'_ !#W%_\ /^/W/_,?^OF%_P"?,OO7^1^H-%?E]_PO[XZ?]%L\6_\ A1W7
M_P <H_X7]\=/^BV>+?\ PH[K_P".4?\ $/<7_P _X_<_\P_U\PO_ #YE]Z_R
M/U!HK\OO^%_?'3_HMGBW_P *.Z_^.4?\+^^.G_1;/%O_ (4=U_\ '*/^(>XO
M_G_'[G_F'^OF%_Y\R^]?Y'Z@T5^7W_"_OCI_T6SQ;_X4=U_\<H_X7]\=/^BV
M>+?_  H[K_XY1_Q#W%_\_P"/W/\ S#_7S"_\^9?>O\C]0:*_+[_A?WQT_P"B
MV>+?_"CNO_CE'_"_OCI_T6SQ;_X4=U_\<H_XA[B_^?\ '[G_ )A_KYA?^?,O
MO7^1^H-%?E]_PO[XZ?\ 1;/%O_A1W7_QRC_A?WQT_P"BV>+?_"CNO_CE'_$/
M<7_S_C]S_P P_P!?,+_SYE]Z_P C]0:*_+[_ (7]\=/^BV>+?_"CNO\ XY1_
MPO[XZ?\ 1;/%O_A1W7_QRC_B'N+_ .?\?N?^8?Z^87_GS+[U_D?J#17Y??\
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MH=N+5Y@ !(8MFPOA5&[&>!Z59'PZ\ 1>(+7Q5%X'TA=4L;46UCJ2Z;$+BW@
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M (]7ZP?F ?\ ?5'_ 'U1Q_=_\>HX_N_^/4 '_?5'_?5'']W_ ,>HX_N_^/4
M'_?5'_?5'']W_P >HX_N_P#CU !_WU1_WU1Q_=_\>HX_N_\ CU !_P!]4?\
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M/5/V>_A;^T-_P5Q^(?@7XJ:))?:-8>%[2^73[>\EMTED6PTV)0S0LK[0)2P
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M[\/;#XG_  MUF'6-(U2U,^GW4>Y%EP64HP9=T;JZE'1E#HRLK*&4@>5_ ?\
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MKCXB7-R8M*.HK*;;21%;[)3<'R9R\Q&R(1<HQ8)6GX=^/W[2OQU^!?AOXA_
MGP1X1\,ZI=R:A!XR_P"%@WT\\>@7=C<-:SVRPVNPW.9XIP)?-B54C#D-NVB7
MQ+\+/VGO#GQIN/V@O@SIO@6:]\5>!['2?&WA7Q#X@O(8+;4+-YY+:YMKR&QD
M>XC3[7<1NK0PEU6-OD)(7A/$O[%W[0=M\%_A_P#!&SU7PSXTT2UU'5M9^+NE
MZUXFO-#C\4:E=7!NE3S;6SN6:T%Q<7+M 442". -D;E(1+<[;X;_ !^_:@_:
M'_9F\(_%'X)>$/ NE:UKUU>IK%]XFU&\NM.LXK:XE@%Q;1P)')=QW!A\R,F2
M+;'*K$OW[;]CCX\:[^T;\#[7XD>)='TZUOEU;4M,NIM#O&N--OY+.\EM6N[.
M5P&DMY3%O0D9 )4EMNYN _:&^"/[2_QI^%G@SX::'X1\$:/H,=Y,/B)X'T_Q
MY?65MJ.G1H4M=-M]0ATOS$MV^1ID%O$65/)5MK,Q]I^#ECXPTCP/:Z%XP^''
MACPHVG@6VGZ+X0UB2]L;>U156)49[.TV8'R^6(MJA1@GH 1UB=*E3[M1)TJ5
M/NT /3I4U0ITJ:@"0=*!UH'2@=:F)420=:E3[U1#K4J?>JB25.M2)UJ-.M2)
MUH DC^^O^\*]6KRF/[Z_[PKU:LZG0VH]0HHHK,V"BBB@ HHHH *X+QS_ ,C+
M-_NI_P"@BN]K@O'/_(RS?[J?^@BKI_$9U/A,0]:;)UIQZTU^M:G.<WX[^$7P
MI^* MS\3/AGX?\1?8U86AU[18+SR V-P3S4;;G SCK@>E<WXY\$^)OA=\&-2
MT/\ 9&^'OA33M8C(FTG1YK46>GM(74R%D@"C<5#8Y7+8RP%>C'I4= 'SC^Q;
M^S%\5/ 7COQI^TA^TA+I+>.O'%PJM9Z.Q:'3;-<'R@W3+,L8VY?"P1G>Q9@/
M;K;X;_#[3O&=U\2-/\#:/!XBOH!!>Z]#I<*WMQ$ @$;SA?,=0(HQ@L1A%]!6
MZ_WJ8_2@#"\.?#7X>^#]4U37/"7@;1]+OM<G$^M7FG:;%!+J$H9F\R=D4&5L
MNYRY)R['N<\Y;_LO_LTVMI-I]O\ L\^!EM[IE-S"OA*R"3;<[=P\K#8W-C/3
M)QUKOJCH*B8K?#?X>/XP@^(<G@31F\06UO\ 9[?7&TN+[9%%@CRUFV[PN&8;
M0<8)XIOCKX:?#OXFV$.F?$CP'HWB"UMYO-M[76]+ANXXI,8WJLJL%;!(R.<5
MN4C_ ':G[0I;F!I?PQ^&^A^#I/AYHOP_T2S\/S0R13:';:3"EG)&^?,4PA=A
M#9.X8PV><U3NO@S\(KKP9#\-;KX7>'9/#MN^^WT"31+=K*)MQ;<L!3RP=S,V
M0N<L3U)KJ*8WWJH1S^M?#'X<:]=Z-J&N^ =%OKCP[*LF@3WFEPROIC@H0UN6
M4F$@QH<ICE%]!4'C?X0?"CXFO:R?$CX9>'_$#6*LMFVN:+!=&!6P6">:C;02
M 3C&<#T%=(_6FT 9OASPOX:\':1#X>\(^'K'2M/M5*VVGZ;:)!!$"<D+&@"K
MDDG@=37+:1\%M"\/?'#6OC=HVI7EO=>(-%MK'6--5U^SW4D#'RKEAMW>:L9,
M8.X+M/3/-=O3'^]0!F>&/"/A7P+H$/A?P5X:T_1]-M]QM]/TNS2W@BW,6;:B
M *,L2QP.22>IJ76=&TCQ%I-QH.OZ7;WUC>0M#=V=Y"LD4\;##(Z,"&4C@@@@
MBKC_ ':90!E?\(AX4'A;_A!1X:T_^Q/L/V(:/]BC^RBUV>7Y'E;=GE[/EV8V
MXXQ3]#\.:!X4T:W\.^%]$L]-T^UCV6MC86B0PPKZ+&@"J,]@,5>/6FR4 <?8
M_ #X%:5XC7QEI?P8\*6VL1W!N(]4M_#MLERLQ.3)YH0-N)R2V<G)J#4?@WH.
MM_&W3?C?K-_=7%[HNAS:?H]A($-O;-,^Z6Y7Y=PF9 (R=V-F1CG-=J>E1T%1
M&-]ZF/TI[_>IC]*"AM1GK4E1GK0 A^\*4]*0_>%*>E1+<F1$GW::_P!ZG)]V
MFO\ >IQ)&/TIIZ4Y^E-/2J CIK]:=37ZT :W@'GQ3;_1_P#T US?C#]@_P"!
MGCCQ7J7C'6SK/VS5+V2ZNO)U *GF.Q9L#9P,GI72> ?^1IM_H_\ Z :]$KKP
MF.QF!DY8>HX-Z-IVT.7%8/"XV*C7@I):JZN>"_\ #N;]GCUU[_P:#_XBC_AW
M-^SQZZ]_X-!_\17O5%=_^L6>?]!,_P#P)G'_ &#DO_0/'[D>"_\ #N;]GCUU
M[_P:#_XBC_AW-^SQZZ]_X-!_\17O5%'^L6>?]!,__ F']@Y+_P! \?N1X+_P
M[F_9X]=>_P#!H/\ XBC_ (=S?L\>NO?^#0?_ !%>]44?ZQ9Y_P!!,_\ P)A_
M8.2_] \?N1X+_P .YOV>/77O_!H/_B*/^'<W[/'KKW_@T'_Q%>]44?ZQ9Y_T
M$S_\"8?V#DO_ $#Q^Y'@O_#N;]GCUU[_ ,&@_P#B*/\ AW-^SQZZ]_X-!_\
M$5[U11_K%GG_ $$S_P# F']@Y+_T#Q^Y'@O_  [F_9X]=>_\&8_^(H_X=S?L
M\>NO?^#0?_$5[U11_K%GG_03/_P)A_8.2_\ 0/'[D>"_\.YOV>/77O\ P:#_
M .(H_P"'<W[/'KKW_@T'_P 17O5%'^L6>?\ 03/_ ,"8?V#DO_0/'[D>"_\
M#N;]GCUU[_P:#_XBC_AW-^SQZZ]_X-!_\17O5%'^L6>?]!,__ F']@Y+_P!
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MX+_P[F_9X]=>_P#!H/\ XBC_ (=S?L\>NO?^#0?_ !%>]44?ZQ9Y_P!!,_\
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M?N_,U%^&'C0#!TM?_ A/\:D'PU\8XYTQ?_ A/\:RU\4>)<9_X2*^_P# Q_\
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MN'K7R=_P]%TK_HBL_P#X4"__ !FC_AZ+I7_1%9__  H%_P#C->G_ *H\1?\
M/C\8_P#R1YG^M.0_\_OPE_D?6.X>M&X>M?)W_#T72O\ HBL__A0+_P#&:/\
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M_CM'/][_ ,=HQ_O48_WJ #G^]_X[1S_>_P#':,?[U&/]Z@ Y_O?^.T<_WO\
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M%% %6T_Y"5W_ +R?^@BK55;3_D)7?^\G_H(JU0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %C1?^0W9?\ 7U'_ .A"N'^./_)4=4_[8_\ HB.N
MXT7_ )#=E_U]1_\ H0KA_CC_ ,E1U3_MC_Z(CJ?M%_\ +L\K^-'P>\,_'?P
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M1.M1IUJ1.M $D?WU_P!X5ZM7E,?WU_WA7JU9U.AM1ZA11169L%%%% !1110
M5P7CG_D99O\ =3_T$5WM<%XY_P"1EF_W4_\ 015T_B,ZGPF(>M-DZTX]:9+S
MQ[5J<Y^?W[:GP?T']HS_ (*@>&?@WXCG:&UU/X;SP_:H\EK698-2FAEP"-VR
M4(^TD!@N#P:\J^)W[)'QU\+?LK^._B_^U.DDFK>#['1_"_@FVFGCD6VL8KZ%
M&ECV#&PJX2-\@D--D<J:_1FX_9O^%=W\>(?VD[S19I/%EMIYLK>^-Y)L2$HR
M;1'G9]UVYQGFM+XO_"3P1\<_AYJ'PM^(NFR7>C:IY7VVWBN'A9_+E25?G0AA
MAT4\'M0!\.?'?PYK/PL^#'[//[>W@*UN)KCPGX7T*P\606[E?/L6MHU&XX(0
M'?/;LQ!)^T1_W!2^&O&_B3XN_%WXY_M_^$8I+_3_ (?^'[K2?ARTVYX8YDMR
M&NHPPP L>^=HR.?MISS7KO[8[?$;X<_!>R_9!_9__92U3QAH_B#PR^C6NLM=
M>9:Z.V!''OR&(=%Q()9FB16V,'8JX7U3]DC]GG3_ -G?]G'0?A%>VMK-=):-
M+X@D2-62YNYOFFR<#S%!/EJ2,E(T!Z55P/@ZY\!)I7['T'_!0&S_ &O/%3_$
M]KE+8S2>(@5>3[4$.G;67SBRP_.8RQ0HI.SRR&JW^V1\+]!^*/CG]GOXO^-]
M:OK.^^,5KIL?B[R;B**WM$$>G)YMMN0^3E;B1LR%P,+P,$'Z[M_^"97[%%MX
MO'C)/@O;F9;K[0+%]2N6M/,W9_U!DV;?^F>-F.-N.*[SXZ?LV?!?]I'P_:^&
MOC!X,CU2WL+@SZ?(L[P36[D88J\95@& &5SM)"D@E5PF-'RC^UWYOP6T_P"#
M'[('PZ^,VK>&_ >K:A=6&N>+%U9%N)$CN$BE@DFB557:99%?("990XPC4?!_
M1Y_V0/\ @H'X9_92^$7Q@U;Q#X/U[0IY]8\/ZUJ27#:9<^1<S9 C5$A<B&-S
MA0S1R?,#E&KZ.;]A[]F*7X.0_ :\^&,-QX9M[QKRUL[C4+AY8+AOO2I.9/,1
MCWVL 0<8QD&U\"OV._V>?V;+VZUGX1^ 4L=0O(?)N-0N+R6XF:+<#Y8:5FV*
M2%)"XW%1G.!B;A+<_/G]GO\ 9PF^,/[*WQ6^*&K?%;Q-I\?@N^OM4T;0]-O@
MEH]];V9F\^96!+,5"QJ5*L@!()W8'0?M(_$'QC\2/^"<OP5\9>-_$%SJ6J7/
MBJZBN=0NI"TTPAENX$9VZLVR-06))8Y))))/W1\/OV2_@E\,/AMXD^$O@[PW
M<6^A^+5N!KEO)J4TC3">'R9,.S%DRG'RD8[5CZW^PW^SMKWPCT'X'ZCX4NG\
M.^&;Z6[T:T_M6<-#+(\CL3('W/EI7X)(&:H1\S^+M N_VVOVZO&_P'^-WQ;U
MSP[X?\,PX\/>%=+ODMS>M'M(G"R*R.Q5GE+%&?:XVD*AQ];?LV^#M#\#_!_2
M=!\.?%N^\=64?FM;^)K[4UO&N09&&%D1F78F-@4$A0N.HK'^.7[%/[-W[0VO
M1^+/BA\.X[K55A$+:C9WDUM+)&.BOY3*),< %@2 , @<5V'PK^$?P^^"?@FU
M^'?PO\-Q:3I-FSM#;12.Y+,Q9G9W)9V)/5B3T'0 4 ?(_P#P25N[&PO/C'J.
MIW,4-O;^(K=YI[APJ1*#=$LS'@ #G)[5C_!2'PG\>_\ @I[\1O$G@".'5O!<
MWAN:RUZZMLM:7J/;V]M)'O'RLLDR.00<.(V<9&37ME[_ ,$N_P!C74M0FU2^
M^'=\\UQ,TLS?\)!=@,S-D])/4UZA\,O@I\+/V?O!\WAOX1> +?3K5$,KV]F-
MTUU(%."\DK;I'/0%WXZ9 Z%P/S_OOBMXG_8[^&'QE_8CO[N:XU.\U2.'P7))
M$9&N+2]"I.2<X4M:^6RJH^661^ISCLOVC_V9/BSX#^$/PI^!'@O5Y=2T^/3I
MY/%O@W1_%5OI^H:Q>,R33R1^;G[4JLVU3Y<IC55.TCD=9X*^'WQ=_;'_ &R?
M#_QY^+W[.=]X!T7P!8+$8=6F=I-1O(II);<HY2(NBO*L@*HT?[I@7;S,+]!?
M'3]D/X!?M'W]GJ_Q;\#+J%]80>1:7T-[-;RI#N+>63$R[EW,Q ;."S8QN- '
MPO>Z-\,_BC^P3XRM+'6?'D.L?#77H+M= \3:JEQ_9GFNMLMN&\M0T(43MA8X
M6$@.00H+>G?"'X(_#WX8_P#!.KQQ\0?!OB:^O-2\:?#F.[URVNKZ*2.UDC2X
M4+$J(K(N]ID.\L<QD9RK5]/^ ?V5O@/\,/AUJGPE\(?#VUAT'6TD76+6::65
M[P,NT[Y'8N<#IAAM_AP:YOP7^P+^R[\.K#7],\(^ 9[:/Q+I,NF:HS:Q=.SV
MCLI:)2TAVC*J<C!XZT ?/'[,/P9O/A[^R2O[:D?C+7-7\4Z+X(UAO#NEWEXK
M:?I<2>>JE8F4L=NUI&&X*2S?*3\Q\]N/!(M?V2A^W?!^UCXE;XC-<K;R-_PD
M VES=;#8%,>:6$1$FPML*C.SR_FK]"OAS\+_  ;\*/A]9_#'P9I9AT;3X9([
M6UN)FFPKNSL"SDEOF8]:\M'_  3F_8[3Q7_PEZ?""#S_ #O.:U;4+G[*7W;O
M]1YFPKG_ )9XV8XVXXH*1\U_'&X\4?'G]I+]G^?5O&5UX<U+Q7\/;&;4-4T>
M;R)HFG$S2^002(V<,RKU*^8.#C!U/@U:WGP _:T\:_LQ?#+XBZIXD\&_\(?>
M7-Y:ZA=K<?V;="WW,Q* (L@D/EL55<^8H8%D&.Q_;$_9[N_C5^VU\-]/UOX:
MZOJG@]M!:VUF\L;.=;6W^>Y8*\\8 B()3@L#R!WP?<_A/^R?\!_@=I.I:7\-
M? D5A_;%N8-2NFN))KB:,C!C\V1BRI_LJ0,@'&>: LS\_/A[\#KK4?V#]9_:
M03XG>);/4O"?B(-X>TNQU+R[*W;SK5&FV!=RSDROAU9?NIG.,5ZW\8)_&?A/
MPA\$?^"@EL]U>7VG:9I]IXXEA4L]S;NFWSGPNT%U::)G;',L0':OJ'2?V2/@
MAH?P6U#]G[3?#=POA;5+CS[RQ.I3%F??&^1)NWCYHTX![>]>4?M:Q_$/P7\*
M+7]D?X'_ +,6I>*-'UKP^-.M=;^T&2VTME<*JON5L.B@.))7C4,5(+;6 +ZC
MMH9?[(MO_P -%?M<_$#]K.ZD^T:-I%P=!\&MN9HG55"M.F[!0F(*VW&/],?N
M,U]9'I7G_P"S!\%;/]G[X(>'_A?%Y;75E:^9JD\>,37DAWS,#M!9=[%4)&=B
MJ#TKT ]*B7Q$LB3[M-?[U.3[M-?[U$1#'Z4T]*<_2FGI5 1TU^M.IK]: -;P
M%_R--O\ \#_] -?!/[1H'_"_O&F?^AFO>_\ TV:OO;P%_P C3;_\#_\ 0#7P
M3^T:1_PO[QIG_H9KWM_TV:OT#P^_Y&%;_ OS1\-QW_N-'_$_R.+POH/SHPOH
M/SHROJ/RHROJ/RK]8/S ,+Z#\Z,+Z#\Z,KZC\J,KZC\J #"^@_.C"^@_.C*^
MH_*C*^H_*@ POH/SHPOH/SHROJ/RHROJ/RH ,+Z#\Z,+Z#\Z,KZC\J,KZC\J
M #"^@_.C"^@_.C*^H_*C*^H_*@ POH/SHPOH/SHROJ/RHROJ/RH ,+Z#\Z#M
M S@?G1E?4?E78_!+X%^._CSXK7PSX.L@L,.UM1U292(+.,G&YCW8\[4&2V#V
M#$8U\11PM%U:LE&*W;-:-&MB*JITHMR>R1C> OA_XM^)OB:W\(>"=#FOKZX_
MU<<?W4'=W8\(@)&6) &1W(K[U_9D_9AT;]G/3X4?4VOM<U-2=8O(V98054D1
MQH?X5).&/S-DGY00J]/\"?@!X$^ 7A=="\)VOF74JJVI:I.H\Z[D'<_W%&?E
MC'"^[%F/77("ZI: #^*3_P! K\?XDXJJ9M?#T/=I+[Y>;[+R^\_5^'N&:>5Q
M5>O[U5_='T[OS^XN4445\:?6!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 4],_X_-0_Z_!_Z)CJY5/3/^/S4/\ K\'_ *)CJY0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $=W_QZR?\ 7-OY4W3O^0?!_P!<5_E3
MKO\ X]9/^N;?RING?\@^#_KBO\J )J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JGJ7_'_I_P#U]-_Z)DJY5/4O^/\ T_\ Z^F_]$R4 7**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JVG_(2N_\ >3_T$5:J
MK:?\A*[_ -Y/_015J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M +&B_P#(;LO^OJ/_ -"%</\ ''_DJ.J?]L?_ $1'7<:+_P ANR_Z^H__ $(5
MP_QQ_P"2HZI_VQ_]$1U/VB_^79\[?MZ_"KQA\:?V0_&WPY^'VD+?ZYJ&FQMI
MMDTRQ_:)(IXY?+#.0JLP0J"2!DC) K"F\':C\=_VB?A-\:/%7[/>KZ-IOAG0
M?$_^B^++6S,^FWDLNEK;2E()YE1G6*Y*')8!23M)&??4Z"ECFMS,;973S%C5
MF3(W;<D X],@U1!\9?$+X7?M):'XW\2:UH'P_P#%#:!??'/4M=NK[P7I^C76
MO) V@:?:6MQ8_P!J9AB1I1<QRN!YH0%1A'?-3]E;]G?X[^%/&WPKU'Q5\/->
MLK/0?C%XWU:\_MJ:R:>RT^^TRY2VDE%F1;AI)I<$0*(][L5 4YK[@"J3RM/"
MJ.BBID!X1^WO<^/+GP=X5\._#_X*>*O%UP/'6BZU=/X;AM76T@TW4[2[E63S
M[B(AY(U81A0P+*=Q08)P_C=^RWX4_:__ &B_AQXJ^-?P5O;[PA:_#G5);RRU
M:Y-O)INI37&G/#!-]FFXE"+< A7=,HW)P"?ICITII,<8RX4+R6)Z"B)43Y*T
M3]F>]_8N^+'Q.\;_ +&_[/>ZTN/@_8CP]I<=])+#J'B!+V_)C8S3%^(VM68!
ME!3H0Q)JK\,O@QX@^+7P-^*7PB\0_"3XGZ9X_P#B)X'NH]?^)GQ.L]/B@U"]
M\HQ0VT:6=Y.;:VB:9C';H@1(@_+.27^P8[NU-O\ ;A*GE>7O\S<-I7&<Y],5
M8B*2?.N#Z&J*/F>RU;]I#X\?$?X9W?C;]FG6?!MC\-9;O7_%K:M?V+KJ6L#2
MY[*WL]-:WN)6EA+7EPYEE6,;8H^C-MK+_8SF^*&N?%N/XE_M,?LX?$T?$?7[
M.>VNO$VKV.GQ^'_#5G@S?V=81QWTDD<),:*93&TLTFUG*CA?K)>6R?2I(P!T
M%!,CYEL+_P"*$G_!3&X^(#_LZ>-E\+R_#F/PBOBB2&R^Q_:8]0EN_M/%T9/L
MQ1E4-L\S?P8P.:]?_9O\2_#CQGX)U34?AC\+I/"VF0^+]7L;JSDTRWM5N[VW
MO)+>ZN0L#,L@>>.3YR=S$$L <UWT:(%VA!^52H!C.*"3X+^&OP$_:"B_8U^'
M_P  ?%?[+NLWEU\(?'UIJ7BK0M0U#3_L/C2Q6YO2T5FYN=MSY?GV]T([I88V
M>!4SGD8_[8'PU\=^/_"'Q>_:.UO]G_5_ _A3Q1H_@CP_-X)U"2PBU+Q3>P^)
M[=Y+ZX6UN&CB=8IA:1F27>RG):-54']$(^%P/7-9OC;P%X0^)7AQ_"?CG08-
M2TV6X@N);.Y!V-+!.D\+\$<K+&CCW44 >"_ CP;XI\;?M:V_Q[TO]F'4?A;X
M9T3X:S>&6BUY;""]UF=[NVD@C%M8S3HEO:PVK!)'<$FZ*H@523QGAS]G?XT6
MGCR+5;KX?7BV\?[9E_XN:4LF!HKZ#<VZ7OWO]6965,?>R>F.:^QXP /E7%34
M ?$?PE_8[\7>%/V(_AOX7E^"<=GXUTGXY:?XFU91;PK=P*GBC=+>M(#RPTT[
M=VXMY)V=/EKC-!_9"_:)T+Q GP9\4:%\4M0*_&$^+5\2:!I/@Z/1C*VL?:TU
MDWT\1U)+E(?OQ_-(WEFW5O)<8_1,<CD4*!NSBDBD2( , #_ZU2I]ZHEZU*GW
MJ9)*G6I$ZU&G6I$ZT 21_?7_ 'A7JU>4Q_?7_>%>K5G4Z&U'J%%%%9FP4444
M %%%% !7!>.?^1EF_P!U/_017>UP7CG_ )&6;_=3_P!!%73^(SJ?"8AZTU^M
M./6FOUK4YQIZ5'4AZ5'0 Q_O4Q^E/?[U,?I0 VHZDJ.@J(4C_=I:1_NU/VA2
MW&4QOO4^F-]ZJ$,?K3:<_6FT 1TQ_O4^F/\ >H :_P!VF4]_NTR@",]:;)3C
MUILE #3TJ.I#TJ.@J(Q_O4Q^E/?[U,?I04-J,]:DJ,]: $/WA2GI2'[PI3TJ
M);DR(D^[37^]3D^[37^]3B2,?I33TIS]*:>E4!'37ZTZFOUH UO )_XJFWQZ
M/_Z :^5_C3^QU^TCXM^+WB;Q1X>^'#7%CJ&NW5Q9S_VM9KYD;RLRG#2AAP>A
M -?5'@'_ )&FW^C_ /H!KT2O8R;.L5DE:56@DW)6UN^M^C1Y6;9/ALXI1IUF
MTHN^FGZ,_.O_ (89_:I_Z)8W_@ZL?_CU'_##/[5/_1+&_P#!U8__ !ZOT4HK
MZ'_7_./Y(?<__DCPO]1\J_GG]Z_R/SK_ .&&?VJ?^B6-_P"#JQ_^/4?\,,_M
M4_\ 1+&_\'5C_P#'J_12BC_7_./Y(?<__D@_U'RK^>?WK_(_.O\ X89_:I_Z
M)8W_ (.K'_X]1_PPS^U3_P!$L;_P=6/_ ,>K]%**/]?\X_DA]S_^2#_4?*OY
MY_>O\C\Z_P#AAG]JG_HEC?\ @ZL?_CU'_##/[5/_ $2QO_!U8_\ QZOT4HH_
MU_SC^2'W/_Y(/]1\J_GG]Z_R/SK_ .&&?VJ?^B6-_P"#JQ_^/4?\,,_M4_\
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M** "BBB@ HHHH **** "BBB@ HHHH *IZE_Q_P"G_P#7TW_HF2KE4]2_X_\
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M0!5*H"@'RD4H]2XGRS8>+OVIO^'19TD? GP9_P (S_PSZ\7]MGXDW'VP6/\
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M<OA+4=)'@.PGL?",OA7Q1J.BRZ;;S+$LL2R:?<0LRN((L[BV=ONV0F1XO?\
MPD^%WP=_8I\ ^"OVXM#U'QGJ6EW\Z:'X#L-4O-2;5+VYEGDM=(2$R[=1:WA9
M84>?<B" R9106'L'[#/PK^('P:_9UTKP3\2H_L>H?;;Z[M=!75GOUT"RGNI)
M;;2Q=/EKC[-$Z0^821E"%+(%-6_$O['OP/\ &FG^%[/Q-;^++F?P9-=R^&=8
M_P"%C:XFIV;W0*SG[>EX+J3>C%/GD;"'8N%^6NW^'7P\T#X9>'V\-^'-0URY
MMVN&F\SQ!XGO]6GW, "//OII9=O PF[:.< 9.0DZ!.E2I]VHDZ5*GW: 'ITJ
M:H4Z5,.E $@Z4#K0.E ZU,2HD@ZU*GWJB'6I4^]5$DJ=:D3K4:=:D3K0!)']
M]?\ >%>K5Y3']]?]X5ZM6=3H;4>H4445F;!1110 4444 %<%XY_Y&6;_ '4_
M]!%=[5>XTC2[N8SW6FV\CGJTD*DG\<549<K)E'F5CR\]::_6O3CX>T+_ * M
MG_X#+_A2?\([H)ZZ+:?^ R_X5?M$9^R/,#TJ.O4_^$<T#_H"6G_@,G^%)_PC
MF@_] 6S_ / 5/\*/:![(\J?[U,?I7K'_  C/A_OHEG_X"I_A1_PC/A[_ * =
MG_X"I_A1[0/9'DM1UZ]_PC/A[_H!V?\ X"I_A2?\(MX;_P"@!9?^ J?X4O:>
M0*F>19 ZFFL1MZUZ_P#\(MX;_P"@!9?^ J?X4?\ "+>&O^A?LO\ P%3_  I<
MP>S/'J8WWJ]C_P"$5\,_]"_8_P#@(G^%'_"*>&._ARQ_\!$_PI^T\@]EYGC,
MG!S3:]H/A/PN>OARQ_\  -/\*/\ A$O"_P#T+EC_ . :?X4>T\@]D>)TQ_O5
M[=_PB/A7_H6[#_P#3_"D_P"$0\*GKX:T_P#\ X_\*/:>0>R/$'^[3*]R_P"$
M/\*?]"UI_P#X!Q_X4?\ "'>$_P#H6=/_ / */_"CVGD'LCPD]:;)7O'_  AO
MA+_H6-/_ / */_"C_A#/"/\ T*^G?^ ,?^%/V@>R/!3TJ.O?/^$+\(_]"OIO
M_@#'_A2_\(7X1'_,K:;_ . ,?^%+VGD-4SY_?[U,?I7T$?!7A _\RMIO_@#'
M_A1_PA/A#OX5TW_P C_PH]IY#]F?/=1GK7T1_P (3X._Z%33?_ "/_XFC_A"
M/!O_ $*>F?\ @OC_ /B:/:>0>S/G<]<TTL,=:^BO^$'\&'KX2TO_ ,%\7_Q-
M'_"#>"_^A1TO_P %\7_Q-+F)]GYGSFHP,4Q_O5]'?\(+X*_Z%#2__!?%_P#$
MTG_"">"_^A1TO_P7Q_X4U*P>R/F]^E-/3%?27_"">"N_@_2C]=.C_P */^$#
M\$?]";I/_@MB_P#B:?M ]D?---?K7TO_ ,(#X'_Z$W2?_!;%_P#$T?\ " ^!
M_P#H3=)_\%L7_P 32]IY![+S/G[P"/\ BJ;?_=?_ - ->B5Z!;^"/!UI,+BU
M\*:;'(.CQV$:D?B!5G^P=#_Z UK_ . Z_P"%/V@>R/-J*])_L'0_^@-:_P#@
M.O\ A1_8.A_] :U_\!U_PH]H'LCS:BO2?[!T/_H#6O\ X#K_ (4?V#H?_0&M
M?_ =?\*/:![(\VHKTG^P=#_Z UK_ . Z_P"%']@Z'_T!K7_P'7_"CV@>R/-J
M*])_L'0_^@-:_P#@.O\ A1_8.A_] :U_\!U_PH]H'LCS:BO2?[!T/_H#6O\
MX#K_ (4?V#H?_0&M?_ =?\*/:![(\VHKTG^P=#_Z UK_ . Z_P"%']@Z'_T!
MK7_P'7_"CV@>R/-J*])_L'0_^@-:_P#@.O\ A1_8.A_] :U_\!U_PH]H'LCS
M:BO2?[!T/_H#6O\ X#K_ (4?V#H?_0&M?_ =?\*/:![(\VJG=G&JVO\ O2?^
M@5ZK_8.A_P#0&M?_  '7_"F/X;T!V5SHEGN7[K?94R/TH]H'LCSFBO2?[ T/
M_H#6O_@.O^%']@Z'_P! :U_\!U_PH]H'LCS:BO2?[!T/_H#6O_@.O^%']@Z'
M_P! :U_\!U_PH]H'LCS:BO2?[!T/_H#6O_@.O^%']@Z'_P! :U_\!U_PH]H'
MLCS:BO2?[!T/_H#6O_@.O^%']@Z'_P! :U_\!U_PH]H'LCS:BO2?[!T/_H#6
MO_@.O^%']@Z'_P! :U_\!U_PH]H'LCS:BO2?[!T/_H#6O_@.O^%']@Z'_P!
M:U_\!U_PH]H'LCS:BO2?[!T/_H#6O_@.O^%']@Z'_P! :U_\!U_PH]H'LCS:
MBO2?[!T/_H#6O_@.O^%']@Z'_P! :U_\!U_PH]H'LCS:BO2?[!T/_H#6O_@.
MO^%']@Z'_P! :U_\!U_PH]H'LCRK2SF\U#_K\'_HF.KE>C1^&_#\19DT.S!=
MLL1;*,G &3QZ 4_^P=#_ .@-:_\ @.O^%+VGD'LCS:BO2?[!T/\ Z UK_P"
MZ_X4?V#H?_0&M?\ P'7_  I^T#V1YM17I/\ 8.A_] :U_P# =?\ "C^P=#_Z
M UK_ . Z_P"%'M ]D>;45Z3_ &#H?_0&M?\ P'7_  H_L'0_^@-:_P#@.O\
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M_8.A_P#0&M?_  '7_"CV@>R/-J*])_L'0_\ H#6O_@.O^%']@Z'_ - :U_\
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M UK_ . Z_P"%'M ]D>;45Z3_ &#H?_0&M?\ P'7_  H_L'0_^@-:_P#@.O\
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M_H!V?_@*G^%'_",^'^VB6?\ X"I_A1[3R#V1Y>G6I$ZUZ9_PCF@_] 6S_P#
M5/\ "E_X1S0!TT6T_P# 9?\ "G[1![(\VC^^O^\*]6!SS5,>']"'(T6U_P#
M=?\ "KE1*7,5"/*%%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%!('4T %% ((R#1N'K0 444$@=
M30 44 @]#1G')H ** <]** "B@L!U-)O7&=PH 6B@$'D&B@ HHI-Z#JP_.@!
M:* <\BB@ HHH) &2: "B@,K?=;-% !102!R32;T_O#\Z %HHH+!1N8XH **-
MPQG-&<]* "BBB@ HHHH ***,CIF@ HHS10 4444 %% (/0T4 %%%% !1106
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M>^-6D:+KNHS&WCN;F/1-(GW2:FT$4JJPEDM/-F62"$RNA%:7[0/_  6F\%?
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M5"66+3/^"JKZE^R[^S;^TI_PHQ8Q^T)\3-%\(_V,?$Q/]@?V@MX?M/G?9?\
M2O+^R8\O9%N\S[Z[>=[3?^";>JZC^U!X9_:/^,'[6GC+QU'X&UZ\UCP5H.L>
M']!M9--N;FWN+=HWU"RT^&]GMECNI MNTPC.V(2"01@5Q'AK_@C)I7AF\^'/
MAW_AL;XB7_P_^$/Q*M?&'PW^'.H6>EM9:1+#//,+<W"6JW=RB_:)(HC+,WE1
M,4 /RLI[@O?*GB+_ (*Y?&/PWX.^(7Q[O/V&+IOA/\)_B9K7A3QUXN7Q[";\
M6^FZK-8SZI8Z=]E_TN!$C2656FA=&:2.,3B)I#M?$W_@II^T'X8U3XVZC\,O
MV$YO%GA7X"Z[):^,->'Q$@LYM0M8],LM1F;3[5K5VN+J*&Z=WMY&B0HD7ESR
MR2F&/AO@U_P3*^+'QT\)_$SP+^TA^T/\0M%^&'BKX\>,]6U+X.VNEZ3:VFM:
M?)XHNKVW9KX69U 6EW'Y3O&EPI>.1E#*C[!<TG_@GI\?OCQ\5/VEO#_C/]IK
MXA?#KX;_ !#^*-Q'J7@_0="T;R?%.DS>&]'M)KB*]NK*:ZM_,*3VS-%(!B [
M0C;G8_=A[YSVG_\ !3OPQ\&?C1^TU^TYKWC'6O$G@&'PO\*;OX<^&K[Q'%96
MHFURSN1%Y37\T=KIZ2O+#+<3,R*D<32/N\L Z%W_ ,%[? FA?"CXI>)M2^'?
M@KQ)XJ^&>@:/KW]A_"OXR67B?3M:TV^U*'3V,%_;VZM'<P2R@26\MNIR\.QG
M242#V'7/^"37[/>O#XE::-6UC3-+\?:/X.L=+L]%F2"3PH_AE&&EW-A*RN1+
M&YC?]X'4^4%971G5LO5_^"5^J^/O@GXV^$/QK_:_\6>+W\91Z9!_:,WA/0-,
M338++4([Y!##IUC;J9))(PLDCEMRA  -BFC]V'[PQ1_P4J_;+;]HC_ACT_\
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M] 44+D#!HJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBOD'_@J)^T5_P47_ &=M/C\=?LC>#_@E8^!M"\*W^L^.?'GQ
MG\07<-M;30L@AL(H+62*02RAB8Y"71VRC>20AF<5S.PF['U]17A/_!,S]J_Q
MM^W#^PM\./VIOB-\.E\*ZYXNT1Y]2T>)7$(DCN)8#/")"66"<1">)6+$1S(-
M[XWMR/[5G[0_[0_C#]JK0?\ @G[^R!XE\/\ A3Q9J'@.Y\9^,_B!XGT&358_
M#^B_:&LK5;.R$L,=U>3W8?!EE$<45M(S)*710^5\U@N?4F:*^:_ 7CW]J/\
M8]\&WUS^W=\8?#/Q$T/^W/#VC>%?&WA?PG)I&JWM]JNIII_E7VGB62W14GN;
M7;-!(N8V?=$&3+]5^T!^WG\#OV:IO'T'Q*76 WPW^'MCXT\1_P!GZ>)A_9EW
M=WEI#Y7SC?+YMC/E.,+M.3G 7*+F/:J*^4=:_P""P?[->AZ9H.I7?PR^+^[Q
MA?ZM:^!=-_X5+JJZCXI^P6EI=--I]BT2W4\,T=Y'Y4OE!#Y<S.8TA=Q8\0_\
M%?/V5O"WBS_A'-;\.?$B/3]->W@\<>+H_AKJ4NA>"+R6V@N?L6LZA'$T%E/&
MES )EW,+=I,3&/:Q#Y9=@YHGU-17RW\</^"NG[+/P ^)?C3X7^,= ^(NHW7P
MWO;1/B%J7A7X<:CJUAX;L[C3X=034;VXM8W2"U\F;EF.\M#-A"(RU<GXA_X*
MI^*-!_X*OV_[!=O^SYXSU;PG=^ =.O[?Q)H?P_O;IO[1N[^.-;\W22^2-%2"
M55DNO+PEQ'*A?Y"M'+(.:)]H45\@_M:?\%._$G[,7[=/PZ_9=M_V:_B)XHT3
MQ1X4U;4M9U#PG\.;[5)Y)HI;)+;[%)#($>*+SIS=Y1C$)+0Y7S/FF^*'_!4O
MX/Z[?_%;X$?"V+XC:=XJ\ V/B*P\0>.-/^%MQJ>D>$KRQT>2_2]N)R5M'!"D
M0P22JTTL8C9461'8Y6'-$^N**^5-<_X*9?#3]G[X4?#_ %;XJ>%OBYXSM]4^
M'>F^(?$GQ%\+_!?4KC2[&SDM5D?4K][..2&S#!99G@C>5H54Y&W86ZK]G[]H
MGQ=\4_VY?C)\*X_%UEJG@GPWX!\"ZUX0-C'"T9;51K+3S+.@S,DBVEL5RS*
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M [X>:#X^U&:]^(EU\"?!_CCQ;>#3T@MKC^V(;A5>/R\*K&>RNB8PJJHV8X.
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M3XD?P!H'B[0=>\&WD=KXN\$>.?"MSH^N:1)-")[<S6<X#A9H3YD3C*N.AR&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5^>O_  6"_P""=/[?W[<G[0OPS\6_
M K7/@WKGPU\ VKZA=?#/XQZAJRZ5JVNLTJK=7=KI\!^V1QQ&+RUDEVAO-4H4
MED63]"J*J,G%W1,H\RLSY8^'?PY_X*L_\)%\ ]3^(7Q,^$.@:3X=;Q#'\>O"
MOP_L[C^S]9MW0)HD>E_;;22>+R H:4>;;C+$#S%"J-/]JS]D?XW:S^T3X9_;
M=_8V\9>&-)^)N@>&)_"^MZ/XXMIWT?Q7H,EPMRME<2V^9K.2&X#30W$22%6D
M=7CD1RM?2E<SJ7QB^'6D?%W2?@/J'B'R_%>N^'[[6]+TK[',?.L+.:U@N)O-
M">6NR2]MEVLP9O,RH8*Q4YF'*?-?Q9_9?_X*%_M(_ 7Q?I?QA^,7PSTOQ9<:
MSX8UGX>>%?#^C7=QH.B7NB:Q'JJ_:[R7R[R]^UR0PPRNL<*PQQ*8X2Y<R>;?
M'7_@G;^WQ^U#X;_:"UCXP^+_ (56?B'XO?!/1_!GAG3-!U#46L="FL[[49VC
MFN);7S)XF^V>:)UB1MTCQ^2!$LLOZ!UB_$+XC> /A+X0O/B#\4?&^D>&]!T\
M(=0UK7M3AL[2V#.$4R33,J)EV51N(RS #DBA28<J9Y/\<?V9?&OQ*_;-^!7[
M16@:AI$>B_#"U\51ZY:WD\HNIFU*QM[>#[.JQLK;6B;?O=,*1C<<@?&OQR_X
M(1>+O%?Q[^)WB/P?IG@3Q/X3^+/BZZ\0W]UXX\?>,-.NO#TUXJ?;;4:;HM[;
MV>K6[N)'3S)+651*8Y))E12/T6UCXO\ P]T'XI:'\%=5UUHO$WB31M1U71=+
M^RRM]IL["2TCNI/,"F--CWUJ-KLK-YN5#!7*ZOB[Q7H/@3PIJGC?Q3??9=+T
M;3YK[4KGRGD\FWB0R2/M0%FPJDX4$G' )H4I1#EBSYF\3_L*_$74/AY^UQX-
MT'4_#\,GQWTUK/P2\UY/MLU_X0ZPT-!>L8F9 +FUD?Y/./E,K<N608Z_L4_M
M6_#3]KGX8_M0_!?Q)X!ODTKX(Z;\-/'VC^)I[R+R+2WU"&\>^T]X8F^T2L!-
M$L4WDJ,HY8\I7HWP#_X*9?LB?M.^)M"\*?!7Q%XTU2;Q-:&ZT.^O/A'XET_3
M[J 6[7 E%]=Z?%:JC1*61FE <E54LS*#RO@K_@M1_P $U?'>GZ;K^F_M"W>G
M:)K%QY&F^*?%'@/7=%T6>7>8]@U*_LH;0'>K+@RCE6_NG#O+L+W36_;*_9W_
M &I?&7[0/PI_:>_9+UGP#_PD'@'2_$6C:AH_Q#:]CL[FSU9+$FXCDLU=_-@D
MT^)A"5595D=?-B(#5@^"?V'_ (P>'O@C^U=\-M2USPVVH_'3QMXGUGPG-;WD
MYAM(=2T*RT^%;LF$-&ZS6[LXC$H"%2"S94>G_M(?MX?LK?LFZMIOASXY_$N6
MQU;5K.:\T_0]'\/W^L:A):Q?ZRY-II\$\Z0*>#,R",'(+9%=]\*?BM\-OCE\
M.])^+?P@\::?XB\-Z]:"YTC6M+N!+!=1$D95AW!!4@X*L"I (("]Y(=HW/SB
M_:(_X(P_M.?%C13X?N-.^"'CQ;KX'Z'X,TB^^*$FJ3-\/[ZRTUK:XGT>"&!H
MYEN)B)_/?R)HW"DB556*OJ+]A/\ 8P^*G[,?Q1\1>./B#KN@7=KJ_P '?AWX
M3MX]'NII)%O=!M=2AO)&$D* 0NUY$8F!+,%?<L9 !^G*,8Z"CFE:P<L4?G[K
MO_!-7]LSXI?"/Q#^PM\3/$GPML/@AXC^*VI>*=:\1:3>:E=>)K_3[CQ-)KXT
M]+9X8K:SE,C+";GSK@*BEA$S$;>'^-O_  0D\7^)OCW\3?$7@W3O OBCPG\6
M/%]UXAU"\\=^/_&&G77A^6]"_;K4:;HE[;V>K6[N)'C\Q[251*8Y))E137Z)
M^-_C%\./AUXR\(_#_P 9>(/L>K^/-7GTOPI:_8YI/MUU#97%[)'N1"L6+>UG
MDW2%5.S:"695/3X[8HYI(.2)\3_$_P#X)L?&+QA\:+[QWH7B#PK'I$W[4'@C
MXC6EM>7UR9DTC1?#MEID\+?N&'VHS6K-&NXHR%2TB-E16_;._8V\6#7OV@OV
MH=;^+OA_PCI>I:'\/M>\*ZQ=:;=:E_9VH^$=0OM49[^SB16EMI'DMTVPN\C+
MYA"AE17^X:PS\2?AX_Q _P"%3'QKI!\4KHXU9O#7]I0_V@M@93"+O[/N\SR#
M*#'YNW9O!7.>*.:0<L3\]O\ @G;\7OC#^UU_P56\3?M&^)?$OP\\3:#H/[/M
MOX9G\0?!^\O-0\-VVH2ZT;I;6/4;N*(WETT:O+(L:!($,49+.'9O9? W[)O[
M='[+OQC^(-M^RGXK^%&H?#_XI?$ZX\;ZI>?$"VU'^V/#EY>^1_:$,,-GMAU.
M)O)+0[YK1X3)M9IE09^OA'&.1&O_ 'S3O?%'-V#E[GPGXL_X)[?MPCX5>/?V
M&?A]\5/AK!\#_B)KNOW%UXBU*PO6\4:#IFM7MS>:AIT%OAK:[?S+N=8KR69&
MC60%HI"@KT#Q+^PK\4M5^!'[7WPMT[7?#R7WQ\N-9;P3/+>3^59I=^$K#1HA
M>MY):,BXM9';RQ+B-E8;F)0>_?"?XZ_"OXXR^*(?A=XI_M1O!GBV[\,^)!]A
MGA^QZK;"-I[?]ZB^9M$J?.FY#NX8X..NHYI!RH^*8?V&/VT/@I\<?&7Q)_9>
M\=?#5['XN^#O#^E^//\ A.(;U[C0-0TK3O[/CO=.%L@%]$T&";:=H,2)N$JA
MV0XOP;_8*_;]_9CLOA^WP'^(/PK-XO[.OA?X9^/+CQ"-0D_LB\T;[6T6JZ;Y
M4:_;D)U"X!MIQ;%O*B/FIN91]X48'7%'-(.2)\$_"?\ X)Q?M@_LLZ%\#_BS
M^S]XG^&NK_$CX>? V'X9>-?#_B^\OX=%U6P6>"Z6XL[ZW@:XMIH[B)OOVTB3
M1R8*QLBM7=?'3]E[]OSQKXW^!G[3O@SQI\(;SXI?#72/$FF^)],U2QU2Q\/W
MD>LQ6JM+;%'N+D&V:RAQ&Y N TA+V^0%^O**.:0<J/R\\(?\$%O$OA#XJ+X9
MNO#'P_\ $/P]'Q ;Q%#XBUCXD>-8-6M[-]1-_P#8/['M+^+39)HG.R*\$D2G
M9'+):O('+]_\9_\ @FW^W1!\-_VCOV:?V;OB'\*Q\/\ X^:MX@\1?VMXRCU!
M=9T?4M6M@MW8[+:,PS6SRI^[N6;S;=)&S%<E%%?H)UZBCWQ1SR#DB?/?[;'[
M/_[0GQ6\/?";Q)^SL?!\GBGX7_$JV\3KIWC;4KJUT_4(DTC4M.D@,]K!-)&W
M_$PWJWEL/W?/6OEG]K7]G_3/@?\ LP?M _M%_MX?&?2=)^+/QP_LD>%+?X:P
MW)CT?6]!M9I_#=EH_G-'<7VH+=(TWFL8/M$CB-4A4 '[[^+7QU^%GP.?PTGQ
M0\2_V:?&'BNS\->'?]!GF^UZI=;_ "+?]TC>7N\M_G?:@Q\S#BK/PN^+/P[^
M-.A7WB7X;ZX-2LM-\1:GH5]-]CEA\N_T^\ELKR'$J*3Y=Q!*FX HVW<K,I#$
M4I(.5'E_[!7P%\9_!7]E;3=-^)MC;Q_$#QC->>*_B3+#&JJ_B'597N[R/(9M
MT<#RBUC)9B(;6)<G:*^8_@O_ ,$Z?^"@5_\  /X%_LE_M 0_ O1_"?P7UOPW
MJ<?C#POJ6J:SK]R^CW$4\:V:W-E:1Z>\_D^5).'E(BED0(VXU^B73@"BCF=[
MARJUCX,;_@F+^TMX+^,NI?M8_"?QWX)_X6#HOQT\7>+O!NC^()+J31]3T/7M
M-T^RN;&^DBA$]G=@V*2)/")DC*X9)A(0GGG[7/[*?[0_PI\ ZE^U!\0?$/@N
MY^-7Q>_:3^$[+I^DQW9\-:,-,UJUMM*L][[;FZ17DDDGN=L3R^:0D481!7Z;
M48!ZBCG8<B/SQ_:1_P""8O[9O[9GACXL?$_XY>+OA?HOQ&\8_#G2_ W@WP_X
M3O-0DT72]+M];CU6>:\OI[87%U<32)M4);1I$J!0'+O)7O?[3O[,G[13_M,^
M&?VTOV/]2\#W'C#2_!=[X.U_PS\1IKRWT_4](N+N"\62&[LTEDM+F*>#.3!,
MDJ2,I"%4<?1>IZC9:/IT^J:A+Y=O;0M+/)M)VHHR3@<G ';FO,OA/^VM^S-\
M;O&WA_X<?##XD'4M9\4?#.S^(.@V9T:\@^U>'+J;R8+[=+"JIND(7R7*S+G+
M1@<T<T@Y8GQ9)\.U^#O[2OP0_9_^('QIT/QA\=O&G[3=Y\7/B-HOAK37M[72
M[%O"FKV'F01?,T-E D5C:I+.WF3R$NV7<A<O]G+_ ((0>*/V>_BQX+T:UTOP
M+X@\%> _'%IKVB^,]?\ B!XQDUJ2"TO1>6MN^BP7T.DK=1NJ 7:GR"8P[6+9
M9#^E/C+Q?X.^'OA74/'?C_Q-INB:+I%G)=ZKK&L7D=M:V5NB[GEEED(2-%4$
MEF(  R36BA5ERHXI^TET%R1/D?X'_LN?MS?LN>._CY'\'-:^%FJ>'?B/XK\0
M>._!-[XFGU%;RV\17]G;);V-[!!$$&GQSVY9YHI7F='PJ(1S]1> AX]/@+1A
M\4_[)_X2;^R;;_A(O[ \W[#]N\I?/^S>;^\\GS=^S?\ -MV[N<UD>!_CQ\*?
MB/\ $WQM\'/!GBG[9XD^'=W8VWC+3?L,\?\ 9\MY:)>6R^8Z+'+O@D1\Q,X7
M.&(8$5U]0W<M+E/CCX=_\$P]1TG_ (*'?%?]I?X@ZQX=U;X9>,]#OHO#7@-;
M',EKJ.LV>DVNO7,Y,8"^>FB6H4H[%Q=7.X)G+^,^!O\ @AG\6IO^"<MY^R[\
M8/C;H6J?$2U^)&D^*-#\16ZWJ:;-%HMC9:3I=C<FV:UNTB?3+&.*5H)4EBDG
M>2.5R@+?I;C'048'I5^TD3R1/D#_ ()L_P#!/7Q%^R1XP\8?%7Q]\._!/AW6
MO$NFV.FPVGA'X@>*?$K):6[S2'S[W7KD[P9)=R1Q6T/E9DR\N_Y?GSX*?LX?
MMF?M8_!W]H/]F7PAXB^&?ASX2^//VBOB)8^*/%,D=[-XE@M)/$%U'>6\%J4^
MRR22("J7+RKY2L!Y+E Q_2KXA^//"7PJ\ ZY\3_'NJ?8="\-Z/=:IK5]]G>7
M[/:6\32S2;(U9WVHC':JECC !.!3O OC/PQ\1_!6D?$+P7?_ &O1]>TVWU'2
M;OR7C\^VFC66*38X#+N1E.& 89P0#Q2YGJPY5L?%O[2O_!-'X_?%.T^) \(:
MSX'U*Q\5?'[1O'*>"?%6JZE#I/B?1K3PQ8Z1)I&K/:)O13<VYN@H2YB8VT'F
M(P9E3GO@I_P25^,OPYT'1='N=)^$6@6FG_M;Z9\51X=\"V]W::78:3;^'H=/
M-I;Q20L3=+<QEP2523_79A9_)3]"<#TKC[?X]?"FY^.UU^S1%XG/_";67A.#
MQ-<:*;&<;=*FNIK6.X\[9Y)W302IL#^8-F2H4@DYI!RQ/-_@;^S#X_\ AC^V
MY\=OVE-:U71Y-#^*%CX3AT&TM+B5KNW;2[.Z@N/M"M&J*&:="FQWR =VW !^
M?)O^"8W[6T#_ !4^'&@_$WX=VWAC7OCA-\8OAOXHNK.^GU33_$O]JV6I0V5[
M8@I!)9(]O<0LZSM)(LR.J1-'@_8O[0_[1/P>_92^$&L?'KX^>+O[!\)Z"L!U
M;5O[/N+KR!-<1V\?[JWCDE;,LL:_*AQNR< $C>TCX@^!=?\ %FJ> M$\8Z7>
M:YH<-O-K>BVNH127>GQW <P//"K%XED$4A0L '\MMN=IP*4@Y4?/_P"SY^SM
M^USK_P"T\O[7'[9OB+P#9ZMHO@6Z\*>$_!WPT:ZN;&W@N[JTNKR]N+R\AAFF
MFD>QMD2$1K'"BMS(SEQP?Q<_X)S?&_Q[^T3X_P#BYI/B?PK%IOBKX\?"[QKI
M\-Q>W(GCT_PV+/[=%(%@*B=_L[^2H9D;*[WCYQ]J4=>HHYF'+$^/OVV?^"?_
M ,8_VCOBEXX\:^ _$7AJUL_$WA/X;Z98QZM?7$<D<WA_QG=:Y>,X2!P%>VF1
M(B"Q:4$.(U <Z#?LE?M:>$?VN?C1X^^'WB#X>WGPW^.%K9W6NIK4E]#K>DWU
MKX?&DI! L:/!+"[P6LS3.ZLB^:@B<E9%^L<#TH_"CF8<J/S.\<_\$;OVD?%'
MA'X;>"O$.E_!'X@67AS]GGP[X N+7XF-JMY9^#=6T^U:*YU;1[.*-8;TW!=<
MM.+:<"VB E56>.O7?"'[#G[8?P+_ .&=?&GP.USX;WWB;X;_  %B^%_CZW\6
M7U^+!K<KI#O?Z>UO!YD\B3::^(IA")4E7+0L":^U*,#THYY!R1/R]\!?\$$_
M$7P_^+-OX;D\/> /$7P\L_B%_P )#8^)=9^(OC6#6(;(ZC]O6Q;1[._BTR2X
MB?"1WBO&AV))):NX??[I_P %!_\ @GO\8?VJ/V@?#/Q6T/PQ\)_B!X:TKPC<
M:-_P@/QH74)-*T>_EN!+_;EO;VJO'=W!CQ"T,HB.R-=EQ'N;/V=11SRO<.2-
MK'QK\/?^">OQI\(?\$4KS_@F_>>(?"S^-Y_A/JWA==3M[RX_LD7=TMP(W,A@
M$PB!E7)\HL.<*<#/>?%+_@GG\%[/]C#XM?L^_LJ_ ?X;_#WQ#\1OAAK'AQ;S
M0?#-MI-K-=W6G2VT3W3V<&]HUDD!+;'8*"0I/!^COPHHYF'*CY=^.7[$_P 7
MOB7\4_A#XR\!_$/3O"\/P_\ A=XO\,7>K6;2?;;*\U6PT^VM+NRC"!'$,EH\
MA#O&1B/ ;)V_-_[*_P#P1X_:.^"/[1_PS^--W\/_ -GGPV? G@_7]'UW6/"L
M>K7VJ>+[Z\T];>+4]3:ZCC-UNF!DDMVF#())<7$OF )^F6/:C SG%'-)!RQ/
MSC^#W_!''XRW&@?$GX=?$JY^'WPM\&^/OAGK7AC4O"/P5\1:]>Z/J.I7Q@\K
M6AININMKI36WDN8[6T4[OM,BR3NH /0?L*_\$G?'O[/_ .T[H/QT^*W@/X<6
MK>#M+O(-&UKPY\2/&^M7VH75S"UN\_V;5]0:TT]#$S[H2MZQ+#;*A0,?OS'M
M1@>E'/(.2)\L_MN_!3_@HC^T'I'CO]GOX6:_\%[7X8_$/PO+H4VN>(;+5/[=
M\/V]U;&WOF%LA>VU-V5Y&A)DLUC+*'68(2_1?M%?L4:M\1_V2?"OP"^%?CU-
M/\1?#?4/#>K^ O$7B:W>^A_M+0[BWGMFO8TDC:>.7[.8Y<,"/-9U&Y5%?0E%
M',PY4?'OC?\ 9K_X*&_M(2_#?6OVB[_X-:/)X#^-WA[Q;#H_@F[U:=5L+*VO
M8[PF[NHE-Q/+)<PF*$6\"1+&X::4L-M+X0?\$[/C)X"^/'PB^)_B'7_"MQ8_
M#_X@_%?7]3CM[NX:9X?$^HSW%@( T"@RQQ2[9MS(%.0C2CD_9]&/:CF8<J/B
M*R_X)L_'2U^(DGBL^*?"?V5_VUV^,"QK?7/F#0SX>&F_9_\ CWQ]L\_+;,^5
MY?/F[OEJ_P#LM_L<?M\_LA^$K/\ 9"^%'Q'^%?\ PIW2-8U2;1/&E_9:@_BN
MUTZ]N;F[^R&S3;92744UR56^,P1EC#-:,Q-?9U%'-(.5'YL_L:?\$@/VAO@+
M^TM\&?C;X[\*? ZSG^&,FJQ>*O&?A>;5;KQ/X\:ZTB[LQJ-]<WD0VS---'(]
ML6D0&20I,%CCB/O6C_L ^.=3_P"".EK_ ,$X/&'C+2[7Q+_PIE/"5UKFEM)-
M8QWZ6?E+,IDC21X1*%)RBL4S@*3Q]64=.@H<I,%&*/EGPY^SK^V;\3/VC_@G
M^TK^TRWPPL=2^'5CXNM=;TOP/J&H3PA-3MM.BMC;O=0(TS;K6X:1F$(198T4
M2E6=O/OVJ_\ @FK^T)\:=6^*>N^$O$/@F^L?&7QP\.^-%\#^*-4U&'2_%&DV
M'ABTTB;1]7>T3?'&US!]J4*EU$QMH!)&VYE3[GHHYI!RH_/'X+?\$F/CG\-;
M#3;.+3_A'X9M;/\ :OT?XH+X=\ Q7EIIEAH]MH45A+9V\4D!)NO.1FR2L<V6
ME)A+^0GJO[:'[!_QD_:*^+'Q(\?^"?$'ANVM?&'[)GB7X8:9%JEY/')'J^HS
MB2&:41P.%M0/ONI:0'I&W6OKG'?%'X4<TKW#EC:Q\_\ BG]E3QYK'[4/P!^-
M6EW^BPZ/\*?"'B32=<LVFD6>:74+73H8#;*(BK(IM)-V]HR 4P&R0/+?VDOV
M5OV[_''[=B?M,>$? 7P5\?\ A;POHMC#\+=!^)'C;6-/_P"$:U$>:U]J2VMM
MIMU!)=RLT2)<$^9%' %3;O?/VE11S,.72Q\T^#?V4_CC-_P4GTO]NCQ_=^%+
M;3V_9NA\#ZSH^D:E<S31:X=874)GA\RW17LPNY5D9DE8XS$HY'$_M*?L4?MK
M:WXG_:>^(_[*7Q:\+^%_$WQB\&^"]$\"ZQ>:I<V\VE?V=+?)J4DLD=K*;9WM
MKUQ;RQ"5UD^;]T55J^S*.O44<S#E1\5> ?\ @GY\5_'7[$'CC]@#XS_!3X1_
M#+P1J_AC[%X5N/A3XMU36+BWU$OYHU"Z^W65HTLR3I!<&1I9))I%;S&R=QU?
M G[)7[;OQ0_:1\&_M1?ME^)/A9_;?P@\*ZUIWPTTOP#_ &D]MJ&JZG!#!<:M
M?O<K&T"&& 1K91K,$\Z1OM#E5%?8%%',PY4?%/\ P3D_99_;X_9?UUH/CS\/
MO@OJEUXNNI-0^+7Q5T?Q]JU_XE\2:CY,GE3&*?2+>$0I(5CBMA*D5M 2L:D@
MA^P^'OP:_;OL/^"E'B3]I7QMX6^$\/PYUWPC9^$U.E^,-3FUJ/3]/O-7O+.Z
M^SOIR0>?*^HQI+%Y^V-48H\AP#]348'I1S,.4^/?VZ/^"?GQE_::^)_Q3\:^
M _$GAFUM?''[+&I_#328]6O;B.2'5KF^DG2>41P.%M0C@,ZEI <XC(YKU'QU
M^S5XX\2_MA_!GX_Z7J&DQ:'\.?!?BK1]9M))Y!<3S:G_ &1Y#0((RC(OV";>
M6="-Z;0V6V^XT8'I2YF'*C\\?"^E?MT:C_P4>_:XT_\ 8^NOA7I\.I:OX0M=
M7U_QTM\UYI$O_",VOEW-O!;HT=\%5F(@E> !N2[!BH[3PC_P3]_:V_9/\9>#
MKG]B[XB_#^^TFP^ ^A_#+7IOB+;7T=S9G29[V:VUBV2TW+=,QU"??9.\"_NX
M]MPH)Q]L[5'1>M+3YF'*CXW_ &&?^">OQE_9EUWX#ZCX[\1>&;N'X6_L]:MX
M#US^Q[VX=KC4;K4])NHYK<20(&@$=A,&9RCAG0!""2O+Z)_P36_:0L?V^;7]
MIOPT/AA\.=+C\=W.M^)O$?PQUC7;/4/&NG/Y^--U317?^S6EE,L;SWY>29Y(
M%D18R<+]X4?A1S2#E1^<_A[_ ()?_MW>#_A_\+?V3O#GQ&^%\?PC^#OQXT?Q
MKH&H23:@=?US2;77SJ1LKM/(^SP31)+)AXV<3R1Q _9UWENF\>_\$QOVC=3^
M%>L1>"_&W@U?%VF?MB3_ !K\&VVI75U_9U[;B[,D6GWLJ0&2V=HW<,\4<P1@
MN-X)(^\J/PHYY!R1/G/]JC]E+XU_M3? ;X=W=_XS\,^'OBY\-_&6D^-]%N;>
MSFN_#TFN6<<L;VTT;[;A[*2.XN(]RM',A9)!DIL;Q;XP_P#!-O\ :R_:HT/X
MT?&#]H#Q#\.=+^*'CKX#WGPO\"Z#X2U#4)=#T>QGF:ZEGO+VX@6>ZEFN?).5
MMHU@CAVJLK.[G[UHHYF'*CY(_P""Z(<_\$C/CHLAVLW@[C/;_28:YSQK^P'^
MU3^V[XUF\1_M\>)OA[H.EZ3\+_%/@[POIGPDFO[F>63Q!9QV=]J=Q<7\<8C*
M01XBM%BE56<L\TFU5K[:*J3DK0 %&%%',TK(.5'YI_L[_P#!#OQ7X6\;V=O\
M9_#WP^BT?1_">LZ)'XLT#X@>-=4UC4CJ&E7.EO<PV6IZB;#2'\BZEW#;?*=Q
M6/R?E=/2/A)^Q'_P4%TP_L\_#GXN>-_A!-X+_9[\56LMI=>&[?4HM2\16-KH
M&I:3;W4B2)Y-G.JW46^U0RQR%Y)%GA$202?<E&!Z4<\@Y(GYH7/_  1\_:>M
MOA1\)?!.NV/P:^)5GX'L/%-IJ_P]^)-YJ3>'(KK4];EO[?68!!;;KNZB@<0&
M&XC5 &?RY(R3(W4?#7_@F#^UU\ /@'^S7#\)?$_PSOOB)^S_ *]XKF_LW5)K
MZT\/ZG::T;^,B.2*"2>%HH[F%UC\LJ2KQ^9C$A_0>BCGD')$^??AK^R[\4O#
M7BW]HCQ5XHU70))OC!JMC=Z+_9\DP6W\KPOINE2"<.F4!N;29U"F7]TR$G<2
MH\?^%O[#G[=G[*6A?#KQ7^S-XN^%VJ>(M/\ @#X3^'7Q'\,^-YK^+3+JYT."
M<6^IV-[;0-.NU[RZ4PO"JRQE"3$XR/N*BCF8<IX+^T=^SQ\<?C]\%/AKX4UG
MQ'X7D\5>&?B=X+\4^*KVW@N++3[D:5J]I?7HM8B;B1"RP2"*.1SDE0\BC+#Q
M?XE?\$S?C/XP_80_:!_9BT?7?",/B+XM?&;6O&&BWTUU<+:1VMWKEO?Q+<NM
MN76<00[&"I(H8* Y7YA]Q44<T@Y3X?\ CU^PG^W \'[0WPL_9C\:?"Z/P+^T
M/#J%_J5UXT745U7P[JEWHL&EW*PK LD=Y#,MK$ZN[1&U:1B(KE4$38<__!)W
MXZ7\7CC7H?B3X3TWQ%)J'PRU_P"&]\\=S?6MOK/A6PBB9;^#; 6MII8V0&.0
MN(Y/,PKJ$/WY@>E%'-(.2)\5?M&?LI_\%'_VQOV=KSP'\=]:^"NGW<'C+1=5
MM_A_X=OM<;1?$6GVGF->:9JVI,(YF@N7:)PL5F%B^S*L@NED(7RCP?\ \$9_
MC[9?LW?M'?".V3X-_#Z\^+'BCPKXA\"Z+\/+&]_L+1I]&:RN!;3121QN$EGL
M@KS1Y+^:\PB0GR!^EE%"E)!RH^/?B+^PO^T-^UEXG_X2+]J[5O!>BKX@_9Y\
M:_#KQ5;^ =1O+C['-K.HZ=+:RVINH(_.6*VLW#O)Y9:;;B+8Y"/\+_LG?MV?
M%WXB?"U?VS?'WPON/"_P:\31>(M'O_ =G?IJ?BO58=/N["">ZCFV0:;$$O))
M9((3<AY H5XT!4_7]%'-(.6)\;>"?^">'QB\+_LB_LF_ 277?"JZQ\"?&WA_
M6?&$\%W<?9;R*RTZ^MIQ9MY&Z21I+I67S$B!&XL5. >>^#?_  3A_:/\$?MX
MQ?M,_8OA7X TE?%6HZIXHU+X3ZUK]K-X[MIH+F.*VU'0[ASID$F^>.>:Z#7$
MTDMLC(8BWR_=5%'-(.5'S=\7?V(=<^,W[9OB/XQ>*M9LE\"^*/V<;[X;:E9V
M=Y)'J@FNM1,\DJ Q&-8_(9@'+E@^/D(YKROP!^P)^V[XBT/X-?LX?M$_$?X8
M_P#"J_@5X@T+5='UCP;8WR:]XL;1$4:5'=07 -OI:J\<4MQY,MP9C'L3R$=E
MK[EHP/2CF8<J/(?V*/@%XP_9P^$NL> _&]_IMU>:A\2/%GB"*;29I'C^S:IK
M]]J-NC&1$/F+#=1JXP5#JP5F4!CZ]114^I6P4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %? ?_!2G_A2\O\ P43^#]K\
M?OVOK_X+^&IO@[XRCN?$FF_$"#PS-J$G]I^'BE@-0D*O%N(\XB!XY6%MC=Y9
MD5OORN9^)/P8^$'QEM+73_B]\+/#GBJWL9C-8P>(]#M[Y+>0C!=!,C!&QQD8
M-.+L[BDKGY9^&OVR?CIXG^#GPJ^'_P <OVM_$/A7X#^*/CEX[\,']H[^W;?3
M=4U[PUID<S>'_.U@JD=HU[)'<1M>QI%+,NGJ4=&E>1^1_;4UW5?CG_P3=_:Q
M^'WA#]ISQA\4_@_\(_$'AB^^&OQ,M_&37TFJ-(D+ZKI%U?VIQK5K8B:.<22^
M8P>:,.[O:AA^QOB'P7X3\7>&KKP9XK\-V.IZ/>VQM[S2M0LXYK:>$C!C>)P5
M9<<;2"*BT;X?^!_#?@^'X>>'?!^EV'A^WL_L=OH=EI\45G%;[=ODK"JA!'@X
MV@8P<8J^?R(Y7M<^ ?$?PG^%WQY_:=_9M^%O[./[<7C+7/!<7PR^)B:A\0/"
MOQ2.L:SJT(U'PV\EI_;F^6:,K/)%F2.1942!8@R*37HO[.7C7Q]XE_X)F_&[
MP7\1?B%JWBR\^'^L?$CP;8^)O$5PLVI:E8:9=W]M:27<BJJRSB!(T>3:"Y3<
MV69B?JSPK\'OA3X(BTF'P;\-=!TB/0;&>ST*/3-&@MUTZWG='FA@"(/)CD>.
M-G5,!S&I()45?L? /@?2]%U#PWIO@_2[?3]6N+F?5;&#3XTAO);AF:XDE0+M
MD:5F8NS ERQ+9)-3S%<I^>O_  10^/VGZ?\ !;X/^"/B#_P5I^#7C:WOO@_H
MFF>&_@II6GZ58:YHEZ+.T,=K),FI2SW4UO%'-;O&;>-G;+L$*;#Y[_P3#_;I
M_P""=OPR_P""%'A/X2_M*_'/P/JTR^$=>T_Q%\*[?Q):W&O:LESJ5^HT^+3D
ME^T/-.DJJBA02)%;*K\P_1KPI^QS^R/X%\0VGBSP1^RU\.=&U33Y/,L=4TGP
M186]Q;OC&Z.2.$,AP2,@@U:\!?LK_LR?"KQ$OB_X7?LZ>!?#.K+&T:ZIX?\
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M=37< (@N'EV;VEC#$(Y.Y03@BO/?V/OV$_A7^RCX3@LH]#T'7/%,.L>(+O\
MX3H^&(+;4G@U/6+S4S:F7+R;(_M?E8WX81AMJYV@YXARR/SD^*_QX^.WP/\
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M'O#EC86MU=W%U=6]G9I%'-<3R-+/*RJ &>21W=V(R[.S,2232<[E1C8_)/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gym1fcavvjqs000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000006.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %" EX# 1$  A$! Q$!_\0
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M  P# 0 "$0,1 #\ [^  !%K=";%5OKE84\6;%'ZKM<52H79WN1NA<0L*0,R
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MG_$))@@
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M5,0@[(\&QP_)$G>%I%NE)PB*6J6:1$5LTY<*SR8S7&9T.EP&L
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M7-'93'8\@>79_>?VZ/;K*<:8LULQAA%?C4UZ;,1..$X:.5V'B6H
M                    0LZBGD4;#?(HG[0,H)C3T6MDII@@
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MY$F-,)++YYR++*S,+RR+P+RYYRPPPYXQPYYYYQXXYYY >P
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M\?[US"$3,SKF-<HY2^$<F8OS@W%\'\$XXY<EY9Y8B*8ZZ335HFM>C0LC!
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M03&GHM;)33!       (5]/OR9TGGTV^__P!>7H"9T]%G9":@(
M                       !"NIN.XWHW*PXX_P,J'3M5ES_ /')AANQR7+_
M  ]C_P!^"T1/L\^SSSSQW/'^''' )Y(YYV67^X_&*&?,L)].1X)_\/\ ]O\
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M-+=BX/CHM?'M?PB0$ITW"UX>W%P>'55P5W]P=%ZUP5F'*U1YQ@>W
M                           !XL4Y&!QJC DK!0?@46>?B7AB<=@1WSDC
M TWC'C,S GDXWDK'/+G@OOIG<<<=WE[(?SX*F\)\-\'(\,[QX+X7WDOPGP;O
MG??!^_\ <]][QWWGDWO/=][[Y_U]SW7^(#S@
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M--G@S(EV66'&8I,XTFFGJ2/!
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M:G82+,TBUC6M8B*TC&)B9FLQHB<,)\SHI!@
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MCLG32&)J6?'@HQB8BNF:Q,:(B?!-:SAAC%?!CI7@ Q
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MV-?-Y"C5O#5Q,7<PQ>D<EI2)E:VEJ(_\)BF,6HQY=%JN/@PZXUKRP8
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M4AV:946G<VI2K1'&)E!9A"C L_+(DXO,HSC'/'+'B$L@
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MSEQR3'+S3YHE9&" !PH]7_XQC8_],K+T,5R-UCBQT[9:;?&GHV0K5&3$
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MI/-C#?F8<>>=EF:<:9ESSEF89GEGGESSSEESSS[(T6M,\\[6^SHCFC8EH(2
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MSQSQSSQR _H        !P&]2_P O/:+SH.7\BWC=8XL=.V6FWQIZ-D(,C)B
M        .\#I*_%XZU_J&:>E"<#1:TSSSM;[.B.:-BQ@0D
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M$_:!E!,:>BULE-,$ #A1ZO\ \8QL?^F5EZ&*Y&ZQQ8Z=LM-OC3T;(5JC)B
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M>:=>J5D0( '"CU?_ (QC8_\ 3*R]#%<C=8XL=.V6FWQIZ-D*U1DQ
M %K;%Y+^JGR4M;TXS\<T;]O=W-/DJ?6[Y6.[OY=D'B=KT]XQP4L\*
M  +[>C%^3-^_KVOOZ?+!T)O(_)-T/C&;O1Y6LW>__<9S^UR7^R^79B]%A@
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M'SHX"0         ?0<T!\B/5+S"UG]EFX:+6F>>=K?9T1S1L2\$)
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M +A_]\I)]%Q7_@ ^$7=I]?93_)R/],>^?/WUE??P7/Y1^'_N'_WRDGT7%?\
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MT]%K9*:8( '"CU?_ (QC8_\ 3*R]#%<C=8XL=.V6FWQIZ-D*U1DQ
M %K;%Y+^JGR4M;TXS\<T;]O=W-/DJ?6[Y6.[OY=D'B=KT]XQP4L\*
M  +[>C%^3-^_KVOOZ?+!T)O(_)-T/C&;O1Y6LW>__<9S^UR7^R^79B]%A@
M . WJ7^7GM%YT'+^1;QNL<6.G;+3;XT]&R$&1DQ         %MB[X$=2?F^J
MO3S>0Y9WYN^S)_(N2>N9P55NY[KW'DZX]/E+"Q4KQ@         Z+^CK\ =D
M^=];]BX>.EMY;O=SGY:O/4<A6ON"[EY7X_:]7R=;B+B>Y    ?.VW&\KO:CY
MQ]X>DZ4#?9T1S1L?.C@)         !]!S0'R(]4O,+6?V6;AHM:9YYVM]G1'
M-&Q+P0D             4#;@Q7>BU]I;OUWJ:Y&&):XWK*-0F.S[JC^TC+$;
M*U%KI E=.)U4$*ICE1Q)X_<&T:XWC*#S]C)PYDC8^)V=RY4DL[8I93.)LQ%9
MC&*TBF$SR5G5&FDUKS8)S=-&,3N T[;M9S&P'VPF6K]JM@*^J=3-+<8+NLB,
MU!')66GA42LF=,<ADZG.4MN!B]:FCLJ=LIK%(FYQB/2I"TNK><UHR+4UFM(C
M"*TBD5\$=7@K6F#/NHLYQIHTFV-<)79$OJEN(K9\\"E\$ECW!Y1Q)3">"HA'
MFZ31KN)$WXRV4YL\86%LBE"XKT3LH;B5Z/%7F?@19XT85QY8KYG/ML5?%+6=
MJ1TK8<EO^TZ]V4E--:ZJE6R95O7G$()KDP4\9!C-A9K,H_'WU%%[-NJ5OL9D
M=0LD6DL>DC^Y.ZQR<W9TC<>8U+HL-E/C6YB(I68B*:>%6(IHI$1->2F'@2MZ
MIVP-:V#.JT;W>SK29M;X7!]_*\F+K7J^Z:X2X;S5_7]4*J'B+B\0XN-.L@DJ
M%+(INXU*E2*G.*RR7]^P:#'QV:TY"8QLQA.NMGP_%FO"K&K1,\M/!-5UVI1U
MGJ=5-9E%V\.F-SJ-?:9.MS%\PS+>^+.-KF-F3WAX+,XQ,P=>)5DZ\..&>/&>
M*SOV.7''/'(,;5*S316:<U47^J$JN@G5RSB8&R5>X5V?$L>+(<I=*96T31L2
M\2>/\%9PAD9H>^,;XHY3<J,C"WZ01XO$_$DO$W,O/,PL1R\T\G@FO*LC!  X
M4>K_ /&,;'_IE9>ABN1NL<6.G;+3;XT]&R%:HR8@        "UMB\E_53Y*6
MMZ<9^.:-^WN[FGR5/K=\K'=W\NR#Q.UZ>\8X*6>%         %]O1B_)F_?U
M[7W]/E@Z$WD?DFZ'QC-WH\K6;O?_ +C.?VN2_P!E\NS%Z+#    <!O4O\O/:
M+SH.7\BWC=8XL=.V6FWQIZ-D(,C)B         +;%WP(ZD_-]5>GF\ARSOS=
M]F3^1<D]<S@JK=SW7N/)UQZ?*6%BI7C         !T7]'7X [)\[ZW[%P\=+
M;RW>[G/RU>>HY"M?<%W+ROQ^UZODZW$7$]R    ^=MN-Y7>U'SC[P])TH&^S
MHCFC8^=' 2         #Z#F@/D1ZI>86L_LLW#1:TSSSM;[.B.:-B7@A( <\
M\<<<\\\^QQQ_CSSS_P"W''_[Y ?SSGACECAEGCQGGW7<8<Y<<99]SQQSEW./
M//LY=SQSQSE[''/L<<\<\^Q[(!EGAASAQGGCCR9EW&'&67&/.>?L<Y=QAQSS
MQW67<XY9=SQ[//L8\\^Q[''(#^@       4N;7]+"\;ZV"GEV5+O8NU[9)_.
M]8[6=*\QUJ@-KE$V?J:H0.542HJ4RB8-3ARG;WMN3NBN/8("69RY[M$\$.J/
M+O8B:\DTZ*].EE%J(B(FS6E>68T\R;>D>K<MU1K2=12P+J4; 3^S+KL>\IQ9
MA]>LE7>W$ILI4W*W8HB&1UW>65K3D'(.[+Q;U)*;+D[+@I$E+PQ+$HFG)%.F
MJ9 (    0LZBGD4;#?(HG[0,H)C3T6MDII@@ <*/5_\ C&-C_P!,K+T,5R-U
MCBQT[9:;?&GHV0K5&3$         6ML7DOZJ?)2UO3C/QS1OV]W<T^2I];OE
M8[N_EV0>)VO3WC'!2SPH         OMZ,7Y,W[^O:^_I\L'0F\C\DW0^,9N]
M'E:S=[_]QG/[7)?[+Y=F+T6&    X#>I?Y>>T7G0<OY%O&ZQQ8Z=LM-OC3T;
M(09&3$         6V+O@1U)^;ZJ]/-Y#EG?F[[,G\BY)ZYG!56[GNO<>3KCT
M^4L+%2O&         #HOZ.OP!V3YWUOV+AXZ6WEN]W.?EJ\]1R%:^X+N7E?C
M]KU?)UN(N)[D   !\[;<;RN]J/G'WAZ3I0-]G1'-&Q\Z. D         'T'-
M ?(CU2\PM9_99N&BUIGGG:WV=$<T;$O!"0!4SUNH@T3[IO[!PX^(VS/9?(8P
M[-M30^H8M=$S>'VUSXU(>(>FD4<IAM=3U\7(-X5K<S+&19UD@D26..+P:GD"
M2+GEF5B:6K,UB,8K,TT5BNG_ +5;[*Q*775M,\3R.TQ?<@MZ;/'2L>>GG;3E
M0=VL:2H8+7MS*W'<+!?)Y'"&@C7_  2L2>6+;8C=D9PAWFT;?8H7DU2)">UE
M8&<4B,9BE+<6J3$S68I9IC2<:4FS6F-:0VYUB5;/L]4=5R6JZ+M"37,U2[+B
MOHL^Z2;*JKYD1]<;%1IL<H_1>Q34V&P73N0NYL%D3NX6'84/?^9K6+W'7UJ,
M:X^7RM5O;4BSA6*Q&$5^-%,8G3&FWJI&B728GS--((,/(Y3'&$EYG)\C,#<D
MYN>&.1A')I?/)9G)6?/)?)A?/.&?./=8<\X\\<@UO,      *4^L]7LZF<5U
MA>T$'=+:IZ&6])UUX4_QN&QZ2QF>L[Q7#^T0O)ZMYQGD#=,W6+S(Y!(8^P-"
MQ>4Z8(WE,YIDY1J=:09V)B)G&(FF$S$VJ3X(I.G17DC0DMTNFN*-&KI*.&TL
M10C-XP9>;[@D^W!6ZY6"K/!I[^\<763,9P69RY<8E\<Q3A\]E@Y3]URC3\K^
MZ-(M\:<:^'@\'S4C8GS)Y3&81'7F73.1,41B<<;E+O(9/)W=O8(\PM*(ODY8
MYO+TZJ$C:UMZ0K'(U2M6J2$Q!>/.9IN&/'/(,6JY7LYK;!$-9NDWV"I*'-ET
MXMV=.N,IM6"L"&U\'=,W+&HRMU;J^I$\X+<TCNTJ6\R,F.>"PAU;34^1F"])
MR<32=4]3WELWK25!LK9)+SN&KJ9CST[D1]G?;5G\5KUG=7U468<G9FURECJT
MHUSJ<22<>6@3'&JLB"3CN"N]%&9XB(F=$3/-%=C:!!Y"H@E4E.*4IE)19Z=0
M09@<0>0=AP84<2:7ED6:4:7ECF69AEEAGAEQECESCSQR"$,>HIY%&PWR*)^T
M#*"8T]%K9*:8( '"CU?_ (QC8_\ 3*R]#%<C=8XL=.V6FWQIZ-D*U1DQ
M     %K;%Y+^JGR4M;TXS\<T;]O=W-/DJ?6[Y6.[OY=D'B=KT]XQP4L\*
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MN7E?C]KU?)UN(N)[D   !\[;<;RN]J/G'WAZ3I0-]G1'-&Q\Z. D
M %P]D_Y51WS8M</1#%!R-OK]^V<OL,W^I7*H-V7=V_\ L,E]!8:P%</+
M     #ISZ3_DG)O.+,_]FD=4;T/>?8\I9=_Q+BW$]P[/C64;;"RT6@]< .7S
MK3[(P"PKF0:/3>A]@&.3)XBXFU[L'"=F]==4VB<L%VP9=#K-JV+R+9M6WU]9
M#-(F);E&9I$R>'1VY=D" UMP:G-"B6&&RQ$TFU'!I$Q6)BU.,36-$3YIT5A;
MSTRZSD=8ZUFI)M6-QUO/IC9<WL2=J[\N*J[TM2S9/+36U8JM&1SZEU)U=GE2
M!&4A:F5G84K20S,; W(^&PLO$M0J,+6G"E/!6G17'KY:\\V% @   !"SJ*>1
M1L-\BB?M R@F-/1:V2FF" !PH]7_ .,8V/\ TRLO0Q7(W6.+'3MEIM\:>C9"
MM49,0        !:VQ>2_JI\E+6].,_'-&_;W=S3Y*GUN^5CN[^79!XG:]/>,
M<%+/"@        "^WHQ?DS?OZ]K[^GRP=";R/R3=#XQF[T>5K-WO_P!QG/[7
M)?[+Y=F+T6&    X#>I?Y>>T7G0<OY%O&ZQQ8Z=LM-OC3T;(09&3$
M  6V+O@1U)^;ZJ]/-Y#EG?F[[,G\BY)ZYG!56[GNO<>3KCT^4L+%2O&
M    #HOZ.OP!V3YWUOV+AXZ6WEN]W.?EJ\]1R%:^X+N7E?C]KU?)UN(N)[D
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M7^R^79B]%A@   . WJ7^7GM%YT'+^1;QNL<6.G;+3;XT]&R$&1DQ
M %MB[X$=2?F^JO3S>0Y9WYN^S)_(N2>N9P55NY[KW'DZX]/E+"Q4KQ@
M    Z+^CK\ =D^=];]BX>.EMY;O=SGY:O/4<A6ON"[EY7X_:]7R=;B+B>Y
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M_E5'?-BUP]$,4'(V^OW[9R^PS?ZE<J@W9=W;_P"PR7T%AK 5P\L
M.G/I/^2<F\XLS_V:1U1O0]Y]CREEW_$N+<3W#L^-91ML++1:#UP
MA9U%/(HV&^11/V@903&GHM;)33!  X4>K_\ &,;'_IE9>ABN1NL<6.G;+3;X
MT]&R%:HR8@        "UMB\E_53Y*6MZ<9^.:-^WN[FGR5/K=\K'=W\NR#Q.
MUZ>\8X*6>%         %]O1B_)F_?U[7W]/E@Z$WD?DFZ'QC-WH\K6;O?_N,
MY_:Y+_9?+LQ>BPP   ' ;U+_ "\]HO.@Y?R+>-UCBQT[9:;?&GHV0@R,F(
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M%FVPMC4Q+OK2IL*&O1.;RQSTA7GSR!%JG)$Q2*Q-:331,TF,?:B>=>0*+57
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MEY7X_:]7R=;B+B>Y    ?.VW&\KO:CYQ]X>DZ4#?9T1S1L?.C@)
M!</9/^54=\V+7#T0Q0<C;Z_?MG+[#-_J5RJ#=EW=O_L,E]!8:P%</+
M   #ISZ3_DG)O.+,_P#9I'5&]#WGV/*67?\ $N+<3W#L^-91ML++1:#UP
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MCD*U]P7<O*_'[7J^3K<1<3W(   #YVVXWE=[4?./O#TG2@;[.B.:-CYT<!(
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MN"[EY7X_:]7R=;B+B>Y    ?.VW&\KO:CYQ]X>DZ4#?9T1S1L?.C@)
M   !</9/^54=\V+7#T0Q0<C;Z_?MG+[#-_J5RJ#=EW=O_L,E]!8:P%</+
M      #ISZ3_ ))R;SBS/_9I'5&]#WGV/*67?\2XMQ/<.SXUE&VPLM%H/7
M   #GSZR]F5*V6WJ[5.%_6%KUL3))+"IPS7'A>=HU=3M"TC!+*0OME3J00Q@
MDS57EJV%9B%K<:FAT,?H[*'1RP6JG!<JBL9CRQQ5F=BM+4TK%*3'!K-9B:8T
MK$1IFDQHC6QWJH[(UI,)]6[,ZW=8D,UUA<)W^K^;/];S"VJG*)WJK" 52KHR
MOW>30I5%75[EK83)9F[U?&B5[C'9K,2N"6]-(G1H2I$PLQIPQK9TQ$_%QK-)
MC1HK3D\"ZO4E;9SEJIK*XW9@YEW*OU]IE;;9;V3DG><+-55S&SYY@[I\\"\R
M'3&4F.O#@3F7AD4KX.PRPQYQYXX,9I6::*X<R+_5"6W0GU<LY- XU5[M7:F)
M8\60\RZ<2N/S1E2\2>/\%&0B-,U>R9CDZC)-RHS,)?I7$2\#\"2L3LRS,SBA
M'+S3LE9&" !PH]7_ .,8V/\ TRLO0Q7(W6.+'3MEIM\:>C9"M49,0
M !:VQ>2_JI\E+6].,_'-&_;W=S3Y*GUN^5CN[^79!XG:]/>,<%+/"@
M  "^WHQ?DS?OZ]K[^GRP=";R/R3=#XQF[T>5K-WO_P!QG/[7)?[+Y=F+T6&
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MO]1SC^J/>?N?^A6OO65_GGO&D%[8.S'T#KG]R ?!9N(^JKW^HYQ_5'O/W/\
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M\?MJ1X&9T$S<<KH95+I-)BUE>&9Y*'-B1D8-SSF9BSKA$QRQ'+KU8<NML_\
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MO]1SC^J/>?N?^A6OO65_GGO&D%[8.S'T#KG]R ?!9N(^JKW^HYQ_5'O/W/\
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M29MR>,FR.Z]RN8MVK<69O+R\GA6Z<*>%>6[5K&D85I'(VC^#9LG_ *A^P?\
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MBP;FERA%AUW,X4\)VU\E#6O)2LC^@>N"WK)M;R)C")TQ,S'3'_J8G_I*D$
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M9FLSITK[L<>,<<<<>/8QQXXQQX__ %QQQ['''_\ 7' ,'^@
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MA((\5DM(1+5RJ,O3OX'@W.;8::1,UB.>U:G#EFF'F\ZR$&(
M
M
M
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M>.>>5ZFN6\DKG@AMPQX%KF_\K5*:.3"/!%?.M,!B
M
M            CQ<J%$;:&I;@:C2F+T5YRU,C7&)RLUB1.NUDV#S6ITRG+#DX
M@E9DB1Y*BBL\"U&21-R=CGR05S@$AP    $>:P1(^+QV;=>$B;AT/?JK:#W+
M@@KA><TM=8,[BV-9JSN/"#&YN<']^7(469G*9(L>W=2G*+/<EF9Q,Z(YO\SV
70D,"                       ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gym1fcavvjqs000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 ET# 2(  A$! Q$!_\0
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MU+$=,=:TD1(HUCC4(B@*JJ,  = *Q/&G_(C:]_V#Y_\ T T ;M%%% !1110
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M &[1110 4444 %%%% !45Q=6]I$9;F>*",'!>5PH_,U+7$?$:SN;R+1_(BG
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M **** "L:;Q1I5OJ?]G227(NB2 @LYCG! )!"8(!8<YQR*V:PKG_ )'S2_\
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M_P#0EK3#8FK*K&,I:&6*PM&%&4HQU/0:***]T\ **** "BBB@ HHHH ****
M"BBB@ HHHH S[[7-.TV<0W=SY<A7<!L8\?@/:JO_  EFB?\ /]_Y"?\ PKEO
M'/\ R'(O^O=?_0FKF:\BOCZE.HX)+3^NY[%#+Z52FIMO7^NQVUKXFT=?&>JS
M&\_=O86BJ?+?DA[C/;W%;/\ PEFB?\_W_D)_\*\AA_Y#]Y_U[0?^A2U?J)9C
M53V7]?,TCEE)K=_A_D>N6&K6.J>9]CG\WR\;OE(QG..H]C5VN+\ =-0_[9_^
MS5VE>GAJKJTE.6[/*Q-)4JKA'9!1116Y@%%%% !1110 4444 %%%% !1110
M445QNM^++_3=8N+2&*W:./;@NK$\J#Z^]95JT*,>:9M1H3K2Y8'95A:!_P A
M;Q-_V$U_]);>N:_X3K4_^>%I_P!\-_\ %5EZ3XSU&&_UIUAM29KX.V5;@^1$
MO'S>BBN=8^BSH>75UV/5J*\]_P"$ZU/_ )X6G_?#?_%5U/AO5I]8TZ2XN$C5
MUE* 1@@8P#W)]:NEBZ567+'<SK8.K2CS2V-FBBBNHY0HHHH **** "L+0/\
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MG&85,@S(/51W_"G7-W;647FW5Q%!'G&^5PHSZ9- $U%("",@Y!Z&EH ****
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M=R84\U$^ZKX&0/8'-6**Q_$^K2Z+X?N;R"-I+@8CB 0L [$*&8 $[1G)]@:
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M<JGJW_('O?\ K@__ *":^D/F#S&JM_I\6HVY@F>98V!#+'(5W \$''45:HH
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MZ6SU.T$@@GM_E$@PW#NIR.>X-9%?.8K^-(^HP?\  CZ!1116!TG:^ .FH?\
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M\>)S8S^!(]!JGJW_ "![W_K@_P#Z":N53U;_ ) ][_UP?_T$U](?,'F-%%%
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M*$'_ %^S_P#H$588G^#+^NJ._+/]ZC\_R+]%%%>0?5!74>!/^0U/_P!>Y_\
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M9XX(/XU+_;&F?]!&T_[_ *_XUY&(A)U7H?68.<5AX)OH7:*I?VQIG_01M/\
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M@_YXQ_\ ?(H^SP?\\8_^^14E% $?V>#_ )XQ_P#?(H^SP?\ /&/_ +Y%244
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M)10!']G@_P">,?\ WR*/L\'_ #QC_P"^14E% $?V>#_GC'_WR*/L\'_/&/\
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MQ)&0@)./E8<9-7&TC3VU.'43:1B\A5TCE P0'QN]CG ZU=HH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !116!<>(98-?731;H5,B)OW'/S8_QH WZ*Y'6=5U6/Q1+9:?+<
M,T=O:RQ6Z6P>*0O+*LGF/M^0;4&/F'0XSTIB^+)=.T\2W"QW+?;+I7!E*R+&
MMT\:[5"G(  &25''7- '8T5SDWBB2&QO=0-@#8P3-;1.)B9))5E$."@7A2^>
M02<#.*I_\)%JMWJ-@MIIVV1OM*202R-'')M$9#AV0,1\V/N]<CMF@#KZ*Y6'
MQF+JVCOK:P+6 %MY\CS;9$,P0J%3!#8$BYY'4XS754 %%%% !1110 445R_B
M+Q5-HFI):QVJ2JT0?<S$=21_2HG.,%>0I245=G445RGBG5-2M=4M[73IKE9'
MLIYHHH+43>;*K1A%?Y3M7YCDY7ZB@:[JG]KV]I%##()-1:VG$TNW8!;B3";4
MZ9S][)XQG!^6QG5T5QFI>+;I]$GGBM?LR7-G//8W"R[V.S'WEV_*2"".6]\&
MKI\226]SY;Q%HGO98&N+B39'%M*@+E4/)W':&QG!RV<4 =-17*3^,Q;SWT9L
MXYOL\+S1F"<L) DBH5)*@!LL.A8=02*=)XCU0WUI:1Z?:I/_ &D;*Y1[EBN/
MLYF!1@GICJ.HQWR #J:*YSQ9?WVEP0WEK<7$<:.OF;84:%5WKN:4D%@NTG[N
M,8S1!>W]OXG:#49;R."YF>.R79"8) $W8RN9 V%<_-@<4 ='17*WFNW$?B6>
M&1KR'3[26WA9X(XF1GE(QYA;YMI+*/D''))]+.M^)9M)NYXHM.^TQVULES,_
MGA"%9V7"@CEOESR0/<=P#H:*Y.\\9R6,4R7%C!'>0W+V[H]WB,D0K*,/LR25
M=0!MZY'UZ:TEDGLX)I8O)DDC5FCSG82,D9P.GT% $U%%% !1110 444C':I/
MH,T +17 >!OB%<^+=9GL9K"&W6.W,P9'))(91CG_ 'J(/$&K_9;V\,]W+;1)
M=&9FMEC$+)+MC$3E,/E0V>&Z=1T*4DU="3OL=_17+Q>(M2$UU#+8VSRMJ1L;
M-4N& ;"%R7)3Y0%4G(SGICN:=QXGN9)Q(/-MPD,J2PQLK;94N4B)#%2".3SC
MH>@/1C.THKG/^$H8+J >WMH);:81)#<7#([@N5#$;"0&QE=N_.:IMXVD.G_;
M(=+WI%9R7EQNGV[$C=E<+\N6/RDC(7/?% '7T5CZ1J-_>ZGK,%S!;I!9W8AA
M:.0EF'E1O\P*@?QYZ]\=LFI83:I-K.J6L.I"YMXHE GE@7;#<$G<BA=NX!=I
M())!(YZT ='17'OJ6K3> K34XKB[:],!=C:01LSM@X)5A@+D<[1GTJ]JVLW4
M>A:7-9'S9]0DBC62V53PRERR!R!R%.-W'()STH Z*BL!==^S^&%U!$N;N1)Q
M;,D^R.0R>=Y1#;1MR&)Z<''XU6C\6W"3;;W2Q#&L\ULSQW'F'S8XVD.T;1E2
MJGDX.>,=Z .HHK$\.Z])KR7$AMH(XH]@22&X,JN67<1G:N",@$<\YK;H ***
M* "BBB@ HHKFM?\ $\NC:BELELD@:,/N9B.I(_I6=6K&E'FEL:4J4ZLN6&YT
MM%<SXHU*\L[_ $^VM+FZA\Z*=\6MJ)V=UV;01M.%^8Y/'U%5K#Q!JT&HSQZE
M:(T?VFUMY2LH'D220QY55P=PWL<DD=>,UH9G7T5R$7C@S6DUU'I4S0>5YL#
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B=@'A 1B!-N?.]QG!8;>" ,;FXKT2BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gym1fcavvjqs000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# =P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCQ/_ ,B[=?\  /\ T-:UZ ,C^WO^H5JG_@-_]>C^WO\ J%:I_P" W_UZUZ*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDSM'#(Z)O95)5<XW'TSV
MKD7\2>(8KZ&"2QT7S)E#QVJW[^8P.<?/Y>S)P<<C..* .QHI%)**67:2.1GI
M2T %177_ !Z3?]<V_E4M177_ !Z3?]<V_E0!'IW_ "#+3_KBG_H(JS5;3O\
MD&6G_7%/_015F@ HHHH *\W^)7_(2L/^N+?S%>D5YO\ $K_D)6'_ %Q;^8KS
M\T_W9_+\S&O\!Q%%%%?+'"%%%% !1110!O\ @K_D;K'_ ('_ .@&O8*\?\%?
M\C=8_P# _P#T U[!7TF3_P !^OZ([</\(4445ZIN%9&G?\A_6O\ ?A_]%BM>
MLC3O^0_K7^_#_P"BQ0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<2"
M&VEE)4!$+$L"0,#OBO,=!NM+M+B/5;[6-!XF^6W$RG8,=8PIRIW$X7'?L:]3
MKCSJ]V?&)LX/"Z-;QW BEU  $@%-P8$#L<Y!/''K0!UZL'167E6&12T44 %1
M77_'I-_US;^52U%=?\>DW_7-OY4 1Z=_R#+3_KBG_H(JS5;3O^09:?\ 7%/_
M $$59H **** "O-_B5_R$K#_ *XM_,5Z17F_Q*_Y"5A_UQ;^8KS\T_W9_+\S
M&O\  <11117RQPA1110 4444 ;_@K_D;K'_@?_H!KV"O'_!7_(W6/_ __0#7
ML%?29/\ P'Z_HCMP_P (4445ZIN%9&G?\A_6O]^'_P!%BM>LC3O^0_K7^_#_
M .BQ0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445S2
M>)Y)O%3Z3##!)&EQ]G?;(3*N(A(9"N,! 2%Y/4T =+16'J7B6"T62*WCDENQ
M*D**\;I'O9P@R^,8RW;TXJUH^I/J-I,\\2Q36\\EO*$;*ED.,@^AX- &E17'
M1>,KN9K*-;"(2:FB261,IP%8G_6<<$*,\9ZX]ZGL?%5S<WMFEQ:QVEM/B/S7
MWL'FWR(T:L%V]4&-Q!.X<4 =51110 4444 %%%% !1110 4444 %%%% !7F3
MW#P_%A[:+2;]#+.CM*MS.(Y!L ,C*/W9  Q^'->E2QK-$\3YVNI4X)!P?<<B
MO,;:RCL/B#'86FI3/#%>*^#<WDQC7RO]2P.8^2=VYFSS0!ZC1110 5%=?\>D
MW_7-OY5+45U_QZ3?]<V_E0!'IW_(,M/^N*?^@BK-5M._Y!EI_P!<4_\ 015F
M@ HHHH *\W^)7_(2L/\ KBW\Q7I%>;_$K_D)6'_7%OYBO/S3_=G\OS,:_P !
MQ%%%%?+'"%%%% !1110!O^"O^1NL?^!_^@&O8*\?\%?\C=8_\#_] ->P5])D
M_P# ?K^B.W#_  A1117JFX5D:=_R']:_WX?_ $6*UZR-._Y#^M?[\/\ Z+%
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M/_T TSXP?\C#I_\ UZG_ -#-/\%?\C=8_P# _P#T TSXP?\ (PZ?_P!>I_\
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M-/\ =G\OS,:_P'$4445\L<(4444 %%%% &_X*_Y&ZQ_X'_Z :9\8/^1AT_\
MZ]3_ .AFG^"O^1NL?^!_^@&F?&#_ )&'3_\ KU/_ *&:^DR?^ _7]$=N'^$\
M\HHHKU3<**** "BBB@#K?AI_R/EE_P!<Y?\ T U[S7@WPT_Y'RR_ZYR_^@&O
M>: "BBB@ HHHH **** "BBB@ KDOB+_R+2?]?*?R:NMKDOB+_P BTG_7RG\F
MKEQW^[S]"*OP,\MHHHKY \X**** "BBB@"2W_P"/J#_KHO\ ,5[W7@EO_P ?
M4'_71?YBO>Z][)MI_+]3KPW4****]LZ0K)U+_D.Z+_UTE_\ 1;5K5DZE_P A
MW1?^NDO_ *+:@#6HHHH **** "BBB@ HHHH **** "BBB@ HHKC/B7=);^&A
M&)M1AN9Y/+MY+)I5$;D'$DAC!;8OWL=R ,4 =G45U_QZ3?\ 7-OY5YC9W&KR
M>/+,)=ZO-)]HBP721+:33_LN6D9<; QE]?F!XZ5Z1J+SI92>1"DI*-N#2;<#
M'T- #M._Y!EI_P!<4_\ 015FJVG?\@RT_P"N*?R%6: "BBB@ KS?XE?\A*P_
MZXM_,5Z17F_Q*_Y"5A_UQ;^8KS\T_P!V?R_,QK_ <11117RQPA1110 4444
M;_@K_D;K'_@?_H!IGQ@_Y&'3_P#KU/\ Z&:?X*_Y&ZQ_X'_Z :9\8/\ D8=/
M_P"O4_\ H9KZ3)_X#]?T1VX?X3SRBBBO5-PHHHH **** .M^&G_(^67_ %SE
M_P#0#7O->#?#3_D?++_KG+_Z :]YH **** "BBB@ HHHH **** "N2^(O_(M
M)_U\I_)JZVN2^(O_ "+2?]?*?R:N7'?[O/T(J_ SRVBBBOD#S@HHHH ****
M)+?_ (^H/^NB_P Q7O=>"6__ !]0?]=%_F*][KWLFVG\OU.O#=0HHHKVSI"L
MG4O^0[HO_727_P!%M6M63J7_ "'=%_ZZ2_\ HMJ -:BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ J*Z_X])O^N;?RJ6HKK_CTF_ZYM_*@"/3O^09:?]<4
M_P#015FJVG?\@RT_ZXI_Z"*LT %%%% !7F_Q*_Y"5A_UQ;^8KTBO-_B5_P A
M*P_ZXM_,5Y^:?[L_E^9C7^ XBBBBOECA"BBB@ HHHH W_!7_ "-UC_P/_P!
M-,^,'_(PZ?\ ]>I_]#-/\%?\C=8_\#_] -,^,'_(PZ?_ ->I_P#0S7TF3_P'
MZ_HCMP_PGGE%%%>J;A1110 4444 =;\-/^1\LO\ KG+_ .@&O>:\&^&G_(^6
M7_7.7_T U[S0 4444 %%%% !1110 4444 %<E\1?^1:3_KY3^35UM<E\1?\
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M1\LO^N<O_H!KWFO!OAI_R/EE_P!<Y?\ T U[S0 4444 %%%% !1110 4444
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M U__ )YVG_?\_P#Q-'_" :__ ,\[3_O^?_B:^?\ J&)_D_(X_93[',45T_\
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M' ]Z]?*Z%2BI>T5KV.BA"4;W/#**[?\ X53XD];'_O\ '_XFC_A5/B3UL?\
MO\?_ (FO6.@XBBNW_P"%4^)/6Q_[_'_XFC_A5/B3UL?^_P ?_B: .(HKM_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gym1fcavvjqs000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 > # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **R]=N);6SAEAN'A(N8@VV/=O4N-PZ' QDY]JCTZXU&37;]+N.1+;8C0
MA=@&YQP0<DD $YZ?S -BBJWVB47ZV[Q*$=&9'#Y)QCJ,<?>]35F@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **X+QAJ6LVFIZU'ISR>7'X?:9 )"OE
MR[W&]<*<MP...E86K>(]<2UU/489[^.QOK:6WL7P J2PXVLN/F!?$V21V7%
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M@$'G8%WC YS^!K8H[($$9!R**XS3]-\0::+=8(AL5E$D?F( P$:C);D\$'@
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MI6L,[1NQNQSB@!:*** "BBB@ HJLMS*VH26WD (B*_F;^N<XX_ U9H ****
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MH *#TZXHHH IZ<TS0R^=,9669T!*@8 .!TJY5/3O]5-_U\2_^A&KE !1110
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MQ_[(M6Z ,C?XAB^]!IMP/]F1XB?S#?SH_M34H_\ 7Z%<8]8)HY/YD']*UZ*
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M0(3#OE.#G/RD#\\T =;9?\>%O_UR7^53UQ_A37M:N_#UM/>:/+*?F7?"R(2
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M5/4%E_QX6_\ UR7^53T -=$D7:Z*RGLPR*H3:!I$YS)IEJ6_O"( _F.:T:*
M,C_A'+)!BWEO;;_KC=R ?D21^E<UXV\,ZQ=Z/&NG:I<S+"YDD2XE5<*%.>54
M$_0UWE5=3_Y!5W_UQ?\ D: *OARPN-,\.V-E=R&2XBB D8MNRW4\]ZU*** "
MBBB@ JIJ'^HB_P"N\7_H:U;JIJ/^HB_Z[Q?^AB@"W1110 4444 %%%% !111
M0!QWBIK+^U81J6AWLT+IY8N[>Y$:NIR3&_SKD9'0]<\5UL 46\82/RE"C$9
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M@B+YC;:^Y&7!_$5-52R_UU]_U\?^R+5N@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:L91;1>2B.WVB+(
M9]O\8]C5^N6\8Z?JU[]A.G77DQI* XWE?F) 5O?!K.K-P@Y)7\D*3LKG4#.!
MGKWI:;&&6)%=MSA0&;&,GUIU:#"BBB@ HHHH **** //OB)=-#<6R.(O)*!B
M9S'-&&!.#]G(+N?=<5W5FV^QMV)!S&IR$* \?W3T^G:N8\1:[_9FOPVZ2V,-
MS)"&C+V4UQ*ZY.0-F,#/;)/M72V#W4EE$]X(A.PRWE!@OMPPR..QZ4 6:**P
M]&O[RYU&]BND<;&;']U '(5<8')4 ]3G/:@#1E_Y"MM_UQE_FE6ZH,TIUJ$/
M&JQB&3:P?);E.HQQ5^@ HHHH **** "BBB@ HHHH *BN;6"\A,-Q$LD9[,/U
M]C[U+12:35F!QFA:/KMEK&HL^IHRY _>[I-_<'&1C XZUT6=:4]+"0?5T_QJ
M2V_Y"-]]4_\ 0:NUC3P\:<>6+?WDJ"2LC.^UZFOWM+1O>.Y!_F!0=4E3_6Z7
M?+_NJK_R8UHT5?)+^;\O\AV?<SO[:M%'[U+J+_KI;2#]<8I5US2V_P"7^!?9
MWVG]:T*:Z)(I5T5E/!##-%JG=?=_P0U,;0=9L=5GU 6<V\K-NP5(XV@9^F0:
MVZYW3?#6FVTMZ;5);>03[5DBE8,HVJ<?3)/!S5__ (FMGU\N_B'IB.4?^RG]
M*BG*K&/[U:^7]7$G)+WC3HJE;ZM:3RB$LT-P?^6,Z['_  !Z_AFKM:QDI*Z8
MT[A03@9HHJAD%M=1W:,\8D 5BIWH5.1UZU/5/3O]5-_U\2_^A&KE !1110 4
M44AS@X.#V- "T54TV6::R62=U=RS#*KM& 2.F3Z5;H **** "D) &2<"EJ"\
M57L9U90RF-L@C(/% $P(89!!'J*6JVGHD>G6ZHBJOEKPHP.E6: "BBB@ HHH
MH **** "BBB@ JIJ/^HB_P"N\7_H8JW534?]1%_UWB_]#% %NBBB@ HHHH *
M*** "BBB@#SWQ[<6TVJPZ??:O%;6H@$GV6:'*RM\YSO#!A]S& 1R1ZUW.G2+
M+I=I(@PKPHRC&, J/4G^=8/B739[V]0?VREG;R0,/)/RNS(&8%6!X'(+>R^Y
MKH+(DV%N3,LY,2YE4</P/F'UZT 3T444 5)?^0K;?]<9?YI5NJ,C/_;5NI3"
M""0AMW4Y3C%7J "BBB@ HHHH **** "BBB@ HHJ"]O(=/LIKRX)$,*%W(&2
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MO3Y;"5B08)3R,=_QK2H **** "JNI_\ (*N_^N+_ ,C5JJ>JL%TF[)SS$P&
M222..!0!<HI$8.BNIRK#(-+0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%96FWSW6J:A$+E)X(6"C  *OD[EXZ@?*,GOF@"U+_P A6V_ZXR_S2K=4
M&>1M;A5H655ADVN6&&Y3\:OT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !67+XBTN#5I-+EN@MY'"9WCVGA ,DYQZ<UJ5";2V:<SM;Q&8KL,A0;
MB/3/I0!7TG5['7+!;W3YO.MV)4-@CD=>M7JB@MX+6(16\,<48Z)&H4?D*EH
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M77_0.F_[^)_C0!<HJG]JNO\ H'3?]_$_QH^U77_0.F_[^)_C0!<HJG]JNO\
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MCIMOIS7+0>9FYE,TF^0M\Q],]![4 5KBPLQJ=D!:6^#YF?W2^@]JN?V?9?\
M/G;_ /?I?\*CN?\ D*6/_;3^0J>YCEDA*0R*C$\EESD=QUX/OVH 9_9]E_SY
MV_\ WZ7_  H_L^R_Y\[?_OTO^%<RV@ZV?#BZ7;SPP;) ZL\K,VT'(5F4*3R
M2W?H1U)N75A?RZSY\,1(2\BE+M,4!C$>T@8SGDMP?6@#:_L^R_Y\[?\ []+_
M (4?V?9?\^=O_P!^E_PKG#I&J_VG)<3MO6XN8VPDF[RU'4 X! "[E[Y+ \5K
M:?X=L--GMYK<S[K> VZ;YF8;2<\@GDY[T .U"PLQ%#BTM^;B,?ZI?[P]JM_V
M?9?\^=O_ -^E_P *9J/^J@_Z^(O_ $(4NI0W=Q8RQ65PMO,RD"1ESC((XYX.
M<<\_2@!W]GV7_/G;_P#?I?\ "C^S[+_GSM_^_2_X5SZ:/JBZ596311,(;A9/
M,%R1)&NXG@A0&;H,\9R?QG-CJ']LFXCAW>7>M*6:8H&C, 4   Y^;UZ8/K0!
ML_V?9?\ /G;_ /?I?\*/[/LO^?.W_P"_2_X5S]SI.K/K37<LJ20SO JI&S9A
M"EBW4XQM+#( ))JZOA/3$@2$&ZVI;-:C_2'SL8Y/?K[]: +US860M9B+2W^X
MW_+)?3Z4VRL+(V%N3:6_,2_\LE]![5,T"6VEM!'NV10E%W')P!CD]Z2W65M*
M@$+K'(8EVLR[@.!VR/YT ._L^R_Y\[?_ +]+_A1_9]E_SYV__?I?\*YN/0]=
M72-1L?MD6^Z9CY[R,6YZ_= (!''7*XZGM+>:9J<@2-$$DZ6]J!()F1-T<A:3
MGD\\<'KWZ4 ;_P#9]E_SYV__ 'Z7_"C^S[+_ )\[?_OTO^%<_JFE:C-J$][#
M'M:2-8\";?\ ,) 4(!4;<=3SS^M:$?AC3HI(G4W.8GF=<SMUD^]W_+TH OOI
M]EL;_0[?I_SR7_"J^FV%F=+M";2WR84_Y9#^Z/:I[.QATS3([*WW^3"FU-[E
MFQ[D\FC3L_V1:8.#Y"8./]D4 ._L^R_Y\[?_ +]+_A1_9]E_SYV__?I?\*Q[
M33=6MM9O+N::*ZCG4+]\I@87A1@E<$-W.=V>,56.E:E_9&G6DD1>6.WGB;;<
M,0'*84E^O3(SC/- '0_V?9?\^=O_ -^E_P */[/LO^?.W_[]+_A6#=:7K%Q#
MI1D>$166TSPB1V:;]WM;D8R>6 !X[U-:>%[62SB>\-Q]JD%O+/B=@/,C48P,
M\#/4=Z -C^S[+_GSM_\ OTO^%4[6PLS?7X-I;X$BX_=+_<7VJSI^FV^FK.MO
MYF)YFF?>Y;YFZXST'M26G_'_ *A_UT3_ - 6@"3^S[+_ )\[?_OTO^%']GV7
M_/G;_P#?I?\ "LO7-,U._N;5[6Z18HI0_ED;<'^\W7>!_=P/K5:?2]9>[U:\
M>>(BYL####&S$QN,X SP>IYP"<^U &[_ &?9?\^=O_WZ7_"C^S[+_GSM_P#O
MTO\ A6)_9=Y+;:I!]G*VUX5,:B[9'51&!@?*=IRO3IS2:;H,CSA]1W[[5XVC
M,;E59Q$%8X&,C&!TZCI0!N?V?9?\^=O_ -^E_P *J7MA9B>QQ:6_-Q@_NE_N
M/[4VQ\.V&GSVTT!N-ULCI'OG9AASDY!///K5J^_U]A_U\?\ LCT /_L^R_Y\
M[?\ []+_ (4?V?9?\^=O_P!^E_PJS6))9:C_ &Y#=[(9$BB9=ZRM'O)/"LN"
M, =^Y],4 :7]GV7_ #YV_P#WZ7_"C^S[+_GSM_\ OTO^%82:;?Q6:![< MJ'
MG/#'.64)@@8)&0,[2??)J/\ L34GTFRM_+2*>"X\\$719$8ELC!7YD (P.#[
MC&: .A_L^R_Y\[?_ +]+_A59[:W@U:S,,$49*R E$ ["GZ-%)#I<:2HT9WN5
M1NJJ7)4'\"*=<?\ (5LO]V3^0H NT444 90N3!JUZ!;3RY$9S&H('!]ZKV]I
M86LL<L.D7:M&Q9,\A2<Y(!; ZG\SZUH6W_(4OOI'_(U77Q)H[LJ_;HU+2")0
MX*[F)  &1SDG@]#0!5:PTQXQ&=#FV@ #$8&,!0,'=Q]Q?RH73]+2:65=#G\R
M8DR,4!+9S_M>Y_.M ZWIHG$1O(LE2VX-E0!URW08J5M3L%^]?6P^95YE7J1D
M#KU(Z4 94UE8W,TTEQI=Y,)7WE'4;02H4\9YX ZYP>10;#36V[]$N)"HP&D7
M<<;2O4MGHQ'XU?.N:9]ACO1>PM;ROY<;AL[VSMP/4Y[5-_:5A@G[;;8&[/[U
M?X?O=^W?TH JVDPL[?R8[*^8;F<LRKDEF+$]?4FI_P"T&_Y\;O\ [X'^-32W
MMK!;K<37,,<#8VR/( ISTP>E-BU&RFDCCBO+>2212R*DJDL!U(&>10!'_:#?
M\^-W_P!\#_&J:W[?VS(?L5W_ ,>Z\;!_>;WK9JDO_(;D_P"O9/\ T)J #^T&
M_P"?&[_[X'^-']H-_P ^-W_WP/\ &KM4QJMB6O5%RF;'_CY_Z9_+NY_#F@!/
M[0;_ )\;O_O@?XT?V@W_ #XW?_? _P :+'5['4G=;.?S2BHS84@ ,H9>2.X(
M./>KM &-87[ W?\ H-V<W#?P#T'O5S^T&_Y\;O\ [X'^-&G];S_KY;^0J[0!
M2_M!O^?&[_[X'^-']H-_SXW?_? _QJW)(D,3RR,%1%+,QZ #J:SO^$@TO[+#
M<_:@(IG*(2C9)'7(QD =R>!0!-_:#?\ /C=_]\#_ !H_M!O^?&[_ .^!_C5V
MB@#&N+YCJ5D?L-WQYG\ ]![U<_M!O^?&[_[X'^-%S_R%+'_MI_(55\17.J6U
MA&VDVSS3&5-Y0*Q5,C/!(SD<>V<T 6O[0;_GQN_^^!_C1_:#?\^-W_WP/\:P
MM2U'76OKD6D,]O9B &&4VV_<X=<Y RP)!8#Y>,9J;4]4U1[*QDTV"82F<)<+
MY._;@?,N<8Z\9X''WA0!K_V@W_/C=_\ ? _QH_M!O^?&[_[X'^-9D&I7X\0N
MLXD_LZ10(LP,I5SM"KRO)^^2<D  =.ZVVIZS/JRV[6"QVWFL'E:-OE4;L#.<
M$G"G<./FQU% $^H7[&*'_0;L?Z1'_ /[P]ZM_P!H-_SXW?\ WP/\:74?]5!_
MU\1?^A"KE %+^T&_Y\;O_O@?XT?V@W_/C=_]\#_&KM% %+^T&_Y\;O\ [X'^
M-']H-_SXW?\ WP/\:NT4 9T]Z\EO(BV%WED('R#T^M):WDD5I#&UA=[DC53\
MB]0/K6E10!2_M!O^?&[_ .^!_C1_:#?\^-W_ -\#_&KM5S?6PU!; S+]J:(S
M"/OL! )_,B@"+^T&_P"?&[_[X'^-']H-_P ^-W_WP/\ &H[?7=,N[I+:WNEE
ME<N%55)SL.UN<8X(Q4K:K8K>RV;7"K/%&9'4@@*HP22>G0@_C0 UK]BC#[#=
M\C^X/\:ALKN2&PMXGL+L.D2JPV+U 'O4\.JV5QI\E]%-FWC!+L48%<<G((ST
M]J1=7L7E$8F()@^T M&P4QX!+!B,?Q#OWH 7^T&_Y\;O_O@?XT?V@W_/C=_]
M\#_&G6VIV5W8F]AN%^S#.9'R@7'7.<8_&AM3LEADE%S'(L2AW$1\P@'H<+D\
MT -_M!O^?&[_ .^!_C1_:#?\^-W_ -\#_&FP:UIUPER\5TC):J&F?!"H"NX$
MD\=#FK5M<Q7=M'<0,6BD&5)4C(^AYH K_P!H-_SXW?\ WP/\:K6]U+'=W<C6
M%WMD=2OR+T"@>OJ*UJ* *7]H-_SXW?\ WP/\:/[0;_GQN_\ O@?XU=HH I?V
M@W_/C=_]\#_&C^T&_P"?&[_[X'^-7:* *7]H-_SXW?\ WP/\:J7E^QGL?]!N
M^+C^X/[C^];%4[[_ %]A_P!?'_LCT )_:#?\^-W_ -\#_&C^T&_Y\;O_ +X'
M^-7:* *7]H-_SXW?_? _QH_M!O\ GQN_^^!_C3[C4;2UNH;:>8)+,<(N"<\X
M&3T&20!GJ>*M4 4O[0;_ )\;O_O@?XU ;DSZO9@V\\6$D.9% !X'O6I5*X_Y
M"ME_NR?R% %VBBB@"E;_ /(3OOI'_(UBKX52,0B*&&,Q.7#B5MS'<K<DKS]T
M#Z$UM-;727DT]O-"!*%RLD9."/<$4NW4O^>UK_WY;_XJDT5&5NASY\(*P!8(
MS!=FYI,\;=H&-F#@8'3MZTB^#E$\DSDRR2)L+2W#,0-K+W7KAC70[=2_Y[6O
M_?EO_BJ-NI?\]K7_ +\M_P#%46'SKLC-'AN.>VB@NG=4A=B@BDSE68,5.5Z9
M Z<\=:CD\&:;+'L>2Y/R[20R@D8 4$@<@;5P/49.:UMNI?\ /:U_[\M_\51M
MU+_GM:_]^6_^*IDMW93/ARUDTY;"=W>WC;,2@*NP;"F.![D_4U6L_#'V#Q(=
M2@G'V<QE?*9<D$DDX/0=>OX5J[=2_P">UK_WY;_XJC;J7_/:U_[\M_\ %4"+
ME4E_Y#<G_7LG_H34NW4O^>UK_P!^6_\ BJB%KJ O&N/M%KEHQ'CR6[$G^][T
M :-8W_"+Z<'NR#<A+MP\T8G;:Q&2.^1R<\$<^W%7=NI?\]K7_ORW_P 51MU+
M_GM:_P#?EO\ XJ@"#3M"M=-GCEBDF<QVXMT\Q@<(,=\9)^4=2?;%:=4]NI?\
M]K7_ +\M_P#%4;=2_P">UK_WY;_XJ@!-/ZWG_7RW\A5VLZ"UU" RXN+8^9(7
M.86XS_P+VJ7;J7_/:U_[\M_\50!8GA6XMY86+!9$*$J<$ C'![&L8>$[ 6$=
MBTDSVR.)!&P3&<DG'R_+G/\ #C@?7.CMU+_GM:_]^6_^*HVZE_SVM?\ ORW_
M ,50!<HJGMU+_GM:_P#?EO\ XJC;J7_/:U_[\M_\50 ES_R%+'_MI_(5=K.D
MM=0DN(9C<6P,6[ \EN<C']ZI=NI?\]K7_ORW_P 50!;/0US=CJFH7(L9GE;R
MP9S=8M& *(Q (!Y!.4P.<C-;.W4O^>UK_P!^6_\ BJ-NI?\ /:U_[\M_\50!
MG^'=1O\ 4#??;HR@CG*Q?NBGR^G/<?UZUN53VZE_SVM?^_+?_%4;=2_Y[6O_
M 'Y;_P"*H -1_P!5!_U\1?\ H0JY6=/:ZA<*BFXM1MD5^(6['/\ >J7;J7_/
M:U_[\M_\50!<HJGMU+_GM:_]^6_^*HVZE_SVM?\ ORW_ ,50!<HJGMU+_GM:
M_P#?EO\ XJC;J7_/:U_[\M_\50!<HJGMU+_GM:_]^6_^*HVZE_SVM?\ ORW_
M ,50!<K,GT&SGU(ZANGCN60QLT<Q 93MX(Z=% _$]^:GVZE_SVM?^_+?_%4;
M=2_Y[6O_ 'Y;_P"*H S5\*V<$2):3W$/E2/+%E]^QV!&06R> >!G'J#5EM!M
MVU:34A-.MPZ!"05Q@;>.G0[>AXY) !.:L[=2_P">UK_WY;_XJC;J7_/:U_[\
MM_\ %4 5;/08K"VN+:WN)4AG4@A50$,Q.6&!C.,#&,#'2E308(X/+%Q<Y^SI
M;>9O ;RUSP"!QG/)'M5G;J7_ #VM?^_+?_%4;=2_Y[6O_?EO_BJ *-MX;@M=
M/DL$N9_LS;610%'EN&W;A@8ZXXQCCIR:DA\/6=OIUS91-(J7+!I&.UB3@ ]0
M1SCICN:M;=2_Y[6O_?EO_BJ-NI?\]K7_ +\M_P#%4 4#X7LF21&EN&22 6S
MLO\ JP,;2<9/KDDGCTXK2L+&+3K-;:$L5#,Q+8R2Q))X  Y)X  IFW4O^>UK
M_P!^6_\ BJ-NI?\ /:U_[\M_\50!<HJGMU+_ )[6O_?EO_BJ-NI?\]K7_ORW
M_P 50!<HJGMU+_GM:_\ ?EO_ (JC;J7_ #VM?^_+?_%4 7**I[=2_P">UK_W
MY;_XJC;J7_/:U_[\M_\ %4 7*IWW^OL/^OC_ -D>C;J7_/:U_P"_+?\ Q513
M6NH3/"QN+4>5)O&(6YX(_O>] &C15/;J7_/:U_[\M_\ %4;=2_Y[6O\ WY;_
M .*H 9=Z1;WE]!=R/*KQ8RJL K[6#+NX[, >,5?JGMU+_GM:_P#?EO\ XJC;
MJ7_/:U_[\M_\50!<JE<?\A6R_P!V3^0I=NI?\]K7_ORW_P 52);73WD4]Q-"
M1$K +'&1G./4GTH NT444 %%5[J_M+)&:ZN8H0J%SO<#Y1U/TIMIJ-G?%A:W
M"3;5#G8<X!) _56'X4 6J**BMKF&[@6>WD$D;$@,.^#@_J* ):*** "BHK:Y
MANX!-;R"2,D@,/4$@_J#3W=(UW.RJN0,L<<DX'ZT .HJ*XN(K2VEN)W"0Q*7
M=CT4#DFI: "BBFR2)#$\LC!8T4LS'H .IH =13(Y8YEW1.KKG&5.>:BL[^UO
MXO,M9UE3 .5]QD4 6***:CK(BNC!D895E.010 ZBD=E1&=R%51DD]A5.+5]/
MG6$Q7<3^<Q6/:<EB#@C'L>M %VBBHK:YAO+9+BWD$D,@RKCH: ):*BN+B&UB
M\V=PB;E3)]6(4#\20*EH ***AGN[:VD@CGGCC>=_+B5V +M@G ]3@$_A0!-1
M4-K>6U] )[2>.>$L5$D;!E)!(/(]""*FH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@# \3>'QK$!EC<I<K$8D95R0"1G&2!T%8NI>&+J=9$L5F@63:7\S#,6!D
M)<MNSG=)GMTKIM1U"^M-0L8H--:XM92WVFX$@46Z@9!QU;/M56V\6:;=O#%"
MMP;B8CRX&B*NRE0P;G@#!SR?UI6+4E:S1BR^'+R9H=Z3%8[AY6*ML:7<<AF(
M;[Z] 1VST[0)X5OD$F(P59F/E% (Y,F0[G&_EQY@P1_=^F-J'Q7OTZYO)+(J
MJ6\5S"JR9,B2,RH#Q\IRO/7&>IJ:T\12W&IVUD]CL,CSQ22"4%5>(]!QD@CG
M/&*+/N'-'^7\_P#,J:CX:O-1CLI+?4IK:6"!4)E!9GD3[CMAL<;GR.^X>E5F
M\&70N+B2+4$56:/R04)V[&)4L,X8@''/7&>.VS)XGTV.=(2TN]I?)/[LX5MS
M+ACT'*MCU[9R*BU;Q/!IS7$*0RO/"53+(1&7(#;=WKM.?PID,S3X+EC!\FZ@
M96):2&2,^7*Q:4[F /4"08]T'M@E\&W,W[N:^BN8(SOC%Q&6+OOB<E^<?\LB
M.!_%^>M'XHTZ:[>UA\Z2=)3$R)'D\=6_W1_D52_X3>PEEA>VCFEM2)&EE6,_
M(JA6#X[K@DYZC'2@"#5?"UWJVLWTIEB@MY81&DF"7/[MT*]>%^<$CO@?@DW@
MZX:]C:*^1+6.61TA564HK[LH"#G!W?ABMJT\065[<"&W6=RW*$1G#KDKO!_N
MY&,_3U%5+W6=<@.J_9_#LEQ]EV?9,7"C[7G[V/[NWWZT 4;3PM?V%S%>)=QW
M%Q!!LA1RR(I 8 $+U7YAGCDC/7&)=6\.7FJZY-<+-'!%Y$:I-R7# 2!@O/ .
M\9]?Y7)?%NFVLDD=YYT#1?*Y:,E=^%)0$=3\Z_Y!IT.OO-JJ6AL7CB:40%W<
M;UD,7FX*C(QM[YZ]J ,S_A#I$<^5<0(C3/)E8R&4LR-O&#]\%2 ?0_7*Q>$;
MN!K=HM116A8$,8RP4; IPI..<>Q'KURX>,GDDBBATX-)<1M-;AIL!HUWYW';
M\I^3@<_>'/!K0L/$*WGV]WM)(H+6".X5MV]I$="WW1T(P1CF@#)L_!4\,48G
MOD=T?<F$.$_>(S <]PK#_@1J]!H-TOAF702UM# MNL$,D"D$]=S$=L\=#US5
M^U\06%[J(LH'=I"I=6VX5@,9P3UZ]JHGQ?9--"L:2B-BS.94*'8$D(9<]03&
M1V_E0 ^U\-"U?S4NG#QR2-!&!B-%9F95(ZX&['!'3M6?#X1NX+R*[2] D#L[
MA2^0#('*JQ.3NY!+9X/MBM%?%^E/:O=*TQAC0-(_E\(2VT*?]HD8'\^:KQ^-
M+'[1-YR2QV@1&CG,9P258E3Z-\IQZ_B,@#-0\/WM\VD(!;0);VS)*R;L1/NB
M(,8SG(VM@GI^-5?^$+O1*K#4H]B0&()Y9 <94[6 /*Y4Y[X8_CU-A?PZA"[Q
M+(C1R&.2.1=K(P[$?0@_C5J@#CYO!DLTES(US$3*(RL9#^6@4QDQ[<\I^[X]
M-Q_%\/A?4+&:*YM[J"2:+YXPX8!#AAY0.>(OFSCK\OTQUM% &#J'AQK_ %@7
M_P!I\L_NU^5?F"@2!@#GC=O';^'O43^$T^UZ?<0W]P#:2A]L@5@PYR/N\$Y&
M2.P%='10!DZ+I][IT+0S/:F-III2(D88WON &3T&6'Y=*UJ** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :Z"2-D.0&!!Q6=I^@:;IM@EG#;*T:[<F3YF8J
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gym1fcavvjqs000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000003.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $8 ET# 1$  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!08'"@0! P+_Q !:$   !@(! @,$!0@%
M!P<&#P " P0%!@<  0@1$@D3%!47(3$R6&&8UPH6(D%1<8&1&",S-#4D)3E3
M>*&W&4)B<H*BP1HF)T-'DC925%9C972#A)27H[&TU/_$ !L! 0$! 0$! 0$
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M)_-]B;V#(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD)C;0J,T(29@1AWH&F?I?J/R?S?8LCP9& , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'#.1UFV14=3/DRJ*DG
M_D-9!;C'&6)U6P2!NB/MIQD<@;603B_2YT1N:6+1..)5RB0RA]"SO:I"S-JL
M:)G<58B4PQ4KO6W6_7AUE;T*\2WD?:58R=?6/"%JDUP5?R4N[CC=:-;R4963
MC96BJAH8U363V"JY%'5DJ6N,7?B'QMC,=3BJEO5IIF3(&63',9,>,7KGIEW4
MGFW9I->[F[\+7[]<UFM46 <.^233S XOTCR:8XF]P5LN>"-<S(B$A.*5.C 8
ML$>F5H!+R"4Q#LA L2J!M#T4D1EO;0-"[ 1(PK=)2A&K-K6SMZN<T;-ZWXD4
MTZ;UOIPAK+6^F_EOW\6Y\-X+^3^;[$W\&1@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M/[R):ZK!B$-0K,%O>]BW>YK^;[%D6#(P!@# & , 8 P!@# & , 8 P!@# &
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M9& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M3LY%P/$?Q"N*?-AF+5TA92!3*BD>E;S5TIT3&[.8 A#H2C:R+*E!@W-$E[@
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M"AB PD0%U>HR^DMTO&KTS*R&U0J*4[(#WX-;N5[KLOGPX=Y,G!D8 P!@# &
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MN9CHXLI0#A'1\M&0D/=6AT0)G,Y4!L4J&]8 A89I.;L(MG:_#M1++!!@# &
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M%,@U9R\;/$F!JCC6-<H 24>M$WLZ1&D$K/+3D%G*=D[., 02 8Q!+!H(&SX
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MFGH=QR%& >17EO9$!N7F'?=%,'&[PT$/("P.9L)XUPF4W/Q;K&V;QKZK*YH
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M=A"'9J?:M << A:FV/1:U H\E<A/T).L3D'@&6'!U335T[HWO!1@# & , 8
MP!@# ( ,5&<O4'+U_P"0KE9O&Y3!I)#HC4J^&H:JLY-+":MA-AV%-F@U')3[
M=4LX9^I36"L;G)V.CQL=&>@3*4L>3EC-)$+E:V=\WPMFEV\B?^"# & , 8 P
M!@# & , 8 P!@# & , 8!_@PHLT.PFE@,#OYA, $8=_OT+6];P#$*(U'%?7U
M3 RJ>OS]0U(3NO[_ #"!=<7:T9+)ZI>!A%%:URKZ^J@$*4]WS]1%6([K^_S$
M NO\<MWS?BQ9<EX(P:BCZ:4]?-JFN^N_F(N'1\@7_O$("Q?QZXN^;\6-U<EX
M&$4<<**4]?,JZ)AZ_/TZ#:3^7I3">G\.F7>DN+[\_J3=CR^I@U'$_CVJZ^96
MS>'K\_3N\E2?R](]$]/X=,;\N?R7D-R/+YOS,(HX9\>3NOEPI6EWO]:>52L7
M3]VE+RHU_NZ?9C?ES^2\AN1]/UZ7:811P>H<[KY:"3).OR]/(U NG[O5$J?]
M_7+OOJ]=Y-Q<W\O(PA_ JF#=]27BPD8M?+:=\9!=-_\ XF-*-_\ >U^_&^^K
MUWC<77Z[CY_Z"\,3?X595GM_3Z'^=&H?;T^7]V:D7R^SMQOODO7>3V:YOTO/
MY9=8_H:NB;_"[_L]!T^C_E2@?;^S^[O"+Y?9VXWUQBGZ[!N?ZOE^II-B\4+>
M+A;\!HOB?S\6TQ/EP5S,<BD;]VK$^]IC3G";'-P-$!UM8'U"(P(AI@A"'1FP
M"#5)7^%+KY?(.+2>;?5GGGV]Y":(4M:IMR)JR2-2QAL*-M,&L1U!I2WC4Q2(
MRJ4R*/QJ:&&E+])CR/;<'E&BDB-6:XA,83A&IB2ST9BC3G&SSOU6>?R,[LLL
MM7;/U?US+#_</RA+_LN2ZD?[/.;UN_Y]PSO_ !S.]']U>"-;LOWOFQ[E>69?
M]ER-2#Z?ZYM-_P!_<VG?^/Q_GAN#_*_I]&-V:_-\V_JA[I.8I?\ 8\@F ?3Y
M><U@W\OEU[HP=_'Y_P <EX?NOUWC=G^]X-_H/=ES7*_L;XA@^GR\YI2[_GW0
M(_\ \?WXO#D_7>6T^:]=Q^?F!SI+^A==<F]/U&-2#6_Y[J\7_P#/\^FL7AR?
MKO%I\UZ[A^9_.\K_ -JM8J.GZMMR /7^5<$?O^>OWXO#D_7>+3YKUW$!>1,2
MN-KELKE=LI1.(V5B(>)-.6EH4IX4@8FAD J4.2QZ"TM30A0LS4F&8[K5 4R=
M"%*I.5G! 48;K:<;*S2ZF\_J8:=[/-NVG'E;Z%@G!)D>F.JI&4]-#HSFK)TK
M7)"W1O5MYBI$='(T$I8F K))$>E-$68$M05H10Q 'H(]["+6L3:;R=\ONS<-
M'V^1-C,&Q@%45^<;>9P;DL6SJ1AGAQ7FV6A&5\'=-<GJFEU:7,PUV[M^FQVJ
MM;=]4L=@F6=6RHG9WDL$H@S$I)2*#&YQ<GO11:H8U=66J:Y/)OG9Z/O\"1W$
M:L>4U>L^DE_2#C)&(JSQMMBE<<>^)=6O\0JFM6QL- (M27,)H[&2&3*=)0 :
MV]L9X;6\7:$ 1]&!Q6&E*T8CMPOUM\7]O%D@[BN.LN/]:2RX;CF+1 :WA*).
MNDDH>C#0HT05S@C9VI&0G3%*%SF\/CVXMK%'V-K2K'A_?G-M96="M=%Z1(<(
ME?)$(T7/_B#(_#E*Y\RJ-.$:XNJ(H]RU!"YS#XIJ4N)S+-G>(,L7;X.E>'>-
MJ9C+YJUE((@T%O/12Z.[6)>K:S1K1HAIQ:ENY7O;J^9-:CK5CE[4I3]WPYO=
MVB(W)5M?VK%6J0)D"-^;(Y8<3:)<QM[VD:U[JV)7=$V/"5,Y)FYT<D!"PHXI
M&O6)PEJ#!EY-KD1S;?\ 2133_8AK'_CQ;F#7Y/YOL3>P9& , 8 P!@# & ,
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M"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P"J"$<L.++OXH5M1=IY*T Z29ZXN<=ZJ9XZW7)72U]=K0C=[\KQR*MVQ
MH32,UP7SUA [M(WJ'I4YLA:PNC<)<W$:6IMFC33W4[.UV[V=K/=L^PM?P9&
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M.E^6\8I10Y)94PEB6OHL4(6]-\(@9,<AC2#02FMA1E@"#0OY/YOL61X,C &
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M%*DQ)H! USLUJK'=--73374=(P48 P!@# & , 8 P!@# & , 8 P!@# & ,
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M4TFRY#/I#TQ@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M?7MDR(?P^6_T-;^SKF_V9_:3&[6W=B5.2E04;_\ ;LI6Y:Z=8W>DB_Y[!O\
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M'@MMTN?M-E5U;MW7(O[>P?&CCH_Q82I]KFVHN=/&1=T\FQ4F^ORZ)CS_ /\
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MDBFG^Q#6/_'BW,&OR?S?8F]@R, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MEM/T*.I1[T#_ )VI33@]B_@LNI%U_;_9ZW\?AT^6:6R:R^'I!MI<KK9-3_\
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M/WV]XA;WTU@OY/YOL628,C & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6/\ QXMS!K\G\WV)O8,C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MA,./!%6S0M%MP90?)Y#HL ?6R%:/N&(/R:?FZ^7;;PL61X,C & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M\'Z_4,4!B,DFCTG9^7:1P=SVF+,RU\<B6M![A"?6N)J- <!"D\XKU*D11/F
M[^[067-^"\S,,-]\XI$Q,L@0<(JV+0OK2W/*(M7S!2IU8$CHC)7)P*B/<"/R
M5 23P!.*[Q>69H0.X7;UV&7-^"\S+>^+G;]26KOOC)/P P,N;\%YCWQ<[?J2
MU=]\9)^ &!ES?@O,>^+G;]26KOOC)/P P,N;\%YCWQ<[?J2U=]\9)^ &!ES?
M@O,>^+G;]26KOOC)/P P,N;\%YCWQ<[?J2U=]\9)^ &!ES?@O,YV1ROYF*+9
M=*:!P<@^I6TUVQ6:J5CY;)0QX4>D,ED<50IB';W#;\UY+<HPXFJV[TX?(0F(
ME/G#]1V "RM>[\%?ZG1/?%SM^I+5WWQDGX 8&7-^"\Q[XN=OU):N^^,D_ #
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M[8I\XSUO84%E;5]EL_J=$]\7.WZDM7??&2?@!@9<WX+S'OBYV_4EJ[[XR3\
M,#+F_!>8]\7.WZDM7??&2?@!@9<WX+S'OBYV_4EJ[[XR3\ ,#+F_!>8]\7.W
MZDM7??&2?@!@9<WX+S'OBYV_4EJ[[XR3\ ,#+F_!>9I%F<H.:=4UO8-HR7@]
M E4<K:$2N?/Z9CY<I')[4,L.85\B=2&=N]PI'M!T.0MQY;>B\\GU:L1)'FE^
M9WZ%23:5WF[:?J;4VWCSG=6Y Z)N$=9A3N2)*O3A/YAI"C@DK""U!03B_<"+
MRS= ,#HP'=OL'K8>N^G7!,N;\/U/M]\7.WZDM7??&2?@!@9<WX+S'OBYV_4E
MJ[[XR3\ ,#+F_!>8]\7.WZDM7??&2?@!@9<WX+S'OBYV_4EJ[[XR3\ ,#+F_
M!>8]\7.WZDM7??&2?@!@9<WX+S'OBYV_4EJ[[XR3\ ,#+F_!>9SI'RPYF+;:
MD-,D\'(.&5QFNH;9S@L,Y;) 1XR/3F2SN*LZ9&[>X;?J'HARKQ\-<V[TP/1H
M5#2I\\WUWEDBVC:]WK:UL^W6UN\Z+[XN=OU):N^^,D_ #!,N;\%YCWQ<[?J2
MU=]\9)^ &!ES?@O,>^+G;]26KOOC)/P P,N;\%YCWQ<[?J2U=]\9)^ &!ES?
M@O,>^+G;]26KOOC)/P P,N;\%YCWQ<[?J2U=]\9)^ &!ES?@O,TJRN47,RIJ
MYG]J2[A#!SHI6D*E5@2<J.<M$3U(38]#6)?(WHMA9AT6W@=GH;:VJ0M;8->B
M O7;(2B5IM&[. %D\DWGU?J6#MBX#FVM[D46:26X(4BXLH[6@G% 5D%J %FZ
M#L0=&@"9H)F@B%K0];UK>]?'!#[< 8 P!@# (_<B>*O'?EG%6F%<C*EBEL1M
M@>=R!B125.J"H97<:%4UJ5;2ZMBIO=V[V@U+5C4ZD(UY*9W;%1[<YDJT1HR-
MBIM:-KL]?T.SQN-Q^'1UAB,39&J-1:+,S7'(U'6- F:V1@8&1$0VL[*SMB,L
ME&W-;6WIDZ% A2DE)DB4@H@@L!180Z$,U@# & , 8!%=BYT<*9/9&J<CG+OC
M*^6X*1K(>75[5>E8KK!-ES<M.;E\6)AR>3F2$Z1HG!,H1*F0IO&YD*DYQ!B4
M)I1@0KKF6SM>SMSL[>)*C!!@&GRVPH% CXBFG$TBL/4S^7M]?P5/)Y U,1TR
MG;NA<W-JAD7*<U28;]*7)N97A>A86L*IT5HVMP4D)1DHU RPLWHM,WU+F(%8
M4"M2*MTZK*:16PH4\'.J9IET)D#5*(TYJ&)X<(\]D('QE5+6U6<T/S4Z,KF6
M0I,&A=6Y<WJ=%*DIY0 -PP!@# & , 8 P!@# & :6]6/7T;F4(KN0SF(L4^L
MLN3G5U"7>1-+;*YX5"F]*[3$R'1]8K)=9("*M2U&Y2(3.E6:94"I.K<=ITYQ
M9@@.>LG*/C5)8^QRR.\@J6?HO)K034C')&S6?"W-C?KE6G#3HZH9G5$]'(7*
MQU1X!E)X4C/.D9Q@!!+;A;#OH+9\GI?3AS[#NV"&H2VP8' 3(H5.9G%8<;.Y
M>U5]"2Y0_M;".7SQ\3."QEAD9"Z*DHGR5.R1I=%3:P-FE+HN3MRXY,E-+2GB
M !LC@X(&E N=75<C;&ML1J7!R<G!22B0-Z!$2-2L7+EBD9:=(C2)RS#U*D\P
MLD@DL9IHP  (6@.74_R HGD(S.LBH6Z*INM@8G0;&]O=3V%$[#:F=Y 7H[;4
MZ.$2=G=*@<-D" H D5&E'F)QEJ"P"), ,0K36J:[58ZY@A^;WK6M[WOIK6M[
MWO?RUK7QWO?[L X2@Y2<:'5NJ=X;.0=*N+3?3NOC]'N:*SX6J07 ^M2L;>Z,
MM8JR7H9$Z=6Y>6-$N;XR8YJTBL DQY19VM@P6S5[IJVN6G:=%AUBP"P_SJ_,
M&;Q.;?F+,GNNIK^:DA:9#^:,_C.DNY'")+[*5J_8DL8=+D7MF/.7IG9L]6GT
ML2$[.+[A#<L U"'V# ["*D9T"FD5FA,/E\AKZ6&Q5_:I 7&9Y$5>D$JA;^-J
M5*@M$JC:[>D;\P+]D.K2JWHA>E(-WVX%FM5;CW<S3I[R%H.JYC"*\LZ[:EKJ
M?68J"AKF$SFQ8A$Y;/%@U1:$M+#XZ^NZ!WDAYB\TE 44T)%@S5QQ*(O0E)Q1
M0Q;-YI.RU=M#L&"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'
M!R>4O&A0S5S(D_(.E3F"X)NIK.IWLJT(4-JLRQD;VMC2N!0)P"];2RZ8I9$W
M+V%1&F$U>\DO")4VF(PK"#20BV?)G1HG8L GBV8MT(F\3F#A7DJ50:>HHQ(6
ME]50J:HD#>Z+8C*R&Q6J-C\F2-CLUN"IC=0I7-.B<D*DU, E60,P2S6JUS76
MN9N6 :A$K!@<],EA,'F<5F)T#E[I7TW*C#^UOID/GC(D;E[S#).!L5*A,4J:
MD3PTK'%@<])G1$F<T!ZE*64K($8!RFU^7/%&AY&EAUX\G./5,RY<S)I$ABMK
MW36]=R-9'UJQP;D;ZE8Y?)6=S4,RMP:G1"F<R4HT1ZQM<$Q1XST:@!8JC)Z1
M;[$W]#O#:Y-SPW('=H7HG5I=425R;'-M5$+FYR;EQ!:I$O0+4IAJ98B6)C2E
M"54G-,(4$&%FE&#+&$6Q#[< TM^L>OHK*X-!)-.(C'IM9ZE_15O$7N1-+7)9
M^LBC,.12=+#&-:K(<I,ICK 4:]O9#,F6&M;268X+0DI "-T%GGEIKU=ISUKY
M1\:7MBW*&;D%2SM&]6NEHC;^VV?"US-[[ERQ&WHJ@]II7HU'[S5:]Q;T::"Z
M._.8]4N2$%-@C%!(1BV?)Z7[N?8=VP0U"86# Z^!&S9Y,XK"RYC+V"OHD9*G
M]K8 2>>2M0-)%X8P"=%24+O*I$J+,3,; @VH='4\ RD*4\P.PZ VA2I3(DRA
M8L4$)$B0@U2J5*32R$R9,06(T]0H/-$ HD@DH C#33!!+++"(8Q!#K>] <GJ
M#D'0O(-M>WFA;KJ:ZVB-.GL.1.E3V)$K#;V)XV7LT+6\+(D[NZ=M7F$AV>4E
M6&$G'$?UY0!E;T/8K36J:OI=6N=?P08 P!@# & , 8 P!@'@X)B]AZ!+(.RZ
MLVQ+5C_BPR>W8OPJUP L1,&Q&=%S#'(4DE/YVHH4A*@D8_-LQ7/AN9$S]FHV
MQGVR.) V1S6AT.VEGDE[-*]T_P MK;KUSLK)97N]2Q KD3R[>/$M2ZA$KYAP
M^$J>2W+JGK%@\Z':-HQMBB,>I.Q5%,R1NJ8BB*]XYP:(.\UCT??Z$(9+%G]C
MV2E[!2^<NVUCKK!FRW7?=;2BU:U\VKWSWGE=-/)<-4W'>HN1?B4MO&OFO'ZZ
MD/*"Z;@8>-=52Q)<Y#S?D@86!_W=L9C%M-:*H>0W'YNL2G>5 *?>;!ERZ#5)
M*;!K=D31#2N)0G;PWQ\]U>O7KL*U!M:)7LU=:*]L][-/)-NSZSNM>J^1UI(N
M'J^0RFQKMJ:'^-!Q[>:HD,C*Y 6!)8C D?&:X"K%&ZVM>5'4C.)_7;5/7$)C
M3-7B(;0QYS?'.#'2)>%C0"%GEKD^3R]UKOSX]9EVST7NKES7)OAYF(H)!S/M
M&O\ C37\BM;E]4+#_0E\2FQYD*M7"3UHZNEMPCF'("*22OKF0PZ4MKWJ.*T;
MC'4:#;6]R2/(M-^C7&*.SZWNFC344VU;6GV6<6Y=6OAU',+$Y$^*&^#XTK'F
MR+NK.:/O!WA1*:,5I&>^T3#8_(^2J2@WX=9E94_QUM5AMV:>URVIKF]8VN]U
MNUQ*$.!DHCZ'2IR5.C<]>O7V%H)M9/WI)IV^%:-.Z:RXYZ7>F?LL)V=LDK:@
M)83]E@V>$H0AE!.V'7F!*&,(!B+T/NT 0@!$(/38@AWO>M#D?TP!@# & , 8
M P!@%&WCJ(KAKRF./7,?CI"I).KPXC7PH>6!FB+,YOT@4PVZJPGE*RY,B;69
M&N<C2Q.TLA;@M$0F.++1-9XCR_+UYI0W#-N+M9KCPMG?G?LOV%4G'/@CR(XO
M<VJ)X51"OWI]I>G8&Q^)>UO[JD<E,!=>6+%PT#Q=6L[A)S0Z92'EXY'HAV,8
MT[="UB5K=AF)R"&\12W!MR4HN62;>[:^=M[>6BR6[[M\]+&NTS??BOJ^.7*"
M2P&P[\FEW-O#5.^6I IDSW[+IS7W)!5=\.;IDYUTW6)QG@,!JB>QJI%-P!:Z
M,J!]LAF4$-$-D\91/:IJ"O<G9]?ZDM'>6EMZRS25ESS;=\L\GK?56S,R4<\K
M<HVJ?<K-WJX'",^*_P 8''BG+;H)Y)62VUZXAXZ6^GG+Y.;2N;C_ $O8<^J>
M,V Y-#N-Y5PA:VQ=[<'V"&.:I(@;RC06[?.WPN]K9Y]3:N\^ZSL7?\>+!BSO
MX32Z1<J(CR LTU@IFR(YRPK*WT4DG5VS"PX\![8[FKPII(3M)L@12F2DNC17
M#=&4K3%7&&N\9]E!0,Z@1A0PU[]HVU6Z]%9YK7JM>^=]<R.W@HO<,M26\KN1
MXXFXU#;5QI*+:GGCBUT3;=15]Q[INJV6:16DH EE5B5W V6X[,"VJ9"MM"9Q
M$3FS(UXVEF9"4$<3-*AU&IIK=632OG=-MO-O)W2X)/MXLOWP<Q@'AR?^(7)0
M$]YF-[36<Y*B_@RSFQN0_!(DED?B4LRD%O\ ,**\PAIH*66A 1+U2.E:ND->
MJ4#'[4"6Z3(@HQ(6L/0)3!V4M,TO:92ZK)P5^5V[]UV=!?3^;5(\;.'+B8\W
M/1<0Y,P'F)R\N*4U^OO"#2 SF!?%F>\RKXM8CE2E%WA/3G=BKJ3)"8?5DHC,
M9B-D2-G=6J4NYY[*F9A![K<M&TXQ5OW4K-ZK++XLWIDCLMH7/XHY?)V"Q^86
M;9,)L NN_#Y/HA*PL'(MBJ2VI#)6"+J^6:R44M .-,SB4S.<9N;-&*P6RZ9A
M5#W1L4]A/3&B3>B.'@RE&W#\]U=7T=M6[6X63N^9U3@6+E76OB-6XEMI#:46
MX;V=S_\ $L24XA@I$M8F5TO]RL-LE#5)^228#(1I[K6:UV2^H:%7Z>A0H4R8
M5YKBB5N;TQ*BQ9V<5;XE&%^RUK+L=K\7?DF=8\<'=?21.ZUI':(LMVY/2>/T
M2^P=W9.,CA9,;Y@QF"W;J2-W$E!>T, XRVHCV*5E"F\M7Z<:W<6!H=4+TUOS
MNTN3R@.&8=;5M'=I-76MF[.W*SORO8]&:0Q0<D2FJT^D:HU.28I2!."I"E4#
M+"(Y/I0 ( 'Z(,V(K1P !";H/>$(="UK0P?1@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P#Q%6YPLY)3"[_ !!:H8H#,V^%>&Q)^1G.WA4\H65\
M):91<G("Q:'Y15Y#X2:4D+1295&6FM;7A9*-H4+U*1QFXVPP"1Q$>(YZ]<SL
MI*T7?X[1EU**<7?1YIIWO]$;PZ/',RM>-_%FT#3+IH"#\U;8Y]\P.3CE"7>[
M*YD\:NZT98F<^-T*G4KI>CKILYD(25JD2AB\..A#;%YQ)V5/&I0L @;FQN5B
M97:R>[NQ6CNE=2>=EF[9\+Y<S<;ENOQ5DUCU.TR^U;1A=ABXR\,W7CXZ1J+\
MD8O7]NW)('HT-[.5A4M7G&6>M]@RY<K T-MDU;="^H@U=$7$U]C[$0H4*%;4
M(MVSROG*Z;5TDDU9[RTSTUTY7[QQ1%RLK+Q-+F4V"AM"+\'[-\2KEVUQPJO2
M9<PF/?):15=2ZVOY+?@$S'H^1\<WZ)QUWCU9+&ET314VW"U?Y^#5-@69.8#W
M7%6SDHIOJ6:=NO-7O?JM8L?\22D(OR3NCA!QN?*@8I+&;MMI\D5^68I@#>].
M+?0G&N,K+6'4JV<":3G*+M%N68X0F*JDQ+TV#=(TMF[4C <%T<>@S'*\N*TS
MXO3P5WVV+;DR9,B3)T:-.0D1I""DR5*F*+(3)DQ!82B$Z<@H("B2"2@ +**+
M"$LLL(0 "$(=:T,G]\ I:\<%!:,(X]4CRZHN$O<]M[A9R<KBX&6-1AG<'V0R
M"'RM$_TY/(XA:VI(O<%21R06&W+W32=&>$A(S;6*PZ0I56]#<,VXWLI)K/3+
M-?-%.7&?@?R$XZ\SN('#TN"R9[IL]EHCQ0)[+7)*\FPQ!R[J3B]9=0S.-/L@
M&2-"0ZRKD$" 3E0VJG(*\A&84X *,V6B&F&W)2BY/6[BEQ46]Y:6T2:UMXV/
MAHV^_%N74UR4D,.G-WRODBV<.K=?K;JJ<,E[3!\@O(@BSV5(S.%9QF<<<X'4
MM43^,Q 4\30REZGG=C,4Z9"&"0-S4]+F8+@K=]_#[(EH75[;N]9/)99ZV=W?
M*[:RXVNK?6_+N<=NT-'RZKG$HNC48\33P]7KB^\W6#DU9J""V F9Y8JL5VL"
MT;?X]4A8,JJ5DEYD%?):4VQ5Q05RX*)G&TRU(FVU(]A[M^7NRO:W#JN[/+LM
M9\RYZAGFU+"\'RXFB<PF[KDY.(:(Y,5Q=M57,^O_ +PI]R):8Q,F";0%A=VY
M,R%HH+-) (M+4HZY(0,Z: OL8$PF^V/5JAC+LIJS2C=-/6ROUWTXI]Z*[_"(
M;;6A\HO%VA5=S/DTV+J!X)0IVM&5U,]<-]QB55C7UHL#[026*O#%&F:=JZ>"
MK0F.\U0-JJ1F*9F6URQ^>O1,AQ(U.SM>Z]Z3M=2UMG>^C[U=-W/5/@Y# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD=49J?06?JWRYWX):\#N[ES6XU-5AIJS46$K4O9\B@L-42)H@=C/U5,LUL]
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M8-"'KQL;_:9L2A1WL%1Q6.K.22I2A^%@HYWE*M.-2ULDE&G-MO.RS/PU^E.
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M/3ZA\A.LLMP40IC<G'0.+5[\$GJG>]M&GGVJ_(GE@@P!@# & , 8 P!@# &
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MLM/##9I'Y<<F6-"=0O*9G**K2R!KS0WLK6TC:]_]3E?3KM;YEA>#(P!@# &
M, 8 P!@# & , Y2=1%'J#33SZ:JD\\\P9QQQU=Q PTXTP6QF&FF#9Q#,,,&+
M8QC&+8ABWL0M[WO>\$LN2\$03Y#^#WP=Y-V#JR;$@+\W/H&)MCI*&!28^#1Q
M.VM9JP\C2>/L24AO)4&GKU1ZM2 O1BHXW9AN]B^.52:T?T,2IQD[N_<[+P)=
M0#B?QWKF#Q" ,M1P)R9X5&V:+M2^3Q&-R*1*VYB0$-J(YZ?G%J-7O#D-,G+V
MK<5IABE6=W''#$8,6]QYMOF;44E:RRYK/O/AO7C5%+.XR<C..\#01.J 7W2]
MJ548^Q^(-J=O9U]CP%]A">2KV-F$R:>MLVG@"P202U(<K)3;2 6I?,T:"-73
M7-6*K)II+5/EH0ZD'AF"=YQ:\J(MH!3/+[6XR6?6D44Q(1R"HSZSO^@.0G(Y
MM:%!3\28YAY+3?CQ#7Q>>:6D_-61"4N@BWY./2$--;V27)-=M[I>%\C /WAB
M26PZXCO&RS;I85W&.LB.2)=8-<1KUQ8+C,#R$J*\:-0IYU.5\W>8TXEU?77(
M6P4*%0PPQH/G;Z1%9 ^:9O8[JUR(%*VBSLEGFLFGI;_2N)G)APAY760LL67S
M/E# 6J?2JL^.M5MYU45I8]7,;K%:+N*2VA+&J8.C%=IEB)F^]6^4O$/E!,#F
M<4.A[&N]$U*'\DMT_.(+K++1O5KC9+APMUWZC]HWPWGZIY>Q2Y?94*,TV\QI
MGRQ.CD,@$D8F1,"8\#W#AD. MY\FL6:/JDYN5*4U@+)L].Z]PDJ@#BF6-#<K
M<M+$CGU^27V&]DU;6*CK_J4KZ=5K?,^>N_#/=8-QSF-$FV\VN2J54/PBID,F
M!"E*4E&?Q#B,=C"Q_&UBDIYB@F<F,0UJ-MTO*''M*]$FK'<16S3 <LT[:-OM
MN[V.W4)PM7TM>CA<:BPD<A(7?TQNC 3&SFTXO^E1RP1<ED?5Q&]+0"_,I(DW
L$%/1&'VZH'IZ*]E%!]F;!N_#A%?]L=WYZD]\&1@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gym1fcavvjqs000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &" ET# 2(  A$! Q$!_\0
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M7;M_+C^E7:IZ5$8=+MT/79G\^?ZU<KT8?"CI6P44450PHHHH **** "BBB@
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M "BBB@ HHHH **** "L+QG_R).M_]>4O_H)K=K"\9_\ (DZW_P!>4O\ Z":
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M)!Y7F0J=H?;DXR0Q'MBNIH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/$+:M
MKWB";2M(L-)D73H09Y]2,A!,R,I150C@IG)/'(XXJ_X"6WB\.-;PZ>MC-;W4
ML-S"DK2CSE;#,'8EF!X(SVX[5#XB\-^#[S6[:;6[(->W[>5'*9)%#%%)P2I
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MK%[<VLVFW]KK(>!Y&@N-0L3"6A# (&; !?![=OI0!VE%%% !1110 5A>,_\
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M-PV[LC'KFEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA]LD5G,^W8<,&"J2N/?%;FGW]MJFGV]_9R&2VN(Q)$Y4KN4C(.#R* +-%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 5;C4K&TN(;>YO;:&><XBCDE56D/\
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M!Z***8@HHHH **** -S_ )EBP_Z^KC_T&*J=7/\ F6+#_KZN/_08JIUYM?\
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MXE5CM.-V"0, XYP3F@#3HHHH **** "BBB@ HHHH **** "L+QG_ ,B3K?\
MUY2_^@FMVL+QG_R).M_]>4O_ *": -VN3^)7_(BWW^]%_P"AK765R?Q*_P"1
M%OO]Z+_T-: /!Z***8@HHHH **** -S_ )EBP_Z^KC_T&*J=7/\ F6+#_KZN
M/_08JIUYM?\ B,YJGQ,****R("BBB@ KZ#T#_D7-+_Z](O\ T 5\^5]!Z!_R
M+FE_]>D7_H KJPN[-J.[-&BBBNPW//\ XN?\BU9_]?@_] >O&Z]D^+G_ "+5
MG_U^#_T!Z\;IB"BBB@ HHHH *]\^'?\ R(>F?23_ -&-7@==[8^,-4T#P_I%
MI9>1Y36[2'S$R<F:0>OM43FH*[$Y**NSV>L;4/"NB:KJ<>HWM@LMT@4;M[ -
MM.5W*#M;!Y&X&O-?^%F:_P"EI_WZ/^-'_"S-?]+3_OT?\:R^LP)]K$]'NO!^
MA7L4T<]CGS;HWC,LSJWG$;2P8,"N0,8! J*X\#>&[E($DTQ52& 6ZK'*\:M&
M#D(P5@'&<G#9ZUY[_P +,U_TM/\ OT?\:/\ A9FO^EI_WZ/^-'UF >UB>Q*J
MHH55"JHP !P!2UXY_P +,U_TM/\ OT?\:4?$S7RP&+3K_P \C_C1]9@'M8GL
M5%%%;F@5Y7\8O]9H_P!)O_9*]4KROXQ?ZS1_I-_[)0!Y?1113$%%%% !1110
M!](>&O\ D5='_P"O*'_T 5J5C>';JWC\,:0CSQ*PLH<AG (^1:TOMMK_ ,_,
M/_?P4KH9YQ<:)J[:[<Z<--G9)_$<.K+?_+Y2P*J$C.<[AM*@8[U/KRZO=ZH=
M83P_?R)=Z/=:8+8;"\4ID^5F^; 5@.OI7H'VVU_Y^8?^_@H^VVO_ #\P_P#?
MP4KH+GE-OX<\4:)J@CLAJ'VJ2+3HXIH'0VNV*-4F$V>< !B!WW<5Z[4'VVU_
MY^8?^_@H^VVO_/S#_P!_!1=!<GHJ$7=LS!5N(BQ.  XYJ:F 4444 >+_ !:_
MY&RW_P"O)/\ T-ZX.N\^+7_(V6__ %Y)_P"AO7!TQ!1110 4444  ZU]1CH*
M^71UKZ<-W;*=K7$08<$%QQ28R>O+M&TC6;34-'MI=(NA_8MW?W4MS\NVX63?
ML$9SR6WCKC&.:]*^VVO_ #\P_P#?P4?;;7_GYA_[^"E=!<\R\0Z7K6IS:\D6
MB79/B*SLEA8[<6C(3O64Y^7&<\9S4^EZ3XCT[QE,L"ZBD4VLS74\C,AM'M74
MD>_F9VCVQZ5Z-]MM?^?F'_OX*/MMK_S\P_\ ?P4707)Z*@^VVO\ S\P_]_!3
MDNK>1PB3Q,QZ!7!)IW0$M%%% !1110 4444 %%>2:Y>2'Q1JMP;V9-8M=9L;
M>P@$[#]RP3("9P0P+D\5K>,-0T[4]?TVUN=35=(^RWK,T5T44W$>T8+*1\RY
M)QZT >BUA>,_^1)UO_KRE_\ 031X+N+NZ\$Z+<7S.US)9QL[/]YOEZGW(P:I
M>/;F^B\*ZK%;Z?Y\#V4OF3><J^7\I_A/)H ZJN3^)7_(BWW^]%_Z&M7_ .U-
M>_Z%O_R>C_PK'\4Q>(O$'A^XTV+05B>4H0[7J$## _TH \0HKJ_^%:>+?^?"
MW_\  I:/^%:>+?\ GPM__ I:8CE**ZO_ (5IXM_Y\+?_ ,"EH_X5IXM_Y\+?
M_P "EH Y2BNK_P"%:>+?^?"W_P# I:/^%:>+?^?"W_\  I: *'_,L6'_ %]7
M'_H,54ZZO_A!?%7]DV]G_9L&Z*:20M]K7!W!!_[+^M0?\*]\6?\ 0.M__ I:
MX:M*<IMI&$X2<KHYNBND_P"%>^+/^@=;_P#@4M'_  KWQ9_T#K?_ ,"EK/V-
M3L3[.78YNBND_P"%>^+/^@=;_P#@4M'_  KWQ9_T#K?_ ,"EH]C4[![.78YN
MOH/0/^1<TO\ Z](O_0!7D'_"O?%G_0.M_P#P*6O2M.N]?LM+M+1O#VYH(4C+
M"]3!*J!G]*WP].46[HTI1:>ITU%<U>^(M7T^&.6?PXP62:.%<7J'YG<(OZL*
ML?VIKW_0M_\ D]'_ (5U&QSGQ<_Y%JS_ .OP?^@/7C=>Q^--.\2>*-*@LX=$
M2!HYQ*6>\0@C:1CCZUP__"M/%O\ SX6__@4M '*45U?_  K3Q;_SX6__ (%+
M1_PK3Q;_ ,^%O_X%+3$<I175_P#"M/%O_/A;_P#@4M'_  K3Q;_SX6__ (%+
M0!RE;U[_ ,@S1O\ KS/_ *.EJ[_PK3Q;_P ^%O\ ^!2UHS^!O%4UI8PC3( ;
M: Q$_:UY/F.V?_'OTK&O%RA9$5$VM#DZ*Z3_ (5[XL_Z!UO_ .!2T?\ "O?%
MG_0.M_\ P*6N/V-3L8^SEV.;HKI/^%>^+/\ H'6__@4M'_"O?%G_ $#K?_P*
M6CV-3L'LY=CFZ5?O#ZUT?_"O?%G_ $#K?_P*6E'P^\5@@_V=;\?]/2T>QJ=@
M]G+L>WT5A?VIKW_0M_\ D]'_ (57O?$6KZ?"DL_AQ@KS1PC%ZA^:1PB_JPKT
M3J.EKROXQ?ZS1_I-_P"R5V_]J:]_T+?_ )/1_P"%<AXWT/Q-XK:Q,&C1P?9@
MX.^\0YW;?3Z4 >3T5U?_  K3Q;_SX6__ (%+1_PK3Q;_ ,^%O_X%+3$<I175
M_P#"M/%O_/A;_P#@4M'_  K3Q;_SX6__ (%+0!RE%=7_ ,*T\6_\^%O_ .!2
MT?\ "M/%O_/A;_\ @4M %36?^/R'_KSM?_1$=9]=;?>!_%5W.DBZ9 H6"&+!
MNUZI&J$_CMJM_P *]\6?] ZW_P# I:\^=&;DVD<\H2;>AS=%=)_PKWQ9_P!
MZW_\"EH_X5[XL_Z!UO\ ^!2U/L:G87LY=CFZ*Z3_ (5[XL_Z!UO_ .!2T?\
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M%.M?9%LM9LHS=;8P?+D )\SRW*;5/49P1P: /8Z0D*I9B  ,DGM7G1\9WO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gym1fcavvjqs000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' ;$# 2(  A$! Q$!_\0
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M\\-O!]OC\S>N6D P<B!),!5!)R2W/0=/2GP>,[J[@WPZ<@Y,>XREAYA,JKC
MY7,7)S_%0!V%%<K)XDNX[>SN3%')OTXW3QQ-\DCED4 ,02 -Q_.K(U^ZEC96
MLF@4>:DER&RD;(S*3DJ!C*Y&2.O- '0T5Q \1ZB;:QWWEM$\]K=E@4&XO&3L
M8'."..PP>2#BMK39M:NM6%S.B1Z7):JR)N!;>0A],C^,'/M0!NT444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:E6]M7CAD6YA:.9ML3"08<\\*>YX/3TJ/4O^//\ [:Q?^AK0!;HHHH ****
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M<D8-34 %%%% !52S_P!?>_\ 7?\ ]D6K=4[%B9[W*2+F?(+H0&&U1D9Z\@T
M7**** "BBB@ HHHH **** "JNH6\=S8R)++-$@&XO!(4=<<\$<U:J*Y.+68[
ME3"-\S#(''4^U &#X6:VO%DOH)M5E4J%1KZ08*GD%5!Q^)&:Z)AE&& <CH>A
MKA_AL$%GJ.R]AN@958&*#RL#&.1M7T..O'UKN: .;@\-3K#IWF72))93%PL:
M H5+EC@$9!YQGT%:VJQEK>-A(Z[9HR54C#?.O6KU5-2_X\_^VL7_ *&M %NB
MBB@ HHHH **** "D95=2K ,I&"",@BEHH PYY/[$@DBG?_B7.I$4K'_4''",
M?[OH>W3TK3TZ1)=-M7C=70Q+AE.0>*JZ_I<6KZ//:S.Z+C>&7J".15/2=*NM
M*TJV33KKS(]@8PW(X)/)PPY7K[BN=.I"=DKQ_'_AB-4[=#?HK.35XT=8KZ)[
M.4G \W[C'V<<']#[5HUM&2EL4FF%%%4+N*-M4L'9%+*7P2.1\M4,OT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2$A022 !R2:6B@!D4T5Q&)(9
M4D0]&1@1^8I]4M)_Y!<'T/\ ,U=H **** "BJMU-/'/:I#Y6V5RK;P<CY2>,
M?2K5 !1110 4444 %%%% !1110 4444 %%%% !65XDN?LGAV]G_M Z?L3/VH
M0^;Y?(_A[YZ?C6K00",$9% '&?#EE;2[S:(P//SF,Q#=D?>VH 5SZ-DUV=(%
M5?NJ!]!2T %4M4+_ &5-JJ09HMQ+8P-Z]..:NU4U+_CS_P"VL7_H:T 6Z***
M "BBB@ HHHH **** (KDXM)B?[C?RIEB0=/MB#G]TO3Z5'JM[;Z=I5S=W<;2
M6\2;G14W$CZ=Z32;NVO]*M[NSB,5O*FY$*;"!].U %MT25"DB*Z,,%6&0:S_
M .RFMCNTVX:W_P"F+#?$?^ ]5_ BM*BIE",MQ-)F9_:DEK\NI6S0#_GM'\\1
M_'JOX@?6G3W5N^I:>%GB8OO*@.#N&WJ/6M&N3U/PE:7'B6SO8Y7M]QRR0@+\
MR\@@]C64W5@O<7-^ GS+;4ZRBLW^R/\ J(ZA_P!_O_K4?V1_U$=0_P"_W_UJ
MOFG_ "_B.[[&E16;_9'_ %$=0_[_ '_UJ/[(_P"HCJ'_ '^_^M1S3_E_$+OL
M:5%9O]D?]1'4/^_W_P!:C^R/^HCJ'_?[_P"M1S3_ )?Q"[[&E16;_9'_ %$=
M0_[_ '_UJ/[(_P"HCJ'_ '^_^M1S3_E_$+OL:5%9O]D?]1'4/^_W_P!:C^R/
M^HCJ'_?[_P"M1S3_ )?Q"[[&E16;_9'_ %$=0_[_ '_UJ/[(_P"HCJ'_ '^_
M^M1S3_E_$+OL:5%9O]D?]1'4/^_W_P!:C^R/^HCJ'_?[_P"M1S3_ )?Q"[[&
ME16;_9'_ %$=0_[_ '_UJ/[(_P"HCJ'_ '^_^M1S3_E_$+OL:5(S*BEF(50,
MDDX K._LC_J(ZA_W^_\ K5!>^'DO;*:VDU&_VR*5.9<C\L<TG*I;2/XBN^Q;
MT:1)-)MVC=74@X*G(ZFKU<SX=T&;3]'1;74YD,C%V!C4KGIP",CIZUJ^7J\?
MW;FSF_WX60_F"?Y4H5)\J<XV?R!-VU1HT5G?:=4C^_IT4GO#<?T8"C^U2AQ-
MIU]'ZD1!Q_XZ35>UCU_)CYD377_'W8_]=6_]%M5NN5U3Q?IUKJ]A;E)CA]SN
M4*A,@J.&P>]=51"K"HVH.]@4D]@HHHK0853L5(GO<O(V)\ .Y8 ;5.!GIR35
MRJEG_K[W_KO_ .R+0!;HHHH **** "BBB@ HHHH **** "D;(4E1DXX&>M+2
M$!@01D'@B@#$MM9NYK;393!")+F5HY(5<DC#$%E..@ R2:O:K*B6\:,3N>:,
M+A2?XU_+\:?'I6GQ&,QV5NAB),96,#;DY./3D4:E_P >?_;6+_T-: +=%%%
M!1110 4444 %%%%  >1@T=!@444 %%%% !5.Y_Y"-C]7_P#0:N56FMGEN[><
M3;5BSE-H.[(QU[4 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;'J9!?\ UJ^:X$@#*57)SM  8<#O707$+6_AZ:%G:1H[5E+NVXMA,9)[GWH
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M<#T'S=3R/3I5*"'28X]61Y89%5,6DCL2[''!&,?RX[U;QN*6\HC]K/NCJO\
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M!DEB25@K;<GY?,P"/^ 8)_&G3S'$SOJE;N"K39N_\+,M/^@7=?\ ?:?XT?\
M"S+3_H%W7_?:?XU@BR\.6DDC_;Q<KM=0A<$G,?&WCJ&XR?:H9-*T$(1%K&7)
M8*68 ?Q8SQQT7GOGM5O&XKO$?M*G='2?\+,M/^@7=?\ ?:?XU8L?'-GK5]#I
MC:=<QBZ)CW,ZX'RD]CGM7#:S!ID!@&F3&5<.LC%\DD,<'&.,C%.\+?\ (V:5
M_P!=S_Z U%/,,0ZT:<FM6M@C6GS),]IHHHKWSK,Q&N9(IKA]0$,:RNO,:X4!
MB!R?I3XH[B>,20ZKYB'HR1H0?QI;:(3Z=<0L%(>69<,,CEVK!/A;4HM/CM[3
M56@*)#&!&[(H5(RK8'(!+$-G'8 T =!]EO/^@B__ 'Z7_"C[+>?]!%_^_2_X
M5SDOAC69KB::35@7W/Y!#R+Y09&7<,'KRIQTX-37'AK5=RBTUNXCC\PLR-,Y
M)&Y]N&.<;0RCWV\T ;OV6\_Z"+_]^E_PJ&4O!O\ .UA(]B[VWJ@VKSR?;@_E
M6;:^';V'4[.ZFU%[GR'+.LDK]6#@D<XZ%!CI\IJC-X-OKJ>9[F_5]Y +%G+.
M [,">?EX.,+QQ0!T4237"LT.K"158J2D:'!'4?6I/LMY_P!!%_\ OTO^%<Y_
MPBFIQAHK36I8;<K( B2L-K,[L3W)R&'<$%>*G?PWJKW5RQUJ<0.[-$JS.-HV
MN$!QS\I*]^=O(S0!N?9;S_H(O_WZ7_"J]_:W9TZZ!U!R#"^?W2^AK+;0=;$L
M$@U9V\J5I'596!FY!&<Y"\ KM Q@YZUNW!E.C3&<()OLY\P(<J&V\X]LT <C
M!\-=/-O$?[0O.4'9/3_=I_\ PK33_P#H(WG_ (Y_\3796_\ QZP_[@_E3WD2
M-=TCJJYQEC@5R_4L/_(B/9P['%?\*TT__H(WG_CG_P 31_PK33_^@C>?^.?_
M !-=G'/%+GRY4?'7:P.*DH^I8?\ D0>SAV//[+X<6$@N,ZA>#;.XZ)Z_2K/_
M  K33_\ H(WG_CG_ ,375:=]VZ_Z^7_G3?[5C_M6"R$3L)XV>.964J=N,C@Y
M'4<XQVI_4L/_ "(/9P['+_\ "M-/_P"@C>?^.?\ Q-'_  K33_\ H(WG_CG_
M ,36U8^*K34+*2Y@BDPMTEJ%8CEV(&."<$9Y!Z8-3'Q!"NAW6J?8[O9;/(CP
M[!YGR,5)QG&.,]>E+ZEA_P"1![.'8Y__ (5II_\ T$;S_P <_P#B:K3_  XL
M%O;1/[0O/G+]D_N_[M=0^O;=4CL5L+J1FN3 \D:ADB^0.&8]@0P_&K=U_P A
M*P_WG_\ 0:?U+#_R(/9P['*_\*TT_P#Z"-Y_XY_\31_PK33_ /H(WG_CG_Q-
M=A=726L#R-AF52P3< 6P,G&:SQK\1TNRU!;:9H;IT3@KE"S!1D9YY/;-+ZEA
M_P"1![.'8Y__ (5II_\ T$;S_P <_P#B:/\ A6FG_P#01O/_ !S_ .)KHGUZ
M&._6V^SS,'N_L@D4#:'\O?SZ#MWYIESX@AMM2DLG@DW1^62^1C:[A,]<\%A^
MM'U+#_R(/9P[&!_PK33_ /H(WG_CG_Q-5K/X<6$GVC.H7@VSN.B?_$UV6DZB
MVJ67VEK*YLSYC)Y5RFU_E.,X]#U%+IW2Z_Z^7I_4L/\ R(/9P['*_P#"M-/_
M .@C>?\ CG_Q-'_"M-/_ .@C>?\ CG_Q-=O12^I8?^1![.'8XC_A6FG_ /01
MO/\ QS_XFC_A6FG_ /01O/\ QS_XFNWHH^I8?^1![.'8XC_A6FG_ /01O/\
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MZ )XK:" DPPQQYX.Q ,_E4M4]FH_\_%K_P!^&_\ BZ-FH_\ /Q:_]^&_^+H
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MB4,A3!:5G^565MHW$X!**3CKCFK&S4?^?BU_[\-_\71LU'_GXM?^_#?_ !=
M%RJ6G=+K_KY>EV:C_P _%K_WX;_XNJFGIJ&+K$]K_P ?#_\ +%O_ (J@#7HJ
MGLU'_GXM?^_#?_%T;-1_Y^+7_OPW_P 70!<HJGLU'_GXM?\ OPW_ ,71LU'_
M )^+7_OPW_Q= %ME5U*L 5(P01P144=G:Q.'CMH48=&5 "*AV:C_ ,_%K_WX
M;_XNC9J/_/Q:_P#?AO\ XN@"Y15/9J/_ #\6O_?AO_BZ-FH_\_%K_P!^&_\
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M?_%T;-1_Y^+7_OPW_P 70!%9:'8Z==^?9PK"-C*(D " LVYCCU) _(5)J/\
MRZ?]?*?UI=FH_P#/Q:_]^&_^+JGJ":A_HN9[7_CX3'[EO?\ VJ -9T25"DB*
MZ,,%6&0:I?V-8^;)+Y<@DD&"PF?.,,,#G@#<V .!G(I^S4?^?BU_[\-_\71L
MU'_GXM?^_#?_ != $!T.S\NTB3S4BMHGA1!*W,;  KG.>PQSVI/^$<TCRX8V
MLDD$!0P^:2YCV8VX+$D8VCZXYJQLU'_GXM?^_#?_ !=&S4?^?BU_[\-_\70
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M'[0N<C8<9 !(STR RG'H:NUF0Z';1:JNI.[RW2QF-7<*#@XR20 2> .<UIT
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M35NB@"IOU'_GA:_]_F_^)HWZC_SPM?\ O\W_ ,35NB@"IOU'_GA:_P#?YO\
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MKE8GL5B'V6.Z:0/E2L@!C ..3PX/IM'K5ZRL-'DM5:SM+4P%G VQ#&>4;MZ
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M'Y?2@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIN8F)RZ8(P,9;GCH.*BD\+3R22/)-:3?-))&DD+8#R,KN20V>"ORXZ9]J**
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gym1fcavvjqs000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000007.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" &> IT# 2(  A$! Q$!_\0
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M_3?\$)XM7B_X(]_L[KKJ2+-_PK.P*>=][R2"8C]/*V8]L5\7_P#!/^XN+O\
MX.O/VM?^$G=FNH?A_9IH^[M;^5I7"YYQ@]N^: /L/]@/_@M'^RS^W3^SO\0_
MCO+9:M\.[SX/M<+\6?"OC)52\\->3'+(\DA0X>(B"<*V%;=!(I167%?-&G?\
M'4?PC2TT/XV>,OV _C-H'P%\2>)O[%TGXVWUE UD\GFM%YS0*3^[5D<L$E=P
M(V"J[C97YO?M42^)M(^*_P#P5TN_A$S1Z:9M(BUB33?]7YDWBRT%TK8XWLIO
MP_MYN>:^L_\ @H%!X(_X@Y?AE_9XM_+7P+X+:U\PK_Q_>?!Y^W'\6\S^^-V>
M<T ?HM_P4F_X+%?LD_\ !-#X1Z?\0_B9J6H>)M;\2:3)J'@OP7X7MS-?:U;H
M@=[D,?DAMHT(>29R JYP&;"GM?\ @F7^W9H'_!2C]B_PG^V3X8^'MYX5L?%4
MVH1PZ'?WR7,MO]DOI[,DR(JAMQ@+# & V.U?.'QV^'/AJZ_X-V=4^)'B[P-I
MLGC+3/V(+JPCUZ\TR)M0M(I?#*M<6ZSE?,1'=%+H&"LR*2"0*;_P:N?\H-O@
M_P#]?WB3_P!2#4* /T,HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,T9&
M<5^-?_!6+Q[^V#X^_P"#C?X%_L,? 3]L[QS\+?#?Q(^!ZIKK>&M2<Q1*MWK]
MQ<7$5LY, O'AL4A2X*%T^4@X7%4_V)OB3^TG^PC_ ,%T_B5_P2U\5_ML?$SX
MF?#'4/A3<:_H^M_$K7WUK5M F6SCNEF,I7)9 95*HJJ^8SL!Z@'[/[AC-?/7
M_!2C_@I-\!?^"7_P"7XZ_'&RUC5I-2U6+2O"_A?PY;QRZAK6H29V00K(Z*
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M^+H _2*OS?\ ^#L%6;_@B9\1=JY_XJ'PZ?\ RJV]-_X=]_\ !P=_TFZ\+_\
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M_P 70!^D5%?F[_P[[_X.#O\ I-UX7_\ #*VO_P 71_P[[_X.#O\ I-UX7_\
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M4:)<'69M-M3##-);WUQ:B4(6;:SK K-@[=[-M"C"@ ^G**** "BBB@ HHHH
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M_@#\+XEUS1?AC"DLDVO>*U;$-YJ*N@A>W@1G\N/<^6)W##L* /SG^#?_  4
ML_V(OVC[[]L+]MK]ECXF_$_X^>/?ALOB'1/!/@+05U#_ (5!\,HW9;:*8LP$
M#.%\VYD &"PWL"[ _LC^S#^T7\-OVMOV?/"/[2WP?O;BX\,^--%AU/26NH?+
MF6-Q]R1<G:ZL"K#)P5-?)/\ P4/_ ."+7C;]K_\ ::N/VJ_V<_VY_$'P1\2>
M(OAK+X ^(']E>$8-6CU_P_)*7>W4231&UE.<><I9AM0J%()/U7^R!^S'X"_8
MQ_9E\%_LL_#&XO)]"\$:'%IMA<Z@X:><+DM+(0 -SNS,<  %L 8H ^8_CO\
M\%D/&_[,7[:7AW]FSX[?L ^/-#\"^,/B);>#O"OQA_M:VDT_4[ZYC+0&.W"B
M3:S @Y8;55FYQ@_<E?G#_P '#@']I?L:\?\ -XWA?_T3=U^CU !1110 4444
M %%%% !1110 4444 ? '_!T=_P H*/CG_P!RS_ZD^DU]_P!? '_!T=_R@H^.
M?_<L_P#J3Z37W_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'YN_L\?\K0_P"T%_V;?X?_ /2FTIOB_P#Y6HO"?_9I]S_Z
M=9J=^SQ_RM#_ +07_9M_A_\ ]*;2F^+_ /E:B\)_]FGW/_IUFH _22BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/X]?\D,
M\:?]BGJ/_I+)7R/_ ,&V'_*$7X"_]@75/_3S?U]<?'H_\6,\:?\ 8IZC_P"D
MTE?(_P#P;8'_ (TB_ 7_ + NJ?\ IYOZ /N2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH _.'_@X<_Y"7[&O_9XWA?\ ]$W=
M?H]7YP_\'#G_ "$OV-?^SQO"_P#Z)NZ_1Z@ HHHH **** "BBB@ HHHH ***
M* /DO_@N=^R7\:/VY_\ @EE\4?V6?V>M'M-0\8>*/[$_L>TOKY+:*3[-KEA=
MR[I'^5<0V\A&>I '4U]: YZ4$9&*  .E !1110 4444 %%%% !1110 4444
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M_P#:O\,_&;X8_'G5+?2?$]K:?#NQT63P9?2/;B6.":T16N$B%TKK)+DRI;R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  4^$?AOP'^SI\1]2\2_\+F\/:DLFO>-H9KB6>*&6-?WN<NB$2A J+P3M <
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MHSJ2%SSMZ9KTC0= T/POHEIX:\-:/;:?IVGVZ6]C8V4*Q0V\2*%6-$4 *H
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M?^#AS_D)?L:_]GC>%_\ T3=U^CU !1110 4444 %%%% !1110 4444 %%%%
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MY.#O/^P;:_\ H%3(NG\1XW1114FH4444 %%%% !1110 4444 %%%% !1110
M5]U_L._\F[Z7_P!?=U_Z-:OA2ONO]AW_ )-WTO\ Z^[K_P!&M51)G\)Z[111
M5&(4444 ?!__  7<_8:^/'[97PP^%GB7X ?"GPG\2M2^%OQ*A\2ZG\*?'%X(
M=-\4VGV:6%H)"Q"%E9E(60A2&?.?NMXS_P $K/V _P!IB\_;I\5_M6?M)_\
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MOBCPC9?9/ MS\6O&:ZK%X7@ VK'8Q1P0I&%4D)N#[,Y7!P:]:^*/_!/#P_\
M'']OCP7^VQ\8_BCJ&NZ7\,]%DC^'OPUDL533=)UB1@9-9=]Y,]SL&Q,JHCPI
M!R,GZ.HH ^._^"@?_!$?]DO_ (*+_%RP^.?Q,\=?$KP;XHM_#+^'-8U/X:^+
M%TMM?T5W+MIM\'@E$MN2S95=A8-@D@+CZ6^ WP/^&7[-?P<\-_ 7X->&4T?P
MOX3TF+3M#TV.1G\F",8 +,2S,>26)))))Y-==10!^</_  <.?\A+]C7_ +/&
M\+_^B;NOT>K\X?\ @X<_Y"7[&O\ V>-X7_\ 1-W7Z/4 %%%% !1110 4444
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MKT6C^.-)O/!MKIW_  C=P[6X<6[QDM)L%T9$?Y XMG5D7<#6%^UO_P %W_\
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MBBB@ K\5_B9_R4CQ!_V'+O\ ]'-7[45^*_Q,_P"2D>(/^PY=_P#HYJ_/>/\
M^#A_67_MI\SQ)_#I^K_0PZ***_-3Y4**** "BBB@ HHHH **** "BBB@ HHH
MH *_<0=*_#NOW$'2OT;P_P#^8G_MS_V\^HX;_P"7O_;OZA1117Z,?4!1110
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MP? O_!>S6?"FO:;K%Q/\2(?#NWSO!UF2TL>GWEQ%JD;1PPQQ;55P@ A^Z".
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M?\%'A_RT\!_^$NW_ ,>H _?ZBOP!_P"(D7_@H]_SU\!_^$NW_P >H_XB1?\
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M86L<$,2[8X88PJHOH . *_ 7_B)%_P""CW_/7P'_ .$NW_QZC_B)%_X*/?\
M/7P'_P"$NW_QZ@#]_J*_ '_B)%_X*/?\]? ?_A+M_P#'J/\ B)%_X*/?\]?
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MM?TO]L/PN^IZ'9ZO#+>6B^5=#=+"K%XQEE&6 Y8>HK].Z_([_@NO^Q-^RO\
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M 4444 %%%% 'TY_P1K_Y2:?"/_L8F_\ 2>6OZ7*_FC_X(U_\I-/A'_V,3?\
MI/+7]+E !1110 4444 %%%% !7XK_$S_ )*1X@_[#EW_ .CFK]J*_%?XF?\
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MMK_Z!4R+I_$>-T445)J%%%% !1110 4444 %%%% !1110 4444 %?=?[#O\
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MRH4444 %%%% !1110 4444 %%%% !1110 5^X@Z5^'=?N(.E?HWA_P#\Q/\
MVY_[>?4<-_\ +W_MW]0HHHK]&/J HHHH **** "OAO\ ;N_Y.#O/^P;:_P#H
M%?<E?#?[=W_)P=Y_V#;7_P! J9%T_B/&Z***DU"BBB@ HHHH **** "BBB@
MHHHH **** "ONO\ 8=_Y-WTO_K[NO_1K5\*5]U_L._\ )N^E_P#7W=?^C6JH
MDS^$]=HHHJC$**** "BBB@ HHH;I0 45^2/_  5<_P"#BC]HW]CWXX6?PH_9
MI_8NN)_#NG_$B+PAXB^)GQ*TZZBTN^U \R6FF10RQ-<%$RYG\PJ. 4^96/VQ
M_P %3O\ @I'X%_X)>_L>:A^U'XT\&W/B2\^V6^F>&_#%G=>0VJ:E/GRX3*5?
MRD 5V9MK$*IPK' (!]+45^4/@S_@MG_P4>_9=_:E^#/PB_X*T?LB_#OPCX._
M:#NHK3P'XE^'VM7+RZ)=220((=1$\LJN4:[MED*^4$#LX+A65>D_:#_X..KO
MX-_$[XE:EX/_ & /%'C#X)_!OX@P^#/B9\8;/QM96KZ=JC2")UM]+DC,MW&L
MGR[Q(JG@DJ&7(!^G5%?'G[9O_!1?XD>%?VD?A?\ L*_L.>$M#\5_%7XA>5K6
MLWGB*VGFTKPAX64YFU.]CMY8I"[CY88M\>]^K?=5OL,'B@#\X?\ @X<_Y"7[
M&O\ V>-X7_\ 1-W7Z/5^</\ P<.?\A+]C7_L\;PO_P"B;NOT>H **** /GS_
M (*N?\HX/C-_V(EY_P"@BOYBJ_IU_P""KG_*.#XS?]B)>?\ H(K^8J@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ^G/^"-?_*33X1_]C$W_ *3RU_2Y
M7\T?_!&O_E)I\(_^QB;_ -)Y:_I<H **** "BBB@ HHHH *_%?XF?\E(\0?]
MAR[_ /1S5^U%?BO\3/\ DI'B#_L.7?\ Z.:OSWC[^#A_67_MI\SQ)_#I^K_0
MPZ***_-3Y4**** "BBB@ HHHH **** "BBB@ HHHH *_<0=*_#NOW$'2OT;P
M_P#^8G_MS_V\^HX;_P"7O_;OZA1117Z,?4!1110 4444 %?#?[=W_)P=Y_V#
M;7_T"ON2OAO]N[_DX.\_[!MK_P"@5,BZ?Q'C=%%%2:A1110 4444 %%%% !1
M110 4444 %%%% !7W7^P[_R;OI?_ %]W7_HUJ^%*^Z_V'?\ DW?2_P#K[NO_
M $:U5$F?PGKM%%%48A1110 4444 %!]Z*&Y% 'X[_P#!X+_R0K]G''_1>+;_
M -)9*O?\'A>GZF?V OA'XD3S/[-TCXX:7/K'4(L1L+U0S'L-Q YXRWTKWK]J
MO_@VW_X)[_ME_&OQ!\=_C;XF^*EQJWB+6GU2ZL[/QXT=E;7#  F"%HF$0P.
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M %]W7_HUJ^%*^Z_V'?\ DW?2_P#K[NO_ $:U5$F?PGKM%%%48A1110 4444
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M4_X6%<>![5_$QUJ,I>--@[&G!P1*T7EL^0#N)R <B@#YE_X.'/\ D)?L:_\
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MQT5^SG_$)#^QY_T>E^T%_P"%%I?_ ,KZ/^(2']CS_H]+]H+_ ,*+2_\ Y7T
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MN7P'_P"DBG[3G_A;6'_R#1_Q"Y? ?_I(I^TY_P"%M8?_ "#1_J#B/^?Z_P#
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M];&^\20Z3"NH7-JI#+!)<!?,>,$ A"Q4$ @5N44 )M'>E Q110 %03FBBB@
MKF/BG\:_@Y\#-#A\4?&SXL^&?!^EW%R+>#4O%6O6^GP23$%A&LD[HI8@$[0<
MX!]*Z>OQZ_X/'+?2KO\ 9,^"-IKJQ&QE^-5LEX)VPAB-K*'W$]!MSGVH _5'
MX4?M'?L^?'G[5_PHWX[>#?&?V''VS_A$_%%IJ/V?.,;_ +/(^WJ.N.M9_A7]
MK+]G#QS\?_$7[*WA'XQZ'J'Q&\)V,=[XD\'V]UNO=.MW6)DDD3LI$\)Z])%]
M:_"3]M;X;?L5_L\?\%F?V.;3_@B+J&C6GC;6/$$</Q(TKX5:W]ML3IIN[/'G
M>5(\8#VQU+SU)QY42LX& U?2O[%>H76D_P#!U_\ ME:K9:7+?36OPEL)8;*#
M'F7#+8Z 1&N>[$8'N: /V*%%?E%^T/\ \%XO^"G/[('@&#]I?]JC_@BCJ7@[
MX0-JMM:76O77Q8TZ75+<3':N^QC5I8V+9 WJJYV@D$BO8_V[O^"WR_ /Q]\)
M?V<?V.OV9-6^-7Q:^-'AV'7_  KX3M]7BTRWM]-EC\R.:YN)01&6 <@8"JL3
ML[H-NX ^^J#G'%?!?BK_ (+$?&+]E']@OQY^U[_P4K_86UKX1Z]X/UZ'2-+\
M%V?BJTU4>([B=5\C[)=Q'RRFXMO;+!1&Y&[&#X/\"/\ @YB^(-]^T1\-?A/^
MUU^QGX;\#^'/BUK=OI?A3Q-X1^-6C^));2:X9$A-_:V3L]H"TL2D2[&7<WRG
M8P !^D^@?M;?LU^*OVC=<_9$\._&C0;SXF^&]+34M>\$PW@-_8VCI ZS21]E
M*W-NWTF7UKT6OP)\;_M#?'S]G/\ X.UOVCO$/[,7[*>K?&3QOKGPOTK2-#\(
MZ;JT&GQ*[Z+X:F:YNKJX(CM[=%@92['[[QK_ !9K[T_X)V?\%U- _:BC^-G@
MK]KOX#W7P3\=?L_V<NH?$+0+K5AJ,,-C&'\V6.2-%+LACP556#;XRK-NH _0
M*BOR+M_^#C+]NKQM\"=4_;N^$'_!&_Q!JW[.NDS3/<>.=0^(EE;:DUG#(4EN
M%L K2,JD?,Z!XU(8%R%)K]*/V//VJ/AG^VY^S+X-_:I^#LET/#_C31H]0L[;
M4(U6XM6.5DMY@K,HDCD#QMM9ERIP2,$@%'XI?MR_LO\ P:_:6\!_L>^/_B8M
MK\2?B7#<3>#O"MKI5U=37<,(=I)G:")TMHP(Y,23,BMY4F"=C8]:K\A?V0+L
M?M,?\'7G[07Q*\0-]J7X-?#"W\/^'O,Y6U\Q;5'V9Z'=/=#_ +:/ZUZ+\8/^
M"[/[4NG?\%&/BY_P38_95_X)N7_Q7\9^ 8;*?1;C3_&UOI]O<6\EE#<SSWLE
MTJQVJHUQ%&@#/YC'&0=JL ?IK17Y_P#[ /\ P6Y\3_MR?LB_%[XOZ)^QCXC3
MXI?!?6&TOQ-\']&U1+F[O;KD+';3-&N26CG4JR9#0-P<@GG5_P""W'[?G _X
MA]/VA?\ P+A_^,4 ??GQ0^-7P=^"&A1^*/C3\5_#7@_39)O*BU#Q1KMOI\#R
M'H@DG=5+>V<UJ>%/&'A3QYX<M/&'@?Q-I^M:3?Q>;8ZII-['<6]PF<;HY(R5
M<9'4$BOS,_X*YZM_P0K^&7Q%T7]HO_@KWX>UG4/'/C#X<JOA'P#K5CJNI)8P
M0 M/!9QVD8MK:Y:6=5>2:1-S(A#*JDUY%_P:J_L]^*_B+_P3A^.WA6_^)6M>
M&_ 'Q*\57UGX)M/#/BR'^VO#5K-9M$]U')&TALKG;)$4+KNW0"0J5(+ 'ZV6
M/[2O[.NJ?$V7X*Z9\?/!-QXR@8B?PE;^*K1]3CP 3NM1)YHX(/*]"/6N9^+7
M[<_[+_P+_:+\ _LI?%;XE_V/XY^)XG_X0?2[C2+MH=2:+.]!=)$;>-^,!))%
M9BR@ EAG\(_^#D;_ ()\_L;_ +'/C3]G'X*?\$U/A-<>'_COKGB*1[&W\+ZI
M/)JE_#NB2UNII))"YG:[!\N;(.5F).%&/KC_ (.J]!\=?!_]C/\ 9[_;5L=1
MCF^('P;^+FCO)JD(VB5I;2228@X^ZUS9P<$=&/T(!^P .1FBL[PAXET_QGX3
MTOQAI.[[+JVGPWEMNZ^7+&'7/OAA6C0 %0>M XXHHH S?%_C'PE\/O#%]XU\
M>^*=-T31M,MVGU+5M7OH[:UM(AUDDED(1%'=F(%<3\-_VQ?V1_C'XFC\%?"+
M]J7X<^*M9DC:2/2?#?C>POKEU499A%#,SD =3CBOFW_@XW_Y0H?'S_L6[+_T
MZ6=?B#^UW\(_^"9GP]_X(2?L\?&WX 7GA+2_VHKB^T>?[1X-\0!M>EN=TC3/
M<PPREHW0K$RLRJRN$VG)P0#^G;7/B_\ "CPQX\TGX6^)?B=X=T_Q-KT;R:'X
M=OM:@AOM11,[V@MV<23!<')12!@YKHJ_(_XZ?%+X2:5_P5Q_89\!_M*?L=P^
M*OC5X@^%-G>1_$B^\97EG/H-^EM=-)&UC%_H]RWGQ2G=)]TR''05X+^Q;^WW
M_P %D=9_X+V_'+P8G[*NJ>);J2ST^W\5_"'4OC9;_P!D^ M-+Z<AU2U,DIMY
MW,160Q6Z^83<N#DAJ /WJK,\:>,O"_PZ\':M\0/'&N6^EZ+H6FSZAK&I7DFV
M&TM88VDEF<]E1%9B>P!KX&_:R_X+7?&G0_VYM8_X)V?\$X/V&;[X]?$;PAHT
M>H^.7;Q=;:)INCAQ&PA:YN1Y9<++%N)91ND"#<RN%XOPG_P5YA_X**?L$_MC
M_ ?XJ_L_:I\*?BY\)_A#XHMO&G@C4M32\5 ^E7B>9#*JKN570JP*X&4(+!A@
M ^[?"'[;O[(7CKX'Z7^TKX=_:5\%-X UJ^>RTGQA>>(8+73[JY622(PI-.R*
M9-\4B[,Y)1L#BO4D8.N]6RIY4CO7\W>F?%/]FGX-?\&HG[/7C7]I_P#9)M?C
M'H\GQVU2QT_P[=>,+W0Q:73W&ORB[%Q9_O&PD#Q^6?E82Y/W17Z5_ME?\%G/
MBM^S]^V5X;_X)G?L%_L/P?%/XB+X'M=:N-,UGX@67ARSM[1H_P!W;6TMX0MS
M*L81BH(.&PH8J^T _1JBOCOXG?MV_P#!0G0?V4OA_P#%'X6?\$J?$OB/XH>,
M-0N;/7/AI<>,+.SC\--%Y@$MS>R 1>4Y1=K< A^O3/GO[ __  6:^.7QU_;S
MUK_@FQ^W'^Q!)\%OBE8^%SK^G6=KXTM];M;JV 1MOG6Z[-Q1]X*LP^1@<$8H
M _0:BORC@_X.$OVQ/BO^T)\>OV7_ -D+_@EAJ/Q*\3? [Q]K&DZI>6OCNVL=
M/_LJQNY[9;N:6X12MQ,;:4I;('+;3M+D$#.^.W_!9WX\_MS_ /!!3XE?M?\
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M%)+GPY_PEGBCQ%JWB7QWJ]OJ%\87U.6VN#8+%),$8J";1Y,[6YF8]ZM>(/\
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M]C"=L4UY;P$),5'!<'35.[KF:3^\<@'Z\BDV"E'3I10 4444 %%%% !1110
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M^%OP\\0:[ =6UBRM;66*5;QRZQ6TTC7,WEQOY>/+4.?F#5Y-^PO^S;\--?\
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M=2\)Z7\3+/5K=O#;6-W+,WVMKC'E K'*P&90"0N[:Q*5^JG_  2<_8T\2_L
M_P#!/?X:_LH^-M>M=2USPSHS?VY=:>S-;F\FF>>5(BP!9%:0H&(!8+G S@?1
MF* ,4 ?D%^PA:O\  3_@ZG_:D^&VOX@;XE?#^UU_0UF.&N$'V*1BG][!\[@=
M I_NFN\_8B_98_:+\#_\')_[4_[3'C#X+^(M-^'WBKP/I]MX;\87FFNFGZE,
ML&DJT<,I&UV!AE! Z;&]*^OOC+_P37^ 7QF_;I^&?_!1*]UOQ-H/Q(^&.FW6
MFV-UX=OX(;?6K"995-IJ"202--$HGG*B-HV!F;+'"[?H, #H* /R._X(Z?\
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M?\$E?C5\(O@OX$U/Q-XGUKP_:QZ3H.CVIFNKQTU"UD98T7EB$1FP.<+7D?\
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MW!%=-^T?^Q5^UGXC_P"#3;PC^R;H/[/'BR\^)EGI^ABZ\"V^CR-JD1CUM9I
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7Y-LIDP$8NV$C!8[%P ?0PZ4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gym1fcavvjqs000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %D 2,# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP#GCU&#0!TU<WX"_Y$NP^LO_ *,:NC9U12SL%4=23@"N<\!'/@K3R.0?,_\
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M@#TBBO/+#XN:3?:Y#8"RN8H)I!''<N1U/ RO89]Z]#H **** "BBB@ HHHH
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MBB@ HHHH \X^*MMJT\%C+8&2:V@#--;Q7RVQ$A*^5(VX@.HVN-N>K \XKH_
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M5)XU3QG?168UUI)PR:<;.1!:(N(S&S ]"'$F\L.A '6O84W^6OF8WX&['3-
M#JJ:EJ-MI&FSW]X[);P+ND9$9R!]%!)_ 5;HH \>M?BAJ.H^)H=&BN88+%[H
M%=4_LZX+31EQMA$90!'P=I<G;W%>PUXWYGC@>-YK8#7#<R7:.)-Z?8$A$Y/
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M3VHHH KV=A;V/GF!2&N)FFE9F)+,>_Y  >@ JS110 4444 )0*** %I  .@
MR<\444 )L3CY%X.1QT/K0(T485% SG '?UHHH 3RX\J=BY7[O'3Z4>5'N+;%
MW'J<<FBB@!=B?W5Z8Z=O2E "J%4  < #M110!6M-/MK)[AH$V^?*9G&> [8W
M$>F<9/N2>]60 HP  !V%%% ";$W[]J[P,;L<XILL0EC=264NI7>APP!]#VHH
>H 99VD%A9PVEM&(X(4$<:#L!P*GHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gym1fcavvjqs000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] ET# 2(  A$! Q$!_\0
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MD#H,DDX'8=!5N@ HHHH **** "BBB@ J"XO;:TEMXYYEC>XD\J(,?O-@G'Y
MU/7F7C_1?$NL>)=.DL1%';PN$M"90#YNTR%B.WW,?\!'K0!Z;14%FUP]E"UW
M&L=P4'FHIR V.<'TS4] !1110!G7NOZ-ILX@OM6L+68](Y[E$8_@35Z*6.>)
M989%DC895T.01[&O+_$MQ<:;XDU"&-3;23L'M(K;3[65;K*C)D9SNR7W ].
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MKR[%G%YK122*/O% /E^M2P2F:(.8WCS_  OUIW5[!?H24444QA1110 4444
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M3 Z!H]HP-I'&/;% $M%%% !5/5O^0-??]>\G_H)JY5/5O^0-??\ 7O)_Z":
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MK%Q'C:Q//.>/TK*%6\^5D*7O6-NBBBMS0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/5%\2F]/]F/8"VVC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI&QW6SX!^Z#G\*Y7>_F[]S>9G.<\YK*I6M;0F4[=#T*BLRSUFVE1(YI/*G
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M[::TEN$<+E+R)]KM[D8Q^@-<L543U-(>U3=T=K17GMQ/K_AK/V?Q%8:G O\
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M<&Z!#]?<9Q6'LNM_D9\B<[7^1@_\(-=C[OBK6!_VV/\ C1_PA.HCIXNU<?\
M;5O_ (JNQHI^SB:>SB>9>*O#M[IFDB:76=2U1C(%C@=6<9]>IQ@9_.N9T+3I
M=8U2.RF2XM8Y24$ZPE@K#L?Y5[/JK%-)NW$Y@(B8^: 3LXZ\<_E7*^!9&-Q=
MH=1-Q]Y_*VN.K??YXY_/UHY.S(:M)),ICX7 ?\QN7\;<?_%5+%\-WA;='K<B
MGU6#'\FKO:*:BD:*"1Q-YX5U&TTNZD_X26\:..)F:,AL, "2/O=Z\VKW^N&D
MU>-?'83[?;C"FVQ]F?KY@^3Z_P"UTJE8;=AMAH?BE[&WE@UY5B>-6122< C@
M=*O)I/C%.FO6Y^L0/_LM=;118+')M8>-1]S6+$_6,#_V2O/=>6]36[I=0DCD
MNPP\QX_NDX'3@=L=J]NKCO&>G:;BWF=K6">2=-P,<>YP6&6)(R<?EZT []#E
M_#C^*4T^4Z%&'M_-^<9CSNP/[_MBK\NI_$"'[UG<'_<@C;^5=YI5I9VEBBV0
M@,;#)DA15$GO\O!J]2:?<5F^IY1)XH\:0G]]:WR#U-B/_B:9_P )SK"G$^HR
MVY_Z:V2C^0KUJCK4VEW%RS[GET7C.[DZ^*;6,_[=DW]$JY%X@OYON^,=*'^_
M&%_FM=Y+I]E/_K;.WD_WXE/]*IR^&-"F^_H]C]5@4?R%'OA[_D<Y%=ZW/_JO
M%VC/_NF,_P!*9K%OXD.AW<EQK-G<6PC)D2.,98?4+6S+X$\-2_>TM!_N2.O\
MC63JWP^T*VTZXN;6SNWFC0F.*&4DLW8<Y[T7FN@KS70\Y'45ZC)#XKA'[W7=
M-3_?0#_V6O)K&PNI=3BADMKB7+@21Q'YV7N![XS7K,7PX\-J 6MYY/\ ?F8?
MRQ4QJ2ELB8U)2V12EU+6H/\ 6>*M!7V:10?Y52E\4:C#][Q1HQ_W49OY(:Z>
M+P/X:A^[I41_WV9OYFKD7AO0X?\ 5Z18@^OV=2?SQ5>_Y%^_Y' 2^/-0C^[K
M>GR_[MO)_5!4*^/]?D;$*B?WCMB:]2BLK6#_ %5M#'_N1@5/1:?<+3[_ ('E
M?]O>*+WDZ%))G^(V#?SI\4/BV1]\.DR1'\$_FU>HT4O9I[AR=SQKQ&NLK<P#
M6EVS>7\@+ACMSZ@GO4WA--7>_G&CR1)-Y7SF3IMR/ZXKT7Q+#;?V9-<26%O<
MS",H&EV J,'D%O3T%1>$H;<Z+;3I8V\$PB6,R1[2T@VJ<DCD9/8\UIRZ#\C&
MDTWQI+]^YMS[>:0*A&@^)]VYTL)#_M.W]*[ZBH]G%[H?*CBH]+\3Q_=L]'_X
M$"?YU91/&48PD6DK_N@BNLHJE%+8+(Y7/C7^[IGZT9\:_P!W3/UKJJ*8SE<^
M-?[NF?K7ECYWMGKGFO?:Y'5(-!M_$FEPM#IT:KYOGH40 90;=P_EFC4#/T63
MQ:-$M/L$-FUKL_=EC\V,]^:MM<>.QTL[0_0I_5J["&&*WB6*&)(HU^ZB* !^
M I] CAFN_'XZ:?"?HT7_ ,743:AX^'_,.'X"(_\ LU=]12L^X6?<\[;5?'H_
MYATGX1(?ZU!)J_C@_?TN9O\ MU4UZ712L^XK/N>42ZAXN;[VB3GZ:>O^%9.I
M3ZS+$HU'3[BVBW9#26QC!;TSCZU[;6/XETBTUC26BOIIH[>(^:WE.J9P#U)&
M,5/+;4GE:U/,?"8!\4Z?G_GI_0U[-7G/@OP]I/\ :DEY;W-R+BUF?RP)T(*9
MP,@#)R#UZ>E>C546VM2HMM:HJ76FVE]+ON8A)^XDMRK'@QR;=P(]]BU4LO#M
MCIS0&T,\0AB2+:)F(=4&%W9ZD ]>_?-3ZU%=S:/<1V+.MRP 1HV"L.1G!/MF
MN;O;#78UE@A&HRP+]H%J8KO#JYV&)G9F!91\_!)]P>*HHW(?#>G0"-8UE"1I
M JIYAQ^Y(,9QZC Y[TV/2=+@U$/#.T5UO)=$GP9-SO+AAGD99R/8GMFH[*SU
M6*PU222>0ZA,T@@,DI:-<9V;5Z 9.>F?7H,85MI6L+/)-%!J5NLC+N::X268
M8MIE)!+D?ZQDP"<9]!T .H>RTV*Q72W=%B!5A&TN&^^"/?[V!^E00Z!I$KQ7
ML"[VW>9'*DA/\;N<'T)E<'U!Q6+#I^M.;69[:2.1/)1BTVYBJW:LQ.YV(S&"
M<;CCIFJMKIGB6VT>WM7$XV2Q^9Y4G_+#RV 10LB$,KX+$-SD')'R@ [#3=,@
MTN#R+=YC$H"HDDA8(HX &>U7:K:>D\6FVL=S(\MPL*+)(Z@,S #)(!(!SZ$B
MK- 'G_CG2IFU6"[M-,9RUNX,UMID5T\DN5VI)O!PN.XQ]17<V?FBQMQ-&D4O
MEKOC3[JMCD#V%<?J6IWAU.^C_P"$H:R%O,\:P0V$;?=B64Y9RV[Y6'/R\Y%=
M3H[W4FDV\EW<QW,CH'$J0^5N4\C*Y.#C&>: +U%%% !5/5O^0-??]>\G_H)J
MY5/5O^0-??\ 7O)_Z": &:'_ ,B_IO\ UZQ?^@BI-4-V-,G-C_Q]!?W> #SG
MT/%1Z'_R+^F_]>L7_H(J_0#.9\(6VKVD5Q!J2%8P=T0*J.6)+<@^]=(Z[XV3
M<5W C*]13J*;LV)*R,/2O#,.DWTEW'J.H3-)RZ3R*58XQDX4<X%;E%%2DEL"
M26QF)X>TF.\%XEC&+@/O$G.=W7-:=%%,9BW^EW]SJT5Y#/:JL((C5XB3\P .
M3GGIQ6U115.3:2["44FV'48-8M]X7TR];S%B-M-G(D@.TY^G2MJBB,I1=TQ2
MBI*S1YQXD.M:9'_9]Q>RSV4F"DK+RW^R3U_6M31M>UUM,C(TE[Q1\JS;]I8#
M^?UK<\3I&_AV\#JIPFY<]B.XK3@"+;QK&%"*H "]!70ZR=-7B8*DU4=I'/\
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M@_*C]UYA^\\BAXAUC16TB59);:\9AB.-&5_FP<'VQZTGA;4M)&C110M!;2(
M)D)"EGP 6]\XZTS6O">FR:;*]K"MM-$I<,N<' Z$5%H?A+3'TB":[B-Q+.BR
M$EF7:",@#!K2U'V?7<RO5]IT.F%W;-]VXB/T<5(LB-]UU/T-89\':&>EHP^D
MK_XTP^"M%/2*4?24UG:GW?W?\$UO4[+[_P#@'0T5S?\ PA.EC[LETG^[+_\
M6H_X0VT'W-0U%?I,/\*.6G_-^ <U3^7\3I**YO\ X1+;]S6=27_MK1_PC%X/
MN>(=1'U<G^M')#^;\ YI_P OXG25S6KVFF2>*-,$\%LTLOF&3>HRWR@+G\1Q
M2_\ ".ZJ/N^)+H?[R9_]FKD]4T+5EUY()'>YFG;,4^?O8[^V/TK2E2@W\1E5
MJ32^$]0HKFET7Q % _X2$\#_ )X@TO\ 8_B'MX@_\@"L_9Q_F7X_Y&G/+^5_
MA_F=)17-_P!D>(_^@^O_ 'X%']E>)/\ H/)_WX'^%'LX_P R_'_(?M)?RO\
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M<N?EXZYKT>@ HHHH *IZM_R!K[_KWD_]!-7*IZM_R!K[_KWD_P#030 S0_\
MD7]-_P"O6+_T$5?JAH?_ "+^F_\ 7K%_Z"*OT %%%% !1110 4444 %%%% !
M1110!6O-/M-05%N[=)@ARH8=*?;6L%E (;:)8H@20J]*FHIW=K"LKW"BBBD,
M9-"D\+PR E'4JP!(R#[BJECH]CIKN]I"8V<8;,C-G\R:O44U)I6%RINX4444
MAA62VC2G5OM_]HW 8?+LVKC9G.WIT_6M:BFI-;"<4]PHHHI#"J&H:3;ZF8_M
M#3 )R!'(5&>N>.]7Z*:;3NA-)JS(X(5MX$B5G94& 78L3]2>M2444AA1110
M4444 %%%% &5;Z/)!J;7IU&XD9^'1E7# 9P.G;-:M%%.4G+<2BEL%%%%(844
M44 %%%% %34HKJ>RDBM#")'!4F;.-I!!Z=Z9I-O=6FG16UVT+-$H1#%G!4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *S-3_P"0AHO_ %^-_P"B)JTZS=3_ .0AHW_7XW_H
MB:@#2HHHH **** "BBB@ HHHH *IZM_R!K[_ *]Y/_035RJ>K?\ (&OO^O>3
M_P!!- #-#_Y%_3?^O6+_ -!%7ZH:'_R+^F_]>L7_ *"*OT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV@@ ''R]*L?\(Z__ $'=8_[_ *__ !-6]%OIK_3C+<!!-'/- YC!"L8Y&3<
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M[_K_ /$T?\(Z_P#T'=8_[_K_ /$UMT4 8G_".O\ ]!W6/^_Z_P#Q-5CX<O\
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M;;62.23*EU& YXR3WZXSSC-:5%% %.STNUL)[B:W$H>Y;?*7G=]S8 SAB<'
M X[ #L*2]TJVO[FUGG,WF6K^9%Y<[H V",D*0#P2.>Q-7:* ,Z71+.=HC,US
M(L3!PCW,A4D-O!*EL'#=,^@'0"M&BB@"B^D6;ZH-2*RBZVJI=)W4,%R0"H."
M.3U'>KU%% !1110!7O+&"_A$4_F[0<CRIGC/3'52#WZ5)!!%;6\<$$:QPQ*$
M1%& J@8  ],5)10 4444 (0&!! (/!!J&WL[>U>9X(4C:=_,D*C[S;0N?R4#
M\*GHH **** "J?\ 9=I_: OBCM<#.TO*S*A(P2JD[5..,@ ]?6KE% !1110
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MN".>E7J* ,B3PWIT]U:W=Q%YUY;R+(+AE4.[*I W8 !P#V Z"M>BB@ HHHH
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gym1fcavvjqs000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -?!9<# 2(  A$! Q$!_\0
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MH* /7ZX/XG>.M0\ Z9:ZC;6%M>02R^4RR2,C*V"<C QCBNX@F2YMXIXCF.5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]]\%WVH:GX,TF]U4 7TULKS?+MR?7'N,&I'\)>'I)$D?1;%F3&TF!>,=*V
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M."2=A9VZB1@JDD*!C)(XH YNX\:^*]+^(.DZ%J.G:5+::F3M6SD=IH .I<G
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MGF?TJ9+0:W.DHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BN6UKQK9Z9XNT3PU$R37^H2D2(#_J8PC')]R0,?C74T %%%% !1110
M4444 %%%<7\2[3QA>>'8U\&3^7?+*#(JR*CNG^RS<#\Z .THJAH::E'H5BFL
M212:DL*BY>+[IDQSBK] !17+>*/&MEX>U72-)#)+J.I7*1)#GE(R>7/H.P]3
M]#717EU'8V4]W,P6.&-I&).. ,T 3T5Y@X\::U\)$O= OW.M7LIND\QPK"%F
M)$:EL!2!MZ^A]:[;PG%K4/ABPC\0R))JJQCSV0@\^Y'!/KB@#9HHHH ****
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M))(]L=Z .IHKP;X;^*O$-[\8=2T2^UF[N["V>Y1(IGSPC$+GWXKWF@ HHHH
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M 4444 %%%% !1110 4444 <KXT4M%:@=BQ_2O(O"VJ7FJ76L)>3>8+>YV1\
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M10 4444 %%%% !1110 4444 %%%% !39-XB?RPIDVG:&Z9[9IU07IN!87!M
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M?@A=W487'N<U#X<^(?PS7Q0=3DN-5EU6<"-;_4TW>6O0*NWA1]!W/J:L^/\
MP9J$7Q,T7QUI-G)?6J20O>10#=(-F '"]2"N!QZ4 5O%?B>Z^&_Q6TBSM;RX
M;0[V!'N;6:1I0NYV0LI;)!&T'\ZR/CY>7VD>*=*;3=1OK3[3 3*(;EU5B&P#
M@'%;'BKPI??$KXJ:9>PV-W;:'8P(D]U=0M"7P[/A5<!B><=,5E?'C3M4UOQ5
MI8TO1M4O%M(=LLD%E(Z ELX#!<'CTH J?$?5-8\ >,_#U]::[J5PTMLDUPD\
MQ9'(.&&SI@BNK_: >XT_P]8:E8WMY:W7VCRBT%PZ!EP3R <5R/QJL-4\3:MH
M<VD:)K%RD-@%D*Z?,-C$YP?EZUUOQS6Z\0^$]-MM)TS4[N9YA/LBL)B57!^]
M\O!]CS0!C^)O%6N:/\'_  7>PS74D,_EF_E5SOD4<[2_4;N1FNQ^'^M:3XGU
M.+4?#^K7*V\4!^UZ1<S,QAD8##+NR2.",YQ]*I^';R>+X?\ AW1K[PQJ%[9"
MW-OJ5O+9.KQ8&0<,!N&?3GTK"\'?#\Z7\8/[3T"#4(/#T,)9I+N%X?G8<QJ'
M 9AR.2/7TH Y#QEHD/\ PT#!IK75Z\=Q/ 7F:<^:-R@G##I[8Z5Z]XVLUT3P
M/9^%=.N+J:;5[M;&)KB<R2E78M(2QY("Y'MD5Q'Q#\.:W9_&O3?$T&DWM_IS
MO"Q:SA,K+L 4@@=/7GCFO05CU#7?B;IDM]ILL%II&GR3J[1G8;B5@H4-T)5!
MGCH30!A?&NT_L?X;V]SIUS=6D]C)%!$]O.T?R'@@A2 :QOM-W<_LU-J<E]>?
M;X(_,CN5N'$@/F@?>!R>"1S71_'**YU#P(=+L+&^O+R:XC=8[:UDEPJDY)*@
M@?B:Y:(7J_L[7&@G1]7_ +4*B$6W]G3;B?,#9^[TP#S0!S6FC5KSX%:KX@F\
M1:O]IL[I?)5;I@!ET4Y.<GAO6O1_A_->_$/X/^1J%_<I>([P)=Q2%) R@;6)
M!R>OXUPND6.IP? '6] ET36$U2:Y4QVYT^;+CS$;(^7IA37?? BUO--\#2Z?
MJ%A>V=TEV\A2YMGBRK!<$%@,]#TH XOX+:Y<VGC;6-!\17UU-?1+(BO<73LJ
M&,D.,$X_'VKO+&2/PAX,UOQB7NYC<[[FUM[B=Y!%"3^Z7!)QD88]QG':N=\:
M_#.\U3XPZ5JUC',EE>C=?31\"/8N",]MR\?G7I_BW0/^$C\(:CHJL$:Y@*(Q
MZ!NW\J /&],UG4/$/PUN];6;Q!<>*9II)+=K.TNFB3:V%C4HICVX'.3WK<\;
M:KK%]\!5UK4([[2];A,0< R6\BMYH1B5X.".>?6J7PIU#Q+X)CNO"NM>%]5E
MC68R6T]M;[DR?O OPN. 0<^M=1\78M1OOA;=V*V5S=:A=RQE(+.W>7;B16(.
MT'& .IZT <;X3T'Q1XW^#MM)9^(KRVU"*Z<P.UPP$@#G=O89;Z?[OO3?%WC2
M[\+_ !)L].\4&\N=%CL8HR()&BW2$#=-\I!;!#<9[UVGP1CN+'X?0Z9>V5[9
MWEO+(TD=S;21<,Y(P6 !_#I4GBRUL/$EYJ&C^)_#][)818^Q:C;6K2%"5!.-
M@+9S[$'OTH DT[7[?0_ .M>)K;5GUG3T5IK-I')8 * L;="/FP#WYS7G^EZW
MJ/B7X=:EK7GZ_/XHEG9[0V-I<M%'@C"*44QXQG@FM'X>?#C4QX"\5:3?">UA
MU0LEDMRI5L ?)(R?PY.W(ZTSX4W?B7P(;SPOK/AC5)8C.9+>>UM]\>X\'+\+
M@X!SF@#U#P)JFK:QX.L+O7+&:SU,J4GBFA:)B5)&[:P!&1@_C47C_P#X2<^%
M9T\)1H^INP49=595[E2Q S]:Z"R-TUJKW@59F)8HO1 3PN>Y P">YKA?C(/$
MC^!WC\-QW,DSRA9Q:@F7RL'.T#GKC..U 'G7Q&UC4?#F@>'=4T[5)X-;5_)U
M'R+MI8C*$!*G)*D@]0.F?>MWXL?$#7-)\!>'Y--S!)K$1:>Z0',>%0[0>@+;
MC_WR:YWQOX:US5/A'X4@TWPW>Q_8!B>W,7[[<5Y;8.<$Y))YR>E=%\0-8_LG
MX.:%:ZCH3R+<&*"9;J/FWVK][ /#'!QR._TH P/BE:3^'?"7A/4M/U;4TN+I
M0MRHOI<SY0-G[W!R2./45O\ Q$\7WG@7X?:+IVCRW,5[J4>\S7$QEEA4@%AN
M;DG+8S[5BV7CGX7?:=,-]+K]\M@ MJE^H>*#_:V@\X]\]*Z?XK>&#\2?"&FZ
MYX89;V6W)>-5.#-&W4#/<$=#[T 9GQ N-1\ ^%/#NN:/J=Y]M9D6Z,T[2+<9
M4,=RL2!SZ8XJ'XR:[)>^ O#OB32KN\LY;W:3Y%PZ?*4R5(! .#WJ?Q]9ZOX^
M\,>'-!TK1K^.[0HUVUU;/#';X4*<LP ;G/W<U#\7_#MU;> _#OAC1]/U'49+
M':&:WM))!@+C)*@@$GM0!SOC&76=#^&W@WQ'!XCU5[^X5-VZX.S&S<!M[XP!
MDYS7H?CV]FU7X)6_B!;BYM[TV<%RDEO,T1#.%)^Z>1STKA?'5EJ>K?"/P=I5
MEHFL27UFJBXA_L^;='M3:<_+Z]*Z[7_M-Q^S]8Z5%INIOJ!L8+;[,MA,9 Z*
MH8$;>!QU/![4 9?A77]>A_9WU#5+6ZN;C4HY90LSL9'5=P!.3D\#-+X!\5:9
MXL72;2SU>]TWQ!!<127=O/<NZ7\:,"^"<C..<#!X/49JY\,;G5_#_P +9+(:
M#J+:E!>;GLY[-X_-C=P#M+  \9[\=ZP?$WP[M]5\9Z/>>$-*U/3YI+C??++;
M/#%;8(.X.<#/7A21Q0!F_M!Z>EOXSTN;S[B1KF'<PDDR$^;&%'\(KWOPOX>M
MO#NFF*VN;Z=9MLC&[N6F(.!P"W0>U>4_'SPKK6K:AHVJZ9I]Q?0P*8I4MHS(
MZG=N!VCG'O7K^@WES?Z5#<7%E+9AE7RXIAB0# ^\.Q]J .'^.=BMQ\-KVY:>
M=3;LC+&DF$8EP/F'?K6'\!?#EJ_A2WUPW5\+A9Y4$(N6$...?+Z9]Z[CXGZ'
M?>(OAYJFFZ=&);MU5HX\XW[6!('O@&N3^"\VIZ-X)>QU'1-1M%M9I99FGMG5
MF! VA$QN8]<\4 ><?"#2GUCQ_KMI]NN;2)HI?,:V;:[#?T#=1^%=3\#O$VK2
M^+M:\/7VH7%Y:1(\D)N'+LK*X7[QYP0?T%9?P>M-3T#QWJM_JFAZQ:VUQ#)Y
M<CZ=-@G=NQPO7%2?![3M5TOXG:A=ZAHFK6MM>1RK%+-8RJN2X89)7 X'>@#N
MIHO$\WQ%OV\3F.#PFR&"Q,=WY99SC:5"G>SGD8Q]*YCX*^*]8O\ QEKGAN]O
MKBYLH89)8#,Y9X]DJIC)YY#]_2I=*A\4M\>+N^UO1M1N[6(3)82>63;P XVL
M&/R@8'..:H_"?PYKWAWXO:S+J>C7L4$\$T8N!$?)RTJ.#O. 1A3TR>G% ',M
MX?MY_P!HG^QI+N^\F2Y<-.+AA-_JV;[XY%?36EZ=%I.F06$,L\L<*[5>>0R.
M><\L>37A>LZ!KFA_M VWB+^Q;^]T^6;S%DLX3(!N0I@GHN">Y'%>]6S3O;1M
M<QK',5RZ*<A3Z9H \H^*7C>ZL?%NA^%+6:XMX+N6-[V6V1FE*%L;4"@DY&>@
MS26VI:QIGQ2LHM"T_7IO#-Y&$N1=65R(X9.?F!E7(Z#VJE\9O!FO7.O:5XM\
M/6S75Q8E2\,:[G#(VY6"_P 0XZ#FO0?#GB?4/$EK;2?V%J&EL,&Y^W0[ #W5
M >3SWP* /&?%4NI6_P"T#%HVGZSJ-G:330'8ER[*NY 6P"2.3G\ZN66L:IX5
M_:'?P_#JU_=:=/-'$T=U,9?]9&K]^F"W:H/$EKJ5S\?X=>@T36)-,AGA5KA=
M.FV_*@4D?+R,]Z;K-CJ<_P"T2GB"+1=7?2DO+<FY&GS;<+$BL?N],@T 6/VD
ML_VKX9P<'9/@_P# HZJ_$JYU?P1?^%-4T_7M1:>Y@W2H\Q,1VA> G3&&(Q6C
M\?+'4M<UW1(]*T?5+W['&YF>"RE9!N*$ ,%P3@=NE4?C%:ZEXBA\+II6B:Q<
MM:6I,^W3IOD+!, _+U^4T >E^/Y?&FH>&-+/@^-/,N2KW;^8J.B%01@L0,=<
MXYZ8KS/XC>++OP?XJT/4/#NI3>5-;A[J%;EIH)&5L,H+$@CJ,BMWXJ_\)3J7
M@3P[!H5CJ;V4D06^@A@=93A5 5TQNV_>[8]>U<_\7/"VO:S!X:NM*\-WJVD-
MDMN+>.+?)$>N&5<[?K^>* .H_:#GN=-T72[ZPO+NTN&G:-F@N'3<N,X(!Q7'
M>,IM9T+X=>"_$4'B+56O[E$W;K@[,;-P&WOCIDYS77_'>&_U_P /:/:Z;H^J
M7%P9#.\<5F[F-2O1BH(!]LUS/CRRU/5_A-X-TNRT36);ZS0+<0C3YLQ[4VG/
MR^O2@#T+QG\0[G0?A-IFO0;!J6IVT/E%APK.@8G'L,UFR^#/$FK^$/#6K^'=
M?N(-:,2374MQ=2>7.'4$Y7D<'H,=*->\'W?C/X':)86MM-%JFG6L&V"YB:)O
M,CC"NN& ]\'I3_AIXG\1V'AJ'PYJ?A+5Q?V*F&"9H"D+J/N[G; &!QD9S@8H
M B^)WCB_TWQ'X?\ "4-Q-";KRI-0N+:-FD*EL;4"@GG!/ STQ3K;4]:TGXIV
M$.A:?K]QX9O42*Z%W97(2%R2-P:5<KC@D].35'XP^"O$-[J^D>+M&M?M5[9Q
MHEQ;P@L058L&4=2.2#WZ5Z'X;\3:EXDL[9SH=_ID@VFY:^A\L<=0@/)SZD#
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MP*<[DGJ:X[7?B!9:%JLFGS6T\DD84EEQCD9]?>NPG&&KPOXC?\CK=_[D?_H
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M110 45EZOXDT;0'MTU;4K>T:Y?9")6P7/M6F"&4,I!!&01WH 6BBB@ HHHH
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MP10!T5%%% !1110 445E6GB71;[6+C2+74[>;4+<9EMT?++0!JT444 %%%%
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M5AD'YJD\7L8OVF=,=/E8O!D@>JD?RH ^BZ*** "BBB@ HHHH **** "BBB@
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M7$V=RV\$'(/0UUMDY:,9JHRN:IENBBBJ&%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ^5NM5*VID#QLA[UC,I1BIZBN*O3Y9774QFK.XE%%%<Y JL58,.HI\^F:?K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%(2 "2< 4 ,GG2WA:61L*HR:X6]NVO;YYFZ'H/05<UO5OMDS11DB%
M.![GUK#9\=*M(EL65\FH=NZE?--5]M4(BQ\^:'?G%!.6J(_>H$68TRN:;(F1
M4D382D(W5+5T,SFC&2",@\$5X1XRT!]&\2RP1(?)N&\R# Z@]OP/%?0;PX6L
M74] M=5O+*>X3+VDF]..OL:Y_A9*=F4?"6BKH>@6]L0/-8>9*?5C70*,<@4[
MRFSTJSY0$8IP5W=@M60M'OCR:R;J$AJUG? P*@= _:MW&XV8PA8FI&@*KFM
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MFUM-7F6\L[Z12(VX/R%O8<#W4^HJ]X]O;GQAX O[K0;-KRVLKN&:,C(-TL;
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M+!*DL;='1@P/;J*\WUIM=\+^+-:URWTI-?T>_2-+F"%@9[;8F-NT]5(.2/\
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M>-=[.' /7EOT]ZZ;PYKD7B*9KW0=!>QLX8&)GNK00M/(1\J(/0<EC[*!G)P
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M=?U?Q!?:I%X=:PAMM-G:V>>[B:7SYE'S*H5UV@'@L<_2N9U;5[%?COI#F?\
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MG$(K>*.*,=%1<"K0NANQFL5YRO%1_;"IZT[".B:Y&.M0/.&'6L=+LL#S0;O
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MH2I(_(FI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI
MJ=\FG:=/=OC$:$CW/:K=<-\2M0-OIEM:@X\Z3)^@II78GL</+>2W-S-<SDM)
M(Q8FI+,EIMQJBC?)]:O6X\O'/6MC,TB/2IH^%J$. !FG*34C!SEJ9*0$I[\5
M7G;B@9#T.:8[$FI1_JZ@'+4")E;"8%6[;/RJHS(YPHJBH(-;WA2V^VWKW##*
M(=J?UH Z/1-'$$8=QND;EB:U/[5TR'6(]':\B74)(S(EOGYRH[U>AC"* !7D
M'C'4-2TOXWZ;<Z3I#ZK=#36 MDD"$C/)R>.*SO[R7];,T2]UO^MT>J?VUI8U
MH:,;V+^TC'Y@ML_/M]<5'!XCT6ZUN;1H-1@DU*%=TELK?.HXZ_F*\@T[7M1G
M^-#ZGKFCOH\D&E2,89)0_P H&<Y'%<AI'BC2;'6='\4Q:DC:O<:G)]MM\-N$
M$AP,G&,#CO2CJTN_^;2_X(2T3:_K2[/J!D!'2LZ^L$GB8%:TD=9(U=3E6 (/
MJ*1P,<T]A;GG-Y$UI.T<G_ 3ZUFR/\U==XELP\!E7[R<BN&O+@*,BJNK$EI;
M@(.34$UX.QK)-RS-C-,:0]S6;F*YLK>@1]:HSWK$\&J#W"J.7%5VNU[ FLI5
MHK=DN21HK<$]ZAFG)[U0-VY^Z *A:1VZL:QEBH]"'41=\T9RS8J/S0[X4DU4
MJ:W'):IA7E.20E-MV+\9XYHF^9.*CWJBY9@J^I.!56Y\0:1:*4FOHS)V2/+D
M_EFN^.QJ.@<Q7"MZ'FMK@\BN*.N37,A-AI=U,/[T@$:_KS6C;CQ+?1 &:SLD
M''R@R./Y5SSB)HZ0\<GI6%JNH6%E+NFNH4W#NU \,O/\VH:K>7)[J'V*?P%/
M?PWI=M 7@LH@XYW,-Q_,THV3%H8X\3P,VVRM;J\;MY<>!^9JRUQXAO4_=6-M
M91GO-)O8?@,5;#!<*N !T J["=ZXS75!E)F#_9%]+_Q^ZQ.?]F !!_C1;Z-I
MUI=)/]G$SJ<YF)?/US6O/P2*CB 9_F'%:V07/<_#%Q8WVB6]S9V\,(*X9(T
MVMWK:KROX::R(=4FTIVPDPWQC_:'7]*]4K&2LS1.Z"BBBD,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6TN2DJ'*M@X./Q!H LT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M82_>+$G./PH ]#@GCN;>.>%@T<BAT8'@@C(K&O\ Q=I&GS7$;R3S&V!-PUO
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M6AGB9NC>G(ZBN?/C/3KWP9XIM_%^A-:7ME-'%JEK:OQ<.ZA496S_ !! .IP
M.30!VL'CK0I[^RLVFN()+X$VC7%L\:3]/NLP /45)=>-_#MGJLVF3ZE&MW#
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M-D;2!@\Y(KA;FV@B_9D_=PQKNTB.0X4<L<$GZU+\026^$.ALW+>=8G)_WEH
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M]J7B#^P[6^+7Y5F1#&RK(%Z[6(PV,'IZ5H:CKUAI=Q';3-))<R@LEO!$TLA
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M@ >Y) J^C;XU?&-P!Q0!S6I^!-+U>_L;Z]N=1>YL#NMG%VP\MN/F'N<#-/\
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M%&.I&X]6)QD^@%<KX:\!ZG/X+USPQXDM(H(-1GDN%FMKC>5+.'7C Z, ??%
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M_K0Y^*]^0!G)QP,GI3OM7>NW7^Q+WQ+K&@+H5I$D$+R+.JC?N SQZ"O,#<
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M/M=I;BX:W&PEU/9&W;6/XT =%17->$/&$?C'1)-5L],N[>W#,D8G9 TC+D$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR'&+D['HEI +6S@MP<B*-4!^@Q4U%%>N=H4444 %%%% !1110 4444 %%%%
M!1110 4444 <AXZTO1];&EZ;J%[/87LDS/I]Y X1H9E7/!/J.W?VK-\(ZKXE
MT_QC=^$_$5S;ZH8K47-OJ4,6QRA8J%D7H#QGO]3V['5-#TS6EB74[&&Z$+%H
M_-7.PD8R/2JT\>F>$]&O+ZVTY_*@C,DD=LFZ1P.PR>>IZF@#S6[EO? ?C35]
M!L(W^Q^)AYVF8&5AN6PL@XZ#^+VXK4^*UC!I7PMM;"((D4-U:QJ.QPXS_4UL
M:%J<?CS6+'78M.NK;3-/B8P&]B"/)._!VC)^55R,YY+<9P:Z/6?#>C>(5B75
M].@O%B.469<A?PH X7XN/$NA^$LL@_XGMJ1R.FR3)^G2KNIZY%-\4DT2W^RZ
M;<QV/FS:I(BF:6/(/E1;N!UR2<].G>NAO/ _AC4(X([S1;6=+==L(D4L$'MG
MI5F[\*Z#?/:/=Z5:SO:+M@:1,F,>@- 'G7@"[LH]?\=6RWHE>6Z/E;Y-SR 1
M<GWZ5I?!Z[T]?A#9FXGMQ!"LOVG>PPHW'.[\/6NIU*RT#P]::GK+6MI9S30E
M9K@1@,_& ..3VX%<+\'])\/:KX$L8;JRMY=1MMPG21"&'SDC<#UH R_!7AW3
MG^%.F:;K]S<VD=_J3SZ;<*_ER0G_ )9D$],[2>G.:VK6Z\6Z5K%]X.U:\BUO
M[5I<\ECJ$<?ES)A<!9!VR>AR<^O8>C:CHFF:M:1VNH6,%Q;QD%(W3*KCI@=J
M73]'T[2MWV&TC@+##%1R1]3S0!Y%X)U+P=J'@F+2M=U:]LKRSA-M?6-QJ<T0
M^7@X3?C:?;UQ7J7A6ULK+PU96^FVDEK8HG[B*1RS!,\$YYY'.#ZTVZ\'^'+W
M5AJESHME+? @^>\0+<5M    # '0"@!:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*3Y/N\5[N!R].'/4ZGS&89_5HU?9X?2V]^IR5O>W&FRB.^A8+_?45V-C/'/
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M'H.GM_RYV'SS,/1I#@#\!6_HG@G0= /F6EDKW!^]<3GS)&/J6-=#10 4444
M%%%% !4<T,5Q$T4T:O&PP589!J2B@#AM5^&>GW<C2V,[VC$Y*%=R_ATQ6*OP
MJO#)A]1A">H0D_E7J=%8O#TV[V,W3B^AR6B_#[2M*=9IMUW.O1I!A0?85U@
M P!@"EHK2,(Q5HHM12V"BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$HM/%NJ2:G;R(SV)91:2Y;_5K$![X&2Q_G7I]I))-9PRRIY<CQJSI_=)'(H
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MH M456EU&R@@2>:\MXX9/N2/*H5OH2>:)M1LK:))9[RWBCD&4=Y54,/8D\T
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M?G&#Q2;2T%=&S12 A@"""#T(I:8PHHHH **** "BBB@ HHHH **** "BBB@
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M2R;TBW*V0#@>@Z<5M7O@'4I/%-GXCL?$TUMJ4=J+6Y>2U219TW%CA<@*<GW
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M) SR/2N'\1VEM)\;O# >WB8265P7#(#N(QC/K7H]I:PV-I#:VT8C@A0(B#L
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MD@XR!]* /5Z*\'\(?%;6[SQ-I<-[>_;[;47V2P)8-%]D)Z8?^,5[Q0 4444
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M-]\+M4\0*EDU]IIG61L$QR^7GYE /&?RH ]+J&YN[>SC62XE6-&=4!8]68X
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MHUAK$!AOK9)5[;ATKF;/X6^&K2\^T&U\TYR%?D"NUHI606&111P1+%$@1%&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M97%>9<S(&B7D$D@]JR[RQ"KNC8DGL:UQCS,FI4L_MD\<:C@L,_2I>HUH=_\
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M'9GB6C^&]2UNX$=M;L%_BD<851]:]D\.>';7P[8>1#\\K<R2D<L?\*UTC2)
MD:*JCH ,"G5O2H1IZ]32%-1"BBBMS0**** "BBB@ HHHH **** $) &2<"EK
MROXL:G=:IX3UVUTR=H[/3H\7LZ=))>,0J>^ <MZ<#KG'H?A__D7=-_Z]H_\
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MWH<=#[5FZKX@T:R>:RO9R[B/,\44+S&-#WD" [%//+8%<3\%?L?]E>(/[/\
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MR.2>G>@#>I&=5^\P&?4UR_@+Q/\ \)-X9LKJ5;D73PB24R6TB)R?X790K?\
M 2:K_%#2[#4/A[KDMY9P3RVUC-)!)(@+1,%SE3U'('3TH Z\.C [64XZX-)Y
ML9.!(OYUP_PFTO3X/AEI$D5E;H]W:@W#",9EY/WCW_&N7\*>&=$A^-OB:)=+
MM?+MH89H$,0*Q.3R5'0'CM0!['1139)$BB:21U2- 69F. H'4D^E #J*Y:7X
MD>#H;>:=_$-D88I1"TBL67>>@! ^;IU&16IJ'B32=,53<7+-NB\[;!"\S"/^
M^0@)"^YXH U:*IZ;JVGZOIZ7^G7D-S:."1+&X*\=<^A'<'I67_PG'AP3PQOJ
M0C6:3RHIY(G2"1_[JRE=C'@\!NU '0450U'6;'2RBW4K^8X+)%#$\LC 8R0B
M L0,C)QQFJEOXN\/76CRZM%J]I]AA)$LKOM\LCJK X(;V(S0!M45REU\2O!U
MBEDUSKUM&M\N^ E6^9<XR>/E&>YP*J^/O'">&M'LI;-9IY+Z>)(IX86DC",P
MRVX @DCH!R<\4 =K16<NN6 TAM3GF>VM$!WO=PO 1C_9< _3CGM5:S\6Z)?:
MI_9D5X8[XKO2WN89('D7U02*-P^F: -JBN<G\?\ A.VEO(Y=?LMUFF^XVR;A
M&,@8)&1G) QU]JL?\);H;6UK<0WIN$NH_-A6VA>9V3INV(I8#W(H VZ*IZ9J
MMCK-J;K3[E+B$.T9=<X#*<$<]P:JZUXGT3PZL9U?4[:T:4XC21_G?Z*.3^ H
M UJ*QK'Q;X?U*^OK*SU:VFN+ $W2A^(@.I)/&!@YYXJ.#QCH-QJ,%@M_Y=Q<
M+NMUGADB$XZ@QLZ@/_P$F@#=HK,OO$.F:==&UN)W,ZH)'CAA>4QJ<X9]@.U>
M#R<#BL^^\=^&].L;2^NM1*V=X<07"V\KQN<XQN52 >#P: .CJO/?V=K+#%<7
M<$,D[;(DDD"F1O10>I]A67J_B_0]!N+.#4[Q[=KP@6[&WD*.3T 8*5S[9S7&
M?$BTMU^('P_NU@C%PVIE&E"@,R@+@$]Q0!Z?17!M\08O^%C2Z$;?4%M;:S+N
M5L)G9Y"P (54+;0,_-C!SUKI[WQ)I5A<O;SW#F6)=\HBA>41+C.7*J0@QW;%
M &K5>[O[.P1'O+N"V1W"(TT@0,QZ 9ZD^E%C?6NIV,-[93+-;3+NCD7HP]16
M%XMNO"0CM+/Q/<6?SS(]O!,YWLX("E5')Y(]J .EHK'NO%.@V&JPZ3<:K:QW
M\GW;;S,N!C.2!]T8YR<5!HOC7PWXCU"XL-(U>WN[JW&Z2-,]/4$C##Z9Q0!O
MT45SUQXY\-VDQ2?4U1!-Y#3F)_(63GY#+MV!N#P6H Z&BLK4_$NB:--;PZAJ
M=M!-<NL<$3/EY"QP,*.2,D<XQ56Q\;^&=3UV71++6;:;4HB0T"DYR.H!Q@D=
MP": -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBJU_=)8V$]U(<+$A8T >0_$K6VO?$!L4?]S:#;@=V/7_"N'>8
M+'MI=0OVO+^XN7.6E<N?Q-9CSEGZUNE9&3+[3 1]:KK)ELU6DDRO6HVEX^6J
M$:8G"]Z:)MS<&LS>Q'6IX'XR:H1NV\H"4^*7]]D&L=9R3@&IXY2O)-.XCH#=
M#@4J2[S6-'*2>M7K=\<YK.MK$F2T+DT:7>(Y1GT/<56GTF>./,.)%'YU-')F
M2M%)?EKS3(Y4(XDPZLI]"*Z+1[<+!+<L/]E:M#8S9*J3[BK4CC[,0 !CL*0Q
MUBH,V3WK>66%8"I S7*Q7.PY%74N&D&,\5W8:6EAP-6)8YW(P/:ID@$<JE%R
M3Q6;;S;&ZUHBX ((Y-==S2Q)<6*MOWX!QFF6^GJ>4ZKW ILEPS29SQCFKEE=
M)'&V:5V UQ)#$09&.?>LXVTSDGS'P.O-7Y)U8Y8].E59;Q<<5G5?NB>QS/BB
M%TLE+,>7]:YR)"PQD_G72^)[CS;)1_MUS4+8//2O-7F8LBO4 7;Z52MXE:XB
M&.=XJ[=R;CQWJO;GR[F-CV85+W&CT:"&2-=N]LD>M6H4ER#YKY!_O&JZW'FR
M+BKTI"(K"NW#/0N!(ME]H+^>Y;CY<GH:?%9I;X5.&Z%J;;S +N8].U)<7J*A
MQ]XGK746(\432YZXXYJS%$(X6V@;1Z51#JZ%PV.*;_:16%D'0#% R]DHJX8
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M HHHH **** "BBB@ HHHH **** "LWQ =3_L"]_L9(WU$Q$6XD;:-Q]ZTJ*
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MS/9P3%=6GD42QAPKJYVD ]".V*ZK1O ^GZ%9W,=E>:B;NXC$3ZA//YUP%'0
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M/N<4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5N.S=UQVS2(I=U4=2<"L#,^B=-N#=Z7:7+=984<_B :M54TNW-KI-G;L,-%
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M,P);\,>]0:[9>(KWXE^']<M_#5TUAI\#I,QN;<.3(!G"^9SM[\\\X[$^D44
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MIX8UG1]&\1:G8K$WB/5KC[2(PX"(01MCW<9& <GW-5KOPU?>)?$6@:O+H/\
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MWB')C5@S'\N!7IUA86VFVB6MI$L<2#@"MZ.';?-(TITG>[+-%%%>@=(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCE(^OZ_TJ6[(:1Z?!"EO;QPQC"1J% ]A4E%%9%A1110 4444 %%%% !1110
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M*2R*2I4D9*GJ/:N<;Q/<W^H7UEX?TZ*_>P;9<2SW7D1B3_GFI".2P[\ #UH
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M@?-M]: .MHKA;/X@7W_"53>'-5\,SV6H&V-U:)'=).+A,D=0 %/!]<8/-6]
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M7&17HYLK4W7VHVT)N-NSSO+&_;Z9ZXJ"'1=*M[A;B#3+**=3D2) JL#]0,T
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M'0\#/TH ]WR/6C(SC(KSGPQX0L/^$<T?Q(+N:'5DTD(+J2=A&H:,<LI.,+^
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M4/H:U\U%'!$AW*@!]:DJBT+FH;G_ (]9/]VI32$!E*D9![4 <[U-!7BMS[-
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MQU_Q7J/AM[*XL=2L02R3LI$@!P=I!YQD?G0!F^)/A_JM_KEOXF\/ZO'H^O\
MEB*Z95+PS+Z$$<_B/3TKI/#FB:AIXDO-:U(:CJDRA&E6,(D:C^!!Z9YYY-;]
M</X9^)-KXMUV]T_2-+NIH+.39+>%T$>,XR.<GI0!V%]:)?Z?<V<I81W$31,5
M." P(./?FO-HOAKX@'@"Z\'S:]:&Q =;1TMR'VEMP#G/N>@KU&B@#C/^$<\3
M6UIHC6NM6LE[8AA.9H2(I5*@; !R ,9R<G/Y _X0N>XU;5]=NKB&/5[^P^PI
MY /EQ)P<G(RQR!R>PQ5G4/%\UAX\TKPT^F-LU!)'2Z,HQA!DX4<^G7'6NJH
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MUG#)#.$MOD"L"/W8/?DG+'KCCM7H=% '":!X6\1Z1XOUO6YKG2Y8]4P3$OF
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M1QI#&L<:*B*,!5& *?116904444 %%%% !1110 4444 %%%% !1110 4444
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MS [",@E3CD C(R/6N9LI_%D\:V=Y\/-+BE4>6+I[^)H,=,[0I?'MC\J]"HH
MS="T>+0]+6SB(QO:1MHPNYCDX'89Z"M*BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/C9X-&KZ#_;EH@^U
M6(S( .7C[_E7SBM?<,\$=S;R02J&CD4HRGN",&OC7Q/I#Z'XGU'37&/(F8+]
M.H_2M(LEF8K<UJ6DW05DKUJS!)M84JD>9$25T=GH&I'3M01R?W3_ "N/;UKT
MR,AE#*<@C(->,P2[EKT#PYKBG2)HYV_>6J9&3]Y>U>>U9V,5IH4?%M]Y^HK;
M*?DA'/U-<S(]3S3-<323.<L[%C5*1_FK2E&\AQU8ZI%YYJ$'=4R<5WVT-BY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9C3_  YIUH"#Y5NBY QG@5$]BHFG1116904444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(BIAB=9GLL'/]V.-@WU)%4--T;78-2MY;BV585?+G_A)+J? _P!QH0&^A(H
MV/%.KWF@^'[O5+.RAO#:QF62*2<Q94#)P=K<^W%9]EXCUB]\"Q^(ETBS$TML
MMY%:_;FP8B@?E_+X;';!'O5GQT<> M>S_P ^,O\ Z":YC1-(U!OA/ITR^)-1
M2,Z'$P@6*VVJ/(!V@F+=CMUS[T ;?A_7]=\4>#4UBTL-/L;FZ0/:1S7#S)C)
M!WX52.G;-=4F_P M?,V[\#=MZ9[XKR)#)'^SC:3132Q216896C<J<[SZ5L>)
M[>\^V6M_)IS:UID>F(DUI!/MGM&)8^>J]'W ;>Q^3CO0!V]_K-IIU[IUG._[
M_4)C# @ZDA&<GZ *>?<5H5Y'JMCH^J^(/AO<1@7L$YG3SI5(:1%BR V>>#^M
M1>+64:3XJO\ 3GGO;BR8>5>LWDI8;=O[J(@DL1R>@'.": /8:*\VOX'U+XC>
M'8)[NZ\FYT>5YHTF95<_+G@=.O:L>ST*"YTGQS82W5\;;2II38H+IQY!\O?D
M$')PWKGTH ]4OO[3\ZT_L\V@B\W_ $K[0&W>7C^#'\6<=>*NUY0;Z\O-"^&=
M]-=SM/<RP^>?,($F8B<D=#4AT:+5/'7C>UN;J]-O!:V[QQK<N K-&3G@^O..
ME 'J=%>10Z]J<W@_P+;O+%.VH.R3FZN6A6;8K;59U1CS@=N<<UT7A[0]6M;[
M7;#4[FQMM)O8E>WL;.]>62UR-KD.R)A3U''!Z=\@'=UQS>+=8_X6"/"RZ+9X
M-L;P71OV_P!4&"GY?*^]STSCWKIM,LH--TRVLK9W>&&,(C.^XD#U/>N U"UG
MO/CK%%;ZA/8N-!<F2!8V8CSDXPZL,?AGB@#9U3Q9K-CXXLO#D.BV<RWL;RPW
M+W[)A5Z[E\HX/L"?K45MXNU^[\7ZEX=BT+3A-90I.99-2<*Z,2!C$)(/'(K*
MN[*YL_C)X;%SJEU?EK&X(-PD2E?IY:+^M6]&_P"2V^)/^P9;?^A-0!KZ;XP9
M_$G_  CVLZ<=-U)X_-@ E$L5PHZ['P.1Z$ TYO%<M]KEYI&@6"7\]B0MW/-,
M88(7/\&X*Q+>P''>N9\=,-0^)O@S3[,JU[;SO<S%1DQQ;<?-Z FG?!S;:V/B
M/3;G*ZI!K,[W2O\ >.[&UN>H.* .PL=9OY-=_LJ_THVK_9WG6=)A)$X#*N%.
M <_-DY QQUSQMTPO&)E0LOF$':.^.]9'B*RO[VWA6PB$CJY+ ZG+98&/[T:,
M6^AQ0!M56U"2[AL99+&"&>Y492*:4QJW/.6"MCC/;_&N/30O$0D4FT7 (S_Q
M5=X?T\CFNVE_U3_[IH Y?P+XJU+QAI']J7.D0:?;,S)&%NS,[%3@Y&P #\:Z
MNN#^#_\ R3NU_P"N\W_H9K>UGQ,VE2QI;Z)JNJALAGT^-'$9'9MSK@T 5Y_$
M%_#\0K30##;?8KBSDN!("QDRI QZ <^];NH?;O[/G_LTVXO=A\G[2&,>[MNV
M\X^E>?ZK;QZ[\3O#_P!ICNK:.?2)9'@+>7(N2IV/M/!'0@'M6-9S7*?"OQU9
M_;;HII.IWEI9L9FWI$FW:N[.3C)ZT >O0>=Y$?VC9YVT;_+SMW=\9YQ534M8
MM-*>S2X?]Y>7"V\*#JS-_0#DUP^LV][+;:)>+IW]MV,&GC[3IZ3[)D+8VS(.
MCG"L,<'T[UC:Q9Z-JME\.YH@U[$=16V\ZX0B1DVOE6!.1R.?I0!ZF/[3_MEL
MFT_LKR/E #>?YN>_\.W'XYK$^(/B2^\)>#KS6K"VMIY+<H"L[L -SJ@. /FY
M8<9'UK$:=M*^*&HBW,KP0>'C,EOO)4,)!]T'@=,5QWB:TM=8^ LOB6>5Y]4G
M$,LL_FD_,UP@*8Z;1G@=L"@#V>7^T_[6M_)-I_9OEMYX<-YV_P#AVX^7'7.:
MNUP^JF1?BYH<8GF$<NGW!:/S#MSE>0.@-<5+IOF^$O'=^U]?_:-.U*X-HPNG
M'E%,8QSSZ<T >VT5YKJ>J:AJ7B'0=+:*SNHY]*^U/;W=VUNDTAV@G*QODCGC
M ZUO^!;'6=*M-0L-7O+.<1W3-:Q03M,UM$W*Q,[*I..W'3\!0!U,AD$3&)5:
M3'RAFP"?<X./RKGO _B&Z\3^&EU*\@A@F-Q/$8X22H"2,HY/)Z=>/H*P;%H/
M%GQ \3Z?JK.T6E+!#:VOF%0H92S2X'5B<8/88KD]'U&YTGX6:);6KH%O/$4E
MG*9IVB4QF64X:0*Q4$H 3CO0![;17D6MOXE\'6'B#5+=M,L[*6Q5X;"UO7G:
M*3S41IEW1* H5V)'J!7<:?X?TB"^T[5[&]N$+0E0!-E;O<N0S@_>8 9S0!TM
M%>+:A,86\/ZMILUS=M+XCC@DU>1_*,R/*0T2QY.Y ,KDX'''7CH4TB'5_BCK
M]C=W%X;9;2VG6-;EUVOO)R,'CH.* .B\,^(+_5]=\1:??06T8TNY2*,P%CN#
M)NY)ZGD= *Z:O*M/\+V7B3Q=XZBO;B[B6.\@\MH)VC\MO)'S\=2/?-9_A77]
M1UE?!6D:V\AM;N"[:1G<_P"EF)RL>[O]T9Z\GF@#V6BO-;&P7_A.?$/@^5I9
MO#[Z?%>!6E)^R2,V-JGJ 0-P&>-OO63X'L;>/Q+%H.L2LXTX23Z-(P9?MR,^
M3(6/WF7 &.G.>>P![!7,^-/$-]X<L]-GLX+>476HV]I(9BWRK(^"0!U./?\
M.N6F2Q^'_P 0;V\N5E.GZS:2/ S,6$<T8+O&,]-X&1[KBH?$VBIH?@;P_;A6
M6677;.>4$GY6:3)7DG 7.T?2@#U6BO+/'*PW9\5O"]QJ-U9Z?O5-_DQZ<50L
M&#YRSGK@#G&"0#FI)SJFI>&_"FJRV)UZ(Z1'+>6 GV3.S1H3,H/#$'(Q[\4
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M'P%M8I/$>IW#+^\BMU"'TR>:]_K*>YI'8****D84444 %%%% !1110 4444
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MC9D'9C.-O XKI*0NJD!F STR: .;U#P/I.I>(8==N);_ /M"#_4R)=NHC'<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "CM110!\B^.;'[#XZUF#?O_ -*=\XQ]XY_K
M7/'BNU^+%HUE\1-2RX;S2LHQVRH.*XD<FMEL9DJ\+4BFH>E21]:8%N$U93K5
M-#BK*'F@#U;X=:K)H_A37-0C4.T#(VT]".XKO]$T#2[FTN[B#;)INI.MRL?H
M>I'YUX3IFMWMCI5YIL)06]WCS05R>/0UM:=XOUC3-+&G6MP%@#[UXRRG.>#Z
M5,E=W] 6B.V\5/H=YH-Z%N(I;FWDQ$8K%XO+/]TG&#^-94UNI^'&CRI #(UR
MX9E3D_.>]8NK>+=6UJT%M=21+$6W,L487>?4XZU)I/BO5=*T\V-O)&8-VY1)
M&&V'V]*232^[\"F[_B=?<VL"_$?2(C!&$-JA9-@P3ANHJA/=1:]XNMM'FM;>
M"SCNR (D"LP]":PIO$^I3ZW#JTCQFZA0(IV<8YZC\:S9+V=K\WH?;<%_,W+Q
MAJ:6JN*6SMY'H,4L6N7^M:+=:9;P6MK"[12)'M:,KTR?UK,LKV/1OA_;7L=G
M:SW'VMD5Y8PV!FL>\\::S?6,EK+)$JR#$CQQA6<>Y[UD/J]V^C1Z2Q3[+'(9
M%&WG/UI6=ON&VK_?^1K?$>*!=4L9X($A-Q:)*ZH,#)KA7.!6WK6L7>L20-=%
M"8(A$FU<?*.E8DBG%4E8ENY6<5 ]6B?6JTG6F(KMUJ*7GBK#K\N:@84 >R?
M.UC U>ZP?,)2/\.M>UUY1\"[,1^'[ZZW$M+/M*^F!7J]92W-([!1114C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!ZG\*XJXT_7AX#\&Z9'X<OY+K3)[9KI-T8VB(#=@[^<]OI6RHU6/XAZYJ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \R^.7_(CI_P!?*?UKYQSGK7T=\<?^1&7_ *^4_K7SCCC-:QV(
M>XY>E2)TQ3$.%J6,9:J$31CUJTO057'-6T7Y%- %E&RH [5;MQSS5:# !)J>
M/):D!9'WJL*%$>2>:KA<-BI"I!VF@!ZYSQ2[O>G@JL>.YJ*@ ;.,TBJ&4T]B
M/+QWJ+) - %:3@FJ^,DBK#\U7W;3F@"K)P2*B8C&.]3/RQJ!ASQ3 B--!.X?
M6GMTS3!]X?6@1]9^%O\ D5M,_P"O=/Y5KUD>%O\ D5M,_P"O=?Y5KU@S4***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HKBI/&&O-XEUK2+7P[9S)I4:S
M23MJ;+O1@2H \DX<J,[2<>_>NA\.Z[;^)= M-7M4>.*X7<$?&Y2#@@XXX(-
M&I1110 4444 %%0W=W;V%K)=74R0P1KN=W. !4JL'16&<$9&1B@!:*** "BN
M<\;>)KCPEH!U6&PAO521(VB>Y,+$LP5=N$;)R>AQQFJ]UKOBNRCMI9?#.G2Q
MRSPPR+;ZL[R1"1@NXJ8%! )YP?TR: .KHJG!?^?J-U9_8[N/R I\^2/$4F?[
MC9YQWJY0 4444 %%%% !1110 45S/CKQ#J7AK01?:796MY</-' D,\S(6=V"
MJ% !W')[E> >:Z2/?Y2>;M,FT;MHXSWQ[4 .HHI"0JDL0 .I- "T56L;^VU*
MT6ZM)/-@9F57 (#;202/49'!Z'J*LT %%<[XVUZ]\,^&YM5LK:UG,+*'6XF9
M.&.T;<*=S;BO''UK=MVE^R1-<[!+Y8,FT$+NQS@'H* ):*Y+2O$>KZ]J:7.F
M6ELV@"ZDMGF8GS'"J<RKD@;=X"@ -GDY%=;0 4444 %%%% !16#XQ\03^%_#
M5SK,-G#=K;8:2*6X,.5/'RD(V6+%0 0!SU]<ZR\9W2ZSI&E:WI,=A<:O$TEH
M8+KSURJ;BKY1"K8]B..M '7T444 %%%% !1110 4444 %%97B34Y]&\.7^IV
MZ6[R6L+3$7$C(FU1DY*JQZ X '-+X<O;[4O#FGW^HP);W=S"LSPH"!'NY"\\
MY (!]\].E &I145R\L=K*\"1O*JDJLLA12?=@#@>^#7"Z-XY\2:[X6.OV?A:
MP^SGS/+ADU=EEDV$@[1Y&/X3C)'2@#OZ*Y+Q-XLU30=*TF\M]#AO);^9('@:
M]\IHY'QM /EG<.N3QC X.>+$&M>)$\06.GW_ (>LTM+D2%[RTU(S"$JN0&5H
MD/)P./6@#I:**Y'QQXRN?!5M;:A)I<5UICS)%/,+HK)%D\MY>P[@ ,_>']:
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MD9 H Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^6  !5F"TAMY9Y4!\R=][L>23T'X 4 )>7:6-L9#&\C=(XHER[GLJC_('4D
M$US7G+X8LM0UR>QO=3O[RX7SX-,A\^1,#"H ,<*.I..ON*FUWP-I_B'41?7>
MH:O%(J;%6UOGB51[!:V='TFUT/2X=/L_,,,6<-*Y=V).268\DY/6@"MX>U[_
M (2"Q>Z.DZII@1]GE:E;^2[>X&3Q[US_ (&F&IR>(/%KAGCO[MX[79ER;:#*
M*5 _O$.<#UKJM4TY-6L'LY+BY@1_O-;R;&(],U7\/:!:>&=(CTRQEN'M8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gym1fcavvjqs000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000013.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &" EX# 1$  A$! Q$!_\0
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M[-&0C7[?*A2'R@\9.$7"7C(0_HU"^(I<]\8(NP
M
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MN3OLU\A?@=MGZ"GP*>L>^/FIXO\ LT\>/@9J7Z!KX(G,
M
M                      0=R=]FOD+\#ML_04^"T]8]\?-3Q?\ 9IX\? S4
MOT#7P1.8
M                                              @[D[[-?(7X';9^
M@I\%IZQ[X^:GB_[-/'CX&:E^@:^")S
M
M        $'<G?9KY"_ [;/T%/@M/6/?'S4\7_9IX\? S4OT#7P1.8
M
M                               @[D[[-?(7X';9^@I\%IZQ[X^:GB_[
M-/'CX&:E^@:^")S
M                                                     $'<G?9K
MY"_ [;/T%/@M/6/?'S4\7_9IX\? S4OT#7P1.8
M
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M6/?'S_/J3%Q?]FGCQ\#-2_0-?!$Y@
M
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MX\G?9KY"_ [;/T%/@4]8]\?-3Q?]FGCQ\#-2_0-?!$Y@
M
M                     "#N3OLU\A?@=MGZ"GP6GK'OCYJ>+_LT\>/@9J7Z
M!KX(G,
M                                            0=R=]FOD+\#ML_04
M^"T]8]\?-3Q?]FGCQ\#-2_0-?!$Y@
M
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MY1=HBN(B9HFJB:HBJ(JIF:9G,15$XQ,.WC[7.
M
M      (.Y.^S7R%^!VV?H*?!:>L>^/FIXO\ LT\>/@9J7Z!KX(G,    !Y2N
MI U=*<T-T'3;.%"95H78Y$5#ESVUA2L9[&*7.,]LXSC/;/X9QV'Y%^DVFJ>W
M'')BFJ8YN'[Q$_\ )6A]3Q/M935/:#B$Q35,9TV\1,Q_4].V:]'NXU<VFM@:
M]\\8%NS/9TO;%ZRHMZ*6_1R1J]*B&TPBV4P0SEEB3B7K)RHVRKEDN5N1[AOZ
MZRRX]3^A?6Z2>"<1X=Z>W&NM\4O:RK2S.+WU:YI=%9HOQ3..:WZ6S7;JFGF]
M'5%,7.7TEOFW'L'J+/Z/U.E])3&IIUER]59F<5^BKLZ>BFN(G&:>>W53,QGE
MF(YL<U.<H.HYLWD%I7A?R!W)QKE=;06P=1ZLV-M)Y,;-A)FS1K.KZZU]:KG*
MIUZO1+R.0E;A)NH.-AH3]()!"N119)Y/2C2>+$I5F:]GG:)GR;Y3B9B)SB9Q
MM.)^,2U8<H.IGN^HRO%;6\->+3J9M8N $1SDY%[IUIQ1GN4]DC8QWFN06&Z%
M"B'#6M:[US$OLW.W;"O-CPY391S*O5V RP?R.5UIG'Q^'Y]WP913&_\ %RQF
M8B/'[\],;8WW9R\_^<%AX_<,]1;CT3*,+M:^2&Q^.>H]47^/UQ:-B,"I[]?,
M%4=G0FGZPX2MM\?DIV)6=IFN8QT61GK(Y@(13ULBJ[-S?=_BE,9F?5$S,=.D
M=/5Z_5E,W3[WR3?VBY:9>[ALVYKC0=HWS5FQY6]:*4XX; IUZJCIDO)Z\O6J
M#*JHP5DK<?+Q2BKAIZ-O(Q\C'.<IE<F<9R2J,3TQX]<QOY3Y?F=V<@(
M
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M@VP7(F<_=$1&/*&1H(
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MBFUJ_"F:9CN1<KC>GEGT=[K;F)F*&RX>HMN
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M,7!BYP8IL8,4Q<XR4Q<X[XSC./PSC./QQG'X9Q^.![!UZ-WZ]'Z
M
M                @[D[[-?(7X';9^@I\%IZQ[X^:GB_[-/'CX&:E^@:^")S
M          $(;]X^:WY'45U1]B16'">/2N(&?9X22GZK+'3]&25@WQTU,HJ?
M@0KMFL55A)($PW?MET\$P3H>T/9SAG:;A]>@XE9YHWJT^HM\L:G27IC$7M/<
MF)Y9VB*Z)B;=VF.6Y35&,==Q/A>DXMIJM-J[?-&\V[E.(NV:\8BNW5B<3TYJ
M9S37&U43#6QK'>.V.!5UBM \I%WMITE)+99ZIW6V;NW2,1&IF*FA'R&<Y<.3
MQ4>F=$C^"65<351+G&8X\Q6CQ9D_,.%<>XO]'NNL]G>U=5>JX#<JY.$<=IIK
MKBS:B<4V[F]=<V;<3$7-/5-5_1Q^ZF_I9LS&I:/B6M[-:FCAG&9JO<.KGET7
M$8BJJ**(Z45]:IHIB8BJW,S<L?V/26>68W$QLE'3,>QEHA\SE(J3:-W\=)1[
ME%XP?L7:15VKQF[;G40<M7")R*H+HJ'253.4Y#&*;&<^U6KMN];MWK-RB[:N
MT4W+5VW537;N6ZXBJBNBNF9IKHJIF*J:J9F*HF)B9B6^45T7*::Z*J:Z*XBJ
MFNBJ*J:J9C,54U1,Q5$QO$Q,Q,;PYHS9
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M$P[*/J<P
M                      -;?4DY_P EP*U]6+'6-.-=TVVT1NV+2C79G9T3
MJ*OQ])T?KF3V=L645M4G7[6XE+*6 CR-ZE2(6NOI:T/EG)BN(]C%OG9#*F,S
MO..D;1F=YQTS'W[LE>-_(V$Y'--SO(*)0CVNG>06RM"KOV%@:V:)LSG7IH97
M])8J49LV2!$9!K.-49"*P5T>!G6<M"*2$@>/,[5),8QGQC/X]/AO[I9'@@
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M$S3,3,E#M'U@
M                        #3#UGD)='6V@[#8-1<;=\\>ZYM::<[]U/REV
MAH71NO+'&R5"GXBB/H;<^[D57.O[S7;8]3F()U0CI3,XP;S5=F,G@I-TF8RI
MZ[3,3X3&9GK'2(Z[99<].=_%2'%.B*UCC;J#BO1R.YLE"UAHC;NNMXZQ<595
M[ETC<:_L35D3#U"8/9Y5S+.Y(S9%V^/)).G<E(O'CM13 JZSO,^N8Q/WPSE!
MB  "#N3OLU\A?@=MGZ"GP6GK'OCYJ>+_ +-/'CX&:E^@:^")S
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M(ZQ.)Y*XS37$9B<Q5$3X-A=F
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M&<MQN+O
M                  ><WJI\J=!WZZ["X@W?2CB^\I]9;'XTQ'!RKU/?=RTU
MNC9.VN2$%/1TW>ZI/4!M!6ZB:>UK7EW<7L2X-9^PUR:<-I6 LK*LNFM=D71R
M4TSM5G$8GFGES$1'AO$Q,SX99U=(I*KP7%ZUZTA]-Q&D[CI?D/NO4VZH*!V3
M:MR1%KW36+"W<7?8[+:UZQB[WG%TS*1LBYD+84DU$/"N:JNFFC7VZ93"KKG.
M<[],?"-H^[;'1LZE&SQY&2+2.D5(B0=,';9C+)-FSQ6+>+MU$FLBFS>$49NU
M&2YB.2-G2:C9<R6$ER&2.8N2/-!KKEGNWBYQ$ZEY;#O+;VZ=H5OJC["XCZ9W
M-N).9V:[U@A;-8Z#2;[#L4!2:]EC!Z\U0C,7C:QJ-0J9%5E>5:YJ]>KK-Q94
MR&.28C-/2,T<TQTB9S.WW[1F9]<RS,Z%6[76XN'MU9RV\-H<@YG6/)WD1KXF
MR-PRETG[[+TZ+V3,J:V6FIV[M6\B\5<T56$>>I(F]'!Y<&B%V<4Y:*QK8ER,
M3&T1FFF9B.F<;LS.>&Q-C4;C]M%E1= 7S=+*R:<W*ULDQ3K=J*LL]>M6]*<(
MMY*P-MG;"I$E,-WZ,A(.D$:<RL;U%*!?)NVS=P[B49 QIZQO'6-ISO\ A$_%
M,7%_V:>/'P,U+] U\$3F                  -;_*WA;*6BR)<A^-$IG77(
MBN+&ES>6+(QL7L!1$AO3(/\ !\88-K ]1\;51V^3/#V)!52,M"*B#G,DS\R[
M7=AKNKU4=I.R]W]&]I=+5-[]E53:M<1JB.]3<S^SHU-RF:J)KN1Z#4TU3:U<
M317-VC4^-=GZ[UZ.*\(K^J<5M3Z29HGDMZK$;Q7'V8NU1F)JJCDNQ/+>S$\]
M/;^(_-*+WDJZUALR+_5OR%JF7#"R4F316C"3SB,P8LA(5QL_SARFX0]&=>4K
MC@RDA&$PHX0._C4U'B/V=CNW-KC\U<*XI:_1G:/2<UO4Z&[35:C456OWES2T
MW._%5,1-5W359N6HS53-RU$UT\_ ^T%'$IJT>LH^J<5L9IO::N)H]+-&U5=F
M*M\QC-=J<U41O$U41S1GB/06R@
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MMWQC!,S/6<^'W>3I/)WV:^0OP.VS]!3X+3UCWQ\U/%_V:>/'P,U+] U\$3F
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MXT^JTVKMQ=TM^UJ+<X[]JY37$9WQ/+,\L^JK$QXP[@/M<X
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M^S7R%^!VV?H*?!:>L>^/FIXO^S3QX^!FI?H&O@B<P
M6&TUB"NM:GJ?:(\DK7+/$2$#.QBBSEN20B95JJR?LSN&:S9VB5PV642RJV<(
MKDP;Q)*D/C!L?/J]+I]=I=1HM7;B]IM79N:?46IJJIBY9O43;N43515373%5
M%4QFBJFJ,YB8G=Q7K-K46;MB]1%RU>HJMW*)F8BJBN)IJIF:9B8S$S&8F)CP
MF&)'^;LX9_\ N1C/_P KV!G_ /VV#3OZ->Q'_(5K_KG$?^^.D_5;@'_)UO\
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M49IJHJBJFJ)Z335$S$Q/G$X<T9L@
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MWN[
M         !!W)WV:^0OP.VS]!3X+3UCWQ\U/%_V:>/'P,U+] U\$3F
M                     #\,4IRF(<N#%-C)3%-C!BF*;';)38SWQG&<9SC.
M,XSC.,]LAUZG7JPYW#P)XP[G]:=S6O&=4L+KQF-:=>F2J4OZ93OD[ERU9MU*
M]*NCF[&.XF8.17SG'X*8[F[Z3QKZ/>RG&^>N_P -HT>IKS/UOALQH[W-/6JJ
MBW3.FO53.\U7[%RJ?.,RZ'7]FN#\0YJKNDILW:M_3Z7%BYGQFJ*8]'7,^,W+
M=<^MBA_11YO\;^[CC)R!QLJH,OVF^K]G93(8K4G^SBXS$TM(5]+&>V,JNHN6
MH9CYSV*4N/%XM0_5#MYV9[W9;M''%-';^SPKBN(Q1'V;-J-15=TT1M'-7:O<
M/F9Z1$9STGZ%[1\)[W!^*?7+%/31ZW'3^Y1-R:K<>N:+FFSOZ\W6%ZDMIUG)
MM:MR]X^7;4\LHIZN6UUV/=R%7D%2_@JZ:1\HH111@EX3Y,O 6*W&/VSA-/.2
MF'-8^D_5\+NT:3MGV<UW![TSRQJ]-;KN:6[/]JNBU>F)FU3OFK3:G6S/2*=I
M9V^UM[1UTV>.\+U.AKF<1?M455V*I\9IIKG,TQOO:NWY]75L!U9O_3&ZV97>
MK]CUBVG]%Z=:+9/\-K S2[8SXY"M2)6<_'D_'MXWL:@0V<&P4QO#GMZ+PGM%
MP/CM'/PGB>DUDXYJK5%SDU-%/G<TMV+>IMQZ[EJF)WQ,XEL^BXIP_B%/-H]7
M9O[9FBFN(NTQ[5FKENT?YU$)@'=/O
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MU55^DHHQFN[7S1RU3M$9SB6W4>R-Y
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M+6TS&8G2:JQJ(QYYLW*]G<V=5I=1&=/J;%^,9S9O6[L8\\T55;.Y#[7.
M              #C.WK-@CER^=MF3<IBE,N[72;(E,?/8I<JK'(3!C9_ N,F
M[FS^&.^1C771;IYKE=-%,8B:JZHIIB9Z1FJ8C?PW2:J:8S5,4QYS,1'XSLMZ
M%CKSI9-NVG89PNL;!$D$)1BJLJ?/Y$3237,<YL_P*4N<Y_A@<5.ITU=44TZB
MQ555.(IINVYJF?*(BJ9F?5#&+MN9B(N43,[1$5TS,SY1$3NO(YV8
M   #7]R+ZB&KN-FRG.L;92K].R[6'B9D[^O)5X\:9O+I**H)%S)3C!UZ9/">
M<*XRWP3OG'@.;'?./.NTOTD\)[,<4JX5K-#Q'47J;%F_-S31IIM<MZ)FF(]+
MJ+=?-&-^[CRF6K\6[5:+A&LJT=_3ZJY<IMT7)JM1:Y,7(F8COW*:LQC?;'DE
MOBWROI?*V#M<]3*[:*ZVJ4JPB'J-G)$D7<KR#-1XFHUQ%24DGE(B:>2GRL=(
M_CSCPDR7OD=SV3[7Z'M=8UFHT.FU>FIT=ZW9N4ZN+,5557*)KB:/0W;L8B(Q
M/-,3GI#[N#<;T_&[=^[I[5ZU%BNFBJ+T41,S73-433R5UQB(C?,PRF&V.Z
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MF<K!R=]FOD+\#ML_04^!3UCWQ\U/%_V:>/'P,U+] U\$3F
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M[>NW:>(5VJ;MVY<BW1I:.2W%=<U113B[$<M$3RTXB(Q$;1T9::RZ>7&>CTN
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M"_ [;/T%/@M/6/?'S4\7_9IX\? S4OT#7P1.8
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M@:^")S
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ML8T24\(_(]K-UAJ]9XI1&2C7B)$Y6'9'<))IO&Q5F3ALX6,)C&WRF)^,;)@
M          !!W)WV:^0OP.VS]!3X+3UCWQ\U/%_V:>/'P,U+] U\$3F
M
M                                 (.Y.^S7R%^!VV?H*?!:>L>^/FIX
MO^S3QX^!FI?H&O@B<P
M                                                       !!W)W
MV:^0OP.VS]!3X+3UCWQ\U/%_V:>/'P,U+] U\$3F
M
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MQCXIBXO^S3QX^!FI?H&O@Q3F
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M>L>^/FIXO^S3QX^!FI?H&O@B<P
M
M   !!W)WV:^0OP.VS]!3X+3UCWQ\U/%_V:>/'P,U+] U\$3F
M
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M(95@@
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MF6P $
M                                          $'<G?9KY"_ [;/T%/@
MM/6/?'S4\7_9IX\? S4OT#7P1.8
M
M  *%54T4U%EE")(I$.JJJJ<J::2:9<F.HH<V<%(0A<9,<YLX*4N,YSG&,9R
M^31XT?MD7K%TW>LW*956[MHNDY;.$C?NJ(KHF.DJF;_A.F<Q<_PSD!"W)WV:
M^0OP.VS]!3X+3UCWQ\U/%_V:>/'P,U+] U\$3F
M
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MF/4J]T.#?S'WW]K .Y[7P/,>I5[H<&_F/OO[6 =SVO@>8]2KW0X-_,???VL
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M43-$B):0@)4\1(LY(L9.Q*N$)2%D#,UEL,I:-7SA&0CG.4GC-7.$W"*9_P
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M'OF,<[%@;95BQDQ.9?R;J+;3XQ^?A^=\I7$1.(SU\<[QMOGI^&V'H %8
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MOA%6+>6NC>1;-U_-\QK%Q(.$_"\_?^&T)/>G,QF>2)B(V\=^GE'^/A*4Z?U
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MK06H0#!T@A4Y:-BEHI%I$02,'@N)FB<YC$1CFC$=?[,^<QCWQXX>I\'$
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M)UE[8)"#@8J)>SCW)U#Y=S#M@T;KR;K)U53Y</5%U<G44-X^YS9R'9@
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M.)@8R31FHZ$C*[#L(B/F&[G#UO+,HUJS29M)-!X4KM%^@BFZ2<XPN14JN,'
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M3R!1N1VG.?H424-9?)SM5".22?EGJ1FYR+%7RF;!LC$XSB<>?@D<$
M     10UWSHU]/WNJ,MSZH>6G5L:ZF-FUMKL6H.)_7,0R_%[*WN'2F#R-0C6
MF/Q=/K VCVK?_P JJ0%Q/E*_Z]V=K;;E;2N6J-A4?9U0<.G3%"U:]MD#=*VL
M]9&*1XS2G*W(248HZ:&.0KIN1T99N8Y2JD)DV,9)B8ZQAW@
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M[,_BXN[QU+:5&Q0<]>JO#2TI,-BYCFJQMG.)STS$YZ=<_P ^CTQ P
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M^GCLVD@Q
K                                                     '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gym1fcavvjqs000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #@ =X# 2(  A$! Q$!_\0
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M]<?2GD ]0#2T4 ,>&.22-W16:,[D)'W3@C(_ D?C3Z** # ]*0@$8(!%+10
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MCQMI<-U+%);7+/$S1DA%['![]*B=2$/B=B924=R:7Q(\>E0S8C:<RF.7@80
M,20-W(.T@<\G\JZ&-Q)&KC.& (R,&N4_X3O2-NW[)<X&./+7M^-;^DZI#K%B
M+NW214+%<. #D?2IA6IS=HNXHSC)V3+U%%%:EA1110 5B7=MH,^IMJ=SY9NK
M6-K=I2S816Z@]NA/TS6W6/=:&;B2\87"QK<IL9%C(!'JV&&6]^/?- #].MM)
MT"W@TRR"P1NQ,2;B=Q//!/T-:M4DL&\^VDEN#(+<,$7;CD@ $^X&1_P(U=H
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MNA)6.-<#)Y)H 9IDB2Q3O&P9&G?# Y!YJ[52PZ7'_7P_\ZMT %%%% !1110
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MK#GKVX].;WV6YEUR"ZDMTCCBC8;TDRS$Y !XZ8YQZGVY\V_X3CQ#_P _J_\
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MP.WD%AGM7N'>?0-%%% !7C.I_P#(6O?^OB3_ -"->S5XSJ?_ "%KW_KXD_\
M0C7G9A\,3FQ.R*M>E^!O^1;7_KL_\Z\TKTOP-_R+:_\ 79_YUA@?XOR,\/\
M&;BZA9O!),MS$T4;;78," ?3^53QR)-&LD;JZ,,JRG((K$'AL+:W%NESM29E
MRNUB%5<;5'S9  !Z'//&,5JV%K]AL(+7S#)Y2!-Q&,XKV#M+%%%% &?KW_(
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M.Y>1YY#(\C'J6)Z\8'T%:%-CD2:,21.KHW1E.0?QH J::B1Q3I&JHHG?"J,
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MJA8?>P"!N[XK4LN:?HPTO3X+&UO;E;>! B!@A( ]]M6?LT__ #_S_P#?,?\
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gym1fcavvjqs000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gym1fcavvjqs000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# :,# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YU?^%=
M8N+OQ)<1Z'HYEU +# 6F^1H@Q.]T\O!E^9FW'/.T=!SVFDV3V7A^RL53[,T%
MND(7S/-V;5 QN(&[IUP,UHT4 5;"262W;SG#NDCIN QG#$#C\*M53T[_ %,W
M_7Q+_P"AFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)H9%DB=0R.AR&!Z$$=10!4TI2EK(K.7(GERS 9/SGTXJ]5/3O]3-_P!?$O\
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M)#%;2R+C<B%AGV%25!>_\>%Q_P!<F_E0!XXOQ<\0%0?LNG\C_GF__P 52_\
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M^4DL0" ,  #N:]#KEO#?A*XT35)]1O=1CU&\GB\N2Y> I*W.>3O(Q[ "NIH
MY>Z\"Z;J%[J5Q?75_<"_=)&C\X1B)D!"%"@5A@$CDGWS6WI^EVVFZ-;:5$'D
MMK>%85\YMY*J,#)/6KM% %'2D2*UDCC4*BSR@*!@#YS5ZJ>FD&"4@Y!N)?\
MT,U<H **** ,KQ-_R+&I?]>[_P J\5KVKQ-_R+&I?]>[_P J\5KY[./XL?0Y
M,1\2"BBBO'.8**** $;[I^E=W\1_^2=:=_UU@_\ 0#7"-]T_2N[^(_\ R3K3
MO^NL'_H!KVLF^*?R.G#;L\>HHHKWSK"BBB@ K2\/?\C-I/\ U^1?^ABLVM+P
M]_R,VD_]?D7_ *&* /I2BBB@ HHHH **** "BBB@ HHJE)K&F0R-')J%JDB'
M#*TR@@^A&:3DH[L&TB[15#^W-)_Z"=G_ -_U_P :/[<TG_H)V?\ W_7_ !J?
M:P[H7,A]C)/(]T)I%<),43:FW P#SSSUJY6+9:QI:/=EM1M!NG++F=>1@<]:
MM_VYI/\ T$[/_O\ K_C1[6'=!S(OU!>_\>%Q_P!<F_E5?^W-)_Z"=G_W_7_&
MG27=M>:;<O;7$4R"-@6C<, <=.*:G%NR871\RK]Q?I2TB_<7Z4M4,**** "B
MBB@#Z#\!?\B-I'_7#^IKHZYSP%_R(VD?]</ZFNCH **** "BBB@ HHHH ***
M* "BBB@ H(!&",@USMQXK\HZXD>EW,DFD;#(IDC02*R[MP); 4 'K@^U:]A?
MQ7^E6NHA7ABN(4F"S#:R!@#AAV/- #=+18[61$4*JSR@*HP!\YJ[5+3&5[:1
ME8,IGE((.0?G-7: "BBB@#*\3?\ (L:E_P!>[_RKQ6O:O$W_ "+&I?\ 7N_\
MJ\5KY[./XL?0Y,1\2"BBBO'.8**** $;[I^E=W\1_P#DG6G?]=8/_0#7"-]T
M_2N[^(__ "3K3O\ KK!_Z :]K)OBG\CIPV[/'J***]\ZPHHHH *TO#W_ ",V
MD_\ 7Y%_Z&*S:TO#W_(S:3_U^1?^AB@#Z4HHHH **** "BBB@ HHHH *\2\1
M ?\ "2ZGQ_R\O_.O;:\3\1?\C+J?_7R_\Z\?.?X<?4Y\1LC,P/2C ]***^>.
M,,#THP/2BB@ P/2O1O G_(J:E_UT?_T 5YS7HW@3_D5-2_ZZ/_Z *]'*O]Y7
MHS:A\9XBOW%^E+2+]Q?I2U]0=P4444 %%%% 'T'X"_Y$;2/^N']371USG@+_
M )$;2/\ KA_4UT= !1110 4444 %%%% !1110 4444 <Y=^"-(OI=2DG>^+:
MBZ/< 7D@!*'*X&> /0=JW;>V2WLX[;=)*B($W3.79@/[Q/)/N:FI"0!DG '4
MT 4],4+;RJH 47$N !P/G-7:I:6Z26LCQLK(T\I#*<@_.:NT %%%% &5XF_Y
M%C4O^O=_Y5XK7M7B;_D6-2_Z]W_E7BM?/9Q_%CZ')B/B04445XYS!1110 C?
M=/TKN_B/_P DZT[_ *ZP?^@&N$;[I^E=W\1_^2=:=_UU@_\ 0#7M9-\4_D=.
M&W9X]1117OG6%%%% !6EX>_Y&;2?^OR+_P!#%9M:7A[_ )&;2?\ K\B_]#%
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M8H+B(2@2D IGJ#VXH DTW_42_P#7Q+_Z&:N52TMUDMI'1@RM/*0RG(/SFKM
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MN"BBB@ HHHH ^@_ 7_(C:1_UP_J:Z.N<\!?\B-I'_7#^IKHZ "BBB@ HHHH
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M\C-I/_7Y%_Z&*S:TO#W_ ",VD_\ 7Y%_Z&* /I2BBB@ HHHH **** "BBB@
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M_/P/^^3_ (4?VM8_\_ _[Y/^% %VBJ7]K6/_ #\#_OD_X4?VM8_\_ _[Y/\
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M3_H%WW_@,_\ A7TIVE*BKO\ 8^J?] N^_P# 9_\ "C^Q]4_Z!=]_X#/_ (4
M4J*N_P!CZI_T"[[_ ,!G_P */['U3_H%WW_@,_\ A0![MX"_Y$;2/^N']371
MURO@R\@LO!VF6URS0S1PX>-T8,IR>HQ6[_:UC_S\#_OD_P"% %VBJ7]K6/\
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MIMS<&XFMT*M(6+9Y)&">< ' ^E &M1110 4444 %%%% !1110 4444 %%%%
M!1110 5'<7$-I;27%Q*D4,2EY)'.%50,DD]A4E9VOZ:^L^'=2TR.18GN[:2!
M789"EE(R1^- %BPU"SU2T2[L+F*YMWSMEB8,IP<'!%+%?6T]Y<6D4RM<6VWS
MD'5-PRN?J*XFT\!ZC'?6%]+J*1SV@@1!#+,X"(TOF8WL22XD4<YQM],4FD>
M-1T[P]K=@VJ1+<Z@D2B>%9!RBX+.2Q8E_P"+!'4XH [5M1M$U./33./MDD1F
M6+!)V X)] ,^M6(Y$FC62)U=&Y#*<@_C7'>&/ YT34C?W4T,TK6C6Y5-^(P9
M6?8NYB=@!"C//%8T?PNNH=&GLH-2BMG%F+6V: 2!4_?-(S$%NKJ0C?CCTH ]
M*DD2*-I)'5$499F. !ZDTZO+D^%^JR/.MWK<<UO+I36!B8.V25 4L<_,%8 C
MVX^MF?X9W,\DMP-12&X8/Y0B>4)"=D(CVC=T1HW89_OT >D4U9$=G575F0X8
M \J<9Y]."*\[B^&^H-=Z@;W6GN;:[U!+ID9W&Z,&0E#@C!^=1D'HH]JV_!_A
M.?PU<7DUQ<0W,MU%;B2<*PD>2.,(Q;)(()&1WY.: .KHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>35
<FILENAME>hrmy-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T03:27:40.1754106+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 0158915826f244a7b74d260029b57690 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:hrmy="http://www.harmonybiosciences.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="hrmy-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_hrmyProduct">
    <xbrli:measure>hrmy:Product</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_hrmySegment">
    <xbrli:measure>hrmy:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_hrmyCustomer">
    <xbrli:measure>hrmy:Customer</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_hrmyTranche">
    <xbrli:measure>hrmy:Tranche</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001802665_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20210315">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-21</xbrli:startDate>
      <xbrli:endDate>2020-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200821_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-21</xbrli:startDate>
      <xbrli:endDate>2020-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200821_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-21</xbrli:startDate>
      <xbrli:endDate>2020-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20200821">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20200811_20200811">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-11</xbrli:startDate>
      <xbrli:endDate>2020-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyThreeCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:ThreeCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyThreeCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:ThreeCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyTwoCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:TwoCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyTwoCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:TwoCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:CaremarkLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:CaremarkLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:CaremarkLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:CaremarkLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:PANTHERxSpecialtyPharmacyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:PANTHERxSpecialtyPharmacyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:PANTHERxSpecialtyPharmacyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:PANTHERxSpecialtyPharmacyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyAccredoHealthGroupIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:AccredoHealthGroupIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtMajorCustomersAxis_hrmyAccredoHealthGroupIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hrmy:AccredoHealthGroupIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20210101_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:WAKIXMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtProductOrServiceAxis_hrmyPitolisantsMember_20190212">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:PitolisantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_20190814">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:WAKIXMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-08-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_20190814_20190814">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:WAKIXMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-14</xbrli:startDate>
      <xbrli:endDate>2019-08-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20190801_20190831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-01</xbrli:startDate>
      <xbrli:endDate>2019-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_20201001_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:WAKIXMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_srtProductOrServiceAxis_hrmyWAKIXMember_srtStatementGeographicalAxis_countryUS_srtStatementScenarioAxis_hrmyUponAchievementOfAggregateNetSalesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hrmy:BioprojetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">hrmy:UponAchievementOfAggregateNetSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:WAKIXMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_srtStatementGeographicalAxis_countryUS_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hrmy:BioprojetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hrmy:BioprojetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:MultiDrawLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:CRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:MultiDrawLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:CRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-28</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:MultiDrawLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:CRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:MultiDrawLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:CRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:CreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:CreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-09</xbrli:startDate>
      <xbrli:endDate>2020-01-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20200109_20200109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:MultiDrawLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:CRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-09</xbrli:startDate>
      <xbrli:endDate>2020-01-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:CreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-09</xbrli:startDate>
      <xbrli:endDate>2020-01-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:CreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:CRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:CreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrmy:CreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20191024_20191024">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-24</xbrli:startDate>
      <xbrli:endDate>2019-10-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtStatementGeographicalAxis_hrmyNorthbrookILMember_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">hrmy:NorthbrookILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtStatementGeographicalAxis_hrmyNorthbrookILMember_20180401_20180430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">hrmy:NorthbrookILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtStatementGeographicalAxis_hrmyPlymouthMeetingPAMember_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">hrmy:PlymouthMeetingPAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtStatementGeographicalAxis_hrmyPlymouthMeetingPAMember_20180601_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">hrmy:PlymouthMeetingPAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtStatementGeographicalAxis_hrmyChicagoILMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">hrmy:ChicagoILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtStatementGeographicalAxis_hrmyChicagoILMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">hrmy:ChicagoILMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20170922">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20180108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20180108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190809">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrmy:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-08-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_20191115_20191115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-15</xbrli:startDate>
      <xbrli:endDate>2019-11-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapPlanNameAxis_hrmyTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hrmy:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hrmy:IncentiveAwardPlanTwoThousandTwentyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapPlanNameAxis_hrmyTwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapPlanNameAxis_hrmyTwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountForLackOfMarketabilityMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_20200819">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapRelatedPartyTransactionAxis_hrmyManagementServicesAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hrmy:ManagementServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapRelatedPartyTransactionAxis_hrmyManagementServicesAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hrmy:ManagementServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapBalanceSheetLocationAxis_hrmyCurrentLiabilitiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hrmy:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapBalanceSheetLocationAxis_hrmyCurrentLiabilitiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">hrmy:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_srtProductOrServiceAxis_hrmyWAKIXMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210105_20210106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hrmy:BioprojetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hrmy:WAKIXMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-05</xbrli:startDate>
      <xbrli:endDate>2021-01-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001802665_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001802665</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hrmy:IncentiveAwardPlanTwoThousandTwentyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:EntityRegistrantName id="F_000000" contextRef="C_0001802665_20200101_20201231">HARMONY BIOSCIENCES HOLDINGS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000001" contextRef="C_0001802665_20200101_20201231">0001802665</dei:EntityCentralIndexKey>
  <dei:EntityTaxIdentificationNumber id="F_000002" contextRef="C_0001802665_20200101_20201231">82-2279923</dei:EntityTaxIdentificationNumber>
  <dei:EntityFileNumber id="F_000003" contextRef="C_0001802665_20200101_20201231">001-39450</dei:EntityFileNumber>
  <dei:CurrentFiscalYearEndDate id="F_000004" contextRef="C_0001802665_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000005" contextRef="C_0001802665_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentType id="F_000006" contextRef="C_0001802665_20200101_20201231">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="F_000007" contextRef="C_0001802665_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000008" contextRef="C_0001802665_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000009" contextRef="C_0001802665_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:AmendmentFlag id="F_000010" contextRef="C_0001802665_20200101_20201231">false</dei:AmendmentFlag>
  <dei:EntityWellKnownSeasonedIssuer id="F_000011" contextRef="C_0001802665_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCurrentReportingStatus id="F_000012" contextRef="C_0001802665_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000013" contextRef="C_0001802665_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityVoluntaryFilers id="F_000014" contextRef="C_0001802665_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntitySmallBusiness id="F_000015" contextRef="C_0001802665_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000016" contextRef="C_0001802665_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000017" contextRef="C_0001802665_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:EntityShellCompany id="F_000018" contextRef="C_0001802665_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityIncorporationStateCountryCode id="F_000019" contextRef="C_0001802665_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityAddressAddressLine1 id="F_000020" contextRef="C_0001802665_20200101_20201231">630 W.</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000021" contextRef="C_0001802665_20200101_20201231">Germantown Pike</dei:EntityAddressAddressLine2>
  <dei:EntityAddressAddressLine3 id="F_000022" contextRef="C_0001802665_20200101_20201231">Suite 215</dei:EntityAddressAddressLine3>
  <dei:EntityAddressCityOrTown id="F_000023" contextRef="C_0001802665_20200101_20201231">Plymouth Meeting</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000024" contextRef="C_0001802665_20200101_20201231">PA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000025" contextRef="C_0001802665_20200101_20201231">19462</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000026" contextRef="C_0001802665_20200101_20201231">484</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000027" contextRef="C_0001802665_20200101_20201231">539-9800</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="F_000028" contextRef="C_0001802665_20200101_20201231">Common Stock, par value $0.00001 value per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000029" contextRef="C_0001802665_20200101_20201231">HRMY</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000030" contextRef="C_0001802665_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:DocumentAnnualReport id="F_000031" contextRef="C_0001802665_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000032" contextRef="C_0001802665_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:EntityCommonStockSharesOutstanding id="F_000033" contextRef="C_0001802665_20210315" decimals="INF" unitRef="U_xbrlishares">56891920</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000034" contextRef="C_0001802665_20200630" decimals="0" unitRef="U_iso4217USD">0</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">228631000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">24457000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="F_000037" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">22176000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000038" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">4255000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet id="F_000039" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">3823000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="F_000040" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1088000</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseCurrent id="F_000041" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">6959000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000042" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1436000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000043" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1302000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000044" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">261000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000045" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">262891000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000046" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">31497000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000047" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">938000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000048" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1330000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashNoncurrent id="F_000049" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">750000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000050" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">750000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000051" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">162343000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000052" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">72185000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OtherAssetsNoncurrent id="F_000053" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">152000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000054" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">941000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsNoncurrent id="F_000055" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">164183000</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent id="F_000056" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">75206000</us-gaap:AssetsNoncurrent>
  <us-gaap:Assets id="F_000057" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">427074000</us-gaap:Assets>
  <us-gaap:Assets id="F_000058" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">106703000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000059" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">2556000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000060" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">6360000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000061" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">8942000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000062" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">7917000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000063" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">122727000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000064" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">5500000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000065" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">314000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000066" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">115000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000067" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">134539000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000068" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">19892000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000069" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">212000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000070" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">287000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000071" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">194250000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000072" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">97946000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000073" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">893000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000074" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="F_000075" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">195355000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="F_000076" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">98396000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000077" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">329894000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000078" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">118288000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000079" xsi:nil="true" contextRef="C_0001802665_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000080" xsi:nil="true" contextRef="C_0001802665_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000081" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">348203000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000082" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">12023000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000083" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">51051000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockValue id="F_000084" xsi:nil="true" contextRef="C_0001802665_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000085" xsi:nil="true" contextRef="C_0001802665_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000086" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000087" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">585374000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000088" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">-488195000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000089" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">-422862000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000090" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">97180000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000091" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">-422862000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000092" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">427074000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000093" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">106703000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000094" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000095" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000096" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000097" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">286000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000098" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000099" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">285000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000100" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000101" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">285000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000102" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.25</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000103" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.25</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000104" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000105" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">8030000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000106" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000107" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">8000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000108" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000109" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">8000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000110" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.96</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000111" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.96</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000112" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000113" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">25600000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000114" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000115" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">25510205</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000116" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000117" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">25510205</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000118" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000119" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000120" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000121" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000122" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000123" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000124" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000125" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000126" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000127" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000128" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000129" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">423630000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000130" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">56890569</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000131" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">7787470</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000132" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">56890569</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000133" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">7787470</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000134" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">159742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000135" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5995000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:CostOfGoodsAndServicesSold id="F_000136" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">27738000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold id="F_000137" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1577000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:GrossProfit id="F_000138" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">132004000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="F_000139" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4418000</us-gaap:GrossProfit>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000140" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">19448000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000141" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">69595000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingAndMarketingExpense id="F_000142" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">55824000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense id="F_000143" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">44318000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000144" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">39746000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000145" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">36409000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000146" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115018000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000147" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">150322000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000148" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">16986000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000149" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-145904000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000150" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22639000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000151" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3071000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="F_000152" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-28220000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="F_000153" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-6073000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000154" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-36944000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000155" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-151977000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="F_000156" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-36944000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000157" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-151977000</us-gaap:NetIncomeLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000158" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">26904000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000159" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">35231000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000160" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-63848000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000161" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-187208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasic id="F_000162" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.48</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="F_000163" contextRef="C_0001802665_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-24.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted id="F_000164" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.48</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="F_000165" contextRef="C_0001802665_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-24.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000166" contextRef="C_0001802665_20200101_20201231" decimals="0" unitRef="U_xbrlishares">25772419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000167" contextRef="C_0001802665_20190101_20191231" decimals="0" unitRef="U_xbrlishares">7777441</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="F_000168" contextRef="C_0001802665_20200101_20201231" decimals="0" unitRef="U_xbrlishares">25772419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="F_000169" contextRef="C_0001802665_20190101_20191231" decimals="0" unitRef="U_xbrlishares">7777441</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000170" contextRef="C_0001802665_20181231" decimals="INF" unitRef="U_xbrlishares">293000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000171" contextRef="C_0001802665_20181231" decimals="-3" unitRef="U_iso4217USD">324201000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <hrmy:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000172" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">25510205</hrmy:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000173" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">48868000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <hrmy:TemporaryEquityDividend id="F_000174" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">32160000</hrmy:TemporaryEquityDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000175" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2742000</us-gaap:TemporaryEquityAccretionOfDividends>
  <hrmy:TemporaryEquityDividend id="F_000176" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1098000</hrmy:TemporaryEquityDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000177" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:TemporaryEquityAccretionOfDividends>
  <hrmy:TemporaryEquityDividend id="F_000178" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1973000</hrmy:TemporaryEquityDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000179" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">211000</us-gaap:TemporaryEquityAccretionOfDividends>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000180" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">318510205</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000181" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">411275000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <hrmy:TemporaryEquityDividend id="F_000182" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">22780000</hrmy:TemporaryEquityDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000183" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5562000</us-gaap:TemporaryEquityAccretionOfDividends>
  <hrmy:TemporaryEquityDividend id="F_000184" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">777000</hrmy:TemporaryEquityDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000185" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">53000</us-gaap:TemporaryEquityAccretionOfDividends>
  <hrmy:TemporaryEquityDividend id="F_000186" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3347000</hrmy:TemporaryEquityDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000187" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">921000</us-gaap:TemporaryEquityAccretionOfDividends>
  <hrmy:TemporaryEquityShareConvertedToPermanentEquity id="F_000188" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">318510205</hrmy:TemporaryEquityShareConvertedToPermanentEquity>
  <hrmy:TemporaryEquityValueConvertedToPermanentEquity id="F_000189" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">444715000</hrmy:TemporaryEquityValueConvertedToPermanentEquity>
  <us-gaap:SharesOutstanding id="F_000190" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">7777100</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000191" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-242673000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000192" contextRef="C_0001802665_20181231" decimals="-3" unitRef="U_iso4217USD">-242673000</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="F_000193" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-151977000</us-gaap:NetIncomeLoss>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000194" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9994000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000195" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22166000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000196" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">32160000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000197" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2742000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000198" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2742000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000199" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1098000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000200" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1098000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000201" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000202" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000203" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1973000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000204" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1973000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000205" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">211000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000206" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">211000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000207" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">10370</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000208" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">85000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000209" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">85000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000210" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000211" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:SharesOutstanding id="F_000212" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">7787470</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000213" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-422862000</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="F_000214" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-36944000</us-gaap:NetIncomeLoss>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000215" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1048000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000216" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21732000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000217" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">22780000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000218" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3572000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000219" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1990000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000220" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5562000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000221" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000222" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">778000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000223" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">777000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000224" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">37000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000225" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">16000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000226" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">53000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000227" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3347000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000228" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3347000</hrmy:DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000229" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">563000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000230" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">359000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital id="F_000231" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">922000</hrmy:AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000232" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">6151162</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000233" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">135435000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000234" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">135435000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000235" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">42926630</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000236" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000237" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">444715000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000238" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">444716000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <hrmy:ReclassificationOfWarrantLiabilityToEquity id="F_000239" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5468000</hrmy:ReclassificationOfWarrantLiabilityToEquity>
  <hrmy:ReclassificationOfWarrantLiabilityToEquity id="F_000240" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5468000</hrmy:ReclassificationOfWarrantLiabilityToEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000241" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">37947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000242" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000243" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000244" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4693000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000245" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4693000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_000246" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">12175</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000247" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000248" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <hrmy:RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares id="F_000249" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">465</hrmy:RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000250" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000251" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:SharesOutstanding id="F_000252" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">56890569</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000253" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000254" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">585374000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000255" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-488195000</us-gaap:StockholdersEquity>
  <us-gaap:ProfitLoss id="F_000256" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-36944000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000257" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-151977000</us-gaap:ProfitLoss>
  <us-gaap:Depreciation id="F_000258" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">394000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000259" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">395000</us-gaap:Depreciation>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000260" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9843000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000261" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2815000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff id="F_000262" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff id="F_000263" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">52000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
  <us-gaap:ShareBasedCompensation id="F_000264" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4693000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000265" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9909000</us-gaap:ShareBasedCompensation>
  <hrmy:StockAppreciationRightsMarketAdjustment id="F_000266" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">497000</hrmy:StockAppreciationRightsMarketAdjustment>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000267" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3109000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:PaidInKindInterest id="F_000268" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2538000</us-gaap:PaidInKindInterest>
  <us-gaap:AmortizationOfFinancingCosts id="F_000269" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2412000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="F_000270" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">592000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000271" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17922000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000272" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4255000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories id="F_000273" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2735000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="F_000274" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1088000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000275" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6563000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000276" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1467000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="F_000277" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-789000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="F_000278" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">420000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade id="F_000279" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3804000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade id="F_000280" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4898000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000281" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">18450000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000282" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7763000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000283" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">157000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000284" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-73000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000285" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-2985000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000286" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-75436000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000287" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000288" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">149000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <hrmy:PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination id="F_000289" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2000000</hrmy:PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination>
  <hrmy:PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination id="F_000290" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">52000000</hrmy:PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination>
  <us-gaap:PaymentsToAcquireIntangibleAssets id="F_000291" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">75000000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000292" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-2002000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000293" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-127149000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000294" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">147628000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000295" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">12193000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000296" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">50000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <hrmy:PaymentOfPreferredStockIssuanceCosts id="F_000297" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1132000</hrmy:PaymentOfPreferredStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="F_000298" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">200000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="F_000299" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:PaymentsOfDebtIssuanceCosts id="F_000300" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5804000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts id="F_000301" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5184000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtExtinguishmentCosts id="F_000302" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">102538000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
  <hrmy:PaymentsOfExtinguishmentOfDebtExitFees id="F_000303" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-18047000</hrmy:PaymentsOfExtinguishmentOfDebtExitFees>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000304" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000305" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">85000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000306" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000307" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000308" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">209161000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000309" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">143769000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000310" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">204174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000311" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-58816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000312" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">25207000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000313" contextRef="C_0001802665_20181231" decimals="-3" unitRef="U_iso4217USD">84023000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000314" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">229381000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:InterestPaidNet id="F_000315" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">26203000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet id="F_000316" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4230000</us-gaap:InterestPaidNet>
  <hrmy:CashPaidForMilestones id="F_000317" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2000000</hrmy:CashPaidForMilestones>
  <hrmy:CashPaidForMilestones id="F_000318" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">127000000</hrmy:CashPaidForMilestones>
  <hrmy:PreferredStockAccruedReturn id="F_000319" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">22780000</hrmy:PreferredStockAccruedReturn>
  <hrmy:PreferredStockAccruedReturn id="F_000320" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">32160000</hrmy:PreferredStockAccruedReturn>
  <hrmy:PreferredStockAccretionOfIssuanceCosts id="F_000321" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5562000</hrmy:PreferredStockAccretionOfIssuanceCosts>
  <hrmy:PreferredStockAccretionOfIssuanceCosts id="F_000322" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2742000</hrmy:PreferredStockAccretionOfIssuanceCosts>
  <hrmy:PreferredStockAccruedReturn id="F_000323" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">777000</hrmy:PreferredStockAccruedReturn>
  <hrmy:PreferredStockAccruedReturn id="F_000324" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1098000</hrmy:PreferredStockAccruedReturn>
  <hrmy:PreferredStockAccretionOfIssuanceCosts id="F_000325" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">53000</hrmy:PreferredStockAccretionOfIssuanceCosts>
  <hrmy:PreferredStockAccretionOfIssuanceCosts id="F_000326" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22000</hrmy:PreferredStockAccretionOfIssuanceCosts>
  <hrmy:PreferredStockAccruedReturn id="F_000327" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3347000</hrmy:PreferredStockAccruedReturn>
  <hrmy:PreferredStockAccruedReturn id="F_000328" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1973000</hrmy:PreferredStockAccruedReturn>
  <hrmy:PreferredStockAccretionOfIssuanceCosts id="F_000329" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">921000</hrmy:PreferredStockAccretionOfIssuanceCosts>
  <hrmy:PreferredStockAccretionOfIssuanceCosts id="F_000330" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">211000</hrmy:PreferredStockAccretionOfIssuanceCosts>
  <hrmy:WarrantFinancing id="F_000331" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2359000</hrmy:WarrantFinancing>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000332" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the registrant&amp;#8217;s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December&amp;#160;31, 2020 are incorporated herein by reference in Part III where indicated.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000333" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The Company&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our operating subsidiary, Harmony Biosciences, LLC, was formed on May&amp;#160;17, 2017. Harmony Biosciences Holdings, Inc. (the &amp;#8220;Company&amp;#8221;) was founded on July&amp;#160;25, 2017 as Harmony Biosciences&amp;#160;II, LLC, a Delaware limited liability company, and the Company converted to a Delaware corporation named Harmony Biosciences II, Inc. on September&amp;#160;19, 2017. On February&amp;#160;3, 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company is a holding company and has no operations. The Company&amp;#8217;s operations are conducted in its wholly owned subsidiary, Harmony Biosciences,&amp;#160;LLC (&amp;#8220;Harmony&amp;#8221;). The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Initial Public Offering&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 21, 2020, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&amp;#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company&amp;#8217;s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company&amp;#8217;s convertible preferred stock. Warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 410,239 shares of common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 11, 2020, the Company implemented a 1-for-8.215 reverse stock split of the Company&amp;#8217;s common stock. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&amp;#8217;s Preferred Stock and preferred dividend were proportionately reduced. &lt;font style="Background-color:#FFFFFF;"&gt; All references in the accompanying consolidated financial statements and related notes to the number of shares of common stock, convertible preferred stock, warrants and options to purchase common stock and per share data reflect the effect of the reverse stock split.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <hrmy:LiquidityAndCapitalResourcesTextBlock id="F_000334" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2. LIQUIDITY AND CAPITAL RESOURCES&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operations since inception resulting in an accumulated deficit of $488,195 and $422,862, as of December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company had cash and cash equivalents of $228,631.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 21, 2020, the Company received aggregate proceeds from a common stock offering of approximately $135,435, net of underwriting discounts and commissions and other estimated offering expenses (see Note 11). Additionally, on January 9, 2020, the Company received aggregate proceeds of approximately $200,000 through the loan agreement with OrbiMed Royalty&amp;#160;&amp;amp; Credit Opportunities, LP. This capital raise and debt issuance has resolved the Company&amp;#8217;s significant risks and uncertainties regarding sources of liquidity, which previously raised substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these consolidated financial statements. &lt;/p&gt;</hrmy:LiquidityAndCapitalResourcesTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000335" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation of the Company&amp;#8217;s financial position&lt;font style="Background-color:#FFFFFF;color:#000000;font-family:Arial;"&gt; &lt;/font&gt;for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-family:Times New Roman;font-weight:bold;;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Significant Risks and Uncertainties&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of clinical testing and trial activities of the Company&amp;#8217;s product candidates; the Company&amp;#8217;s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&amp;#8217;s products, if approved; the Company&amp;#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates; and the Company&amp;#8217;s ability to raise capital.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company&amp;#8217;s research and development and clinical trials will result in any successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.77%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the Consolidated Financial Statements, including the notes thereto, and elsewhere in this report.&amp;nbsp;&amp;nbsp;Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating Segments&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company holds all its tangible assets, conducts its operations, and revenues are generated in the U.S. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s consolidated financial statements include cash, cash equivalents, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. Additionally, prior to the IPO, the Company&amp;#8217;s consolidated financial statements included a warrant liability that was carried at fair value and was re-measured at each balance sheet date until it would be exercised or expired. In connection with the IPO, the Warrants were re-evaluated under the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 480 &lt;font style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/font&gt; and reclassified to equity. See Note 13 for a further discussion of the warrants.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;It is the Company&amp;#8217;s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures certain assets and liabilities at fair value in accordance with ASC 820, &lt;font style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;. ASC&amp;#160;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC&amp;#160;820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash shown in the statements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,207&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in restricted cash represent those amounts required to be held as a security deposit in the form of letters of credit for the Company&amp;#8217;s credit card program and the fleet program. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations of Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of the Company&amp;#8217;s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also subject to credit risk from its trade receivables related to its product sales.  The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of December&amp;#160;31, 2020, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&amp;#8220;CVS Caremark&amp;#8221;), which accounted for 44% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (&amp;#8220;Pantherx&amp;#8221;), which accounted for 23% of gross accounts receivable; and Accredo Health Group, Inc. (&amp;#8220;Accredo&amp;#8221;), which accounted for 33% of gross accounts receivable.   &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December&amp;#160;31, 2020, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 27% of gross product revenues. For the year ended December&amp;#160;31, 2019 two customers accounted for 88% of gross product revenues, CVS Caremark accounted for 59% of gross product revenues and Pantherx accounted for 29% of gross product revenues.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost is determined using the&amp;#160;first-in,&amp;#160;first-out&amp;#160;method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We did not capitalize preapproval inventory during 2019.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&amp;#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Asset&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January&amp;#160;1, 2019, the Company adopted ASC 606,&amp;#160;Revenue from Contracts with Customers (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company has determined that the delivery of its product to its customer constitutes a single performance obligation as there are no other promises to deliver goods or services. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore, no amount of consideration has been allocated as a financing component. Taxes collected related to product sales are remitted to governmental authorities and are excluded from revenue.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product Sales, Net&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company began commercial sales of WAKIX&amp;#160;in November 2019. The Company sells WAKIX&amp;#160;to its customers (a limited number of specialty distributors) that, in turn, distribute WAKIX&amp;#160;to patients.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue on sales of WAKIX&amp;#160;when the customer obtains control of the product, which occurs at a point in time, typically upon delivery. Product revenues are recorded at the product&amp;#8217;s wholesale acquisition costs, net of applicable reserves for variable consideration that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the sale of WAKIX. Components of variable consideration include government and commercial contracts, product returns, commercial&amp;#160;co-payment&amp;#160;assistance program transactions, and distribution services fees. These deductions are based on the amounts earned or to be claimed on the related sales and are classified as a current liability or reduction of receivables, based on expected value method and a range of outcomes and are probability weighted in accordance with ASC 606.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognition under contracts will not occur in a future period. The Company&amp;#8217;s analyses contemplate the application of the constraint in accordance with ASC 606. Actual amounts of consideration ultimately received may differ from its estimates. If actual results in the future vary from its estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cost of Product Sold &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of product sold includes manufacturing and distribution costs, the cost of drug substance, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs, and salaries of employees involved with production. The Company began capitalizing inventory upon FDA approval of WAKIX with a portion of the inventory sold during the year ended December&amp;#160;31, 2020 produced prior to FDA approval and, therefore, was previously expensed as research and development expense in 2019 in the amount of $1,323. Excluded from cost of product sold shown and included in general and administrative on the consolidated statements of operations and comprehensive loss is amortization of acquired developed technology of $9,843 and $2,815 for the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments and&amp;#160;pre-FDA&amp;#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Advertising Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We expensed the costs of advertising, including promotional expenses, as incurred. Advertising expense was $13,301 and $7,072 a for the years ended December 31, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes compensation expense relating to stock-based payment transactions in operating results using a fair value measurement method, in accordance with FASB ASC 718,&amp;#160;Compensation-Stock Compensation. ASC&amp;#160;718 requires all stock-based payments to employees to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The vesting periods have a time-based provision consisting of three to five years and expire no more than 10 years after the date of grant. Upon a change of control, certain unvested awards will immediately vest. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;1, 2019, the Company early adopted and accounts for stock-based payments granted to nonemployees in accordance with ASU&amp;#160;2018-07,&amp;#160;Compensation &amp;#8211; Stock Compensation (ASC 718): Improvements to Nonemployee Share &amp;#8211; Based Payment Accounting. The Company determines the fair value of the stock-based payment as the fair value of the equity instruments issued. It is measured on the grant date.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also had nonemployee stock awards subject to a performance condition that are recognized based on probable outcome. On November&amp;#160;15, 2019 the Company modified the award to remove the performance condition resulting in $8,400 of noncash expense that is included in the Company&amp;#8217;s consolidated results of operations for the year ended December&amp;#160;31, 2019 (see Note 13 for further details).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect. The basic and diluted computations of net loss per share for the Company are the same because the effects of the Company&amp;#8217;s convertible securities would be anti-dilutive (see Note&amp;#160;14 for further detail).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets may be reduced by a valuation allowance if, based on all available evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Management judgment is required in determining the period in which a reversal of a valuation allowance should occur. The Company is required to consider all available evidence, both positive and negative, such as historical levels of income and future forecasts of taxable income among other items, in determining whether a full or partial release of its valuation allowance is required. The Company&amp;#8217;s accounting for deferred tax consequences represents the best estimate of those future events. The Company presents deferred income taxes on the Consolidated Balance Sheet on a jurisdictional basis as either a net noncurrent asset or liability.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not sustainable, based solely on its technical merits and consideration of the relevant taxing authority&amp;#8217;s widely understood administrative practices and precedents. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which a change in judgment occurs. At December&amp;#160;31, 2020 and 2019, the Company did not have any unrecognized uncertain tax positions. The Company&amp;#8217;s policy is to include any interest and penalties as a component of income tax expense.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&amp;#160;Act). Under the JOBS&amp;#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&amp;#160;Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&amp;#160;is&amp;#160;no longer an emerging growth company or (ii)&amp;#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&amp;#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued amended guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities in the balance sheet and disclosing key information about leasing arrangements. The new guidance clarifies the criteria for distinguishing between a finance lease and operating lease, as well as classification between the two types of leases, which is substantially unchanged from the previous lease guidance. Further, the new guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a&amp;#160;right-of-use&amp;#160;asset, initially measured at the present value of the lease payments. For finance leases, a lessee should recognize interest on the lease liability separately from amortization of the&amp;#160;right-of-use&amp;#160;asset. For operating leases, a lessee should recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis. For leases with a term of 12&amp;#160;months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and lease liabilities. The new standard will become effective for the Company&amp;#8217;s fiscal year ending December&amp;#160;31, 2022. The Company is currently assessing the impact of this amended guidance and the timing of adoption.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU&amp;#160;No.&amp;#160;2016-13,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;. ASU&amp;#160;No.&amp;#160;2016-13&amp;#160;introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for&amp;#160;available-for-sale&amp;#160;debt securities. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2022 for companies deemed to be small reporting companies as of November&amp;#160;15, 2019, with early adoption permitted. The Company is currently evaluating the potential impact of adoption of this standard on its results of operations, financial position and cash flows and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU&amp;#160;No.&amp;#160;2019-12,&amp;#160;&lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&amp;#160;15, 2020 with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting guidance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;font style="font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/font&gt;, which provides guidance related to reference rate reform. The pronouncement provides temporary optional expedients and exceptions to the current guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (&amp;#8220;LIBOR&amp;#8221;) and other interbank offered rates to alternative reference rates. The guidance was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are currently evaluating the impact of the transition from LIBOR to alternative reference rates but do not expect a significant impact to our consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:InventoryDisclosureTextBlock id="F_000336" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;4. INVENTORY &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;417&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserve for obsolescence&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(174&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:IntangibleAssetsDisclosureTextBlock id="F_000337" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;5. INTANGIBLE ASSET &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;15, 2019, the Company received FDA approval of WAKIX&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&amp;#174;&lt;/sup&gt; (pitolisant) for the treatment of excessive daytime sleepiness (&amp;#8220;EDS&amp;#8221;) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 associated with the License Agreement which the Company capitalized as an intangible asset and paid in November of 2019. The Company determined a useful life of 10 years for such intangible asset, and, as of December 31, 2020 the remaining useful life was 9 years. Prior to this event, all other milestones associated with the License Agreement were expensed through research and development as they did not meet the criteria to be recognized as an intangible asset. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 13, 2020, the Company received notice that the FDA approved the NDA for WAKIX&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&amp;#174;&lt;/sup&gt; for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 associated with the License Agreement which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of December 31, 2020 the remaining useful life was 9 years. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The gross carrying amount and net book value of the intangible asset is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Carrying Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;175,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,657&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Book Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;162,343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <hrmy:LicenseAgreementTextBlock id="F_000338" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;6. LICENSE AGREEMENT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&amp;#160;28, 2017, Harmony entered into the License Agreement whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson&amp;#8217;s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant&amp;#8217;s New Drug Application (&amp;#8220;NDA&amp;#8221;), which was achieved on February&amp;#160;12, 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, including a $2,000 fee, was due upon FDA approval of WAKIX&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&amp;#174;&lt;/sup&gt; (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved on August&amp;#160;14, 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a payment of $2,000 is due upon the FDA approval of the NDA for WAKIX&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&amp;#174;&lt;/sup&gt; for the treatment of cataplexy in adult patients with narcolepsy (the &amp;#8220;Trigger Date&amp;#8221;) which was paid in October 2020 and a $100,000 milestone payment which was paid in January 2021. An additional $40,000 milestone payment is due to Bioprojet upon WAKIX attaining $500,000 in aggregate net sales in the United States. The License Agreement also requires sales-based milestone payments, a fixed trademark royalty and a tiered royalty, all based on net sales, which become due and payable to Bioprojet on a quarterly basis. During the year ended December&amp;#160;31, 2020, the Company incurred $25,580 for sales-based, trademark and tiered royalties recognized as cost of product sold. As of December&amp;#160;31, 2020 and 2019, the Company had accrued $9,006 and $938, respectively, for sales-based, trademark and tiered royalties. At December 31, 2020 the Company had accrued $100,000 for the milestone payment to Bioprojet. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.61%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</hrmy:LicenseAgreementTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="F_000339" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;7. ACCRUED EXPENSES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestone payment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalties due to third parties&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,006&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rebates and other sales deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,803&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;713&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling and marketing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees, consulting, and other services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;510&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;638&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122,727&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000340" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;8. DEBT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Credit Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&amp;#160;28, 2019, the Company entered into a multi-draw loan agreement with CRG Servicing LLC for an aggregate of $200,000 (the &amp;#8220;CRG Loan&amp;#8221;), which matured in March 2025. The Loan bore a fixed rate of 12%. The Loan agreement required compliance with certain financial covenants. The Company could draw three tranches of the Loan based on achieving specific milestones and dates. The Company could elect to pay the interest on the outstanding principal amount as follows: (i)&amp;#160;only 7.5% of the 12% per annum in cash, paid quarterly, starting in March 2019, and (ii) 4.5% of the 12% per annum interest as compounded interest, added to the aggregate outstanding principal balance quarterly; the amount of any such compounded interest being a paid-in-kind loan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, the Company had borrowed $100,000, resulting in cash proceeds received of $94,816, net of issuance costs. The issuance costs of $5,184 were being amortized over the six-year loan term of the CRG Loan. Unamortized debt issuance costs as of December&amp;#160;31, 2019 are $4,592 and are presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;9, 2020 the Company entered into a credit agreement with OrbiMed Royalty&amp;#160;&amp;amp; Credit Opportunities, LP for an aggregate amount of $200,000 (the &amp;#8220;OrbiMed Loan&amp;#8221;), which matures in January 2026. Borrowings under the OrbiMed Loan are collateralized by all of the Company&amp;#8217;s assets, excluding the intellectual property licensed through the License Agreement. The OrbiMed Loan bears an interest rate equal to the sum of (i)&amp;#160;the greater of (a)&amp;#160;1-month LIBOR or (b) 2.00% per annum, plus (ii) 11.00% per annum, paid in cash monthly in arrears on the last day of each month starting in January 2020. At the time of prepayment or repayment of all or any portion of the principal of the OrbiMed Loan, the Company is required to pay an exit fee of 7.0% of the principal amount of the OrbiMed Loan prepaid, repaid, or required to be prepaid or repaid.&amp;nbsp;&amp;nbsp;The Company recorded as a liability and debt discount the exit fee at the origination of the term loan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to entering into the OrbiMed Loan, the Company extinguished the CRG Loan which required a payoff amount of $120,893 consisting of principal repayment, interest, and exit fees. In connection with extinguishment of the CRG Loan, we recognized a loss on extinguishment of $22,639, which included an exit fee of $18,047 and the write-off of the remaining unamortized debt issuance costs of $4,592. The loss on extinguishment of debt was recorded in loss on debt extinguishment within the Company&amp;#8217;s consolidated statements of operations. The net cash received as a result of the transaction, less debt issuance costs of $5,804, was $73,313. These debt issuance costs will be amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The fair value of the OrbiMed loan as of December 31, 2020 was $245,700.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the OrbiMed Loan, the Company issued warrants (the &amp;#8220;Warrants&amp;#8221;) to OrbiMed Royalty&amp;#160;&amp;amp; Credit Opportunities, LP on January&amp;#160;9, 2020. See Note 13 for further discussion of the Warrants. Pursuant to the Warrants, OrbiMed Royalty&amp;#160;&amp;amp; Credit Opportunities, LP, may purchase up to 410,239 shares of the Company&amp;#8217;s Common Stock for an initial exercise price of $16.10 at any time from the date of execution of the Warrants through the expiration date, defined within the Warrants as the earlier of (i)&amp;#160;January&amp;#160;9, 2027 and (ii)&amp;#160;the closing date of a Corporate Reorganization. The fair value of the Warrants using the Black-Scholes option-pricing model was $2,359 at January&amp;#160;9, 2020. The portion of the OrbiMed Loan proceeds allocated to the warrant liability resulted in a debt discount, which is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt and is being amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The unamortized debt discount as of December&amp;#160;31, 2020 is $2,097 and is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The balances of the OrbiMed Loan as of December 31, 2020 and the CRG Loan as of December 31, 2019 were as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability component - principal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exit fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability component - net carrying value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense related to the OrbiMed Loan and CRG Loan were included in interest expense, net in the Consolidated Statements of Operations as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on principal balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on PIK&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of deferred financing costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; Total term loan interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000341" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;9. COMMITMENTS AND CONTINGENCIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Litigation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2019 the Company was involved in ongoing litigation with its former chief executive officer related to arbitration and the value of vested common shares. On October&amp;#160;24, 2019, the Company reached a settlement resulting in $3,466 of general and administrative expense reflected in the Company&amp;#8217;s consolidated results of operations for the year ended December&amp;#160;31, 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company entered into an operating lease for approximately nine thousand square feet of office space in Northbrook, IL, which expired in January 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company entered into an operating lease for approximately thirteen thousand square feet of additional office space in Plymouth Meeting, PA, which expires in May 2024.&amp;nbsp;&amp;nbsp;The term will not commence until the Company takes occupancy in mid-2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not paid. In addition, tenant improvement allowances recorded are amortized as a reduction to rent expense on a straight-line basis over the lease term. Rent expense was $686 for the year ended December&amp;#160;31, 2020, compared to $1,051 for the year ended December&amp;#160;31, 2019. The following table sets forth the lease payment obligations as of December&amp;#160;31, 2020, for the periods indicated below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <hrmy:ConvertiblePreferredStockTextBlock id="F_000342" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;10. CONVERTIBLE PREFERRED STOCK &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the IPO, all outstanding shares of the Company&amp;#8217;s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company&amp;#8217;s convertible preferred stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Series A Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September&amp;#160;22, 2017, the Company issued 270,000,000 shares of Series&amp;#160;A convertible preferred stock for a purchase price of $1.00 per share, or $270,000 in the aggregate. On January&amp;#160;8, 2018, the Company issued an additional 15,000,000 shares of Series A convertible preferred stock for a purchase price of $1.00 per share, or $15,000 in the aggregate. As of December&amp;#160;31, 2019, there were 286,000,000 Series&amp;#160;A convertible preferred stock authorized of which 285,000,000 were issued and outstanding. Each outstanding share of Series A convertible preferred stock accrued dividends at 10% per annum of the Series&amp;#160;A original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series&amp;#160;A convertible preferred stock were cumulative and were compounded annually.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Series B Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;8, 2018, the Company issued 8,000,000 shares of Series&amp;#160;B convertible preferred stock for a purchase price of $1.25 per share, or $10,000 in the aggregate. As of December&amp;#160;31, 2019, there were 8,030,000 shares of Series&amp;#160;B convertible preferred stock authorized, of which 8,000,000 were issued and outstanding.&amp;#160;Each outstanding share of Series&amp;#160;B convertible preferred stock accrued dividends at 10% per annum of the Series&amp;#160;B original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series B convertible preferred stock were cumulative and were compounded annually.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Series C Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;9, 2019, the Company issued 25,510,205 shares of Series C convertible preferred stock for a purchase price of $1.96 per share, or $50,000 in the aggregate. As December&amp;#160;31, 2019, there were 25,600,000 shares of Series C convertible preferred stock authorized, of which 25,510,205 were issued and outstanding. Each outstanding share of Series C convertible preferred stock accrued dividends at 10% per annum of the Series C original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series C convertible preferred stock were cumulative and were compounded annually.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Dividends &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of Series A, Series B, and Series C convertible preferred stock were entitled to receive, when and if declared by the board of directors of the Company, cumulative dividends equal to a 10% per annum of Series A, Series B, and Series C convertible preferred stock. In addition, the holders of the outstanding shares of Series A, Series B, and Series C convertible preferred stock were entitled to receive, when and if declared by the board of directors of the Company, a dividend at least equal to any dividend payable on the Company&amp;#8217;s common stock as if all convertible preferred stock had been converted to common stock. No dividends were declared as of December&amp;#160;31, 2019. As part of the Company&amp;#8217;s IPO, the Company&amp;#8217;s accrued cumulative dividend was paid out to holders of Series A, Series B, and Series C convertible preferred stock in shares of the Company&amp;#8217;s common stock and reflects the reverse stock split in connection with the mandatory conversion of the Series A, Series B, and Series C convertible preferred stock into shares of the Company&amp;#8217;s common stock.&lt;/p&gt;</hrmy:ConvertiblePreferredStockTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000343" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;11. STOCKHOLDERS&amp;#8217; EQUITY (DEFICIT) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;11, 2020, the Company implemented a 1-for-8.215 reverse stock split of the Company&amp;#8217;s common stock. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split with the exception of the preferred stock. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&amp;#8217;s Preferred Stock were proportionately reduced. As of August 11, 2020, all outstanding shares of preferred stock and preferred stock dividend were convertible into shares of common stock on a 1-for-8.215 basis. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 21, 2020, the Company completed its IPO of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&amp;#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 incurred by the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company&amp;#8217;s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the Company&amp;#8217;s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company&amp;#8217;s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,217,285 common shares held by an investor were subject to certain forfeiture provisions that are dependent upon the outcome of certain future events. On November&amp;#160;15, 2019, the Company removed the provision associated with this forfeiture resulting in $8,400 of noncash stock compensation expense reflected in the Company&amp;#8217;s consolidated results of operations for the year ended December&amp;#160;31, 2019. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000344" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;12. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Incentive Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&amp;#160;7, 2017, the Company adopted an equity incentive plan (the &amp;#8220;2017 Plan&amp;#8221;). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company&amp;#8217;s common shares through grants of stock options, stock appreciation rights, or restricted stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;In connection with the Company&amp;#8217;s IPO, the board of directors adopted, and its stockholders approved, the 2020 Incentive Award Plan (the &amp;#8220;2020 Plan&amp;#8221;), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company&amp;#8217;s named executive officers) and consultants of the Company and its subsidiaries. Upon the effectiveness of the 2020 Plan, no further grants will be made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it. The 2020 Plan provides for the grant of stock options, including ISOs and NSOs, SARs, restricted stock, dividend equivalents, RSUs and other stock or cash based awards.&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options under the 2017 Plan and the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in awards granted under the Plan as of December&amp;#160;31, 2020 and 2019, are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards outstanding&amp;#8212;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,375,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards issued&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,035,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(112,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards outstanding&amp;#8212;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,260,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, stock awards issued under the 2017 and 2020 Plans of 987,538 and 573,098 common shares, respectively, were vested. The Company has elected early adoption of ASU No.&amp;#160;2016-09 to recognize forfeitures as they occur. As a result of the adoption, for the year ended December&amp;#160;31, 2020 and 2019, respectively, the Company reversed $3 and $4 out of stock-based compensation previously recorded. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Value of Stock Options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has valued awards for each of the plans included herein using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, the Company estimates its expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&amp;#8217;s stock options has been determined utilizing the &amp;#8220;simplified&amp;#8221; method for awards that qualify as &amp;#8220;plain-vanilla&amp;#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value the awards are summarized in the following table. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.00&amp;#160;-&amp;#160;95.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95.30&amp;#160;-&amp;#160;99.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.32 - 0.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60 - 2.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lack of marketability discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&amp;#160;-&amp;#160;20.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.00&amp;#160;-&amp;#160;31.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.4 - 6.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average per share fair value of awards issued under the Plan was $10.06 and $3.45 in 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was $5,190 and $9,909 for the years ended December&amp;#160;31, 2020 and 2019, respectively, and was recorded in the consolidated statements of operations and comprehensive loss in the following line items: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;703&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued under the 2017 Plan and 2020 Plan are reflected as a component of equity in these consolidated financial statements. Stock appreciation rights are reflected as other non-current liability. The Company will recognize compensation expense for these awards as summarized in the following table. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,046&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,949&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <hrmy:WarrantsDisclosureTextBlock id="F_000345" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;13. WARRANTS&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the OrbiMed Loan, the Company issued Warrants to OrbiMed Royalty&amp;#160;&amp;amp; Credit Opportunities, LP on January&amp;#160;9, 2020. Pursuant to the Warrants, OrbiMed Royalty&amp;#160;&amp;amp; Credit Opportunities, LP, may purchase up to 410,239 shares of the Company&amp;#8217;s Common Stock for an initial exercise price of $16.10 at any time from the date of execution of the Warrants through the expiration date, defined within the Warrants as the earlier of (i)&amp;#160;January&amp;#160;9, 2027 and (ii)&amp;#160;the closing date of a Corporate Reorganization. The fair value of the Warrants using the Black-Scholes option-pricing model was $2,359 on January&amp;#160;9, 2020 and was initially recorded as a warrant liability which was included in warrant liability in the consolidated balance sheet. The portion of the OrbiMed Loan proceeds allocated to the warrant liability resulted in a debt discount, which is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt and is being amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The unamortized debt discount as of December&amp;#160;31, 2020 is $2,102 and is presented in the consolidated balance sheet as a direct deduction from the carrying value of the debt. During the year ended December&amp;#160;31, 2020, a loss of $3,109 was recorded in other expense in the consolidated statements of operations due to the change in the fair value of the warrant liability. See footnote 16 for the fair value of the Warrants.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the IPO, the financial instrument underlying the warrants was converted from the Company&amp;#8217;s Series C Preferred Stock to the Company&amp;#8217;s Common Stock.&amp;nbsp;&amp;nbsp;As a result of this conversion the Warrants were re-evaluated under ASC 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging and reclassified to equity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the changes in the warrant liability for the year ended December 31, 2020 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value at Issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value included in the statement of operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</hrmy:WarrantsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000346" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;14. EARNINGS PER SHARE &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2020 and 2019, the Company used the two-class method to compute net loss per common share because the Company has issued securities (convertible preferred stock) that entitle the holder to participate in dividends and earnings of the Company. Under this method, net income is reduced by the amount of any dividends earned and the accretion of convertible preferred stock to its redemption value during the period. The remaining earnings (undistributed earnings) are allocated to common stock and each series of convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. The total earnings allocated to common stock is then divided by the number of outstanding shares to which the earnings are allocated to determine the earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per common share is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effects of the outstanding convertible preferred stock under the &amp;#8216;if-converted&amp;#8217; method when calculating diluted earnings per share, in which it is assumed that the outstanding convertible preferred stock converts into common stock at the beginning of the period or when issued if later. The Company reports the more dilutive of the approaches (treasury stock or &amp;#8216;if converted&amp;#8217;) as their diluted net income per share during the period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reported a net loss for the years ended December&amp;#160;31, 2020 and 2019, and the weighted average number of shares utilized for basic and diluted net loss per share attributable to common stockholders are the same for these periods because all convertible preferred stock and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact. Additionally, the fair value adjustment for the warrants was excluded from the computation of diluted net loss for the year ended December 31, 2020 since the additional income would have an antidilutive impact.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of basic and diluted net loss per share: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,944&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(151,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulation of dividends on preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,904&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss available to common shareholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(187,208&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share - basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share - diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares of common stock - basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,772,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,777,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares of common stock - diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,772,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,777,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potential common shares issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,260,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,271,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,891,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410,239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,670,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,163,208&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment for warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000347" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;text-transform:uppercase;font-size:10pt;font-variant: normal;"&gt;15. income taxes&lt;font style="text-transform:none;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Details of the provision for income taxes consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(42,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reasons for the difference between the statutory federal income tax rate and the Company&amp;#8217;s effective income tax rate as of December&amp;#160;31, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and liabilities as of December&amp;#160;31, 2020 and 2019, are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired in-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,346&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,628&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,682&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disallowed interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,661&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(102,874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has considered available positive and negative evidence to estimate if sufficient future taxable income will be generated to allow utilization of the existing deferred tax assets. The Company has incurred operating losses and negative cash flows from operations since inception. In light of these considerations, as well as the uncertainty as to when the Company might generate taxable income, the Company has recorded a full valuation allowance of $102,874, which represents an increase of $2,218 in the Company&amp;#8217;s valuation allowance from December&amp;#160;31, 2019 to December&amp;#160;31, 2020. The amount of the net deferred tax asset considered realizable could be adjusted in the future if estimates of taxable income change or if objective negative evidence in no longer present and additional weight may be given to subjective evidence. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the Company has approximately $159,395 and $147,823, respectively, of federal net operating loss ("NOL") carryforward available to offset future federal taxable income.&amp;nbsp;&amp;nbsp;The Company also has approximately $157,743 and $139,336 of state NOL carryforwards as of December 31, 2020 and 2019, respectively, available to offset future state taxable income.&amp;nbsp;&amp;nbsp;All of the Company&apos;s tax years remain open to examination by federal and state taxing authorities.&amp;nbsp;&amp;nbsp;The Company&apos;s pre-2018 federal NOLs expire in 2037 whereas the Company&apos;s NOLs arising in 2018, and subsequent years, have an unlimited carryforward period. The Company&apos;s state NOLs begin to expire in 2037. Utilization of the net operating loss carryforwards may be subject to a substantial limitation due to ownership change limitations that may occur in the future, as required by Section&amp;#160;382 of the Internal Revenue Code of 1986, as amended (the &amp;#8220;Code&amp;#8221;), as well as similar state provisions. These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &amp;#8220;ownership change&amp;#8221; as defined by Section&amp;#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the Company has federal tax credits of $1,603 and $837, respectively.&amp;nbsp;&amp;nbsp;These credits begin to expire in 2037.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock id="F_000348" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;16. FINANCIAL INSTRUMENTS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company primarily applies the market approach to determine the fair value of financial instruments that are measured at fair value on a recurring basis. There were no changes to its valuation techniques used to determine the fair value of financial instruments during the year ended December&amp;#160;31, 2020. The Company&amp;#8217;s financial assets and liabilities which are measured at fair value on a recurring basis were comprised of cash, cash equivalents, and restricted cash of $229,381 and $25,207 as of December&amp;#160;31, 2020 and 2019, respectively, based on Level&amp;#160;1 inputs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of the warrant liability using the Black-Scholes option-pricing model at each balance sheet date or when specific events occur. As discussed in Note 13, in connection with the Company&amp;#8217;s IPO the warrant fair value was updated on August 19, 2020 with the change in fair value recorded in current period earnings as other expense in the consolidated statement of operations and reclassified to equity. During the year ended December&amp;#160;31, 2020, a loss of $3,109 was recorded in other expense in the consolidated statements of operations due to the change in the fair value of the warrant liability.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The range of assumptions used to determine the fair value of the warrant liability through August&amp;#160;19, 2020 were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54.2% - 68.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.17% - 1.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lack of marketability discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1 - 4.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000349" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;17. RELATED-PARTY TRANSACTIONS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company was party to a management agreement for professional services provided by a related party, Paragon. The related party is an entity that shares common ownership with the Company. In addition, the Chairman of the Company&amp;#8217;s board of directors was the President and owner of the entity. For the year ended December&amp;#160;31, 2020 and 2019, respectively, the Company incurred $7,384 and $5,378, respectively, in management fee expense and other expenses to this related party, which are included in general and administrative expense in the consolidated statements of operations and comprehensive loss. The Company terminated the Management Services Agreement upon the consummation of its IPO. The Company is&lt;font style="Background-color:#FFFFFF;"&gt; also party to a right of use agreement with the related party whereby it has access to and the right to use certain office space leased by the related party in Chicago, Illinois&lt;/font&gt;. In addition, the Company had participated in certain transactions with separate related parties that also share common ownership with the Company, primarily related to combined employee health plans. As of December&amp;#160;31, 2020 and 2019, respectively, the amounts due to related parties included in current liabilities were $0 and $1,208, respectively, and the amount included in other assets was $1 and $210, respectively.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000350" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;18. SUBSEQUENT EVENTS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 6, 2021, the Company paid the $100,000 milestone payment to Bioprojet for the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January and F&lt;font style="font-size:9pt;"&gt;e&lt;/font&gt;bruary 2021, the board of directors granted to various employees 882,606 employee stock options to purchase the Company&amp;#8217;s common stock.&amp;nbsp;&amp;nbsp;These awards were granted under the 2020 Plan and vest over a four-year period where 50% cliff vest after the second year and monthly thereafter.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000351" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation of the Company&amp;#8217;s financial position&lt;font style="Background-color:#FFFFFF;color:#000000;font-family:Arial;"&gt; &lt;/font&gt;for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <hrmy:SignificantRisksAndUncertaintiesPolicyTextBlock id="F_000352" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Significant Risks and Uncertainties&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of clinical testing and trial activities of the Company&amp;#8217;s product candidates; the Company&amp;#8217;s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&amp;#8217;s products, if approved; the Company&amp;#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates; and the Company&amp;#8217;s ability to raise capital.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company&amp;#8217;s research and development and clinical trials will result in any successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.&lt;/p&gt;</hrmy:SignificantRisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000353" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.77%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the Consolidated Financial Statements, including the notes thereto, and elsewhere in this report.&amp;nbsp;&amp;nbsp;Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000354" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating Segments&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company holds all its tangible assets, conducts its operations, and revenues are generated in the U.S. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000355" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s consolidated financial statements include cash, cash equivalents, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. Additionally, prior to the IPO, the Company&amp;#8217;s consolidated financial statements included a warrant liability that was carried at fair value and was re-measured at each balance sheet date until it would be exercised or expired. In connection with the IPO, the Warrants were re-evaluated under the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 480 &lt;font style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/font&gt; and reclassified to equity. See Note 13 for a further discussion of the warrants.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;It is the Company&amp;#8217;s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures certain assets and liabilities at fair value in accordance with ASC 820, &lt;font style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;. ASC&amp;#160;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC&amp;#160;820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000356" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash shown in the statements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,207&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in restricted cash represent those amounts required to be held as a security deposit in the form of letters of credit for the Company&amp;#8217;s credit card program and the fleet program. &lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000357" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations of Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of the Company&amp;#8217;s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also subject to credit risk from its trade receivables related to its product sales.  The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of December&amp;#160;31, 2020, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&amp;#8220;CVS Caremark&amp;#8221;), which accounted for 44% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (&amp;#8220;Pantherx&amp;#8221;), which accounted for 23% of gross accounts receivable; and Accredo Health Group, Inc. (&amp;#8220;Accredo&amp;#8221;), which accounted for 33% of gross accounts receivable.   &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December&amp;#160;31, 2020, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 27% of gross product revenues. For the year ended December&amp;#160;31, 2019 two customers accounted for 88% of gross product revenues, CVS Caremark accounted for 59% of gross product revenues and Pantherx accounted for 29% of gross product revenues.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:InventoryPolicyTextBlock id="F_000358" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost is determined using the&amp;#160;first-in,&amp;#160;first-out&amp;#160;method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We did not capitalize preapproval inventory during 2019.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&amp;#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000359" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&amp;#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy id="F_000360" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Asset&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000361" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January&amp;#160;1, 2019, the Company adopted ASC 606,&amp;#160;Revenue from Contracts with Customers (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company has determined that the delivery of its product to its customer constitutes a single performance obligation as there are no other promises to deliver goods or services. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore, no amount of consideration has been allocated as a financing component. Taxes collected related to product sales are remitted to governmental authorities and are excluded from revenue.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <hrmy:ProductSaleNetPolicyTextBlock id="F_000362" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product Sales, Net&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company began commercial sales of WAKIX&amp;#160;in November 2019. The Company sells WAKIX&amp;#160;to its customers (a limited number of specialty distributors) that, in turn, distribute WAKIX&amp;#160;to patients.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue on sales of WAKIX&amp;#160;when the customer obtains control of the product, which occurs at a point in time, typically upon delivery. Product revenues are recorded at the product&amp;#8217;s wholesale acquisition costs, net of applicable reserves for variable consideration that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the sale of WAKIX. Components of variable consideration include government and commercial contracts, product returns, commercial&amp;#160;co-payment&amp;#160;assistance program transactions, and distribution services fees. These deductions are based on the amounts earned or to be claimed on the related sales and are classified as a current liability or reduction of receivables, based on expected value method and a range of outcomes and are probability weighted in accordance with ASC 606.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognition under contracts will not occur in a future period. The Company&amp;#8217;s analyses contemplate the application of the constraint in accordance with ASC 606. Actual amounts of consideration ultimately received may differ from its estimates. If actual results in the future vary from its estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/p&gt;</hrmy:ProductSaleNetPolicyTextBlock>
  <us-gaap:CostOfSalesPolicyTextBlock id="F_000363" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cost of Product Sold &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of product sold includes manufacturing and distribution costs, the cost of drug substance, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs, and salaries of employees involved with production. The Company began capitalizing inventory upon FDA approval of WAKIX with a portion of the inventory sold during the year ended December&amp;#160;31, 2020 produced prior to FDA approval and, therefore, was previously expensed as research and development expense in 2019 in the amount of $1,323. Excluded from cost of product sold shown and included in general and administrative on the consolidated statements of operations and comprehensive loss is amortization of acquired developed technology of $9,843 and $2,815 for the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments and&amp;#160;pre-FDA&amp;#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000364" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments and&amp;#160;pre-FDA&amp;#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:AdvertisingCostsPolicyTextBlock id="F_000365" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Advertising Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We expensed the costs of advertising, including promotional expenses, as incurred. Advertising expense was $13,301 and $7,072 a for the years ended December 31, 2020 and 2019, respectively. &lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000366" contextRef="C_0001802665_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes compensation expense relating to stock-based payment transactions in operating results using a fair value measurement method, in accordance with FASB ASC 718,&amp;#160;Compensation-Stock Compensation. ASC&amp;#160;718 requires all stock-based payments to employees to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The vesting periods have a time-based provision consisting of three to five years and expire no more than 10 years after the date of grant. Upon a change of control, certain unvested awards will immediately vest. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;1, 2019, the Company early adopted and accounts for stock-based payments granted to nonemployees in accordance with ASU&amp;#160;2018-07,&amp;#160;Compensation &amp;#8211; Stock Compensation (ASC 718): Improvements to Nonemployee Share &amp;#8211; Based Payment Accounting. The Company determines the fair value of the stock-based payment as the fair value of the equity instruments issued. It is measured on the grant date.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also had nonemployee stock awards subject to a performance condition that are recognized based on probable outcome. On November&amp;#160;15, 2019 the Company modified the award to remove the performance condition resulting in $8,400 of noncash expense that is included in the Company&amp;#8217;s consolidated results of operations for the year ended December&amp;#160;31, 2019 (see Note 13 for further details).&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000367" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect. The basic and diluted computations of net loss per share for the Company are the same because the effects of the Company&amp;#8217;s convertible securities would be anti-dilutive (see Note&amp;#160;14 for further detail).&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000368" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets may be reduced by a valuation allowance if, based on all available evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Management judgment is required in determining the period in which a reversal of a valuation allowance should occur. The Company is required to consider all available evidence, both positive and negative, such as historical levels of income and future forecasts of taxable income among other items, in determining whether a full or partial release of its valuation allowance is required. The Company&amp;#8217;s accounting for deferred tax consequences represents the best estimate of those future events. The Company presents deferred income taxes on the Consolidated Balance Sheet on a jurisdictional basis as either a net noncurrent asset or liability.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not sustainable, based solely on its technical merits and consideration of the relevant taxing authority&amp;#8217;s widely understood administrative practices and precedents. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which a change in judgment occurs. At December&amp;#160;31, 2020 and 2019, the Company did not have any unrecognized uncertain tax positions. The Company&amp;#8217;s policy is to include any interest and penalties as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <hrmy:EmergingGrowthCompanyStatusPolicyPolicyTextBlock id="F_000369" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&amp;#160;Act). Under the JOBS&amp;#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&amp;#160;Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&amp;#160;is&amp;#160;no longer an emerging growth company or (ii)&amp;#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&amp;#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;</hrmy:EmergingGrowthCompanyStatusPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000370" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued amended guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities in the balance sheet and disclosing key information about leasing arrangements. The new guidance clarifies the criteria for distinguishing between a finance lease and operating lease, as well as classification between the two types of leases, which is substantially unchanged from the previous lease guidance. Further, the new guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a&amp;#160;right-of-use&amp;#160;asset, initially measured at the present value of the lease payments. For finance leases, a lessee should recognize interest on the lease liability separately from amortization of the&amp;#160;right-of-use&amp;#160;asset. For operating leases, a lessee should recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis. For leases with a term of 12&amp;#160;months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and lease liabilities. The new standard will become effective for the Company&amp;#8217;s fiscal year ending December&amp;#160;31, 2022. The Company is currently assessing the impact of this amended guidance and the timing of adoption.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU&amp;#160;No.&amp;#160;2016-13,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;. ASU&amp;#160;No.&amp;#160;2016-13&amp;#160;introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for&amp;#160;available-for-sale&amp;#160;debt securities. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2022 for companies deemed to be small reporting companies as of November&amp;#160;15, 2019, with early adoption permitted. The Company is currently evaluating the potential impact of adoption of this standard on its results of operations, financial position and cash flows and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU&amp;#160;No.&amp;#160;2019-12,&amp;#160;&lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&amp;#160;15, 2020 with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting guidance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;font style="font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/font&gt;, which provides guidance related to reference rate reform. The pronouncement provides temporary optional expedients and exceptions to the current guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (&amp;#8220;LIBOR&amp;#8221;) and other interbank offered rates to alternative reference rates. The guidance was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are currently evaluating the impact of the transition from LIBOR to alternative reference rates but do not expect a significant impact to our consolidated financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock id="F_000371" contextRef="C_0001802665_20200101_20201231">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows.
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash shown in the statements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,207&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="F_000372" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;417&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserve for obsolescence&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(174&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock id="F_000373" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock id="F_000374" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The gross carrying amount and net book value of the intangible asset is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Carrying Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;175,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,657&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Book Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;162,343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000375" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestone payment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalties due to third parties&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,006&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rebates and other sales deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,803&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;713&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling and marketing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees, consulting, and other services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;510&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;638&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122,727&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDebtTableTextBlock id="F_000376" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The balances of the OrbiMed Loan as of December 31, 2020 and the CRG Loan as of December 31, 2019 were as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability component - principal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exit fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability component - net carrying value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock id="F_000377" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense related to the OrbiMed Loan and CRG Loan were included in interest expense, net in the Consolidated Statements of Operations as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on principal balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on PIK&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of deferred financing costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; Total term loan interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000378" contextRef="C_0001802665_20200101_20201231">The following table sets forth the lease payment obligations as of December&amp;#160;31, 2020, for the periods indicated below:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000379" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in awards granted under the Plan as of December&amp;#160;31, 2020 and 2019, are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards outstanding&amp;#8212;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,375,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards issued&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,035,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(112,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Awards outstanding&amp;#8212;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,260,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000380" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value the awards are summarized in the following table. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.00&amp;#160;-&amp;#160;95.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95.30&amp;#160;-&amp;#160;99.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.32 - 0.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.60 - 2.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lack of marketability discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&amp;#160;-&amp;#160;20.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.00&amp;#160;-&amp;#160;31.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.4 - 6.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000381" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was $5,190 and $9,909 for the years ended December&amp;#160;31, 2020 and 2019, respectively, and was recorded in the consolidated statements of operations and comprehensive loss in the following line items: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;703&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <hrmy:SummaryOfFutureCompensationExpenseTableTextBlock id="F_000382" contextRef="C_0001802665_20200101_20201231">The Company will recognize compensation expense for these awards as summarized in the following table.
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,046&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,949&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</hrmy:SummaryOfFutureCompensationExpenseTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000383" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the changes in the warrant liability for the year ended December 31, 2020 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value at Issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value included in the statement of operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000384" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of basic and diluted net loss per share: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,944&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(151,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulation of dividends on preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,904&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss available to common shareholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(63,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(187,208&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share - basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share - diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares of common stock - basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,772,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,777,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares of common stock - diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,772,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,777,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000385" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potential common shares issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,260,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,271,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,891,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410,239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,670,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,163,208&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment for warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000386" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Details of the provision for income taxes consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,198&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(42,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000387" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reasons for the difference between the statutory federal income tax rate and the Company&amp;#8217;s effective income tax rate as of December&amp;#160;31, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000388" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and liabilities as of December&amp;#160;31, 2020 and 2019, are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired in-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,346&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,628&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,682&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disallowed interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,661&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(102,874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="F_000389" contextRef="C_0001802665_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The range of assumptions used to determine the fair value of the warrant liability through August&amp;#160;19, 2020 were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54.2% - 68.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.17% - 1.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lack of marketability discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1 - 4.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000390" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821_20200821" decimals="INF" unitRef="U_xbrlishares">6151162</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000391" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200821_20200821" decimals="INF" unitRef="U_xbrlishares">802325</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000392" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821" decimals="INF" unitRef="U_iso4217USD_xbrlishares">24.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000393" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821_20200821" decimals="-3" unitRef="U_iso4217USD">135435000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000394" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821_20200821" decimals="-3" unitRef="U_iso4217USD">12193000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000395" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200821_20200821" decimals="INF" unitRef="U_xbrlishares">42926630</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000396" contextRef="C_0001802665_20200821" decimals="INF" unitRef="U_xbrlishares">410239</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000397" contextRef="C_0001802665_20200811_20200811">1-for-8.215</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000398" contextRef="C_0001802665_20200811_20200811" decimals="4" unitRef="U_xbrlipure">0.1217</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000399" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">135435000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromLinesOfCredit id="F_000400" contextRef="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">200000000</us-gaap:ProceedsFromLinesOfCredit>
  <hrmy:NumberOfApprovedCommercialProducts id="F_000401" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_hrmyProduct">1</hrmy:NumberOfApprovedCommercialProducts>
  <us-gaap:NumberOfOperatingSegments id="F_000402" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_hrmySegment">1</us-gaap:NumberOfOperatingSegments>
  <hrmy:NumberOfMajorCustomers id="F_000403" contextRef="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_20200101_20201231" decimals="INF" unitRef="U_hrmyCustomer">3</hrmy:NumberOfMajorCustomers>
  <hrmy:NumberOfMajorCustomers id="F_000404" contextRef="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_20200101_20201231" decimals="INF" unitRef="U_hrmyCustomer">3</hrmy:NumberOfMajorCustomers>
  <hrmy:NumberOfMajorCustomers id="F_000405" contextRef="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_20190101_20191231" decimals="INF" unitRef="U_hrmyCustomer">2</hrmy:NumberOfMajorCustomers>
  <hrmy:NumberOfMajorCustomers id="F_000406" contextRef="C_0001802665_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_20190101_20191231" decimals="INF" unitRef="U_hrmyCustomer">2</hrmy:NumberOfMajorCustomers>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000407" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyThreeCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000408" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyThreeCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000409" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyTwoCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.91</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000410" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyTwoCustomersMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.88</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000411" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.44</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000412" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.40</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000413" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.72</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000414" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyCaremarkLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.59</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000415" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.23</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000416" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.33</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000417" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.19</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000418" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyPANTHERxSpecialtyPharmacyLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.29</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000419" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyAccredoHealthGroupIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.33</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000420" contextRef="C_0001802665_srtMajorCustomersAxis_hrmyAccredoHealthGroupIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.27</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000421" contextRef="C_0001802665_20200101_20201231">generally between three and ten years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <hrmy:CapitalizedResearchAndDevelopmentExpense id="F_000422" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1323000</hrmy:CapitalizedResearchAndDevelopmentExpense>
  <us-gaap:AdvertisingExpense id="F_000423" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13301000</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense id="F_000424" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7072000</us-gaap:AdvertisingExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000425" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_20200101_20201231">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000426" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_20200101_20201231">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000427" contextRef="C_0001802665_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms id="F_000428" contextRef="C_0001802665_20200101_20201231">On November 15, 2019 the Company modified the award to remove the performance condition</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
  <us-gaap:OtherNoncashExpense id="F_000429" contextRef="C_0001802665_20190101_20191231" decimals="0" unitRef="U_iso4217USD">8400</us-gaap:OtherNoncashExpense>
  <hrmy:RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions id="F_000430" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">50000</hrmy:RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent id="F_000431" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent id="F_000432" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:InventoryRawMaterials id="F_000433" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">396000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryRawMaterials id="F_000434" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">384000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryWorkInProcess id="F_000435" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">2660000</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryWorkInProcess id="F_000436" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">417000</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryFinishedGoods id="F_000437" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">941000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryFinishedGoods id="F_000438" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">287000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryGross id="F_000439" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">3997000</us-gaap:InventoryGross>
  <us-gaap:InventoryGross id="F_000440" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1088000</us-gaap:InventoryGross>
  <us-gaap:InventoryValuationReserves id="F_000441" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">174000</us-gaap:InventoryValuationReserves>
  <hrmy:LicenseAgreementMilestonePaymentsPaid id="F_000442" contextRef="C_0001802665_20191101_20191130" decimals="-3" unitRef="U_iso4217USD">75000000</hrmy:LicenseAgreementMilestonePaymentsPaid>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="F_000443" contextRef="C_0001802665_20200101_20201231">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="F_000444" contextRef="C_0001802665_20210101_20210131">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 id="F_000445" contextRef="C_0001802665_20200101_20201231">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
  <hrmy:LicenseAgreementMilestonePaymentsPaid id="F_000446" contextRef="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210131" decimals="-3" unitRef="U_iso4217USD">100000000</hrmy:LicenseAgreementMilestonePaymentsPaid>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths id="F_000447" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">18569000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo id="F_000448" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">18569000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree id="F_000449" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">18569000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour id="F_000450" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">18569000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive id="F_000451" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">18569000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000452" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">92845000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill id="F_000453" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">175000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill id="F_000454" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">75000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000455" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">12657000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000456" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">2815000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <hrmy:LicenseAgreementMilestonePaymentsDue id="F_000457" contextRef="C_0001802665_srtProductOrServiceAxis_hrmyPitolisantsMember_20190212" decimals="-3" unitRef="U_iso4217USD">50000000</hrmy:LicenseAgreementMilestonePaymentsDue>
  <hrmy:LicenseAgreementMilestonePaymentsDue id="F_000458" contextRef="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_20190814" decimals="-3" unitRef="U_iso4217USD">77000000</hrmy:LicenseAgreementMilestonePaymentsDue>
  <hrmy:LicensingAgreementMilestoneFees id="F_000459" contextRef="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_20190814_20190814" decimals="-3" unitRef="U_iso4217USD">2000000</hrmy:LicensingAgreementMilestoneFees>
  <hrmy:LicenseAgreementMilestonePaymentsPaid id="F_000460" contextRef="C_0001802665_20190801_20190831" decimals="-3" unitRef="U_iso4217USD">2000000</hrmy:LicenseAgreementMilestonePaymentsPaid>
  <hrmy:LicenseAgreementMilestonePaymentsPaid id="F_000461" contextRef="C_0001802665_srtProductOrServiceAxis_hrmyWAKIXMember_20201001_20201031" decimals="-3" unitRef="U_iso4217USD">2000000</hrmy:LicenseAgreementMilestonePaymentsPaid>
  <hrmy:LicenseAgreementMilestonePaymentsDue id="F_000462" contextRef="C_0001802665_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210131" decimals="-3" unitRef="U_iso4217USD">100000000</hrmy:LicenseAgreementMilestonePaymentsDue>
  <hrmy:LicenseAgreementAdditionalMilestonePaymentsDue id="F_000463" contextRef="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_srtProductOrServiceAxis_hrmyWAKIXMember_srtStatementGeographicalAxis_countryUS_srtStatementScenarioAxis_hrmyUponAchievementOfAggregateNetSalesMember_20201231" decimals="-3" unitRef="U_iso4217USD">40000000</hrmy:LicenseAgreementAdditionalMilestonePaymentsDue>
  <hrmy:AmountOfAggregateNetSalesAttaining id="F_000464" contextRef="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_srtStatementGeographicalAxis_countryUS_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">500000000</hrmy:AmountOfAggregateNetSalesAttaining>
  <us-gaap:CostOfGoodsAndServicesSold id="F_000465" contextRef="C_0001802665_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">25580000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:AccruedRoyaltiesCurrent id="F_000466" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">9006000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="F_000467" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">938000</us-gaap:AccruedRoyaltiesCurrent>
  <hrmy:AccruedMilestonePaymentCurrent id="F_000468" contextRef="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_20201231" decimals="-3" unitRef="U_iso4217USD">100000000</hrmy:AccruedMilestonePaymentCurrent>
  <hrmy:AccruedMilestonePaymentCurrent id="F_000469" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">100000000</hrmy:AccruedMilestonePaymentCurrent>
  <hrmy:AccruedRebatesAndOtherSalesDeductionsCurrent id="F_000470" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">7803000</hrmy:AccruedRebatesAndOtherSalesDeductionsCurrent>
  <hrmy:AccruedRebatesAndOtherSalesDeductionsCurrent id="F_000471" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">713000</hrmy:AccruedRebatesAndOtherSalesDeductionsCurrent>
  <hrmy:AccruedResearchAndDevelopmentCurrent id="F_000472" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">2186000</hrmy:AccruedResearchAndDevelopmentCurrent>
  <hrmy:AccruedResearchAndDevelopmentCurrent id="F_000473" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">894000</hrmy:AccruedResearchAndDevelopmentCurrent>
  <us-gaap:AccruedMarketingCostsCurrent id="F_000474" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1905000</us-gaap:AccruedMarketingCostsCurrent>
  <us-gaap:AccruedMarketingCostsCurrent id="F_000475" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1547000</us-gaap:AccruedMarketingCostsCurrent>
  <hrmy:AccruedProfessionalFeesConsultingAndOtherServices id="F_000476" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1081000</hrmy:AccruedProfessionalFeesConsultingAndOtherServices>
  <hrmy:AccruedProfessionalFeesConsultingAndOtherServices id="F_000477" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">510000</hrmy:AccruedProfessionalFeesConsultingAndOtherServices>
  <hrmy:AccruedDebtIssuanceCostsCurrent id="F_000478" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">638000</hrmy:AccruedDebtIssuanceCostsCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000479" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">746000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000480" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">260000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000481" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228" decimals="INF" unitRef="U_iso4217USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityExpirationDate1 id="F_000482" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228_20190228">2025-03-31</us-gaap:LineOfCreditFacilityExpirationDate1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000483" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228" decimals="INF" unitRef="U_xbrlipure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <hrmy:DebtInstrumentNumberOfTranches id="F_000484" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228_20190228" decimals="INF" unitRef="U_hrmyTranche">3</hrmy:DebtInstrumentNumberOfTranches>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000485" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228_20190228" decimals="3" unitRef="U_xbrlipure">0.075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <hrmy:DebtInstrumentCompoundInterestRate id="F_000486" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190228_20190228" decimals="3" unitRef="U_xbrlipure">0.045</hrmy:DebtInstrumentCompoundInterestRate>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000487" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231" decimals="-3" unitRef="U_iso4217USD">100000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:ProceedsFromIssuanceOfDebt id="F_000488" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">94816000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:DeferredFinanceCostsNet id="F_000489" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231" decimals="-3" unitRef="U_iso4217USD">5184000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DebtInstrumentTerm id="F_000490" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20190101_20191231">P6Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredFinanceCostsGross id="F_000491" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231" decimals="-3" unitRef="U_iso4217USD">4592000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000492" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109" decimals="INF" unitRef="U_iso4217USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityExpirationDate1 id="F_000493" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109">2026-01-31</us-gaap:LineOfCreditFacilityExpirationDate1>
  <hrmy:DebtInstrumentVariableInterestRate id="F_000494" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109" decimals="4" unitRef="U_xbrlipure">0.0200</hrmy:DebtInstrumentVariableInterestRate>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000495" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109" decimals="4" unitRef="U_xbrlipure">0.1100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <hrmy:DebtInstrumentExitFeePercentage id="F_000496" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109" decimals="3" unitRef="U_xbrlipure">0.070</hrmy:DebtInstrumentExitFeePercentage>
  <us-gaap:ExtinguishmentOfDebtAmount id="F_000497" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20200109_20200109" decimals="-3" unitRef="U_iso4217USD">120893000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000498" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20200109_20200109" decimals="-3" unitRef="U_iso4217USD">22639000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <hrmy:ExtinguishmentOfDebtExitFees id="F_000499" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20200109_20200109" decimals="-3" unitRef="U_iso4217USD">18047000</hrmy:ExtinguishmentOfDebtExitFees>
  <us-gaap:WriteOffOfDeferredDebtIssuanceCost id="F_000500" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyMultiDrawLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20200109_20200109" decimals="-3" unitRef="U_iso4217USD">4592000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
  <us-gaap:DeferredFinanceCostsNet id="F_000501" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109" decimals="-3" unitRef="U_iso4217USD">5804000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:ProceedsFromIssuanceOfDebt id="F_000502" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109" decimals="-3" unitRef="U_iso4217USD">73313000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:DebtInstrumentTerm id="F_000503" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109">P6Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFairValue id="F_000504" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">245700000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000505" contextRef="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109" decimals="INF" unitRef="U_xbrlishares">410239</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000506" contextRef="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109" decimals="INF" unitRef="U_iso4217USD_xbrlishares">16.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000507" contextRef="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109_20200109" decimals="-3" unitRef="U_iso4217USD">2359000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:DeferredFinanceCostsGross id="F_000508" contextRef="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">2097000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000509" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
  <hrmy:DebtInstrumentExitFees id="F_000510" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">14000000</hrmy:DebtInstrumentExitFees>
  <hrmy:UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing id="F_000511" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">19750000</hrmy:UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing>
  <us-gaap:LongTermDebtNoncurrent id="F_000512" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">194250000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000513" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231" decimals="-3" unitRef="U_iso4217USD">102538000</us-gaap:DebtInstrumentCarryingAmount>
  <hrmy:UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing id="F_000514" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231" decimals="-3" unitRef="U_iso4217USD">4592000</hrmy:UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing>
  <us-gaap:LongTermDebtNoncurrent id="F_000515" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyCRGServicingLLCMember_20191231" decimals="-3" unitRef="U_iso4217USD">97946000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="F_000516" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">26203000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="F_000517" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4231000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:PaidInKindInterest id="F_000518" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2538000</us-gaap:PaidInKindInterest>
  <us-gaap:AmortizationOfFinancingCosts id="F_000519" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2412000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="F_000520" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">592000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:InterestExpenseDebt id="F_000521" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">28615000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000522" contextRef="C_0001802665_us-gaapDebtInstrumentAxis_hrmyCreditAgreementMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7361000</us-gaap:InterestExpenseDebt>
  <us-gaap:LitigationSettlementExpense id="F_000523" contextRef="C_0001802665_20191024_20191024" decimals="-3" unitRef="U_iso4217USD">3466000</us-gaap:LitigationSettlementExpense>
  <hrmy:OperatingLeaseOfficeSpace id="F_000524" contextRef="C_0001802665_srtStatementGeographicalAxis_hrmyNorthbrookILMember_20180430" decimals="INF" unitRef="U_utrsqft">9000</hrmy:OperatingLeaseOfficeSpace>
  <hrmy:OperatingLeaseExpirationMonthAndYear id="F_000525" contextRef="C_0001802665_srtStatementGeographicalAxis_hrmyNorthbrookILMember_20180401_20180430">2020-01</hrmy:OperatingLeaseExpirationMonthAndYear>
  <hrmy:OperatingLeaseOfficeSpace id="F_000526" contextRef="C_0001802665_srtStatementGeographicalAxis_hrmyPlymouthMeetingPAMember_20180630" decimals="INF" unitRef="U_utrsqft">15000</hrmy:OperatingLeaseOfficeSpace>
  <hrmy:OperatingLeaseExpirationMonthAndYear id="F_000527" contextRef="C_0001802665_srtStatementGeographicalAxis_hrmyPlymouthMeetingPAMember_20180601_20180630">2024-05</hrmy:OperatingLeaseExpirationMonthAndYear>
  <hrmy:OperatingLeaseOfficeSpace id="F_000528" contextRef="C_0001802665_srtStatementGeographicalAxis_hrmyChicagoILMember_20201231" decimals="INF" unitRef="U_utrsqft">13000</hrmy:OperatingLeaseOfficeSpace>
  <hrmy:OperatingLeaseExpirationMonthAndYear id="F_000529" contextRef="C_0001802665_srtStatementGeographicalAxis_hrmyChicagoILMember_20200101_20201231">2024-05</hrmy:OperatingLeaseExpirationMonthAndYear>
  <us-gaap:OperatingLeaseExpense id="F_000530" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">686000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000531" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1051000</us-gaap:OperatingLeaseExpense>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000532" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000533" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">875000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000534" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">892000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000535" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">334000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000536" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">2635000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:TemporaryEquitySharesIssued id="F_000537" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20170922" decimals="INF" unitRef="U_xbrlishares">270000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000538" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20180108" decimals="INF" unitRef="U_xbrlishares">15000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000539" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20170922" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000540" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20180108" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000541" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20170922" decimals="-3" unitRef="U_iso4217USD">270000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000542" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20180108" decimals="-3" unitRef="U_iso4217USD">15000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000543" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:TemporaryEquitySharesIssued id="F_000544" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20180108" decimals="INF" unitRef="U_xbrlishares">8000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000545" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20180108" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.25</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000546" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20180108" decimals="-3" unitRef="U_iso4217USD">10000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000547" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:TemporaryEquitySharesIssued id="F_000548" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190809" decimals="INF" unitRef="U_xbrlishares">25510205</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000549" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190809" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.96</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000550" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190809" decimals="-3" unitRef="U_iso4217USD">50000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000551" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000552" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000553" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesBConvertiblePreferredStockMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000554" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_hrmySeriesCConvertiblePreferredStockMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:DividendsPreferredStock id="F_000555" contextRef="C_0001802665_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DividendsPreferredStock>
  <us-gaap:PreferredStockConversionBasis id="F_000556" contextRef="C_0001802665_20200811_20200811">1-for-8.215</us-gaap:PreferredStockConversionBasis>
  <hrmy:PreferredStockConversionRatio id="F_000557" contextRef="C_0001802665_20200811_20200811" decimals="4" unitRef="U_xbrlipure">0.1217</hrmy:PreferredStockConversionRatio>
  <hrmy:UnderwritingDiscountsAndCommissionsAndOfferingExpenses id="F_000558" contextRef="C_0001802665_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200821_20200821" decimals="-3" unitRef="U_iso4217USD">12193000</hrmy:UnderwritingDiscountsAndCommissionsAndOfferingExpenses>
  <us-gaap:CommonStockVotingRights id="F_000559" contextRef="C_0001802665_20200101_20201231">one vote for each share</us-gaap:CommonStockVotingRights>
  <hrmy:CommonStockNumberOfSharesSubjectToForfeitureProvisions id="F_000560" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">1217285</hrmy:CommonStockNumberOfSharesSubjectToForfeitureProvisions>
  <us-gaap:ShareBasedCompensation id="F_000561" contextRef="C_0001802665_20191115_20191115" decimals="-3" unitRef="U_iso4217USD">8400000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000562" contextRef="C_0001802665_us-gaapPlanNameAxis_hrmyTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000563" contextRef="C_0001802665_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000564" contextRef="C_0001802665_20191231" decimals="INF" unitRef="U_xbrlishares">2375218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000565" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3035400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000566" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">37947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000567" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">112545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000568" contextRef="C_0001802665_20201231" decimals="INF" unitRef="U_xbrlishares">5260126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000569" contextRef="C_0001802665_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000570" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">24.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000571" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000572" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000573" contextRef="C_0001802665_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">17.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000574" contextRef="C_0001802665_20190101_20191231">P8Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000575" contextRef="C_0001802665_20200101_20201231">P8Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <hrmy:StockVestedDuringPeriodShares id="F_000576" contextRef="C_0001802665_us-gaapPlanNameAxis_hrmyTwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">987538</hrmy:StockVestedDuringPeriodShares>
  <hrmy:StockVestedDuringPeriodShares id="F_000577" contextRef="C_0001802665_us-gaapPlanNameAxis_hrmyTwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">573098</hrmy:StockVestedDuringPeriodShares>
  <hrmy:ShareBasedCompensationExpenseIncome id="F_000578" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3000</hrmy:ShareBasedCompensationExpenseIncome>
  <hrmy:ShareBasedCompensationExpenseIncome id="F_000579" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4000</hrmy:ShareBasedCompensationExpenseIncome>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000580" contextRef="C_0001802665_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000581" contextRef="C_0001802665_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000582" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.5500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000583" contextRef="C_0001802665_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.9530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000584" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.9580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000585" contextRef="C_0001802665_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.9930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000586" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000587" contextRef="C_0001802665_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000588" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000589" contextRef="C_0001802665_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount id="F_000590" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0000</hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount>
  <hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount id="F_000591" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.2600</hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount>
  <hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount id="F_000592" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.2048</hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount>
  <hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount id="F_000593" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.3100</hrmy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000594" contextRef="C_0001802665_20190101_20191231">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000595" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000596" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000597" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000598" contextRef="C_0001802665_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000599" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5190000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000600" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9909000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000601" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">586000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000602" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">287000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000603" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">703000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000604" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">351000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000605" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3901000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000606" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9271000</us-gaap:AllocatedShareBasedCompensationExpense>
  <hrmy:FutureShareBasedCompensationExpenseYearOne id="F_000607" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">11046000</hrmy:FutureShareBasedCompensationExpenseYearOne>
  <hrmy:FutureShareBasedCompensationExpenseYearTwo id="F_000608" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">10915000</hrmy:FutureShareBasedCompensationExpenseYearTwo>
  <hrmy:FutureShareBasedCompensationExpenseYearThree id="F_000609" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">9928000</hrmy:FutureShareBasedCompensationExpenseYearThree>
  <hrmy:FutureShareBasedCompensationExpenseYearFour id="F_000610" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">8949000</hrmy:FutureShareBasedCompensationExpenseYearFour>
  <hrmy:FutureShareBasedCompensationExpenseYearFive id="F_000611" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">5003000</hrmy:FutureShareBasedCompensationExpenseYearFive>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000612" contextRef="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200109" decimals="-3" unitRef="U_iso4217USD">2359000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="F_000613" contextRef="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20201231" decimals="-3" unitRef="U_iso4217USD">2102000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000614" contextRef="C_0001802665_us-gaapLineOfCreditFacilityAxis_hrmyOrbiMedRoyaltyCreditOpportunitiesLPMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3109000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="F_000615" contextRef="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2359000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000616" contextRef="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3109000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <hrmy:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity id="F_000617" contextRef="C_0001802665_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5468000</hrmy:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000618" contextRef="C_0001802665_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">5260126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000619" contextRef="C_0001802665_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">2271632</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000620" contextRef="C_0001802665_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">36891576</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000621" contextRef="C_0001802665_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">410239</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000622" contextRef="C_0001802665_20200101_20201231" decimals="0" unitRef="U_xbrlishares">5670365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000623" contextRef="C_0001802665_20190101_20191231" decimals="0" unitRef="U_xbrlishares">39163208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000624" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-6416000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000625" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-32508000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000626" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4198000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000627" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-9641000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <hrmy:ValuationAllowanceIncomeTaxExpenseBenefit id="F_000628" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2218000</hrmy:ValuationAllowanceIncomeTaxExpenseBenefit>
  <hrmy:ValuationAllowanceIncomeTaxExpenseBenefit id="F_000629" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">42149000</hrmy:ValuationAllowanceIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000630" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-2218000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000631" contextRef="C_0001802665_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-42149000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000632" contextRef="C_0001802665_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000633" contextRef="C_0001802665_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000634" contextRef="C_0001802665_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.114</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000635" contextRef="C_0001802665_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="F_000636" contextRef="C_0001802665_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="F_000637" contextRef="C_0001802665_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000638" contextRef="C_0001802665_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.060</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000639" contextRef="C_0001802665_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.277</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000640" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">45346000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000641" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">50628000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000642" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">44983000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000643" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">41427000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits id="F_000644" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">4075000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits id="F_000645" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">5158000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000646" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1604000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000647" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1682000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <hrmy:DeferredTaxAssetsDisallowedInterest id="F_000648" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">7751000</hrmy:DeferredTaxAssetsDisallowedInterest>
  <hrmy:DeferredTaxAssetsDisallowedInterest id="F_000649" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">1661000</hrmy:DeferredTaxAssetsDisallowedInterest>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent id="F_000650" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">121000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent id="F_000651" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">160000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="F_000652" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">65000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="F_000653" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsInventory id="F_000654" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">100000</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsOther id="F_000655" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">71000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000656" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">61000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000657" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">104116000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000658" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">100823000</us-gaap:DeferredTaxAssetsGross>
  <hrmy:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance id="F_000659" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">102874000</hrmy:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
  <hrmy:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance id="F_000660" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">100656000</hrmy:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000661" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">102874000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000662" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">100656000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesOther id="F_000663" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1242000</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DeferredTaxLiabilitiesOther id="F_000664" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000665" contextRef="C_0001802665_20201231" decimals="-3" unitRef="U_iso4217USD">1242000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000666" contextRef="C_0001802665_20191231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000667" contextRef="C_0001802665_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2218000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:OperatingLossCarryforwards id="F_000668" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">159395000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000669" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-3" unitRef="U_iso4217USD">147823000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000670" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" unitRef="U_iso4217USD">157743000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000671" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231" decimals="-3" unitRef="U_iso4217USD">139336000</us-gaap:OperatingLossCarryforwards>
  <hrmy:OperatingLossCarryforwardsExpirationPeriod id="F_000672" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2037</hrmy:OperatingLossCarryforwardsExpirationPeriod>
  <hrmy:OperatingLossCarryforwardsExpirationPeriod id="F_000673" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2037</hrmy:OperatingLossCarryforwardsExpirationPeriod>
  <hrmy:OperatingLossCarryforwardsExpirationPeriod id="F_000674" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2037</hrmy:OperatingLossCarryforwardsExpirationPeriod>
  <hrmy:OperatingLossCarryforwardsExpirationPeriod id="F_000675" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">2037</hrmy:OperatingLossCarryforwardsExpirationPeriod>
  <us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="F_000676" contextRef="C_0001802665_20200101_20201231">These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
  <hrmy:PercentageOfChangeInOwnership id="F_000677" contextRef="C_0001802665_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.50</hrmy:PercentageOfChangeInOwnership>
  <hrmy:PeriodOfChangeInOwnership id="F_000678" contextRef="C_0001802665_20200101_20201231">P3Y</hrmy:PeriodOfChangeInOwnership>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000679" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">1603000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000680" contextRef="C_0001802665_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-3" unitRef="U_iso4217USD">837000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:WarrantsAndRightsOutstandingChangeInValuationTechnique id="F_000681" contextRef="C_0001802665_20201231">false</us-gaap:WarrantsAndRightsOutstandingChangeInValuationTechnique>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000682" contextRef="C_0001802665_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20200819" decimals="1" unitRef="U_xbrlipure">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000683" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20200819" decimals="INF" unitRef="U_xbrlipure">54.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000684" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20200819" decimals="INF" unitRef="U_xbrlipure">68.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000685" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20200819" decimals="INF" unitRef="U_xbrlipure">0.17</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000686" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20200819" decimals="INF" unitRef="U_xbrlipure">1.56</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000687" contextRef="C_0001802665_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountForLackOfMarketabilityMember_20200819" decimals="1" unitRef="U_xbrlipure">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingTerm id="F_000688" contextRef="C_0001802665_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_20200819">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm id="F_000689" contextRef="C_0001802665_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_20200819">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000690" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapRelatedPartyTransactionAxis_hrmyManagementServicesAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">7384000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000691" contextRef="C_0001802665_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapRelatedPartyTransactionAxis_hrmyManagementServicesAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5378000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000692" contextRef="C_0001802665_us-gaapBalanceSheetLocationAxis_hrmyCurrentLiabilitiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000693" contextRef="C_0001802665_us-gaapBalanceSheetLocationAxis_hrmyCurrentLiabilitiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">1208000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesNoncurrent id="F_000694" contextRef="C_0001802665_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:DueFromRelatedPartiesNoncurrent>
  <us-gaap:DueFromRelatedPartiesNoncurrent id="F_000695" contextRef="C_0001802665_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">210000</us-gaap:DueFromRelatedPartiesNoncurrent>
  <hrmy:LicenseAgreementMilestonePaymentsPaid id="F_000696" contextRef="C_0001802665_srtCounterpartyNameAxis_hrmyBioprojetMember_srtProductOrServiceAxis_hrmyWAKIXMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210105_20210106" decimals="-3" unitRef="U_iso4217USD">100000000</hrmy:LicenseAgreementMilestonePaymentsPaid>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward id="F_000697" contextRef="C_0001802665_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210228" decimals="INF" unitRef="U_xbrlishares">882606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000698" contextRef="C_0001802665_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210228">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000699" contextRef="C_0001802665_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210228" decimals="2" unitRef="U_xbrlipure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="F_000700" contextRef="C_0001802665_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_hrmyIncentiveAwardPlanTwoThousandTwentyMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210228">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="#F_000190" xlink:label="F_000190_lbl" />
    <link:footnote xlink:type="resource" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common stock of Harmony Biosciences Holdings, Inc.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000190_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000207" xlink:label="F_000207_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000207_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000212" xlink:label="F_000212_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000212_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000232" xlink:label="F_000232_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000232_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000235" xlink:label="F_000235_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000235_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000241" xlink:label="F_000241_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000241_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000246" xlink:label="F_000246_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000246_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000249" xlink:label="F_000249_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000249_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000252" xlink:label="F_000252_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000252_lbl" xlink:to="FNT_000000" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>36
<FILENAME>hrmy-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T03:27:40.1754106+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 0158915826f244a7b74d260029b57690 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:hrmy="http://www.harmonybiosciences.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.harmonybiosciences.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.harmonybiosciences.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrmy-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrmy-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrmy-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrmy-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&apos; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100060 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResources" id="Role_DisclosureLiquidityAndCapitalResources">
        <link:definition>100070 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventory" id="Role_DisclosureInventory">
        <link:definition>100090 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAsset" id="Role_DisclosureIntangibleAsset">
        <link:definition>100100 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreement" id="Role_DisclosureLicenseAgreement">
        <link:definition>100110 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100120 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100130 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100150 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit" id="Role_DisclosureStockholdersEquityDeficit">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensation" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock Incentive Plan and Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrants" id="Role_DisclosureWarrants">
        <link:definition>100180 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShare" id="Role_DisclosureEarningsPerShare">
        <link:definition>100190 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100210 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100220 - Disclosure - Related-party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100230 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryTables" id="Role_DisclosureInventoryTables">
        <link:definition>100260 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetTable" id="Role_DisclosureIntangibleAssetTable">
        <link:definition>100270 - Disclosure - Intangible Asset (Table)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100290 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100300 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensationTables">
        <link:definition>100310 - Disclosure - Stock Incentive Plan and Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsTables" id="Role_DisclosureWarrantsTables">
        <link:definition>100320 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables" id="Role_DisclosureEarningsPerShareTables">
        <link:definition>100330 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100340 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100350 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails" id="Role_DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Liquidity and Capital Resources - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryScheduleOfInventoryNetDetails" id="Role_DisclosureInventoryScheduleOfInventoryNetDetails">
        <link:definition>100400 - Disclosure - Inventory - Schedule of Inventory Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetAdditionalInformationDetails" id="Role_DisclosureIntangibleAssetAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Intangible Asset - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" id="Role_DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails">
        <link:definition>100420 - Disclosure - Intangible Asset - Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails" id="Role_DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails">
        <link:definition>100430 - Disclosure - Intangible Asset - Schedule of Gross Carrying Amount and Net Book Value of Intangible Asset (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100450 - Disclosure - Accrued Expenses -Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" id="Role_DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails">
        <link:definition>100470 - Disclosure - Debt - Balances of OrbiMed Loan and CRG Loan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" id="Role_DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails">
        <link:definition>100480 - Disclosure - Debt - Interest Expense Related to OrbiMed Loan and CRG Loan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Summary of Lease Payment Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityDeficitAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Stockholders&apos; Equity (Deficit) - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInAwardsGrantedDetails" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInAwardsGrantedDetails">
        <link:definition>100540 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Changes in Awards Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails">
        <link:definition>100550 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Assumptions Used to Value Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100560 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfFutureCompensationExpenseDetails" id="Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfFutureCompensationExpenseDetails">
        <link:definition>100570 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Future Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" id="Role_DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInWarrantDetails" id="Role_DisclosureWarrantsSummaryOfChangesInWarrantDetails">
        <link:definition>100590 - Disclosure - Warrants - Summary of Changes in Warrant (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100600 - Disclosure - Earnings per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="Role_DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>100610 - Disclosure - Earnings per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails2" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails2">
        <link:definition>100630 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails">
        <link:definition>100640 - Disclosure - Income Taxes - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100650 - Disclosure - Income Taxes - Schedule of Significant Components of Company&apos;s Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails" id="Role_DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails">
        <link:definition>100680 - Disclosure - Financial Instruments - Schedule of Range of Assumptions Used to Determine Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Related-party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="hrmy_DebtInstrumentExitFees" name="DebtInstrumentExitFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" name="UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" name="ValuationAllowanceIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_TemporaryEquityDividend" name="TemporaryEquityDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_TemporaryEquityShareConvertedToPermanentEquity" name="TemporaryEquityShareConvertedToPermanentEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_TemporaryEquityValueConvertedToPermanentEquity" name="TemporaryEquityValueConvertedToPermanentEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" name="DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" name="AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_ReclassificationOfWarrantLiabilityToEquity" name="ReclassificationOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" name="RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_StockAppreciationRightsMarketAdjustment" name="StockAppreciationRightsMarketAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" name="PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_PaymentOfPreferredStockIssuanceCosts" name="PaymentOfPreferredStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" name="PaymentsOfExtinguishmentOfDebtExitFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_CashPaidForMilestones" name="CashPaidForMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_PreferredStockAccruedReturn" name="PreferredStockAccruedReturn" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_PreferredStockAccretionOfIssuanceCosts" name="PreferredStockAccretionOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_WarrantFinancing" name="WarrantFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_LiquidityAndCapitalResourcesTextBlock" name="LiquidityAndCapitalResourcesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_LiquidityAndCapitalResourcesAbstract" name="LiquidityAndCapitalResourcesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_LicenseAgreementTextBlock" name="LicenseAgreementTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_ConvertiblePreferredStockTextBlock" name="ConvertiblePreferredStockTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_FinancialInstrumentsAbstract" name="FinancialInstrumentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" name="SignificantRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_ProductSaleNetPolicyTextBlock" name="ProductSaleNetPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" name="SummaryOfFutureCompensationExpenseTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_OrganizationAndDescriptionOfBusinessLineItems" name="OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_OrganizationAndDescriptionOfBusinessTable" name="OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_LiquidityAndCapitalResourcesLineItems" name="LiquidityAndCapitalResourcesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_LiquidityAndCapitalResourcesTable" name="LiquidityAndCapitalResourcesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" name="OrbiMedRoyaltyCreditOpportunitiesLPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_NumberOfApprovedCommercialProducts" name="NumberOfApprovedCommercialProducts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_ThreeCustomersMember" name="ThreeCustomersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_TwoCustomersMember" name="TwoCustomersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_CaremarkLLCMember" name="CaremarkLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_PANTHERxSpecialtyPharmacyLLCMember" name="PANTHERxSpecialtyPharmacyLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_AccredoHealthGroupIncMember" name="AccredoHealthGroupIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_NumberOfMajorCustomers" name="NumberOfMajorCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_CapitalizedResearchAndDevelopmentExpense" name="CapitalizedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" name="RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_LicenseAgreementMilestonePaymentsPaid" name="LicenseAgreementMilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_WAKIXMember" name="WAKIXMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_LicenseAgreementMilestonePaymentsDue" name="LicenseAgreementMilestonePaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_LicensingAgreementMilestoneFees" name="LicensingAgreementMilestoneFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_AmountOfAggregateNetSalesAttaining" name="AmountOfAggregateNetSalesAttaining" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" name="LicenseAgreementAdditionalMilestonePaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_AccruedMilestonePaymentCurrent" name="AccruedMilestonePaymentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_LicenseAgreementLineItems" name="LicenseAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_LicenseAgreementTable" name="LicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_BioprojetMember" name="BioprojetMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_UponAchievementOfAggregateNetSalesMember" name="UponAchievementOfAggregateNetSalesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_PitolisantsMember" name="PitolisantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" name="AccruedRebatesAndOtherSalesDeductionsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" name="AccruedProfessionalFeesConsultingAndOtherServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_AccruedDebtIssuanceCostsCurrent" name="AccruedDebtIssuanceCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_DebtInstrumentNumberOfTranches" name="DebtInstrumentNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_DebtInstrumentCompoundInterestRate" name="DebtInstrumentCompoundInterestRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_MultiDrawLoanAgreementMember" name="MultiDrawLoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_CRGServicingLLCMember" name="CRGServicingLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_CreditAgreementMember" name="CreditAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_DebtInstrumentVariableInterestRate" name="DebtInstrumentVariableInterestRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_ExtinguishmentOfDebtExitFees" name="ExtinguishmentOfDebtExitFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="hrmy_DebtInstrumentExitFeePercentage" name="DebtInstrumentExitFeePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" name="OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_NorthbrookILMember" name="NorthbrookILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_PlymouthMeetingPAMember" name="PlymouthMeetingPAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_ChicagoILMember" name="ChicagoILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_OperatingLeaseOfficeSpace" name="OperatingLeaseOfficeSpace" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="hrmy_OperatingLeaseExpirationMonthAndYear" name="OperatingLeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_PreferredStockConversionRatio" name="PreferredStockConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" name="UnderwritingDiscountsAndCommissionsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" name="CommonStockNumberOfSharesSubjectToForfeitureProvisions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" name="IncentiveAwardPlanTwoThousandTwentyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" name="TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_StockVestedDuringPeriodShares" name="StockVestedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_ShareBasedCompensationExpenseIncome" name="ShareBasedCompensationExpenseIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_FutureShareBasedCompensationExpenseYearOne" name="FutureShareBasedCompensationExpenseYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_FutureShareBasedCompensationExpenseYearTwo" name="FutureShareBasedCompensationExpenseYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_FutureShareBasedCompensationExpenseYearThree" name="FutureShareBasedCompensationExpenseYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_FutureShareBasedCompensationExpenseYearFour" name="FutureShareBasedCompensationExpenseYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_FutureShareBasedCompensationExpenseYearFive" name="FutureShareBasedCompensationExpenseYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_DeferredTaxAssetsDisallowedInterest" name="DeferredTaxAssetsDisallowedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="hrmy_PercentageOfChangeInOwnership" name="PercentageOfChangeInOwnership" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_PeriodOfChangeInOwnership" name="PeriodOfChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_OperatingLossCarryforwardsExpirationPeriod" name="OperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="hrmy_ManagementServicesAgreementMember" name="ManagementServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="hrmy_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>37
<FILENAME>hrmy-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T03:27:40.1754106+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 0158915826f244a7b74d260029b57690 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="hrmy-20201231.xsd#TemplateLink" roleURI="http://www.harmonybiosciences.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10300.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10150.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockAppreciationRightsMarketAdjustment" xlink:type="locator" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" xlink:type="locator" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsOfExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentOfPreferredStockIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="hrmy_PaymentOfPreferredStockIssuanceCosts" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="hrmy_StockAppreciationRightsMarketAdjustment" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10280.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10290.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10300.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10310.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10340.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryScheduleOfInventoryNetDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureInventoryScheduleOfInventoryNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryScheduleOfInventoryNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:type="locator" xlink:label="us-gaap_InventoryGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryRawMaterials" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryWorkInProcess" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryFinishedGoods" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedDebtIssuanceCostsCurrent" xlink:type="locator" xlink:label="hrmy_AccruedDebtIssuanceCostsCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedProfessionalFeesConsultingAndOtherServices" xlink:type="locator" xlink:label="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedResearchAndDevelopmentCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" xlink:type="locator" xlink:label="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedMilestonePaymentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedMilestonePaymentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="hrmy_AccruedMilestonePaymentCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="hrmy_AccruedResearchAndDevelopmentCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="hrmy_AccruedDebtIssuanceCostsCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" xlink:type="locator" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFees" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="hrmy_DebtInstrumentExitFees" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_PaidInKindInterest" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails2" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails2">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DeferredTaxAssetsDisallowedInterest" xlink:type="locator" xlink:label="hrmy_DeferredTaxAssetsDisallowedInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:type="locator" xlink:label="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="hrmy_DeferredTaxAssetsDisallowedInterest" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>38
<FILENAME>hrmy-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T03:27:40.1754106+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 0158915826f244a7b74d260029b57690 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="hrmy-20201231.xsd#TemplateLink" roleURI="http://www.harmonybiosciences.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10310.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11100.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" xlink:type="locator" xlink:label="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityShareConvertedToPermanentEquity" xlink:type="locator" xlink:label="hrmy_TemporaryEquityShareConvertedToPermanentEquity" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityValueConvertedToPermanentEquity" xlink:type="locator" xlink:label="hrmy_TemporaryEquityValueConvertedToPermanentEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityDividend" xlink:type="locator" xlink:label="hrmy_TemporaryEquityDividend" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:type="locator" xlink:label="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:type="locator" xlink:label="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityDividend" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityValueConvertedToPermanentEquity" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityShareConvertedToPermanentEquity" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_ReclassificationOfWarrantLiabilityToEquity" order="12620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="14700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="14760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WarrantFinancing" xlink:type="locator" xlink:label="hrmy_WarrantFinancing" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockAccretionOfIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PreferredStockAccretionOfIssuanceCosts" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockAccruedReturn" xlink:type="locator" xlink:label="hrmy_PreferredStockAccruedReturn" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CashPaidForMilestones" xlink:type="locator" xlink:label="hrmy_CashPaidForMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsOfExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentOfPreferredStockIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" xlink:type="locator" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockAppreciationRightsMarketAdjustment" xlink:type="locator" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10350.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="hrmy_StockAppreciationRightsMarketAdjustment" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="hrmy_PaymentOfPreferredStockIssuanceCosts" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="hrmy_CashPaidForMilestones" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_PreferredStockAccruedReturn" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_PreferredStockAccretionOfIssuanceCosts" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_WarrantFinancing" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_ReclassificationOfWarrantLiabilityToEquity" order="12960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:type="locator" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessTable" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="hrmy_OrganizationAndDescriptionOfBusinessTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesTable" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesTable" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesLineItems" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="hrmy_LiquidityAndCapitalResourcesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_LiquidityAndCapitalResourcesTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CapitalizedResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="hrmy_CapitalizedResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NumberOfMajorCustomers" xlink:type="locator" xlink:label="hrmy_NumberOfMajorCustomers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NumberOfApprovedCommercialProducts" xlink:type="locator" xlink:label="hrmy_NumberOfApprovedCommercialProducts" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccredoHealthGroupIncMember" xlink:type="locator" xlink:label="hrmy_AccredoHealthGroupIncMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PANTHERxSpecialtyPharmacyLLCMember" xlink:type="locator" xlink:label="hrmy_PANTHERxSpecialtyPharmacyLLCMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CaremarkLLCMember" xlink:type="locator" xlink:label="hrmy_CaremarkLLCMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoCustomersMember" xlink:type="locator" xlink:label="hrmy_TwoCustomersMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ThreeCustomersMember" xlink:type="locator" xlink:label="hrmy_ThreeCustomersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_ThreeCustomersMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_TwoCustomersMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_CaremarkLLCMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_PANTHERxSpecialtyPharmacyLLCMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_AccredoHealthGroupIncMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_NumberOfApprovedCommercialProducts" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_NumberOfMajorCustomers" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_CapitalizedResearchAndDevelopmentExpense" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherNoncashExpense" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_WAKIXMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedMilestonePaymentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedMilestonePaymentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AmountOfAggregateNetSalesAttaining" xlink:type="locator" xlink:label="hrmy_AmountOfAggregateNetSalesAttaining" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" xlink:type="locator" xlink:label="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicensingAgreementMilestoneFees" xlink:type="locator" xlink:label="hrmy_LicensingAgreementMilestoneFees" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsDue" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PitolisantsMember" xlink:type="locator" xlink:label="hrmy_PitolisantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UponAchievementOfAggregateNetSalesMember" xlink:type="locator" xlink:label="hrmy_UponAchievementOfAggregateNetSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_BioprojetMember" xlink:type="locator" xlink:label="hrmy_BioprojetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementTable" xlink:type="locator" xlink:label="hrmy_LicenseAgreementTable" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementLineItems" xlink:type="locator" xlink:label="hrmy_LicenseAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="hrmy_BioprojetMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_StatementScenarioAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="hrmy_UponAchievementOfAggregateNetSalesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_StatementGeographicalAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_ProductOrServiceAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_PitolisantsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_WAKIXMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrmy_LicenseAgreementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsDue" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicensingAgreementMilestoneFees" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_AmountOfAggregateNetSalesAttaining" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_AccruedMilestonePaymentCurrent" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="locator" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_ExtinguishmentOfDebtExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFeePercentage" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFeePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentVariableInterestRate" xlink:type="locator" xlink:label="hrmy_DebtInstrumentVariableInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentCompoundInterestRate" xlink:type="locator" xlink:label="hrmy_DebtInstrumentCompoundInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentNumberOfTranches" xlink:type="locator" xlink:label="hrmy_DebtInstrumentNumberOfTranches" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_CRGServicingLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_MultiDrawLoanAgreementMember" xlink:type="locator" xlink:label="hrmy_MultiDrawLoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_MultiDrawLoanAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_CRGServicingLLCMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_CreditAgreementMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentNumberOfTranches" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentCompoundInterestRate" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentVariableInterestRate" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentExitFeePercentage" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_ExtinguishmentOfDebtExitFees" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12050.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" xlink:type="locator" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFees" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_CRGServicingLLCMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_CreditAgreementMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_CRGServicingLLCMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentExitFees" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_CreditAgreementMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaidInKindInterest" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="10450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="hrmy_OperatingLeaseExpirationMonthAndYear" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLeaseOfficeSpace" xlink:type="locator" xlink:label="hrmy_OperatingLeaseOfficeSpace" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementExpense" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ChicagoILMember" xlink:type="locator" xlink:label="hrmy_ChicagoILMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PlymouthMeetingPAMember" xlink:type="locator" xlink:label="hrmy_PlymouthMeetingPAMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NorthbrookILMember" xlink:type="locator" xlink:label="hrmy_NorthbrookILMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="hrmy_NorthbrookILMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="hrmy_PlymouthMeetingPAMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="hrmy_ChicagoILMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hrmy_OperatingLeaseOfficeSpace" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hrmy_OperatingLeaseExpirationMonthAndYear" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" xlink:type="locator" xlink:label="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:type="locator" xlink:label="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockConversionRatio" xlink:type="locator" xlink:label="hrmy_PreferredStockConversionRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hrmy_PreferredStockConversionRatio" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="10800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ShareBasedCompensationExpenseIncome" xlink:type="locator" xlink:label="hrmy_ShareBasedCompensationExpenseIncome" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockVestedDuringPeriodShares" xlink:type="locator" xlink:label="hrmy_StockVestedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" xlink:type="locator" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_IncentiveAwardPlanTwoThousandTwentyMember" xlink:type="locator" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hrmy_StockVestedDuringPeriodShares" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hrmy_ShareBasedCompensationExpenseIncome" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" xlink:type="locator" xlink:label="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInWarrantDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureWarrantsSummaryOfChangesInWarrantDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInWarrantDetails">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PeriodOfChangeInOwnership" xlink:type="locator" xlink:label="hrmy_PeriodOfChangeInOwnership" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PercentageOfChangeInOwnership" xlink:type="locator" xlink:label="hrmy_PercentageOfChangeInOwnership" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLossCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="hrmy_OperatingLossCarryforwardsExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hrmy_OperatingLossCarryforwardsExpirationPeriod" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hrmy_PercentageOfChangeInOwnership" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hrmy_PeriodOfChangeInOwnership" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="hrmy_CurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ManagementServicesAgreementMember" xlink:type="locator" xlink:label="hrmy_ManagementServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="hrmy_ManagementServicesAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="hrmy_CurrentLiabilitiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_IncentiveAwardPlanTwoThousandTwentyMember" xlink:type="locator" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_BioprojetMember" xlink:type="locator" xlink:label="hrmy_BioprojetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="hrmy_BioprojetMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_WAKIXMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="10530.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>39
<FILENAME>hrmy-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T03:27:40.1764351+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 0158915826f244a7b74d260029b57690 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFees" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFees" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument exit fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DebtInstrumentExitFees" xlink:to="hrmy_DebtInstrumentExitFees_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" xlink:type="locator" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" />
    <link:label xml:lang="en-US" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unamortized debt discount associated with exit fee, debt financing costs and discount with warrant financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" xlink:to="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation allowance income tax expense (benefit).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" xlink:to="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line3</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SeriesAConvertiblePreferredStockMember" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SeriesBConvertiblePreferredStockMember" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SeriesCConvertiblePreferredStockMember" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NONCURRENT ASSETS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total noncurrent assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NONCURRENT LIABILITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total noncurrent liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONVERTIBLE PREFERRED STOCK</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, net of placement costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY (DEFICIT):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock - $0.00001 par value; 10,000,000 shares and 0 shares authorized at December 31, 2020 and 2019, respectively; 0 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock&#8212;$0.00001 par value; 500,000,000 shares and 423,630,000 shares authorized at December 31, 2020 and 2019, respectively; 56,890,569 shares and 7,787,470 issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net product revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of product sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling And Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on debt extinguishment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulation of dividends on preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss available to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET LOSS PER SHARE:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares of common stock - basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares of common stock - diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityDividend" xlink:type="locator" xlink:label="hrmy_TemporaryEquityDividend" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TemporaryEquityDividend" xlink:to="hrmy_TemporaryEquityDividend_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityShareConvertedToPermanentEquity" xlink:type="locator" xlink:label="hrmy_TemporaryEquityShareConvertedToPermanentEquity" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityShareConvertedToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity share converted to permanent equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TemporaryEquityShareConvertedToPermanentEquity" xlink:to="hrmy_TemporaryEquityShareConvertedToPermanentEquity_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityValueConvertedToPermanentEquity" xlink:type="locator" xlink:label="hrmy_TemporaryEquityValueConvertedToPermanentEquity" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityValueConvertedToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value converted to permanent equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TemporaryEquityValueConvertedToPermanentEquity" xlink:to="hrmy_TemporaryEquityValueConvertedToPermanentEquity_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:type="locator" xlink:label="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividends and dividends in excess of retained earnings adjustments to additional paid in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:to="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:type="locator" xlink:label="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of dividends in excess of retained earnings adjustments to additional paid in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:to="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ReclassificationOfWarrantLiabilityToEquity" xlink:to="hrmy_ReclassificationOfWarrantLiabilityToEquity_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible Preferred Stock, beginning balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible Preferred Stock, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance cost, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preferred stock dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends And Dividends In Excess Of Retained Earnings Adjustments To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preferred stock accretion</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Dividends In Excess Of Retained Earnings Adjustments To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Preferred stock dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Preferred stock accretion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion Of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock upon initial public offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock upon initial public offering, net of issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityValueConvertedToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, Conversion of Series A, B, C convertible stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityValueConvertedToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Converted To Permanent Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityShareConvertedToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, conversion of Series A, B, C convertible stock to common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TemporaryEquityShareConvertedToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Share Converted To Permanent Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, C convertible stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, C convertible stock to common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase and cancellation of common units withheld for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" xlink:type="locator" xlink:label="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" />
    <link:label xml:lang="en-US" xlink:label="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase and cancellation of common units withheld for taxes, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" xlink:to="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase and cancellation of common units withheld for taxes, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase And Cancellation Of Common Units Withheld For Taxes Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase and cancellation of common units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired During Period Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase and cancellation of common shares, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible Preferred Stock, Ending balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible Preferred Stock, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockAppreciationRightsMarketAdjustment" xlink:type="locator" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment" />
    <link:label xml:lang="en-US" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock appreciation rights market adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_StockAppreciationRightsMarketAdjustment" xlink:to="hrmy_StockAppreciationRightsMarketAdjustment_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" xlink:type="locator" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire in process research and development other than through business combination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" xlink:to="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentOfPreferredStockIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of preferred stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PaymentOfPreferredStockIssuanceCosts" xlink:to="hrmy_PaymentOfPreferredStockIssuanceCosts_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsOfExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of extinguishment of debt exit fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" xlink:to="hrmy_PaymentsOfExtinguishmentOfDebtExitFees_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CashPaidForMilestones" xlink:type="locator" xlink:label="hrmy_CashPaidForMilestones" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CashPaidForMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid during the year for milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CashPaidForMilestones" xlink:to="hrmy_CashPaidForMilestones_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockAccruedReturn" xlink:type="locator" xlink:label="hrmy_PreferredStockAccruedReturn" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockAccruedReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock accrued return.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PreferredStockAccruedReturn" xlink:to="hrmy_PreferredStockAccruedReturn_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockAccretionOfIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PreferredStockAccretionOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockAccretionOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock accretion of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PreferredStockAccretionOfIssuanceCosts" xlink:to="hrmy_PreferredStockAccretionOfIssuanceCosts_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WarrantFinancing" xlink:type="locator" xlink:label="hrmy_WarrantFinancing" />
    <link:label xml:lang="en-US" xlink:label="hrmy_WarrantFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_WarrantFinancing" xlink:to="hrmy_WarrantFinancing_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones associated with acquired in-process research &amp; development (IPR&amp;D)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Asset Acquired Other Than Through Business Combination Written Off</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock appreciation rights market adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Appreciation Rights Market Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash paid-in-kind interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on debt extinguishment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Trade receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable Trade</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Milestone associated with acquired in-process research &amp; development (IPR&amp;D)</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire In Process Research And Development Other Than Through Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Milestone and acquisition of intangible asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Initial public offering issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preferred stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Preferred Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Extinguishment Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of debt exit fees</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Extinguishment Of Debt Exit Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercised options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax payments for employees shares withheld</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH&#8212;Beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH&#8212;End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Cash Flow Information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the year for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CashPaidForMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the year for milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CashPaidForMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Milestones</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosures of Noncash Investing and Financing Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockAccruedReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock accrued return</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockAccruedReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Accrued Return</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockAccretionOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockAccretionOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Accretion Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_WarrantFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant financing</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_WarrantFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Financing</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesTextBlock" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and capital resources.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LiquidityAndCapitalResourcesTextBlock" xlink:to="hrmy_LiquidityAndCapitalResourcesTextBlock_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesAbstract" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesAbstract" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and capital resources.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LiquidityAndCapitalResourcesAbstract" xlink:to="hrmy_LiquidityAndCapitalResourcesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Capital Resources [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Capital Resources</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Capital Resources [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementTextBlock" xlink:type="locator" xlink:label="hrmy_LicenseAgreementTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementTextBlock" xlink:to="hrmy_LicenseAgreementTextBlock_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementAbstract" xlink:type="locator" xlink:label="hrmy_LicenseAgreementAbstract" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementAbstract" xlink:to="hrmy_LicenseAgreementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ConvertiblePreferredStockTextBlock" xlink:type="locator" xlink:label="hrmy_ConvertiblePreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ConvertiblePreferredStockTextBlock" xlink:to="hrmy_ConvertiblePreferredStockTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plan and Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="hrmy_WarrantsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_WarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_WarrantsDisclosureTextBlock" xlink:to="hrmy_WarrantsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Note Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_WarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_WarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="hrmy_FinancialInstrumentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FinancialInstrumentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FinancialInstrumentsAbstract" xlink:to="hrmy_FinancialInstrumentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FinancialInstrumentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related-party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" xlink:to="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Finite Lived Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ProductSaleNetPolicyTextBlock" xlink:type="locator" xlink:label="hrmy_ProductSaleNetPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ProductSaleNetPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product sale net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ProductSaleNetPolicyTextBlock" xlink:to="hrmy_ProductSaleNetPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ProductSaleNetPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Sales, Net</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ProductSaleNetPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Sale Net Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Product Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:type="locator" xlink:label="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:to="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Gross Carrying Amount and Net Book Value of Intangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balances of OrbiMed Loan and CRG Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense Related to OrbiMed Loan and CRG Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income And Interest Expense Disclosure Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Payment Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Awards Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Value Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" xlink:type="locator" xlink:label="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of future compensation expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" xlink:to="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Future Compensation Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Difference Between Statutory Federal Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Components of Company&apos;s Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments -Schedule of Range of Assumptions Used to Determine Fair Value of Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessLineItems" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="hrmy_OrganizationAndDescriptionOfBusinessLineItems_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:type="locator" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessTable" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:to="hrmy_OrganizationAndDescriptionOfBusinessTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock upon exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesLineItems" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesLineItems" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and capital resources.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="hrmy_LiquidityAndCapitalResourcesLineItems_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesTable" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesTable" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and capital resources.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LiquidityAndCapitalResourcesTable" xlink:to="hrmy_LiquidityAndCapitalResourcesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity And Capital Resources [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Capital Resources [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lender Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit Facility, Lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Lender [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">OrbiMed Royalty &amp; Credit Opportunities, LP.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OrbiMed Royalty &amp; Credit Opportunities, LP.</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Orbi Med Royalty Credit Opportunities L P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity And Capital Resources [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LiquidityAndCapitalResourcesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Capital Resources [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate proceeds from loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Lines Of Credit</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NumberOfApprovedCommercialProducts" xlink:type="locator" xlink:label="hrmy_NumberOfApprovedCommercialProducts" />
    <link:label xml:lang="en-US" xlink:label="hrmy_NumberOfApprovedCommercialProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of approved commercial products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_NumberOfApprovedCommercialProducts" xlink:to="hrmy_NumberOfApprovedCommercialProducts_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="hrmy_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ThreeCustomersMember" xlink:type="locator" xlink:label="hrmy_ThreeCustomersMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ThreeCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Three customers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ThreeCustomersMember" xlink:to="hrmy_ThreeCustomersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ThreeCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Three Customers</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ThreeCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Three Customers [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoCustomersMember" xlink:type="locator" xlink:label="hrmy_TwoCustomersMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two customers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TwoCustomersMember" xlink:to="hrmy_TwoCustomersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Customers</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoCustomersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Customers [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CaremarkLLCMember" xlink:type="locator" xlink:label="hrmy_CaremarkLLCMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CaremarkLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Caremark LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CaremarkLLCMember" xlink:to="hrmy_CaremarkLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CaremarkLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Caremark LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CaremarkLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Caremark L L C [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PANTHERxSpecialtyPharmacyLLCMember" xlink:type="locator" xlink:label="hrmy_PANTHERxSpecialtyPharmacyLLCMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PANTHERxSpecialtyPharmacyLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">PANTHERx Specialty Pharmacy LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PANTHERxSpecialtyPharmacyLLCMember" xlink:to="hrmy_PANTHERxSpecialtyPharmacyLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PANTHERxSpecialtyPharmacyLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PANTHERx Specialty Pharmacy LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PANTHERxSpecialtyPharmacyLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P A N T H E Rx Specialty Pharmacy L L C [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccredoHealthGroupIncMember" xlink:type="locator" xlink:label="hrmy_AccredoHealthGroupIncMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccredoHealthGroupIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accredo Health Group, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccredoHealthGroupIncMember" xlink:to="hrmy_AccredoHealthGroupIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccredoHealthGroupIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accredo Health Group, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccredoHealthGroupIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accredo Health Group Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Product Line [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_NumberOfApprovedCommercialProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of approved commercial products</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_NumberOfApprovedCommercialProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Approved Commercial Products</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NumberOfMajorCustomers" xlink:type="locator" xlink:label="hrmy_NumberOfMajorCustomers" />
    <link:label xml:lang="en-US" xlink:label="hrmy_NumberOfMajorCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of major customers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_NumberOfMajorCustomers" xlink:to="hrmy_NumberOfMajorCustomers_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_NumberOfMajorCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customers</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_NumberOfMajorCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Major Customers</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives of the assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CapitalizedResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="hrmy_CapitalizedResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CapitalizedResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CapitalizedResearchAndDevelopmentExpense" xlink:to="hrmy_CapitalizedResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CapitalizedResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CapitalizedResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of acquired developed technology</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time-based vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of modification award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Expense</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognized income tax position from current period tax positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" xlink:to="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized income tax positions</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recognized Income Tax Position From Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:type="locator" xlink:label="us-gaap_InventoryGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reserve for obsolescence</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory, net</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_WAKIXMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">WAKIX.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_WAKIXMember" xlink:to="hrmy_WAKIXMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_WAKIXMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upon FDA Approval of WAKIX</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_WAKIXMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">W A K I X [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement milestone payments paid</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life of intangible asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Remaining Amortization Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net Amortization Expense Rolling Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Rolling Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Rolling Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Rolling Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Rolling Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Carrying Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Gross Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Book Value</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsDue" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementMilestonePaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments Due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementMilestonePaymentsDue" xlink:to="hrmy_LicenseAgreementMilestonePaymentsDue_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicensingAgreementMilestoneFees" xlink:type="locator" xlink:label="hrmy_LicensingAgreementMilestoneFees" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicensingAgreementMilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement milestone fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicensingAgreementMilestoneFees" xlink:to="hrmy_LicensingAgreementMilestoneFees_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AmountOfAggregateNetSalesAttaining" xlink:type="locator" xlink:label="hrmy_AmountOfAggregateNetSalesAttaining" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AmountOfAggregateNetSalesAttaining_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of aggregate net sales attaining.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AmountOfAggregateNetSalesAttaining" xlink:to="hrmy_AmountOfAggregateNetSalesAttaining_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" xlink:type="locator" xlink:label="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement additional milestone payments due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" xlink:to="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedMilestonePaymentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedMilestonePaymentCurrent" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedMilestonePaymentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone payment current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccruedMilestonePaymentCurrent" xlink:to="hrmy_AccruedMilestonePaymentCurrent_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementLineItems" xlink:type="locator" xlink:label="hrmy_LicenseAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementLineItems_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementTable" xlink:type="locator" xlink:label="hrmy_LicenseAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_LicenseAgreementTable" xlink:to="hrmy_LicenseAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_BioprojetMember" xlink:type="locator" xlink:label="hrmy_BioprojetMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_BioprojetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bioprojet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_BioprojetMember" xlink:to="hrmy_BioprojetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_BioprojetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bioprojet</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_BioprojetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bioprojet [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UponAchievementOfAggregateNetSalesMember" xlink:type="locator" xlink:label="hrmy_UponAchievementOfAggregateNetSalesMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_UponAchievementOfAggregateNetSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upon achievement of aggregate net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_UponAchievementOfAggregateNetSalesMember" xlink:to="hrmy_UponAchievementOfAggregateNetSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_UponAchievementOfAggregateNetSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attaining $500,000 Aggregate Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_UponAchievementOfAggregateNetSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upon Achievement Of Aggregate Net Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PitolisantsMember" xlink:type="locator" xlink:label="hrmy_PitolisantsMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PitolisantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pitolisant&#8217;s.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PitolisantsMember" xlink:to="hrmy_PitolisantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PitolisantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upon Acceptance by FDA of Pitolisant&#8217;s</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PitolisantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pitolisants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based, Trademark and Tiered Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementMilestonePaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement, milestone payment due</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementMilestonePaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicensingAgreementMilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing agreement milestone fees</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicensingAgreementMilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement Milestone Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement, additional milestone payment due</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Additional Milestone Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AmountOfAggregateNetSalesAttaining_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of Aggregate Net Sales Attaining</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AmountOfAggregateNetSalesAttaining_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Aggregate Net Sales Attaining</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued Sales Based Trademark and Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedMilestonePaymentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedMilestonePaymentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Payment Current</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" xlink:type="locator" xlink:label="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued rebates and other sales deductions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" xlink:to="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedResearchAndDevelopmentCurrent" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccruedResearchAndDevelopmentCurrent" xlink:to="hrmy_AccruedResearchAndDevelopmentCurrent_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedProfessionalFeesConsultingAndOtherServices" xlink:type="locator" xlink:label="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedProfessionalFeesConsultingAndOtherServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued professional fees, consulting, and other services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" xlink:to="hrmy_AccruedProfessionalFeesConsultingAndOtherServices_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedDebtIssuanceCostsCurrent" xlink:type="locator" xlink:label="hrmy_AccruedDebtIssuanceCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedDebtIssuanceCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued debt issuance costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_AccruedDebtIssuanceCostsCurrent" xlink:to="hrmy_AccruedDebtIssuanceCostsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedMilestonePaymentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties due to third parties</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rebates and other sales deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Rebates And Other Sales Deductions Current</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Marketing Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedProfessionalFeesConsultingAndOtherServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees, consulting, and other services</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedProfessionalFeesConsultingAndOtherServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Consulting And Other Services</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedDebtIssuanceCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_AccruedDebtIssuanceCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Debt Issuance Costs Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentNumberOfTranches" xlink:type="locator" xlink:label="hrmy_DebtInstrumentNumberOfTranches" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentNumberOfTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument number of tranches.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DebtInstrumentNumberOfTranches" xlink:to="hrmy_DebtInstrumentNumberOfTranches_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentCompoundInterestRate" xlink:type="locator" xlink:label="hrmy_DebtInstrumentCompoundInterestRate" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentCompoundInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument compound interest rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DebtInstrumentCompoundInterestRate" xlink:to="hrmy_DebtInstrumentCompoundInterestRate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_MultiDrawLoanAgreementMember" xlink:type="locator" xlink:label="hrmy_MultiDrawLoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_MultiDrawLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Multi-draw loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_MultiDrawLoanAgreementMember" xlink:to="hrmy_MultiDrawLoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_MultiDrawLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multi-draw Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_MultiDrawLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Multi Draw Loan Agreement [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_CRGServicingLLCMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CRG Servicing LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CRGServicingLLCMember" xlink:to="hrmy_CRGServicingLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRG Servicing LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C R G Servicing L L C [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CreditAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CreditAgreementMember" xlink:to="hrmy_CreditAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CreditAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CreditAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Expiration Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentNumberOfTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of tranches</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentNumberOfTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Number Of Tranches</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest payable in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentCompoundInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of Compounded interest rate</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentCompoundInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Compound Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Gross</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentVariableInterestRate" xlink:type="locator" xlink:label="hrmy_DebtInstrumentVariableInterestRate" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument variable interest rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DebtInstrumentVariableInterestRate" xlink:to="hrmy_DebtInstrumentVariableInterestRate_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_ExtinguishmentOfDebtExitFees" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ExtinguishmentOfDebtExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishment of debt exit fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ExtinguishmentOfDebtExitFees" xlink:to="hrmy_ExtinguishmentOfDebtExitFees_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFeePercentage" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentExitFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument exit fee percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DebtInstrumentExitFeePercentage" xlink:to="hrmy_DebtInstrumentExitFeePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable interest rate</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Variable Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis spread on variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentExitFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument exit fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentExitFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Exit Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of loan, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Debt Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ExtinguishmentOfDebtExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exit fee</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ExtinguishmentOfDebtExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Debt Exit Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="locator" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write-off of the remaining unamortized debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Write Off Of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants initial exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">OrbiMed</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CRG</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liability component - principal</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exit fee</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DebtInstrumentExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Exit Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liability component - net carrying value</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">OrbiMed Royalty &amp; Credit Opportunities, LP and CRG Servicing LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OrbiMed and CRG</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Orbi Med Royalty Credit Opportunities L P And C R G Servicing L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt Excluding Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total term loan interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NorthbrookILMember" xlink:type="locator" xlink:label="hrmy_NorthbrookILMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_NorthbrookILMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Northbrook, IL.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_NorthbrookILMember" xlink:to="hrmy_NorthbrookILMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_NorthbrookILMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Northbrook, IL</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_NorthbrookILMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Northbrook I L [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PlymouthMeetingPAMember" xlink:type="locator" xlink:label="hrmy_PlymouthMeetingPAMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PlymouthMeetingPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Plymouth Meeting, PA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PlymouthMeetingPAMember" xlink:to="hrmy_PlymouthMeetingPAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PlymouthMeetingPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plymouth Meeting, PA</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PlymouthMeetingPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plymouth Meeting P A [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ChicagoILMember" xlink:type="locator" xlink:label="hrmy_ChicagoILMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ChicagoILMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chicago, IL.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ChicagoILMember" xlink:to="hrmy_ChicagoILMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ChicagoILMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chicago, IL</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ChicagoILMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chicago I L [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Expense</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLeaseOfficeSpace" xlink:type="locator" xlink:label="hrmy_OperatingLeaseOfficeSpace" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLeaseOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OperatingLeaseOfficeSpace" xlink:to="hrmy_OperatingLeaseOfficeSpace_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="hrmy_OperatingLeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OperatingLeaseExpirationMonthAndYear" xlink:to="hrmy_OperatingLeaseExpirationMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLeaseOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease square feet of office space</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLeaseOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Convertible preferred stock, purchase price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Convertible preferred stock aggregate amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage preferred stock accrued dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock dividend declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Preferred Stock</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockConversionRatio" xlink:type="locator" xlink:label="hrmy_PreferredStockConversionRatio" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock conversion ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PreferredStockConversionRatio" xlink:to="hrmy_PreferredStockConversionRatio_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:type="locator" xlink:label="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" />
    <link:label xml:lang="en-US" xlink:label="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions and offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:to="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, conversion basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Basis</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PreferredStockConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of shares upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions And Offering Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" xlink:type="locator" xlink:label="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock number of shares subject to forfeiture provisions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" xlink:to="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock number of shares subject to forfeiture provisions</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Number Of Shares Subject To Forfeiture Provisions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncash stock compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="hrmy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_IncentiveAwardPlanTwoThousandTwentyMember" xlink:type="locator" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive award plan two thousand twenty.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" xlink:to="hrmy_IncentiveAwardPlanTwoThousandTwentyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Award Plan Two Thousand Twenty [Member]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" xlink:type="locator" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen equity incentive plan and two thousand twenty incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" xlink:to="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 and 2020 Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan And Two Thousand Twenty Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options contractual term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Awards, Awards outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Awards, Awards issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Awards, Awards exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Awards, Awards forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Awards, Awards outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Awards outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Awards issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Awards exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Awards forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Awards outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockVestedDuringPeriodShares" xlink:type="locator" xlink:label="hrmy_StockVestedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="hrmy_StockVestedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock vested during period shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_StockVestedDuringPeriodShares" xlink:to="hrmy_StockVestedDuringPeriodShares_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ShareBasedCompensationExpenseIncome" xlink:type="locator" xlink:label="hrmy_ShareBasedCompensationExpenseIncome" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ShareBasedCompensationExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation expense (income).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ShareBasedCompensationExpenseIncome" xlink:to="hrmy_ShareBasedCompensationExpenseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_StockVestedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock vested</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_StockVestedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Vested During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ShareBasedCompensationExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense (income)</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ShareBasedCompensationExpenseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Expense Income</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" xlink:type="locator" xlink:label="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions lack of marketability discount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" xlink:to="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lack of marketability discount</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average per share fair value of awards issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling And Marketing Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearOne" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearOne" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future share based compensation expense year one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FutureShareBasedCompensationExpenseYearOne" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearOne_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearTwo" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future share based compensation expense year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FutureShareBasedCompensationExpenseYearTwo" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearTwo_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearThree" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future share based compensation expense year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FutureShareBasedCompensationExpenseYearThree" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearThree_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearFour" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future share based compensation expense year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FutureShareBasedCompensationExpenseYearFour" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearFour_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearFive" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future share based compensation expense year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FutureShareBasedCompensationExpenseYearFive" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Share Based Compensation Expense Year One</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Share Based Compensation Expense Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Share Based Compensation Expense Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Share Based Compensation Expense Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Share Based Compensation Expense Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unamortized debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:label xml:lang="en-US" xlink:label="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:to="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value at Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value included in the statement of operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss available to common shareholders</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Denominator</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - basic</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share - diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DeferredTaxAssetsDisallowedInterest" xlink:type="locator" xlink:label="hrmy_DeferredTaxAssetsDisallowedInterest" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DeferredTaxAssetsDisallowedInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets disallowed interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DeferredTaxAssetsDisallowedInterest" xlink:to="hrmy_DeferredTaxAssetsDisallowedInterest_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:type="locator" xlink:label="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets liabilities net before valuation allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DeferredTaxAssetsDisallowedInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disallowed interest</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DeferredTaxAssetsDisallowedInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Disallowed Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net Before Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PercentageOfChangeInOwnership" xlink:type="locator" xlink:label="hrmy_PercentageOfChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PercentageOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PercentageOfChangeInOwnership" xlink:to="hrmy_PercentageOfChangeInOwnership_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PeriodOfChangeInOwnership" xlink:type="locator" xlink:label="hrmy_PeriodOfChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="hrmy_PeriodOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_PeriodOfChangeInOwnership" xlink:to="hrmy_PeriodOfChangeInOwnership_lbl" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLossCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="hrmy_OperatingLossCarryforwardsExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLossCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_OperatingLossCarryforwardsExpirationPeriod" xlink:to="hrmy_OperatingLossCarryforwardsExpirationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLossCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_OperatingLossCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PercentageOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PercentageOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Change In Ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PeriodOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_PeriodOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Change In Ownership</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes to valuation techniques</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique" xlink:to="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Change In Valuation Technique</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash, cash equivalents, and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Quantitative Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lack of Marketability Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Discount For Lack Of Marketability [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability, fair value measurement inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ManagementServicesAgreementMember" xlink:type="locator" xlink:label="hrmy_ManagementServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ManagementServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Management services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_ManagementServicesAgreementMember" xlink:to="hrmy_ManagementServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_ManagementServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_ManagementServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Management Services Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="hrmy_CurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrmy_CurrentLiabilitiesMember" xlink:to="hrmy_CurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="hrmy_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="hrmy_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management fee expense and other expenses to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts due to related parties - current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts due from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesNoncurrent" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer&apos;s Equity, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed To Issuers Equity Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer&apos;s Equity, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed To Issuers Equity Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Option</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee stock options to purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting period (in years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Award vesting rights (percentage)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Award requisite service period (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>40
<FILENAME>hrmy-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T03:27:40.1764351+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 0158915826f244a7b74d260029b57690 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/role/TemplateLink" xlink:href="hrmy-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hrmy-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" xlink:type="locator" xlink:label="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityShareConvertedToPermanentEquity" xlink:type="locator" xlink:label="hrmy_TemporaryEquityShareConvertedToPermanentEquity" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityValueConvertedToPermanentEquity" xlink:type="locator" xlink:label="hrmy_TemporaryEquityValueConvertedToPermanentEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityDividend" xlink:type="locator" xlink:label="hrmy_TemporaryEquityDividend" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:type="locator" xlink:label="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" xlink:type="locator" xlink:label="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityDividend" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityValueConvertedToPermanentEquity" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_TemporaryEquityShareConvertedToPermanentEquity" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_ReclassificationOfWarrantLiabilityToEquity" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="14690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="14750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="15010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="15030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="15050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="15070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="hrmy-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="hrmy_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WarrantFinancing" xlink:type="locator" xlink:label="hrmy_WarrantFinancing" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockAccretionOfIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PreferredStockAccretionOfIssuanceCosts" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockAccruedReturn" xlink:type="locator" xlink:label="hrmy_PreferredStockAccruedReturn" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CashPaidForMilestones" xlink:type="locator" xlink:label="hrmy_CashPaidForMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsOfExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentOfPreferredStockIssuanceCosts" xlink:type="locator" xlink:label="hrmy_PaymentOfPreferredStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" xlink:type="locator" xlink:label="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockAppreciationRightsMarketAdjustment" xlink:type="locator" xlink:label="hrmy_StockAppreciationRightsMarketAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="hrmy_StockAppreciationRightsMarketAdjustment" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="hrmy_PaymentOfPreferredStockIssuanceCosts" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="hrmy_PaymentsOfExtinguishmentOfDebtExitFees" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="hrmy_CashPaidForMilestones" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_PreferredStockAccruedReturn" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_PreferredStockAccretionOfIssuanceCosts" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_WarrantFinancing" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hrmy_ReclassificationOfWarrantLiabilityToEquity" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="hrmy-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResources" xlink:href="hrmy-20201231.xsd#Role_DisclosureLiquidityAndCapitalResources" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResources">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesTextBlock" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesTextBlock" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesAbstract" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesAbstract" xlink:to="hrmy_LiquidityAndCapitalResourcesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventory" xlink:href="hrmy-20201231.xsd#Role_DisclosureInventory" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventory">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAsset" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAsset" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAsset">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreement" xlink:href="hrmy-20201231.xsd#Role_DisclosureLicenseAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreement">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementTextBlock" xlink:type="locator" xlink:label="hrmy_LicenseAgreementTextBlock" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementAbstract" xlink:type="locator" xlink:label="hrmy_LicenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementAbstract" xlink:to="hrmy_LicenseAgreementTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="hrmy-20201231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebt" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="hrmy-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="hrmy-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ConvertiblePreferredStockTextBlock" xlink:type="locator" xlink:label="hrmy_ConvertiblePreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="hrmy_ConvertiblePreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensation" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrants" xlink:href="hrmy-20201231.xsd#Role_DisclosureWarrants" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrants">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="hrmy_WarrantsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="hrmy_WarrantsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShare" xlink:href="hrmy-20201231.xsd#Role_DisclosureEarningsPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments" xlink:href="hrmy-20201231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="hrmy_FinancialInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_FinancialInstrumentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="hrmy-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="hrmy-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:type="locator" xlink:label="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ProductSaleNetPolicyTextBlock" xlink:type="locator" xlink:label="hrmy_ProductSaleNetPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hrmy_ProductSaleNetPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureInventoryTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetTable" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetTable" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetTable">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" xlink:type="locator" xlink:label="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="hrmy_SummaryOfFutureCompensationExpenseTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureWarrantsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureEarningsPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="hrmy-20201231.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="hrmy_FinancialInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_FinancialInstrumentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:type="locator" xlink:label="hrmy_OrganizationAndDescriptionOfBusinessTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="hrmy_OrganizationAndDescriptionOfBusinessTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessTable" xlink:to="hrmy_OrganizationAndDescriptionOfBusinessLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesLineItems" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesTable" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesTable" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LiquidityAndCapitalResourcesAbstract" xlink:type="locator" xlink:label="hrmy_LiquidityAndCapitalResourcesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesAbstract" xlink:to="hrmy_LiquidityAndCapitalResourcesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesTable" xlink:to="hrmy_LiquidityAndCapitalResourcesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LiquidityAndCapitalResourcesLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CapitalizedResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="hrmy_CapitalizedResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NumberOfMajorCustomers" xlink:type="locator" xlink:label="hrmy_NumberOfMajorCustomers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NumberOfApprovedCommercialProducts" xlink:type="locator" xlink:label="hrmy_NumberOfApprovedCommercialProducts" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccredoHealthGroupIncMember" xlink:type="locator" xlink:label="hrmy_AccredoHealthGroupIncMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PANTHERxSpecialtyPharmacyLLCMember" xlink:type="locator" xlink:label="hrmy_PANTHERxSpecialtyPharmacyLLCMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CaremarkLLCMember" xlink:type="locator" xlink:label="hrmy_CaremarkLLCMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoCustomersMember" xlink:type="locator" xlink:label="hrmy_TwoCustomersMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ThreeCustomersMember" xlink:type="locator" xlink:label="hrmy_ThreeCustomersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="hrmy_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hrmy_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_ThreeCustomersMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_TwoCustomersMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_CaremarkLLCMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_PANTHERxSpecialtyPharmacyLLCMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="hrmy_AccredoHealthGroupIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesTable" xlink:to="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_NumberOfApprovedCommercialProducts" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_NumberOfMajorCustomers" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_CapitalizedResearchAndDevelopmentExpense" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherNoncashExpense" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryScheduleOfInventoryNetDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureInventoryScheduleOfInventoryNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryScheduleOfInventoryNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:type="locator" xlink:label="us-gaap_InventoryGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryGross" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_WAKIXMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedMilestonePaymentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedMilestonePaymentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AmountOfAggregateNetSalesAttaining" xlink:type="locator" xlink:label="hrmy_AmountOfAggregateNetSalesAttaining" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" xlink:type="locator" xlink:label="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicensingAgreementMilestoneFees" xlink:type="locator" xlink:label="hrmy_LicensingAgreementMilestoneFees" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsDue" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsDue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementLineItems" xlink:type="locator" xlink:label="hrmy_LicenseAgreementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PitolisantsMember" xlink:type="locator" xlink:label="hrmy_PitolisantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UponAchievementOfAggregateNetSalesMember" xlink:type="locator" xlink:label="hrmy_UponAchievementOfAggregateNetSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_BioprojetMember" xlink:type="locator" xlink:label="hrmy_BioprojetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementTable" xlink:type="locator" xlink:label="hrmy_LicenseAgreementTable" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementAbstract" xlink:type="locator" xlink:label="hrmy_LicenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementAbstract" xlink:to="hrmy_LicenseAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="hrmy_BioprojetMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_StatementScenarioAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="hrmy_UponAchievementOfAggregateNetSalesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_PitolisantsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_WAKIXMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementTable" xlink:to="hrmy_LicenseAgreementLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsDue" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicensingAgreementMilestoneFees" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_LicenseAgreementAdditionalMilestonePaymentsDue" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_AmountOfAggregateNetSalesAttaining" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_LicenseAgreementLineItems" xlink:to="hrmy_AccruedMilestonePaymentCurrent" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedDebtIssuanceCostsCurrent" xlink:type="locator" xlink:label="hrmy_AccruedDebtIssuanceCostsCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedProfessionalFeesConsultingAndOtherServices" xlink:type="locator" xlink:label="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedResearchAndDevelopmentCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" xlink:type="locator" xlink:label="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_AccruedMilestonePaymentCurrent" xlink:type="locator" xlink:label="hrmy_AccruedMilestonePaymentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="hrmy_AccruedMilestonePaymentCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="hrmy_AccruedResearchAndDevelopmentCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedMarketingCostsCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="hrmy_AccruedProfessionalFeesConsultingAndOtherServices" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="hrmy_AccruedDebtIssuanceCostsCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="locator" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ExtinguishmentOfDebtExitFees" xlink:type="locator" xlink:label="hrmy_ExtinguishmentOfDebtExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFeePercentage" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFeePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentVariableInterestRate" xlink:type="locator" xlink:label="hrmy_DebtInstrumentVariableInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentCompoundInterestRate" xlink:type="locator" xlink:label="hrmy_DebtInstrumentCompoundInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentNumberOfTranches" xlink:type="locator" xlink:label="hrmy_DebtInstrumentNumberOfTranches" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_CRGServicingLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_MultiDrawLoanAgreementMember" xlink:type="locator" xlink:label="hrmy_MultiDrawLoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_MultiDrawLoanAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_CRGServicingLLCMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_CreditAgreementMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentNumberOfTranches" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentCompoundInterestRate" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentVariableInterestRate" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentExitFeePercentage" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_ExtinguishmentOfDebtExitFees" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" xlink:type="locator" xlink:label="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DebtInstrumentExitFees" xlink:type="locator" xlink:label="hrmy_DebtInstrumentExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_CRGServicingLLCMember_li0l2" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_CRGServicingLLCMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_CreditAgreementMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_CRGServicingLLCMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_CRGServicingLLCMember_li0l2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_DebtInstrumentExitFees" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CreditAgreementMember" xlink:type="locator" xlink:label="hrmy_CreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrmy_CreditAgreementMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaidInKindInterest" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="hrmy_OperatingLeaseExpirationMonthAndYear" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLeaseOfficeSpace" xlink:type="locator" xlink:label="hrmy_OperatingLeaseOfficeSpace" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ChicagoILMember" xlink:type="locator" xlink:label="hrmy_ChicagoILMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PlymouthMeetingPAMember" xlink:type="locator" xlink:label="hrmy_PlymouthMeetingPAMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_NorthbrookILMember" xlink:type="locator" xlink:label="hrmy_NorthbrookILMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="hrmy_NorthbrookILMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="hrmy_PlymouthMeetingPAMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="hrmy_ChicagoILMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hrmy_OperatingLeaseOfficeSpace" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hrmy_OperatingLeaseExpirationMonthAndYear" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="hrmy_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesAConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesBConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrmy_SeriesCConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" xlink:type="locator" xlink:label="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:type="locator" xlink:label="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PreferredStockConversionRatio" xlink:type="locator" xlink:label="hrmy_PreferredStockConversionRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hrmy_PreferredStockConversionRatio" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ShareBasedCompensationExpenseIncome" xlink:type="locator" xlink:label="hrmy_ShareBasedCompensationExpenseIncome" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_StockVestedDuringPeriodShares" xlink:type="locator" xlink:label="hrmy_StockVestedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" xlink:type="locator" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_IncentiveAwardPlanTwoThousandTwentyMember" xlink:type="locator" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_TwoThousandSeventeenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hrmy_StockVestedDuringPeriodShares" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hrmy_ShareBasedCompensationExpenseIncome" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInAwardsGrantedDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInAwardsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInAwardsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" xlink:type="locator" xlink:label="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfFutureCompensationExpenseDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfFutureCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfFutureCompensationExpenseDetails">
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearFive" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFive" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearFour" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearFour" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearThree" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearThree" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearTwo" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearTwo" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FutureShareBasedCompensationExpenseYearOne" xlink:type="locator" xlink:label="hrmy_FutureShareBasedCompensationExpenseYearOne" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearOne" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearTwo" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearThree" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearFour" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="hrmy_FutureShareBasedCompensationExpenseYearFive" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" xlink:type="locator" xlink:label="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInWarrantDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureWarrantsSummaryOfChangesInWarrantDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInWarrantDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="hrmy_ValuationAllowanceIncomeTaxExpenseBenefit" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:type="locator" xlink:label="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_DeferredTaxAssetsDisallowedInterest" xlink:type="locator" xlink:label="hrmy_DeferredTaxAssetsDisallowedInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="hrmy_DeferredTaxAssetsDisallowedInterest" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PeriodOfChangeInOwnership" xlink:type="locator" xlink:label="hrmy_PeriodOfChangeInOwnership" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_PercentageOfChangeInOwnership" xlink:type="locator" xlink:label="hrmy_PercentageOfChangeInOwnership" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_OperatingLossCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="hrmy_OperatingLossCarryforwardsExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hrmy_OperatingLossCarryforwardsExpirationPeriod" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hrmy_PercentageOfChangeInOwnership" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hrmy_PeriodOfChangeInOwnership" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_FinancialInstrumentsAbstract" xlink:type="locator" xlink:label="hrmy_FinancialInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_FinancialInstrumentsAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_FinancialInstrumentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrmy_FinancialInstrumentsAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="hrmy_CurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_ManagementServicesAgreementMember" xlink:type="locator" xlink:label="hrmy_ManagementServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="hrmy_ManagementServicesAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="hrmy_CurrentLiabilitiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="hrmy-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="hrmy_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_IncentiveAwardPlanTwoThousandTwentyMember" xlink:type="locator" xlink:label="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_WAKIXMember" xlink:type="locator" xlink:label="hrmy_WAKIXMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="hrmy-20201231.xsd#hrmy_BioprojetMember" xlink:type="locator" xlink:label="hrmy_BioprojetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="hrmy_BioprojetMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="hrmy_WAKIXMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hrmy_IncentiveAwardPlanTwoThousandTwentyMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hrmy_LicenseAgreementMilestonePaymentsPaid" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969704104376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HARMONY BIOSCIENCES HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001802665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2279923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 W.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">539-9800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HRMY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,891,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December&#160;31, 2020 are incorporated herein by reference in Part III where indicated.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703245704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 228,631<span></span>
</td>
<td class="nump">$ 24,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">22,176<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">3,823<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,959<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">262,891<span></span>
</td>
<td class="nump">31,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NONCURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">162,343<span></span>
</td>
<td class="nump">72,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">164,183<span></span>
</td>
<td class="nump">75,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">427,074<span></span>
</td>
<td class="nump">106,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">6,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="nump">7,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">122,727<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">134,539<span></span>
</td>
<td class="nump">19,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NONCURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, net</a></td>
<td class="nump">194,250<span></span>
</td>
<td class="nump">97,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">195,355<span></span>
</td>
<td class="nump">98,396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">329,894<span></span>
</td>
<td class="nump">118,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>CONVERTIBLE PREFERRED STOCK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, net of placement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.00001 par value; 10,000,000 shares and 0 shares authorized at December 31, 2020 and 2019, respectively; 0 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;$0.00001 par value; 500,000,000 shares and 423,630,000 shares authorized at December 31, 2020 and 2019, respectively; 56,890,569 shares and 7,787,470 issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">585,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(488,195)<span></span>
</td>
<td class="num">(422,862)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">97,180<span></span>
</td>
<td class="num">(422,862)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 427,074<span></span>
</td>
<td class="nump">106,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>CONVERTIBLE PREFERRED STOCK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, net of placement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>CONVERTIBLE PREFERRED STOCK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, net of placement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>CONVERTIBLE PREFERRED STOCK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, net of placement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696829032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,510,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">423,630,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">56,890,569<span></span>
</td>
<td class="nump">7,787,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">56,890,569<span></span>
</td>
<td class="nump">7,787,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,030,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,510,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,510,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969704120056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 159,742<span></span>
</td>
<td class="nump">$ 5,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sold</a></td>
<td class="nump">27,738<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">132,004<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,448<span></span>
</td>
<td class="nump">69,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">55,824<span></span>
</td>
<td class="nump">44,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">39,746<span></span>
</td>
<td class="nump">36,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">115,018<span></span>
</td>
<td class="nump">150,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">16,986<span></span>
</td>
<td class="num">(145,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(22,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(3,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(28,220)<span></span>
</td>
<td class="num">(6,073)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(36,944)<span></span>
</td>
<td class="num">(151,977)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(36,944)<span></span>
</td>
<td class="num">(151,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Accumulation of dividends on preferred stock</a></td>
<td class="num">(26,904)<span></span>
</td>
<td class="num">(35,231)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (63,848)<span></span>
</td>
<td class="num">$ (187,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (24.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (24.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares of common stock - basic</a></td>
<td class="nump">25,772,419<span></span>
</td>
<td class="nump">7,777,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares of common stock - diluted</a></td>
<td class="nump">25,772,419<span></span>
</td>
<td class="nump">7,777,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695043160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th" colspan="2"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series C Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series B Convertible Preferred Stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series C Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series B Convertible Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (242,673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (242,673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, beginning balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 324,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,777,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(151,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance cost, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,510,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,973)<span></span>
</td>
<td class="num">$ (32,160)<span></span>
</td>
<td class="num">$ (1,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,973)<span></span>
</td>
<td class="num">$ (22,166)<span></span>
</td>
<td class="num">$ (1,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital', window );">Preferred stock accretion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(2,742)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(2,742)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_TemporaryEquityDividend', window );">Temporary equity, Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">32,160<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Temporary equity, Preferred stock accretion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (422,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(422,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">318,510,205<span></span>
</td>
<td class="nump">25,510,205<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, ending balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 411,275<span></span>
</td>
<td class="nump">$ 51,051<span></span>
</td>
<td class="nump">$ 348,203<span></span>
</td>
<td class="nump">$ 12,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,787,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(36,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
<td class="num">(22,780)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
<td class="num">(21,732)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital', window );">Preferred stock accretion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(922)<span></span>
</td>
<td class="num">(5,562)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (563)<span></span>
</td>
<td class="num">$ (3,572)<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (359)<span></span>
</td>
<td class="num">$ (1,990)<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_TemporaryEquityDividend', window );">Temporary equity, Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347<span></span>
</td>
<td class="nump">22,780<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Temporary equity, Preferred stock accretion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock upon initial public offering, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">135,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock upon initial public offering, net of issuance costs, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,151,162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_TemporaryEquityValueConvertedToPermanentEquity', window );">Temporary equity, Conversion of Series A, B, C convertible stock to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (444,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_TemporaryEquityShareConvertedToPermanentEquity', window );">Temporary equity, conversion of Series A, B, C convertible stock to common stock, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(318,510,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible stock to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 444,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">444,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible stock to common stock, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,926,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,947<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase and cancellation of common units withheld for taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares', window );">Repurchase and cancellation of common units withheld for taxes, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and cancellation of common units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and cancellation of common shares, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,175)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 97,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 585,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (488,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, Ending balance, Shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,890,569<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="15"></td></tr>
<tr><td colspan="15"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock of Harmony Biosciences Holdings, Inc.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of dividends in excess of retained earnings adjustments to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccretionOfDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends and dividends in excess of retained earnings adjustments to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DividendsAndDividendsInExcessOfRetainedEarningsAdjustmentsToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase and cancellation of common units withheld for taxes, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_RepurchaseAndCancellationOfCommonUnitsWithheldForTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_TemporaryEquityDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_TemporaryEquityDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_TemporaryEquityShareConvertedToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity share converted to permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_TemporaryEquityShareConvertedToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_TemporaryEquityValueConvertedToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value converted to permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_TemporaryEquityValueConvertedToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696561560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (36,944)<span></span>
</td>
<td class="num">$ (151,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization</a></td>
<td class="nump">9,843<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Milestones associated with acquired in-process research &amp; development (IPR&amp;D)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,693<span></span>
</td>
<td class="nump">9,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_StockAppreciationRightsMarketAdjustment', window );">Stock appreciation rights market adjustment</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant expense</a></td>
<td class="nump">3,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash paid-in-kind interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs amortization</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">22,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(17,922)<span></span>
</td>
<td class="num">(4,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,735)<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(6,563)<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">789<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade payables</a></td>
<td class="num">(3,804)<span></span>
</td>
<td class="nump">4,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">18,450<span></span>
</td>
<td class="nump">7,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">157<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,985)<span></span>
</td>
<td class="num">(75,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination', window );">Milestone associated with acquired in-process research &amp; development (IPR&amp;D)</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Milestone and acquisition of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,002)<span></span>
</td>
<td class="num">(127,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering</a></td>
<td class="nump">147,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering issuance costs</a></td>
<td class="num">(12,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PaymentOfPreferredStockIssuanceCosts', window );">Preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long term debt</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(5,804)<span></span>
</td>
<td class="num">(5,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Extinguishment of debt</a></td>
<td class="num">(102,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PaymentsOfExtinguishmentOfDebtExitFees', window );">Extinguishment of debt exit fees</a></td>
<td class="num">(18,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercised options</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax payments for employees shares withheld</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">209,161<span></span>
</td>
<td class="nump">143,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</a></td>
<td class="nump">204,174<span></span>
</td>
<td class="num">(58,816)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="nump">25,207<span></span>
</td>
<td class="nump">84,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="nump">229,381<span></span>
</td>
<td class="nump">25,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="nump">26,203<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_CashPaidForMilestones', window );">Cash paid during the year for milestones</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_WarrantFinancing', window );">Warrant financing</a></td>
<td class="nump">2,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">5,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockAccruedReturn', window );">Preferred Stock accrued return</a></td>
<td class="nump">22,780<span></span>
</td>
<td class="nump">32,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockAccretionOfIssuanceCosts', window );">Accretion of issuance costs</a></td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockAccruedReturn', window );">Preferred Stock accrued return</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockAccretionOfIssuanceCosts', window );">Accretion of issuance costs</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockAccruedReturn', window );">Preferred Stock accrued return</a></td>
<td class="nump">3,347<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockAccretionOfIssuanceCosts', window );">Accretion of issuance costs</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_CashPaidForMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid during the year for milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_CashPaidForMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PaymentOfPreferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of preferred stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PaymentOfPreferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PaymentsOfExtinguishmentOfDebtExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of extinguishment of debt exit fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PaymentsOfExtinguishmentOfDebtExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire in process research and development other than through business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PreferredStockAccretionOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock accretion of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PreferredStockAccretionOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PreferredStockAccruedReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock accrued return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PreferredStockAccruedReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_StockAppreciationRightsMarketAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock appreciation rights market adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_StockAppreciationRightsMarketAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_WarrantFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_WarrantFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700314232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Company</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating subsidiary, Harmony Biosciences, LLC, was formed on May&#160;17, 2017. Harmony Biosciences Holdings, Inc. (the &#8220;Company&#8221;) was founded on July&#160;25, 2017 as Harmony Biosciences&#160;II, LLC, a Delaware limited liability company, and the Company converted to a Delaware corporation named Harmony Biosciences II, Inc. on September&#160;19, 2017. On February&#160;3, 2020, the Company changed its name to Harmony Biosciences Holdings, Inc. The Company is a holding company and has no operations. The Company&#8217;s operations are conducted in its wholly owned subsidiary, Harmony Biosciences,&#160;LLC (&#8220;Harmony&#8221;). The Company is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. The Company is headquartered in Plymouth Meeting, Pennsylvania. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company&#8217;s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company&#8217;s convertible preferred stock. Warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 410,239 shares of common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 11, 2020, the Company implemented a 1-for-8.215 reverse stock split of the Company&#8217;s common stock. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s Preferred Stock and preferred dividend were proportionately reduced. <font style="Background-color:#FFFFFF;"> All references in the accompanying consolidated financial statements and related notes to the number of shares of common stock, convertible preferred stock, warrants and options to purchase common stock and per share data reflect the effect of the reverse stock split.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700373288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity And Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LiquidityAndCapitalResourcesTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2. LIQUIDITY AND CAPITAL RESOURCES</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operations since inception resulting in an accumulated deficit of $488,195 and $422,862, as of December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company had cash and cash equivalents of $228,631.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, the Company received aggregate proceeds from a common stock offering of approximately $135,435, net of underwriting discounts and commissions and other estimated offering expenses (see Note 11). Additionally, on January 9, 2020, the Company received aggregate proceeds of approximately $200,000 through the loan agreement with OrbiMed Royalty&#160;&amp; Credit Opportunities, LP. This capital raise and debt issuance has resolved the Company&#8217;s significant risks and uncertainties regarding sources of liquidity, which previously raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months from the date of issuance of these consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700416568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position<font style="Background-color:#FFFFFF;color:#000000;font-family:Arial;"> </font>for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Risks and Uncertainties</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of clinical testing and trial activities of the Company&#8217;s product candidates; the Company&#8217;s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#8217;s products, if approved; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates; and the Company&#8217;s ability to raise capital.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company&#8217;s research and development and clinical trials will result in any successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.77%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the Consolidated Financial Statements, including the notes thereto, and elsewhere in this report.&nbsp;&nbsp;Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Segments</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds all its tangible assets, conducts its operations, and revenues are generated in the U.S. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements include cash, cash equivalents, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. Additionally, prior to the IPO, the Company&#8217;s consolidated financial statements included a warrant liability that was carried at fair value and was re-measured at each balance sheet date until it would be exercised or expired. In connection with the IPO, the Warrants were re-evaluated under the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480 <font style="font-style:italic;">Distinguishing Liabilities from Equity</font> and reclassified to equity. See Note 13 for a further discussion of the warrants.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is the Company&#8217;s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, <font style="font-style:italic;">Fair Value Measurements and Disclosures</font>. ASC&#160;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC&#160;820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in the statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of cash flows</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,381</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,207</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in restricted cash represent those amounts required to be held as a security deposit in the form of letters of credit for the Company&#8217;s credit card program and the fleet program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its trade receivables related to its product sales.  The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of December&#160;31, 2020, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#8220;CVS Caremark&#8221;), which accounted for 44% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (&#8220;Pantherx&#8221;), which accounted for 23% of gross accounts receivable; and Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for 33% of gross accounts receivable.   </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 27% of gross product revenues. For the year ended December&#160;31, 2019 two customers accounted for 88% of gross product revenues, CVS Caremark accounted for 59% of gross product revenues and Pantherx accounted for 29% of gross product revenues.</p>
<p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable. </p>
<p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the&#160;first-in,&#160;first-out&#160;method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We capitalize inventory costs associated with our products prior to regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We did not capitalize preapproval inventory during 2019.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Asset</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January&#160;1, 2019, the Company adopted ASC 606,&#160;Revenue from Contracts with Customers (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company has determined that the delivery of its product to its customer constitutes a single performance obligation as there are no other promises to deliver goods or services. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore, no amount of consideration has been allocated as a financing component. Taxes collected related to product sales are remitted to governmental authorities and are excluded from revenue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Sales, Net</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company began commercial sales of WAKIX&#160;in November 2019. The Company sells WAKIX&#160;to its customers (a limited number of specialty distributors) that, in turn, distribute WAKIX&#160;to patients.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue on sales of WAKIX&#160;when the customer obtains control of the product, which occurs at a point in time, typically upon delivery. Product revenues are recorded at the product&#8217;s wholesale acquisition costs, net of applicable reserves for variable consideration that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the sale of WAKIX. Components of variable consideration include government and commercial contracts, product returns, commercial&#160;co-payment&#160;assistance program transactions, and distribution services fees. These deductions are based on the amounts earned or to be claimed on the related sales and are classified as a current liability or reduction of receivables, based on expected value method and a range of outcomes and are probability weighted in accordance with ASC 606.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognition under contracts will not occur in a future period. The Company&#8217;s analyses contemplate the application of the constraint in accordance with ASC 606. Actual amounts of consideration ultimately received may differ from its estimates. If actual results in the future vary from its estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Product Sold </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sold includes manufacturing and distribution costs, the cost of drug substance, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs, and salaries of employees involved with production. The Company began capitalizing inventory upon FDA approval of WAKIX with a portion of the inventory sold during the year ended December&#160;31, 2020 produced prior to FDA approval and, therefore, was previously expensed as research and development expense in 2019 in the amount of $1,323. Excluded from cost of product sold shown and included in general and administrative on the consolidated statements of operations and comprehensive loss is amortization of acquired developed technology of $9,843 and $2,815 for the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and&#160;pre-FDA&#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advertising Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expensed the costs of advertising, including promotional expenses, as incurred. Advertising expense was $13,301 and $7,072 a for the years ended December 31, 2020 and 2019, respectively. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes compensation expense relating to stock-based payment transactions in operating results using a fair value measurement method, in accordance with FASB ASC 718,&#160;Compensation-Stock Compensation. ASC&#160;718 requires all stock-based payments to employees to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The vesting periods have a time-based provision consisting of three to five years and expire no more than 10 years after the date of grant. Upon a change of control, certain unvested awards will immediately vest. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;1, 2019, the Company early adopted and accounts for stock-based payments granted to nonemployees in accordance with ASU&#160;2018-07,&#160;Compensation &#8211; Stock Compensation (ASC 718): Improvements to Nonemployee Share &#8211; Based Payment Accounting. The Company determines the fair value of the stock-based payment as the fair value of the equity instruments issued. It is measured on the grant date.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also had nonemployee stock awards subject to a performance condition that are recognized based on probable outcome. On November&#160;15, 2019 the Company modified the award to remove the performance condition resulting in $8,400 of noncash expense that is included in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019 (see Note 13 for further details).</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect. The basic and diluted computations of net loss per share for the Company are the same because the effects of the Company&#8217;s convertible securities would be anti-dilutive (see Note&#160;14 for further detail).</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets may be reduced by a valuation allowance if, based on all available evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Management judgment is required in determining the period in which a reversal of a valuation allowance should occur. The Company is required to consider all available evidence, both positive and negative, such as historical levels of income and future forecasts of taxable income among other items, in determining whether a full or partial release of its valuation allowance is required. The Company&#8217;s accounting for deferred tax consequences represents the best estimate of those future events. The Company presents deferred income taxes on the Consolidated Balance Sheet on a jurisdictional basis as either a net noncurrent asset or liability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#8217;s widely understood administrative practices and precedents. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which a change in judgment occurs. At December&#160;31, 2020 and 2019, the Company did not have any unrecognized uncertain tax positions. The Company&#8217;s policy is to include any interest and penalties as a component of income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued amended guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities in the balance sheet and disclosing key information about leasing arrangements. The new guidance clarifies the criteria for distinguishing between a finance lease and operating lease, as well as classification between the two types of leases, which is substantially unchanged from the previous lease guidance. Further, the new guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a&#160;right-of-use&#160;asset, initially measured at the present value of the lease payments. For finance leases, a lessee should recognize interest on the lease liability separately from amortization of the&#160;right-of-use&#160;asset. For operating leases, a lessee should recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis. For leases with a term of 12&#160;months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and lease liabilities. The new standard will become effective for the Company&#8217;s fiscal year ending December&#160;31, 2022. The Company is currently assessing the impact of this amended guidance and the timing of adoption.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,&#160;<font style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font>. ASU&#160;No.&#160;2016-13&#160;introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for&#160;available-for-sale&#160;debt securities. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2022 for companies deemed to be small reporting companies as of November&#160;15, 2019, with early adoption permitted. The Company is currently evaluating the potential impact of adoption of this standard on its results of operations, financial position and cash flows and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,&#160;<font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting guidance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU No. 2020-04, <font style="font-style:italic;">Reference Rate Reform (Topic 848)</font>, which provides guidance related to reference rate reform. The pronouncement provides temporary optional expedients and exceptions to the current guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) and other interbank offered rates to alternative reference rates. The guidance was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are currently evaluating the impact of the transition from LIBOR to alternative reference rates but do not expect a significant impact to our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700313112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4. INVENTORY </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">941</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for obsolescence</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700185448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Net Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Asset</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">5. INTANGIBLE ASSET </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;15, 2019, the Company received FDA approval of WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pitolisant) for the treatment of excessive daytime sleepiness (&#8220;EDS&#8221;) in adult patients with narcolepsy. This event triggered a milestone payment of $75,000 associated with the License Agreement which the Company capitalized as an intangible asset and paid in November of 2019. The Company determined a useful life of 10 years for such intangible asset, and, as of December 31, 2020 the remaining useful life was 9 years. Prior to this event, all other milestones associated with the License Agreement were expensed through research and development as they did not meet the criteria to be recognized as an intangible asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 13, 2020, the Company received notice that the FDA approved the NDA for WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for the treatment of cataplexy in adult patients with narcolepsy. This event triggered a milestone payment of $100,000 associated with the License Agreement which the Company capitalized as an intangible asset and paid in January of 2021. The Company determined a useful life of 9 years for such intangible asset, and, as of December 31, 2020 the remaining useful life was 9 years. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,845</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The gross carrying amount and net book value of the intangible asset is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,657</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Book Value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,343</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,185</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700286680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementTextBlock', window );">License Agreement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">6. LICENSE AGREEMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;28, 2017, Harmony entered into the License Agreement whereby Harmony acquired the exclusive right to commercialize the pharmaceutical compound pitolisant for the treatment, and/or prevention, of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and Parkinson&#8217;s disease as well as any other indications unanimously agreed by the parties in the United States and its territories. A milestone payment of $50,000 was due upon acceptance by the FDA of pitolisant&#8217;s New Drug Application (&#8220;NDA&#8221;), which was achieved on February&#160;12, 2019 and was expensed within research and development for the year ended December 31, 2019. A milestone payment of $77,000, including a $2,000 fee, was due upon FDA approval of WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pitolisant) for treatment of EDS in adult patients with narcolepsy, which was achieved on August&#160;14, 2019. The $2,000 payment and $75,000 milestone payment were paid in August and November 2019, respectively. In addition, a payment of $2,000 is due upon the FDA approval of the NDA for WAKIX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for the treatment of cataplexy in adult patients with narcolepsy (the &#8220;Trigger Date&#8221;) which was paid in October 2020 and a $100,000 milestone payment which was paid in January 2021. An additional $40,000 milestone payment is due to Bioprojet upon WAKIX attaining $500,000 in aggregate net sales in the United States. The License Agreement also requires sales-based milestone payments, a fixed trademark royalty and a tiered royalty, all based on net sales, which become due and payable to Bioprojet on a quarterly basis. During the year ended December&#160;31, 2020, the Company incurred $25,580 for sales-based, trademark and tiered royalties recognized as cost of product sold. As of December&#160;31, 2020 and 2019, the Company had accrued $9,006 and $938, respectively, for sales-based, trademark and tiered royalties. At December 31, 2020 the Company had accrued $100,000 for the milestone payment to Bioprojet. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.61%;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701242648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7. ACCRUED EXPENSES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties due to third parties</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,006</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rebates and other sales deductions</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,803</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,186</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees, consulting, and other services</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,727</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969788979176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">8. DEBT </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Credit Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;28, 2019, the Company entered into a multi-draw loan agreement with CRG Servicing LLC for an aggregate of $200,000 (the &#8220;CRG Loan&#8221;), which matured in March 2025. The Loan bore a fixed rate of 12%. The Loan agreement required compliance with certain financial covenants. The Company could draw three tranches of the Loan based on achieving specific milestones and dates. The Company could elect to pay the interest on the outstanding principal amount as follows: (i)&#160;only 7.5% of the 12% per annum in cash, paid quarterly, starting in March 2019, and (ii) 4.5% of the 12% per annum interest as compounded interest, added to the aggregate outstanding principal balance quarterly; the amount of any such compounded interest being a paid-in-kind loan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had borrowed $100,000, resulting in cash proceeds received of $94,816, net of issuance costs. The issuance costs of $5,184 were being amortized over the six-year loan term of the CRG Loan. Unamortized debt issuance costs as of December&#160;31, 2019 are $4,592 and are presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;9, 2020 the Company entered into a credit agreement with OrbiMed Royalty&#160;&amp; Credit Opportunities, LP for an aggregate amount of $200,000 (the &#8220;OrbiMed Loan&#8221;), which matures in January 2026. Borrowings under the OrbiMed Loan are collateralized by all of the Company&#8217;s assets, excluding the intellectual property licensed through the License Agreement. The OrbiMed Loan bears an interest rate equal to the sum of (i)&#160;the greater of (a)&#160;1-month LIBOR or (b) 2.00% per annum, plus (ii) 11.00% per annum, paid in cash monthly in arrears on the last day of each month starting in January 2020. At the time of prepayment or repayment of all or any portion of the principal of the OrbiMed Loan, the Company is required to pay an exit fee of 7.0% of the principal amount of the OrbiMed Loan prepaid, repaid, or required to be prepaid or repaid.&nbsp;&nbsp;The Company recorded as a liability and debt discount the exit fee at the origination of the term loan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to entering into the OrbiMed Loan, the Company extinguished the CRG Loan which required a payoff amount of $120,893 consisting of principal repayment, interest, and exit fees. In connection with extinguishment of the CRG Loan, we recognized a loss on extinguishment of $22,639, which included an exit fee of $18,047 and the write-off of the remaining unamortized debt issuance costs of $4,592. The loss on extinguishment of debt was recorded in loss on debt extinguishment within the Company&#8217;s consolidated statements of operations. The net cash received as a result of the transaction, less debt issuance costs of $5,804, was $73,313. These debt issuance costs will be amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The fair value of the OrbiMed loan as of December 31, 2020 was $245,700.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the OrbiMed Loan, the Company issued warrants (the &#8220;Warrants&#8221;) to OrbiMed Royalty&#160;&amp; Credit Opportunities, LP on January&#160;9, 2020. See Note 13 for further discussion of the Warrants. Pursuant to the Warrants, OrbiMed Royalty&#160;&amp; Credit Opportunities, LP, may purchase up to 410,239 shares of the Company&#8217;s Common Stock for an initial exercise price of $16.10 at any time from the date of execution of the Warrants through the expiration date, defined within the Warrants as the earlier of (i)&#160;January&#160;9, 2027 and (ii)&#160;the closing date of a Corporate Reorganization. The fair value of the Warrants using the Black-Scholes option-pricing model was $2,359 at January&#160;9, 2020. The portion of the OrbiMed Loan proceeds allocated to the warrant liability resulted in a debt discount, which is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt and is being amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The unamortized debt discount as of December&#160;31, 2020 is $2,097 and is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The balances of the OrbiMed Loan as of December 31, 2020 and the CRG Loan as of December 31, 2019 were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component - principal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,538</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exit fee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,750</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component - net carrying value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,946</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense related to the OrbiMed Loan and CRG Loan were included in interest expense, net in the Consolidated Statements of Operations as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on principal balance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on PIK</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of deferred financing costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Total term loan interest expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,615</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969802278984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">9. COMMITMENTS AND CONTINGENCIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is subject to claims and suits arising in the ordinary course of business. The Company accrues such liabilities when they are known, if they are deemed probable and can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2019 the Company was involved in ongoing litigation with its former chief executive officer related to arbitration and the value of vested common shares. On October&#160;24, 2019, the Company reached a settlement resulting in $3,466 of general and administrative expense reflected in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into an operating lease for approximately nine thousand square feet of office space in Northbrook, IL, which expired in January 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into an operating lease for approximately fifteen thousand square feet of office space in Plymouth Meeting, PA, which expires in May 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an operating lease for approximately thirteen thousand square feet of additional office space in Plymouth Meeting, PA, which expires in May 2024.&nbsp;&nbsp;The term will not commence until the Company takes occupancy in mid-2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the lease payments provide for rental payments on a monthly basis and on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not paid. In addition, tenant improvement allowances recorded are amortized as a reduction to rent expense on a straight-line basis over the lease term. Rent expense was $686 for the year ended December&#160;31, 2020, compared to $1,051 for the year ended December&#160;31, 2019. The following table sets forth the lease payment obligations as of December&#160;31, 2020, for the periods indicated below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">892</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,635</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703232072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ConvertiblePreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10. CONVERTIBLE PREFERRED STOCK </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all outstanding shares of the Company&#8217;s convertible preferred stock were automatically converted into shares of common stock and the accrued dividend payable to holders of the convertible preferred stock was paid out in shares of common stock, resulting in a total of 42,926,630 shares of common stock being issued to former holders of the Company&#8217;s convertible preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series A Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;22, 2017, the Company issued 270,000,000 shares of Series&#160;A convertible preferred stock for a purchase price of $1.00 per share, or $270,000 in the aggregate. On January&#160;8, 2018, the Company issued an additional 15,000,000 shares of Series A convertible preferred stock for a purchase price of $1.00 per share, or $15,000 in the aggregate. As of December&#160;31, 2019, there were 286,000,000 Series&#160;A convertible preferred stock authorized of which 285,000,000 were issued and outstanding. Each outstanding share of Series A convertible preferred stock accrued dividends at 10% per annum of the Series&#160;A original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series&#160;A convertible preferred stock were cumulative and were compounded annually.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series B Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;8, 2018, the Company issued 8,000,000 shares of Series&#160;B convertible preferred stock for a purchase price of $1.25 per share, or $10,000 in the aggregate. As of December&#160;31, 2019, there were 8,030,000 shares of Series&#160;B convertible preferred stock authorized, of which 8,000,000 were issued and outstanding.&#160;Each outstanding share of Series&#160;B convertible preferred stock accrued dividends at 10% per annum of the Series&#160;B original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series B convertible preferred stock were cumulative and were compounded annually.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series C Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;9, 2019, the Company issued 25,510,205 shares of Series C convertible preferred stock for a purchase price of $1.96 per share, or $50,000 in the aggregate. As December&#160;31, 2019, there were 25,600,000 shares of Series C convertible preferred stock authorized, of which 25,510,205 were issued and outstanding. Each outstanding share of Series C convertible preferred stock accrued dividends at 10% per annum of the Series C original issue price, subject to adjustment for stock splits, combinations, recapitalizations, stock dividends and similar transactions. Preferred dividends on the Series C convertible preferred stock were cumulative and were compounded annually.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of Series A, Series B, and Series C convertible preferred stock were entitled to receive, when and if declared by the board of directors of the Company, cumulative dividends equal to a 10% per annum of Series A, Series B, and Series C convertible preferred stock. In addition, the holders of the outstanding shares of Series A, Series B, and Series C convertible preferred stock were entitled to receive, when and if declared by the board of directors of the Company, a dividend at least equal to any dividend payable on the Company&#8217;s common stock as if all convertible preferred stock had been converted to common stock. No dividends were declared as of December&#160;31, 2019. As part of the Company&#8217;s IPO, the Company&#8217;s accrued cumulative dividend was paid out to holders of Series A, Series B, and Series C convertible preferred stock in shares of the Company&#8217;s common stock and reflects the reverse stock split in connection with the mandatory conversion of the Series A, Series B, and Series C convertible preferred stock into shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969708029528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11. STOCKHOLDERS&#8217; EQUITY (DEFICIT) </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;11, 2020, the Company implemented a 1-for-8.215 reverse stock split of the Company&#8217;s common stock. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split with the exception of the preferred stock. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s Preferred Stock were proportionately reduced. As of August 11, 2020, all outstanding shares of preferred stock and preferred stock dividend were convertible into shares of common stock on a 1-for-8.215 basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 21, 2020, the Company completed its IPO of common stock, in which it sold 6,151,162 shares, including 802,325 shares pursuant to the underwriters&#8217; over-allotment option. The shares began trading on the Nasdaq Global Market on August 19, 2020. The shares were sold at an IPO price of $24.00 per share for net proceeds of approximately $135,435, after deducting underwriting discounts and commissions and offering expenses of approximately $12,193 incurred by the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the Company&#8217;s stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the Company&#8217;s board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. The Company&#8217;s common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,217,285 common shares held by an investor were subject to certain forfeiture provisions that are dependent upon the outcome of certain future events. On November&#160;15, 2019, the Company removed the provision associated with this forfeiture resulting in $8,400 of noncash stock compensation expense reflected in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701353368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plan and Stock-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12. STOCK INCENTIVE PLAN AND STOCK-BASED COMPENSATION</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;7, 2017, the Company adopted an equity incentive plan (the &#8220;2017 Plan&#8221;). Under the 2017 Plan, directors, officers, employees, consultants, and advisors of the Company can be paid incentive compensation measured by the value of the Company&#8217;s common shares through grants of stock options, stock appreciation rights, or restricted stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In connection with the Company&#8217;s IPO, the board of directors adopted, and its stockholders approved, the 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;), in order to facilitate the grant of cash and equity incentives to directors, employees (including the Company&#8217;s named executive officers) and consultants of the Company and its subsidiaries. Upon the effectiveness of the 2020 Plan, no further grants will be made under the 2017 Plan. However, the 2017 Plan will continue to govern the terms and conditions of outstanding awards granted under it. The 2020 Plan provides for the grant of stock options, including ISOs and NSOs, SARs, restricted stock, dividend equivalents, RSUs and other stock or cash based awards.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options under the 2017 Plan and the 2020 Plan have a 10-year contractual term and vest over the vesting period specified in the applicable award agreement, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in awards granted under the Plan as of December&#160;31, 2020 and 2019, are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Awards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards outstanding&#8212;December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,375,218</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards issued</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035,400</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.54</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,947</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,545</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards outstanding&#8212;December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,126</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.58</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, stock awards issued under the 2017 and 2020 Plans of 987,538 and 573,098 common shares, respectively, were vested. The Company has elected early adoption of ASU No.&#160;2016-09 to recognize forfeitures as they occur. As a result of the adoption, for the year ended December&#160;31, 2020 and 2019, respectively, the Company reversed $3 and $4 out of stock-based compensation previously recorded. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Value of Stock Options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has valued awards for each of the plans included herein using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, the Company estimates its expected stock volatility based on historical volatility of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for the time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value the awards are summarized in the following table. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.00&#160;-&#160;95.80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.30&#160;-&#160;99.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32 - 0.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60 - 2.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00&#160;-&#160;20.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.00&#160;-&#160;31.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4 - 6.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average per share fair value of awards issued under the Plan was $10.06 and $3.45 in 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was $5,190 and $9,909 for the years ended December&#160;31, 2020 and 2019, respectively, and was recorded in the consolidated statements of operations and comprehensive loss in the following line items: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued under the 2017 Plan and 2020 Plan are reflected as a component of equity in these consolidated financial statements. Stock appreciation rights are reflected as other non-current liability. The Company will recognize compensation expense for these awards as summarized in the following table. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,046</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,915</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,949</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,003</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969707979352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">13. WARRANTS</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the OrbiMed Loan, the Company issued Warrants to OrbiMed Royalty&#160;&amp; Credit Opportunities, LP on January&#160;9, 2020. Pursuant to the Warrants, OrbiMed Royalty&#160;&amp; Credit Opportunities, LP, may purchase up to 410,239 shares of the Company&#8217;s Common Stock for an initial exercise price of $16.10 at any time from the date of execution of the Warrants through the expiration date, defined within the Warrants as the earlier of (i)&#160;January&#160;9, 2027 and (ii)&#160;the closing date of a Corporate Reorganization. The fair value of the Warrants using the Black-Scholes option-pricing model was $2,359 on January&#160;9, 2020 and was initially recorded as a warrant liability which was included in warrant liability in the consolidated balance sheet. The portion of the OrbiMed Loan proceeds allocated to the warrant liability resulted in a debt discount, which is presented in the consolidated balance sheets as a direct deduction from the carrying value of the debt and is being amortized as additional interest expense over the six-year loan term of the OrbiMed Loan. The unamortized debt discount as of December&#160;31, 2020 is $2,102 and is presented in the consolidated balance sheet as a direct deduction from the carrying value of the debt. During the year ended December&#160;31, 2020, a loss of $3,109 was recorded in other expense in the consolidated statements of operations due to the change in the fair value of the warrant liability. See footnote 16 for the fair value of the Warrants.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO, the financial instrument underlying the warrants was converted from the Company&#8217;s Series C Preferred Stock to the Company&#8217;s Common Stock.&nbsp;&nbsp;As a result of this conversion the Warrants were re-evaluated under ASC 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging and reclassified to equity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the changes in the warrant liability for the year ended December 31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair Value at Issuance</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value included in the statement of operations</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,468</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703175112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">14. EARNINGS PER SHARE </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company used the two-class method to compute net loss per common share because the Company has issued securities (convertible preferred stock) that entitle the holder to participate in dividends and earnings of the Company. Under this method, net income is reduced by the amount of any dividends earned and the accretion of convertible preferred stock to its redemption value during the period. The remaining earnings (undistributed earnings) are allocated to common stock and each series of convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. The total earnings allocated to common stock is then divided by the number of outstanding shares to which the earnings are allocated to determine the earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per common share is computed under the treasury stock method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effects of the outstanding convertible preferred stock under the &#8216;if-converted&#8217; method when calculating diluted earnings per share, in which it is assumed that the outstanding convertible preferred stock converts into common stock at the beginning of the period or when issued if later. The Company reports the more dilutive of the approaches (treasury stock or &#8216;if converted&#8217;) as their diluted net income per share during the period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reported a net loss for the years ended December&#160;31, 2020 and 2019, and the weighted average number of shares utilized for basic and diluted net loss per share attributable to common stockholders are the same for these periods because all convertible preferred stock and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact. Additionally, the fair value adjustment for the warrants was excluded from the computation of diluted net loss for the year ended December 31, 2020 since the additional income would have an antidilutive impact.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulation of dividends on preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,904</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common shareholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,848</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187,208</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential common shares issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,126</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,271,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,891,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410,239</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,670,365</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,163,208</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for warrants</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703091176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;text-transform:uppercase;font-size:10pt;font-variant: normal;">15. income taxes<font style="text-transform:none;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Details of the provision for income taxes consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,416</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,198</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,641</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reasons for the difference between the statutory federal income tax rate and the Company&#8217;s effective income tax rate as of December&#160;31, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019, are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired in-process research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,346</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,628</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforward</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,983</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,682</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disallowed interest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,751</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,661</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,116</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,823</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,874</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,656</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,874</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,656</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has considered available positive and negative evidence to estimate if sufficient future taxable income will be generated to allow utilization of the existing deferred tax assets. The Company has incurred operating losses and negative cash flows from operations since inception. In light of these considerations, as well as the uncertainty as to when the Company might generate taxable income, the Company has recorded a full valuation allowance of $102,874, which represents an increase of $2,218 in the Company&#8217;s valuation allowance from December&#160;31, 2019 to December&#160;31, 2020. The amount of the net deferred tax asset considered realizable could be adjusted in the future if estimates of taxable income change or if objective negative evidence in no longer present and additional weight may be given to subjective evidence. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company has approximately $159,395 and $147,823, respectively, of federal net operating loss ("NOL") carryforward available to offset future federal taxable income.&nbsp;&nbsp;The Company also has approximately $157,743 and $139,336 of state NOL carryforwards as of December 31, 2020 and 2019, respectively, available to offset future state taxable income.&nbsp;&nbsp;All of the Company's tax years remain open to examination by federal and state taxing authorities.&nbsp;&nbsp;The Company's pre-2018 federal NOLs expire in 2037 whereas the Company's NOLs arising in 2018, and subsequent years, have an unlimited carryforward period. The Company's state NOLs begin to expire in 2037. Utilization of the net operating loss carryforwards may be subject to a substantial limitation due to ownership change limitations that may occur in the future, as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), as well as similar state provisions. These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section&#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company has federal tax credits of $1,603 and $837, respectively.&nbsp;&nbsp;These credits begin to expire in 2037.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969702994968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">16. FINANCIAL INSTRUMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company primarily applies the market approach to determine the fair value of financial instruments that are measured at fair value on a recurring basis. There were no changes to its valuation techniques used to determine the fair value of financial instruments during the year ended December&#160;31, 2020. The Company&#8217;s financial assets and liabilities which are measured at fair value on a recurring basis were comprised of cash, cash equivalents, and restricted cash of $229,381 and $25,207 as of December&#160;31, 2020 and 2019, respectively, based on Level&#160;1 inputs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of the warrant liability using the Black-Scholes option-pricing model at each balance sheet date or when specific events occur. As discussed in Note 13, in connection with the Company&#8217;s IPO the warrant fair value was updated on August 19, 2020 with the change in fair value recorded in current period earnings as other expense in the consolidated statement of operations and reclassified to equity. During the year ended December&#160;31, 2020, a loss of $3,109 was recorded in other expense in the consolidated statements of operations due to the change in the fair value of the warrant liability.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The range of assumptions used to determine the fair value of the warrant liability through August&#160;19, 2020 were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.2% - 68.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17% - 1.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 4.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969702942232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party Transactions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">17. RELATED-PARTY TRANSACTIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was party to a management agreement for professional services provided by a related party, Paragon. The related party is an entity that shares common ownership with the Company. In addition, the Chairman of the Company&#8217;s board of directors was the President and owner of the entity. For the year ended December&#160;31, 2020 and 2019, respectively, the Company incurred $7,384 and $5,378, respectively, in management fee expense and other expenses to this related party, which are included in general and administrative expense in the consolidated statements of operations and comprehensive loss. The Company terminated the Management Services Agreement upon the consummation of its IPO. The Company is<font style="Background-color:#FFFFFF;"> also party to a right of use agreement with the related party whereby it has access to and the right to use certain office space leased by the related party in Chicago, Illinois</font>. In addition, the Company had participated in certain transactions with separate related parties that also share common ownership with the Company, primarily related to combined employee health plans. As of December&#160;31, 2020 and 2019, respectively, the amounts due to related parties included in current liabilities were $0 and $1,208, respectively, and the amount included in other assets was $1 and $210, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703183544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">18. SUBSEQUENT EVENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 6, 2021, the Company paid the $100,000 milestone payment to Bioprojet for the FDA approval of the NDA for WAKIX for the treatment of cataplexy in adult patients with narcolepsy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January and F<font style="font-size:9pt;">e</font>bruary 2021, the board of directors granted to various employees 882,606 employee stock options to purchase the Company&#8217;s common stock.&nbsp;&nbsp;These awards were granted under the 2020 Plan and vest over a four-year period where 50% cliff vest after the second year and monthly thereafter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696719320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position<font style="Background-color:#FFFFFF;color:#000000;font-family:Arial;"> </font>for the periods presented. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock', window );">Significant Risks and Uncertainties</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Risks and Uncertainties</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of clinical testing and trial activities of the Company&#8217;s product candidates; the Company&#8217;s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#8217;s products, if approved; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates; and the Company&#8217;s ability to raise capital.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has one commercially approved product, WAKIX, and there can be no assurance that the Company&#8217;s research and development and clinical trials will result in any successfully commercialized products in addition to WAKIX. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.77%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the Consolidated Financial Statements, including the notes thereto, and elsewhere in this report.&nbsp;&nbsp;Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Segments</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds all its tangible assets, conducts its operations, and revenues are generated in the U.S. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Makers in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined it operates in a single operating segment and has one reportable segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.61%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:6.61%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements include cash, cash equivalents, accounts payable, and accrued liabilities, all of which are short term in nature and, accordingly, approximate fair value. Additionally, prior to the IPO, the Company&#8217;s consolidated financial statements included a warrant liability that was carried at fair value and was re-measured at each balance sheet date until it would be exercised or expired. In connection with the IPO, the Warrants were re-evaluated under the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480 <font style="font-style:italic;">Distinguishing Liabilities from Equity</font> and reclassified to equity. See Note 13 for a further discussion of the warrants.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is the Company&#8217;s policy, in general, to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment), which, if material, are disclosed in the accompanying footnotes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, <font style="font-style:italic;">Fair Value Measurements and Disclosures</font>. ASC&#160;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC&#160;820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:6.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in Money Market Funds. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in the statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of cash flows</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,381</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,207</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in restricted cash represent those amounts required to be held as a security deposit in the form of letters of credit for the Company&#8217;s credit card program and the fleet program. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its trade receivables related to its product sales.  The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of December&#160;31, 2020, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#8220;CVS Caremark&#8221;), which accounted for 44% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (&#8220;Pantherx&#8221;), which accounted for 23% of gross accounts receivable; and Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for 33% of gross accounts receivable.   </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 27% of gross product revenues. For the year ended December&#160;31, 2019 two customers accounted for 88% of gross product revenues, CVS Caremark accounted for 59% of gross product revenues and Pantherx accounted for 29% of gross product revenues.</p>
<p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable. </p>
<p style="margin-bottom:0pt;margin-top:1pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the&#160;first-in,&#160;first-out&#160;method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We capitalize inventory costs associated with our products prior to regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We did not capitalize preapproval inventory during 2019.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. The Company&#8217;s leasehold improvements primarily relate to its new corporate headquarters in Plymouth Meeting, PA, and are generally being amortized through the end of the lease term in May 2024. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations and comprehensive loss in the period realized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Asset</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January&#160;1, 2019, the Company adopted ASC 606,&#160;Revenue from Contracts with Customers (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company has determined that the delivery of its product to its customer constitutes a single performance obligation as there are no other promises to deliver goods or services. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore, no amount of consideration has been allocated as a financing component. Taxes collected related to product sales are remitted to governmental authorities and are excluded from revenue.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ProductSaleNetPolicyTextBlock', window );">Product Sales, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Sales, Net</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company began commercial sales of WAKIX&#160;in November 2019. The Company sells WAKIX&#160;to its customers (a limited number of specialty distributors) that, in turn, distribute WAKIX&#160;to patients.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue on sales of WAKIX&#160;when the customer obtains control of the product, which occurs at a point in time, typically upon delivery. Product revenues are recorded at the product&#8217;s wholesale acquisition costs, net of applicable reserves for variable consideration that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the sale of WAKIX. Components of variable consideration include government and commercial contracts, product returns, commercial&#160;co-payment&#160;assistance program transactions, and distribution services fees. These deductions are based on the amounts earned or to be claimed on the related sales and are classified as a current liability or reduction of receivables, based on expected value method and a range of outcomes and are probability weighted in accordance with ASC 606.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognition under contracts will not occur in a future period. The Company&#8217;s analyses contemplate the application of the constraint in accordance with ASC 606. Actual amounts of consideration ultimately received may differ from its estimates. If actual results in the future vary from its estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sold</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Product Sold </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sold includes manufacturing and distribution costs, the cost of drug substance, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs, and salaries of employees involved with production. The Company began capitalizing inventory upon FDA approval of WAKIX with a portion of the inventory sold during the year ended December&#160;31, 2020 produced prior to FDA approval and, therefore, was previously expensed as research and development expense in 2019 in the amount of $1,323. Excluded from cost of product sold shown and included in general and administrative on the consolidated statements of operations and comprehensive loss is amortization of acquired developed technology of $9,843 and $2,815 for the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and&#160;pre-FDA&#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Liabilities due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and&#160;pre-FDA&#160;approval milestone payments made for licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advertising Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expensed the costs of advertising, including promotional expenses, as incurred. Advertising expense was $13,301 and $7,072 a for the years ended December 31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes compensation expense relating to stock-based payment transactions in operating results using a fair value measurement method, in accordance with FASB ASC 718,&#160;Compensation-Stock Compensation. ASC&#160;718 requires all stock-based payments to employees to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The vesting periods have a time-based provision consisting of three to five years and expire no more than 10 years after the date of grant. Upon a change of control, certain unvested awards will immediately vest. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;1, 2019, the Company early adopted and accounts for stock-based payments granted to nonemployees in accordance with ASU&#160;2018-07,&#160;Compensation &#8211; Stock Compensation (ASC 718): Improvements to Nonemployee Share &#8211; Based Payment Accounting. The Company determines the fair value of the stock-based payment as the fair value of the equity instruments issued. It is measured on the grant date.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also had nonemployee stock awards subject to a performance condition that are recognized based on probable outcome. On November&#160;15, 2019 the Company modified the award to remove the performance condition resulting in $8,400 of noncash expense that is included in the Company&#8217;s consolidated results of operations for the year ended December&#160;31, 2019 (see Note 13 for further details).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect. The basic and diluted computations of net loss per share for the Company are the same because the effects of the Company&#8217;s convertible securities would be anti-dilutive (see Note&#160;14 for further detail).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets may be reduced by a valuation allowance if, based on all available evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Management judgment is required in determining the period in which a reversal of a valuation allowance should occur. The Company is required to consider all available evidence, both positive and negative, such as historical levels of income and future forecasts of taxable income among other items, in determining whether a full or partial release of its valuation allowance is required. The Company&#8217;s accounting for deferred tax consequences represents the best estimate of those future events. The Company presents deferred income taxes on the Consolidated Balance Sheet on a jurisdictional basis as either a net noncurrent asset or liability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#8217;s widely understood administrative practices and precedents. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which a change in judgment occurs. At December&#160;31, 2020 and 2019, the Company did not have any unrecognized uncertain tax positions. The Company&#8217;s policy is to include any interest and penalties as a component of income tax expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued amended guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities in the balance sheet and disclosing key information about leasing arrangements. The new guidance clarifies the criteria for distinguishing between a finance lease and operating lease, as well as classification between the two types of leases, which is substantially unchanged from the previous lease guidance. Further, the new guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a&#160;right-of-use&#160;asset, initially measured at the present value of the lease payments. For finance leases, a lessee should recognize interest on the lease liability separately from amortization of the&#160;right-of-use&#160;asset. For operating leases, a lessee should recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis. For leases with a term of 12&#160;months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and lease liabilities. The new standard will become effective for the Company&#8217;s fiscal year ending December&#160;31, 2022. The Company is currently assessing the impact of this amended guidance and the timing of adoption.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,&#160;<font style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font>. ASU&#160;No.&#160;2016-13&#160;introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for&#160;available-for-sale&#160;debt securities. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2022 for companies deemed to be small reporting companies as of November&#160;15, 2019, with early adoption permitted. The Company is currently evaluating the potential impact of adoption of this standard on its results of operations, financial position and cash flows and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,&#160;<font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting guidance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU No. 2020-04, <font style="font-style:italic;">Reference Rate Reform (Topic 848)</font>, which provides guidance related to reference rate reform. The pronouncement provides temporary optional expedients and exceptions to the current guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) and other interbank offered rates to alternative reference rates. The guidance was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are currently evaluating the impact of the transition from LIBOR to alternative reference rates but do not expect a significant impact to our consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_EmergingGrowthCompanyStatusPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ProductSaleNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product sale net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ProductSaleNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_SignificantRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703105688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that equal the amount reflected in the statements of cash flows.
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in the statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of cash flows</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,381</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,207</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969706629000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">941</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for obsolescence</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969780865112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Net Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects the future annual amortization expense for the unamortized intangible assets to be as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,845</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amount and Net Book Value of Intangible Asset</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The gross carrying amount and net book value of the intangible asset is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,657</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,815</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Book Value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,343</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,185</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703020408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payment</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties due to third parties</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,006</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rebates and other sales deductions</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,803</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,186</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,547</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees, consulting, and other services</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,081</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">746</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,727</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969780876936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Balances of OrbiMed Loan and CRG Loan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The balances of the OrbiMed Loan as of December 31, 2020 and the CRG Loan as of December 31, 2019 were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component - principal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,538</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exit fee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,750</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability component - net carrying value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,946</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Expense Related to OrbiMed Loan and CRG Loan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense related to the OrbiMed Loan and CRG Loan were included in interest expense, net in the Consolidated Statements of Operations as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on principal balance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on PIK</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of deferred financing costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Total term loan interest expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,615</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700447448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Lease Payment Obligations</a></td>
<td class="text">The following table sets forth the lease payment obligations as of December&#160;31, 2020, for the periods indicated below:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31,</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">892</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,635</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969780896856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Changes in Awards Granted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in awards granted under the Plan as of December&#160;31, 2020 and 2019, are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Awards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards outstanding&#8212;December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,375,218</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards issued</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035,400</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.54</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,947</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,545</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awards outstanding&#8212;December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,126</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.58</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Awards</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value the awards are summarized in the following table. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.00&#160;-&#160;95.80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.30&#160;-&#160;99.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32 - 0.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60 - 2.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00&#160;-&#160;20.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.00&#160;-&#160;31.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4 - 6.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was $5,190 and $9,909 for the years ended December&#160;31, 2020 and 2019, respectively, and was recorded in the consolidated statements of operations and comprehensive loss in the following line items: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,190</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,909</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfFutureCompensationExpenseTableTextBlock', window );">Summary of Future Compensation Expense</a></td>
<td class="text">The Company will recognize compensation expense for these awards as summarized in the following table.
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,046</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,915</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,949</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,003</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_SummaryOfFutureCompensationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of future compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_SummaryOfFutureCompensationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969788612968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Warrant Liability</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the changes in the warrant liability for the year ended December 31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, beginning of period</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair Value at Issuance</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value included in the statement of operations</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,468</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, end of period</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701217096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,944</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulation of dividends on preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,904</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss available to common shareholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,848</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187,208</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share - diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares of common stock - diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,772,419</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,777,441</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential common shares issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted-average shares outstanding as well as the warrant fair value adjustments excluded from the numerator are as follows: </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,126</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,271,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,891,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410,239</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,670,365</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,163,208</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for warrants</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701226104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Details of the provision for income taxes consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,416</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,198</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,641</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Difference Between Statutory Federal Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reasons for the difference between the statutory federal income tax rate and the Company&#8217;s effective income tax rate as of December&#160;31, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Company's Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019, are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired in-process research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,346</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,628</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforward</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,983</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,682</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disallowed interest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,751</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,661</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,116</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,242</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,823</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,874</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,656</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,874</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,656</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969707998664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Financial Instruments -Schedule of Range of Assumptions Used to Determine Fair Value of Warrant Liability</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The range of assumptions used to determine the fair value of the warrant liability through August&#160;19, 2020 were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.2% - 68.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17% - 1.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lack of marketability discount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 4.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969694714696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 21, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">410,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio, description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-8.215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock upon initial public offering, net of issuance costs, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,151,162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible stock to common stock, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,926,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,926,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock upon initial public offering, net of issuance costs, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,151,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 135,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock upon initial public offering, net of issuance costs, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock of Harmony Biosciences Holdings, Inc.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701348920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LiquidityAndCapitalResourcesLineItems', window );"><strong>Liquidity And Capital Resources [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 488,195<span></span>
</td>
<td class="nump">$ 422,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">228,631<span></span>
</td>
<td class="nump">24,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 135,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember', window );">OrbiMed Royalty &amp; Credit Opportunities, LP.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LiquidityAndCapitalResourcesLineItems', window );"><strong>Liquidity And Capital Resources [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Aggregate proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LiquidityAndCapitalResourcesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LiquidityAndCapitalResourcesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703281784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Product </div>
<div>Segment </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_NumberOfApprovedCommercialProducts', window );">Number of approved commercial products | Product</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful lives of the assets</a></td>
<td class="text">generally between three and ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_CapitalizedResearchAndDevelopmentExpense', window );">Capitalized research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,323,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired developed technology</a></td>
<td class="nump">$ 9,843,000<span></span>
</td>
<td class="nump">2,815,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 13,301,000<span></span>
</td>
<td class="nump">7,072,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant date expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Description of modification award</a></td>
<td class="text">On November 15, 2019 the Company modified the award to remove the performance condition<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Noncash expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Unrecognized uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Time-based vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Time-based vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions', window );">Recognized income tax positions</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_NumberOfMajorCustomers', window );">Number of customers | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_NumberOfMajorCustomers', window );">Number of customers | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_ThreeCustomersMember', window );">Three Customers | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_ThreeCustomersMember', window );">Three Customers | Product Revenues | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_TwoCustomersMember', window );">Two Customers | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_TwoCustomersMember', window );">Two Customers | Product Revenues | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_CaremarkLLCMember', window );">Caremark LLC | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_CaremarkLLCMember', window );">Caremark LLC | Product Revenues | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_PANTHERxSpecialtyPharmacyLLCMember', window );">PANTHERx Specialty Pharmacy LLC | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_PANTHERxSpecialtyPharmacyLLCMember', window );">PANTHERx Specialty Pharmacy LLC | Product Revenues | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_AccredoHealthGroupIncMember', window );">Accredo Health Group, Inc | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=hrmy_AccredoHealthGroupIncMember', window );">Accredo Health Group, Inc | Product Revenues | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_CapitalizedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_CapitalizedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_NumberOfApprovedCommercialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of approved commercial products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_NumberOfApprovedCommercialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized income tax position from current period tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_RecognizedIncomeTaxPositionFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hrmy_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hrmy_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hrmy_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hrmy_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hrmy_CaremarkLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hrmy_CaremarkLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hrmy_PANTHERxSpecialtyPharmacyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hrmy_PANTHERxSpecialtyPharmacyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hrmy_AccredoHealthGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hrmy_AccredoHealthGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969706544616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 228,631<span></span>
</td>
<td class="nump">$ 24,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statements of cash flows</a></td>
<td class="nump">$ 229,381<span></span>
</td>
<td class="nump">$ 25,207<span></span>
</td>
<td class="nump">$ 84,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696728392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for obsolescence</a></td>
<td class="num">(174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">$ 3,823<span></span>
</td>
<td class="nump">$ 1,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696813736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life of intangible asset</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember', window );">Upon FDA Approval of WAKIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember', window );">Upon FDA Approval of WAKIX | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementMilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementMilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hrmy_WAKIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969702900536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Asset - Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract', window );"><strong>Finite Lived Intangible Assets Net Amortization Expense Rolling Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2021</a></td>
<td class="nump">$ 18,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2022</a></td>
<td class="nump">18,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2023</a></td>
<td class="nump">18,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2024</a></td>
<td class="nump">18,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2025</a></td>
<td class="nump">18,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 92,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700411608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Asset - Schedule of Gross Carrying Amount and Net Book Value of Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Net Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12,657)<span></span>
</td>
<td class="num">(2,815)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="nump">$ 162,343<span></span>
</td>
<td class="nump">$ 72,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695913768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Aug. 14, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,738<span></span>
</td>
<td class="nump">$ 1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued Sales Based Trademark and Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedMilestonePaymentCurrent', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsDue', window );">License agreement, milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_PitolisantsMember', window );">Upon Acceptance by FDA of Pitolisant&#8217;s</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsDue', window );">License agreement, milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember', window );">Upon FDA Approval of WAKIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsDue', window );">License agreement, milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicensingAgreementMilestoneFees', window );">Licensing agreement milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember', window );">Upon FDA Approval of WAKIX | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sales-based, Trademark and Tiered Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember', window );">Bioprojet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedMilestonePaymentCurrent', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember', window );">Bioprojet | Upon FDA Approval of WAKIX | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember', window );">Bioprojet | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AmountOfAggregateNetSalesAttaining', window );">Amount of Aggregate Net Sales Attaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember', window );">Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementAdditionalMilestonePaymentsDue', window );">License agreement, additional milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccruedMilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccruedMilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AmountOfAggregateNetSalesAttaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate net sales attaining.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AmountOfAggregateNetSalesAttaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementAdditionalMilestonePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement additional milestone payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementAdditionalMilestonePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementMilestonePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments Due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementMilestonePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementMilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementMilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicensingAgreementMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing agreement milestone fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicensingAgreementMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hrmy_PitolisantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hrmy_PitolisantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hrmy_WAKIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hrmy_BioprojetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=hrmy_UponAchievementOfAggregateNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=hrmy_UponAchievementOfAggregateNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696398888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses -Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedMilestonePaymentCurrent', window );">Milestone payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties due to third parties</a></td>
<td class="nump">9,006<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent', window );">Rebates and other sales deductions</a></td>
<td class="nump">7,803<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Selling and marketing</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedProfessionalFeesConsultingAndOtherServices', window );">Professional fees, consulting, and other services</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_AccruedDebtIssuanceCostsCurrent', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 122,727<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccruedDebtIssuanceCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued debt issuance costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccruedDebtIssuanceCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccruedMilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccruedMilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccruedProfessionalFeesConsultingAndOtherServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued professional fees, consulting, and other services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccruedProfessionalFeesConsultingAndOtherServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued rebates and other sales deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccruedRebatesAndOtherSalesDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696128472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>Tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 21, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,639,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock upon exercise of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember', window );">OrbiMed Royalty &amp; Credit Opportunities, LP.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock upon exercise of warrants | shares</a></td>
<td class="nump">410,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants initial exercise price | $ / shares</a></td>
<td class="nump">$ 16.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 2,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember', window );">OrbiMed Royalty &amp; Credit Opportunities, LP. | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hrmy_MultiDrawLoanAgreementMember', window );">Multi-draw Loan Agreement | CRG Servicing LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DebtInstrumentNumberOfTranches', window );">Number of tranches | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Percentage of interest payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DebtInstrumentCompoundInterestRate', window );">Percentage of Compounded interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Cash proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,816,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Amortized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of loan, amount</a></td>
<td class="nump">120,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">22,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ExtinguishmentOfDebtExitFees', window );">Exit fee</a></td>
<td class="nump">18,047,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of the remaining unamortized debt issuance costs</a></td>
<td class="nump">4,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember', window );">Credit Agreement | CRG Servicing LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember', window );">Credit Agreement | OrbiMed Royalty &amp; Credit Opportunities, LP.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Cash proceeds received</a></td>
<td class="nump">$ 73,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Amortized issuance costs</a></td>
<td class="nump">$ 5,804,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of loan</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DebtInstrumentVariableInterestRate', window );">Variable interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DebtInstrumentExitFeePercentage', window );">Debt instrument exit fee percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DebtInstrumentCompoundInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument compound interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DebtInstrumentCompoundInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DebtInstrumentExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DebtInstrumentExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument number of tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DebtInstrumentVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument variable interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DebtInstrumentVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ExtinguishmentOfDebtExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of debt exit fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ExtinguishmentOfDebtExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hrmy_MultiDrawLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hrmy_MultiDrawLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_CRGServicingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_CRGServicingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696433736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Balances of OrbiMed Loan and CRG Loan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability component - net carrying value</a></td>
<td class="nump">$ 194,250<span></span>
</td>
<td class="nump">$ 97,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember', window );">Credit Agreement | OrbiMed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Liability component - principal</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DebtInstrumentExitFees', window );">Exit fee</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing', window );">Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing</a></td>
<td class="num">(19,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability component - net carrying value</a></td>
<td class="nump">$ 194,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember', window );">Credit Agreement | CRG Servicing LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Liability component - principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing', window );">Unamortized debt discount associated with the exit fee, debt financing costs and discount with warrant financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,592)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability component - net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DebtInstrumentExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DebtInstrumentExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized debt discount associated with exit fee, debt financing costs and discount with warrant financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_CRGServicingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_CRGServicingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695899816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense Related to OrbiMed Loan and CRG Loan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash paid-in-kind interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs amortization</a></td>
<td class="nump">$ 2,412<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember', window );">Credit Agreement | OrbiMed and CRG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest on principal balance</a></td>
<td class="nump">26,203<span></span>
</td>
<td class="nump">4,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash paid-in-kind interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs amortization</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total term loan interest expense</a></td>
<td class="nump">$ 28,615<span></span>
</td>
<td class="nump">$ 7,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hrmy_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPAndCRGServicingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695311336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 24, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement, amount | $</a></td>
<td class="nump">$ 3,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=hrmy_NorthbrookILMember', window );">Northbrook, IL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLeaseOfficeSpace', window );">Operating lease square feet of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLeaseExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=hrmy_PlymouthMeetingPAMember', window );">Plymouth Meeting, PA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLeaseOfficeSpace', window );">Operating lease square feet of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLeaseExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=hrmy_ChicagoILMember', window );">Chicago, IL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLeaseOfficeSpace', window );">Operating lease square feet of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLeaseExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_OperatingLeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_OperatingLeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_OperatingLeaseOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_OperatingLeaseOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=hrmy_NorthbrookILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=hrmy_NorthbrookILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=hrmy_PlymouthMeetingPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=hrmy_PlymouthMeetingPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=hrmy_ChicagoILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=hrmy_ChicagoILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703019368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Payment Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696185736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 09, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>Sep. 22, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">318,510,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 411,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">286,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">270,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 348,203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 270,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 12,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,510,205<span></span>
</td>
<td class="nump">25,510,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,510,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 51,051,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible stock to common stock, Shares</a></td>
<td class="nump">42,926,630<span></span>
</td>
<td class="nump">42,926,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock of Harmony Biosciences Holdings, Inc.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrmy_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969694741400">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 21, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th">
<div>Nov. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio, description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-8.215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-8.215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PreferredStockConversionRatio', window );">Preferred stock conversion ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote for each share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions', window );">Common stock number of shares subject to forfeiture provisions | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Noncash stock compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 4,693<span></span>
</td>
<td class="nump">$ 9,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares upon initial public offering | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,151,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares upon initial public offering | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,151,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 135,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses', window );">Underwriting discounts and commissions and offering expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares upon initial public offering | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock of Harmony Biosciences Holdings, Inc.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock number of shares subject to forfeiture provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_CommonStockNumberOfSharesSubjectToForfeitureProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PreferredStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PreferredStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_UnderwritingDiscountsAndCommissionsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695895096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ShareBasedCompensationExpenseIncome', window );">Stock-based compensation expense (income)</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average per share fair value of awards issued</a></td>
<td class="nump">$ 10.06<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 9,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hrmy_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hrmy_IncentiveAwardPlanTwoThousandTwentyMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember', window );">2017 and 2020 Plans | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_StockVestedDuringPeriodShares', window );">Stock vested</a></td>
<td class="nump">987,538<span></span>
</td>
<td class="nump">573,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ShareBasedCompensationExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense (income).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ShareBasedCompensationExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_StockVestedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock vested during period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_StockVestedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hrmy_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hrmy_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hrmy_IncentiveAwardPlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hrmy_IncentiveAwardPlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hrmy_TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701471768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation - Summary of Changes in Awards Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Awards, Awards outstanding, Beginning balance</a></td>
<td class="nump">2,375,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Awards, Awards issued</a></td>
<td class="nump">3,035,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Awards, Awards exercised</a></td>
<td class="num">(37,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Awards, Awards forfeited</a></td>
<td class="num">(112,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Awards, Awards outstanding, Ending balance</a></td>
<td class="nump">5,260,126<span></span>
</td>
<td class="nump">2,375,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Awards outstanding, Beginning balance</a></td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Awards issued</a></td>
<td class="nump">24.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Awards exercised</a></td>
<td class="nump">8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Awards forfeited</a></td>
<td class="nump">10.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Awards outstanding, Ending balance</a></td>
<td class="nump">$ 17.58<span></span>
</td>
<td class="nump">$ 8.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Balance</a></td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
<td class="text">8 years 3 months 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969703460440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation - Summary of Assumptions Used to Value Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">95.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">95.80%<span></span>
</td>
<td class="nump">99.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.32%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.56%<span></span>
</td>
<td class="nump">2.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount', window );">Lack of marketability discount</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount', window );">Lack of marketability discount</a></td>
<td class="nump">20.48%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions lack of marketability discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695886664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 9,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,901<span></span>
</td>
<td class="nump">$ 9,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969871013256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Incentive Plan and Stock-based Compensation - Summary of Future Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FutureShareBasedCompensationExpenseYearOne', window );">2021</a></td>
<td class="nump">$ 11,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FutureShareBasedCompensationExpenseYearTwo', window );">2022</a></td>
<td class="nump">10,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FutureShareBasedCompensationExpenseYearThree', window );">2023</a></td>
<td class="nump">9,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FutureShareBasedCompensationExpenseYearFour', window );">2024</a></td>
<td class="nump">8,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FutureShareBasedCompensationExpenseYearFive', window );">2025</a></td>
<td class="nump">$ 5,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FutureShareBasedCompensationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future share based compensation expense year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FutureShareBasedCompensationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FutureShareBasedCompensationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future share based compensation expense year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FutureShareBasedCompensationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FutureShareBasedCompensationExpenseYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future share based compensation expense year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FutureShareBasedCompensationExpenseYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FutureShareBasedCompensationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future share based compensation expense year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FutureShareBasedCompensationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FutureShareBasedCompensationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future share based compensation expense year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FutureShareBasedCompensationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969696820472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember', window );">OrbiMed Royalty &amp; Credit Opportunities, LP.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock upon exercise of warrants</a></td>
<td class="nump">410,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants initial exercise price</a></td>
<td class="nump">$ 16.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="nump">$ 3,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants | OrbiMed Royalty &amp; Credit Opportunities, LP.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of the Warrants</a></td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=hrmy_OrbiMedRoyaltyCreditOpportunitiesLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969702930248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Changes in Warrant (Details) - Warrants<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair Value at Issuance</a></td>
<td class="nump">$ 2,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value included in the statement of operations</a></td>
<td class="nump">3,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity', window );">Reclassification to equity</a></td>
<td class="num">$ (5,468)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969780964200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,944)<span></span>
</td>
<td class="num">$ (151,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Accumulation of dividends on preferred stock</a></td>
<td class="num">(26,904)<span></span>
</td>
<td class="num">(35,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (63,848)<span></span>
</td>
<td class="num">$ (187,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (24.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (2.48)<span></span>
</td>
<td class="num">$ (24.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares of common stock - basic</a></td>
<td class="nump">25,772,419<span></span>
</td>
<td class="nump">7,777,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares of common stock - diluted</a></td>
<td class="nump">25,772,419<span></span>
</td>
<td class="nump">7,777,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700495640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,670,365<span></span>
</td>
<td class="nump">39,163,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 3,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,891,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,260,126<span></span>
</td>
<td class="nump">2,271,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">410,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969700380168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (6,416)<span></span>
</td>
<td class="num">$ (32,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4,198<span></span>
</td>
<td class="num">(9,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_ValuationAllowanceIncomeTaxExpenseBenefit', window );">Valuation allowance</a></td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">42,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">$ (2,218)<span></span>
</td>
<td class="num">$ (42,149)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_ValuationAllowanceIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_ValuationAllowanceIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969780896856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(11.40%)<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(27.70%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969694713432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 45,346<span></span>
</td>
<td class="nump">$ 50,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">44,983<span></span>
</td>
<td class="nump">41,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">4,075<span></span>
</td>
<td class="nump">5,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credits</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DeferredTaxAssetsDisallowedInterest', window );">Disallowed interest</a></td>
<td class="nump">7,751<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">104,116<span></span>
</td>
<td class="nump">100,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance', window );">Net deferred tax asset</a></td>
<td class="nump">102,874<span></span>
</td>
<td class="nump">100,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(102,874)<span></span>
</td>
<td class="num">(100,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total</a></td>
<td class="nump">$ 1,242<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DeferredTaxAssetsDisallowedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets disallowed interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DeferredTaxAssetsDisallowedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities net before valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969694732232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 102,874<span></span>
</td>
<td class="nump">$ 100,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 2,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PercentageOfChangeInOwnership', window );">Percentage of change in ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_PeriodOfChangeInOwnership', window );">Period of change in ownership</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 159,395<span></span>
</td>
<td class="nump">$ 147,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLossCarryforwardsExpirationPeriod', window );">Operating loss carryforwards expiration period</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">2037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 1,603<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 157,743<span></span>
</td>
<td class="nump">$ 139,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_OperatingLossCarryforwardsExpirationPeriod', window );">Operating loss carryforwards expiration period</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">2037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_OperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_OperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PercentageOfChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PercentageOfChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_PeriodOfChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_PeriodOfChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969702985960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique', window );">Changes to valuation techniques</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 229,381<span></span>
</td>
<td class="nump">$ 25,207<span></span>
</td>
<td class="nump">$ 84,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 3,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether valuation technique or approach changed for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingChangeInValuationTechnique</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969704202664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Range of Assumptions Used to Determine Fair Value of Warrant Liability (Details)<br></strong></div></th>
<th class="th"><div>Aug. 19, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability, fair value measurement inputs</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability, fair value measurement inputs</a></td>
<td class="nump">54.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability, fair value measurement inputs</a></td>
<td class="nump">68.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability, fair value measurement inputs</a></td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability, fair value measurement inputs</a></td>
<td class="nump">1.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Lack of Marketability Discount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability, fair value measurement inputs</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969701701704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=hrmy_CurrentLiabilitiesMember', window );">Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties - current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Amounts due from related parties</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=hrmy_ManagementServicesAgreementMember', window );">Management Services Agreement | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Management fee expense and other expenses to related party</a></td>
<td class="nump">$ 7,384<span></span>
</td>
<td class="nump">$ 5,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=hrmy_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=hrmy_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=hrmy_ManagementServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=hrmy_ManagementServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139969695919976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock Option | 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Employee stock options to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember', window );">Upon FDA Approval of WAKIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember', window );">Upon FDA Approval of WAKIX | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember', window );">Bioprojet | Upon FDA Approval of WAKIX | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrmy_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrmy_LicenseAgreementMilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hrmy_LicenseAgreementMilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hrmy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hrmy_IncentiveAwardPlanTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hrmy_IncentiveAwardPlanTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hrmy_WAKIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hrmy_WAKIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hrmy_BioprojetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hrmy_BioprojetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$$6'!&P/XU;0(:;&T/ ?Z*^RK8B]W2#A=LN=3+C/K:H7F^8$0HB(8Q=NP'N
M#)Y4!T_" #)GRI#I=$IV=@ \">PN* \JJ\3.T?F#;7_2<QQ-?%LO9T<1Q=/B
MK&B4GI!TRN'90=,]L]V3)B%?@:ES?@&!K+*SF^S&R&UZFK&4QL@HO=QP!LZU
M ^#WE93F<&-?4)R@7?\#4$L#!!0    ( "1">5)6%W6R&P<  %H?   8
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M%*-Y-&$B'N.<9?S;D(]CW?YT,I^.1X/>8C@ U[UQ;](?@OGGX7 Q!Q_!W7P
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MQ+*!OCRQ:@ *\_-8+!H$LQ4UJU4<T:NXC\EP(LLZ:%4!325H4<DP1]5G(+4
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MDG=EM@^[^^XE@YT+(^AM&:[%7)7H5?'NV+WM;M[C>.%\WAZO[>B_2P!:E+3
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MP3X,V>7*M$2T[,%__L?%Z>GQLU\O+S_PCR?/'F9%C8FSJB]-1LME1?DGB8S
M5YN9<0[$)X!X[7EAVVR=8DKKXXNK9K4NZBV6/7GRS"7XKAMG>61Z>A^M^^)X
M[\_US+0=J;X.G/-I9"G2GBWO11-:0[IO^B?IHZQKLB*K^]74M !B3NS6M(Z
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M<9CC@L.B&[+-I7-($T@)&2EV-]XM'4D_*Y<H:$@GI5B"\N(OBT@$##RG#,F
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MR3YHO95W1ZI'JNR#CTWXF+-('?,C>E+ TIQY(7O0KWH) TI$AC/-DS!.*W*
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M?Y67Q,B*=XBO=[NT0L)[OR*3'I$N&0OA+ZJ"OKR9<7A+Y\*G#P<> S@CZWW
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M"L=L)">%OPN*MD7--(^39*+//*$E*P0B94*&X5D@R6[D*H+/\6DD-(J>\*)
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M;G)7?' L*.]X%-453]%4LZ>NW@Z<H>W1/Z2X6YB5O/(N$@+%#BO<"4?H$Q4
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M:!_@SI>(=F?X!-WK.?T)4$L#!!0    ( "1">5)A9Z>=-0,  -T&   9
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MH7%#6+'$E0S2..!Y(82^*"9!O^3GOP!02P,$%     @ )$)Y4CG "Q[T"
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MPOU8BBDV +@C;B?[A+EQQ51&LJ-(=IM\IO^MA$.IW+.,99XK[@/TV3>39U4
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M?3UN"]<\6)M!L//X2$QMP),S?I9XXY/C#5@OK V; 3O8_M=P^@]02P,$%
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MH*XQ-8!CW+&?O0B(E42TI8C"TZV2EOFC6ES)C$GC$<@K+/"I]D9WM*JULMH
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M7J+KP.T4*,\'H0MJ2S@K^>_"M+"NH'@<CK/5X3N_&;Q#>MU 7M@XI?:!(N>
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M6AI"FT;PC"+)/LDN: WMVI2$=E44(U\/&N^T^U*:2GH',4HBEX*OJ-43 "Y
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M7O;XV\"U E.O1Z][Q_&9)^X\BL7CX0)R[NQ9[PR0;F1'.69N0#K"U0&!X97
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MN (+&/1L(9O"Y8!;SK37QN8-)]YUX@P56FERRM1J2MV%G2( *L8G^F.Z !$
MC79&R2:R\_3B&F:IZ<]J0U.X34EDBBJ29&G:@FO&KR,X?5^Q4UV!,B[4R\Z@
ME\0'(>=MZA_@YUX1S$D%XO12H7=63U-\-GB1#>58EU4#^YXCX/L5Z0MKZF7Q
M[49R&U+>"Z/HPN$^=T[EH\Q),UA+5'DGCN+.I\[9$_<,Q7XTBC)DQ,YH&*6?
M8!?VQM&83&ZDN]]=6.1,B1SU#*7@D0"2?39+HM$>F5U0.S#+YN1]9L=5;&KM
M7X?C+.$7WD;W:R<AE&$T^MZ?I[_U1R_1+L.]Q4' ;'[N[6Q[-9HV-X)_S9M[
MU:6P2SH[0>&"7.-H?]0%V]Q5FH$W5;@?S(VGVT;X+.AZAY8-:'UAJ LW P[0
M7AB/_@%02P,$%     @ )$)Y4J*4DDNA P  ]P<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&ULK551C^(V$/XK5GKJ$T<@L(5> 8EEMRI2]PX!;555
M?3#)0*Q+[-0VF^7?]QL'LG#7VZ>^)/9XYIMOQC/C26WL9Y<3>?%2%MI-H]S[
MZD,<NS2G4KJNJ4CC9&]L*3VV]A"[RI+,@E%9Q$FO]T-<2J6CV23(5G8V,4=?
M*$TK*]RQ+*4]W5-AZFG4CRZ"M3KDG@7Q;%+) VW(_U:M+'9QBY*IDK131@M+
M^VDT[W^X'[)^4/A=4>VNUH(CV1GSF3?+;!KUF! 5E'I&D/@]TX**@H% XY\S
M9M2Z9,/K]07]YQ [8ME)1PM3_*$RGT^C<20RVLMCX=>F_H7.\=PQ7FH*%[ZB
M;G0'4$Z/SIOR; P&I=+-7[Z<\W!E,.Y]PR Y&R2!=^,HL'R07LXFUM3"LC;0
M>!%"#=8@IS1?RL9;G"K8^=F:"NDI>U])ZT]B:Z5V,N3+36(/?-:*TS/6?8.5
M? .KGX@GHWWNQ*/.*+L%B$&L99=<V-TG;R(^4-H5@WY')+VD]P;>H(UV$/ &
M;T<K5E]%*_Z:[YRWV/W]AI]AZV<8_ S_EZR^C=4?=<7Z\=?Y]O'A_6J^WOXI
MMNOYQ\U\L5U^^K@1VYS$PI25U"=12R<:E]X(B3+1Z"MTD!?R8*E9H8]%9<V>
M'/>5+(0C^ZQ2<BQ]5K@WL3O!V)Y3%? ZG#%Y,+H;_-V<">6$U +8BAWGT@N7
M2PO U)0E&L_4FJS+5872]CDT6L)=L41?9IGBU'2:DUPJ-!NL]M>:WW\W3OJC
MGYS8&6DS/LR416,;ZT+4K+J"3_#G:'76>+V@-.2Z HT<]B>2%D(.%B5&Y0ZJ
MES(+UDFO_V,'<;J*PM@H3IUK.D+I]&@MS-^-.H/Q,-B\N^L,1N,OK92^OH<]
M@<P+)JJCAB5 [47B^-I\CGQ^D?PZ5VDND%/V6QR9-F /A AQ@8PC,\P&Q07,
M?EL7T&+6*0K/%"H+F,[CQV0<9P?3G6VX Q@'5X;9GO/0!4QAG.O>5)@G"T<!
MAX&?7B/;7,IHWI;:L3*O_GGHASD,IPJ^EZM/M]!<1H4SUP5L>:2RP9'3U>*V
M971;AS522:A=Y46.DI IV(24<F!!/<!!P' I68\W"^A[T!:NDO@6A $?&N!K
M>.@N< _H@HY8%NA2H]Q_C8KX:AB79 _AR>%F.&K?S.56VKYJ\V:8OZHW3^*3
MM >%FREH#]->=W07-4%<-MY48;3OC,=#$98Y7F:RK(#SO3'^LF$'[5L_^Q=0
M2P,$%     @ )$)Y4M,[$A)V @  .P4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&ULI51M3]LP$/XKIV@?49.FA3'41FJA:&R",3I@TK0/;G)M/!([
MV)>&_ON=G39TTJ@F[8OC>WO\G'./1XTV3S9')'@I"V7'04Y4G86A37,LA>WI
M"A5'EMJ4@M@TJ]!6!D7FB\HBC*/H)"R%5$$R\KY;DXQT3854>&O UF4IS&:*
MA6[&03_8.>[D*B?G")-1)58X1[JO;@U;88>2R1*5E5J!P>4XF/3/ID.7[Q,>
M)#9V;P^NDX763\ZXRL9!Y AA@2DY!,&?-9YC43@@IO&\Q0RZ(UWA_GZ'?NE[
MYUX6PN*Y+AYE1ODX. T@PZ6H"[K3S4?<]G/L\%)=6+]"T^;&'P)(:TNZW!8S
M@U*J]BM>MO>P5W :O5$0;PMBS[L]R+.\$"22D=$-&)?-:&[C6_753$XJ]U/F
M9#@JN8Z2>;VP^%RC(IBM>;6CD!C6!<-T"S%M(>(W(/HQ7&M%N869RC#[$R!D
M/AVI>$=J&A]$O,"T!X/^$<11'!W &W1-#CS>X%^;A!^3A27#(_'S /RP@Q]Z
M^.'_W.%!"">],UN)%,<!:\NB66.0]$][,+^?SF=?[V<WWV#VP.L<OBCX)%3-
M"H(3?T-\3Y0CG.NR$FH#E9"9=[SK1]%1%$4\-@7R("GDV*9T-$G#5.K*Z%\L
M>U:VS[^\F("HV+D6!>BE]]VPS\4?)Y^OOG>9Q/(G#\1I*8]=5>#+!B2++&,U
M\#$D_34WDG)0PO"48F4W/;AZ)2]4!I> \+<?$.X-=(EFY65K(=6UHG:V.V_W
M,DQ:0;RFM\_*M3 KJ2P4N.32J/?^. #32K4U2%=>'@M-+#:_S?EU0^,2.+[4
MFG:&.Z![+Y/?4$L#!!0    ( "1">5)OVPPVZ2(   !T   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;.U=6X_;QI)^]Z\@O-F%#7#DD68<C^,DP'AL
MG_AL+H8GEP46^T")+8DQ12IL4F.=7[_U555?*%$<^^0LL ]Y2#P2V=W5U76_
MM+Z^JYL/=FU,FWS<E)7]YN&Z;;=?/7EB%VNSR>RDWIJ*GBSK9I.U]+%9/;';
MQF0Y#]J43V;GYU\^V61%]?#;K_F[=\VW7]==6Q:5>=<DMMMLLF;_TI3UW3</
MIP_=%^^+U;K%%T^^_7J;K<RM:7_9OFOHTQ,_2UYL3&6+NDH:L_SFX?7TJY>S
M"PS@-WXMS)V-_DZPE7E=?\"'M_DW#\\!D2G-HL44&?VS,S>F+#$3P?&'3OK0
MKXF!\=]N]C>\>=K,/+/FIBY_*_)V_<W#JX=);I995[;OZ[OOC&[H*>9;U*7E
M_R=W\N[3RX?)HK-MO='!!,&FJ.3?[*,B(AIP=7YBP$P'S!AN68BA?)6UV;=?
M-_5=TN!MF@U_\%9Y- %75#B5V[:AIP6-:[^]E=-(ZF5R6ZRJ8EDLLJI-KA>+
MNJO:HEHE[^JR6!3&)H_<7X^_?M+2TIC@R4*7>2G+S$XL,YTE/]15N[;)ZRHW
M>7^")P2S!WSF '\Y&YWQE5E,DHMIFLS.9^<C\UUX1%SP?!<GYAO:\7]?SVW;
M$.'\S\@"EWZ!2U[@\L0"+S-;6.#Y76.LJ=H,5#F$R=%IP*5?V6VV,-\\W&*B
M9F<>#L^=_+PVR:*N+&TGSUJ3)\NBRJI%D96)I5<,,5=KDW6V,\G<F"JA^;99
M0^\5%<:!Y8MV3P39KHE[/'JV34&3;$M"T,I4ILG*<H_G9MO*V);6_:4J\.D6
MZS!DUQO3$&TEC_[CWZYFL_,7?[N^?L=_3E\\3K(* Q=EEYN$IDNR_'<B?8&O
M,@MC+6B4 .*YEUG1)-MXIS0_'MS4FVU6[3'M]-D+&^UW6]N"WQPYR*?^()^.
M'F3,)^\+^\$R^+]4"].T) 9;HIRA8_W3D_)Y'FZ1Q'/#.* !C2'A.O^=Y%W2
MUDF65-UF;AH@9TDT7#>6D)2U":V19,LE7BM:/P,=+&&49)FL'%!'E) S[B;)
M;;=8^[GTO-)DWK6\=E6W25EL^-S;.N43<5,2# O:,NVO3(@@>#DLTS98@D5S
MP7L\<9+;ILZ[!<.>,S';%X/O9?.B!,W2_NLY$$<0K+HR(XB)1K<TS0X0U"1"
MFP]&$*!STXP+FLVT0BC+IM[X1_1ZU6'C'=@#@!-3Y0G1X]Q@*[G9D7[;TK,Y
MB5("K.&YLJIP@!+3+ SM+N71.:E6(+ENTK'MVC0IE@JVR>_=<656=5L0<NB,
M=G63S4M#![* "B48"5B!+.S%G8(@@S^M&J-R =P6H:>'>CZZ<6":K+ D?K)M
MT6;E)*9=4FM-0TN0U%AG=.(5I-2&Q /(K=S[_;J5T^2WZ_]\^U^I6[4Q3,)S
M4%R26=LU1*E&:'L(* B*K"'*%<SS26&+_#E0)2C1DK C\2-4"U$&<&VW@ 1:
M=@ N0%K\(X!H^=U<^ 2[9X@GR2M9S>$Y'LS?>>0VYH^NH&43&\F!ELP?&2=8
M%#%I8R:/J+LQ.QA!>,<3.J'WSI3\[Q%M"S',B[HUBW55E_5JSX.WZXRLG87I
M6L:+I^/^&8K4,++Q*C'5KFCJBM%*+-P0P 3V.JM6QD&=&[(D<[S0;6M1$B1:
MB.HZPB/T&%$J\S^(SFRV9;TWQBK>*AQ(5JEP$M9V6*6]MK#QZ",)2MHN?>@@
M\QL V>XG(S+_2R_SOQP5S[]8,&_RFB37!ML>$O"?-P-C4S2NUV&#^GE &4-W
M!I(A?B;[F5'/@NV#28Q?A<F!>&2S%27!7*+27P3TMFX@L;,-]+L,R N[*&MB
M+#E?8:K(CGCCX;SU<*:J$' ,&$#:P%AA5R@#3&M*:^Z8?WG2PNKJDP,]UY@R
M$R7",VTR8HF630/ U@5\W?STZ]M79]/G(D3-QU9Q<+<NB-V+5KBY((JEW=9=
MX_%"HK>#+(\PKIHJA1=1YF2$8^%%4QM"?KTI%D$/VFBG(#@:20P,;*=*MWP6
M^@W3+G%]8D'^CF;7)BOI((O*2:\%2;R&CE&V0N\2C*H+B>S)'-TRV(WA%X53
M5_B3>4YEP[PC24^BBE[+%GK>@D/B6=(YM NV]@A^>L.:7+F0@#8?05VT8AY$
M%CVT$2T=GO B:YH];TA)AT:7=;4Z*PM(;Z(Z WPZ74&H(G%00"GQHPDY&<RG
MSD;89'NB/"+-)I:")'-%7$7'UP.%9%OF)'9$$V-<_\QS_;-1GOW)FT:W9L54
M/L3WGSM'3XZNR8ZP;/-"[/4Q)-2C^J6-;3W!*DE\0])3+#\QQ6,+?'([2<+J
MUJV.E\EM)3!SIQ=(!>OYL2AO00I0_\)'5F14S"Q%)?$ \"&Q<;;+BI+-#3EL
M$C',W-!-3>E4DUA'+$S6A5E&L)$O5[";_P,)+S8M"<)%P<>[IB.#-5N6]0)
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MHLC=UM1S<-_ZFR .-A\;:PIPXT,-:N#!PG4[B"(P]^3;0C_^=+R9_EZZ'E1
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M)CJQDS?FQOB/-N"K"OM@1^QX.<".X]P86@-G][7W,0ERTGF0ZSY]>*(?6O[
M]:R]9LMPH56H;PRY(S$24.>N=$G3G+S3J"_"_274XEUB(&0BZ1[#@?:LE4BT
M9%GJJ-"QGU@<N%1L\$9%KD>0>PZ'P?/]G5'!":":<W<;)R>]/<RTQB, MK\9
MI-G3KM2:_524>%TJ\LM4F100L,$55YXB<R,9J>RCWEK$)Z?L+0;MP4T+2/V0
M[=;L>^AS3G:O*XV+:,6C)EA1_:1%R9(UX13T_3OB6@^UF@$8O:G7 -H#YZ(/
MO7H$HCU[\A3XX$,5\V((K9KDXRRFX8N:LF3G[GSB\HT[%GS%,DIH\O7H_KY%
M=_U7JOD]]A7*X@,,>789(-D8.LO"WV4!FOB2%(^@PO-4J#S7-%[4 =B[H\.U
M( JB-,S-]S>*@G.Z[3#:DX5T(^-^:-]VS<**,XA'5VW$5^?X1M%3R&''0LJ9
MM;&U,BL.^0>%%?D=)4)#5A5.K9<PAW 2"6&-;!R0-+$MG#JI!2 :EKK2&!5W
M:\-/D0S% 302"N1,HG1G:,76(!W$#:R#V=-P Q_$5(_P>T(JNGL&AS.'PQ/W
MY H7NN;0W7%UB1\^0#N2+A.=%!F++[7OXY;[/MA-_9VTDLVE>Y)0($T'N-2N
M4"1!/\)251_0]^-X27ZRYJ6-1, R)FQ7U&XE4UZXS8;O6;H-\9'M+%QHZ?<7
MAD1S-[HNI/B8HZ%,0?BQ@S9<7AVRS;X;E6B,[_C./K)PUPJJ<):X@1A%--!C
M1)CU4:YJBT2[! \EA$LR1 [J?2RP!C;>$]^NHYZ[G-M>!70!W])D$FH@'#P]
M_W>'$]J&]!P%H7 CG=L29PV% 71:<<!(M.E!1\^Q< BBV L8J3GBHM2QJ%YL
M.[E^6C75@,U(F'?NTND^>H99J]?Y[W^J J+(!0SX%$CL2Q99N_M=F6"?!M7I
M&C6J0I?A;+PY\#71V@I'\3<:BK8 W?PM]T,/FEE_9L*C*X^JQ+@!*QF@]TER
M+-?=-*PG_?=NLR4F:EJ^3N&ENZ_Z%E]U6XMB#>"*CG*6/.(!/[V\Q;>/73]
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MUZ@W'@7,-$.J$5"7?C!L-=*8\=N<YCH89T#GF=9X$!Q ^T\Q_PM02P,$%
M  @ )$)Y4NAJ3IJ/ @  504  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&ULA51-;]LP#+WK5PC>,+1 4'\V<;HD0-*N6 \=BK1;#\,.BLW80F4IDY2D
M_?>CY,3-AC:[6"+%]_@HDQIME7XR-8"ESXV09AS4UJXNPM 4-33,G*D52#Q9
M*MTPBZ:N0K/2P$H/:D281%$_;!B7P63D?7=Z,E)K*[B$.TW-NFF8?IF!4-MQ
M$ =[QYQ7M76.<#):L0KNP7Y?W6FTPHZEY U(PY6D&I;C8!I?S#(7[P-^<-B:
M@SUUE2R4>G+&33D.(B<(!!36,3!<-G )0C@BE/%[QQET*1WP<+]GO_:U8RT+
M9N!2B4=>VGH<Y $M8<G6PL[5]BOLZCEW?(42QG_IMHU-DX 6:V-5LP.C@H;+
M=F7/NWLX .31.X!D!TB\[C:15WG%+)N,M-I2[:*1S6U\J1Z-XKAT/^7>:CSE
MB+.3&[D!:95^H2</;"' G(Y"B[SN-"QV'+.6(WF'(T[HK9*V-O2++*'\FR!$
M09VJ9*]JEAQEO(+BC*9QCR91$AWA2[LJ4\^7_K?**VX*H<Q: _TY71BKL2U^
M'<F0=1DRGR%[)\,]3DNY%D#5DKYF^P;VK>L\3M7!>U3B5!8*)\!8*!VUK8$N
ME<!1XK*Z(%.#3H*W!<T"='=C_WKB(9FS+;:-!<V9,.0C28=]]\TS\HA30[FD
M*ZT*,(8DO7X_(ED\(-=<<NRLDE9*E88,LY@D^8 <Z*NT0D3:&PX').Y%>4[F
M8$!OG$A-U<(H[*@"9 'D)!YDY)1\^I G<?*9/"C+!*8]+-4)ZN5)BJLG>^NW
MA >MWH"N_$ ;O*2UM&W7=][NS9BVH_(:WCXXMTQ77!HJ8(G0Z&QP'E#=#G%K
M6+7R@[-0%L?0;VM\]T"[ #Q?*F7WADO0O:23/U!+ P04    "  D0GE2V$BE
M?P@#   P!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R-54U/XS 0
MO>=76-$>0*K(1YM24%NI+;#+@17B:[5:[<%-IHF%8W=MA\+^^AT[:0ALJ;BT
M8V?FS9MY]GB\D>I1%P"&/)=<Z(E?&+,^#0*=%E!2?237(/#+2JJ2&ERJ/-!K
M!31S024/XC <!B5EPI^.W=ZUFHYE93@3<*V(KLJ2JI<Y<+F9^)&_W;AA>6'L
M1C =KVD.MV#NU]<*5T&+DK$2A&92$ 6KB3^+3N>)]7<.#PPVNF,36\E2RD>[
MN,PF?F@) 8?46 2*?T^P ,XM$-+XTV#Z;4H;V+6WZ!>N=JQE234L)/_!,E-,
M_)%/,EC1BIL;N?D&33V.8"JY=K]DT_B&/DDK;639!".#DHGZGSXW??A,0-P$
MQ(YWG<BQ/*.&3L=*;HBRWHAF#5>JBT9R3%A1;HW"KPSCS/12&"IRMN1 9EKC
M(3BXH[@X' <&T:U/D#9(\QHI_@ IBLF5%*;0Y%QDD+T%")!6RRW><IO'>Q'/
M(#TB_:A'XC .]^#UVUK[#J__R5HU^8X%GS^GO,J8R,E7*;,-XYS\FBVU47A@
M?N_).FBS#ES6P0=9;_$>917FE"O,M<;3"!FYJ$RED(80%>5D5DIEV%_JSJGU
M$1H(7CAR+VC]"4/^8[]+HOU4[@H@"UFNJ7@AX*AH8G!O5;.A-1O:90,=-M:U
MZC!BKXQHW4\CR=(NT)WC==>GWD^@2A,0KL$H*)1+4%94#T6-O"]>-.HEPQ.[
MBCMVOV,/.G:RM>^DH1S#3^+>:)#LD2EI94H^+=-7);4F"ZK4BZ6-\E3"8'LR
M=V#F.&+( ^65\WTORRY5]F>VJN0N8[K-2%\S"LQHAQIYVF:T,KQO/6'Z3=MG
M&CV];K_=)7J_$YUX.VNUNAPGO3 ,T6J,69I69<6I/;[= ^L=1'%OF!Q[A]X!
MBA$E:+QMDT4;QKW^H&_1XEXTVBE8T)EB):C<S6ILBB54#[1VMWT.9O44?'6O
MWY(KJG(F-.&PPM#PZ!@54/5\KA=&KMU,7$J#$]:9!3YIH*P#?E]):;8+FZ!]
M)*?_ %!+ P04    "  D0GE20?'Z1N<"  #Q!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q]5,ENVS 0O?,K"+4H6D"(-B]R:AMPEJ(]!#7L+H>B
M!TH:640HT26I./[[#BE;=8/8%XD<OGGS9LB9Z4ZJ1UT!&/I<BT;/O,J8[740
MZ+R"FNDKN84&3TJI:F9PJS:!WBI@A7.J11"'X2BH&6^\^=39EFH^E:T1O(&E
MHKJM:Z;V-R#D;N9%WM&PXIO*6$,PGV[9!M9@OF^7"G=!SU+P&AK-94,5E#-O
M$5W?#"S> 7YPV.F3-;699%(^VLV78N:%5A (R(UE8/A[@EL0PA*AC#\'3J\/
M:1U/UT?V3RYWS"5C&FZE^,D+4\V\U*,%E*P59B5WG^&0S]#RY5)H]Z6[#ILD
M'LU;;61]<$8%-6^Z/WL^U.'$(0W/.,0'A]CI[@(YE7?,L/E4R1U5%HUL=N%2
M==XHCC?V4M9&X2E'/S-?Y+EJH:#WSWC-&C1]_XUE O2':6"0WH*"_$!UTU'%
M9ZBBF#[(QE2:WC<%%/\3!*BK%Q<?Q=W$%QGO(+^B2>33.(S#"WQ)GVSB^)(S
M?$NV=\G115-0ESD3FOY:9-HH?!Z_+X08]"$&+L3@3(@U=DW1"J"RI"]K^UI)
M+[,=&>!X.[G$=M#&LIL*:"D%=A5O-M=DH=%(L&)09Z#ZJKVT1!/RP+$$1C9
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M7HV''E7=@.DV1FY=4V?2X(APRPIG,B@+P/-22G/<V #]E)__!5!+ P04
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MJV;Q)(8"2[Z5[EKOWF-7S]CSY5K:\(5=&SMF,>1;ZW3=@2F#6JAVY7=='PX
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MQ@?0>:FUVV^\0/^NSO\ 4$L#!!0    ( "1">5+C^[CV_ 0  /(+   9
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M\E1>NDO"-)I1B68%ELF&+3;"E):]-Z)QWP>PB]=AU#THT4&M.BC68D8,<]7
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M:W-H965T<R]S:&5E=#,T+GAM;)U6VV[C-A!]UU<0;E%D 6UTM66GC@'G4K1
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M0-D-N+Z16+*=8 T,3['%/U!+ P04    "  D0GE2$!(6XX<$  "L"P  &0
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ME!7 \Z64IEY8 TV#/OT/4$L#!!0    ( "1">5*S[M=YL (  ,8%   9
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M4J/NQ2  74V-RK!J[3MUH2SUO5_F-&A1NP#:SY2RC>$(VM$]_@502P,$%
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MD)-D1#S/L4O0A7:GGKQ^1YDWUCLT2M5D,#DYG*$8+N]NV]A6/00[GQO653/
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M[,.@G0'NKY2RSQ,7H.[LX]]02P,$%     @ )$)Y4NDKY*)Y!@  Z"(  !D
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MQC]\MDWH,$PVXA^M\(_\^+,Y[A6N[7[=G+V344OVHB!\#G/T#.8@&-"-,,/
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M8!DH^P!^?RNE>;BP#E8OMQS]#U!+ P04    "  D0GE2NHA'**4"  #G!@
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MF%JQA7)8X0U5CWSW#=IZQB9?QJFLGVC7Q$:^A;*-5+QLP5I!25CSQF^M#WL
M-S@"\%J ]U6 WP+\NM!&65W6'"N<)H+OD##1.IL9U-[4:%T-8>8K+I30NT3C
M5'K/ML 4%^_H"BUTB^0;"HBOT+_U'[J5SN>@,*'R0D<]+^;H_.P"G2'"T%/!
M-Q*S7":VTFI,3CMKF6\;9N\(\QRR$?+=2^0YGC, GWT9[DX^PVWM06>$UQGA
MU?G\_QHQ)S*C7&X$H%\W2ZF$;K7?)QC\CL&O&8(C#(]XI[^< D$P'?2K@8<U
MW/Q]V]2?A(F]W3=E("8.NIA/NH).5W!2UXO^S\RWK 3/0 XJ:Q*,]UB],'0.
MI/6# C<:EC;NI(U/2KLCC.C>SM&:\^$>&_=()X%[(*P?X\5'A(6=L/"DL*Y;
M+M%:\&'3PAZM/YE$!]KZ0:X3Q\/BHDY<=+K10(+8 M)G/.)+R2G(#%@&0R*C
M'O^5&QUIJ+CCCT_R/W&%J>ZHSB(&:H@['NAESS\PJ!\T8)"]=P":R^<[%FO"
M)**PTC!G%.D"17.@-Q/%J_I,7'*E3]AZ6.@[$(0)T/LKSM7'Q!RSW:V:_@50
M2P,$%     @ )$)Y4F ]5&-# P  #@L  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&ULO59M3]LP$/XK5K0/(&WDI6\4M95:2K5NL"$88]*T#VYR3:TY
M=F8[+4C[\3LG:2B09B_2^)+8SCW/W3TYVS?82/5=KP ,N4NXT$-G94QZXKHZ
M7$%"]9%,0>"7I50)-3A5L:M3!33*00EW \_KN@EEPAD-\K5+-1K(S' FX%(1
MG24)5?<3X'(S='QGNW#%XI6Q"^YHD-(8KL'<I)<*9V[%$K$$A&92$ 7+H3/V
M3V9^8 &YQ6<&&[TS)C:5A93?[60>#1W/1@0<0F,I*+[6< J<6R:,XT=)ZE0^
M+7!WO&6?Y<EC,@NJX53R6Q:9U= Y=D@$2YIQ<R4W;Z%,J&/Y0LEU_B2;PK;7
M<TB8:2.3$HP1)$P4;WI7"K$#0)YZ0% "@J> ]AY JP2T_A30+@'M/P5T2D#G
M*:"[!] M =U<^T*L7.DI-70T4')#E+5&-CO(?U>.1H&9L)5U;11^98@SH[DP
M5,1LP8&,M<9*?D/&4<3L7Z><S$51N[8&#J9@*./Z$$UNKJ?DX-4A>468()]6
M,M-41'K@&HS(\KIAZ7U2> _V>/?)A11FI<F9B""JP<]^@P\:"%R4HM(CV.HQ
M"1H9WU%Q1%K^:Q)X@5\3T&DS_&-H*KA7 Y\VPS_(-<(]"_?[-?"S9O@XB[?>
M:^&S9O@4PGW!/]*R5=56*^=K[>&;,<$,D',\.B+RM- T^7J.]F1N(-'?&KRU
M*V_MW%M[C[=S%N*!!X3&"@#//H/;A0-N('22TGN[HG' ZLIL6E!W<VI[&*]'
MO8[GH0CK7?6?6P6[1H_"[E1A=QK#OM&PS#CA; E$+G$_53)1*U/=GFHF[)-[
MH*IN,\Z:@;Y7AWR45+=*JMM(=07V4F,B)ME#>G41-=/4IO(HH%X54*]9Y11/
ML-ET3,9IJN0:CS;4^G;\?OZE@?RX(C]^@3KO5][Z_ZW.3_M_4<&^]W"'>/^H
M+OE)KK.%AA^9#?1LC<\&"?R=6\M_ <G]X,%?\-]$GY3<NZK[GO=<=W?G&D]
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MB O.1VA7U=.M#HPLW4192H/SR2US_"" L@EXOI;2O 1V2+6?F/0/4$L#!!0
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MQ@#/9T+H]<8,(/7 .?H%4$L#!!0    ( "1">5(]??\T%@,  "@)   9
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M#<66+Y6%KK_)IET;>"1=:R/+%HP*2BZ:7_;0)F('$-(>0-@"PF< .NP!#%K
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MDUCG*KKWH9LHWMB>W'&E.]P.*_VD@C ']'[!N3I,3)L/CW3Z!U!+ P04
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MV3CNQ'H[7;:Z)1H[=O976%:J&!15#"ZM N#MEI$M%@3@F!X2H2LA]SX\26P
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M<,<SK3[3(HW_2$6IZ" U<S7%8=BX<<UY57$.7N'L!_!5<)TJ^(4GF/P(X)(
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MC?S4R?/U94V; P7I6104R(+KW6>S9GBY*=O,N-G2])0;-ZZ?^HG33K>QT_V
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M[=@C^X%F?U6Z8W+!Z?Q<X)PH0_^*LDSN;Q_[AA9K>X!_$IJN _9Q23<VE&8
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M;"]W;W)K<VAE971S+W-H965T-C$N>&ULK59=C]HZ$/TK5M2'5FK))PE4@+1
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M<4[J> (_#HS<5H?8I31X)*YN-_C5 LH:X/N5E.8\L.?B^CMH^A]02P,$%
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MB$3M!.C]2BG[L' &FK%T_A]02P,$%     @ )$)Y4OY3*RB? @  U@8  !D
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M#5_.J;1/U/:QGH/R1BI>]V"MH":L>^/7_ASV 'Y\!!#T@. ](#H""'M ^%E
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MZ2YEAY7^\8 P 7J_Y%SM)B;!\"M+_P)02P,$%     @ )$)Y4N[/.*J8 P
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M*A%<DEMEG2FPX,Z2#^01Y4\+"43/R)2K>1A<6A0O]]6TY*N%E#A-KL&!06)
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M:THU'?:EV!)IK!'-+&QLK#>J8=RD<:XE/F7HIX?WD%(-\?F:2OU"'B3EBMH
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M3V)[F>"?%TAC@,\W0NB7A?DN;O[EYG\#4$L#!!0    ( "1">5*"J:ZF+ ,
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M(XY@#L #AD11M0\>[$?A;I\*VU^ZIK\!4$L#!!0    ( "1">5*7BKL<P
M !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6
MH@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.
MD4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,
M<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW'
M]I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ )$)Y
M4L;5#!AV!0  *BX   \   !X;"]W;W)K8F]O:RYX;6S%FDMSXC@0@/^*BLMF
M#UG K\RD0JJ80'92E0E43&6/*6$+4,6V&,GD]>NG;6"F3:!K+QU.Q+9B?VY;
M^EHM7[P8^S0UYDF\YEGA>JU%62[/VVV7+%0NW3]FJ0HX,C,VER5LVGG;+:V2
MJ5LH5>99V^MTHG8N==&ZO-B>:VS;>,.4*BFU*6!GM>-!JQ?WYWBU*9ZUTU.=
MZ?*MUZK_SE1+Y+K0N7Y7::_5:0FW,"_?C=7OIBAE%B?69%FOU5T?>%"VU,F'
MW7$%.9%35^\IY?1> DBO%77@A#-M75FWJ,\O@?%90>/UUJHTUSHKE1W(4OUK
MS6JIBWEU&KB+-KJ-.@[;WW40S^W_":.9S72B!B99Y:HHUW&T*JL "[?02]<2
MA<Q5K[5M(F21BF%10I#$3;$^%;2M[A0N?9.N[[H$7!1#>Z[A@+U):W ^R*O1
M73RZO1GT)\.!^-:_[=]=#47\?3B<Q C0(P"]HP&*D[%$D#X!Z7\B9#R!GQ_#
M.P <78O1>'B/( ,",C@:)!QZ0) A 1D>#[(??T>0$0$9\4*.[%P6^KT^4/?N
M@7*)U<MZV\P0Y!D!><8+>:M_KG1:#3H5X95<:AA^Q;UR9F43Y1#D%P+R"R]D
MO,IS:=\@:"+6\T+#OTD8,?M)8E8P8B+(KP3D5U[(F^(9&AC[AH?L#C5F=[B!
M2EG,JXN*OG.JQ%RD2YAE<@O-"@=0<ZM4U1:#40[I,DL$WB>[4F#AUV4%B%_^
M+J6-+K,W!FK:B!%EARZW'DR>Z[)JY-8C!N1KD#JI(M'-@%%VZ'+KP4!?A)2Q
M>O7'5LV4M?!8X](D3QB1<D.760XUS,)DJ;+N+S&$01B&X).!@G_7Y=^8DI)#
ME]D.-26DH]!AJ_19C#.Y5EE]X!1C4GKH,OOA/VDM"*'Q_E$FZ#*K8"AM 9W"
MB:6R(EY(JW"63#G!8W="8G(E)O*UT5L]R@<>LP^N=2%A^("TXZ9PI:V;-^#(
M>06S$^ZKG2H]74H+'70"KYF3]72W04C9P6.V0[R:.O5S54TAA\^[H:-4X3&K
M@LS:'CV,2<G"8Y8%C>EC3$H8'K,P?J>7XF0BX=(.2\*C).$Q2V(WS]P -O@H
M.WC,=MA-Z_8&D-*%QZR+*K_;!^53IO"934$F>N($8U+R\)GE068HC4'&IS3B
M,VMDFZ'L?<QD28K9'A]3E;V(E$=\9H_@G&4O'&4/G]D>>Y.7O924//QCEJ*:
MO80RB7_,8E03DQ**?\QRU&. ,2FM^,Q:H3%#7&ZF1!.P3TFVB<VIB.%\Z0H2
M"6#>[,>8E&@"9M%\R').13^%=Q7:59T?8U*B"9A%LP<3!Q5C4MH)F+5#8C9Z
M>D"NA3"KYT.ILOG4,28EH8!90A\RW%/\S/L8D[)0P&RA.L]M=IL_"YV-E#*@
M+!0P6VB#^4U"*IE ,"&$(SO5/R# MT;B%=F LE# ;*$-)O0D994KMP]?;"H6
M&).R4,!L(7H>@4N((66A\)C3G<: %%(6"KD7X@]7MJN>A3$I"X7,%J*KVWC<
M#"D+A=RE,W+RB$L_(66AD+N01F+B?#,DU^2Y"VDD)LXW0\I"X6>LO!S$C# F
M9:'PF$LOCV<8D[)0^$E++P>\CC$I"X7,%D*8:%ITM8 D%"R$,2/*0A&SA?94
M8S PQJ0L%#%;B,1LR#*B+!2QSX50X:@Y#QI;\XPQ*0M%['.A@Y@#/6L\=,I"
MT6>6X9J857D!8U(6BI@MM(.Y.RAA3/+;,&8+[:\;_N;%F)2%(F8+'<+</'V,
M25DH8K;0X57:.J08D[)0Q%Z1VUFJ/5A..*,L=%9;J%TW=I<7*:35A4KOX!(.
M]B<R2\965#_K+ZJ"L/H88K;*LBO8-RI@$IMN/W7>?J9]^0M02P,$%     @
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M@R*K09'5H,AJ4&0U*+(>_Z>L]\ZM_SA^?):=;?JW?#;^67'Q E!+ 0(4 Q0
M   ( "1">5('04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ )$)Y4OU0:IWO    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )$)Y4IE<
MG",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    "  D0GE2/2.11+P&  !-&P  &               @($.
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )$)Y4E87
M=;(;!P  6A\  !@              ("!  \  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( "1">5)U@Y"NU0,  'X3   8
M  " @5$6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  D
M0GE22L&Q(A@%  #-$0  &               @(%<&@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ )$)Y4KO243.["   =BX  !@
M         ("!JA\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( "1">5+'VZOU2PD  !(I   8              " @9LH  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  D0GE2!00;2<H&  ";$
M&               @($<,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ )$)Y4F8ZO=O1!   ; H  !@              ("!'#D  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "1">5*X<8]6DR$
M '%C   8              " @2,^  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  D0GE2-[-198D"  !)!0  &0              @('L
M7P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "1">5)A
M9Z>=-0,  -T&   9              " @:QB  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ )$)Y4AAG=^FE P  9P<  !D
M     ("!&&8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M"  D0GE280$#X>@"  #P!0  &0              @('T:0  >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "1">5(YP L>] @  +\7   9
M              " @1-M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ )$)Y4AI*P^)$!0  00P  !D              ("!/G8  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  D0GE2Z;]C.$$%
M  !R$P  &0              @(&Y>P  >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( "1">5*_8NN #@8   8.   9              "
M@3&!  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ )$)Y
M4CZ;F(>B"0  &A<  !D              ("!=H<  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  D0GE2'^]$(%X%  "]#   &0
M        @(%/D0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( "1">5*XM+*VO08  &T2   9              " @>26  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ )$)Y4H([EE[1!P  V!,
M !D              ("!V)T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  D0GE29%Q<[G $   \"@  &0              @('@I0
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "1">5*BE))+
MH0,  /<'   9              " @8>J  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ )$)Y4M,[$A)V @  .P4  !D
M ("!7ZX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  D
M0GE2;]L,-NDB    =   &0              @($,L0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "1">5+%<]ZOO@(  #4&   9
M          " @2S4  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#
M%     @ )$)Y4NAJ3IJ/ @  504  !D              ("!(=<  'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  D0GE2V$BE?P@#   P
M!P  &0              @('GV0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;%!+ 0(4 Q0    ( "1">5)!\?I&YP(  /$%   9              " @2;=
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ )$)Y4K+Y
M: -T P  !P@  !D              ("!1.   'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"% ,4    "  D0GE2T9$Y.HD"  !C!0  &0
M    @('OXP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M "1">5+C^[CV_ 0  /(+   9              " @:_F  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ )$)Y4BI0FX*F @  F04  !D
M             ("!XNL  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  D0GE2 YD#? @$  "6"0  &0              @(&_[@  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "1">5(0$A;CAP0
M *P+   9              " @?[R  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ )$)Y4K/NUWFP @  Q@4  !D              ("!
MO/<  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  D0GE2
M%4)R8Y4$  !:$0  &0              @(&C^@  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( "1">5)IX[@>_@(  .4'   9
M      " @6__  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ )$)Y4NDKY*)Y!@  Z"(  !D              ("!I (! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  D0GE2NHA'**4"  #G!@
M&0              @(%4"0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( "1">5)+<N,DI@(  &$'   9              " @3 , 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ )$)Y4F ]5&-#
M P  #@L  !D              ("!#0\! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  D0GE2()XE['$"  !N!@  &0
M@(&'$@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "1"
M>5)<:(<B<0(   P&   9              " @2\5 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ )$)Y4OFA"DK3!   #1<  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( "1">5)S[V&&9 ,  %D,   9
M  " @4\M 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M)$)Y4OPX7 !( @  L 4  !D              ("!ZC ! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  D0GE2X$R&'60%  #('   &0
M            @(%I,P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( "1">5+K0CRHZ@0  "42   9              " @00Y 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ )$)Y4OWBWC1_ P
M.0P  !D              ("!)3X! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  D0GE2I)DO>*,#  !G#   &0              @(';
M00$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "1">5)P
M&-S6BP,   \.   9              " @;5% 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ )$)Y4LV67?D? P  LPH  !D
M     ("!=TD! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "1">5*_5EU,* ,  &<*   9              "
M@259 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ )$)Y
M4I>]CR^? @  \ 8  !D              ("!A%P! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    "  D0GE2&".)))T"  "8!P  &0
M        @(%:7P$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( "1">5*Z&ENKT@,  !,-   9              " @2YB 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ )$)Y4A&XH9MS!   H@X
M !D              ("!-V8! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    "  D0GE2_E,K*)\"  #6!@  &0              @('A:@$
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( "1">5+NSSBJ
MF ,  )80   9              " @;=M 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ )$)Y4G2_ :X$ P  M@@  !D
M ("!AG$! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  D
M0GE2'M:#N:8#  #7#0  &0              @('!= $ >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( "1">5*"J:ZF+ ,  /82   -
M          "  9YX 0!X;"]S='EL97,N>&UL4$L! A0#%     @ )$)Y4I>*
MNQS     $P(   L              ( !]7L! %]R96QS+RYR96QS4$L! A0#
M%     @ )$)Y4L;5#!AV!0  *BX   \              ( !WGP! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( "1">5+;=K!Q,0(  (DI   :
M      "  8&" 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( "1">5*DR,-W^@$  +0H   3              "  >J$ 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !. $X 614  !6' 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>431</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock Incentive Plan and Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensation</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Related-party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Intangible Asset (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetTable</Role>
      <ShortName>Intangible Asset (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAsset</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stock Incentive Plan and Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationTables</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrants</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Liquidity and Capital Resources - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLiquidityAndCapitalResourcesAdditionalInformationDetails</Role>
      <ShortName>Liquidity and Capital Resources - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Inventory - Schedule of Inventory Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureInventoryScheduleOfInventoryNetDetails</Role>
      <ShortName>Inventory - Schedule of Inventory Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Intangible Asset - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetAdditionalInformationDetails</Role>
      <ShortName>Intangible Asset - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Intangible Asset - Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfExpectedFutureAnnualAmortizationExpenseForUnamortizedIntangibleAssetsDetails</Role>
      <ShortName>Intangible Asset - Schedule of Expected Future Annual Amortization Expense for Unamortized Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Intangible Asset - Schedule of Gross Carrying Amount and Net Book Value of Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIntangibleAssetScheduleOfGrossCarryingAmountAndNetBookValueOfIntangibleAssetDetails</Role>
      <ShortName>Intangible Asset - Schedule of Gross Carrying Amount and Net Book Value of Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Accrued Expenses -Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses -Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Debt - Balances of OrbiMed Loan and CRG Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtBalancesOfOrbimedLoanAndCRGLoanDetails</Role>
      <ShortName>Debt - Balances of OrbiMed Loan and CRG Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Debt - Interest Expense Related to OrbiMed Loan and CRG Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureDebtInterestExpenseRelatedToOrbimedLoanAndCRGLoanDetails</Role>
      <ShortName>Debt - Interest Expense Related to OrbiMed Loan and CRG Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Summary of Lease Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeasePaymentObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Changes in Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfChangesInAwardsGrantedDetails</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation - Summary of Changes in Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Assumptions Used to Value Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfAssumptionsUsedToValueAwardsDetails</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation - Summary of Assumptions Used to Value Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock Incentive Plan and Stock-based Compensation - Summary of Future Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureStockIncentivePlanAndStockBasedCompensationSummaryOfFutureCompensationExpenseDetails</Role>
      <ShortName>Stock Incentive Plan and Stock-based Compensation - Summary of Future Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Warrants - Summary of Changes in Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInWarrantDetails</Role>
      <ShortName>Warrants - Summary of Changes in Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Earnings per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Earnings per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Earnings per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureEarningsPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Earnings per Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Income Taxes - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Statutory Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Financial Instruments - Schedule of Range of Assumptions Used to Determine Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureFinancialInstrumentsScheduleOfRangeOfAssumptionsUsedToDetermineFairValueOfWarrantLiabilityDetails</Role>
      <ShortName>Financial Instruments - Schedule of Range of Assumptions Used to Determine Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Related-party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="hrmy-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.harmonybiosciences.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>hrmy-20201231.xml</File>
    <File>hrmy-20201231.xsd</File>
    <File>hrmy-20201231_cal.xml</File>
    <File>hrmy-20201231_def.xml</File>
    <File>hrmy-20201231_lab.xml</File>
    <File>hrmy-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001564590-21-015274-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-015274-xbrl.zip
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MOM]/F6%A1N?M6/<FNC&KMB$_92=]-4EJZ:^:93\^A[U\P:^WZ+7TOV+;7ZN
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MFD%_H!4"[5*TV+F#7WCKQDP/H5NF\5'3(.:!L!&PO1+MD-;O;0CL)]<984V
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MQ@&Z.#R!@\:(H^E2<$N6/^D,#S?D?&NJ&)9GA!/,)C$HG0?C]""EC')I>;(
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M8& YYN(N'!';SE.62O#K(O[4$(G:&1M07ZXN0W![T38VP15A@Q,J*;&SG%(
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MC-&0P-WO_.6];3GL;,S!5C6@YC/S LO0;:'C,026!$#57INS,HR'WRH_3JT
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M3@8<MX$4G#*2*WMVKEPCX*;%15!/T83/;4F(CSA31CY^!^Q&:-DY(18T"4(
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M&M_4^)T3.Y0-:_S&U&+5F[+==_,_E=$N2IF)\$#DH#IIVE!P7J!8WM$^H-.
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M9:VV:;6B7D>M:%/6.K9>S8$<27%ZDTA=FWMGE-U%)$XG21 B?L=UCJ1"0L1
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ML/&M3,S9R22(??K8"-P6Y0?ZY1S+\8+(RRE=^#K/".Z)&X S!VQ=,!IPM(R
M*"(8XTJ5"^%BSPBL\)323!.TX,BEKLI&QI_@H_ W/_?(LP'^WV@=2/B6^&J^
MBF[8Z\'QX"%>! HFMLMT$^5TO>XX[</.0_T0!$BURT 15BTJP*\B?P;$;HXW
M1'P=:L^06FT _ZR:8#$;A1W*JA]XQ"#7$K[Y\V9J\ZFV]U:WZ'CI\F['[5;W
M>?MS6%%[#WL/I"@8R.]/T'W@!>KFG"QN$K%3L#0@08]O4-F*S&'KF&\A-@<N
M%B3[$B&?VRWH]%I'UB.$NSQKCX^?T0VP"8-&I&?LI?ZR-[."[;]Q+:+7MQ:G
M/14<JVL0L.%7AG_;EXG8\//&A9%A#^#Q<!T?;7I-@"6H21X ;_V?U@/8M*<!
M;_UML3.\@]E?9-@#,#R C4LCL 0UR0/@&,#3>@";1LXX!F"+G>$=S/XBPQY
M!5=OXU, EJ F>0 < WA:#V#;!3;8 [!_I\GZRU9DV .8@8M;WU@+C:VQ@)K9
M?ZGROXUP#[Z-9"+=82:3+;O6ID? !9H;M$/E LU-1D]Y%UR@^>4\$"[4;)L(
M;KE0\V*WY(6+&9JDW^ZE.:K(O&7O?H4SLK>X-&"KS"4F=_<B!)>8?,+N28/>
MMF/"7&+R&9R7JL3D%NI.T+]TW8FJQ.3#JD>JRI.C9#R%%Z-;F60!+.A+HGLE
M7F7PS,)2D]UG*S5I6:7)3AM+35[^?O[UV\7[3^?BR]?SC^=?OYY_$%??/I_]
M[^Z4)OMM$JO2=<@CP#-%49^++Y\=+&LCXCQ+,U>5O% %]XI'EA2[*]A)3 I^
M N(@']U)K(B3 V'<+/!@[&GQ>%$2JAJ_J/!'+Q9E (NJ/<#] 1#0Q[HR5'0%
M7AT!@\BDG-O*>;@IE?7!I6&-IL5?=>IU 5WX2$9%ID2_ZYQT!Z#<V\LF?"WI
MK33-57D=7?UP9HX/I-^&9<)F]<[]3+>ZY,VN5!N\D@D6_CP5I=H3I/=V1[0_
M1^)*3K*9^DK=+I5O.IJMMTJ\VCUJ.Z#2\7\&;RM254.<KA0O*N(F)GGBC:CV
M4X)%V6"4UYT6C#H!.:"1'0'/O=8?+.IGNC<WB;QQ,TE%/75MPNK#Q\Z">GYZ
MZFYDUH+K'"Y=AWC"Z:O/+)C]Z<KJ5KHL*:A#THG=XT$YVX?1&K3I*$ZHP!A\
M3I6VZQY7:Z?A2P+YIC)OB7,7GIY3[VL3:E8;I\+-1*?]$]'(C:)\7"BZ^37!
MG$%R ">:FR*R8U;\=?U_YRGY,P2(^F(Z"8,LI<IEU_ VU1%#->VY$](6_RE^
MI1XW)H9U P,00S=1SJY+5=C2EB'\U=/:(#X,":*TEX_S4)6(Q4^JWP&;QCG5
M4D.BH-G;L!A@4U3J^YU6J0]22L=K:-/WFZJC[N&<.EJF3!^DCF#2O<=-NE)+
M3J67CM?22M4G[E-/:T]F8SWUOD%Z2JPF JNG4CV=[;1Z.LUO@"$K'CY95 :]
M\/8.G4-0&=WVX;R3=+:I5CH9S&JEPQ5::5T/Z= 9+'/G5L]TH2HR%OXX#^F>
M;S]0\\!P#5(XJ]?."B=[]Z&DW,YH&"SY:X0QBHV"4UHAAY!>GT5@84$6JC )
M,*P$7G%4-PX<)Q@*7WHAE2F^GA+W7<=N0KL=/X#GLW@NGN*8;%<QK_PSQPZT
M($'S(OB89<P6AZX3B+J3+(R@V4DZMPJN@:["ZLV903DP'7.QMWA5YPLSB)?B
ME#"BN&IA(Q>K.\,2JL@@]G\Q!FJ)R]B E2A1+G1U46FL67V*L;\D6Q6#H]#G
MLC\6.GT!C]4#B_68Y*/0KL4HUR-VY!?-25)Z(Y$P.EAJPU[@L/#52'I5JQ9\
M%!2)[P)S%-'9%/]:MU.;+J,6XEUG(89E^.M?UCROJ+?5HK]I(,[_S(-L>AEG
M\IZ.6KV]Z:C5Z;34B<8_/G_Z</[URD!"G/_?WRZ^_5.\^7#^\>+LXMO;'>VN
M=:;X[1%; 2O;-"S8"W3*TOJUS<!XHAHA45^DS@$,?G#<ZG8.%RJ-=057G(*F
M5^XR*HAR2R! M[CPS_@N*G<$GJ=&0P,Y!/\U\@(P.& S,]T(2*DSU2(J O%-
MP4Z XB5#D<@LB=%MO<5^(3#E("U,(NF_I>JO5'CRAR<GF:'EYBS\U>)C'O1B
MDY"F7;/Q],=XHOL<X*8"MS)H1T']P*K3+,G5PLAZ39)X@FTBXDCU/*$N$7H[
MHB:?3J2G&T_)Q N*'5=*+<K<"2S'0UOL+!XOB#QL4:;Z_2"Q$Q];550$J'7S
M<*O^2S?8?"*B)6&_M%1Z>4+MTI92!'XGDUO=6 .W,/2AO#QCG#,HB_AH=GN^
MBDA%:$NQNJ@X?/G1Y=PN#=ESYG>525=;ELJHK3JGI"8>I@!1"X]=:N]3*A71
M7:A+4)!#2>>Y&3E2\Z>JP(-J$PXBF(*J%P.G<]AQ.H.N)BL^XH4YH08VU^EU
MR_#$)$^0I<BYPL^2 -X!3P)3F98+^?8 >[*HC;(21=6O1(]T+6_<"+>\]!G-
MGI=NZKM_BK^'\37HGU_=Y#OV&"J7W#EQ=)LL8R!B$%H'^,LP)*ZY"H=T^[5#
M(Q*+" 8%;O:D](F%Z@V/7G=ZATX?_B?HM@BXMM0R!B99+A9_\,&!@5VTUHU(
M89"V2M\,@9OQ,=TC9N%WND[GI&<TO)F:2.Y8OR+#$Z_[R3/;*!A)W(*!(:"P
M5Z#&;21#U:4(M H0$/D-@S+C("NZ%JK75FBUU'!$%0<MFY0?4^<A,G$D5-56
M SZ"L%*Z'(SRCS67I7>'(G$S:E-I;N32N6WBHMDOVCKFY T,<QPC!'G"A [W
MU@U"VA>J[CT@%""TDSB=B6+!!)3.Q6F"L)4*5RV-^!6>,37XG%7^MLY."+L]
M13&^+,<3HJ'Z@F,:H^*CB;;4,-/42P+E%%1_A&_3(&B^X*$@^DX>2TX&) ;'
M0X7.=D=T.@Y0U.D>']8[;BIQN$8^P@:@$BB=:$5H]&P%B^F"LH?O#&60Y<J&
M:R(ISE!]52>2%EQY"0 Z?(Z$J1PDIP' BXLRU?#S$EMOU?;XG</%'3_',3HD
MRJ_3WQ=NFL;@9*+P:B\H2,V9UEN"'CM]T.(P'2"7YZ8CS5IH[$"[JE:EUK0$
MK7("U][ZUG?,U0.?AV?&$K\J!_PL3K.4W+_WZ%-^T:W=%NZC^\^WCYX5EVWO
MH[MZ'RTN+L_.+[]=_'XNOGPZO:0>U?2'@_>G5^?8K_K7+^>75Z??+CY?[N9^
M6CGM%Q'V-4-]^R5T=ZAO]8)M]=&BA"K7!Z]3I265^[Z"(A.DR!M\NM *W?8[
M'()H5?ZN\^YM2_R&7A^-7#[@5$;8*3HHP[_ -(7Q5$IEVE"GP.131_<O!L4W
M'^\M.EA3T+*:7TVQC6'KF!O>0=F+^;XP@#(5V2B)\YL1=G>,E)*K;8^+(RET
M3B5JY,KB.LKDPF8Y('WZF"1(*ZTK3A__6JS@O>M]OTGP;.Q )\>K6P!E9]5%
MT=J5 >P%7IOF2\46N$DS_5*U1[C%/RN.Z[8-03Z]P]&^+&9>>'*6>6FO1[<.
M* ?6];#9.I@0&IOX@4P\&E2<S*R8I/B6P>DE?XLWU09Q&0DB%[NUSS4:3]_J
M_5(I'[,249(%7,# #]R$PAUEEK2$G16%8K"W?/%NN7H'7<UAGI 3J3F>&L=>
M8UC=UQO6NC2C%W^'X2FG_GOUHD>9_#FE.*MPC!&QT4M11T_*@3#\91?A2M4T
M@!;JTT&F_.9RRD6[ULKC*)&9$=2*Z!=7G]7'+^$?CK@Z_4JGS75)=2J?'I$%
MM2%)'7V]^LT,BNF/)(H/KBE,I69NI *1S*.HE!<@=D(!7-4"A0MXHPP!5G"I
M7:'HM _(,T3^2%POHQ,Z[%.,;Z!'7C6.Q9]H_Z1:X&(L,1@&E8-:Q0\5X:L(
MH$,Q#6\42-WF%G=E. XNCB)["4*;Z(<!1/+AO9$;W2CW'6<7A^*-B[O,81 M
M_"J:P[>[I-C/B #47'JA$.+Z%;SW], E--6>A@+IJ6ZWFSY1[]NGO@M0(C(_
MBZ?\;$.Z[C[M';[#HU;_>-LU6[;L,-ER-;JXM]ZS Y FW5N'^0%% )WNJZW>
M=NZTC@;K%619?7-9Z9&GN+IL#Y27.?6UCH?+U/V.KY\V.JD=.N8%R]S9 P K
M^N:#PXK>?BC_H$E(_V!?%3WLD=T;N:>K/]?)1'NZ_"^8I6&'?6$C;P$(9.29
MZ&R\&P(E&^]]-MY?Y=@-,#=W3]=_5AU\["D%OLED;(?EM+ VKCTP65VP?ZGE
MU:<-NU^/4\7ZS(-SH_1T<3(GBD2[#>7M!7K\/9_S:A-:#:CTOD8)U;TL?-L
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M /;! PY WUJ?F1T 6Y!@Y64K,NP 5' =.R?];></LPQQ!*!)\( #L&G0C",
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ML1Q!"(J31M#,//\YX+P\S-1D7,#W.A,^Z-XXCS)'SSE(8429XKU+__[II8H
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M(S>5M7RO31S]%SAU1]]_]R%JP.'N&L:)S^7MA*Z[GF_!!_>XVD.G.V@[G>[
M6C@Y <969&B'QDA8@ 1;J\9"Q];J(3M?IWO4<0:]KK5PLK6R[\R+]\1GE F5
M!9A[,Y,'M<T3+]X(VQ)S9X76/&24Y\".00G7_SGN=KKVXL629"LRO)&U!0F6
M$5N186M3P=4;.,<G'>?P:-.H*0M2D_:A3Q4UL"CWTB;,_M"7:[9Y)&M/[J5-
MR#0@?+K>M0#6A7:B5P]^/Q[!77<\^IVVT^UMNY['6J)G:DH6/PO@JN73LFVS
M!AZV;;N)'MNVEP[ALGVS302MO.;HQSF>@W9;^V?TOL69&V[SQ'?%/GN/86E
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MY0%ROV9N/9J6%9CS'#O!2.,8*0 _BL,VON>!"+DWZ.8%Z"KHR<5YAFR*NQG
M,_:^XQ]<L,)*0\+2M)>C_CJ*0Y#O%.<\@7U-X(F;),XGZ7[;/\/\:+Y-E:/F
M#-K:BASWCF;X;HEF1<=3#[%,1[T4J9?NAO[ZESP]N''=R<\7)%G?W!\?@M0#
M^06I^P;?>!\"K_SMO_]+B+\63WX$RQ-YH TOHC1+\C'ZJPM>$H'_RZN/_X*=
M:J]__ I]1)SS5SG\Y=49_K9SW.X.!H?_0D3:G7:'_M'I]CJO_O8 8APOV19J
M1KH&+C?9"#0SL/I#V/*!Q24'+?'QXO+T\NSB]).XN+SZ]O6W7\\OOUUM)E4#
M"X7*=+LF"7A:"<P#_:X0%1\*%/SJ.ZAN<L5<V-8 W_L2[!>X+%(90#=(:,-"
MZFU8\!.(1<E0RD"X("MC<#1RVM]FM1=!7>(^"W:/J/&NW3109@M>N</_@SU!
M8;1@ BB%U18ID]XH"L 7246>JOWLPV?HY_1E?)PTNK*_]VVH%NW=JO'5-ID4
M31BXUV 7T7?3V\,'4D.1 ?4_>&.XPQ[2-MI1FVET/.!=7(ERST"E94G@*2\,
M'J!=9Q<\YN..4GS=0Z?;/IIQD>>7N=17ADGA+"+Q"7R8L'JQ U2=Y-E.61Y3
M2*I-[CQGX6_ (8)ALQ+P*?!DP5CO0]?[?G#E@;5&KX(B' > IX</C,$="9$1
M)$K9M1O2IC\=2=REHT,'MITB&8A", 03C\XC6C3T1EL"S*,/>CM/4[4WOXSA
MG0YL\.#?H*XCY0F)NR ;+0T[7'SY7%N$L;P[X)1\XE/ "(8YS6_R-!/(%\0F
MY;#:T8&/&B^7$12<"T:(8&SM,H&L1;!\M5F# 1*TJC)*9>%?8S@"@_'T97)M
M46"1W$;82+&\%X+$ 6F4#D"9R,"/_/! R08!4BXORDS/Z;1/:/'F&AXPT71F
MIGJC42?5FJS4$B\F5$\1<;56EI/"%P=VR<<3!<PZIF.Q@,,^(,YO1EHF#%58
M"@>J;O1'8PSFI3]OAN*3QLS-D#T%\_7QR"^OVN#=P882#T! ;,J?]=$*_:P/
M;7#G(I/RB$:?KWBP2'>2RI^+?[P3^@RFW38++MO1AN]HT&KO11WH#P&%1'TQ
M#63HVWH0VVUU^ON 1@,2'4Y:@\%"*';][+K=:ML*RKZ(QT]/>"?YV2L%[(T)
M.?^!^S_PDF[CT,W(][&U>L.^"$H#BI_LK1TY[+>Z/XD#,3AN'=N*SK[(R5,:
M%-Z3/!4J7X/T^\$PD1@#@9VD3#.!"3GL?37<J/#FY!DW)YTC-"J=EKU-S_9%
M3GB78B,JGUR5+*'.+8L8+1Z-8'8+.V(-MRV\8;$P\,7B8:%)X7W*DP>^\&10
MO*%\UTV+ ;/W98LEX5W*\W5EAAU*OW5H*S L(O==Z]M"6H)YD[!*9%TS/;6>
MT_I5AIB$\\5-LNDW(W'[GKS6D[W):SUJB:_GGTZ_G7\X^'+Z]=L_Q;>OIY=7
MIV??+CY?[FAR*Z9P39 AU#40F(![HS+)W)M$JG\-,7T^B8<R3=5%LU0FMX$G
M4W69PE=W"C UD_A+C><(X#/W!N\J4FZ1^3<1T-T_&%OE";F92$=N(O&FYW@<
MFQ<$9O/RZ/Y#<>=-I[:/W  6%\W=+S(R^*YCO&L##_A! CY+G*2T<GS\"WP7
M4T#4=3KZ<GG+DR;8$A^! &OGR2U-#373\,L;H:^/G-YQ7^6>'CJ]H^/9MX+(
M!&4H99E?1],U,^Y2E4$7I+-(5)FU\-TPU]EZ^A:)OD4X#J( 5(F^=KA)"A^.
M0XFX<@0OXS"8+EB_#:MRR-3U6OCUK]7*K@J>.BWY+I_$U??S\;B\Y81YSA=?
M/M>'#E*42N3Z0C#?N]YWO.\1^0?:_*@-F9("=9W.X/VDN$^;(W'+690<6&=A
MNAT&;!]DZDJ>!W,G .C:#CY.P\$O<+CB5DJ,MY"EH&OT(I24+'P]73 \/'L&
MJ($ .>(B#(,H5NO["RX0I[]($,H['FJ4P LFKKZ26DR@=F&'EI9*>!83:<T)
MJ"QW3$Y'(I%PWB^;CI$J7PP&ZX?WKNGBD1Q/PG@*'#R2;@BO3D(7;V&=;IIK
M75W.*O-'9]=@\GN185O+.<<4Q-=M?772Z;;GY*^ 4]\",P=4PJ>SV5&=O"Z2
MR#OMV=LS"RZC/, <U^WX57G'\)Q2G1=9[</VLUGMCFUF^[@EKGY[?W7^?W\[
MO_PFSG_?_"J*E:FYGR/Q/VZ4N\E4#$@B.G5QG[B!8M'7V#4)8!8P49EF,"K\
M;4I*#$3C?1"#N?ZW5/8<G__XX53=7X$]1V'R+N%W^/<_3O_WXO^53V:)=+,B
MO]QS,W<2RA^DI%P_#S/X3!:012"5$+D)Z%LY2:>;W?V:=9UM .&B @%%_..L
MK:EF<#+1):ED35]?)_1R!=\"E^0&,ZB5TL1)Q'E:ZLQ4'!]WG4%[4&E1??]1
MYVG#.Y,\\4982V&9%Z0U.+VXXD*?JVZODFXLI@1&5"I>()7\!50W$>(63Z?U
MQ<]AG">U>Y]D(\5A^R?AA<%PJ!YVAYD>*96@H7SE5>%8,+=L%)(U!'[#QYZ&
M?^[9>AG,TRFP6WV-<*D"KNOI]WA!Z?/PU*,C%MAR?P$GRINJ_U^HM#O/I[1G
MM^E*J"Q2XT0ME(<OJKJ%\O8V4^,V:I!OLXYT=2'.<*FI6L"UE!'6*,#22[Z^
MJ(2?P-T2:5BW9"ETN6"0"=Z<T@X]7E3TL%!,58SDMX@*#UQE11F2TS%(J.>*
M-\;U\;^?GGXQ+]&33&I_!^NMZ!(G:IZ11'\7-5IA(^A*R,3$;L5^K%J[*N,3
M1VL[[\LC2:= =4UL4=.]Q1256DJ+64H?G,\P5%DVQ15R35I]L]_TEBMH)!8'
MB$K7N@05*_,LTA?K*0*E/$;)>/KS57 3X5TV8"),!DI/(_^WLGX/^*TK5$CW
M,2ID*=$?% '<5+5L'"-\F" :Q!5$78*Z1M]E6N<^^A01GWERS6LCFR*BR^[L
MFKO[9*9B2)13O0&\.>PJ]Z4L=^$.A_@8U14HRV44)260V)7XHP<0J))65[DW
M*L?2>L<1U[FZ(1W%F2@*J&2QH[?,:DAT2F&+#)"&(I.J,)<27[INC)LPM=U;
MH9' #?9SC^;ODX).WRU]MKSA%HOXFK;5B;S)83<7)]/*HX:_ZDOB2 @]/HR*
MFD9FM&A57Z/X$P9Z<B2 NON,U61 4/""Z[54M<9@+PD$I9"!VGPJK144D\5+
MLW@C3VU;?3DF8L>)<]^R4P<+4*FI2W^ME4?R)LX"#!P,W=LXH<MR(,48^H&Y
MPJ35#*LU%:@HHM!/19 E)2MBD*D&0[$%OV="B1M@I,6=H#I9ZCFN(\*T#6RP
M#!>ACE#5^\"-(+K^8.0"Y1YHG MJ.VJ[5P8[,-BCJM9$,5T&3>C2-<GW,B#0
MI,*^;Z0YCSAU7$15*^E$B4Q5L3TEO:HDS!1T"T70L)+<U)@ME<PI!22H0EZ(
M.,VZ)3ZHKQ7\9;Y,ORN92A<BPI) E0G( EUK1W..<GM24]D9TIW(VP! I9AI
M(>A&K:$YV59"<!W$5(T!V.5&;2 G(Q>@\V2>$5U*.:['-)7VE*FNFR.CVR")
MHV(CGL"$_>*ZM)ZU+R>2.+06/05IRS%T6\18=0RUVEPJND4(B%LX/TJU%52%
MM688SJ(B/ADL%W[(T7]+<))9/<2UB1-3WSO]ELK/P_.RJ(#AX/2>;8\T+^-'
M1]O=$_VF"B.6=-BI(RBUP2FW"@NW0POV/KA-J239.!LA>_M=&J4H2$J-N^PJ
MHJV<$^4_3.($'8HBBDRZJPR_IE4I2F/;5AZ]JNW46!474?Y*45 !G!55"2.1
MZ*O@L#),I8J'T*!T2(-?7QB'J<F)&4M7E6= KC+:E.%T\XJ$9Y]_O_AP4)1\
M D T6=3Y3Y IO1N ;@$"Q'E2DLHO*Q.6B].^E2/NXB3T[P(?/^PE,<9LXG'@
M59Y;:BR^=F$!7E8:AN#1OU%G.: 34U14A7;1)P)!5-@:#V-*@*Q:"CRK:KM0
M)#ZJ3C:P^@0\J'3J#?Z3M*/6XM=88P2/91)9;.(T#4&[@G<$JZ!-75&$U-?Z
M<HSA360XC,Y5QD7562W9:Q9TJOU&"]+<!&]CP<Z#,$!;J\X)J@,%(!4H[@#=
M)OH3[$651BV\6JQ"YP? K8EIK\ Z*L-BP%>;"AY&%;;5X(F%&].ZEITY99 W
M2,JOQ*7K!*_Z-NP\!QV+=YZ?R\V0)NX^;S0%%N=+*;"$ODA=&)2BT$Y?9FY$
MBSI.5"%2;4NKDLU%N*MUU1(5L5--;'JXJ(*HG368KA;5*B%A2"6%4&669Z-F
M<2Q<IU*YF,90UD95<@T&AE0[.HQ)6/B+U2GOV2B00V-N'Z1'U2C%KV"Z:-\+
M,_0"DN11?%<4H?;4 6T*4N])?<P,S_I8O2*GC(R;TME&7Q&+2],^##Y$\Z6B
MO[-UJ<N:+CX:AYJSB16G;V!5\2P5E;K6NPIEPFCY^L\+U<Q:JF2F_IX;)+]C
M?9G/PT6Y3NI=4_L</JM;N)Z2><:B0<=/I.F>3;<A8.+WHB)0Y209H.UD!M7,
M =M]\?TBGKZT2%T1?IZX4Y0KI>[@MPENX(S4!8<T)Y"Z2NY)1R!>*AD;RX6[
MY-'!ZVK4!'4*9314U:.-.D[@?I25Q$.5RH%1<^4N77SYO#R$M/:BL5+\HC)1
MH#,Q>P+]IV"NZ!\N7]49.S#+ BZK!H?Q]9!<W:(PN_R!P0"JRI?HTJ0^)<\L
MJOY6+O0/-4]]"@H?EZJP8NTHM.+R*K2/NX+(IP/4]W3":QZQ?#R]>E\[8EGX
MWEGLD[-'4S-?/[TZJ[W=/VZ+Q0?1ILCK.D<4%LV#=(0?^V3DP) [>4Y5X6JG
M)BNKQUU)6932(WN)/0 2BG7H:GO& 9#&/-VP$JR-AWD79.:7!E7).CE&DIU#
MNU/%OS!0='!O-<P%I2_AO46U0&OU.HM0^8H2FH!+=!-7%32+"+L1\#+ESSCT
M,_+(O"#Q\C'68D9_Y$V*L7N0TK)? 4:8@#!!@F^^U2F(%&1&O8-10$>Y8VJW
M7?ENJ*J(HCC!81QGM)?>M&RFC;QC>F$:IK2DZUK<@,^11B?M1\H+5(,XQB*-
M:^H#PUS_JN:@^0<^7"6@S:8<E@H(\_/@<]J;3FL,DQI'$4JY%ZH8N%?27AB[
M4E#$5"^8"G13&E.LSER'E%!2&8DW*J !>IW&?5L4$L?2>I@Q8M0GOY;9'1[2
MZK.7,A&25J?B/N-JQ60UE!B!<E0$A;'G%AKG64@K=8T*N\/$'<N[./FNXJ>8
M)$5/&-0 =S_!L'B1YBR36UVKMVA\4B2X@H(&R9F6:;2P\="+IR.V<L3Q+%QF
M\J@1O"(;5WCX)$SE&/7\L;$+S@ PO.X3HT*.?^8QY5$F%"]6X6"<O"Y0KTK9
M?I[]E<XQIG_JM@#S("AVR%5Z<5'FE42_8(4*][*<KAX(T')U8!J=#;1<*-E%
MS%OOCQ2>"U% ?9?$WX$__/@.MU#DX6"MC1 #/6GU18H[T7BDS/3Z'ENM\@%Y
M.-N[*CY3NMCH6O9[P?L&H?*H['U3YQI24Y1/KM#3IWRX2#KTT+K. #QXG*9O
M%EV[]]!U3N!(#-<A<='Q8K$QV1\*]^[EW,4TIIK31G7V-)_H@X)K; R292&5
MG8[* WZ=8K XSWNM4$8]^G$&^\+3R,?_G%>[PZ]E\?+%?Y\/B@R>+Y^PNS8W
M;"D@<48[;/Q_8="(\*T(J?Z^.[GBM!QUF%V/+!0N1E$@7\4%5,X'P*!"#2.8
M2H@<#N^A0X[YNN,JKYL<K@#6#[I[C-$%[9PH^TG9NTJ;XY$+U60O,I)]\X#"
M'!?TUZ^PHJGX50G21]A<%^:;["SY!JK?G[IKIDXW8#4>J+/RY.LA-?_+4S]<
ME-YUU",))/@P#B8L5%<_$CD,U7UW_5+])E35O6]#!?M4-T:M+F3]?$4RU"0&
M@];)\5Q7TUK;VGMZ1QN7T!4!GN(6^G:U@C7598KVWH/Y]MX/@>BI #$MT^-.
MR9X?')@?4 30 9N^Q8HSO7:K=X]\%31\4=FR DJZR6B'B/WT<@V;[:'_0PL[
ML(EJ+(QLKNP&IS17W:V:JTZO=6S(&A)\H:UB>[:P.<JB._G+]C8[3@N,DMBA
MCMBT6P!"S29LI%;8:+#1V$5%R4;#-!J=$SOT%1N-QM2/U?O#W:_#N/2P8D.1
M>?[*I63U=Q^8!M207<,\OYC"LPFZU]8BUEW/J5H/M5VO%-SM'CN#7L=:,%_0
MG; )E@8H1C91MB#!)HI-U"Z;J+[3/SRR%DNV4$^WY;7M_'/',/M:3U"S(V!D
MP:&G31A9<_ZPCK^Q*B#-6M%.].J^Q^,1W'7WX^C0FN/8=;4DBYX%<+%=LQ,>
MMFN[B1[;-;9K^RIZ6SM;7K71]N,<KP-U6_MG[+[%6!GP(7?%TI&Z)3YSWVM9
M.LN.T6M1:<KZ5;<MA_]6^'1[S.:[<3:R"L^]=OH:?W[R=,CNNC/8[9XXO>-M
MIP$L<PB7JMB]%$MKM"X;1:OA8:/(1I&-XF.,XJ'3;6\[\:!1-E'!4:"Q"KCM
MQDC^0I5*-J#*"Q=CGOVD#95_3G73 ;-!\8+*-ZKSG<A&<5HU3];=-*C\XC6V
M9PY]U48@Q7*C6.7'E]2GKXB$X(2HO8',,JQ:CC$!>#^H>LLN+!2L'O&P*NXD
MB6\2=UP6,!R&6'A'_]8LH$/_TM5LJII:CRF0-5-J*X[PYI&J+H]]:LYHEO@O
MLY+6T3Y7TC))1& 3=382'2NK9F$_5^Q[I+MCA>&J1G%%]2PL>"6G106X(1:N
MHF)Q)#VJ7E911-_L'I!F09:KAG<?5,]R[&^ RZM7Y;R682"I5BCVBEDX0B7/
MJ< :GV,,;BH92P @;(Q%4IN6+6?,E[&]B/SA25GK;TZE+HLF++KD%M7*HPJ_
M?C&@[F;P4?I8W;CX$!9[UZ^>Q<DDUIUI4"=02P;C\^E\-P(L6RQ_8(].K"#L
M4U>P,,9.!OA]_&KY>:.(V5P@MR5^K7H"&52L]R[#0J#Z@U1]&"O2&DW!##(6
MK>5)2\VU+2TX14\-6X29JT3*JP+M2N.6*R@X9=-BC#:*T;<Z>=TPC<VBTB9-
M5>56K!*;N'Y1&!B-?ZW;D=D0, 5T =L:UX $!JI;)#8S0R2QO+8NZU96TJ\&
M+RJ:QUAEG9KD8#E>X=ZXB)G((RQIAB7AZ=E%[QN-;^L,++'9DE_:.&2GB41.
M >,YT^O-#]!*72LI+!N_F=7H:NUZ6^(L3X$%L-LC#7X7)_@D%MD#*FL:Z(:1
M5),M(YG4#%[8]I;X!WPWQJZ_5-\_NT?Z]$+J KB )BU!58_$PFN_U"S<T04"
M/;V,<AA)O2D%UHW#$6X2^-:B3V 5QT2BHA6?/IW5*N*?_7Y5_M$LC>\4;1%J
M7^KW5W_HG?AR>OGM'^=??XBK$KTO"KWIW+>_@ ",9/+C_N]V>_=]%[$[]9#F
ML?B'ZH7U]R3.)PZH5*]5;P*@'KO_J[U[O@K"]&3*!YN1;%?Y?-2.)W63QW+0
M_I.Q9-4^4C4=>B=,MIOEL=5O%DRS"JOYMTSVF&&MHQ4OML0#J-(Y$:!:EI+D
M^'C%AYQ5%#D\6?$F+6T)4;JK7MRPF<2#S>93[!<W:$.PI<^^P#YUI;6@WH4K
MN/"D<Y\F-1EQL5X\ZMYG;DR>7#Q&Y^0^W?I"[/FR7IVJM)^J=B1Z<Z-KY&.-
M;/"UD]E.SLZ"EL[%KC](BNKE,RX2C(SN!_83,PAI;/^7;]KKN_N+"+0%>N4K
M^A8>OWS?PLY\.R_+]OPEX9;Q\5-V*-PN@Q=+#70[06H9X1>]0L+X3G6Y]^*4
MFE-$$HT0-I>F+8%NGG6&?PUJ+?5R:L '8U1*;A@D*:[=F?U5G&?5K\82-HM*
MSU!WQ&I^+?$Y3W1[(6I %(N[!/8*13,+C9G:[:)7?PV;G;'$5@)Q"#-S%CWC
MJJ6I9D"P \&@0%KUB(8] 440%ZU;]QLLAJR]7+ZH=R!CM3E'=5+T+56/T0M_
MYAA_H5XW5>]MU RJ]S0\G@!W&.VM<>MMMD"E+BFJB6W5]QY[?U/K$>S&6"BB
MEK@8UMZ=?U7UU,;FM[HW2]'QJ^B=&^FN*VH#.:3.8K2.BAC4MXT:8]2>=5-C
M2W:AF\"4G8;+IZCI&&Y4=:M*T(\W4O=#5E7<ZQOCQXCIVNWNMRNG?\BB13M\
MQ2 T$@0[LZ0Q[-B*NNX$<-DWOFQF9W1R+]NW8Z5ZQ^PT4T2/:F&_?^<^-;%T
M"E8QV\R7[4 +9E%-ZZ^-QJ"R>*]LH'PM(SD,2&N4LJ("\$K,I/].M8^_"U*0
M7 K Z;7B,/!*E"KN0*[!]C:J(;1J6$S-.$G:"I6D)HF!F.54#(SN& A"G&-O
M)P^#+&8)?\R$S)495U.O0L.*B^>I#/]! 7$HK/<]0GV5ND.)'01 >(88=_-P
M%MCY&KN\3F+L7HVAMM#%*!Y\M3C.J-K XEA$(A1,\ !4,7Y88M6[?L%<6N(/
M;#SF4\S#(,8$Z%Y,MR*,GU._-?1-'R=EQPNES&HOX$N"_5\SI<SP((78:O==
M@MJZ9;%NU0LF(QT#MI,4,?6Z@ U /LYU!RZ,R7NZ,P7QZ!B;WBH502'YZL^!
MZD&<9Z:W %](7%S, 38<$]H9P-;FJJM[V;(]3^4P!_$(;F4I>47S9-UV,)R6
M[=!4P(-T$?R$\0 PQI_0^& ?9I0?8'Q9-1'4TW[ S*C]J/*5EDQT*&OS%#HX
M01U+]1]"G%$MM%K3PN'B"5<.@HH>%\'C"'C&TR<1&&]W?? SDDPW6OX23L?@
M>(W$KU)B<TQ'?#G5>J7L*JU(&*BN[IH@0,HXOU$-0V7DUZ9>ME_]U9UBJ*D/
MR@8[H12MF,BN9W38"JLOU3L&A=5!1#QT=$NX-"MZORYA+AIK'-\6G=#F&YD4
M.E*U@\=58*B;>K3$*GR\O*D)+JMJNUVVI4LD+"=%STP-H=["N''LEX9K81^D
M97NQ^HZM$+TOL([L-/)+K;-B!W?RG#LXUMVLNUEWL^[>:]V]KE:>C;YEL(_&
MT]13(N''  \V/V$+V+E>=8,V*_%%L:F"@H)(N ?;?&/)6O!H/S\DWJDKSJ*G
M7:5","Y2])PK=L(H]=(;14"7FVFI(BJ5H(+9-?6H8F&%=@R2)9J['LV:T>JS
M 0FU@(.0&B '<XMT$Z,-<%9UI*]&GS46Q>AEE(.2DES4>=C!4K5LIS9\]6;=
MNAU[2URIIMV&<KL-Y)T^X:BZ=ZLQ\-A--6NMCP:<@ZWJ995AX\'XU+U;MQP?
M5FV><7:XZ5:]H)&^.H4@,K]'RLEL&AW?1(24FDA%[@C;'1>G,CHJ4UY-K 55
ME!*M5*WN<EQ.C.*8&.W$5>8J2:-,\4':D*\ 2U1Y$.425=:4XH,J@XH28*KU
M8)9&V8Y==5D&=(8RH4[IE9&7L^-6H2.C@_NP#$0&:D"8_Q)_^Q[M6U?67]7!
MZE=%;ESX<H][T&%EO:B.%U%0&"3< WU]#IRL0O7_XT;@H4V-SM'ED:YQANCZ
M\02E$CO6#]H#XRBDH!])Z5F,YWM>H?[/R@/A-_K%MRAU>%8 7.YC2C%U,E7-
MU?'8Q*L/4)XH.Q2JGZA4Y>JALMFOD8<%RF5"$J=BC,674AV,=;5/2Z%1G?CH
MJ!2LZR+WD73MC=&MO9[)J7L M\1O$1XQ%#1!Q831SVQ:J;^T2'U0:I#44)$8
MIL*=J5I.'.KC@7& 5O FCGW2VWBR@$VC'>H:'14ZAA:N7<FTZD;O:^^Q3%^4
MQ8R47DV56L4#;ZD/?NC01&> 8[+CW)<!L;@Z(2O7DU3RH@YM3)HI7$IRE&^G
M2\$JB6C,&9Q7Y.549Z\7G66'.'DPN)/T9_$F>%NQHFI2/IP6]" F>9.^+1)[
M"\J_@]>6OJ<_2CY]?!T&-VZ9$VH.2V.8@U04HAT6"J)+46_5]1N?OS4>!V:/
MM05>\'21NKKV9)!)WYCCEQQ89\ WB!10Q*!R"F.F0SI'7?*]>M)D*;&46GLK
M#Q *U7V;SBDJ"58<CY:T/%8AQ@C04R)AI\3-!>RK#UAP@J'.*IUCU@6LBN\I
M%8@Z1].P0!T<EJR<'1Z+@#J!;SD"3R]JY)PY$E;'._<R;4D?S+U,-8'FIUB*
MN!Y0NG1"I+^LSH(J3D*)+)7<$FZHPY,AU0W]XU8JJ)XQOH3Q""#, U;\Z1=D
M!&=LHDW&XGG,,]B2YU#]:Y[SYQ/*3<(7SBFP%GPWF1;'V\4IJ@XZE!H5F8BR
MN(F9=:K+DEDHGRY1I[91K*V%1H>81W]UD4:\&@63";E\@!<PI4]'7;JA?)&2
M8!PK*A:";<80^%Y%MHQG]>:&#K9FW\'K/!.7HBGK"">E!B@&5$ZH_$%[$T]Y
MSK5T>6W48.(89@!_(2JO"KDWB91&$W&3RIK?5 [XQ)W2<A"S1<\*/]9)RG1G
M 3ZBLAJUCPP6+$[ _ +]*\:LJP*5$($!G9(C*?UAP>QA8NX/VF&&89'%4*:E
MUT[>BU!.D.F_WN"V)L*E@(UW<Q"\I X.+$#=T"(_1TO40@_^7I=<>?"C9#S%
M" U.Z@KF="E7!,L'W3V^R:2)))!*X ==/BZ@THQXN"G3U_+&C8S,!<W"("E_
MG/[OQ?\S_)A(7&*$]AJ4%IU\UU1#BOWC9U^9T:#@J+LB#,9TDR'*:23X3G4K
MHKP&$2>DY-V,'%/8Q8,A+?\H%WQF N),7O,>[*Y,LB_8"N#%K"40D@TUO99%
MNP2RK46BIO+T8\_+,>\V0R<N#K0FAX6#;S*=J.LC(@<U6=K2EO@RE]5=RU_*
MS._4S@3N1C',WJ7K-G_F@0ZX4"Z*0QEG:&K02_3(Y]/I42GY;40O_&U=RY<^
M3DPAEM([JKQ),^)2NEHZ &1L$\$@4=H+_DDGF41^D*";63$YF04Z8U&^#:VE
M *-%PY-!(826S%A?V34L1Q&Q+\2TG+MCY,&CI*2.\5B%O1<?:'-J;!-2C"T6
M]_KH\JWAL^EUUNXFE8[F4.I8)]U@P\^K8X5$5ME"E4<(WK:;1.J01'D>7N@"
M__A5VIPRI=I^:K,(#\$,*6BIDA+S)*%H() L" .5*)047T=R&K?&C/RM,NRG
MXF7ZI(N^(FA?21OZ/,/$R.KK:ENAOJ,D6!VK8&YWXA/5R"71?OJ^J)[*E5K"
MNTIG!/5[YXOW SHT39YUXI);3E(W_RX*OF(.]68<@<K1 D87[;)R]S>W(ZP[
MIJB0DI2"+0OV+/IP#C<BBV(1.<5DS#@2[#31!2452=Q1A)W5&=KRLT\W<L-I
MJHXL,CF>A,5^72LW\RII2:!L%0.*4X\"U87,S7F[>&B(<7(Z6*4PC3H=4*'G
MZ@9FF4%+>;&N&E7%R\OH@%XE\,!TP8OU32M1J4I\3:7YH&(7%=MW*7!(8,]<
M[E%']Z!$0+'.'E-2Y$WQ*ZHFG>!,"84U'_I^IWBV#D":?1Z28[C">>[ML?-\
MIA./2R<:C_)WYP+AV6Q>-64J*,V48E9PCHFP*AETSE1JCZ4\_(=Q_"2_P41V
M97,=\?'#:6EXT: Z(HFGX GCUK"\8AY@:0S,6%=W;DW92-6>99C0JAV1ZL"!
M4T8-X'?@3+LWLI@.3A-><^EJ ^;:@^*)IY).[6[C\+8XFM2?F L!Z.U"D2&+
M*Z_R8LD%Q$65.;.%VU,$22=XPEKIM>I5(JW.J\W6O;.I9TD'GCJ;N_9U6*QC
M!@+N7#0-\A9SF,/I6OG2Q4.H<NA"Y)S5>-UQ>MU>2YS7]O!S*?FX/E4Z5EV0
MJ,R;SDS1MP.P:D-*UYAN9>$=H1;' E'*12I+SJZ9TI'6<I;(??9T<9>%Q^&X
MIA/GN-^C$5]WG>/.81D5I4RC^X'!-]4Y3Q79"Z?+K\#M[OF?P58?#+8Z5VRU
MM&SP[@0;OBZ3K,47%T RT,L'Q^F3]O*7:D.U@XND\BA)PRP5X]H1W#VW/Y9.
M:7<LVV\3T%) %KTE).51B3&HD -0I,9&L2 -3!=<-PRTEF^.,5*+Z@$$"?4.
M*'#4[D9ZS9I74V:\.J-,BE2#5*QQZM^J76LQ"?R^BJ23@2MVJ<7=&>WKUEU7
M?"=7FGWIE&:"[N;]*R#2Q W\8FDZ<%W\MO#!9Q=O;G;UA)/R"$)OD#%F4*S
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M&Q;6%#?/? J36C_P,7WN^RMYODF!T)<Q:.].CUX=Y@FE,($HN$&8OEVX'=W
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ML+1@YP13V* BH_7'*E89:@U<R$CP=J8.;18H@_X(/$+4JJY:)^,()TH.9P9
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M^7KLRRJ>[^'CH&A6'#=6AS*M?<A$Y@-:!VRV$^J^ZF"10AZ"B@SJ&2A(((]
M10;UC*!G!F.P."$'X58K/'ANR+T1T'>R)M5N,">>Y!LV\T6)&4Y9+=!*'B@&
MMJ'H'XRJ=1<9M R$$]"]L=QT41#DH?;Q$.H9*$@@CT!%!O6,H&<4U#+ (,']
M3]#PW!"?&-YTSEU0DSP2VUU6S?G%B#04K8/QM.XB@_: <-"GIXQQYQ,8*"W@
M(=0S4)! 'H&*#.J9%5SCR1 L3LA!N/,)#YY;8MN4 MSMI"/_3@+Z%VYV F<8
M#*$A,F@,[#HOVIO(35=[1AYJ'P^AGH&"!/((5&10SXAZ1AM6[7^+/-0FMQ.W
M.^N"Y]IS9\3W+=<Q;&E&B-_CW0)"F[F?/3$/EWB/UA1/@()G)HRN(3)H*NPT
M%>2Q A8IY"&HR*">@8($\@A49%#/K.#2E*:+L2,'X3YHF^#Y0.X#R?+]T'"F
MA/JB?H!'/J&S"T;6$!DT!; D8:NA@<U)J&V@(($\ A49U#8KN/3*I8>0@]KD
M>-;;?F?_EI\GAMD5W_M,&JDWN?<)I\<G)'Q:$ XMUH0:)2),]+)5]_='\-3M
MCM&PZ>.EA=A.E)+(>@#@0KT&$Q[4:Z>)'NJUDH43]*8W<E&OG;23;;KAO4TD
MM8_*KFD6VV2+(#S-PU/$%F$D+M($/8-GIXV5JAWOCFVC' '94S=B%%7MC=2J
M1Z0.;<AL%;&=9$LP4A>5(FAX4"FB4D2EN$^*=D^KW,N\DRHQ0B,!(P^W9EW[
M5X%!B9=>95J/[/.OKT+__,$PEJ]OIW-BAC:YFEU,IUY(S"^6<6_9%NMS>L=N
MO:/#>V^[T^_O_OXW2?KUY7TL5SE[I629;\\^_45I-1CI9^PH+9OC#9F]/;MD
MWRIC6=5U[2]55ND?LL(_*.I .7M7 CI%I7^+4.E]C6KG/#RV4O"PKST\^][-
MB71OV"Q;W)?<F130OZ^\>^LK,:4OKN%(!O_Z YF2Q3WQI('2DQC1^=%F=O'E
MS6\Y%RH3Z8EXA/TX<VW;??)?K]$N7E>1L&"+(>;AMV<R70#$MAF74GY/_X[Y
MG_\=2Y8II2;Q4CD2"P'*>[:Q],GKY,,;*184LBPF VZ.81U:6FF3_DAM>L]&
M7'L7='7873+]$LM\U#0*D-1Y073HD"E-*#SJ6:/FW*@_W,%$"5GS3;-(@M1A
MFXF8W+NVN2>Z>QT%BD1QE#FOZ/(;*I.W::X3IP5363#$S1&S-^&0'V5^Z[%!
MB0\?2I3XHL17)C"$#4K\UAP3CYVRTS?SDUC-,Y7KBR6]U@FD<VGI6<[46AHV
MV+,O3'&?/CHM."Q6((:..Q^@$-,SAM.>J)WZKH8JRSVY\KX&G@'LKF!$#04$
M"-10J*%.6$,ILMK3\)0Z-%A )]"CW_OQAQ6P.MU@\Y/0?  "!,HOJ,A$9@):
M =P*&.[AIB(3=9>)4,\  0)9!"HRJ&?6X-JK^B9R4IL\SKKB X!R72%A]KMC
M+%POH*\P)9-5[#8M?^J&3B 9ON].+2.@/SQ9P9RG6)/8:>U%U\XLQW!82G14
MWIMG8J?W\YN>#(^.1+BRX2@1F*PK2&N@52%TK%'3/O3TPIER:..PV?ZL3'HC
MK>D]7ZQ34P2K7V"@A!JM93(1-5J;T4.-5E*C#7O:1(4A*E&A555H#==;V^R\
M=[AVR>;<:8<$TI3ZW<_,,:? A$WO,6\W43J,70O"SEAWYA3KSA3,;<.Z,X5W
MOB?#GEK96^]DY1F4NJ@3(:.#.A%U(NK$/:">C'H3L U$0*K$=A=C*TFAFDJ>
M;2H!][*46[;HVV=68(#XP6>'^LSDPC&3+SY&O<$^6/[4=OW0(]L+PHT.5A .
M8F&VA$!)]S3)(S9/"PC<#47:''-5B(T77+.<J1V:]'?+H?_//JK'@Q7T!UZ_
MS76XU.7/O@WH/PM* E[+[6I)/".PZ 4Y]=NJ+3]YGW)[W2L9U\S!#31+,8FV
M.!!I@2"]T0)!@Q$7WMTK_O,G,3SIH\-DOEB$$RSS8%F<ROL]AS;>,5\3JB["
MO!/(Z+0F[Z1= A%4F*K6K)-3M$,@E5H%EW("!R8PC =&I2$VJ- Z@1TJM-96
MDD6%=F#7&BO.'GH_PW56=6:3UC-@,\XQP@L$"*SFA]7\3CAS0]5[JCP BR66
M5H"*#"HH($"@@D(%=<(*:MA3!PI8*%$_U>?RMCMG"1(\HLM[_?G_P,8#T88
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M11Z! 4;KXFLGK,N9D2]Q*U\R NFS[X=,M5?1X@=' ;5X-V( B 6J\YP<@-Y
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M!?=RT-?! M51%JKJ7:)VZ8X,ZRAKM  9U"XKN.3*H4ODH#9YEW@NKR7-%O"
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M6GB&M,/E$OYEV*$16*XC&;;M/AG.E,#8I,>R%BW+E\&R%O5;'D=.<L)J%KN
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M 0ZARE)L-!@H:\V5"H<;MGO56I'V$Z"H5=;%%G]/VQV*!(!OQ9?9#AQJH]P
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M_&\R#>[<3ZXW(U9 %]2UYSY:?K9QNK:CV\ONW>&L)4CIKXZ3'=9J@\M2G=]
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MEY1RGC$-0L-F!WI5D;"[_(CU M+C/P=?U<F'&IRGZN,'1<!RS@8CX.BK,H)
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MH.M#3XD^J*SN0,'&S^.QJM?2=F$+&#5!S?_#6E*GW:@5$>8">0ZG"3,SUFL
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M9/.4)P"F/#G,E+7-XDL#(+ZT N)KS8I@-AO]_M=7W!%XS?[[[O\'4$L#!!0
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MG@A<$?HK!L'GW&^7CKE1-8DU\M0ZBUJ'[#HJ.K+9X<(;]'3(10;;T^"^D/]
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MI,HGI<=KKSST2DDTOTZ424<D>L-HXUX>B++)9K0%+P"'K&(UT[NOL.;U7]]
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M.$(N\A^A;5S$Z&E:@RMMMTRYDK$8(%15H/SJ^"%A56B(#,,BAR $G  Q):W
M9CB*_7\M,POR@R+8>U!-1XV-SC+\_N&'WBIL"K/%=Y]6P?6EXT=I\A3/P<L3
M/$ OH(:07.O$U*\UGT?(];,42?]A&I-K)_J%8CZ.\/E/F)ZRAK.-HE Z8TS%
M!^9T9UX>)CV!T_./R(]C1!?L!(*[_;'5:[HFKIDZ2BK07""^BB"\;SZG_-(C
MEDU--X8 ;51UC['@65G&BNAF?$7^\(D?0WMWKS]EEO^D1:]1DW=C4YO@0ZOH
M0EX;MXH^M%^VNOWRH?6I?:U/WPDTQGL1K4\KNNF]TUV+J+B;WON7V5;NO?G]
MU;IH*_?>_!ZO7?1._&#^)!?NQ 6VQ;D4S"^(;'"2P<7GKQS]1_-+A=M!W\UI
MF\M1]P99+\=._1VXS).32TB\\G3O)53GI\ME]IOYU<JJ9-:^;Y=+V7P=J$K*
M=;T4CG\[Z#E8Q"B7W&?S>]JHFF4U(4$NLL.6414&YBUU#]N$6+C?IG;3JB0F
MD.]A4^_F=DX+D P?WOC9? TOD0]5*96BO*Y<'A9TN&Q;'ANI>UP0YFN;M@4A
MEJC))62^8FE;0B69N[QQ^,O5)INYVC:U4N] (J"L_5Q6[U^>[JVJ[^!R,5\5
MMV/!0.I\N'3,5\.-(@*5-5W\.@+S-6^#BKB-0Z5XG1^_B<!\S=),.MU5A'(9
M6JN%FLZP<F?WB04AE':$ BD/SZ7SR7REU$@U5[8"X%(PWP1LT$AA,U@KVAV"
MWYUBK5:!"J>R(PB7A[4*I87)(M(%AE\_8[YR:28I0&,@+I27K&NVVSKEO>4M
MB#6TK60*>G=Q<;P\G5O:F(T+9=\5+Z@''[_K:M^U;)%"J;O?PX+["-I=0%7M
M,FVZ'*Q=J<A?[W%J072E'5E!&NIRZ9BOB\7.C:H;+^_?56T-^WYS@9BOL@5+
M@D3;O_-;ZLS7-= V^1LQE:VV_E;=10?'774# X>^+[,=<!$&OXC/ CL$?&E(
M;L!7W7?"16#^!MJF"(KOI.&7$IJO".2EL7MO$+]2;Y]Q2]W1*>X>4W>3V(5/
M6 EN$J%A]."$RSS0-%)'W,B?9^!6L3E^">/:/G'![FD/<@5:>=-8^\.9<!-9
MBZB4U+!3Q<5.BR@BV1R]P7'FX+Z;TZG+;]P=,=9.-B5=5^$.I:VF:G^;JQ%B
M;*PQU@QD 3F%72N6JF<8I145-PE3>,,)OR'YW D"=OA=U0LL?PB[ :GI4,K>
M<X.+I(%3H,%(A]L$#K<)%/2P(]F4NHVR.XO3ST#3LIR(]O5W@Y[2K]I;9VL4
M5: ;TH7<"P*<55^EF[IXQR,!(DJZN]X.X3RO/:1D%CD!6NJ:&V=&_W-,MQ)"
MK7!F)H%[,XE0VT=4/T]5W3%Y3WS/=Z+%&D_@'E3E1)3843RB!%\=!0^KX#DS
M/%F !X=4E<"G4 D!I5VTMG@@TKW+B@E)=;D3.<()]RJ#4NR,XUT_9QM<#S3U
M,6L &\-?2EY=?2S0_L>^OF>2L[ZH'UKQ,N3RTQT+@O5$J]1.N%:3<MCF-\NJ
MWDUPY6['<7[6BU/%3"\W5'(Q:,]$X;,<39PDB$NF>:WAAJ'V)A>![CYI8@N]
M70FLXS>_*R#@/((+CX(<K$ W4"O!5IS5.7AS=7LS(PGJ@>&-3\V-_K<DD7(G
M&^^/J=O2Z5H($M4VQP;7RK8D%*$JFV.#4X,4Z R!Z(@-G4;;D53CL!IOIZG;
MZE0RJ>JBKC9T:>U*''61=HG.JSKR4 8^1>-1MJA8EETM1HC@)*(46LP_:3J,
M67DGTF@41V_9E*;Z[CQ"'BSGHH*(K@CT5B5*L\CS%C$E48\L?WTK:[T7G]--
M9D$W[;3?)"@2(D90S9UJ='J'R.L[44A')CW7369)6C!S09>G"YM\(M0D/??W
M_C7R1GCA!/$BF]##^1Q'<1*F&__@%GBI#H"BBO? ENIJI5XZ;IH9.6 J,(('
MK.II[1LB53'<(CZ@H;AR&E(KHVI#@T7?!"BUSN&NY=:$RS5JZJ-L,)A87.@O
M(:HF/HNQR$HR,9!6%6*HU2LUJ+=U(<>OV^4L%%]H$[Y=X43A31+#S19CPHUU
M1WRPYH28F[D4#&Z1T$P*@J<)+@C#?872@A X+MH0>&Q/"%OG?XE8G Z_UETR
MFSG18CBY\Q_"M' LC)?M>YF'' =T8;?JX6IO0+-\72W@4G*F6A8"7N+H&P47
M,9T^=IYO,4GY(N=9TUW8&4N4IM2)AEV90"7Z+]8B@UV8L$:9+;LE\2R6LSZJ
M\"%'?@ E^?VK;LALQ\FZKT->3N'CRBI'=MJ]]%BDZ"$])YTM^$^6(<K>DQ-Y
MK&?M-?;R(M:U( 15SZR3&2P9MU,^E$GROA[!_38"^K[]*/UQ-GG!8FMG4*-G
M6_J/[UFA=<8PK+*TU7%52*KGI;%MDG;+ :N3HJ>5<%USTQX 00TEJ3UJ:32R
M/:2XK31 U$""BN),Q>W$^W3^SM@)\!M!DR08^(^P0CH@8355-]2$">-H>1D<
M^457)_O >4 @S5!-1VJ6K3(PKIT_<72>D)@:*Y&XG5/VN JIKL;.KRVXRWRD
MH-E20:21/-GU?_@Q5>$SUMC0">B\]!)7C#MA4A)R)E&\)F/ZU[9\Z4<_KYUG
M?Y;,Q$-R!0]UQAL]A\%YVWRH*]Y&;(^&<;;QB)E\24;GQ#D3#<%M/:!$=R^5
MVH[NE:B?K".E92\:4\[A =U*,ON!0U5,>H>%LP5C AJ6KB2CJNZ;L$S%,$'+
M'8KY+^'KI(:0DK/!SMV%<!CE-/3,*A2ZTYD3_6IAD>S0VC=$&M=^SDD+"F"+
MEI1%FS;^\_ ?R GBZ=<()_.KT 7F:E72D.+JMG<S_J,_>KZ;LTNV WK<8TYV
MQUT,!N= YD1(29[@(\2$#V>IX$DI#L9/.#^4 5DH>E2.!_HMDN:B\.&N;-&L
M8F[C+"NN6FH(V,=SEU;_IK\ 8OX7/2DU+\6":[ ,/!#-#KD>@+/RP'35Y^?)
M0L<R+^<EY.S)K !<O@IMR=FKT3]80"U:DI[7$*D=F7ABFR"N-"ALR+0#XBPP
MWW@"F>ZF%6VA++"3.4AS$\1@($7.)QRU;H74%NK*(R.'JUDO=;K1BA_LN3QT
M-QX02Y<7=GM42F'79</EH%N/"Z7-=R$&DWH3U:?/"_OTL(A?U8;DX";(:QSC
MQO0ITJ45>;R#]^C1W2Q"6B'NQ("JL&]&K3AZW1I 5@U*@E^';J$** AA8D#X
MF&/?Y_6_E0-@3B.J>J_#;JX#+LRUX)AT6_.U[@412.N S/8C%*7)X,($(HY(
MMZ4ICV@S78NWHM*]:=145C7U XODU?$.0H87'380AD *)!>#N>NVU3FQG<>:
M"\#@N^W:F@?5V<6Y)'[3;5%W+PE@"OE*-"<&'SM;627B%01<)+H=4MW/EKKJ
MCUP6!E\6W9HL"FIY.'YS3:6V\+=;NY5+[KWA%?]M2:Z=XL!<;!_V?ZOJMA25
M2U+W0;1[2196-7,![+D!+%^PGHOH!1R5Q-L2<*D8?17REK728D\."<IF-=^
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M MFV)PGRMC4-H)>U$!E%S8P8#]F5$^R.37@_[E(2:IKDD'@X^8JQMV[^WN$
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ML4[US@-JR%45%14NFR$UFQS6:I %_M=?&!GX,S]35608?H.UKX=0E>LC5#I
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M;P",?12$\<-_?+-/WWBI'X;?@#3SXL"+4 S_XYL#3+_YW__Y/_Z??_^?;]Z
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MVVJ6XVX5,>2);J%(PZ]R$PQ0@$A=S!XS.OJH09+V>CN"&]W")QCOX05N *F
M1,"_A-GCV1YGH"U,BK?.R7.D^/\':^]%Q<6TQ ^Y+Z(,9Z$Z/,S +D'!WL]
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MG!4]2=62]N69X19T[L"5E =YN=:OT "-I;GBI!F])>:> UF] E/M=)K'P$^
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M]>7U1[ X6U_^<KF^7-ZYX:\#F$?#;3X_EGDZ(A7[:1;*%0"G!T!4( ? "R5
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MJPL*,SD20Q(L"><-+69SD9'V60.E9=I>J-;J>LVF@;$B%&:*'X%P&W&S%+[
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M71>6H16X0XJ&'.6T)\$EQ>QQ1B.%"K/#-<JTQB]]D@:<"NR4;/8T8 4*,"Q
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MEQ(D:R97S5]$1,PN^U(8D.-,<ZA'U&+F&NI'>OIEF66F*MM&/H[IVF*#IA/
M8-T-&B%]/<%S;$K7J>H))I[>U,_UM)U&IT\ZW:*#%V4'!K;:[5"2[6.ZSGAU
M(W]"0E6B]AEF201+I]'9(U@<'OS.V^Y^SFFJJ8$CZL:%,:@ZQTC/TO/@LWY*
MP2"9#K8U*IL)JNT4M1!<@1N#YT]&7&E0FFU<F3QN,F(C9:<=IMJ7]WJW,,,=
M#0SR*DX+'Z?#/7T3\!QN0G_PDOM/K'TQ?" R.8T5%! PF)$'D#<)\B$,4E+1
M*C\Q0$OJ;/E;.RHC2 EA^N.27N$6=K Y)*LO%W+0YG[V"8A=>?A<GDVD;%CG
MF8L:I-$B;3D>+\^TS9]KFC#,2.I*\Q&V;G@UA)@AIR;4?#@M'AX2FO[ KA98
MD3-OJ_;3U!(W LLY2XDP3BA..1,;.N'*#Y<L=ICJ)_J R):<]_$B#!OL?;E3
M5=*B-(?D_:*MS*WX01?<C7@<F/8G#)G$!H5V84ZE0"-2M*G6)E'QID.E*A(>
M0Y&CAWC0=H,B/(+2V8U4ECOT]0TY'-LOJZ25VE)>H0;8<3U<\$!=QH\>5U&Q
MN$7?5-O*5))IU2?M;6^^1G\4[WDJ6WHNC(K*=J_JI>M*?) K8&Y+=/0&1^;;
M*C/M2).L,N7 _VI.-_"/_O[)^P=*SO9X:HK[W51V5[3MF^HN*)9DWM%R\=,F
MA1Z+HVY[N&5=[M54/"CD&]G8E/)<=I>\UCKY7<P> 7J6;A7XFMVYGP8D91TG
M3<Y]/"\B4/=U8_N-:_Q;6$20XM:B^,N:8P&1,"O#. H$_!S)A;%:)PNHUT#.
M6;R:+IBY"YCA8RA[:D="C36*([3$VC/2CC3!5W59/Q)E)\J>D6,QUFY]U&,:
MQRQ=BRYL9I.Q94GE2*"ML;@Z\Q*(9S>_75V=*8:5X)N:7!])LA)4.0K ,"[$
M5+OE4;==W+)R;71;,?'P>+*D<-34%?^_,V/Q=+.X7O]E>?MRMX-D-3P[W#QZ
MR=;S#^H!)B-*TQ?Z15L)P1P6%+@@!W8E*A7X0XK&=)RKVI&(;J*&Q_98C<IW
M0<$"7(,U^ M8@I96&<T""]]/8(#^ C'(X\<$[7>7L:\8_ITR-'VI0Z:5@.=X
M@ $"BGA"WKUQ(=1E2$*RAG.5D-K)C#8VAL>S]79$[4T@+9BJ"-\9\;$XH_>L
MX]LP_>WT< IC_Y&,+%2O*O7+&E ;I$>VA;%@%1$02% @NG$,2)H[I&I'UWF*
MVBDZE"Q-<]?IV *Y/NIWG?IEF62J+ON_(ZJ#N\Z($MG1=9XZ(JH,IVG*%_-]
MZO06^C!\(OO3ZF5BVV7H$],FT\JXAY6M*Z'<B)=>:I"LN5RE(6IE8*H1&RDS
MGI):.?$>\K.*5V&L$1,]@H;576\5;.7Z X$ '-&1\GQR-"$EJSE-"8\4BI1S
M 7)N")A#4YPU;J6!V4TIQNB .1<[R@B,@+D1,3(\=<]DZH9SF)/.^0N!<F3J
M0E0Q,&NIBC'(2BGV:X\4 4]=D=(TG,.<M$<*"Y-IIB3Y-O91\]5'8;VB!I#3
M+=K>X4!P3)<C@2/)&U(THN,<1;WT&!J;29V?I:\JJQSXKGQ![[!F(<#"/0*R
M4Y1FH>]%^8.[9/MH^N.QQU9&0F,X85'NH.R][=$.<E,X^8Q]])4!IK.5@=UV
MQ^,L*S2((W:M.^5X^?%3&(?;_5;-,1M?TKRQ415BWCFY^.F=46QAU&H$9ZP9
MU0PYJE-Z+QI.6?^2[C6B%ZM.R<0[X)1""Z-6(SACS:AF2(-%JR:YAJY[2?3*
M9"6K25H>3=SHL<I<5!F6JW$QG[9%M69A"G- 4"+FB_)C/TR3VV"U@V3F&3_<
MP0?Z$IC*<DF'$/U)>*M0FPZ'<C"0<C0WUDCZ:4+2EG.6DJ,X*7# G10;LLL[
M7OI(_D>>OWCR(DCWJ=,L"?T,)P'\BT4<U']0^:0A[T.9%W'O6Y._ Q_#G- _
M 2S13FC=_J10AGT@?43/,0ACD#V2EUF\C,XG4UI<COQ^$Z%GA43278:I?F-<
M)BUT?GU@N:6Z.,LEEK;TAJ]3=^9Z6&E64A*9RT$&Q,G8-W>+SJ;R1VFK401A
MZOW"&SS"(-[] )7>N>J68W!WJB+7]I9A0E;5=P6>&WV[%&%=.X='!G29G/:]
MPPK4^!4VL5-DAYN(3.GB@'3W.](C+-,LW)(*NY]3N-E'5^$35!H8*PH>5/91
M'LC*:2\*3T<K,,<^ 3!'!WL*#R*"3W([&;EX:0I=&6#KN0 :Q,"LZ(X:3%-H
M6F&[  <%.F#P@.(/OTQ.*WB'_X)D5 XQJ8_TW?HG&"'6:/8TM/305%Z@]J5H
M.0!+-](+<#)QH.@T+H,2/W]-VX41K3*]2,O*LZ"R?NU=GD<3U^+';&=TW,0<
ME::4"BY8&FAB<2Q]BY(L_!>-E-7F$L=,_!#>1W!!>R(S;7N"R3TJ;PE4$.F*
MIH^S90(+%O'?,N@_QBA"#X>Q[W $6-<L3,/X02&%=GU[P(6!(VD6;FR4&'*!
M,]J-C78B4+^)W#-Z=&SOWBBV<RWCT4O@J9?2M7VB (W#!7D,_H&NF9T>RH_<
M> ?RH\6SEP3TCU_(\#5^P/.2$ 5J;T0;Q1UPP\"@'A8J)85;^.:>0(,G!D7F
MYAC+C:BTXCS()CFOR5'RC4^""B@LJ*H&*KJ1\_G5SW'] -6-_\E5!%S'*?+0
M?;]Y[YOFQ6DS9&LD3''E)&0&=*!CF5#"?/KYF) 9;$#>%($%F'L9R*C;--./
M.69>C8M4$\^]7-ZY%Z2=4CF><^8R]"$+.Y]00(^8D*^<P]1/PAW]=ARL82+W
M-L8X>DS0XTGH93Y754#HQF0%'WA$*X<2EFVG,S&$DB;Q-3N8L2$6T1A45095
M?R4+.E3KD3/@*GN$R35V6G* 0WU]0_AU?7<0B+.P=\[DN[6ZT<4#DC"0@S;G
MD4/E@]SHRDL<XNV.6^BCAYBLB5[&/MK"M?=R@]*0A!)Y;>ULGR0X\MB8HO([
M^9,Y^@"::^BZ@%:V1TIE0$BU 9GW G8<DSTJZ#.-^%R@]@$G#@$-=A%DA)E9
MND,U77;[@H%C1],V-3IJ)=,"8"B08[$G'+DF?*I2^\#8W?95Z-V'49@=+E#R
M&<=!0AY7KAJ'ZZK2E\O+U.]L9#',N_'G."DIWN?0*KX\UE! F5ND:]^Y\,AC
MM  %&!44L/5 S*-TY("\C)\P*$H.M][S)P\[7NA%2DL +0+T*1(*M- ]>,]@
MFXMW(X"ZN4!2)G+2[CP."@1 C/^IW_AV/?X+2GZ[C.EKQZF>RS<D&+!]3:)Y
MIR?BR=6"'0-PS.W%A(C\7F F-XU_Y/F4@<L8W/0Q8-?W+\(X3!]A\!&A0,_W
M&Q(,F+\FT;SOY^+! Y'OF.N+^1"YOL!*;MK^R/4+ CYV$V#7\S\F2#/;\V\:
ML#:59/ZN62'_!#P0!,=\O&YYD6]7[.*6E8]\^6.W?>VZ\"]>M&=W.& *$\5;
M"UU2#!C]2.I  GYB!,3P@1P]+Y9VJ&RPP=,I=)_B#Z0^Q([HF,.W\R1R_A;+
M.<A)6U 4." ',G*NMP"XAJ;65XXNZ(9EZHRAPAQ<O,I_%?IDLV#QD$"ZP?8I
MQ!Z:H1CRG;7TQ@NE3ONH2--<L)62;F6QGB,#+X<&VQP;[#@X_DL8N+ JKT8I
M4C?NVQ%ZD#L?#[_V$5QMR%@L@^0&3] \*$_?HU<Z!*(@=<".NS2*A:HT')O<
M_V7H]/(367+/\0%3 /Q*5>BIS3+:B0UUOI&^Q>?#;62>5F-EOWBIF%5RAWM0
MG#Y4RG:*OZM7MDHDR]Y+ N3J$P>:OBY8)P6HSSRNF3NJ6WJ5Y(8>K^QG7OYH
M$0<<.Y6O<=XC8)"YCP5^72[>P0B2,I23UJ][?$K/J.4X&O7+Q6/\+XN_7OZ7
MXON<M>]HCM<K,JR,RJE\%T;<(@.C-B.X8LS:SOV.', X7_"*<'B6B3: (@X_
M>V)<<1XS7\ "_!5<@O^:[*VE_7T*_[DG=Y+)C)P\.:#Z;$RKB $#5+%(&_4O
M<R! D1QZ J./&21I+D=9B#H(F.9M&$%SU5^&Z1!BE A;HZ=Y!43[BS ])G.6
MB^ZPF.8MF$:3-=[A$PLP1H*UMP8:+#@9!QWO[;5;R4G3M_G^1$.CCK6QJ[PN
MM4H4R,G39T9&OIUC'ET+>5>R!;3'"A\E6I&.>>= 8628/<>VOJH>*KWO-:L6
M1O7&%9"@P,SO%:;@IK-Q(R?/O)C>1FG32TZ>C<@KY5M8LL@+.6X@6:P(RP"D
MY1Q=3Y@"*J429M.D<Z!-)F&6E1HW8Q=GZN@Y;B&9-(3Q0[5\FD8=)FT(*_UA
M%Z2-RVT<K:R]VD6Q&^$IQ[S<$*??W#-E66X@5/)?JT$X30&D#GM=PZRJ(+]%
M?8LBK,3#)R_;)V%V6-RG6>+Y2I?^S&%:\1,E'<9T'*Q8W66X:H#K!G+EP*^Y
M>N[/D_2\3"[1:# YQE&N#HT%ZE[#EXRKO'Z&T1/\A.+LT=1J@0J@E6B35\!\
M3XSYZ<BWC@2(ADO(18>JY5\%_7*95IAEB5Y%JF6: :::.WUV>[K[&_22]3.R
MES::.&.Y2QW72I+X,,<DT<*[=FX0V7G.' _(!'D2(/K@3(!F$_]8"T,K97)(
M4_@'0;:2!;Z?>Q:HL6\D#Y2VGC?3QG(!46DNV> "FVF49," )O 0 FPE%?QA
MYJF@1KV)3%!:>M8TF\H#1*/9I '\E7'2  6:PC_P5ZRD@1_FG@:JU!M) X6E
M9TVSL32 O^E.&KB&!E?I[:V]6[HF[GRH5NF17MZV&&S&J)#>W!B])D>]P;0N
MR/+%C_8!CF!2Z.8YC"*5D)&5.*0NA R"C2<Y, XX\Y+DP#<N]ZX<856D$>D9
M<QZ4\5 [CB[&7X$*<EAW>J>%[^^W^XA4BJEVK*9&IFW2[8Q3Q&@VRNE4H&H#
M$C=B<P#?DL/1+DO/B%NU@:<6YYKI"O?+MOJ7RA"-'&TX1>@W6H=H<*7^WJ.S
MYWOY1XGEA-FJX(.%3U? !X.[<)M8B4[I\CV%97N.?'2Y&#E,=@1P >6JNLG)
M&>18K7(M^A097HB\:@/[:HJ-Z$S]Q"$50VJY$!M$KS:+!RR9].DX"=YY6/8B
MR]@!06DODA&EZ4C]HJWX$H.E#S/GP*2Z&T@)-/!R;!?2DP*/2-&H U)3F?D6
M04#+U'N1T7ZP3ZRA'K$;9J2^T2N4$'63@9O=I"3O;1VFC.'U\I[O)WL8-*4J
MO!XB)48WWW6*M9/K&.2Q:^7O';G@79*L(04S&LEN5RK79_LD&,I95V;O5_:E
M)Q?<HY^6MCQSU7GA5<\II.M@=GW;D#,8K'TX1T<X*E'99R3WS"ZZ %S>D96J
M&CIQ"R)MY8W5$3PC(UZ8[+PD.UQ[6Z7:F.+OZM6O$\DR[R95%$!@IB\;V$D
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M-^JTAE.FC6I6G6H,65_IO5)Y$+%7A*GUYRM[U:".MF.N9*LH3;,=<$Q0ZV[
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M:$>4N,8#)EN/7(FS7@PSX.<W'Y[4AO_B8P02G2@V[; ZSX,P-/>U!V!:.9K
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MZA5NAJ<GF-RC(I(J,"# "DC6HQHKD.390\J&=)XI'E$$#91PH$J9>CVKECV
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M^0,V+/_&/FP^8C]XV_FO_P-02P,$%     @ )$)Y4E\^T];&4P  (GD& !4
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MT[W5G1M?$P ]M&#9OR<((3@#A*,X^#\JTX,X6&:[/RJ3K$K0.EQ77\TVA.M
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M\]TCSP'5#(RY.V\=A6SW>S;]*KE]276&:63\H2MFP_I.HBMFLS/> X_149]
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M@F<S9"\]_(^HCD6FB:&A#[B2/N!Z)JL'OM>QO["\]$EG7'HPL'V\3N[8EU&
M/10$(\?!B91WWISXJ_B/KU%H81>J)E4-US5E6ELN'9<9EG>P)"Y=TP$K#!-N
M6&PC_NG3FFZ=*^*]T%^QX"YC[1QT@P'3UG)].^**E<"E&X\S5D_(''):DKA=
M*Z!WC316-?;C2-5CM'I&_GC.G6=7ENLBYW*SC6FE?PAJTU-[*&WS?!<$$7*N
M(Z;@DYR-V#$8\*7';FI>7"J4JGG..W@)U!A)TY/757(9S;BEARN*4S6 ;UY+
MZ&CJQ6<CY 3,^[L=_HY5KK;<2?3L8GM,;XEL%D!BB1/5UA<V2);4Q,<VVGJT
M0<NRF$CK^^\1O<:_4K?/=BA*F=,BAS4U'=!=B%9"7,M0U3$O8ZJ"6%);_,PE
MR3A\0$QU0Z:BA(@6U^-D#.=YYR,MZ]^*LSW9FGVT5O1?9_00#.C=A1EX9&5A
M#[3V!:AID2IZ#K"#+7^SP]'H#<,V<C$17<_=TGQG^"K*^5A+K#TV+3.G,GP!
M%1#0<Q)885Q+]X"' +QNR@DUIO=S:K'5U/DI12WZ?H<=:H &Q,7.EK?)SKUX
MI]E6AK/4VPM% [;N45<+'(&O#NYINC R="&Y_XBP0NA+[$=,P9+*PX#C]=EH
MO,H/4U)ZV'.,?C42(P6;LMBZV]^0%\:!)VXE$YAISYO5F'D42%R:2.[-C@/U
M<0#J"*B2:SL'SDS=+Z_79!PYO#N(F<NPALN,P!UZIC?^481FL;\W _"CF8:P
M&@ !00 .J)E=E!0!6AHLRC#\9&:ZHP8=*1!<Y"@/NK,8Y=H1;0ZSF=TD%2[F
MJF2)#,K/PV$%@;(JN8;C:FS1A'M,D7"H2'&KJS4.+7>* A+YE(+"A+6ZPW0M
M44U:'LWI'FQ#4"U]19<E+$FKA$A;*2OQ"Y&M<[%NJLH!,2U!U-R&<J/PBAZ-
M&VJFQ)FXH,"J&$$=LDW9\O:0LWU/.K+M:!7%M6VNT1S;L,4G0DTJ=%FV;8_/
MCJJPI2 UR2#K,WY SI1L+#?<)%MOO%X3/XR\V+"ZGXA'XJ$4=:P8!M!6I]Q:
M=ESN]9XI:Q\>J:^FU99$T'A],0WEZQT6HA>@I)Q#\-L,,6+MFK$@@8DX^KT(
M?8NO9R*RI_H2[:[43!5H[>O2OL2\A4\H C]A>Q$3!^U6B$65H4?QZR5ZI7X.
M$>N9(ZC.D_PU0=!#"S;4:6,H>+7B,!KL*I8&4>#>;7J6ACH #YPP6I,/6NJ
ML2UR^X07'J:*R_)"JLM(%/<8F1 7LRXC"IV4Z@;LFKM2@61:+M!IVY=;XG^G
MPOGL')M9;Q,2Q'P%:;=TV(5:E*;4]977M\ZJB6PIQ[76$N)) ')W5.$KK?P
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M<<AL^N,_OC^)L+?[UTU!EW;&^H;(PK?62VQ;+FRZ2P@TQC.]?Z'#02%S7D)
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M4I=;M4-1KGKDGJ7 '1I3IC*%-TX%%?TYP)P%>@S <@8J"+47:X]_^K1V<7@
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MV*3G:/;5E!X/"J^RM08^B1NNG(0ZLA<H7S;S#.TQ<$6\$'L1*]6VIMS%A39
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M%*F^U>RO/,M(Y9';NRIC E!5VEA]J=@OH;Z$;&ZMQ9\ZB=_Q?48Z7G5A=NQ
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M_,?_!U!+ 0(4 Q0    ( "1">5+[PJSJ?SL! *JP%@ 1              "
M 0    !H<FUY+3(P,C Q,C,Q+GAM;%!+ 0(4 Q0    ( "1">5(\<B:54Q<
M *$) 0 1              "  :X[ 0!H<FUY+3(P,C Q,C,Q+GAS9%!+ 0(4
M Q0    ( "1">5+620>$NQ,  '4Q 0 5              "  3!3 0!H<FUY
M+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  D0GE2'&]P;?,V   0U ,
M%0              @ $>9P$ :')M>2TR,#(P,3(S,5]D968N>&UL4$L! A0#
M%     @ )$)Y4M!(^ZSN@P  V^L' !4              ( !1)X! &AR;7DM
M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( "1">5)?/M/6QE,  ")Y!@ 5
M              "  64B @!H<FUY+3(P,C Q,C,Q7W!R92YX;6Q02P4&
/  8 !@"* 0  7G8"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
